

THE STATE OF SOUTH CAROLINA
In The Supreme Court

APPEAL FROM SPARTANBURG COUNTY
Court of Common Pleas

Roger L. Couch, Circuit Court Judge

Case No. 2007-CP-42-1438

State of South Carolina ex. rel. Alan Wilson in his
capacity as Attorney General of the State of South
Carolina, ... Respondent,

v.

Ortho-McNeill-Janssen Pharmaceuticals, Inc., f/k/a
Janssen Pharmaceutica, Inc., and/or Janssen, L.P., and
Johnson & Johnson, Inc., ... Defendants.

Of whom Ortho-McNeill-Janssen Pharmaceuticals, Inc.
is Appellant.

RECORD ON APPEAL - VOLUME XI

**Nelson Mullins Riley
& Scarborough LLP**
C. Mitchell Brown
William C. Wood, Jr.
A. Mattison Bogan
Miles E. Coleman
Post Office Box 11070
Columbia, SC 29201
(803) 799-2000

**Richardson Plowden
& Robinson, P.A.**
Steven J. Pugh
Steven W. Hamm
Mason A. Summers
1900 Barnwell Street
Post Office Drawer 7788
Columbia, SC 29202
(803) 771-4400

**Drinker Biddle
& Reath LLP**
Edward M. Posner
Chanda A. Miller
One Logan Square
Suite 2000
Philadelphia, PA 19103
(215) 988-2700

Attorneys for Appellant

**Office of Attorney
General**
The Honorable Alan
Wilson
C. Havird Jones, Jr.
1000 Assembly Street
Room 519
Columbia, SC 29201
(803) 734-3656

Bailey Perrin Bailey
Fletcher V. Trammell
Robert W. Cowan
Elizabeth W. Dwyer
440 Louisiana, Ste 2100
Houston, TX 77002
(713) 425-7100

**Harrison White Smith &
Coggins, P.C.**
John B. White, Jr.
Donald C. Coggins, Jr.
178 West Main Street
Post Office Box 3547
Spartanburg, SC 29304
(864) 585-5100

Simmons Law Firm, LLC
John S. Simmons
1711 Pickens Street
Columbia, SC 29202
(803) 779-4600

Attorneys for Respondent

INDEX TO RECORD ON APPEAL

PAGE

VOLUME ONE

I. ORDERS/JUDGMENTS

Order of Remand, dated July 10, 2007	1
Order Denying the State's Motion for Non-Jury Determination, dated August 27, 2011	7
Order Regarding Defendant's Motions for Summary Judgment and Parties' Motions <i>in Limine</i> , dated February 25, 2011	8
Penalty Order, dated June 3, 2011	27
Order Denying Defendant's Motion for Judgment Notwithstanding the Verdict or, in the Alternative, for a New Trial, dated December 20, 2011	44
Order Denying Defendant's Motion to Alter or Amend the Judgment and/or for a New Trial, dated December 20, 2011	50
Order Granting the State's Motion to Transfer Case and Certify the Case for Review by this Court, dated February 27, 2012	56

II. PLEADINGS

Complaint, filed April 23, 2007	58
Second Amended Complaint, filed March 19, 2010	102
Defendants' Answer to Plaintiff's Second Amended Civil Action Complaint, filed April 11, 2010	121

III. TRANSCRIPTS

<u>Hearing Transcript, February 2, 2011</u>	143
MOTIONS	143
<u>Transcript of Trial, March 7-22, 2011</u>	182
MOTIONS	194
PLAINTIFF'S OPENING STATEMENT	320

PUBLISHED DEPOSITION OF MAGALI HAAS	366
PUBLISHED DEPOSITION OF SALLY BERRY	399
TESTIMONY OF WILLIAM WIRSHING	
Direct Examination by Mr. Trammell	414
VOLUME TWO (Begins at R. 501)	
Cross Examination by Mr. Campion	593
Redirect Examination by Mr. Trammell	674
TESTIMONY OF LAURA PLUNKETT	
Direct Examination by Mr. Trammell	687
Cross Examination by Mr. Murphy	885
VOLUME THREE (Begins at R. 1001)	
Redirect Examination by Mr. Trammell	1038
Re-Cross Examination by Mr. Murphy	1078
Redirect Examination by Mr. Trammell	1084
PUBLISHED DEPOSITION OF EDWARD BRANN	1087
PUBLISHED DEPOSITION OF DONNA OHYE	1116
TESTIMONY OF ANGIE ALDERMAN	
Direct Examination by Mr. White	1139
Cross Examination by Mr. Pugh	1175
Redirect Examination by Mr. White	1177
PUBLISHED DEPOSITION OF GAHAN PANDINA	1186
PUBLISHED DEPOSITION OF RILEY SMITH	1208
TESTIMONY OF JAMES ASSEY	
Direct Examination by Mr. Coggins	1214
Cross Examination by Mr. Murphy	1230

Redirect Examination by Mr. Coggins	1236
Re-Cross Examination by Mr. Murphy	1244
Redirect Examination by Mr. Coggins	1245
Re-Cross Examination by Mr. Murphy	1248
PUBLISHED DEPOSITION OF RONALD KALMEIJER.....	1249
PUBLISHED DEPOSITION OF JOHN JACOPPI.....	1251
PUBLISHED DEPOSITION OF PHILOMENA MCARTHUR.....	1256
PUBLISHED DEPOSITION OF PATRICIA DESANTIS	1282
PUBLISHED DEPOSITION OF AMY GROGG	1284
PUBLISHED DEPOSITION OF OLGA MITELMAN	1295
TESTIMONY OF DAVID PATTERSON	
Direct Examination by Mr. Coggins.....	1299
Redirect Examination by Mr. Coggins	1316
Re-Cross Examination by Mr. Pugh	1317
PUBLISHED DEPOSITION OF IVO CAERS.....	1320
MOTION.....	1331
TESTIMONY OF RAMY MAHMOUD	
Direct Examination by Mr. Campion.....	1371
VOLUME FOUR (Begins at R. 1484)	
Cross Examination by Mr. Trammell	1484
Redirect Examination by Mr. Campion.....	1645
Re-Cross Examination by Mr. Trammell.....	1665
TESTIMONY OF IVO CAERS	
Direct Examination by Mr. Campion.....	1672
MOTION.....	1722

TESTIMONY OF IVO CAERS

Cross Examination by Mr. Simmons.....1726

TESTIMONY OF MICHAEL CHESTER

Direct Examination by Mr. Pugh.....1763

Cross Examination by Mr. Coggins.....1819

MOTION.....1887

TESTIMONY OF MICHAEL CHESTER

Cross Examination by Mr. Coggins.....1906

Redirect Examination by Mr. Pugh 1919

Re-Cross Examination by Mr. Coggins.....1922

TESTIMONY OF SHELDON BRADSHAW

Direct Examination by Mr. Murphy 1925

VOLUME FIVE (Begins at R. 1980)

Cross Examination by Mr. Simmons.....1980

TESTIMONY OF ROBERT BANK

Direct Examination by Mr. Murphy 1987

Cross Examination by Mr. White 2005

Redirect Examination by Mr. Murphy.....2024

Re-Cross Examination by Mr. White.....2025

TESTIMONY OF BRENDA RATLIFF

Direct Examination by Mr. Murphy 2029

Cross Examination by Mr. White 2043

Redirect Examination by Mr. Murphy.....2058

Re-Cross Examination by Mr. White.....2060

PUBLISHED DEPOSITION OF JOHN WILLIAMS.....2082

PUBLISHED DEPOSITION OF PAM DERUITER	2084
MOTIONS	2086
TESTIMONY OF DAVID FABBRI	
Direct Examination by Mr. Pugh	2103
Cross Examination by Mr. Coggins.....	2140
Redirect Examination by Mr. Pugh	2210
Re-Cross Examination by Mr. Coggins	2216
Redirect Examination by Mr. Pugh	2217
TESTIMONY OF JOHN NEWCOMER	
Direct Examination by Mr. Murphy	2221
Cross Examination by Mr. Trammell	2269
Redirect Examination by Mr. Murphy	2313
PUBLISHED DEPOSITION OF EDWARD BRANN	2339
MOTIONS	2340
PLAINTIFF'S CLOSING ARGUMENT	2418
DEFENDANTS' CLOSING ARGUMENT	2454
PLAINTIFF'S CLOSING ARGUMENT	2457
CHARGE BY THE COURT	2469

VOLUME SIX (Begins at R. 2480)

<u>Transcript of Penalty Hearing, April 18-19, 2011</u>	2539
PLAINTIFF'S OPENING STATEMENT.....	2546
TESTIMONY OF JAMES WOODLOCK	
Direct Examination by Mr. Coggins.....	2559
Cross Examination by Mr. Murphy	2595
Redirect Examination by Mr. Coggins	2607

Re-Cross Examination by Mr. Murphy	2612
TESTIMONY OF JAY SMITH	
Direct Examination by Mr. Coggins.....	2616
Cross Examination by Mr. Pugh.....	2629
PLAINTIFF'S PRESENTATIONS	2646
DEFENDANT'S OPENING STATEMENT	2712
TESTIMONY OF JOHN NEWCOMER	
Direct Examination by Mr. Murphy	2743
Cross Examination by Mr. Trammell	2760
Redirect Examination by Mr. Murphy.....	2767
Re-Cross Examination by Mr. Trammell.....	2769
TESTIMONY OF WILLIAM WECKER	
Direct Examination by Mr. Campion.....	2770
Cross Examination by Mr. Trammell	2812
Redirect Examination by Mr. Campion	2834
Re-Cross Examination by Mr. Trammell.....	2836
PLAINTIFF'S CLOSING STATEMENT	2875
DEFENDANT'S CLOSING STATEMENT	2889

IV. CHARGES

Plaintiff the State of South Carolina's Proposed Requests for Charge, filed March 17, 2011	2903
Defendants' Requested Jury Instructions, filed March 17, 2011	2913
Plaintiff the State of South Carolina's Request for Charge No. 1; Amended Request for Charge No. 6; Request for Charge No. 7; Request for Charge No. 8; and Amended Proposed Form of Verdict, filed March 18, 2011	2957

VOLUME SEVEN (Begins at R. 2966)

Plaintiff the State of South Carolina's Objections to Defendants' Requested Jury Instructions, filed March 18, 2011	2966
Defendants' Requested Verdict Sheet, filed March 18, 2011	2985
Defendants' Objections to Plaintiff's Proposed Requests for Charge and Proposed Verdict Sheet and Defendants' Request for Corrective Instruction, filed March 20, 2011	3000
Verdicts as to Johnson & Johnson, Inc. and Ortho-McNeil-Janssen Pharmaceutica, Inc., f/k/a Janssen Pharmaceutica Inc., and/or Janssen L.P., filed March 22, 2011	3030

V. EXHIBITS

Plaintiff's Trial Exhibits:

P0077 Risperdal Business Plan 2004.....	3034
P0164 Letter from R. Katz to V. Wagner-Weber, dated May 1, 2000	3087
P0165 E-mail from S. Dodd to R. Mahmoud and others, dated July 20, 2000	3089
P0166 E-mail from A. Grogg to J. Vandenbossche and others, dated August 1, 2000	3094
P0167 E-mail from A. Grogg to J. Vandenbossche and others, dated August 1, 2000	3095
P0200 Letter from L. Stockbridge to T. McIntyre, dated January 5, 1999	3102
P0232 Letter from T. Abrams to A. Shetty, dated April 19, 2004.....	3107
P0254 E-mail from R. Mahmoud to N. Dac and others, dated October 10, 2000	3112
P0280 August 2008 Risperdal Package Insert	3115
P0357 Diabetes Package Insert Revision, Field Training, dated November 2003	3127
P0387 Field Training, dated October 31, 2003	3157

P0435 Risperdal Hyperglycemia/Diabetes Labeling power point, IDC, dated January 13, 2004	3197
P0438 Letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated July 21, 2004	3229
P0442 Trial 113 Topline Results, dated September 9, 1999.....	3231
P0462 E-mail from S. Reines to G. Pruden, dated October 23, 2003.....	3246
P0477 E-mail from S. Reines to J. Grebb, dated November 30, 2003	3247
P0520 Letter from R. Katz to C. McGowan, dated September 12, 2003	3249
P0571 Letter from R. Temple to R. Wasserman, dated December 29, 1993	3253
P0631 1996 Risperdal Package Insert (published in 1997 Physicians' Desk Reference).....	3257
P0640 2006 Risperdal Package Insert.....	3263
P0641 March 2006 Risperdal Package Insert (published in 2007 Physicians' Desk Reference)	3270
P0643 1994 Risperdal Package Insert.....	3278
P0648 July 1998 Risperdal Package Insert.....	3283
P0649 May 1999 Risperdal Package Insert	3287
P0653 December 2000 Risperdal Package Insert	3291
P0656 Revised July 2002 Risperdal Package Insert.....	3295
P0657 March 2003 Risperdal Package Insert	3299
P0661 December 2003 Risperdal Package Insert	3303
P0662 February 2005 Risperdal Package Insert	3311
P0665 October 2006 Risperdal Package Insert.....	3351
P1027 Letter from S. Danese to R. Wasserman, dated February 9, 1994	3397

VOLUME EIGHT (Begins at R. 3406)

P1078 Risperdal 2003 Business Plan Summary	3406

P1105 E-mail from C. Shaw to B. Goff, dated September 17, 2003	3493
P1224 October 2001 Risperdal Package Insert.....	3496
P1264 Risperdal 2000 Business Plan.....	3501
P1552 Risperdal Growth Acceleration, dated February 26, 2001	3552
P1564 Differential Effects of Antipsychotics on Type II Diabetes, presented May 3-5, 2001.....	3676
P1662 Janssen First Cycle 1999	3680
P1670 Risperdal Q&A, dated July 26, 1996.....	3747
P1728 Letter from E. Brann to R. Katz, dated August 10, 2000	3753
P1731 Letter from D. Ohye to T. Abrams, dated April 28, 2004	3758
P1736 Letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated November 10, 2003.....	3762
P1741 Janssen submission to FDA, dated August 8, 2000.....	3764
P2049 September 1996 Risperdal Package Insert	3777
P2061 April 1995 Risperdal Package Insert	3781
P2352 Draft letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated November 2003.....	3788
P2353 Draft letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated November 2003.....	3790
P2354 Draft letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated November 2003.....	3791
P2364 E-mail from S. Reines to J. Waldstreicher, dated April 28, 2004	3792
P2610 Letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated April 16, 2003	3795
P2613 E-mail from S. Reines to F. Grossman, dated March 10, 2004.....	3801
P2614 E-mail from S. Reines to F. Grossman, dated June 10, 2004.....	3805
P2618 Risperdal Training Meeting.....	3806

VOLUME NINE (Begins at R. 3906)

P2651 E-mail from G. Pruden to R. Mahmoud, dated October 5, 2003	3973
P2653 Abbreviated Clinical Study Report, Trial 113, dated December 18, 1997 – February 26, 1999	3976

VOLUME TEN (Begins at R. 4406)

P2653 Abbreviated Clinical Study Report, Trial 113, dated December 18, 1997 – February 26, 1999, Cont.	4406

VOLUME ELEVEN (Begins at R. 4906)

P2653 Abbreviated Clinical Study Report, Trial 113, dated December 18, 1997 – February 26, 1999, Cont.	4906

VOLUME TWELVE (Begins at R. 5406)

P2653 Abbreviated Clinical Study Report, Trial 113, dated December 18, 1997 – February 26, 1999, Cont.	5406
P2662 Draft letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated November 2003	5430
P2682 Memo Regarding Medication Problem, Trial 113, dated September 22, 1999	5431

Plaintiff's Penalty Hearing Exhibits:

P1 Letter from S. Pugh to D. Coggins, dated April 13, 2011	5436
P6 Sample Call Note Data	5439
P7 Call Note Report Generated by James Woodlock	5441
P8 Call Note Report Generated by James Woodlock	5443
P9 Call Note Example	5446
P17 Court Filings (Offered; not admitted into evidence)	5447
P18 Johnson & Johnson 2010 Annual Report	5590
P19 Johnson & Johnson 2004 Annual Report	5668
P20 Johnson & Johnson 2003 Annual Report	5746
P21 Plaintiff's Calculations Regarding Potential Violations	5820

P22 Johnson & Johnson 10-K for Fiscal Year Ended January 2, 2011 (Offered; not admitted into evidence).....	5825
P2720 Plaintiff's Calculations Regarding Sample Quantity Data	5835
P2722 Plaintiff's Calculations Regarding Number of Sales Calls When Samples Were Left	5836

Defendants' Trial Exhibits:

D0351 Letter from Janssen Pharmaceutica Inc. to Healthcare Providers with Risperdal Package Insert, dated November 10, 2003	5837
D0442 Letter from Janssen Pharmaceutica Inc. to Healthcare Providers, dated July 21, 2004.....	5843
D0498 August 2007 Risperdal Package Insert	5851

VOLUME THIRTEEN (Begins at R. 5899)

D0807 Volume 1 of the 2000 Submission to FDA.....	5899
D0821 Volume 15 of the 2000 Submission to FDA.....	6165

VOLUME FOURTEEN (Begins at R. 6384)

D0841 Letter from R. Katz to E. Brann, dated March 3, 2002.....	6384
D0843 Letter from R. Katz to M. Zoschg, dated December 4, 2003.....	6418
D0919 Letter from S. Merchant to R. Katz, dated March 29, 2004	6457

VOLUME FIFTEEN (Begins at R. 6884)

D3097 Letter from R. Katz to V. Wagner-Weber, dated May 1, 2000	7051
D3140 Letter from E. Brann to R. Katz, dated September 24, 2003	7053
D3175 Letter from R. Katz to C. McGowan, dated September 11, 2003	7063
D3179 Letter from S. Merchant to R. Katz, dated November 26, 2003	7066
D3180 Letter from R. Katz to S. Merchant, dated November 21, 2003	7077
D4337 Chapter 4 of the 2004 Version of the FDA's Regulatory Procedures Manual.....	7080
D6211 Letter from S. Merchant to R. Katz, dated April 18, 2002	7119

D6253 Letter from M. Brony to D. Ohye, dated October 14, 2004.....	7315
D7008 Expert Report of William E. Wecker, Ph.D., dated December 3, 2010 (Referred to in Trial Transcript as “Def. Exh. A.”)	7318
D7174 Chart of South Carolina Department of Health and Human Services Drug Utilization Review Program – Patient Drug History Profile	7367
D7185 “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” The Journal of Clinical and Applied Research and Education Diabetes Care, 27:2 (2004); 596-601	7375

VOLUME SIXTEEN (Begins at R. 7382)

D7186 SC-DMH Laboratory Monitoring Guidelines for Antipsychotic Medications	7382
D7294 IND 31,931 Risperidone Tablets Annual Report July 1, 1998 – June 30, 1999.....	7388
D7336 Letter from W. Murray Yarbrough to T. Engles, dated September 19, 2003.....	7489
D7337 South Carolina Medicaid & SHP Claims Data, June 2003-October 2004 (Referred to in Trial Transcript as “Def. Exh. B”).....	7494
D7338 South Carolina Medicaid & SHP Claims Data, November 2004-December 2005 (Referred to in Trial Transcript as “Def. Exh. C”).....	7495

Defendants’ Penalty Hearing Exhibits:

D2 2007 Zyprexa Package Insert (Offer of proof; not admitted into evidence).....	7496
D5 South Carolina Fee for Service, State Health Plan, and HMO Claims Data – Antipsychotic Prescriptions by Month	7532
D6 Calculation of Net Cost of Risperdal to the State (Columns 1-7 admitted).....	7533

Court’s Exhibits:

C-2 Federal Regulations	7540

C-3 Court's Rulings on Objections to Openings	7584
C-4 Defendants' Offer of Proof	7586
C-5 Charge by Court.....	7654
C-6 Question from the Jury.....	7670
C-7 Question from the Jury.....	7671

Physical Exhibit:

P5 Hard Drive containing sales call data produced by Defendants	7672

VI. MISCELLANEOUS AND OTHER MOTIONS

Tolling Agreement, dated February 20, 2007	7673
Notice of Removal, filed May 22, 2007	7678
Plaintiff the State of South Carolina's Motion to Exclude the Testimony of Certain Risperdal Prescribers at Trial, filed July 2, 2010.....	7737
Defendants' Motion <i>in Limine</i> and Memorandum of Law in Support Thereof to Preclude the Introduction into Evidence of the April 19, 2004 DDMAC Letter and Any Evidence of or Reference to the Letter at Trial, filed January 7, 2011.....	7747
Plaintiff the State of South Carolina's Notice of Motion and Motion to Exclude the Expert Testimony of Sheldon Bradshaw, filed January 13, 2011	7817

VOLUME SEVENTEEN (Begins at R. 7837)

Plaintiff the State of South Carolina's Motion to Exclude the Expert Testimony of Dr. William E. Wecker, filed January 13, 2011	7837
Plaintiff the State of South Carolina's Response in Opposition to Defendants' Motion <i>in Limine</i> to Preclude the Introduction of Evidence of the April 19, 2004 DDMAC Letter and Any Evidence of or Reference to the Letter at Trial, filed January 18, 2011	8093
Defendants' Memorandum of Law in Opposition to Plaintiff's Motion to Exclude the Testimony of Certain Risperdal Prescribers at Trial, filed January 20, 2011	8102

Plaintiff the State of South Carolina's Response in Opposition to Defendants' Motion for Summary Judgment as to Plaintiff's Unfair Trade Practices Claim Based on November 10, 2003 Mailing, filed January 21, 2011	8171

VOLUME EIGHTEEN (Begins at R. 8325)

Plaintiff the State of South Carolina's Response in Opposition to Defendants' Motion for Summary Judgment as to Plaintiff's Unfair Trade Practices Act Claim Based on the FDA Approved Package Insert, filed January 21, 2011	8325
Defendants' Memorandum of Law in Opposition to Plaintiff's Motion to Exclude the Expert Testimony of Dr. William E. Wecker, filed January 21, 2011	8344
Plaintiff the State of South Carolina's Reply to Defendants' Response in Opposition to the State's Motion to Exclude the Expert Witness Testimony of Defendants' Expert Witness, Dr. William E. Wecker, filed January 31, 2011	8483
Defendants' Objections to Plaintiff's Opening Statement, filed March 8, 2011	8525
Plaintiff the State of South Carolina's Response in Opposition to Defendants' Objections to Plaintiff's Opening Statement, filed March 14, 2011	8530
Defendants' Motion for a Directed Verdict and Memorandum of Law in Support Thereof, filed March 14, 2011	8600
Plaintiff the State of South Carolina's Response in Opposition to - Defendants' Motion for a Directed Verdict, filed March 15, 2011	8632
Defendants' Reply in Support of Motion for a Directed Verdict, filed March 15, 2011	8664
Plaintiff the State of South Carolina's Motion for a Directed Verdict as to Defendants' Eighth Affirmative Defense on Statute of Limitations, filed March 21, 2011	8667
Defendants' Offer of Proof for the Expert Testimony of Dr. William E. Wecker, filed March 21, 2011	8696

VOLUME NINETEEN (Begins at R. 8803)

Defendants' Offer of Proof for the Post-2007 FDA-Approved Package Insert for Zyprexa and the 2010 FDA-Approved Package Insert for Latuda, filed March 21, 2011	8803
Defendants' Renewed Motion for a Directed Verdict and Memorandum of Law in Support Thereof, filed March 21, 2011	8870
Defendant Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Motion and Memorandum in Support Thereof for Judgment Notwithstanding the Verdict or, in the Alternative, for a New Trial, filed April 1, 2011	9030
Plaintiff's Pre-trial Brief to the Court (Civil Penalty Phase), filed April 15, 2011	9107
Janssen's Penalty Hearing Brief, filed April 15, 2011	9115
Plaintiff the State of South Carolina's Memorandum of Law in Support of its Response in Opposition to Defendant's Motion for Judgment Notwithstanding the Verdict or, in the Alternative, for a New Trial, filed April 15, 2011	9225

VOLUME TWENTY (Begins at R. 9303)

Defendant's Offer of Proof for the Testimony of Prescriber Physicians; and Robert L. Bank, M.D., and Brenda Ratliff, M.D., filed April 18, 2011	9343
Plaintiff the State of South Carolina's Post Civil Penalties Hearing Submission, filed May 3, 2011	9401
Defendant Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Post-Penalty Hearing Brief, filed May 3, 2011	9426
Reply Memorandum of Law in Support of Defendant Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Motion for Judgment Notwithstanding the Verdict or, in the Alternative, for a New Trial, filed May 3, 2011	9440
Defendant Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Motion and Memorandum of Law in Support Thereof to Alter or Amend the Judgment and/or for a New Trial, June 13, 2011	9455
Plaintiff the State of South Carolina's Response in Opposition to Defendant's Motion to Alter or Amend the Judgment and/or For a New Trial, filed July 7, 2011	9492

Defendant Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Reply in Support of its Motion to Alter or Amend the Judgment and/or for a New Trial, filed July 15, 2011	9525

VII. CERTIFICATE OF COUNSEL

7. Arndt SV, Flaum M and Andreasen NC: Longitudinal patterns of prediction, change and stability in positive and negative symptoms. *Schizophrenia Research*, 9:92, 1993.
8. Flaum M, Hubbard WH, Arndt SV, Andreasen NC: The validity of subjective reporting of positive and negative symptoms in schizophrenia. *Schizophrenia Research*, 9:99, 1993.
9. Nopoulos PC, Flaum M, Andreasen NC, Swayze VW: Gray matter heterotopias in schizophrenia. *Schizophrenia Research*, 9:205, 1993.
10. Roy MA, Flaum M, Arndt S, Crowe RR, Andreasen NC: Neuroanatomical correlates of familial and sporadic schizophrenia. *Schizophrenia Research*, 9:208, 1993.
11. Roy MA, Flaum M, Gupta S, Jaramillo L: Epidemiological and clinical correlates of familial and sporadic schizophrenia. *Schizophrenia Research*, 9:139, 1993.
12. Andreasen NC, Swayze V, O'Leary DS, Miller D, Flaum M, Gupta S: Structural brain abnormalities revisited: Measurement of volumes and surface structures based on three-dimensional magnetic resonance. *Schizophrenia Research*, 9:191, 1993.
13. Gupta S, Rajaprabhakaran R, Arndt SV, Flaum M, Andreasen NC: Premorbid adjustment as a predictor of phenomenological and neurobiological indices in schizophrenia. *Schizophrenia Research*, 9:99, 1993.
14. Swayze VW, Andreasen NC, O'Leary, Flaum M, Sickels W, Miller DD, Ziebell S: Long-term follow-up study of frontal lobotomy in schizophrenia. *Schizophrenia Research*, 9:210, 1993.
15. Flaum M, Arndt SV, Andreasen NC: The reliability of distinguishing "primary" vs. "secondary" negative symptoms. 32nd annual meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii, December 15, 1993.
16. Nopoulos PC, Flashman LA, Flaum M, O'Leary DS, Andreasen NC: Stability of neuropsychological function in schizophrenia over time. American College of Neuropsychopharmacology 32nd annual meeting, Honolulu, Hawaii, December 13, 1993.
17. Arndt S, Cizadlo T, Harris G, O'Leary DS, Flaum M, and Andreasen NC: The correlation of IQ with brain size, surface complexity and curvature from MR images in normal adults. American College of Neuropsychopharmacology 32nd annual meeting, Honolulu, Hawaii, December 13, 1993.
18. Okazaki Y, Andreasen NC, Okubo T, Minami Y, Maeda H, Nakane Y, Ochi M, Flaum M, Arndt S: Similarities and dissimilarities of brain structures of identical twins concordant and discordant for schizophrenia. Presented at the Winter Workshop on Schizophrenia. Les Diablerets, Switzerland, January 26, 1994.
19. Andreasen NC, Harris G, Cizadlo T, Arndt SV, O'Leary D, Swayze V, Flaum M, Yuh WTC, Ehrhardt J: A quantitative method for measuring sulcal and gyral complexity: Brainplot and Brainmap. *Schizophrenia Research*, 11: 137, 1994.

20. Gupta S, Hubbard WC, Flaum M, Arndt SV, Andreasen NC: The Iowa prospective study of recent-onset psychoses: One year follow-up of symptoms and psychosocial functioning in first episode patients. *Schizophrenia Research*, 11: 176, 1994.
21. Amador XF, Flaum M, Andreasen NC, Strauss DH, Gorman JM: Insight into illness in schizophrenia and schizoaffective and mood disorders: Results from the DSM-IV field trials. *Schizophrenia Research*, 11: 180, 1994.
22. Gupta S, Hubbard WC, Arndt S, Flaum M, Andreasen NC: Neurological soft signs in neuroleptic naive schizophrenic patients vs. normal controls. *Schizophrenia Research*, 11: 195, 1994.
23. Flaum M, O'Leary DS, Arndt SV, and Hichwa R. Acute effects of cigarette smoking on cerebral blood flow: A PET study. "New Research", American Psychiatric Association 147th Annual Meeting, Philadelphia, Pennsylvania.
24. Flaum M. The diagnosis of schizophrenia in DSM-IV: How different? "New Research", American Psychiatric Association 147th Annual Meeting, Philadelphia, Pennsylvania.
25. Flaum M, O'Leary DS, Cizadlo T, Arndt SV, Hichwa R, Kirchner P and N.C. Andreasen. Acute effects of cigarette smoking on cerebral blood flow: A PET study. American College of Neuropsychopharmacology. 33rd annual meeting. San Juan, Puerto Rico, Dec. 12-16, 1994. Scientific Abstracts, p.148.
26. Andreasen NC, Flaum M, Arndt SV, Hichwa R, O'Leary DS and JC Ehrhardt. PET ^{15}O H_2O and functional MR for the study of regional cerebral blood flow: A comparison. American College of Neuropsychopharmacology. 33rd annual meeting. San Juan, Puerto Rico, Dec. 12-16, 1994. Scientific Abstracts, p.66.
27. Kronengold H, Amador XF, Bracha HS, Flaum M, McGlashan T, Pandurangi A, Robinson D, Tohen M: Schizophrenia, season of birth, and phenomenological features. *Schizophrenia Research*, 15: 11, 1995.
28. Gupta S, Flashman LA, Flaum M, Nopoulos PC, O'Leary DS, Andreasen NC: Is the neuropsychological dysfunction in schizophrenia progressive? *Schizophrenia Research*, 15, 120, 1995
29. Marcinko L, Amador X, Flaum M, McGlashan T, Pandurangi A, Robinson D, Tohen M: Gender differences in schizophrenia: Findings from the DSM-IV Field Trials. *Schizophrenia Research*, 15: 16-17, 1995
30. Miller DD, Flaum MA, Nopoulos P, Arndt S, Andreasen NC: The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure. *Schizophrenia Research*, 15:159, 1995
31. Nopoulos P, Swayze V, Flaum M, Andreasen N: Structural brain abnormalities in schizophrenic patients with and without cavum septi pellucidi as measured by MRI. *Schizophrenia Research*, 15:94, 1995
32. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Tohen M: Racial differences in the expression of psychosis. *Schizophrenia Research*, 15: 21, 1995

-
33. Roy M-A, Flaum M, Andreasen NC. Winter and non-winter born Schizophrenic cases: A comprehensive study. *Schizophrenia Research*, 15:47-48, 1995
 34. Flaum M, Sonka M, Arndt S, Cizadlo T, Stoneall S, and N.C. Andreasen: A new automated method of identifying neuroanatomic regions of interest on imaging data. American College of Neuropsychopharmacology, 34th annual meeting. San Juan, Puerto Rico, Dec. 11-15, 1995. Scientific Abstracts, p. 233.
 35. Nopoulos PC, Flaum M, and N.C. Andreasen: Gender differences in schizophrenia: Brain morphology. American College of Neuropsychopharmacology, 34th annual meeting. San Juan, Puerto Rico, Dec. 11-15, 1995. Scientific Abstracts p. 159
 36. Flaum M, Cizadlo T, Arndt S, O'Leary DS, Nopoulos P, Hurtig R, Zheng J, and J.C. Ehrhardt: Informing the choice of activation thresholds in fMRI paradigms. *Neuroimage*, 3:S59, 1996
 37. Flaum M, Sonka M, Arndt S, Cizadlo T, Stoneall S, and N.C. Andreasen: Automated morphologic and functional analysis of neuroanatomic regions of interest on MR imaging data. *Neuroimage*, 3: S131, 1996.
 38. Wassink TH, Rose S, Flaum M and NC Andreasen: The prevalence and predictive validity of early depressive symptoms in the course of schizophrenia. *Schizophrenia Research*, 24:25, 1997.
 39. Rodriguez R, Flaum M and PC Nopoulos: The effect of cumulative neuroleptic exposure on caudate and putamen volumes. *Schizophrenia Research*, 24:154, 1997.
 40. Flaum M, O'Leary DS, Johnson D, Arndt S, Cizadlo T, Hichwa R and NC Andreasen. Relationship between symptom dimensions and cerebral blood flow in schizophrenia as assessed by 15H2O PET. *Schizophrenia Research*, 24:165, 1997.
 41. O'Leary DS, Andreasen NC, Hurtig RR, Arndt S, Flaum MA and RD Hichwa. A PET study of auditory attention deficits in patients with schizophrenia: A replication and extension of previous findings. *Schizophrenia Research*, 24:170, 1997.
 42. Ho BC, Flaum M and NC Andreasen: The dependence on financial support from social agencies early in the course of schizophrenia. *Schizophrenia Research*, 24:223, 1997.
 43. Andreasen NC, Flaum M, Nopoulos P, Arndt S, Harris G, Heckel D, and T. Cizadlo: Measurement of cortical surface anatomy in schizophrenia. *Neuroimage*, 5: S276, 1997.
 44. Flaum M, Nopoulos P, Arndt S, Cizadlo T, and NC Andreasen: An MRI study of gray matter, white matter and cerebral spinal fluid volumes in patients with schizophrenia vs. normal controls. *Neuroimage*, 5: S277, 1997.
 45. Cizadlo T, Harris G, Heckel D, Flaum M, Christian BS, O'Leary DS and NC Andreasen: An automated method to quantify the area, depth and convolutions of the cerebral cortex from MR data: ("BRAINSURF"). *Neuroimage*, 5: S407, 1997
-

Michael Flaum, M.D.

D. Manuscripts under review:

1. Flaum M, Hubbard W, Arndt S, Andreasen NC: Validity of symptom assessment in psychotic disorders: Information variance across different sources of history. Submitted (*Psychological Medicine*)
2. O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC: Cognitive correlates of the negative, disorganized and psychotic symptom dimensions of schizophrenia. Submitted (*Schizophrenia Research*).
3. Jackson HJ, McGorry PD, Dakis J, Harrigan S, Henry L, Mihalopoulos C, Flaum M: The inter-rater and test-retest reliabilities of prodromal symptoms in first-episode psychosis. Submitted (*American Journal of Psychiatry*).
4. Flaum M, O'Leary DS, Cizadlo T, Arndt S, Hichwa R: Acute effects of cigarette smoking on cerebral blood flow as assessed by $O^{15}H_2O$ PET: A pilot study. Submitted (*Biological Psychiatry*)

Active Grant Support:

Funding Source: Scottish Rite Schizophrenia Research Program
Title: *Mapping the effects of antipsychotic medication on cerebral blood flow using functional magnetic resonance imaging*
Role on Project: Principal Investigator
Percent Effort: 10%
Salary Support: None
Total Project Period: 8/1/95 - 7/31/97
Current year funding: \$34,500
Description: This grant is to study a group of patients with schizophrenia with functional magnetic resonance imaging (fMRI), on and off antipsychotic medications. Normal controls will also be studied with fMRI.

Funding Source: Nellie Ball Trust Research Fund
Title: *Mapping Attentional Circuits in Schizophrenia with Functional Magnetic Resonance Imaging, and Modulation of Attention via Cigarette Smoking*
Role on project: Principal Investigator
Percent Effort: 10%
Salary Support: None
Total Project Period: 9/1/97 - 8/31/98
Current year funding: \$20,000
Description: To examine the acute effects of nicotine exposure on performance of attentional tasks and regional cerebral blood flow during the performance of some of these tasks in a group of patients with schizophrenia who also are heavy cigarette smokers.

Funding Source: NIMH, MH31593:
Title of Project: *Phenomenology and Classification of Schizophrenia*
Role on project: Co-Principal Investigator (P.I.: N.C. Andreasen)
Percent Effort: 30%
Salary Support: 30%
Active dates: 9/1/93 - 6/30/98
Current year funding: \$380,610
Description: To conduct a prospective longitudinal study of first episode and recent-onset psychotic patients

Funding Source: NIMH, MH43271:
Title: *MHCRC: Neurobiology and Phenomenology of Major Psychoses*
Role on project: Co-Principal Investigator (P.I.: N.C. Andreasen)
Percent Effort: 30%
Salary Support: 30%
Active dates: 9/01/94 - 8/31/99
Current year funding: \$1,152,190
Description: To provide centralized core resources (including an in-patient unit for care of patients in experimental protocols) for the study of schizophrenia.

Funding Source: NIMH (MH40856)
Title: *Brain Imaging in the Major Psychoses*
Role on project: Co-Investigator (P.I.: N.C. Andreasen)
Percent Effort: 5%
Salary Support: none
Active dates: 8/1/93 - 7/31/98
Current year funding: \$323,419

Michael Flaum, M.D.

Description: To conduct multimodality neuroimaging studies of normal individuals and patients with psychotic illnesses

Funding Source: NIMH (MH19113)

Title: *Research Training, Major Psychoses & Clinical Neurobiology*

Role on project: Mentor (P.I.: N.C. Andreasen)

Percent Effort: 5%

Salary Support: none

Active dates: 9/1/94 - 8/31/99

Current year funding: \$121,132

Description: To provide postdoctoral research training to MD's and Ph.D's, focussing on the neurobiology of Schizophrenia and related psychotic disorders

Funding Source: NIMH (MH14620)

Title: Postdoctoral Fellowship in Psychiatric Genetics

Role on project: Mentor (P.I.: R. Crowe)

Percent Effort: 5%

Salary Support: none

Active dates: 7/1/89 - 6/30/97

Current year funding: \$104,500

Description: To provide postdoctoral research training to MD's and Ph.D's, focussing on molecular and epidemiological genetic approaches to major mental illnesses

Grants Pending:

Funding Source: NIMH

Title: *Acute Marijuana Effects on Regional Cerebral Blood Flow*

Role on project: Co-Investigator (PI: D. O'Leary)

Percent Effort: 5%

Salary Support: none

Proposed period of support: 4/1/97 - 3/31/00

Requested costs for initial year: \$268,687

Description: To examine the effects of marijuana smoking on regional brain activity as measured by PET and fMRI in a group of casual users and those with marijuana dependence.

IOWA STATE BOARD
OF MEDICAL EXAMINERS
EXECUTIVE HILLS - WEST
LES MOINES IA 50319



ALWAYS NOTIFY THIS OFFICE OF
ANY NAME/ADDRESS CHANGE

(TEAR ALONG PERFORATION LINE)

This is to certify that the below named has renewed the

LICENSE TO PRACTICE MEDICINE AND SURGERY

in the State of Iowa for the period

DECEMBER 1, 1995 TO DECEMBER 1, 1997

This evidence of renewal shall be displayed in connection with the Original


LICENSE

FLAUM, MICHAEL ALAN

MD

CHRISTOPHER G. ATCHISON
DIRECTOR OF PUBLIC HEALTH

588-3251 Rev 3/91



JERRY E. BRANSTAD GOVERNOR
CHRISTOPHER G. ATCHISON
DIRECTOR OF PUBLIC HEALTH

**IOWA STATE BOARD
OF MEDICAL EXAMINERS**


THIS IS TO CERTIFY THAT

LICENSE NO. [REDACTED] EXPIRING **12/01/97**

FLAUM, MICHAEL ALAN MD

HAS RENEWED IN THE STATE OF IOWA
A **LICENSE TO PRACTICE
MEDICINE AND SURGERY**

IOWA STATE BOARD
OF MEDICAL EXAMINERS
EXECUTIVE HILLS - WEST
DES MOINES IA 50319



TERRY E. BRANSTAD, GOVERNOR

ALWAYS NOTIFY THIS OFFICE OF
ANY NAME/ADDRESS CHANGE.

(TEAR ALONG PERFORATED LINE)

This is to certify that the below named has renewed the
LICENSE TO PRACTICE MEDICINE AND SURGERY

In the State of Iowa for the period
DECEMBER 1, 1997 TO DECEMBER 1, 1999

This evidence of renewal shall be displayed in connection with the Original **LICENSE**

FLAUM, MICHAEL ALAN

MD

CHRISTOPHER G. ATCHISON
DIRECTOR OF PUBLIC HEALTH

598-3251 Rev 3/91



TERRY E. BRANSTAD, GOVERNOR
CHRISTOPHER G. ATCHISON
DIRECTOR OF PUBLIC HEALTH

**IOWA STATE BOARD
OF MEDICAL EXAMINERS**

THIS IS TO CERTIFY THAT

LICENSE NO. [REDACTED] **EXPIRING** **12/01/1999**
FLAUM, MICHAEL ALAN **MD**

**HAS RENEWED IN THE STATE OF IOWA
A LICENSE TO PRACTICE
MEDICINE AND SURGERY**

CURRICULUM VITAE

EVELYN M. HOWANITZ, M.D.

Home Address:

REDACTED

Work Address:

Department of Psychiatry N.J. V.A. Health Care System
East Orange & Lyons, New Jersey 07018-1095
(phone#) (201) 676-1000 Ext. 1424

Education:

1971	Barnard College, NY, NY	B.A.
1977	Temple University School of Medicine, Philadelphia, PA	M.D.
1978	St. Luke's Medical Center NY, NY	Flexible Internship
1979	Metropolitan Hospital, NY, NY	Medical Internship
1982	Mount Sinai Hospital & Medical Center NY, NY	Neurology Residency
1984	Mount Sinai Hospital & Medical Center NY, NY	Psychiatry Residency

License and Certifications:

NY State # REDACTED

Board Certified in Psychiatry 1986.

Board Eligible in Neurology

DEA#REDACTED

University Appointments:

1993 - present	Mount Sinai School of Medicine, Asst. Prof. of Psychiatry
1991- 1992	Cornell University Medical College, Instructor in Psychiatry
1985 - 1991	Albert Einstein College of Medicine, Asst. Prof. of Psychiatry
1984 - 1985	State University of New York at Stony Brook, Asst. Prof. of Psychiatry

Hospital Appointments:

1997 - present	V.A. New Jersey Health Care System East Orange & Lyons N.J., Attending Psychiatrist and Director of Geropsychiatry program
1993 - 1997	V.A. Hospital, Montrose, NY, Chief, Geropsychiatry.
1991 - 1992	New York Hospital, Westchester Division, Attending Psychiatrist in Geriatrics.
1985 - 1991	Jacobi Hospital, Bronx, New York, , Unit Chief of Inpatient Services and Director of Consultation Liaison Services.

E. Howanitz, M.D.
Curriculum Vitae
page 2.

1984- 1985 University Hospital of the State of N.Y. at Stony Brook, Stony Brook, NY, Attend. Psychiatrist and Director of Pain Services

Journal Reviews:

Reviewer for Archives of General Psychiatry, International Journal of Geriatric Psychiatry, and Journal of Nervous and Mental Diseases

Major Research Interest:

Schizophrenia ; Dementia ; Geriatric Psychiatry

Publication:

Fricchione, G. and Howanitz, E.: Aprosodia and Alexithymia-A Case Report. Psychother. Psychosom 43:156-160, 1985.

Howanitz, E. and Freedman J.: Reasons for Refusal of Medical Treatment by Patients Seen by a Consultation-Liaison Service. Hosp. Comm. Psych. 43:278-9, 1992.

Fricchione, G. and Howanitz, E.: Psychological Adjustments to End-Stage Renal Disease and the Implication of Denial. Psychosomatics 33:85-91, 1992.

Chen, C., Balogh, M., Bathija, J. Howanitz, E., et al: Substance Abuse Among Psychiatric Inpatients. Comprehensive Psychiatry 33:60-64, 1992

Howanitz, E., Pardo, M., and Losonczy, M.: Photosensitivity to Clozapine. J. Clin Psychiatry 56:589, 1995.

Howanitz, E., Bajulaiye, R., and Losonczy, M.: Magnetic Resonance Imaging Correlates of Psychosis in Alzheimer's Disease. Journal of Nervous and Mental Disease 183:548-9, 1995.

Howanitz, E., Losonczy, M., Schaefer, C., Pinsley, A., Harvey, P.: SPECT Imaging of Cognitive Decline in Elderly Schizophrenia, in press.

Howanitz, E., Pardo, M., Stern, R., Losonczy, M., Efficacy and Safety of Clozapine versus Chlorpromazine in Geriatric Schizophrenia, in press.

CUT OFF THIS STRIP

INSTRUCTIONS
REVERSE

997376

READ INSTRUCTIONS
ON REVERSE SIDE

CUT OFF THIS STRIP

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT
HAS REGISTERED

HOWANITZ, EVELYN

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

08/31/98
REGISTRATION PERIOD ENDS

Evelyn Howanitz
SIGNATURE OF REGISTRANT

LICENSE/CERTIFICATE NO.

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

READ
INSTRUCTIONS
ON REVERSE
SIDE

CUT OFF THIS STRIP

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED

HOWANITZ EVELYN

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

08/31/00

REGISTRATION PERIOD ENDS

Evelyn Howanitz
SIGNATURE OF REGISTRANT

LICENSE/CERTIFICATE NO

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

CUT OFF
THIS STRIP

479817

READ
INSTRUCTIONS

ON REVERSE
SIDE

CUT OFF
THIS STRIP

HUSSAM MIHTAR, M.D.
8899 UNIVERSITY CENTER LANE, SUITE 380
SAN DIEGO, CALIFORNIA 92122
TELEPHONE (619) 453-4441
FAX (619) 623-8519

Hussam Mihtar
5/23/97

Curriculum Vitae
of
Hussam Mihtar, M.D.

Clinical Practice:

7/1995-- Private Practice
8899 University Center Lane
Suite 380
La Jolla, CA 92122

Academic Appointment:

7/1995-- Assistant Clinical Professor
UCSD, Department of Psychiatry

7/1995-6/1996: Medical Director
In-Patient Psychiatry
UCSD Medical Center
San Diego, California

Education:

7/1994-6/1995: Chief Resident
Department of Psychiatry
Univ. of Cal., San Diego
San Diego, California

7/1992-6/1994: Residency in Psychiatry
Univ. of Cal., San Diego
San Diego, California

7/1991-6/1992: Internship in Psychiatry
University of Cincinnati
Cincinnati, Ohio

2/1989-3/1991: Research Assistant
Biobehavioral Laboratory
Department of Psychiatry
Charles R. Drew University
Los Angeles, California

5/1986-5/1988: Residency in Psychiatry
Mezza Military Hospital
Damascus, Syria

9/1979-4/1986: University of Damascus, School of Medicine
Damascus, Syria
(Combined Pre-Medical and Medical Six Year Program)
M.D. Degree Conferred April 1986

Professional Activities:

1998-- Co-Facilitator of the residents' group in the Residency Training Program,
Department of Psychiatry, University of California, San Diego

1993-- Staff Member of the Department of Psychiatry, University of California,
San Diego for the International European Drug Abuse Treatment
Training Project, Caltanissetta, Italy and Portoroz, Slovenia

1993-- Staff Member of the International/Transcultural Mental Health Education and
Training Committee, University of California, San Diego

1994-1996 Residency Selection Committee, Department of Psychiatry, University
of California, San Diego

1994-1996 Graduate Education Committee, Department of Psychiatry, University
of California, San Diego

1994-1996 Task Force Committee, Department of Psychiatry, University of
California, San Diego

1994-1995 The psychiatric consultant to The Liver Transplant Surgical Services at
University of California, San Diego

1995-- Assistant Clinical Professor, Department of Psychiatry, University of
California, San Diego

Professional Affiliations:

1992-- San Diego Psychiatric Society, Member

1991-- American Psychiatric Association, Member

1991-- American Medical Association, Member

1994-- World Psychiatric Association, Member

1997-- Arab American Psychiatric Association, Council Member

1994-1995 San Diego Psychiatric Society, Council Member in Training

1994-1995 California Psychiatric Association, Committee of Residents, San Diego
Representative

1994-1995 California House Officer Medical Society, San Diego Representative

Page 3

Awards:

1993: Eli Lilly U.S. Psychiatric Congress Fellowship

Research Experience:

10/89-5/91: "Dysregulation of the blood cortisol and Neurotransmitters in Response to Biopsychological stressors in Depressed Patients"
An on-going study at UCLA/Drew University Medical Center
Los Angeles, CA

6/90-5/91: "CPK as a Prognostic Parameter in Acutely Psychotic Afro-American Males." An on-going study at UCLA/Drew University Medical Center
Los Angeles, CA

Examinations:

FLEX	Passed Part I and II, June 1990
FMGEMS	Passed Part II, January 1990
NMBE	Passed Part I, September 1989

Publications:

Khoury, H., M.D., B.P.T.T., and Mihtar, H., M.D., "an Evaluation Study of the Methods of Diagnosis and Therapy of Psychiatric Diseases and its effectiveness at University of Damascus Ibn Seena Psychiatric Hospital", Presented to the Annual Health Ministry Conference, Damascus, Syria, 1986. (Honored as a Reference in the National Medical Library)

Personal Information:

Date of birth:	September 22, 1961
Place of Birth:	Damascus, Syria
Marital Status:	Single
Visa Status:	U.S. citizen

Remove your new pocket certificate from the receipt portion and carry with you at all times.

MEDICAL BOARD OF CALIFORNIA
1426 HOWE AVENUE
SACRAMENTO, CA 95825-3236
916-263-2571

MEDICAL BOARD OF CALIFORNIA
1426 HOWE AVENUE
SACRAMENTO, CA 95825-3236
916-263-2571

PHYSICIAN AND SURGEON
CERTIFICATE NO. [REDACTED] EXPIRATION 09/30/98
HUSSAM NIHTAR
8899 UNIVERSITY CTR LANE #380
SAN DIEGO CA 92122

ORIGINAL ISSUANCE DATE
09/08/97

Signature
[Signature]

RECEIPT NO.
12804118

CERTIFICATE NO.
[REDACTED]

EXPIRATION
09/30/98

RECEIPT NO.
21801128

This is your RECEIPT. Please save for your record.

1. Report any loss immediately in writing to the Board.
2. Notify the Board of any name or address change in writing.
3. Please sign and carry the Pocket certificate with you.
4. Please include your certificate on any correspondence to this office.

CURRICULUM VITAE

Name: Philip David Kanof M.D. Ph.D.
Home Address: REDACTED
Office Address: Psychiatry Service (116A)
Tucson VA Medical Center
Tucson, Arizona 85723
Date of Birth: November 29, 1951
Place of Birth: Brooklyn, New York
Phone: REDACTED (home)
(520)-792-1450, ext. 6902 (office)
E-mail Address: kanof@tucson.va.gov

Education:

1968 - 1972: Harvard College, Cambridge, Massachusetts.
A.B. in physics, summa cum laude.
1972 - 1978: Yale University School of Medicine, New Haven,
Connecticut. M.D.
1972 - 1978: Yale University Graduate School of Arts and Sciences,
New Haven, Connecticut. Ph.D. in pharmacology.

Research and Professional Experience:

3/96 - present: Research Associate Professor of Pharmacology,
University of Arizona College of Medicine,
Tucson, Arizona.
2/95 - present: Medical Director, Substance Abuse Treatment Program,
Tucson VA Medical Center, Tucson, Arizona.
7/94 - present: Director, Psychopharmacology Research Program,
Tucson VA Medical Center, Tucson, Arizona.
2/92 - present: Associate Professor of Psychiatry,
University of Arizona College of Medicine.
11/91 - 1/95: Chief, Psychiatry Service, Tucson VA Medical Center.

- 3/91 - 11/91: Medical Director, Psychiatric Day Hospital Program,
Bronx VA Medical Center, Bronx, New York.
- 7/90 - 2/91: Director, Dual Diagnosis Treatment Program,
Bronx VA Medical Center
- 7/89 - 6/90: Unit Chief, Acute Psychiatric Treatment Unit,
Bronx VA Medical Center
- 7/87 - 6/89: Director of Residency Training and Education,
Department of Psychiatry, Mt. Sinai Medical Center,
New York, New York.
- 1/83 - 11/91: Assistant Professor of Psychiatry, Mt. Sinai School of Medicine,
New York, New York.
- 7/82 - 6/87: Medical Director, Drug Dependency Treatment Program,
Bronx VA Medical Center.
- 1980 - 1982: Resident in Psychiatry, Mt. Sinai Medical Center, New York, New
York.
- 7/79 - 12/79: Resident in Psychiatry, New York State Psychiatric Institute,
New York, New York
- 1978 - 1979: Intern in Medicine, Montefiore Hospital,
Bronx, New York.

Honors, Awards, and Board Certification:

Phi Beta Kappa, 1972.

Sigma Xi, 1972.

Henry L. Moses Research Prize, 1978.

Diplomate, American Board of Psychiatry and Neurology, 1984.

Added Qualifications in Geriatric Psychiatry, 1994.

Listed in Best Doctors in America—Pacific Region, 1996. (Category: Psychiatry,
Psychopharmacology)

Dean's Teaching Scholar—University of Arizona College of Medicine, 1996-7.

Publications:

1. Hegstrand, L.R., Kanof, P.D. and Greengard, P.: Histamine-sensitive adenylyate cyclase in mammalian brain. Nature 260: 163-165, 1976.

2. Kanof, P.D., Hegstrand, L.R. and Greengard, P.: Biochemical characterization of histamine-sensitive adenylate cyclase in mammalian brain. Arch. Biochem. Biophys. 182: 321-334, 1977.
3. Kanof, P.D., Ueda, T., Uno, I. and Greengard, P.: Cyclic nucleotides and phosphorylated proteins in neuronal function. Society of Neurosciences Symposia 2: 399-434, 1977.
4. Kanof, P.D. and Greengard, P.: Brain histamine receptors as targets for antidepressant drugs. Nature 272: 329-333, 1978.
5. Walter, U., Kanof, P.D., Schulman, H. and Greengard, P.: Adenosine 3':5'-monophosphate receptor proteins in mammalian brain. J. Biol. Chem. 253: 6275-6280, 1978.
6. Kanof, P.D. and Greengard, P.: Pharmacological properties of histamine-sensitive adenylate cyclase from mammalian brain. J. Pharmacol. Exp. Ther. 209: 87-96, 1979.
7. Kanof, P.D. and Greengard, P.: Pharmacological properties of histamine-sensitive adenylate cyclase from guinea pig cardiac ventricular muscle. Mol. Pharmacol. 15: 455-461, 1979.
8. Johns, C.A., Haroutunian, V., Greenwald, B.S., Mohs, R.C., Davis, B.M., Kanof, P., Horvath, T.B. and Davis, K.L.: Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Development Research 5: 77-96, 1985.
9. Kanof, P.D., Greenwald, B.S., Mohs, R.C. and Davis, K.L.: Red blood cell choline. II. Kinetics in Alzheimer's disease. Biol. Psychiatry 20: 375-383, 1985.
10. Haroutunian, V., Kanof, P.D. and Davis, K.L.: Pharmacological alleviations of cholinergic lesion induced memory deficits in rats. Life Sci. 37: 945-952, 1985.
11. Kanof, P.D.: Drugs used in psychiatric disorders. In: Manual of Drug Therapy. (Scheinberg, D.A. and Scheinberg, L., eds.), Raven Press, New York, pp. 210-227, 1985.
12. Haroutunian, V.H., Kanof, P.D. and Davis, K.L.: Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res. 386: 397-399, 1986.

13. Kanof, P.D., Johns, C.A., Davidson, M., Siever, L.J., Coccaro, E.F. and Davis, K.L.: Prostaglandin receptor sensitivity in psychiatric disorders. Arch. Gen. Psychiatry 43: 987-993, 1986.
14. Haroutunian, V., Kanof, P.D., Tsuboyama, G.K., Campbell, G.A. and Davis, K.L.: Animal models of Alzheimer's disease: behavior, pharmacology, transplants. Canadian J. Neurological Sci. 13: 385-393, 1986.
15. Handelsman, L., Cochrane, K.J., Aronson, M.J., Ness, R., Rubinstein, K.J. and Kanof, P.D.: Two new rating scales for opioid withdrawal. Am. J. Drug Alcohol Abuse 13: 293-308, 1987.
16. Kanof, P.D., Coccaro, E.F., Johns, C.A., Siever, L.J. and Davis, K.L.: Platelet ³H-imipramine binding in psychiatric disorders. Biol. Psychiatry 22: 278-286, 1987.
17. Kanof, P.D., Davidson, M., Johns, C.A., Mohs, R.C. and Davis, K.L.: Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. Am. J. Psychiatry 144: 1556-1560, 1987.
18. Kanof, P.D., Johns, C.A., Davidson, M., Siever, L.J., Coccaro, E.F. and Davis, K.L.: Platelet alpha₂-adrenergic receptor function in psychiatric disorders. Psychiatry Res. 23: 11-22, 1988.
19. Haroutunian, V., Kanof, P.D. and Davis, K.L.: Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Res. 487: 200-203, 1989.
20. Santucci, A.C., Haroutunian, V., Tsuboyama, G.K., Kanof, P.D. and Davis, K.L.: Therapeutics of Alzheimer's disease for clinical and preclinical issues. Prog. Clin. Biol. Res. 317: 1111-1130, 1989.
21. Kanof, P.D., Coccaro, E.F., Johns, C.A., Davidson, M., Siever, L.J. and Davis, K.L.: Cyclic AMP linked receptors on polymorphonuclear leukocytes in psychiatric disorders. Biol. Psychiatry 25: 413-420, 1989.
22. Haroutunian, V., Kanof, P.D., Tsuboyama, G. and Davis, K.L.: Restoration of cholinomimetic activity by clonidine in cholinergic/noradrenergic lesioned rats. Brain Res. 507: 261-266, 1990.
23. Haroutunian, V.H., Kanof, P.D. and Davis, K.L.: Interactions of forebrain cholinergic and somatostatinergic systems in the rat. Brain Res. 496: 98-104, 1989.

24. Santucci, A.C., Kanof, P.D. and Haroutunian, V.H.: Infusion of NMDA into the nucleus basalis of Meynert, frontal or lateral cortex of rats: Effects on memory and cholinergic brain neurochemistry. Pharmacology Biochemistry and Behavior 33: 485-488, 1989.
25. Santucci, A.C., Kanof, P.D. and Haroutunian, V.H.: Effects of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats. Psychopharmacology 99: 70-74, 1989.
26. Haroutunian, V.H., Mantin, R. and Kanof, P.D.: Frontal cortex as the site of action of physostigmine in nucleus basalis of Meynert-lesioned rats. Physiology and Behavior 47: 203-206, 1990.
27. Haroutunian, V., Tsuboyama, G.K., Kanof, P.D. and Davis, K.L.: Pharmacological consequences of cholinergic plus noradrenergic lesions. In: Current Research in Alzheimer Therapy (Giacobini, E. and Becker, R., eds.) Taylor and Francis, New York. pp. 63-71, 1989.
28. Santucci, A.C., Kanof, P.D. and Haroutunian, V.H.: Fetal transplant-induced restoration of spatial memory in rats with lesions of the nucleus basalis of Meynert. J. Neural Transplantation 2: 65-74, 1991.
29. Santucci, A.C., Kanof, P.D. and Haroutunian, V.H.: Serotonergic modulation of cholinergic systems involved in learning and memory in rats. Dementia 1: 151-155, 1991.
30. Kanof, P.D., Mohs, R.C., Gross, J., Davidson, M., Bierer, L. and Davis, K.L.: Platelet phospholipid synthesis in Alzheimer's disease. Neurobiol. Aging 12: 65-69, 1991.
31. Kanof, P.D.: Neurotransmitter receptor function. In: Brain, Behavior, and Psychiatry (Davis, K.L., Klar, H. And Coyle, J.T., eds.) W.B. Saunders Co., 1990.
32. Kanof, P.D.: Pathophysiology of pain. In: Brain, Behavior, and Psychiatry (Davis, K.L., Klar, H. and Coyle, J.T., eds.) W.B. Saunders Co., 1990.
33. Handelsman, L., Aronson, M.J., Ness, R., Cochrane, K.J. and Kanof, P.D.: The dysphoria of heroin addiction. Am. J. Drug Alcohol Abuse 18: 275-287, 1992.
34. Kahn, R.S., Davidson, M., Kanof, P., McQueeney, R., Singh, R.R. and Davis, K.L.: Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: A study of prostaglandin-dopamine interactions. Psychopharmacology 103: 95-98, 1991.

35. Kanof, P.D., Aronson, M.J., Ness, R., Cochrane, K.J., Horvath, T.B. and Handelsman, L.: Levels of opioid physical dependence in heroin addicts. Drug Alcohol Dependence 27: 253-262, 1991.
36. Kanof, P.D., Handelsman, L., Aronson, M.J., Ness, R., Cochrane, K.J., and Rubinstein, K.: Clinical characteristics of naloxone-precipitated withdrawal in human opioid dependent subjects. J. Pharmacol Exp. Ther. 260: 355-363, 1992.
37. Kanof, P.D.: Lysophosphatidylethanolamine formation in rat cortical synaptosomes. Neurochem. Res. (in review)
38. Kanof, P.D., Aronson, M.J. and Ness, R.: Organic mood syndrome associated with detoxification from methadone maintenance. Am. J. Psychiatry 150: 423-428, 1993.
39. Santucci, A.C., Gluck, R., Kanof, P.D., and Haroutunian, V.: Induction of memory and cortical cholinergic neurochemical recovery with combined fetal transplantation and GM1 treatment in rats with lesions of the NBM. Dementia 4: 273-281, 1993.
40. Ness, R., Handelsman, L., Aronson, M.J., Hershkowitz, A., Goldstein, A. and Kanof, P.D.: The acute effects of a rapid medical detoxification upon dysphoria and other psychopathology experienced by heroin abusers. J. Nerv. Ment. Dis. 182: 353-359, 1994.
41. Santucci, A.C., Kanof, P.D. and Haroutunian, V.: Cholinergic marker deficits induced by lesions of the NBM are attenuated by nerve growth factor in young, but not in aged F344 rats. Brain Research 609: 327-332 (1993)
42. Santucci, A.C., Kanof, P.D. and Haroutunian, V.: Transient enhancement of cholinergic neurochemical markers induced by NGF in aged F344 rats. Dementia 6: 179-184 (1995).
43. Haroutunian, V., Davidson, M., Kanof, P.D., Perl, D.P., Powchik, P., Losonczy, M., McCrystal, J., Purohit, D.P., Bierer, L.M. and Davis, K.L.: Cortical cholinergic markers in schizophrenia. Schizophrenia Res. 12: 137-144 (1994)
44. Bierer, L.M., Haroutunian, V., Gabriel, S., Knott, P.J., Carlin, L.S., Purohit, D.P., Perl, D.P., Schmeidler, J., Kanof, P.D. and Davis, K.L.: Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficit. J. Neurochem. 64: 749-760, 1995.

45. Giesser, B., Kanof, P.D., Elkin, R. and Aisen, M.: Neurology: Specialty Board Review. Fourth Edition. Appleton and Lange, Stamford, Connecticut, 1996.
46. Bell, I.R., Walsh, M.E., Goss, A., Gersmeyer, J., Schwartz, G.E. and Kanof, P.D.: Cognitive dysfunction and exposures in geriatric veterans. J. Chronic Fatigue (in press)
47. Kanof, P.D.: Medicinal use of marijuana. N. Engl. J. Medicine (in press)
48. Tracy, K., Adler, L.A., Rotrosen, J., Edson, R., Lavori, P. and the Veterans Affairs Cooperative Study #394 Study Group: Interrater reliability issues in multicenter trials. Part 1: Theoretical concepts and operational procedures in VA Cooperative Study #394. Psychopharm. Bulletin 33: 53-57, 1997.
49. Edson, R., Lavori, P., Tracy, K., Adler, L.A., Rotrosen, J. and the Veterans Affairs Cooperative Study #394 Study Group: Interrater reliability issues in multicenter trials. Part 2: Statistical procedures used in VA Cooperative Study #394. Psychopharm. Bulletin 33: 59-67, 1997.
50. Caliguiri, M.P., Lohr, J.B., Rotrosen, J., Adler, L., Lavori, P., Edson, R., Tracy, K. and the Veterans Affairs Cooperative Study #394 Study Group: Reliability of an instrumental assessment of tardive dyskinesia: Results from VA Cooperative Study #394. Psychopharmacology (in press)

READ
INSTRUCTIONS

ON REVERSE
SIDE

CUT OFF THIS STRIP

The Unibersity of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED

KANOF PHILIP D

FOR PRACTICE IN NEW YORK STATE AS A (N)

10/31/97

REGISTRATION PERIOD ENDS

SIGNATURE OF REGISTRANT

PHYSICIAN

LICENSE/CERTIFICATE NO.

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

CUT OFF
THIS STRIP

READ
INSTRUCTIONS

ON REVERSE
SIDE

CUT OFF
THIS STRIP

CUT OFF THIS STRIP

READ
INSTRUCTIONS

ON REVERSE
SIDE

The University of the State of New York	
THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED	
THE STATE EDUCATION DEPARTMENT	
HAS REGISTERED [REDACTED]	
KANOF PHILIP D [REDACTED]	
FOR PRACTICE IN NEW YORK STATE AS A (N)	
PHYSICIAN	
10/31/99 REGISTRATION PERIOD ENDS	[REDACTED] LICENSE/CERTIFICATE NO.
<i>Philip Kanof</i> SIGNATURE OF REGISTRANT	COMMISSIONER OF EDUCATION
REGISTRATION CERTIFICATE — NOT A LICENSE	

CUT OFF
THIS STRIP

READ
INSTRUCTIONS

ON REVERSE
SIDE

CUT OFF
THIS STRIP

41580295210

5-041945

CURRICULUM VITAE

MARY ANN KNESEVICH, M.D.

St. Paul Medical Center at
Southwestern Medical Center
Professional Building I, STE 924
5959 Harry Hines BLVD
Dallas, TX 75235
214.879.6263
FAX 214.879.6854

CURRICULUM VITAE

MARY ANN KNESEVICH, M.D.
St. Paul Medical Center at
Southwestern Medical Center
Professional Building I, STE 924
5959 Harry Hines BLVD
Dallas, TX 75235
214.879.6263
FAX 214.879.6854

Citizenship:

United States

SSN:

REDACTED

MARTIAL STATUS:

Single

EDUCATION:

Indiana University, 1972-1975, B.A. with high honors, (Economics)

University of Chicago, 1975-1976, (Economics)

Indiana University School of Medicine, 1976-1981, M.D.

RESIDENCIES:

Assistant Resident in Psychiatry, Barnes Hospital and allied hospitals, July 1981 - June 1986.

Chief Resident in Psychiatry, Barnes Hospital and Washington University School of Medicine, July 1985 - June 1986.

UNIVERSITY APPOINTMENTS:

Assistant in Psychiatry, Washington University School of Medicine, St. Louis, Missouri, July 1981 - June 1986.

UNIVERSITY APPOINTMENTS; CONTINUED:

Instructor in Psychiatry, Washington University School of Medicine, St. Louis, Missouri, July 1986 - February 1990.

Instructor in Program in Physical Therapy, Washington University School of Medicine, St. Louis, Missouri, January 1988 - February 1990.

Clinical Assistant Professor, University of Texas Southwestern Medical Center, Dallas, Texas, February 1992 -.

HOSPITAL AND CLINICAL APPOINTMENTS:

Visiting Registrar, Maudsley Hospital, London, England, May - June 1985.

Assistant Psychiatrist, Barnes Hospital, St. Louis, Missouri, July 1985 - February 1990.

Assistant in Psychiatry, Jewish Hospital of St. Louis, St. Louis, Missouri, July 1985 - February 1990.

Consultant Psychiatrist, Malcolm Bliss Mental Health Center, St. Louis, Missouri, July 1986 - February 1990.

Director of Psychiatric Consultation Service, Jewish Hospital of St. Louis, St. Louis, Missouri, July 1986 - February 1990.

Medical Director, Charter Counseling Center, Charter Hospital of Grapevine, Grapevine, Texas March 1990 - April 1991.

Psychiatrist, Charter Hospital of Grapevine, Grapevine, Texas, 1990 -.

Consultant Psychiatrist, Terrell State Hospital, Terrell, Texas, April 1991 -.

Psychiatrist, St. Paul Medical Center at Southwestern Medical Center, Dallas, Texas, May 1991 -.

Courtesy Privileges, Baylor Medical Center at Grapevine, Grapevine, Texas, May 1991-.

Consultant Psychiatrist, American Transitional Care Hospital of Dallas - Ft. Worth, Ft. Worth, TX, August 1991 -.

CERTIFICATION:

Diplomate National Board of Medical Examiners, July 1982.

American Board of Psychiatry and Neurology (Psychiatry), March 1988.

PROFESSIONAL SOCIETIES:

- Member, American Medical Association, 1983 -.
- Member, American Psychiatric Association, 1989 -.
- Member, Eastern Missouri Psychiatric Association, 1989 -
- Member, Texas Medical Association, 1991 - (pending).

LICENSURE:

- Missouri, 1985.
- Texas, 1990.

COMMITTEES:

- Utilization Review, Jewish Hospital of St. Louis, Missouri, January 1987 - February 1990.
- Utilization Management, Washington University Medical Alliance Corporation, Medical Center Health Plan, May 1989 - February 1990.
- Committee on Continuing Medical Education, St. Paul Medical Center at Southwestern Medical Center, Dallas, Texas, October 1991 -.

RESEARCH ACTIVITIES:

- NIMH-CRB Collaborative Program on the Psychobiology of Depression, Co-Investigator, July 1986.
- Cognitive Therapy with Controls in Clinical Depression, Co-Investigator, July 1986.
- Principal Investigator, Clomipramine Study 62 and 67, Department of Psychiatry at Jewish Hospital, 1988 - February 1990.
- Principal investigator, Clozapine Study 71, Department of Psychiatry at Jewish Hospital, 1988 - February 1990.
- Principal Investigator, Amperozide B201, Terrell State Hospital, Terrell, Texas, March 1991 - October 1991.
- Principal Investigatory, ICI #204,636, Terrell State Hospital, Terrell, Texas, October 1991 - September 1992.

RESEARCH ACTIVITIES; CONTINUED:

Principal Investigator, Abecamil 357, St. Paul Medical Center, Dallas, Texas, February 1992 - February 1993.

Principal Investigator, Risperidone 207 and 208, Terrell State Hospital, Terrell, Texas, April 1992 -.

Principal Investigator, Pfizer CP-88,059-1, Terrell State Hospital, Terrell, Texas, September 1992 -.

Cognex, TIND, 1992 - present.

Principal Investigator, Paroxetine, St. Paul Medical Center, Dallas, Texas, January 1993-.

Principal Investigator, Seroquel Relapse Prevention Study (5077IL/0015), St. Paul Hospital, Dallas, Texas, August 1993 -.

Principal Investigator, Seroquel 5077IL/0013:0007, Terrell State Hospital, Terrell, Texas, September 1993 -.

Principal Investigator, Zotepine BPI 1201, Terrell State Hospital, Terrell, TX, September 1993 -.

Principal Investigator, Zotepine BPI 1201X, Terrell State Hospital, Terrell, TX, September 1993 -.

EDITORIAL ACTIVITIES:

Reviewer, Archives of General Psychiatry, 1988.

MANUSCRIPTS IN PREPARATION:

Knesevich, M.A. and Knesevich, J.W.: Unpredictable hypertensive responses with the use of monoamine oxidase inhibitors.

Pardo, P. et al: A twin study of attention in schizophrenia.

Knesevich, M.A.: Compliance with medication in a therapeutic trial.

Murphy, George, et al: Prediction of relative response to medication/psychotherapy in depressed patients.

MANUSCRIPTS IN SUBMISSION:

Murphy, George, et al: Cognitive behavioral therapy with controls in depression. Achieves of General Psychiatry, in submission.

Wetzel, R.D., et al: Prescribing therapy for depression: The role of learned resourcefulness. Psychological Reports.

PUBLICATIONS:

Rice, J.P., Endicott, J., Knesevich, M.A., and Rochberg, N. The estimation of diagnostic sensitivity using stability data. An application to major depressive disorder, Journal of Psychiatry Research, 21:337-345, 1987.

Aleem, A. and Knesevich, M.A. Schizophrenia - like psychosis associated with vein of galen malformation: a Case Report. Canadian Journal of Psychiatry, 32:226-227, 1987. Knesevich, M.A, Scheftner, W. and Rice, J.P. Medical illness and depression. 1988 New Research Program and Abstracts. 141st Annual Meeting of American Psychiatric Association, p. 48, 1988.

Aschauer, H.N., Aschauer-Trucker, G., Isenberg, K.I., Todd, R.D., Knesevich, M.A., Garver, D.L., Reich, T. and Cloninger, C.R.: No evidence for linkage between chromosome 5 markers and schizophrenia. Human Heredity, 40: 109-115, 1990.

Moldin, Steven, et al: Association between major depressive depressive disorder and physical illness. In press, Psychological Medicine.

Wetzel, R.D., Knesevich, M.A., Brown, S.L., Wolff, H.A., Horn, C.J. Jr., Cloninger, C.R., Correlates of Tridimensional Personality Questionnaire Scales with selected MMPI Scales. Psychological Reports 1992; 71: 1027-1028.

PRESENTATIONS:

New Treatment Options for Schizophrenia. Baylor College of Medicine, Houston, Texas, June 1, 1989.

Treatment-Resistant Depression. Texas Tech University Health Center, Lubbock, Texas, July 14, 1989.

Clozapine-A New Treatment for Refractory Schizophrenic Patients. Menniger Clinic, Topeka, Kansas, September 28, 1990.

Clozapine-A New Treatment for Refractory Schizophrenic Patients. Grand Rounds (Psychiatry). University of Kansas School of Medicine, Kansas City, Kansas, September 29, 1989.

PRESENTATIONS; CONTINUED:

Prescribing Therapy for Depression: The Role of Learned Resourcefulness. Association for Advancement of Behavior Therapy, Washington D.C., November 4, 1989. (Poster)

Teleconference sponsored by Sandoz Pharmaceuticals. Clinical Use of Clozaril, January 15 and January 23, 1990.

Treatment of Depression. Rosewood Hospital, Houston, Texas, January 18, 1990.

New Insights into the Treatment of Schizophrenia, St. Joseph's Hospital, Houston, Texas, January 19, 1990.

Recognition and Treatment of Depression. Regional Hospital, St. Louis, Missouri, January 22, 1990.

New care for the Schizophrenic Patient. Tampa General Hospital, Tampa, Florida, February 9, 1990.

Clozaril - The Atypical Antipsychotic. MaComb County Mental Health Center, Mount Clemens, Michigan, February 26, 1990.

Treatment of Refractory Schizophrenia. Arizona Sate Hospital, Phoenix, Arizona, March 23, 1990.

Treatment of Refractory Schizophrenia. East Valley Camelback Hospital, Phoenix, Arizona, March 24, 1990.

Treatment of Resistent Schizophrenia. Western Tennessee Psychiatric Society, Memphis, Tennessee, March 29, 1990.

New Treatment of Resistent Schizophrenia. West Virginia Alliance for the Mentally Ill, Fairmont, West Virginia, April 21, 1990.

A Twin Study of Attentional Dysfunction in Schizophrenia. Meeting of Society of Biological Psychiatry, New York, New York, May 1990. (Abstract).

Recognition and Treatment of Obsessive-Compulsive Disorder. DePaul Hospital, St. Louis, Missouri, May 8, 1990.

Clozapine the Atypical Antipsychotic. University of West Virginia Psychiatry Grand Rounds, Morgantown, West Virginia, June 13, 1990.

The Use of Clozapine in the Treatment-Resistant Schizophrenic. Northern Kentucky Psychiatric Association, Louisville, Kentucky, June 21, 1990.

PRESENTATIONS; CONTINUED:

The use of Clozapine in the Management of Resistant Schizophrenic Patients in the State Mental Health System. First Eastern Missouri Region Public Psychiatry Conference, St. Louis, Missouri, June 29, 1990.

Clozapine - The Atypical Antipsychotic. St. Dominick's Hospital - Department of Psychiatry, Jackson, Mississippi, July 10, 1990.

The Use of Clozapine, Mississippi State Hospital, Jackson, Mississippi, July 24, 1990.

Update on Clozapine. Western Neuropsychiatric Institute/University of Utah School of Medicine, Salt Lake City, Utah, July 31, 1990.

Clozapine - Clinical Application. Scott and White Clinic - Department of Psychiatry, Temple, Texas, August 2, 1990.

Clozaril Review. Department of Mental Health - State of Louisiana, Baton Rouge, Louisiana, August 30, 1990.

Clozaril: An Update. National Mental Health Association 7th Annual Scientific Symposium, Houston, Texas, September 14, 1990.

Clozapine - Current Clinical Review. Medical College of Ohio, 8th Annual Conference of Psychopharmacology, Toledo, Ohio, September 26, 1990.

Clozapine: The 2nd Year. "Adverse Effects: Management and Practical Experiences." 42nd Institute on Hospital and Community Psychiatry, Denver, Colorado, October 9, 1990.

Clozapine: A clinical Review. Louisiana State University Psychiatry Grand Rounds, New Orleans, Louisiana, November 29, 1990.

Current Clinical Review of Clozaril. Eastern Tennessee Psychiatric Society, Jackson City, Tennessee, February 20, 1991.

Clozaril: An Update. Eastern Oklahoma Psychiatric Society, Tulsa, Oklahoma, March 26, 1991.

Managing Adverse Effects of Typical and Atypical Antipsychotics: A Clinical Case Conference. 144th Annual American Psychiatric Association, New Orleans, Louisiana, May 14, 1991.

Clinical Use of Clozaril. Great Rivers Community Mental Health Center, St. Louis, Missouri, August 29, 1991.

PRESENTATIONS; CONTINUED:

Geriatric Depression. Balboa Naval Hospital, San Diego, California, September 13, 1991.

What's New in Pharmacologic Treatment of Schizophrenia. 20th Psychiatric Forum, St. Paul Medical Center at Southwestern Medical Center, September 19, 1991.

What's New in Anti-Psychotic Medication. Dallas Veteran's Administration Hospital, Dallas, Texas, October 17, 1991.


Stress and the Corporate Woman. Proctor and Gamble, Dallas, Texas, October 25, 1991.


New Developments in anti-Psychotic Medications. Psychiatry Ground Rounds, University of Kansas Medical Center, Kansas City, Kansas, November 8, 1991.


Novel Antipsychotics: Past, Present, and Future. Psychiatry Grand Rounds, Memphis Veteran's Administration Hospital, Memphis, Tennessee, November 14, 1991.

Novel Antipsychotics: Past, Present, and Future. Psychiatry Ground Rounds, University of Arkansas, Little Rock, Arkansas, November 15, 1991.

New Pharmacologic Treatments for Anxiety. Psychiatry Grand Rounds, University of Oklahoma, Oklahoma City, Oklahoma, October 8, 1992.







CURRICULUM VITAE
February 1996

NAME:

Alex J. Kopelowicz, M.D.
SSN# REDACTED
DEA Registrations# REDACTED
California Medical License# REDACTED

ADDRESS:

REDACTED

EDUCATION:

B.A., Psychology, Haverford College, 1984
M.D., Medicine, Rutgers Medical School, 1988
Psychiatric Resident, UCLA/San Fernando Valley Residency
Training Program, 1988-1992
Research Fellow in Social & Community Psychiatry, UCLA School
of Medicine, July 1992 - Present
NIMH Research Fellow, February 1994 - Present
Diplomate, American Board of Psychiatry and Neurology, 1994

PROFESSIONAL ACTIVITIES:

UCLA-San Fernando Valley Residency Program
Chief Resident, In-Patient Psychiatry, 1991-92
Member, Resident Selection Committee, 1990-91
Member, Bio-ethics Committee, 1990-91
Member, Planning Committee, 1990-91
Member, Suicide and Violence Committee, 1989-1991
Research Associate, Dept of Psychiatry, 1989-91
Resident Representative, National Alliance for the Mentally
Ill, 1991
Chairman, Resident Committee for Development of On-Call
Guidelines (ABC's of Call Manual), 1991
Staff Psychiatrist, Manos de Esperanza Community Mental Health
Center, 1991-92
Resident Representative, Hospital & Community Psychiatry
Conventions, 1991-92
UCLA/San Fernando Valley Psychiatric Residency Program Social
& Community Psychiatry Track 1991-92

UCLA-L.A. County Department of Mental Health/Fellowship in
Social & Community Psychiatry
Staff Psychiatrist, San Fernando Mental Health Service, July
1992 - January 1993
Medical Director, San Fernando Mental Health Service, January
1993 - Present
Medical Director, Partial Hospitalization Program, Valley
Hospital Medical Center, September 1992 - April 1994
Member, Mission Statement Committee, LA County Department of
Mental Health, June 1993 - January 1994

Member, System of Care Committee, LA County Department of Mental Health, January 1994 - July 1994
Member, Training Committee, Los Angeles Department of Mental Health, June 1994 - Present

COMMUNITY ACTIVITIES:

Member, Board of Directors, Human Interaction Research Institute, November 1994 - Present
Vice-President, Latino Behavior Health Institute, May 1995 - Present
Member, Advisory Board, Step Up Partners Program, June 1994 - Present

PUBLICATIONS:

Kopelowicz A, Bidder TG: Dementia Praecox: Inescapable fate or psychiatric oversight? Hospital and Community Psychiatry 43:940-941, 1992

Liberman RP, Kopelowicz A, Young A: Biobehavioral therapy in the rehabilitation of psychotic patients. Italian Journal of Psychiatry & Behavioral Sciences 3:129-138, 1993.

Liberman RP, Kopelowicz A, Young A: Biobehavioral treatment and rehabilitation of schizophrenia. Behavior Therapy 25:89-107, 1994.

Kopelowicz A, Liberman RP: Self-management approaches for seriously mentally ill persons. Directions in Psychiatry 14:17: 1-8, Aug 24, 1994.

Kopelowicz A, Liberman RP: Accelerated recovery in schizophrenia. In: Carpinello B, Rudas N (Eds): La Riabilitazione in Italia: Lo Stato del III Congresso Nazionale della Societa Italiana di Riabilitazione sicosociale. Cagliari, Italy: Nuova Editoriale, Sarda, 1994.

Kopelowicz A: Friendship, intimacy and sexuality. The Journal of the California Alliance for the Mentally Ill 5:1;7-8, 1994.

Liberman RP, Kopelowicz A: Recovery from schizophrenia: Is the time right? The Journal of the California Alliance for the Mentally Ill 5:3;67-69, 1994.

Liberman RP, Kopelowicz A: Basic elements in biobehavioral treatment and rehabilitation of schizophrenia. International Clinical Psychopharmacology 9(suppl 5):51-58, 1994.

Kopelowicz A, Cooper L, Liberman RP: Social skills training and psychiatric rehabilitation. World Association of Psychiatric Rehabilitation Bulletin 7:6-7, 1995.

Kopelowicz A, Liberman RP: The biobehavioral treatment and rehabilitation of schizophrenia. Harvard Review of Psychiatry

3:55-64, 1995.

Axer H, Johannsen C, Kopelowicz A: Implementation of psychiatric rehabilitation in a forensic psychiatric facility. *Psychosocial Rehabilitation Journal* 19:69-72, 1995.

Hernandez M, Kopelowicz A, Ocampo J: Self-help in the Mexican-American community. *The Journal of the California Alliance for the Mentally Ill* 6:3;62-63, 1995.

Kopelowicz A, Corrigan P, Wallace C, Liberman RP: Biopsychosocial rehabilitation. In: Tasman A, Kay J, Lieberman JA, (Eds).: *Psychiatry*. Philadelphia: W.B. Saunders Company, in press.

Kopelowicz A, Corrigan P, Schade M, Liberman RP: Social skills training. In: Mueser KT, Tarrier N, (Eds).: *Psychosocial functioning in schizophrenia*, Allyn & Bacon: Boston, MA, in press.

Kopelowicz A: Schizophrenia. In: *Case Studies in Abnormal Psychology*, Gorenstein EE, (Ed.). HarperCollins College Publishers: New York, in press.

Kopelowicz A: El tratamiento biopsicosocial por los pacientes con esquizofrenia. *Area de rehabilitación psicosocial integral*, 1:41-49, 1995.

PROFESSIONAL PRESENTATIONS:

Topics in Neuropsychiatry: Neuroanatomy of Schizophrenia. Presented to Department of Psychiatry, UCLA-San Fernando Valley Program, March 5, August 8 and October 11, 1991.

The Use of the Computer in Psychiatric Training. Presented to the Psychiatry Residents of UCLA-San Fernando Valley Program, July 2, 1991.

Evaluation of the Suicidal Patient. Presented to the Psychiatry Residents of UCLA-San Fernando Valley Program, July 15, 1991.

Evaluation of the Violent Patient. Presented to the Psychiatry Residents of UCLA-San Fernando Valley Program, July 22, 1991.

Psychopharmacology of Neuroleptic Medications. Presented to the Psychiatry Residents of UCLA-San Fernando Valley Program, July 29, 1991.

Topics in Neuropsychiatry: Neurochemistry of Behavior. Presented to Department of Psychiatry, UCLA-San Fernando Valley Program, January 2, 1991.

Schizophrenia and Anti-Psychotic Medications. Presented to AMI Group, San Fernando, California, October 13, 1992. (in Spanish)

Positive and Negative Symptoms of Schizophrenia. Presented to AMI Group, Van Nuys, California, October 21, 1992.

Schizophrenia and Anti-Psychotic Medications. Presented to AMI Group, La Puente, California, November 11, 1992. (in Spanish)

Biopsychosocial Rehabilitation. Presented to Doctoral Candidates at UCLA School of Public Health, February 18, 1993.

Partial Hospitalization Programs and the Allied Health Professionals. Presented to the Staff at Valley Hospital Medical Center. April 7, 1993.

Social Skills Training Modules. Presented to the Staff at Topanga West Board & Care Home. April 14, 1993.

Managing Innovation and Change - A Strategic Approach for Mental Health Systems (Presented by the Center for Improving Mental Health Systems). Speaker and Panelist. Department of Mental Health (L.A. County) Systemwide Meeting. May 19, 1993.

Clozaril and Schizophrenia. Presented to AMI of Van Nuys, California, October 12, 1993.

Biobehavioral Interventions in Schizophrenia. Presented at the Congreso Nacional de Psiquiatria Mexicana, Zacatecas, Mexico October 31, 1993. (in Spanish)

Behavioral Family Management. Presented to AMI of Metropolitan State Hospital, Norwalk, California, November 13, 1993.

Social Skills Training in Psychiatric Practice. Invited workshop at the Association for the Advancement of Behavioral Therapy annual convention, Atlanta, Georgia November 18, 1993.

Social Skills Training Modules. Presented to members of the Los Angeles County Department of Mental Health, December 3, 1993.

Biopsychosocial Rehabilitation. Presented to the UCLA School of Public Health. February 10, 1994.

Social Skills Training. Presented to the La Puente AMI, June 15, 1994.

Rehabilitacion Biopsicosocial. Presented in Spanish to La Alianza Para Enfermos Mentales, La Puente Mental Health Center, August 17, 1994.

Biopsychosocial Rehabilitation. Presented to the Van Nuys

AMI, September 21, 1994

History of Community Psychiatry. Presented to the Psychiatric Residents of UCLA-San Fernando Valley Program, September 27, 1994

Biobehavioral Therapy for the Treatment Refractory Schizophrenic. Presented to the Los Angeles County Department of Mental Health System-wide Meeting, October 26, 1994

Psychiatrists and the Prescription of Medication. California Alliance for the Mentally Ill Conference, San Francisco, California, October 28, 1994.

The Practice of Biobehavioral Therapy with Schizophrenics. Institute presented at the Association for the Advancement of Behavioral Therapy Annual Meeting, San Diego, CA, November 10, 1994

Skills Training Modules: Strategies for Dissemination and Utilization of a Rehabilitation Innovation. Presented at AABT Annual Meeting, San Diego, CA, November 12, 1994

Social & Independent Living Skills Modules. Presented at Service Area II Advisory Committee meeting, Canoga Park, CA, December 8, 1994

Social & Independent Living Skills Modules. Presented at Our Lady of Lourdes Home, Tujunga, CA January 6, 1995

Biopsychosocial Rehabilitation. Presented at the San Gabriel Valley Alliance for the Mentally Ill meeting, Pasadena, CA, January 11, 1995

Mental Health Systems of Care. Presented to the Doctoral Candidates, UCLA Department of Psychology, January 20, 1995

Biopsychosocial Rehabilitation. Presented to the Service Area II Residential Care Home Operators, Mission Hills, CA, January 23, 1995

Biopsychosocial Rehabilitation of the Seriously Mentally Ill. Presented to the South Bay Alliance for the Mentally Ill, Torrance, CA, Feb 20, 1995

Recovery from Madness. Presented to UCLA undergraduates, Los Angeles, CA, February 23, 1995

Community Psychiatry and the System of Care. Presented to the staff at the San Fernando Mental Health Center, Mission Hills, CA, March 8, 1995

Biopsychosocial Rehabilitation. Presented to the UCLA School of Public Health, Los Angeles, CA, March 8, 1995

Role of Mental Health Professionals in the Recovery Process. Presented at The Los Angeles Approach: New Developments in Collaboration between Mental Health, Alcohol, and Drug Services, Culver City, CA, March 23, 1995

Social Skills Training with Hispanic Schizophrenics. Presented at the Transcultural Psychiatry Lecture Series, Santa Monica Mental Health Center, Santa Monica, CA, April 12, 1995

Social Skills Training Modules. Presented to the Post-doctoral Fellows, UCLA Department of Psychology, UCLA, April 26, 1995

Treatment of Serious Mental Illness. Presented to the San Fernando Valley Alliance for the Mentally Ill, Van Nuys, CA, May 17, 1995

Future Trends in Psychosocial Rehabilitation. Presented at the Annual Meeting of the National Mental Health Association, Washington, DC, May 19, 1995

Metodo Biopsicosocial Para el Tratamiento de Enfermos con Esquizofrenia. Presented to the Pacific Clinics El Camino AMI Group, Santa Fe Springs, CA July 5, 1995

Introduction to DSM-IV. Presented to the PGY-1 Residents of the UCLA/San Fernando Valley Psychiatry Residency Training Program, Sepulveda VA Medical Center, July 12, 1995

Clinical Implications of the Changes in DSM-IV: An Overview and an Introduction. Presented as part of a Department of Mental Health Conference on DSM-IV, Olive View Medical Center, July 24, 1995

Biobehavioral Treatment of Latinos with Serious Mental Illness. Presented at the World Federation of Mental Health Conference, Dublin, Ireland, August 16, 1995

Biobehavioral Treatment of Latinos with Serious Mental Illness. Presented at the Latino Behavioral Health Institute, Los Angeles, CA, Sept 14, 1995

Mental Health System of Care in Los Angeles County. Presented at the Los Angeles AMI Meeting, Los Angeles, CA, September 18, 1995

Esquizofrenia. Presented as part of the Series Educacional Sobre Enfermedades Mentales, Whittier, CA, October 4, 1995

Social Skills Training: The Mediating Role of Culture. Presented at the Third Annual Conference on Psychopathology, Psychopharmacology, Substance Abuse and Culture, Los Angeles, CA, October 6, 1995

The Homeless Mentally Ill. Presented at the Sherman Oaks

Chamber of Commerce, Sherman Oaks, CA, October 11, 1995

Ethnic Differences in Psychopharmacology. Presented at the UCLA Meet the Experts Colloquium, Westwood, CA, October 11, 1995

Tratamiento de la Esquizofrenia. Presented as part of the Series Educacional Sobre Enfermedades Mentales, Whittier, CA, October 11, 1995

Double Stigmatization: Treatment of Latinos with Serious Mental Illness. Presented at the California Alliance for the Mentally Ill conference, Los Angeles, CA, October 27, 1995

Dissemination and Utilization of Innovative Psychosocial Strategies in Public Mental Health Systems. Presented at the American Public Health Association Annual Conference, San Diego, CA, November 1, 1995

Biobehavioral Treatment of Serious Mental Illness. Presented as Grand Rounds at Detroit Psychiatric Institute, Detroit, MI, November 3, 1995

Social Skills Training Modules. Presented to Alternative Health Care, Inc., Chatsworth, CA, November 8, 1995

Psychopharmacology. Presented to UCLA Undergraduates as part of their Abnormal Psychology course, Los Angeles, CA, November 29, 1995

Understanding and Preventing Relapse. Presented to UCLA/NPI PGY-2 Residents, Los Angeles, CA, December 22, 1995

Recovery from Madness: Introduction to Community Mental Health. Presented to UCLA undergraduates, Mission Hills, CA, January 18, 1996

One Flew Over the Cuckoo's Nest. Guest lecture at American Literature Class, Taft High School, Woodland Hills, CA, January 22, 1996

Ethnopsychopharmacology. Lecture to the PGY-3 Psychiatric Residents at UCLA NPI, January 30, 1996

REVIEWER:

American Journal of Psychiatry 1993-present
American Journal of Psychotherapy 1994
Archives of General Psychiatry 1992-present (co-reviewer with Dr. Robert Liberman)
Behavior Therapy 1994-present
Journal of Behavior Therapy & Experimental Psychiatry 1994-present

Risperidone: Clinical Study Report RIS-USA-113

Journal of Nervous and Mental Disease 1993-present
Psychiatric Services 1995-present
Psychiatry 1993-present
Schizophrenia Bulletin 1992-present

Curriculum Vitae
John Lauriello, M.D.

Address

Telephone

Site: The University of New Mexico
Department of Psychiatry, Research
943 Stanford NE, Med-6 Bldg
Albuquerque, NM 87131-5326

office: (505) 277-2281
fax: (505) 277-1691
pager: (505) 251-7434

Hospital: University of New Mexico Mental Health Center
2600 Marble NE
Albuquerque, NM 87131

(505) 843-2800

Current State Medical License New Mexico REDACTED

Academic Rank

Assistant Professor Department of Psychiatry University of New Mexico -- July 1994-present

Work

Associate Medical Director of the UNM Mental Health Center -- January 1996 -present
Director of the UNM Mental Health Center Continuing Care Clinic -- July 1995-present
Attending Psychiatric Emergency Services of the UNM Mental Health Center -- August 1994-June 1995
Unit Chief Palo Alto Mental Health Clinical Research Center 4C2 -- July 1993-July 1994

Committees

University of New Mexico Department of Psychiatry Research Steering Committee 1994-present
University of New Mexico Department of Psychiatry Residency Training Committee 1996-present

Fellowships

Public Health Service Institutional Research Service Award-University of San Diego Psychopharmacology and Psychobiology -- 1990-1991
Veterans Affairs Fellowship Award in Clinical Psychopharmacology--VAMC -- July 1991-June 1993
Postdoctoral Fellow Dept of Psychiatry and Behavioral Sciences--Stanford University -- July 1992-June 1993

Residency

New York Hospital-Payne Whitney Clinic -- 1986-1990

Medical School

Temple University Medical School Philadelphia, Pennsylvania -- 1982-1986

Colleges

Yale College New Haven, Connecticut -- 1978-1982
Graduated Cum Laude with Honors in History

896

T.P.F. THIS FORM IS NOT TO BE REPRODUCED

Curriculum Vitae
John Lauriello, M.D.

Page 2

Qualifications

National Board of Medical Examiners--Diplomate -- 1986
American Psychiatric Association--Member -- 1987-present
Medical Licenses:
State of New Mexico ~~REDACTED~~ July 1994-present
State of California -- 1990-present
New York State -- 1987-1990
American Board of Psychiatry and Neurology--Certification -- 1992

Associations

American Psychiatric Association -- 1987-present

Grants

1995 National Alliance for Research on Schizophrenia and Depression Young Investigator Award-- "A Double Blind Study of Fluoxetine Treatment for Clozapine Induced Sedation."

Funded Studies

Treatment of Nightmare in Rape Victims with PTSD--4 year NIMH funded study (Dr. Barry Krakow Principal Investigator)--psychiatric consultant on comorbidity diagnosis

Previous Clinical Trials Experience

Abbott Pharmaceuticals, Inc. Study M-098 Double Blind Study of Atypical Antipsychotic Sertindole versus Placebo and Haldol 1993-1994. P.I. Palo Alto VAMC.

Boots Pharmaceuticals, Inc. Studies BPI 1201 and BP 1201X Double Blind and Open Label Studies of the Antipsychotic Zotepine 1994-1996. Sub P.I. University of New Mexico.

Pfizer Inc. Studies Ziprasidone (CP-88,059) Protocols 128-108, 128-108E, 128-114, and 128-116 Double Blind and Open Label Studies of the Antipsychotic Ziprasidone 1994-1996. Sub P. I. University of New Mexico.

Janssen Pharmaceutica Study RIS-USA-72 Safety and Efficacy of Risperidone 8mg QD and 4mg QD Compared to Placebo in the Treatment of Schizophrenia 1995-1996. P.I. University of New Mexico.

Abbott Pharmaceuticals, Inc. Study M95-372 A Double Blind, Randomized, Comparison of the Safety and Efficacy of Sertindole and Risperidone in Treatment Resistant Schizophrenic Patients 1996-present. P.I. University of New Mexico.

Otsuka America Pharmaceutica A Dose Ranging Study of the Efficacy and Tolerability of OPC-14597 in Acutely Relapsing Hospitalized Schizophrenic Patients 1996. P.I. University of New Mexico.

Eli Lilly and Company B1Y MC HCHR 12274 Fluoxetine vs. Placebo in Bulimia Relapse Prevention 1996-present. - Sub-P.I. University of New Mexico.

Presentations

Payne Whitney Grand Rounds-- "The Violent Patient" -- 1986

Payne Whitney Grand Rounds-- "The Management of the Borderline Patient" -- 1988

Curriculum Vitae

John Lauriello, M.D.

Page 3

Presentations (cont'd)

Faculty CME Course "Extrapyramidal Syndromes: An Integrative Approach" American Psychiatric Association Meeting -- 1989

Payne Whitney Grand Rounds Senior Research Award Presentation "A Treatment of Akathisia Scale--A Validity and Reliability Study" -- 1990

Las Vegas State Hospital Grand Rounds--Psychotropic Medications During Pregnancy -- May 1995

Recent Advances in the Diagnosis and Treatment of Depression, Bipolar Disorder and Schizophrenia Conference Santa Fe New Mexico -- June 1995

Research Posters and Abstracts

"Suicidal Behavior in Schizophrenia" Haas G, Lauriello J, Dixon L, et al. New Research Poster American Psychiatric Association Annual Meeting San Francisco -- 1989

"The Schedule of Questions for Individuals with Restless Movements--A Treatment Scale for Akathisia" Lauriello J, Weiden P, and Leon A. Young Investigators Poster American Psychiatric Association Annual Meeting New Orleans -- 1991

"Anticholinergics and Mood" Kenny W, Lauriello J, Gillin JC. Young Investigators Poster American Psychiatric Association Annual Meeting New Orleans -- 1991

"The Effects of Pilocarpine an Orally Active Muscarinic Agonist on Sleep in Depression and Normal Controls" Lauriello J, Kenny W, Sutton, et al. Association of Professional Sleep Societies Toronto -- 1991

"The Relationship of Age to Tissue Volume Deficits in Schizophrenia and Chronic Alcoholism: A Quantitative MRI Study" Lauriello J, Lim KO, Mathalon DH, Rosenbloom MJ, Sullivan EV, Zipursky RB, Pfefferbaum A. American College of Neuropsychopharmacology Puerto Rico -- Dec 1991

"The Relationship of Slow Wave Sleep to Ventricular Volume in Schizophrenia" Benson KI, Lim K, Lauriello J, Zarcone VP, Pfefferbaum A. International Congress on Schizophrenia Research Colorado Springs, CO -- April 1993

CSF Brain Metabolites, CT Brain Volumes, and Psychopathology" Lauriello J, Shear PF, Faull KF, Faustman WO, Pfefferbaum A. International Congress on Schizophrenia Research Colorado Springs, CO -- April 1993

"MRI Predictors of Clozapine Response: A Preliminary Study" Lauriello J, Mathalon D, Sullivan E, Ringo D, Lim K, Pfefferbaum A. American Psychiatric Association Annual Meeting Philadelphia -- 1994

"Effects of Seroquel (ICI204,636) on Platelet Serotonin-2 Binding in Schizophrenia" Faustman WO, Ringo D, Lauriello J, Lim K, Pfefferbaum A, Bardgett M, Csernansky J. International Congress on Schizophrenia Research--VA -- April 1995

"Cortical Gray Matter Volume Deficits in Women with Schizophrenia" Lauriello J, Hoff A, Weineke M, DeMent S, Faustman WO, Sullivan EV, Lim K, Pfefferbaum A. International Congress on Schizophrenia Research--VA -- April 1995

Publications

Lauriello J, Kenny W, Sutton L, Golshan S, Ruiz C, Kelsoe J, Rapoport M, Gillin JC. The cholinergic REM sleep

Curriculum Vitae
John Lauriello, M.D.

Page 4

Publications (cont'd)

- induction test with pilocarpine in depressed and normal controls. *Biol. Psychiatry* 1993 Jan, 33:33-39.
- Gillin JC, Lauriello J, Kelsoe J, Rapaport M, Golshan S, Kenny W, Sutton L. No antidepressant effect of Biperiden compared with placebo in depression: A double-blind 6 week clinical trial. *Psychiatry Research* 1995 58(2):99-105.
- Benson KL, Sullivan EV, Lim KO, Lauriello J, Zarcone VP, Pfefferbaum A. Slow wave sleep and computed tomographic measures of brain morphology in schizophrenia. *Psychiatry Research* 1996 60:125-134.
- Faustman WO, Ringo D, Lauriello J, Lim K, Pfefferbaum A, Bardgett M, Czernansky J. Effects of Seroquel (ICI204,636) on platelet serotonin-2 binding in schizophrenia. Letter to the Editors, accepted by *Journal of Clinical Psychopharmacology*.

Reviews and Chapters

- Lauriello J, Jeste D. Neuroleptic treatment of schizophrenia. *Comprehensive Therapy* 1992 Jan 18(1):30-35.
- Lauriello J, and Keith SJ. Psychosocial treatment of schizophrenia. In *Current Psychiatric Therapy II*, editor Dunner DL, in press.

Awards


- AOA Medical Honor Society—Temple University School of Medicine
- Temple University School of Medicine O. Spurgeon English Award for Excellence in Psychiatry
- Payne Whitney Clinic—New York Hospital Alumni Award Outstanding Resident Prize
- The William T. Lhamon Research Prize for Best Payne Whitney Senior Research Project
- The Best Doctors in America: Central Region 1996-1997



THE UNIVERSITY OF NEW MEXICO • HEALTH SCIENCES CENTER
SCHOOL OF MEDICINE

Human Research Review Committee
Office of Research
BMSB, Room B79
Albuquerque, NM 87131-5116
(505) 272-1129 / (505) 272-9875
FAX (505) 272-0803

January 22, 1998



PSYCHIATRY RESEARCH OFFICE

XC: -Janssen Pharmaceutical
Attn: Albert Gianaroli
-RIS-INT-50 Study File
-HRRC 97-359 file

TO: John Lauriello, M.D.

FROM: Joseph Scaletti, Ph.D., Co-Chair, Human Research Review Committee

SUBJECT: Review of Research Project Involving Human Subjects

HRRC 97-359, "Risperidone vs Olanzapine in the Treatment of Schizophrenia in Elderly Patients."

was reviewed by the Human Research Review Committee on January 6, 1998
and is now APPROVED on January 21, 1998

(Approval of protocol and consent form with the revisions and clarifications requested in the memos of 1/7/98 and 1/15/98, which were generated from Committee review on 1/6/98.)

In the course of this research if any unusual or unexpected hazards to subjects occur notify the committee immediately giving detail and your assessment of the occurrence.

Federal laws require annual reapproval of research projects using human subjects, and more frequently if requested by the HRRC. You will be sent a request for a progress report at the appropriate time.

The committee requests for its files a copy of printed reports arising out of this research project.

Please give the HRRC number and title of the research project when writing to the committee.

All correspondence should be addressed to:

The Human Research Review Committee
c/o Dean's Office, BMSB, Room 177
UNM School of Medicine
Albuquerque, New Mexico 87131

TMF - RIS-INT-50 CY - LAURIELLO (TAB APPROVED)
RCA

REVISED July 10, 1997

CURRICULUM VITA
WILLIAM B. LAWSON, M.D. Ph.D.

Personal

Business Address:

Chief, Psychiatry and Mental Health (116A)
Richard L. Roudebush VA Medical Center
1481 W. 10th Street
Indianapolis, Indiana 46202
(317) 267-8753
Private Line: (317) 635-7401 ext. 3853
Fax: (317) 269-6333
email: REDACTED
LAWSON.WILLIAM_B@INDIANAPOLIS.VA.GOV

Place of Birth:

Richmond, VA

Date of Birth:

November 27, 1945

Citizenship:

United States of America

SSN:

REDACTED

Marital Status:

Married, two sons

Current Appointments:

Chief, Psychiatry and Mental Health
Roudebush VA Medical Center
Professor, Department of Psychiatry
Indiana University School of Medicine
Indianapolis, Indiana
Adjunct Member Graduate Faculty in the
Department of Psychology, University of Memphis,
Memphis, Tennessee

EDUCATION:

Undergraduate:

Howard University
Washington, D.C.
B.S., 1966

Graduate:

University of Virginia
Charlottesville, VA
M.A., 1969
University of New Hampshire
Durham, N.H.
Ph.D., 1972

Medical School:

Pritzker School of Medicine
University of Chicago
Chicago, IL
M.D., 1978

William B. Lawson, M.D., Ph.D.

Medical Postgraduate: Internship, Stanford University
School of Medicine, Stanford, CA
1978-1979

Residency: Dept. of Psychiatry and Behavioral Sciences,
Stanford University School of Medicine, Stanford,
CA, 1979-1982

Fellowships: Staff Psychiatrist and Clinical Research Fellow,
Adult Psychiatry Branch, Intramural Research
Program, National Institute of Mental Health,
St. Elizabeth's Hospital, Washington, D.C.
1981-1984

Faculty Fellowship: Alcohol and Other Drug Abuse, Vanderbilt
University, Nashville, TN
Sponsored by National Institutes on Alcohol Abuse
and Alcoholism, 1991

Certification: Diplomate, American Board of Psychiatry and
Neurology, 1984
Forensic Certification, State of Tennessee, 1989
AIDS Trainer, Association of Black Psychologists,
Sponsored by the Center for Disease Control,
Washington, D.C., 1991
AIDS Trainer, American Psychiatric Association,
Sponsored by the National Institute of Mental Health,
Washington, D.C., 1992
Diplomate American, Board of Psychiatry and
Neurology in the Subspecialty of Psychiatry with
added qualifications in Addiction Psychiatry, 1994

PROFESSIONAL EXPERIENCE:

Full Time Positions:

1996-Present Chief, Psychiatry and Mental Health
Richard L. Roudebush VA Medical Center
Indianapolis, IN

1996-Present Professor, Department of Psychiatry
Indiana University School of Medicine
Indianapolis, IN

1991-1996 Associate Professor with Tenure, Dept. Of Psychiatry,
University of Arkansas for Medical Sciences,
Little Rock, AR

1994-1996 Associate Professor of Pharmacology and Toxicology,
University of Arkansas for Medical Science,
Little Rock, AR

1991-1996 Medical Director, Schizophrenia and Substance Abuse Program,
VA Medical Center,
North Little Rock, AR

William B. Lawson, M.D., Ph.D.

1991-1996	Chief, Chronic Mentally Ill Section, VA Medical Center, North Little Rock, AR
1986-1991	Assistant Professor, Dept. of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN
1986	Chief, Psychiatric Research, Long Beach VA Medical Center, Long Beach, CA
1984-1986	Assistant Professor, Dept. of Psychiatry and Human Behavior, University of CA, Irvine, CA
1984-1986	Director of Research, Metropolitan State Hospital, Norwalk, CA
1971-1974	Assistant Professor, Dept. of Psychology, University of Illinois at Champaign-Urbana, Urbana, IL

Part Time Positions:

1993-1996	Ethnic Issues Consultant, University of Tennessee School of Medicine, Memphis, TN.
1992-1996	Psychiatric Consult, Pulaski County Jail, Little Rock, AR
1989-1991	Director, Office of Minority Student Affairs Vanderbilt University School of Medicine, Nashville, TN
1988-1991	Consultant, Meharry Medical College, Nashville, TN
1988-1991	Chief Medical Officer, Dept. of Mental Health and Mental Retardation, State of Tennessee
1982-1984	Psychiatrist, D.C. Institute of Mental Hygiene, Washington, D.C.
1982-1984	Assistant Professor, Dept. of Psychiatry, Howard University School of Medicine Washington, D.C.

MEDICAL LICENSES:

DEA REDACTED
Arkansas REDACTED (Lapsed)
California REDACTED
Washington, D.C. REDACTED (Lapsed)
Tennessee REDACTED (Lapsed)
Indiana REDACTED

William B. Lawson, M.D., Ph.D.

HONORS AND AWARDS:

- 1997 Appointed member, National Scientific Advisory Board of the Depressive and Manic Depressive Society.
- 1996 Appointed member, Committee of Black Psychiatrists of the Council on National Affairs, American Psychiatry Association.
- 1996 Selected as Chair, Council on Scientific Assembly, National Medical Association
- 1996 Elected as a Fellow of the American Psychiatric Association.
- 1996 Gold Medalist, American Tae Kwon Do Association World Championship
- 1995 Commendation for Veterans Administration research by Jesse Brown, Secretary of Veteran Affairs.
- 1995 Invited to the National Advisory Council Meeting of the Substance Abuse, Mental Health, and Services Administration.
- 1995 Invited to the National Advisory Council Meeting of the National Institute of Drug Abuse.
- 1994-1996 Arkansas Statewide Chair, United Negro College Fund.
- 1994-1995 State of Arkansas Attorney Generals Task Force for Youth Violence:
Invited to attend signing of Youth Violence Legislation by Governor.
- 1994-1995 Master of Ceremonies Annual Statewide Banquet, United Negro College Fund.
- 1994-1997 President, Black Psychiatrists of America.
- 1994 Invited to the National Advisory Council Meeting of the National Institute of Drug Abuse.
- 1994 Special Achievement Award, Black Psychiatrists of America.
- 1993-1995 Participant and Mentor, Minority Research Training in Psychiatry Program, Sponsored by the American Psychiatric Association and National Institute of Mental Health.
- 1993 Keynote speaker and Veterans Administration Achievement Honoree, EEO/Black Advisory Committee, VA Awards Banquet.
- 1993 Research Honoree, Opening Ceremonies, New Biomedical Research Center, University of Arkansas for Medical Sciences.
- 1993 Appointed to the State of Arkansas Attorney General's Task Force for Youth Violence.
- 1993 Invited to the Meeting of the American College of Neuropsychopharmacology to address minority recruitment.
- 1992, 1993 Received the "Red Sash Award" for excellent Medical School teaching by graduating class.
1995, 1996
- 1992, 1993 Gold Medalist, U.S. Senior Nationals Judo Championships, Masters Division.
- 1992 Award of Appreciation, Council for African-American Progress,
Little Rock, Arkansas.

William B. Lawson, M.D., Ph.D.

- 1992 Elected member, Collegium International Neuropsychopharmacologium.
- 1992 "Recognizing Excellence in Action" award from the National AIDS Information and Education Project, Association of Black Psychologists.
- 1992 Recognized as one of five "National Mentors for the Severely Mentally Ill" by the National Alliance for the Mentally Ill at the One Hundred, Forty-Fourth Annual Meeting of the American Psychiatric Association.
- 1991 Keynote Speaker, Arkansas Alliance for the Mentally Ill Annual Meeting.
- 1989 Member, State of Tennessee Governor's Task Force on Alzheimer's Disease, 1990-Chair.
- 1989 Recognized for bringing "New Hope Through Research", Mental Health Association in Nashville.
- 1988 Represented the American Psychiatric Association in testifying to the Presidential Commission on AIDS Hearings, Nashville, TN.
- 1988 Member, State of Tennessee Governor's Black Health Task Force.
- 1987-1988 Member, State of Tennessee Governor's Task Force on AIDS.
- 1986 Service Award, Southern California Association of Black Psychologists.
- 1984 Appreciation and Recognition, Norwalk, CA Chapter, Alliance for the Mentally Ill.
- 1983 Alcohol, Drug Abuse, and Mental Health Administration Service Award.
- 1980-1982 American Psychiatric Association, National Institute of Mental Health Minority Fellowship.
- 1976 Kazi Award for Service to the Student National Medical Association.
- 1975 Medical Student Research Fellowship, Chicago Diabetic Association.
- 1974 Named "Excellent Teacher", University of Illinois, Champaign-Urbana.
- 1970-1971 Psi Chi Psychological Honor Society, President University of New Hampshire Chapter.
- 1966 Letter, Varsity Wrestling, Howard University.
- 1962 Tuition Scholarship, Howard University.

PROFESSIONAL ACTIVITIES: EXTRAMURAL:

- 1997 Member, Education Committee
Marion Co. Mental Health Association
- 1995-1996 Advisor to the Arkansas Depression and Manic Depressive Association.
- 1995-1996 Member of Board of Directors, Minority Disabilities Advocacy
Network, Inc. (MINDANET, INC)
- 1992-1996 Psychiatric Consultant, Pulaski County Jail

William B. Lawson, M.D., Ph.D.

1987-1991 Medical Officer, Tennessee Department of Mental Health and Mental Retardation
 1986-1991 Consultant, Meharry Medical College
 1982-1984 Consultant, Rock Creek Foundation of the Mentally Retarded, Silver Springs, MD
 1981 Transcultural Issues, Family Disturbance Workshops, Washington, D.C. Police Dept.
 1979-1981 Consultant, New Day Drug Abuse Center, Palo Alto, CA
 1978 Externship, Kenyatta National Hospital, Kenya, East Africa
 1976-1978 Facilitator, Follow-up on Woodlawn Community Psychiatric Project
 1974 Consultant, Garfield Park Mental Health Center, Chicago, IL
 1972-1974 Consultant, Kenneth Kuumba Drug Center, Champaign, IL

State and Local Governmental Organizations:

1996-Present Member, Superior Court of Marion County, Indianapolis, Indiana
 Alcohol and Substance Abuse Task Force
 1993-1996 Member, State of Arkansas Attorney General's Task Force on Youth Violence
 1992 Participant, Arkansas Minority Health Summit
 1988-1991 Chair, AIDS Education and Policy Committee, Tennessee Department of Mental Health and Mental Retardation
 1988-1991 Chair, Minority Mental Health Committee, Tennessee Department of Mental Health and Mental Retardation
 1988-1991 Chair, Dual Diagnosis Committee, Tennessee Department of Mental Health and Mental Retardation

PROFESSIONAL ORGANIZATIONS:

1996-Present Aesculapian Medical Society
 1996-Present American Society of Clinical Psychopharmacology
 1994-Present American Academy of Addiction Psychiatrists
 1995-Present Member, Research Committee
 1985-Present American Association for the Advancement of Science
 1978-Present American Medical Association
 1995-Present National Advisory Council on Family Violence
 1980-Present American Psychiatric Association
 1997-Present Member, Corresponding Task Force on Sub-Saharan (South) Africa
 1996-Present Member, Committee of Black Psychiatrists
 1991-1995 Observer-Consultant, Research Council
 1993-1995 Observer-Consultant, Committee of Minority and Under represented Groups

William B. Lawson, M.D., Ph.D.

1993-1995	Member, Kemp Fund Fellowship and Lily Award Committee
1971-Present	American Psychological Association
1991-1996	Arkansas Medical and Dental and Pharmaceutical Association
1991-1996	Chair, Continuing Education Committee
1991-1996	Arkansas Psychiatric Society
1994-1996	Member, Legislative Liaison Committee
1991-1996	Arkansas Medical Association
1980-Present	Association of Black Psychologists
1980-1981	Chapter Chair, Bay area, California
1984-1986	Chapter Chair, Southern California
1980-Present	Black Psychiatrists of America
1994-1997	President
1993-1994	President-Elect
1994-Present	Editor, Black Psychiatrists Newsletter
	Editor, Black Psychiatrists Quarterly
	President, Black Psychiatrists of California
1984-Present	Chair, Research Committee
1982-1984	Vice President
1992-Present	Collegium International Neuropsychopharmacologium
1996-Present	Indiana Psychiatric Society
1986-Present	National Medical Association
1993-Present	Council on Scientific Assembly
1995-1996	Acting Chair
1996-Present	Chair
1992-1994	Chair, E.Y. Williams Clinical Scholars of Distinction Award
1988-Present	Society for Biological Psychiatry
1991-Present	Society for the Neurosciences
1971-Present	Society for the Psychological Study of Social Issues
1990-Present	Society for the Study of Psychiatry and Culture

OTHER EXTRAMURAL ACTIVITIES:

1997	Organized Conference and Tour of Treatment Providers "Schizophrenia: The Future is Now" Indianapolis, Indiana
1995 & 1996	Organized Annual Transcultural Conference of Black Psychiatrists of America in Barbados, West Indies and Senegal, West Africa respectively
1994-1995	Organizer and Chair: "People United to Promote Youth"
1993	Organized Conference "Gang Violence", Little Rock, AR

William B. Lawson, M.D., Ph.D.

1992-Present	Member, Advisory Committee to the Little Rock School Board for a "Drug Free Arkansas".
1989-1991	Board of Directors, Center for Living and Learning, Franklin, Tennessee.
1987-1990	Board of Directors, Tennessee American Civil Liberties Union
1984-1991	Board of Directors, Psychological and Counseling Service, Washington, D.C.
1982-1984	Board of Directors, Professional Advisory Committee, Mental Health Council of Washington, D.C.
1982-1984	Board of Directors, Vice-Chairman, Technical Advisory Committee, Hillcrest Children's Center

PROFESSIONAL ACTIVITIES: INTRAMURAL:

1996-Present	Chair, Clozaril Committee, Richard L. Roudebush VAMC Indianapolis, IN
1996-Present	Member, Mental Health Council, VISN 11
1996-Present	Member, Executive Committee, Department of Psychiatry, Indiana University School of Medicine
1996-Present	Member Strategic Planning Committee, Richard L. Roudebush VAMC, Indianapolis, IN
1996-Present	Member, Improving Organizational Performance, Richard L. Roudebush VAMC, Indianapolis, IN
1996-Present	Member, Medical Executive Committee, Richard L. Roudebush VAMC, Indianapolis, IN
1996-Present	Member, Ad Hoc Committee on Human Subjects, Indiana University School of Medicine
1996-Present	Member, Office of Veterans Affairs Committee on Patient Abuse
1994-1996	Member, Advisory Committee for the Center of Alcohol and Drug Abuse Studies, University of Arkansas for Medical Sciences
1994-1996	Member, Arkansas Center for Neurosciences
1994-1996	Member, Human Research Advisory Committee, University of Arkansas for Medical Sciences
1993-1996	Member, Chancellor's Committee on Race Relations, University of Arkansas for Medical Sciences
1993-1994	Member, Martin Luther King Planning Committee, University of Arkansas for Medical Sciences, and for McClellan Veteran Administration Medical Center
1992-1996	Chairman, Clozapine Coordinating Committee, VA Medical Center, North Little Rock, AR
1992-1996	Member, Dean's Minority Advisory Committee, University of Arkansas for Medical Sciences
1991-1996	Member, Minority Retention and Recruitment Committee, University of Arkansas for Medical Sciences
1991-1996	Member, Medical Student Clerkship Committee, Dept. of Psychiatry, University of Arkansas for Medical Sciences
1991-1993	Member, Clinical Executive Board, VA Medical Center, North Little Rock, AR

William B. Lawson, M.D., Ph.D.

1991-1993	Member, Residency Training Committee, Dept. of Psychiatry, University of Arkansas for Medical Sciences.
1990-1991	Faculty Advisor, Vanderbilt Judo Club
1990-1991	Member, Center on Ethics, Vanderbilt University
1990-1991	Chairman, Minority AIDS Subcommittee, Vanderbilt AIDS Project
1990-1991	Faculty Advisor, Student National Medical Association, Vanderbilt Chapter
1990-1991	Faculty Advisor, Black Pre-medical Organization, Vanderbilt University
1990-1991	Member of Martin Luther King Weekend Planning Committee, Vanderbilt University.
1987-1991	Member, AIDS Project, Vanderbilt University
1986-1991	Admissions Committee, School of Medicine, Vanderbilt University Medical Center
1974-1978	Chairman, University of Chicago Chapter, Student National Medical Association
1971-1973	Member, Special Admissions Committee, Dept. of Psychology, University of IL, Champaign-Urbana

OTHER SIGNIFICANT ACTIVITIES:

1991-Present	Life Member, National Association for Advancement of Colored People,
1991-Present	NIDAN (second degree black belt) Judo, Chodan (first degree black belt), Tae Kwon Do
1990-1991	American Civil Liberties Union, Board of Directors, Nashville, Tennessee Chapter
1993-1996	Chair, Counseling Committee, and Teacher, New Members Class, Mt. Pleasant Baptist Church
1992-1996	Assistant Coach, Little Rock Judo Club
1967-1968	Vice President, Young Democrats, State of Virginia
1965-Present	Member - Omega Psi Phi Fraternity

REVIEWER, EXTRAMURAL GRANTS:

1996	National Institute of Mental Health: Minority Mental Health Research Centers, Washington, D.C.
1993	Center for Mental Health Services, Rockville, MD
1993	National Institute of Disability Research, Rockville, MD
1987-1990	National Institute of Health: Minority Access to Research Careers, Rockville, MD
1988	National Institute of Mental Health: Minority Training Center for the Chronically Mentally Ill, Bethesda, MD
1986	National Institute of Mental Health, Clinical Investigator Award, Bethesda, MD

William B. Lawson, M.D., Ph.D.

GRANT SUPPORT:

- 1995-1996 "The Rural Syphilis Prevention and Control Initiative: A Community-Based Behavioral Intervention Project", William Henry Masters, P.I., to the Jefferson Comprehensive Health Center from the Center for Disease Control \$90,000 to provide research evaluation.
- 1996-1997 "An Observational Study on the Clinical Management of Patients Treated with REVIA for Alcohol Dependence", DuPont Merck Pharmaceutical Company, \$2,500. Principal Investigator.
- 1995-1996 "Training Project on Depression for Members of the Black Psychiatrists of America and Other Health/Mental Health Professionals." National Institute of Mental Health, D'ART Program, Principal Investigator, \$5,000.00.
- 1995-1996 "An Open, multicenter study to Evaluate the Tolerability and Safety of Risperidal Tablets to Elderly subjects with Psychotic Disorders." Janssen Research, Principal Investigator, \$60,000.
- 1994 "A Special Issue of Black Psychiatrists of America Quarterly", Volume 21, Center for Substance Abuse Prevention, The Black Psychiatrists of America, The National Clearinghouse for Alcohol and Drug Information, Inventory Number: PHD698, \$10,000.00. Editor
- 1994-1996 "Interdisciplinary Drug-Abuse Training for Health Sciences", National Institutional Drug Award, Dr. D. McMillan, P.I., Faculty
- 1994-1996 "Family Life Centers at Historically Black Colleges and Universities: Brother to Brother Program", to provide research evaluation, Philander Smith, Office of Minority Health, Public Health Service, \$60,000.00.
- 1994-1995 "Cocaine Effects in Schizophrenia: A Pilot Study", University of Arkansas for Medical Sciences, Pilot Study Program, \$7,790.00. Principal Investigator
- 1994-1996 "Comparison of Seroquel (ICI 204,636) and Chlorpromazine in the Treatment Resistant Schizophrenia: Zeneca Pharmaceutical, \$200,000.00. Principal Investigator
- 1993-1994 "Investigation of the Brain Stem Reticular Formation in Schizophrenia," Dr. C. Karson, P.I., Supplement to Investigate Minority Patients, National Institute of Co-Investigator
- 1992-1996 "Clinical and Economic Impact of Clozapine Treatment on Refractory Schizophrenia," VA Multi-Center Study, Veterans Administration and Sandoz, Inc., \$266,764, P.I. this site, and member of the project executive committee.
- 1992-1995 "AIDS Training for Rural Mental Health Care Providers," Dr. John F. Aruffo, P.I. (10%), Center for Mental Health Services and American Psychiatric Association.
- 1992-1998 "Research Center on the Psychobiology of Ethnicity," P.I.: Keh-Ming Lin, National Institute of Mental Health. Consultant.
- 1990-1991 "Faculty Development in Alcohol and Other Drug Abuse", Dr. Peter Martin, P.I. National Institutes on Alcohol Abuse and Alcoholism. Faculty Fellow, \$10,000.
- 1989-1990 "Clozaril in Treatment-Resistant Patients", Sandoz Research Institute, \$11,000. Principal Investigator
- 1989 "Effects of Neuroleptics on Eating Behavior and Energy Metabolism", Vanderbilt University Research Council, \$10,000. Principal Investigator Neuropsychiatric Institute, \$40,000.
- 1988-1990 "Biological Correlates of Disturbed Water Regulation in Schizophrenia", Scottish-Rite Foundation, \$50,000. Principal Investigator

William B. Lawson, M.D., Ph.D.

- 1988-1991 "Minority High School Student Research Apprentice Program" National Institute of Mental Health Co-Investigator
- 1988-1991 "Chief Medical Officer and Clinical Consultant", State of Tennessee, Tennessee Department of Mental Health and Mental Retardation, \$120,000
- 1987-1988 "Double-Blind Comparison of Two Dose Ranges of Tiospirone and Placebo in Schizophrenic Patients", Bristol-Myers Company, \$120,000. Principal Investigator
- 1984-1986 "Double-Blind Comparative Evaluation of Oral Clozaril vs. Chlorpromazine Plus Benztropine in Treatment Resistant Schizophrenic Patients Who Have Failed on Haloperidol Plus Benztropine", Sandoz Research Institute, \$180,000. Principal Investigator
- 1976-1978 "Taste Detection in Diabetics and Their Relatives," Chicago Diabetic Association Research Grant, \$1,000. Principal Investigator
- 1972-1973 "Taste Preference in Diabetic Rats", University of Illinois Research Board Grant, \$8,000. Principal Investigator
- 1972-1973 "Taste Preferences in Aversion in Albino Rats", National Institute of Health, Small Grant, \$10,000. Principal Investigator
- 1970-1971 National Institute of Mental Health Training Fellowship, \$2,000. Fellow

PUBLICATIONS: REFERRED JOURNALS:

1. Lawson, W.B., Hagstrom, E. and Walter, G.: Salt Preference in Desalinated Rats. Physiology and Behavior, 12:733-739, 1974.
2. Lawson, W.B., Zeidler, A. and Rubenstein, A.A.: Taste Detection and Preference in Diabetic Patients. Clinical Research, 24:5294, 1976.
3. Lawson, W.B., Zeidler, A. and Rubenstein, A.: Taste Detection and Preference in Diabetics and their Relatives. Psychosomatic Medicine, 41:219-227, 1979.
4. Lawson, W.B., Yesavage, J.A. and Werner, P.D. Race, Violence and Psychopathology. Journal of Clinical Psychiatry, 45:294-297, 1984.
5. Kirch, D.G., Bigelow, L.B., Weinberger, D.R., Lawson, W.B. and Wyatt, R.J.: Polydipsia and Chronic Hyponatremia in Schizophrenic Inpatients. Journal of Clinical Psychiatry, 46(5):179-181, 1985.
6. Lawson, W.B., Karson, C.N. and Bigelow, L.B.: Clinical Correlates of Polyuria in Schizophrenic Patients. Psychiatry Research, 14:323-331, 1985.
7. Lawson, W.B.: The Black Family and Chronic Mental Illness. American Journal of Social Psychiatry, 6:57-61, 1986.
8. Lawson, W.B.: Racial Issues in Psychiatric Research. Hospital and Community Psychiatry, 37:50-54, 1986.
9. Parent, M., Roy, S., Sramek, J., Lawson, W.B. and Herrera, J.: Effect of Molindone on Weight Change in Hospitalized Schizophrenic Patients. Drug Intelligence and Clinical Pharmacy, 20:873-875, 1986.
10. Herrera, J and Lawson, W.B.: Effects of Consultation on the Ward Atmosphere in a State Psychiatric Hospital. Psychological Reports, 60:423-428.

William B. Lawson, M.D., Ph.D.

11. Karoun, F., Karson, C.N., Bigelow, L., Lawson, W.B. and Wyatt, R.J. Preliminary Evidence of Reduced Combined Output of Dopamine and its Metabolites in Chronic Schizophrenia. Archives of General Psychiatry, 44:604-607, 1987.
12. Lawson, W.B., Waldman, I. and Weinberger, D.R. Schizophrenic Dementia: Results of Neuropsychological Testing and Clinical Correlates. Journal of Nervous and Mental Disease, 176:207-212, 1988.
13. Lawson, W.B., Williams, B. and Pasion, R. Effects of Captopril on Psychosis and Disturbed Water Regulation in Schizophrenia. Psychopharmacology Bulletin, 24:176-178, 1988.
14. Lawson, W.B., Jeste, D.V. and Hanin, I. RBC and Plasma Choline in Chronic Schizophrenia. Psychiatry Research, 29:45-53, 1989.
15. Herrera, J., Freinhar, J., Sramek, J., Lawson, W.B. and Alvarez, W. Adjunctive Clonazepam in the Chronic Schizophrenia. International Journal of Psychosomatic Medicine, 38:17-20, 1991.
16. Lawson, W.B., Roy, S., Parent, M., Herrera, J., Karson, C. and Bigelow, L. Fluid Uptake Patterns in Schizophrenia vs. Normal Controls. Progress in Neuropsychopharmacology and Biological Psychiatry, 16:39-44, 1992.
17. Lawson, W.B., Herrera, J.M. and Costa, J. The dexamethasone suppression test as an adjunct in diagnosing depression. Journal of the Association for Academic Minority Physicians, 3:17-19, 1992.
18. Cuffel, B., Heithoff, K., Lawson, W.B. Correlates of Patterns of Substance Abuse Among Patients with Schizophrenia. Hospital and Community Psychiatry, 44:247-251, 1993.
19. Strickland, T, James R, Myers H, Lawson W.B., Bean X, Mapps J: Psychological Characteristics Related to Cocaine Use During Pregnancy: A Postpartum Assessment. Journal of the National Medical Association, 85: 758-760, 1993.
20. Lawson, W. B., Karson, C.N.: Clinical Correlates of Body Weight Changes in Schizophrenia, Journal of Neuropsychiatry and Clinical Neurosciences, 6:187-188, 1994.
21. Lawson, W. B., Hepler N, Holladay J, Cuffel B.: Race as a Factor in Inpatient and Outpatient Admissions and Diagnosis, Hospital and Community Psychiatry 45:72-74, 1994.
22. Prell, G.D., Green, J.P., Elkashef, A.M., Khandelwal, J.K. Linnoila, M., Wyatt, R.J., Lawson, W.B., Iagar, A.C., Kaufmann, C.A., and Kirch, D.G.: The Relationship Between Urine Excretion and Some Biogenic Amines and Their Metabolites in Cerebrospinal Fluid of Schizophrenia Patients Schizophrenia Research, 19:171-176, 1996.
23. Lawson, W.B. Clinical Issues in the Pharmacotherapy of African Americans. Psychopharmacology Bulletin, 32, 275-281, 1996.
24. Lawson, W.B. The Art of Pharmacotherapy with Treatment - Resistant Patients. Journal of Psychopathological and Behavioral Assessment. In Press.
25. Lawson, W.B. The Art and Science of the Psychopharmacotherapy of African Americans. Mount Sinai Journal of Medicine, 63, 301-305, 1996.

BOOK CHAPTERS AND INVITED REVIEWS:

1. Lawson, W.B. Consequences of the Biological Foundations of Behavior for the Black Child. Reflections on Black Psychology. Smith, W.D., Burlew, A.K., Mosely, M.H. and Whitney, W.B. (Eds.), University Press of America, Washington, D.C., 1979.

William B. Lawson, M.D., Ph.D.

2. Lawson, W.B. Hypertension and Diabetes Mellitus: A Challenge for the Black Behavioral Scientists. Research Directions of Black Psychologists. Boykin, A.Q., Franklin, A.J. and Yates, J.F. (Eds.), Russell Sage Foundation, New York, 1979.
3. Parron, D.L. and Lawson, W.B. Minorities in Clinical Research In Psychiatry: A Challenge for the Future. Clinical Research Careers in Psychiatry. Pincus, A. and Pardes, H. (Eds.), American Psychiatric Press Inc., Washington, D.C., 1986.
4. Lawson, W.B. Biological Markers in Neuropsychiatric Disorders, Racial and Ethnic Factors. Family, Culture, and Psychobiology, Sorel, E. (Ed.), Legas, New York, 1990.
5. Strickland, T., Lawson, W.B., Lin, K-M, Fu, P. Interethnic Variation to Lithium Therapy Among African-American and Asian-American Populations. Psychopharmacology and Psychobiology of Ethnicity. Lin, Keh Min, Poland, E., Nakasaki, G. (Eds), American Psychiatric Association Press, Inc., Washington, D.C., 1993.
6. Lawson, W.B. Pharmacological Approaches to Disturbances in Water Regulation in the Severely Mentally Ill. Water Balance in Schizophrenia, Schnur, D (Ed.), American Psychiatric Association Press, Inc., Washington, D.C., 1996.
7. Lawson, W.B., Psychopharmacology and African American Mental Health, African American Mental Health, Jones, R. (Ed.), Cobb and Henry, Hampton, VA 1996.

LETTERS TO EDITOR:

1. Lawson, W.B. Race Violence and Psychopathology, Dr. Lawson replies (Letter). Journal of Clinical Psychiatry, 46:407, 1985.
2. Lawson, W.B. Polyuria and Schizophrenia, the author replies (Letter). Psychiatry Research, 17:331-332, 1986.
3. Lawson, W.B. Response to Clozaril Editorial (Letter). Hospital and Community Psychiatry, 42:537-538, 1991.

PUBLISHED ABSTRACTS:

1. Lawson, W.B., Zeidler, A. and Rubenstein, A.A.: Taste Detection and Preference in Diabetic Patients. Clinical Research, 24:529A, 1976.
2. Bear, D., Lawson, W.B., Burns, S. and Tacke, U. Clozapine in Idiopathic Parkinsons. Biological Psychiatry, 25:163A, 1989.
3. Lawson, W., Schmidt, D. and Okpaku, S. Polydipsia, Hyponatremia, and Smoking in Schizophrenia. Biological Psychiatry, 25:183A, 1989.
4. Lawson, W., Schmidt, D. and Okpaku, S. Polydipsia, Hyponatremia, and Cotinine Levels in Schizophrenia. Schizophrenia Research, 2:160, 1989.
5. Lawson, W., Kazumi, H., Inagami, T., Kirch, D., Robertson, G., Morales, E., and Jager, A.: Neuroendocrine Determinants of Disturbed Water Regulation in Schizophrenia. Schizophrenia Research, 4:377-378, 1991.
6. Lawson, W., Hepler, N. and Holladay, J.: Diagnosis of Blacks in a State System. Schizophrenia Research, 4:263, 1991.
7. Lawson, W., Kirch, D., Shelton, R., Daniels, D., Jager, A. and Robertson, G.: Computer Tomographic and Endocrine Findings in Schizophrenic Patients with Hyponatremia. Biological Psychiatry, 1991.

William B. Lawson, M.D., Ph.D.

8. Lawson, W.B. and Clothier, J.: Substance Abuse and the Neurobiological Aspects of Schizophrenia. Society for Neuroscience Abstracts, 18:573, 1992.
9. Lawson, W.B.: Substance Abuse and Schizophrenia. Biological Psychiatry, 31:243A, 1992.
10. Lyon, N., Lawson, W.B., Amick, R., and Karson, C.: The Profile of Cognitive Impairment in Elderly Schizophrenic Subjects. Biological Psychiatry, 18:193A, 1992.
11. Lawson, W.B., Cuffel, B.: Race and Treatment of Schizophrenic Veterans. Schizophrenia Research, 9:102, 1993.
12. Lawson, W.B.: Cocaine and Alcohol Use in Schizophrenics. Schizophrenia Research, 9:202, 1993.
13. Lyon, M., Hudzik, T., Lawson, W.B., McMillan, D.E.: Potential Animal Model of Increased ETOH Intake in Schizophrenics: Prenatal or Amphetamine Exposure vs. Pair-Feeding Control Condition. Schizophrenia Research, 9:243, 1993.
14. Lawson, W.B., Karson, C.: Schizophrenic Dementia: Racial Issues. Biological Psychiatry, 35:702, 1994.
15. Lawson, W.B.: Movement Disorders in Schizophrenic Substance Abusers. Biological Psychiatry, 35:731, 1994.
16. Lawson, W.B., Gore, T.: Race and Substance Abuse in Schizophrenia. Biological Psychiatry, 37:370, 1995.
17. Lawson, W.B., Neihus, C., Creer, M.: Cocaine and Cocaine Levels in Psychiatric Patients. Biological Psychiatry, 41, 75, 1997.
18. Lawson, W.B.: Race and Movement Disorder in Substance Abusing Schizophrenia. Schizophrenia Research, 24: 271, 1997

BOOK REVIEWS, EDITORIALS, OTHER PUBLICATIONS:

1. Lawson, W.B. Salivary influences on fluid preferences and aversions in the albino rat. Dissertation Abstracts International, 34:1, 1973.
2. Lawson, W.B., and Woolridge, T.J.: AIDS Policy, Tennessee Department of Mental Health and Mental Retardation, 1988.
3. Lawson, W.B.: Is Neurobiological Research Relevant to Black Psychiatrists? The Black Psychiatrists of America Quarterly, 13:3-4, 1984.
4. Lawson, W.B.: Racial Issues in Psychiatric Diagnosis: Biopsychological Perspective. The Black Psychiatrists of America Quarterly, 14:4-8, 1985.
5. Lawson, W.B.: Book review of Schizophrenia: Treatment, Management and Rehabilitation. Bellack, A.S. (Ed.). In Book Reviews in the Neurosciences. Blors Corporation, Robert G.Owens, Madison, WI, 1985.
6. Lawson, W.B.: New technologies offer hope for victims of mental illness. Special article to the "Nashville Banner" and "Nashville Daily", Oct. 3, 1988.
7. Lawson, W.B.: Guest Editorials to the "Nashville Pride", and "Nashville Weekly", for Mental Health Awareness Week, Oct. 14, 1988.
8. Lawson, W.B., Hepler, N. and Holladay, J.: Over commitment and Misdiagnosis of Blacks in the State Mental Health System. Report to the Legislature of Tennessee, 1990.

William B. Lawson, M.D., Ph.D.

EDITOR-IN-CHIEF:

1994-Present Black Psychiatrists of America Newsletter
1988-1994 Black Psychiatrist Quarterly

CONSULTANT EDITOR:

1986-1992 American Journal of Drug and Alcohol Abuse

GUEST REVIEWER, REFERRED JOURNALS:

Biological Psychiatry
Hospital and Community Psychiatry/Psychiatry Services
Journal of the American Medical Association
Journal of the National Medical Association
Journal of Neuropsychiatry
Life Sciences
Psychiatry Research
Schizophrenia Bulletin
Schizophrenia Research

PRESENTATIONS AT PROFESSIONAL MEETINGS:

1. Lawson, W.B.: The Effects of Atropine-Induced Desalination on Salt Preference. Presented at the Eastern Psychological Convention, 1969.
2. Lawson, W.B. and Hagstrom, E.: Salivary Influences on Fluid Preferences and Aversions in the Albino Rat. Presented at the Psychonomic Society, 1972.
3. Lawson, W.B. and Albin, R.: Effects of Long-Term Alloxan-Induced Diabetes Mellitus on Saccharin and Glucose Preference. Presented at the Midwestern Psychobiological Association, 1974.
4. Lawson, W.B. Perspectives of a Black Psychiatric Researcher. Meeting of the American Psychiatric Association, Los Angeles, CA, 1984.
5. Lawson, W.B., Karson, C.N. and Jeste, D., Tardive Dyskinesia and Disturbances in Water Regulation. Fortieth Annual Convention of the Society of Biological Psychiatry, Dallas, TX, 1985, Abstract #71.
6. Lawson, W.B., Herrera, J. and Costa, J. The Dexamethasone Suppression Test in Hispanic Patients. Fortieth Annual Convention of the Society of Biological Psychiatry, Dallas, TX, 1985, Abstract #71.
7. Lawson, W.B. Epidemiology of Polydipsia. One-Hundred and Thirty-Ninth Annual Meeting of the American Psychiatric Association, Washington, D.C., 1986.
8. Lawson, W.B. "Back to Africa". Session Chair, One-hundred and Fortieth Annual Meeting of the American Psychiatric Association, Chicago, IL, 1987.
9. Lawson, W.B. "Back to Africa Revisited". Session Chair, One Hundred and Forty First Annual Meeting of the American Psychiatric Association, Montreal, Canada, 1988.
10. Harris, T., Bell, C. and Lawson, W.B. "Psychiatry and Homicide in the Black Community". One Hundred and Forty First Annual Meeting of the American Psychiatric Association, Montreal, Canada, 1988.

William B. Lawson, M.D., Ph.D.

11. Lawson, W.B. "What Kills Black Men". Session Chair, Annual Meeting of the American Psychological Association, Atlanta, Georgia, 1988.
12. Lawson, W.B. "Biological Markers in Neuropsychiatric Disorders. Racial and Ethnic Issues," Annual Meeting of the American Society for Social Psychiatry in Washington, D.C., 1988.
13. Lawson, W.B. "New Pharmacological Approaches to Schizophrenia." Annual Meeting of the National Medical Association, Los Angeles, CA, 1988.
14. Lawson, W.B. "The Psychiatrist and Minority Admissions Educational Objectives." One Hundred Forty-Second Annual Meeting of the American Psychiatric Association, San Francisco, CA, 1989.
15. Lawson, W.B., Schmidt, D., Nelson, B., Morgan, C., Roznoski, M. and Okpaku, S. "Diurnal Polydipsia and Smoking in Schizophrenia." One Hundred Forty - Second Annual Meeting of the American Psychiatric Association, San Francisco, CA, 1989.
16. Lawson, W.B. "Is DSM IV the Answer?" One Hundred Forty -Third Annual Meeting of the American Psychiatric Association, New York, NY, 1990.
17. Lawson, W.B., Schmidt, D. and Morales, E. "Disturbed Water Metabolism in Schizophrenia." One Hundred Forty -Third Annual Meeting of the American Psychiatric Association, New York, NY, 1990.
18. Lawson, W.B., Williams, I.M. and Hill, J. "Chlorpromazine Induced Weight Gain". Twentieth Annual Meeting of the Society for Neuroscience, St. Louis, MO, 1990.
19. Lawson, W.B., Healer, N., Okpaku, S., Townsend, W. and Griffith, E. "Misdiagnosis and Over commitment of Minorities". One Hundred Forty -Fourth Annual Meeting of American Psychiatric Association, New Orleans, LA, 1991.
20. Lawson, W.B., Kirch, D., Shelton, R., Daniels, D., Jager, A. and Welch, L. "Structural Abnormalities in Schizophrenic Patients with Hyponatremia". One Hundred Forty-Fourth Annual Meeting of American Psychiatric Association, New Orleans, LA, 1991.
21. Lawson, W.B., Williams, I., Tadashi, I., Kirch, D., Robertson, G.L., and Jager, A. Response to Osmotic Challenges in Schizophrenia. Paper presented at the One Hundred and Forty-Fifth Annual Meeting of the American Psychiatric Association, Washington, D.C., 1992.
22. Lawson, W.B. "Cultural Factors in Pharmacotherapy." Paper presented at the One Hundredth Annual Meeting of the American Psychological Association, Washington, D.C., 1992.
23. Lawson, W.B., "Cocaine and Alcohol Use in Schizophrenia." Paper presented at the Thirty-Third Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1992.
24. Lawson, W.B., "Homicide as an African American Health issue, presentation at a meeting of the Arkansas Medical Dental Pharmacological Association, 1992.
25. Lawson, W.B., "AIDS." One Hundredth Anniversary of the Arkansas Medical Dental Pharmaceutical Association, 1993.
26. Lawson, W.B., "Atypical Schizophrenia and Dementia," First Annual Conference on Psychopathology, Psychopharmacology, Substance Abuse and Ethnicity, Los Angeles, 1993.
27. Lawson, W.B., "Treatment Approaches to HIV: Issues for Mental Health Professional Sixteenth Annual Transcultural Conference, Black Psychiatrists of America, Grenada, West Indies, 1993.
28. Lawson, W.B., "Depression" presented at the North Little Rock Veterans Administration Hospital, 1993.

William B. Lawson, M.D., Ph.D.

29. Lawson, W.B., "Psychopharmacology: An Update on Clinical and Research Issues," Sixteenth Annual Transcultural Conference, Black Psychiatrists of America, Grenada, West Indies, 1993.
30. Lawson, W.B., "Cocaine Effects in Schizophrenia and Substance Abuse", Eleventh Annual International Neurotoxicity Conference, Little Rock, AR, 1993.
31. Lawson, W.B., Symposium Chair: Psychopharmacology for Minorities and the Undeserved, Symposium Presenter: "Is the Better Mouse Trap Enough? The Clozapine Story". Ninety-Eighth Annual Convention of the National Medical Association, San Antonio, TX, 1993.
32. Lawson, W.B., Symposium Chair: "Post Traumatic Stress Disorder: Implications for African Americans". Symposium Presenter: "Post Traumatic Stress Disorder and Misdiagnosis." Ninety-Eighth Annual Convention of the National Medical Association, San Antonio, TX, 1993.
33. Lawson, W.B., Symposium Chair: "Are There Racial Differences in Treatment", Symposium Presenter: Lawson W., Cuffel B, Fisher E., "Race, Diagnosis and Treatment in the VA," presented at the One Hundred Forty-Sixth Annual Meeting of the American Psychiatric Association, San Francisco, CA., 1993.
34. Lawson, W.B., Symposium Chair, "Addiction and the Mentally Ill: The Triple Whammy", presented at the One Hundred Forty-Sixth Annual Meeting of the American Psychiatric Association, Philadelphia, PA., 1994.
35. Lawson, W.B., "Violence in the Black Community: A Public Health Concern", presented at the One Hundred First meeting of the Arkansas Medical Dental Pharmaceutical Association, Eureka Springs, AR., 1994
36. Lawson, W.B., "Everything You Always Wanted to Know About Sleep", presented at the One Hundred First Meeting of the Arkansas Medical, Dental, Pharmaceutical Association, Eureka Springs, AR., 1994.
37. Lawson, W.B., Cuffel, B. "Racial Comparisons in Schizophrenic Veterans", presented at the One Hundred Forty-Sixth Annual Meeting of the American Psychiatric Association, Philadelphia, PA., 1994.
38. Lawson, W.B., Symposium Chair "Update in Psychopharmacology", Symposium Presenter, "New Treatment Approaches for Severe Mental Illness", presented at the Ninety-Ninth Annual Convention of the National Medical Association, Orlando, Florida, 1994.
39. Lawson, W.B., "Dementias of Schizophrenia and Alzheimer's Disease: Are They Related", presented at the Ninety-Ninth Convention of the National Medical Association, Orlando, Florida, 1994.
40. Lawson, W.B., "Sleep Disturbances in Aging and Dementia", presented at the Ninety-Ninth Convention of the National Medical Association, Orlando, Florida, 1994.
41. Lawson, W.B. and Gore, T. "Race and Substance Abuse in Schizophrenia" presented at the Fifteenth Annual Meeting of the Society for Biological Psychiatry, Miami, Florida, 1995.
42. Lawson, W.B., Symposium Chair, "Diversity in Psychopharmacology" and presenter "Clinical issues in Ethnopsychopharmacology", at the One Hundred Forty-Eighth Annual Meeting of the American Psychiatric Association, Miami, Florida, 1995.
43. Lawson, W.B., "Aids Training for Rural Mental Health Centers", presented In the Issue Workshop: "HIV/AIDS Training and Rural Psychiatry at the One Hundred Forty-Eighth Annual Meeting of the American Psychiatric Association, Miami, Florida, 1995.
44. Lawson, W.B., Chair, "Current issues: Science and Practice", Symposium Presenter, "Management of Severe Mental Implications for African Americans", One Hundredth Annual Convention of the National Medical Association, Atlanta, Georgia, 1995.

William B. Lawson, M.D., Ph.D.

45. Lawson, W.B., "Racial Differences in Substance Abusing Schizophrenics" and "The Art of Pharmacotherapy with Treatment Resistant Schizophrenia," Third Annual Conference for Psychopathology, Psychopharmacology, Substance Abuse, and Culture, Los Angeles, CA, 1995.
46. Lawson, W.B., Workshop: "Ethnicity in the Pharmacologic Treatment Process," Thirty-fifth Annual Meeting of the New Clinical Drug Evaluation Unit Program (NCDEU), Orlando, FL, 1995.
47. Lawson, W.B., "Race and Substance Abuse in Schizophrenia," Tenth Annual meeting of the American Academy of Psychiatrists in Alcoholism and Addictions, Amelia Island, FL, 1995.
48. Lawson, W.B., "Clinical Issues in Ethnopharmacotherapy," presentation, "Developing a Black Mental Health and Substance Abuse Agenda for the Americas: Let's Find Solutions," Overall Theme, Eighteenth Annual Transcultural Conference of the Black Psychiatrists of America. Dr. Lawson chaired the program committee and served as the overall moderator of this meeting, Barbados, W.A., 1995.
49. Komoroski, R.A., Heimberg, C., Lawson, W.B., Cardwell, D. and Karson, C.N., "A Localized, In Vivo ¹H NMR Spectroscopy Study of schizophrenics", Society of Magnetic Resonance Third Scientific Meeting, European Society for Magnetic Resonance in Medicine and Biology Twelfth Annual Meeting, Nice, France, 1996.
50. Lawson, W.B., "New Treatment for Alcohol and Substance Abuse's 103rd Annual Meeting of the Arkansas Medical Dental Pharmaceutical Association, Memphis, Tennessee.
51. Lawson, W.B., Symposium Discussant, "Bicultural Units: Challenges and Strategies", 149th Annual Meeting of the American Psychiatric Association, New York, New York.
52. Lawson, W.B., Symposium Chair, "Race and Psychiatric Issue in the Prison System", American Psychiatric Association 1996 Institute on Psychiatric Services, Chicago, Illinois.
53. Lawson, W.B., "Race and Psychiatric Issues in the Prison System", American Psychiatric Association 1996 Institution on Psychiatric Services, Chicago, Illinois.
54. Lawson, W.B., "Infectious Disease Issues in Psychiatric Patients", American Psychiatric Association 1996 Institute on Psychiatric Services, Chicago, Illinois.
55. Lawson, W.B., "Movement Disorders in Substance Abusing Schizophrenia," Winter Conference on Brain Research, Breckinredge, Colorado, 1997.
56. Lawson, W.B., "Multidimensional Approaches to Violence Prevention and Intervention," National Association of Black Social Workers, Detroit Michigan, 1997.
57. Lawson, W.B., "Race and Movement Disorder in Drug Abusing Schizophrenia," International Congress on Schizophrenia Research, Colorado Springs, Colorado, 1997.
58. Lawson, W.B. "Diversity and Psychosis", Symposium Chair, One hundredth fifteenth Annual Meeting of the American Psychiatric Association, San Diego, California, 1997.
59. Lawson, W.B., "Treating Psychosis in African Americans" One hundredth fifteenth Annual Meeting of the American Psychaitric Association, San Diego, CA, 1997.
60. Lawson, W.B., & Shavers, Erina, "Update in Psychopharmacology of the Treatment of Psychosis," One hundredth and second Annual Meeting of the National Medical Association, Honolulu, Hawaii, 1997.
61. Lawson, W.B., Participant, "Symposium on Diversity," Annual Meeting of the Southeastern Psychological Association, Atlanta, Georgia, 1997.

William B. Lawson, M.D., Ph.D.

INVITED PRESENTATIONS:

- 1989 "Diagnosis and Psychotropic Medication in Racial and Ethnic Minorities." State of Ohio Skills Development Workshops for Case Managers, Cincinnati, Ohio.
- 1990 "Clozapine." Annual meeting of the Mental Health Association of Tennessee, Murfreesboro, Tennessee.
- 1990 "Minority Health." Annual meeting of the Link, Memphis, Tennessee.
- 1990 Keynote Speaker, Founder's Day, Omega Psi Phi Fraternity, Nashville, Tennessee.
- 1992 "New Treatments for the Mentally Ill" at the Gradus Program for Veterans' Families of the Mentally Ill, John L. McClellan Memorial Veterans Hospital.
- 1992 "Racial Issues in Neuropsychiatry", presentation at University of San Francisco Medical Center, Department of Psychiatry, San Francisco, California.
- 1992 "Violence in the African American Community." Annual meeting, Arkansas Association of Black Social Workers.
- 1993 Panelist, "Diagnosis, Misdiagnosis, Medication, Hospitalization and Clinical Perspective", Sixth Annual Mental Health Diversity Conference, Columbus, Ohio.
- 1993 "Clozaril", Ninth National Fairweather Lodge Conference, Hot Springs, AR.
- 1993 "The Impact of AIDS on Minorities in Arkansas", Delta Region on AIDS Education and Training, Little Rock, AR.
- 1993 "Substance Abuse in Black and White", Alternative Perspectives in Substance Abuse Issues Today. Workshop coordinated by the Little Rock Fighting Back, Little Rock, AR.
- 1993 "Dual Diagnosis", Bridgeway Treatment Center, Little Rock, AR.
- 1993 "Panic Disorder", Advocacy Services, Inc., Annual Mental Health Institute, Little Rock, AR.
- 1994 "Recovery from a Minority Perspective", Recovery Forum of the Ohio Department of Mental Health, Columbus, OH.
- 1994 "Psychiatric Misdiagnosis", Seventh Annual Mental Health Cultural Diversity Conference of the Ohio Department of Mental Health, Cleveland, OH.
- 1994 "Treating Depression in African Americans", presented at Liberty Medical Center, Baltimore, MD.
- 1994 Keynote Address, "Gang Violence at a Public Health Concern", Youth, Health and Alternative Behavior Seminar, sponsored by New Future of Little Rock, AR.
- 1994 "Causes and Prevention of Violence", presented at the annual meeting of the Arkansas Educational Association, Little Rock, AR.
- 1994 AETN panel Participant on Gang Violence, Arkansas Educational Television Network (AETN), and Consultant, "Gang Violence: Arkansas Responds", AETN, Conway, AR.
- 1994-1995 Presented "Aids and Mental Health" as part of a Regional Aids Interfaith Network Training Team at Local Churches.
- 1995 "What works: Services for people with dual diagnosis in the VA System", presented at the Fifteenth Annual Meeting of the National Alliance for the Mentally Ill, Washington, D.C.

William B. Lawson, M.D., Ph.D.

- 1995 "Depression in African Americans", presented at The Black Healthcare Coalition, Kansas City, MO.
- 1995 "Cultural Diversity and Misdiagnosis", presented at The 1995 Mental Health Institute Program of the Mental Health Council of Arkansas, Hot Springs, AR.
- 1995 "The New Paradigm of the 20th Century", presented at The Minority AIDS Education Task Force Retreat, sponsored by the Arkansas Department of Health, Lake DeGray, AR.
- 1995 "Team Teaching Approach: Doctor/Patient Relationships", presented at The Eighth Annual Mental Health Cultural Diversity Conference, sponsored by the Ohio Department of Mental Health, Cincinnati, OH.
- 1996 "A Pharmacologic Management of Depression in African American Patients," presented at the Symposium "Recognizing and Treating Depression in African Americans", sponsored by the Mental Health Association in Illinois, Chicago, IL.
- 1996 Keynote address, "Making Dr. Martin Luther King's dream come alive in King and Queen County", presented at the First Annual Martin Luther King Tribute of the King and Queen African-American History and Research Organization. King and Queen C.H., VA.
- 1997 "The Challenge for African American Psychiatrists; Diversity in Psychopharmacology, Earline Houston Memorial Lecture in Public Psychiatry. Allegheny University Hospitals and Medical College of Pennsylvania, Philadelphia, PA.
- 1997 "Substance Abuse and Mental Illness in African Americans. Consultation Solomon Carter Fuller Institute and Grand Rounds Boston University School of Medicine, Boston, MA.
- 1997 "Violence and Aids in the Black Community", Institute for African American Health, Inc., Tallahassee, FL.
- 1997 "Symptom Dimensions in Schizophrenia" presented at the Conference "Schizophrenia, The Future is Now", Indiana University School of Medicine, Indianapolis, IN.

NOTEWORTHY ACADEMIC PRESENTATIONS:

- 1987 "Racial and Cultural Issues in Psychiatry." Tennessee Psychiatric Association, Memphis, Tennessee.
- 1990 "Implications of Race and Ethnicity for Behavioral Genetic Investigations." First Annual Lloyd Elam Symposium, Meharry Medical College, Nashville, Tennessee, 1990.
- 1991 "Disturbed Water Regulation in Schizophrenia", Grand Rounds, Department of Psychiatry, University of Florida College of Medicine Gainesville, Florida.
- 1992 "Schizophrenia and Substance Abuse", Grand Rounds, Department of Psychiatry Medical College of Virginia, Richmond, Virginia.
- 1992 "Racial and Ethnic Issues in the Treatment of Psychiatric Disorders", Grand Rounds, New York Medical College, Metropolitan Hospital Center.
- 1992 "Black on Black Violence, Mental Health Implications." Annual meeting of the Arkansas Psychiatric Association.
- 1993 "Race and Ethnicity in Psychiatric Research", Grand Rounds, Department of Psychiatry, Columbia University Medical Center, New York, New York.
- 1993 "Treatment Modalities for Depression in Minorities", The Washington Chirurgical Society Meeting in conjunction with the National Institute Of Mental Health, Bethesda, MD.

William B. Lawson, M.D., Ph.D.

- 1993 Keynote Speaker: "Barriers to Informed Consent", National Education Workshop on Human Subject Protection, sponsored by the National Institute of Health, Office for Professional Health Risks and the Food Drug Administration, Tampa, FL.
- 1993 "Misdiagnosis and Delusional Depression in Minorities", National Institute of Mental Health, "Delusional Depression in Late Life" Conference, Washington, D.C.
- 1993 "Rural Mental Health" Seventh Annual Conference in Counseling and Treating People of Color, sponsored by the Center for Mental Health Services, Mental Health and Substance Abuse Administration, Honolulu, Hawaii.
- 1994 "Implications of Mental Health for African Americans", Martin Luther King, Jr., Memorial Symposium, University of Arkansas at Little Rock.
- 1994 "Dual Diagnosis", Twenty-First Annual Mid-South Summer School on Alcohol and Drug Abuse Problems, University of Arkansas at Little Rock.
- 1994 "Race in Mental Health Research", presentation to the Child Clinical Psychology Internship Program, Division of Pediatric Psychiatry, University of Arkansas for Medical Sciences.
- 1994 Workshop presentation, "Clinical Geriatric Research in a Managed Care Environment", sponsored by the National Institute of Mental Health, Rockville, MD.
- 1994 "African American Veterans with PTSD and Misdiagnosis", presented at the Veterans Administration at the African American Veterans and PTSD Conference, St. Louis, Missouri.
- 1994 Participant, National Medical Association, National Institute of Health Workshop on Violence in the African American Community: A Public Health Issue, Washington, D.C.
- 1994 "Treatment Issues Across Ethnicity", presentation at Resident Seminar, University of Maryland Medical Center, Baltimore, MD.
- 1994 "Racial Issues in Psychopharmacology", Grand Rounds, Howard University Medical Center, Washington, D.C.
- 1995 "Clozaril", presented at Grand Rounds, Fayetteville VAMC, Fayetteville, AR.
- 1995 "Recognizing and Treating Depression in African Americans", presented at Grand Rounds, Temple University, Philadelphia, PA.
- 1995 "Racial and Ethnic Factors in Psychiatric Research", presented at Grand Rounds, Elmhurst Hospital/Mt. Sinai Medical Center Services, Elmhurst, N.Y.
- 1995 "The Art and Science of Ethnopharmacology", presented at the Grand Rounds of the Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR.
- 1995 "Race and Substance Abuse in Schizophrenia", presented at a poster session of the Grand Rounds of the Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR.
- 1995 "Racial Issues in Psychopharmacology", presented at the Scientific Meeting of the Ohio Psychiatric Association and Central Neuropsychiatric Association, Cleveland, OH.
- 1995 "Clinical Issues in the Pharmacotherapy of Racial and Ethnic Minorities", presented at the Eighth Annual New York State Office of Mental Health Research Conference, New York, NY.
- 1996 "Comorbidity of Substance Abuse and Mental Illness", presented at Grand Rounds, Memphis Mental Health Institute and sponsored by University of Tennessee Medical Center, Memphis, TN.

William B. Lawson, M.D., Ph.D.

- 1997 "The Challenge for African American Psychiatrists; Diversity in Psychopharmacology, Earline Houston Memorial Lecture in Public Psychiatry. Allegheny University Hospitals and Medical College of Pennsylvania, Philadelphia, PA.
- 1997 "Substance Abuse and Mental Illness in African Americans. Consultation Solomon Carter Fuller Institute and Grand Rounds Boston University School of Medicine, Boston, MA.
- 1997 "Violence and Aids in the Black Community", Institute for African American Health, Inc., Tallahassee, FL.
- 1997 "Symptom Dimensions in Schizophrenia" presented at the Conference "Schizophrenia, The Future is Now", Indiana University School of Medicine, Indianapolis, IN.
- 1997 "Racial and Ethnic Issues in Psychopharmacology," presented at the Grand Rounds of the Indiana University School of Medicine.

RADIO AND TELEVISION APPEARANCES:

- June 1991 "Panic Disorder in Minorities" on "Ounce of Prevention" BET, Channel 14.
- May 1992 "Misdiagnosis in African Americans" on "Shaping the Future," BET, Channel 14.
- 1993 "Gang Violence", TV Channel 7, Radio KARN.
- 1993 "Psychiatric Says Social Needs Drive Youth to Gangs", newspaper, interview with Arkansas Democrat-Gazette.
- 1994 Panel participant, "Gang Violence: Arkansas Responds". Arkansas Educational Television Network.

STATE OF INDIANA
HEALTH PROFESSIONS BUREAU

RENEWAL NO.

LICENSE NO.

WILLIAM B LAWSON

IS DULY LICENSED AS PRESCRIBED BY INDIANA LAW AS
PHYSICIAN

MEDICAL LICENSING BOARD

TO ENGAGE IN SUCH PURSUIT UNTIL 06/30/99
UNLESS SUSPENDED OR REVOKED BY LAW.

WRITTEN
SIGNATURE

William B. Lawson
DO NOT SIGN UNLESS EXAMINED BY BOARD

CURRICULUM VITAE

NAME: Michael David Lesem

HOME ADDRESS: REDACTED

OFFICE ADDRESS: 6750 West Loop South, Suite 1050
Bellaire, Texas 77401
(713) 665-6446

CITIZENSHIP: U.S.A.

BIRTH DATE: January 18, 1955

PLACE OF BIRTH: Austin, Texas

MARITAL STATUS: Single
Two children: Nicholas and Alexander

EDUCATION

B.A. 1976 University of Texas, Austin
Cum Laude, History

M.D. 1981 University of Texas, Houston

PROFESSIONAL TRAINING

1981-82 Medical Internship, St. Paul's Hospital, Dallas, Texas

1982-85 Residency in Psychiatry, University of Texas

1984-85 Chief Resident, Psychiatry, University of Texas, Houston

1985-87 Medical Staff Fellow, Laboratory of Clinical Science, National
Institute of Mental Health, Bethesda, MD.

PROFESSIONAL EXPERIENCE

1994-95 Medical Director, Geropsychiatric Unit, HCA Medical Center

1991-94 Medical Director, Behavioral Health Center, Heights Hospital

1992-93 Medical Director, Adult Services, Spring Shadows Glen

1989-90 Intensive Care Unit Director, Houston International Hospital

1989-90 Intensive Study Unit Director, Harris County Psychiatric Center

1988-89 Chief Adult Service, Harris County Psychiatric Center

1987-89 Geriatric Unit Director, Harris County Psychiatric Center

1987-89 ECT Service Director, Harris County Psychiatric Center

1984 Co-director, Neuropsychiatric Consultation Service, Hermann Hospital

MEDICAL LICENSES

1981 Texas: REDACTED
1985 Maryland: REDACTED
1986 Washington, D.C.: REDACTED

ACADEMIC APPOINTMENTS

1989-95 Clinical Assistant Professor, Department of Psychiatry, UTMSH

HOSPITAL APPOINTMENTS

1987 Harris County Psychiatric Center - Active Staff
1987 Hermann Hospital - Active Staff
1990 Park Plaza Hospital - Courtesy Staff
1990 Methodist Hospital - Courtesy Staff
1990 St. Luke's Hospital - Courtesy Staff
1990 ATH Heights Hospital - Active Staff
1991 Diagnostic Center Hospital - Courtesy Staff
1992 Spring Shadows Glen - Active Staff
1995 West Oaks Hospital - Courtesy Staff
1995 Clear Lake Regional Medical Center - Courtesy
1996 Gulf Pines Hospital- Active Staff
1996 TIRR - Provisional Consulting
1995 Texas Orthopedic Hospital - Consulting
1997 Memorial Southwest Hospital - Courtesy
1997 Memorial Northwest Hospital - Provisional

BOARD CERTIFICATION

1986 American Board of Psychiatry and Neurology Certification, November 1986
1992 American Board of P & N, Geriatric Psychiatry, Certification, March 1992

PROFESSIONAL ORGANIZATIONS

American Neuropsychiatric Association
American Medical Association
Texas Medical Society
Harris County Medical Society
American Psychiatric Association
Texas State Society of Psychiatric Physicians
Houston Geriatric Society
Central Neuropsychiatric Association
Texas Medical Foundation
The Mental Health Association
American Academy of Clinical Psychiatrists, Inc.

PROFESSIONAL ASSOCIATIONS

1991-present Houston Neuropsychiatric Association, Inc., Staff

1992-present Clinical Research Association, Co-Investigator

HONORS AND AWARDS

Undergraduate

1976 B.A., Cum Laude
1976 Student Senate Committee Appointment

Medical School

1978 Merit Scholarship
1978 Elected President, Phi Rho Sigma
1981 Hoffman-LaRoche Biologic Psychiatry Award for Outstanding Student in Psychiatry, UTMSH
Class of 1981

Postgraduate

1984-85	Appointment, Chief Resident, Department of Psychiatry, University of Texas Medical School
1987-88	Dean's Teaching Excellence List - UTMSH
1988-89	Dean's Teaching Excellence List - UTMSH
1988-89	Resident's Service Award (Outstanding Faculty Member as Voted on by Psychiatry Residents - UTMSH)
1989-90	Inpatient Teaching Award, presented by Psychiatry Residents-UTMSH
1988-90	Dean's Teaching Excellence List - UTMSH

COMMITTEES

1987-1988	Admissions Committee Interview - UTMSH
1987-1989	Research Committee - UTMSH -Department of Psychiatry
1988-1989	Laboratory Utilization Overview Committee - UTMSH - Department of Psychiatry
1988-1989	Resident Training Committee - UTMSH - Department of Psychiatry
1988-1989	Executive Committee - HCPC
1987-1989	Pharmacy and Therapeutics Committee - HCPC
1987-1989	Medical Records Committee - HCPC
1988-1989	Research Facilitation Committee - HCPC
1991-1994	Utilization Review Committee - Heights Hospital
1995	TSPP-Liason Committee Geriatric Psychiatry and Texas Dept. Of Health

LECTURES AND PRESENTATIONS

A Case of Schizoaffective Disorder in an Elderly Patient. University of Texas Medical School - Houston, Department of Psychiatry, Grand Rounds, November 1982

Alcoholism and Affective Disorders - Two Case Presentations. University of Texas Medical School - Houston, Department of Psychiatry, Grand Rounds, March 1984

State-Related Changes in Plasma NE in Anorexia Nervosa. LCS Section, NIMH Seminar, June 1987

CSF 5H1AA and Prolactin Response to M-cpp in Anorexia Nervosa. LCS Section, NIMH Seminar, June 1987

What's New with ECT. University of Texas Medical School - Houston, Department of Psychiatry, Grand Rounds, January 1988. (CME Credit)

Psychogenic Polydipsia. University of Texas Medical School Houston, Harris County Psychiatric Center, Grand Rounds, February 1988. (CME Credit)

The Psychiatric Presentation of Brain Tumors. University of Texas Medical School - Houston, Harris County Psychiatric Center, Grand Rounds, September 1988. (CME Credit)

Sandoz Pharmaceutical Distinguished Speaker Program 1988 - 1992.

"An Overview of the Treatment of Depression"

Settegast Clinic, Strawberry Clinic, Fort Bend Hospital, Gulf Coast Hospital

Galveston County Hospital, Casa de Amigas Clinic, Baytown Health Clinic

Cypress Fairbanks Medical Center, Dept. of Family Practice, UTMB, Heights Hospital. (CME Credit)

Dista Pharmaceutical Speaker Program 1989 - 1992

"Managing Treatment Resistance of Depression"

Harlingen Medical Society, Austin Internal Medicine Society, Travis County Chapter of Texas Academy of Family Physicians, N.W. Medical Center. (CME Credit)

HIH Lecture Series on Hospital Psychiatry Dec. 1989

The Differential Diagnosis of Depression. (CME Credit)

Grand Rounds, St. Joseph Hospital, Houston, Texas - Department of OB-GYN, February 7, 1990
Diagnosis and Treatment of Bulimia (CME Credit)

Grand Rounds, Baylor College of Medicine, Department of Psychiatry, February 14, 1990
Behavior Modification and the Treatment of Anorexia Nervosa on a Research Unit. (CME Credit)

Invited Speaker, Neurobiology of Mania Symposium, UTMSH, February 17, 1990

"Complicated Mania". (CME Credit)

Diagnostic Hospital, Houston, Lecture Seminar: Cerebral SPECT Scanning and Neuropsychiatry, January 31, 1991

National Institute of Mental Health. New Clinical Drug Evaluation Unit. May 1992, June 1993, May 1994. (CME Credit)

Depression and Insomnia. Heights Hospital, Houston, Texas, June 1992. (CME Credit)

Houston Alliance for Mentally Ill, Invited speaker. Imaging and Neuropsychiatry, September 1992

Depression and Insomnia. Diagnostic Hospital, Houston, Texas, October 1992

Psychiatric Emergencies. Heights Hospital, Houston, Texas, November 1992

The Psychiatric Evaluation of the Spine Patient, Invited speaker: Fondren Orthopedic Group, Spine Symposium, January 1993.

New Developements in Antipsychotic Medications. TMA Section on Neurology program. May 1994

Lectures at UTMSH, Department of Psychiatry, MSII Behavioral Science Course; 1988-1991.

Overview of Anorexia Nervosa

Overview of Bulimia Nervosa

Overview of Neuroendocrine System and Psychiatric Illness

Lectures at UTMSH, Department of Psychiatry, PGYI Lecture Series; 1988 - 1990

Evaluation of the ER Patient

Catatonia

ECT

MAOIs

Neuroendocrine Overview

Lectures at UTMSH, Department of Psychiatry PGYII Lecture Series: 1988 - 1990

Neuromodulators and Peptides: Basic Biology

Neuroendocrine and Peptide Hypotheses of Psychiatric Disorders

Lectures at UTMSH, Department of Psychiatry, PGYII Lecture Series: 1988 - 1990

Anorexia Nervosa - Overview with Emphasis on Biology and Hospital Treatment

Bulimia Nervosa - Overview with Emphasis on Biology and Hospital Treatment

The Efficacy and Safety of Three Doses of Sertindole Versus Three Doses of Haloperidol in Schizophrenic Patients, American Academy of Clinical Psychiatrists, Fort Lauderdale, FL, October 10-12th, 1996

Regional Advisory Committee for analysis of Serlect (Sertindole) data, Hotel Crescent Court, Dallas, Texas, October 19, 1996

Brewerton, TD, Lesem, MD, Kennedy, A. Decreased Plasma Leptin Levels in Bulimia Nervosa, APA Annual Meeting, May 17-22, 1997, San Diego, California.

ABSTRACTS:

Lesem, M.D., George, D. T., Kaye, W. H., Brewerton, T. D., Brandt, H. A., Goldstein, D., and Jimerson, D. C. Decrease in Plasma Norepinephrine Following Nutritional Stabilization in Underweight Patient with Anorexia Nervosa. Abstract of the Fifteenth C.I.N.P. Congress, December 1986.

Brewerton, T.D., Mueller, E.Z., George, D. T., Brandt, H. A., Lesem, M.D., Narang, P., Jimerson, D. C., and Murphy, D. L. Blunted Prolactin Response to m-CPP in Bulimia. Abstract of the Fifteenth C.I.N.P. Congress 1986.

Lesem, M. D., Gold, P. W., Hegg, A. P., and Jimerson, D. C. Relationship Between CSF CRH and MHPG in Anorexia Nervosa. Proceedings on 141st Annual Meeting American Psychiatric Association: NR:271 2988

Obarzanek, E. O., Lesem, M. D., and Jimerson, D. C. Resting Metabolic Rate During Weight Gain in Anorexia Nervosa. Fed. Proceed. 46:1336. 1987

Brewerton TD, Mueller EA, Brandt HA, Lesem MD, Jimerson DC, Murphy DL. Neuroendocrine studies with 5 HT agents in bulimia. Am Psychiatr Assoc Annual Mtg Proceedings 1987; 140:85-86 (#38E).

Jimerson, D.C., Brewerton, T. D., Hegg, A. P., Lesem, M. D., Murphy, D. L. Serotonin function in anorexia nervosa; longitudinal perspectives. Proceeds AM Coll. Neuropsychopharmacology 1987: 26.74.

Brewerton, T. D., Mueller, E. A., Brandt, H. A., Lesem, M. D., Murphy, D. L., Jimerson, D. C. Evidence for serotonin dysregulation in anorexia. Proceeds Am. Psychiatric Assoc. 1987: 140:NR195.

Obarzanek E, Lesem MD, Jimerson DC. Reduced resting metabolic rate in bulimic patients. Am Psychiatr Assoc New Res Prog.Abst 1987; 140:127 (#NR204).

Brandt, H. A., Hegg, A. P., Kassett, J. A., Lesem, M. D., Jimerson, D. C. Naloxone as a probe of opioid function in the eating disorders. Proceeds Third Int. Conf. on Eating Dis. 1988: 232.

Brewerton, T. D., Mueller, E. A., Brandt, H. A., Lesem, M. D., Murphy, D. L., and Jimerson, D. C. Dysregulation of 5-HT Function in Bulimia Nervosa. Proceedings of the 141st Annual Meeting American Psychiatric Association: NR:304. 1988.

Lesem, M. D., Swan, A. C., Obarzanek, E. O., and Jimerson, D. C. Effect of Weight Loss on Central Norepinephrine and Resting Metabolic Rate in Healthy Controls. Proceedings of ACNP 1988: 27:170.

Obarzanek, E. O., Lesem, M. D., and Jimerson, D. C. Enhanced Thermic Effect of Food after Exercising During Refeeding of Anorexic Patients. Proceedings of the Annual Meeting of FASEB. 1988: 2:A1224.

Demitrack, M. A., Lesem, M. D., Brandt, H. A., Piggot, T. A., Jimerson, D. C., and Gold, P. W. CSF Oxytocin in Anorexia Nervosa. Proceedings of 141st Annual Meeting American Psychiatric Association: NR:283. 1988.

Hegg, A. P., Lesem, M. D., Brandt, H. A., and Jimerson, D. C. Weight Loss, Opiate Function, and Eating Behavior. Proceedings of the 141st Annual Meeting American Psychiatric Association NR:293. 1988.

Jimerson, D. C., Lesem, M. D., Kaye, W. H., and Brewerton, T. D. Symptom Severity and Neurotransmitter Studies in Bulimia. Psychopharmacology 1988: 96:S124.

Brewerton, T. D., Brandt, H. A., Lesem, M. D., Hegg, A. P., Murphy, D. L., and Jimerson, D. C. Serotonin Dysregulation in Bulimia Nervosa. Abstract of the Third International Conference on Eating Disorders, 1988: 229.

Jimerson, D. C., Kaye, W. H., and Lesem, M. D. Evidence for Altered CSF HVA Levels in Bulimia. Proceedings of the 141st Annual Meeting American Psychiatric Association; NR: 121. 1988.

- Brandt, H. A., Hegg, A. P., Lesem, M. D., Piggott, T. A., Jimerson, D. C. Endogenous opioid system (EOS) dysregulation in anorexia nervosa and bulimia nervosa. *Psychopharmacology* 1988: 96:S183.
- Jimerson, D. C., Lesem, M. D., Kaye, W. H., Hegg, A. P., and Brewerton, T. D. Serotonin and Symptom Severity in Eating Disorders. *Biological Psychiatry* Vol. 25 No. 7a Suppl. Page 141a. 1989.
- Jimerson, D. C., Lesem, M. D., Hegg, A. P., and Brandt, H. A. Neurotransmitter Function in Major Depression and Eating Disorders. *Proceedings of the Regional Congress on Biological Aspects of Non-Psychotic Disorders, World Federation of Societies of Biological Psychiatry*, 1989: 182.
- Jimerson, D. C., Lesem, M. D., Hegg, A. P., Brewerton, T. D. Serotonin and human eating disorders. *Proceeds The New York Academy of Sciences Conference on Neuropharmacology of Serotonin* 1989: 38.
- Jimerson, D. C., Lesem, M. D., Seibel, M. M., Brewerton, T. D. CSF 5-HIAA and HVA alterations in bulimia: relationship to plasma estradiol levels. *Proceeds ACNP* 1989: 28:192.
- Jimerson, D. C., Obarzanek, E., Lesem, M. D., Piggott, T. A., and Brandt, H. A. Reduced Metabolic Rate in Bulimia Nervosa: Effect of Dietary Stabilization. *Biological Psychiatry* Vol. 25 No. 7a Suppl. pgs. 18a-19a, 1989.
- Brewerton, T. D., Brandt, H. A., Lesem, M. D., Hegg, A. P., Murphy, D. L. and Jimerson, D. C. Dysregulation of 5-HYT function in bulimia nervosa: relationship to anorexia nervosa and major depression. *Proceeds Regional Congress on Biological Aspects of Nonpsychotic Disorders, World Fed. of Societies of Biol. Psychiatry* 1989: 42.
- Clothier, J. C., Freeman, T., Pazzaglia, P., Lesem, M. D., and Swan, A. Sodium Valproate Treatment of Bipolar Patients. *Proceedings of the 142nd Annual Meeting of the American Psychiatric Association: NR:216.* 1989.
- Demitrack, M. A., Lesem, M. D., Kalogeras, K., Brandt, H. A., Granger, L., Gold, P. W. Plasma and Cerebral Fluid Abnormalities of Arginine Vasopressin Secretion in Patients with Bulimia Nervosa. *Proceedings ACNP*, 1989.
- Lesem, M. D., Kaye, W. H., Bissette, G., Jimerson, D. C., and Nemeroff, C. B. CSF Immunoreactive - TRH Levels in Anorexia. *Proceedings of the 143rd Annual Meeting American Psychiatric Association: NR:504,* 1990.
- Freeman, T. W., Clothier, J. L., Pazzaglia, P., Lesem, M. D., Swann, A. C., and Roache, A. Valproate in Mania: A Double Blind Study. *Proceedings of the 143rd Annual Meeting American Psychiatric Association; NR:393.* 1990.
- Walton, B. C., Jimerson, D. C., Lesem, M. D., Franko, D., Leirne, J. M., Covino, N. A. Impulsivity in Bulimia. A Serotonin Connection. *Proceedings on 144th Annual Meeting American Psychiatric Association: NR:121.* 1991.
- Jimerson DC, Lesem MD, Brewerton TD, Walton BE. Symptom chronicity and neurotransmitters in bulimia. *Am Psychiatr Assoc Annual Mtg Proceedings* 1992; 145:139 (#12C).

Walton BE, Jimerson DC, Lesem, MD. CSF and plasma tryptophan levels in bulimia nervosa and controls. *Am Coll Neuropsychopharmacology Annual Mtg Prog* 1992; 31:158.

Walton BE, Jimerson DC, Lesem, MD, Brewerton TD. Serotonin function in bulimia nervosa: Influence of plasma tryptophan. *Clin Neuropsychopharmacol* 1992;15 (suppl 1B):549B (#P-90-619).

Jimerson DC, Beyer LC, Lesem MD. Plasma HVA and dopamine function in patients with bulimia nervosa. *Clin Neuropsychopharmacol* 1992; 15(suppl 1B):548B (#P-90-617).

Jimerson DC, Lesem MD, Beyer LC. The role of central catecholaminergic pathways in eating disorders. *Neuroendocrinology Letters* 1992; 14:186.

Jimerson DC, Beyer LC, Lesem MD. Dopamine function in patients with bulimia: Comparison of HVA concentrations in plasma and CSF. *Biol Psychiatry* 1992; 31:139A (#181).

Claghorn, JL, Lesem, MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. *Journal of Affective Disorders* 34(1995); 165-171.

ARTICLES:

Reed, K., Lesem, M. D., and O'Malley, M.: Repercussions of Redefining a Consultation-Liaison Service in a General Teaching Hospital. *Letter of Hospital and Community Psychiatry*, 38:673-674. 1987.

Obarzanek, E. O., Lesem, M. D., and Jimerson, D. C. Enhanced Thermic Effect of Food after Exercising During Refeeding of Anorexic Patients. *Proceedings of the Annual Meeting of FASEB*. 1988: 2:A1224.

Lesem, M. D., George, D. T., Kaye, W. H., Goldstein, D. S., and Jimerson, D.C. State-Related Changes in Norepinephrine Regulation in Anorexia Nervosa. *Biological Psychiatry*. 25:509-512. 1989.

Demitrack, M. A., Lesem, M. D., Brandt, H. A., Pigott, T. A., Jimerson, D. C., Altemms, M., and Gold, P. W. Neurohypophyseal Dysfunction: Implications for the Pathophysiology of Eating Disorders. *Psychopharm Bull*. 25 (3). 1989.

Obarzanek E, Lesem MD, Goldstein DS, Jimerson DC. Reduced resting metabolic rate in patients with bulimia nervosa. *Arch Gen Psychiatry* 1991; 48:456-462.

Demitrack, M. A., Lesem, M. D., Listwak, S. J., Brandt, H. A., Jimerson, D. C., and Gold, P. W. Cerebrospinal Fluid Oxytocin in Nervosa and Bulimia Nervosa: Clinical and Pathophysiologic Considerations. *Am. J. Psychiatry*, July, 1990.

Jimerson, D. C., Lesem, M.D., Kaye, W. H., Hegg, A. P., and Brewerton, T. D. Eating Disorders and Depression: Is there a Serotonin Connection? *Biological Psychiatry* 28: 443-454. 1990.

Clothier, J. L., Pazzaglia, P. J., Freeman, T. W., Lesem, M. D., Swann, A. C. Plasma Level Response Characteristics of Valproate in the Treatment of Manic Syndrome. *Annals of Clinical Psychiatry*. 1991. Vol. 3, pp 321-324.

Freeman, T. W., Clothier, J. L., Pazzaglia, P., Lesem, M. D., Swann, A. C. A Double-Blind Comparison of Valproic Acid and Lithium in the Treatment of Acute Mania. *American Journal of Psychiatry*, January 1992. Vol. 149, pp 108-111.

Lesem, M. D., Berrettini, W. H., Kaye, W. H., and Jimerson, D. C. Measurement of CSF Dynorphin A 1-8 Immunoreactivity in Anorexia Nervosa and Normal Weight Bulimia. *Biological Psychiatry*, 29:244-252. 1991.

Jimerson, D. C., Lesem, M. D., Brewerton, T. D. Low Serotonin and Dopamine Metabolic Concentrations in CSF from Bulimic Patients with Frequent Binge Episodes. *Archives of General Psychiatry*. Vol. 49, No. 2:132. 1992.

Cherry, L. M., Funk, J., Lesser, J. M., Lesem, M. D. Gender Differences and the Interpretation of Genetic Instability in Alzheimer's Disease. *Mutation Research*. 275 (1992) 57-67.

Brewerton, T. D., Mueller, E. A., Lesem, M. D., Brandt, H. A., George, D. T., Murphy, D. L., and Jimerson, D. C. Neuroendocrine Responses to m-Chlorophenylpiperazine and L-Tryptophan in Bulimia. *Archives of Gen. Psychiatry*. Vol. 49, No. 11:852. 1992.

Counts, D. R., Gwirtsman, H., Carlsson, L. M. S., Lesem, M. D., Cutler, G. B. The Effect of Anorexia Nervosa and Refeeding on Growth Hormone-Binding Protein, the Insulin-Like Growth Factors (IGFs), and the IGF-Binding Proteins. *Journal of Clinical Endocrinology and Metabolism*. Vol. 75, No. 3:762. 1992.

Obarzanek E, Lesem MD, Jimerson DC. Resting metabolic rate of anorexia nervosa patients during weight gain. *American Journal of Clinical Nutr*. 60: 666-75. 1994.

Lesem MD, Kaye WH, Bissette G, Jimerson DC, Nemeroff CB. Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa. *Biol Psychiatry*. 35: 48-53. 1994.

Claghorn, JL, Lesem, MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. *Journal of Affective Disorders* 34: 165-171. 1995.

ARTICLES SUBMITTED

Mantzoros, C., Flier, J.S., Lesem, M.D., Brewerton, T.D., Jimerson, D.C. Relationship between cerebrospinal fluid and plasma leptin levels in healthy volunteers and in patients with anorexia nervosa. For submission to *The New England Journal of Medicine*, July 1996.

CHAPTERS:

Jimerson, D. C., Lesem, M. D., Hegg, A. P., and Brewerton, T. D. Serotonin in Human Eating Disorders - a chapter in the Neuropharmacology of Serotonin. Whitaker-Azmitia, P. M. and Peroutka, S.J. (eds). 1990.

Brewerton, T. D., Brandt, H. A., Lesem, M. D., Murphy, D. L., and Jimerson, D. C. Serotonin in Eating Disorders - a chapter in Serotonin in Major psychiatric Disorders. Cocarro, E. F. and Murphy, D. L. (eds) 1989.

Claghorn, JL, Lesem, MD. A Review of Recent Developments in Antidepressant Agents- a chapter in Progress in Drug Research. Ernst Jucker (ed) 1996.


GRANTS:



- 1988 **BRSg - Principal Investigator - Lithium-Clonazepam Treatment of Lithium Resistant Manic-Depressive Illness.**
- 1988 **DuPont - Principal Investigator - A Preliminary Study of DuP 996 in Dementia of Alzheimer's Type.**
- 1990 **MSDRL - Co-Investigator - A Triple-Blind, Parallel Study Comparing Two Dose Ranges of Remoxipride to Haloperidol in Hospitalized Patients with Schizophrenia.**
- 1990 **Abbott - Co-Investigator - Comparison of the Efficacy and Safety of Depakote and Lithium in the Treatment of the Manic Phase of Bipolar Disorder.**
- 1992 **Upjohn - Principal Investigator - Deracyn SR versus Xanax, generalized anxiety disorder.**
- 1992 **Merck - Principal Investigator - A double-blind, placebo- controlled study of the safety, tolerability, and preliminary efficacy of oral L705, 126 in patients suffering from acute migraine.**
- 1993 **Abbott - Co-Principal Investigator - Safety and efficacy of 3 fixed doses of Abbott-75200 for the treatment of Major Depressive Disorder and a double-blind, placebo-control outpatient study.**
- 1993 **Hoechst - Co-Principal Investigator - Multicenter, double-blind, parallel group 36 week safety, tolerance and efficacy comparison of placebo and mentane (275 mg/D, 300 mg/D, 375 mg/D) in outpatients with Alzheimer's disease.**
- 1993 **Merck - Co-Principal Investigator - A multicenter, double-blind, placebo-control dose ranging study of MK-462 in Acute Migraine.**
- 1993 **Lilly - Co-Principal Investigator - Olanzapine versus Haloperidol in the treatment of schizophrenia and other psychotic disorders.**
- 1993 **Organon - Co-Principal Investigator - A multicenter, active and placebo-controlled study of Organon-4428 in outpatients with Major Depression.**
- 1993 **Abbott - Co-Principal Investigator - An open-label assessment of the long term safety of sertindole in the treatment of patients with schizophrenia and other psychotic disorders.**
- 1994 **Abbott - Principal Investigator - A Double-blind, Placebo-Controlled, Dose-Response comparison of the safety and efficacy of three doses of Sertindole and three doses of haldol in Schizophrenic patients.**

- 1994 **Abbott-Principal Investigator** - An open label assessment of the long term safety of Sertindole.
- 1994 **Janssen-Principal Investigator**- Clinical evaluation of efficacy and safety of Sabeluzole in the treatment of Alzheimer's Disease.
- 1994 **American Cyanamid Company-Principal Investigator**- A Phase III, 28-Day, multi center, randomized, double-blind, comparative and placebo controlled parallel group safety, tolerance, and efficacy study of 5,10 and 20 mg of CL 284,846 (Zelaplon), compared with 10 mg of Zolpidem or placebo, in adult outpatient with Insomnia.
- 1994 **American Cyanamid Company-Principal Investigator**- A phase III, 6 month open-label safety and tolerance study of 5, 10, or 20 mg of CL 284,846 (Zalaplon), administered once-daily, in adult outpatients with Insomnia.
- 1994 **American Cyanamid Company-Principal Investigator**- A phase III, 14-day,multi center, randomized, double-blind, placebo-controlled parallel-group, safety, tolerance, and efficacy study of 5 and 10 mg of Zaleplon (CL 284,846), and 5 mg of Zolpidem (Ambien) in elderly outpatients with Insomnia, with a six month open-label extension phase.
- 1994 **Pfizer Inc. - Principal Investigator**-Forty week, double-blind study evaluating the safety and efficacy of two dose regimens of Oral Cp-88,, 059-1 (80-120mg, QD, and 40-80 mg BID) and Haloperidol 5-20 mg daily) in the maintenance treatment of outpatients with Schizophrenia or Schizo affective disorder,
- 1994 **Pfizer Inc. - Principal Investigator** - Phase III, six week, double-blind, multi center, placebo-controlled study evaluating the efficacy and safety of two fixed doses of oral (Cp-88,059-1) Ziprasidone (40 mg, BID and 80 mg, BID) in the acute exacerbation of Schizophrenia and Schizo affective disorder.
- 1994 **Solvay Pharmaceuticals- Principal Investigator**- Flesinoxan in the treatment of major depressive disorder: A single-center, double-blind, parallel group, placebo-controlled comparison with Imipramine in outpatients.
- 1995 **Organon, Inc. - Principal Investigator** - A long-term, multicenter, active and placebo controlled fixed-dose efficacy and safety study of Org 4428 in outpatients with major depression
- 1995 **Organon, Inc. - Principal Investigator** - An eight-week, multicenter, active and placebo controlled fixed-dose efficacy and safety study of Org 4428 in outpatients with major depression.
- 1995 **Pharmaco LSR - Principal Investigator** - A study of the efficacy of 4mg BID and 8mg QD Iloperidone (HP 873) administered to Schizophrenic and Schizoaffective patients for 42 Days followed by open - label treatment for one year.

- 1995 **Janssen Pharmaceutica - Principal Investigator - A randomized, double-blind, placebo controlled study of Risperidone for treatment of behavioral disturbances in subjects with dementia.**
- 1995 **Janssen Pharmaceutica - Principal Investigator - A dose-finding trial, comparing three fixed doses of Mazapertine to Risperidone and placebo: Multicenter, double-blind, parallel group study.**
- 1996 **Janssen Pharmaceutica - Principal Investigator - Mazapertine dose-finding trial, comparing three fixed doses of Mazapertine to risperidone and placebo: multi center, double-blind, parallel-group study.**
- 1996 **Parmaco LSR - Vanguard - Principal Investigator - A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi center, Single-Dose, Dose-range-Finding Study to Assess the Efficacy and Tolerability of VML 251 in the Acute Treatment of Migraine.**
- 1996 **Janssen Pharmaceutica - Principal Investigator - A Randomized, double-blind, placebo-controlled trial to compare the safety and efficacy of a single dose of alniditan (1.4 or 1.8 mg) given subcutaneously, to sumatriptan (6 mg) subcutaneous, in 735 subjects with moderate to severe migraine headache. The pharmacokinetics of alniditan and sumatriptan will be documented in a subgroup of subjects.**
- 1996 **Novartis (formally Sandoz) - An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg bid (3 mg/day) through 6 mg bid (12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting**
- 1996 **Pfizer Inc. - Principal Investigator - An Open-label, Multi center Clinical Trial Evaluating the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Alzheimer's Disease**
- 1996 **Pfizer Inc. - Principal Investigator - A Phase III Randomized Study Comparing 2 Doses of Intramuscular Ziprasidone (2 mg and 10 mg) in Subjects with Psychosis and Acute Agitation**
- 1996 **Pfizer Inc. - Principal Investigator - A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome**
- 1996 **Janssen Pharmaceutica - Principal Investigator- Open Evaluation of the Long-Term Efficacy, Safety and Tolerability of 1.4 mg Alniditan in the Acute Treatment of Migraine Attacks**

REFERENCES: Available Upon Request





PLEASE NOTE OUR NEW ADDRESS AND PHONE NUMBER -
P.O. BOX 2018, AUSTIN, TX 78768-2018, 512/305-71

CURRICULUM VITAE

Douglas Frederick Levinson, M.D.

Department of Psychiatry
Medical College of Pennsylvania at EPP
Philadelphia, PA 19129
Phone: 215-842-4558 (Office)
[REDACTED] (Home)

Date of birth: February 16, 1949
Married (Patricia Pekarik Garrity)
Three children (Michael, Matthew, David)

Education

A.B. magna cum laude in Social Relations, Harvard College, 1970
M.D. University of Pennsylvania School of Medicine, 1976

Postgraduate Medical Training

Intern in Pediatrics, Albert Einstein College of Medicine (Bronx Municipal Hospital Center),
1976-7
Resident in General Psychiatry, Mt. Sinai Hospital and Medical Center (New York), 1977-9
Fellow in Child and Adolescent Psychiatry, Albert Einstein College of Medicine, 1979-81
Research Fellow in Psychiatry, Albert Einstein College of Medicine (Bronx Psychiatric
Center), 1981-2

Professional Experience

Medical College of Pennsylvania, Department of Psychiatry:
Professor of Psychiatry, 1994-
Associate Professor of Psychiatry, 1987-1994
Assistant Professor of Psychiatry, 1982-1987
Director, Mid-Atlantic Schizophrenia Genetics Project, 1988-
Director of Psychiatry Residency Training, 1992-
Chief, Neuropsychiatric Unit, 1983-1992
Co-director, Psychophysiology Laboratory, 1982-1990

Boards

Diplomate in Psychiatry, American Board of Psychiatry and Neurology (1981, [REDACTED])
Diplomate in Child Psychiatry, American Board of Psychiatry and Neurology (1982,
#REDACTED)

Professional Associations

American Psychiatric Association
Society of Biological Psychiatry
American Society of Human Genetics

Editorial Boards

Schizophrenia Bulletin (Associate Editor)

Publications

1. Levinson, Douglas F.: Report on the mental health and retardation area boards, Massachusetts Department of Mental Health, 1969.
2. Levinson, Douglas F., and Crabtree, Loren H., Jr.: Ward tension and staff leadership in a therapeutic community for hospitalized adolescents. *Psychiatry*, 42:220-240, 1978.
3. Levinson, Douglas F., Edelberg, Robert, and Bridger, Wagner H.: The orienting response in schizophrenia: Proposed resolution of a controversy. *Biol Psychiatry*, 19:489-507, 1984.
4. Levinson, Douglas F., and Edelberg, Robert: Scoring criteria for response latency and habituation in electrodermal research. *Psychophysiology*, 22:417-426, 1985.
5. Levinson, Douglas F., and Simpson, G.: The emergency treatment of affective disorders. *Emerg Health Serv Review*, 3:42-47, 1985.
6. Levinson, Douglas F., Edelberg, R., and Maricq, H.: The skin conductance orienting response in neuroleptic-free schizophrenics: Replication of the scoring criteria effect. *Biol Psychiatry*, 20:646-653, 1985.
7. Levinson, Douglas F., and Simpson, George M.: EPS with fever: Heterogeneity of the neuroleptic malignant syndrome. *Arch Gen Psychiatry*, 43:839-848, 1986.
8. Schmidt, Katalin, Delaney, Mary Anne, Jensen, Martin, Levinson, Douglas F., and Levitt, Maria E.: Methylphenidate challenge in manic boy. (Letter) *Biol Psychiatry*, 21:1107-1109, 1986.
9. Levinson, Douglas F., and Levitt, Maria E.M.: Schizoaffective mania reconsidered. *Am J Psychiatry*, 144:415-425, 1987.
10. Levinson, Douglas F.: The manic patient. *Emerg Med Services*, 16:28, 1987.
11. Levinson, Douglas F.: Toward full disclosure of financial incentives and referral restrictions by health care plans. *New England J Medicine*, 317:1729-1731, 1987.
12. Levinson, Douglas F., and Simpson, George M.: Sequelae of neuroleptic malignant syndrome. (Letter) *Biol Psychiatry*, 22:237-241, 1987.
13. Levinson, Douglas F., and Acquaviva, J.: Exacerbation of panic disorder during propranolol therapy. *J Clin Psychopharm*, 8:193-195, 1988.
14. Levinson, Douglas F., Simpson, G.M., Singh, H., Cooper, T.B., Laska, E.V., and Midha, K.K.: Neuroleptic plasma level may predict response in patients who meet a criterion for improvement. (Letter) *Arch Gen Psychiatry*, 45:878-879, 1988.
15. Levinson, Douglas F.: Twin studies and genetic models of schizophrenia. (Letter) *Arch Gen Psychiatry*, 45:876-877, 1988.
16. Levinson, Douglas F.: What HMOs should tell their subscribers, and what you can do about it. *Consultant*, 29(5):118-125, 1989.
17. Levinson, Douglas F., Simpson, G.M., Singh, H., Yadalam, K., Jain, A., Stephanos, M.J., and Silver, P.: Fluphenazine dose, clinical response and extrapyramidal symptoms during acute treatment. *Arch Gen Psychiatry*, 47:761-768, 1990.
18. Mueser, Kim T., Yarnold, P.R., Levinson, D.F., Singh, H., Bellack, A.S., Kee, K., Morrison, R.L., and Yadalam, K.G.: Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. *Schizophrenia Bulletin*, 16:31-56, 1990.
19. Singh, Hardeep, Levinson, Douglas F., Simpson, George M., Lo, E.-S., and Friedman, Eitan: Acute dystonia during fixed-dose neuroleptic treatment. *J Clin Psychopharmacol*, 10:389-396, 1990.

20. Simpson, George M., Yadalam, Kashinath G., Levinson, Douglas F., Stephanos, Mary Jeanne, Lo, E.-S., and Cooper, Thomas B.: Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. *J Clin Psychopharmacol*, 10:417-421, 1990.
21. Levinson, Douglas F.: Pharmacologic treatment of schizophrenia. *Clinical Therapeutics*, 13(3):326-352, May/June 1991.
22. Levinson, Douglas F., and Mowry, Brian M.: Defining the schizophrenia spectrum: Issues for genetic linkage studies. *Schizophrenia Bulletin*, 17(3):491-514, 1991.
23. Levinson, Douglas F.: Skin conductance orienting response in unmedicated RDC schizophrenic, schizoaffective, depressed and control subjects. *Biol Psychiatry*, 30:663-683, 1991.
24. Levinson, Douglas F., Singh, Hardeep, and Simpson, George M.: Timing of acute clinical response to fluphenazine: A controlled study. *Brit J Psychiatry*, 160:365-371, 1992.
25. Gratz, Silvia S., Levinson, Douglas F., and Simpson, George M.: The treatment and management of neuroleptic malignant syndrome. *Prog Neuro-Psychopharmacol & Biol Psychiat*, 16:425-443, 1992.
26. Levinson, Douglas F.: Linkage information in small family structures: Comparison of pedigrees with three to five affected members. *Psychiatric Genetics*, 3:45-56, 1993.
27. Friedman, Eitan, Hoau-Yan-Wang, Levinson, Douglas, Connell, Thomas A., and Singh Hardeep: Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. *Biol Psychiatry*, 33:520-525, 1993.
28. Mowry, Bryan J., and Levinson, Douglas F.: Genetic linkage and schizophrenia: Methods, recent findings and future directions. *Australian and New Zealand Journal of Psychiatry*, 27:200-218, 1993.
29. Levinson, Douglas F.: Power to detect linkage with heterogeneity in samples of small nuclear families. *American Journal of Medical Genetics (Neuropsychiatric Genetics)*, 48:94-102, 1993.
30. Webb, Carmen, Levinson, Douglas F., and Gladis, Madeline: Schizotypal and paranoid personality in the relatives of patients with schizophrenia and affective disorders: A review. *Schizophrenia Research*, 11:81-92, 1993.
31. Maier, Wolfgang, Lichtermann, Dirk, Minges, Jurgen, Hallmayer, Joachim, Heun, Reinhard, Benkert, Otto and Levinson, Douglas F.: Continuity and discontinuity of affective disorders and schizophrenia: Results of a controlled family study. *Arch Gen Psychiatry*, 50:871-883, 1993.
32. Gladis, Madeline, and Levinson, Douglas F.: Delusions and schizophrenia spectrum disorders: Diagnostic issues. *Schizophrenia Bulletin*, 20:747-754, 1994.
33. Levinson, Douglas F., Simpson, George M., Lo, E.-S., Cooper, Thomas B., Singh, Hardeep, Yadalam, Kashinath, and Stephanos, Mary Jeanne: Fluphenazine plasma levels, dosage, efficacy and side effects. *American Journal of Psychiatry*, 152:765-771, 1995.
34. Levinson, Douglas F.: Detection of vulnerability loci by association and sib pair methods. *Genetic Epidemiology*, 12:631-636, 1995.
35. Mowry, Bryan J., Nancarrow, Derek J., Lennon, David P., Sandkuijl, Lodewijk A., Crowe, Raymond R., Silverman, Jeremy M., Mohs, Richard C., Siever, Larry J., Endicott, Jean, Sharpe, Lawrence, Walters, Marilyn K., Hayward, Nicholas K., Levinson, and Douglas F.: Schizophrenia susceptibility and chromosome 6p24-22. *Nature Genetics*, 11:233-234, 1995.

36. Levinson, Douglas F., Mowry, Bryan J., Sharpe, Lawrence and Endicott, Jean: Penetrance of schizophrenia-related disorders in multiplex families after correction for ascertainment. *Genetic Epidemiology*, In press.

Abstracts

1. Levinson, Douglas F.: Who is an affected relative in genetic linkage studies of schizophrenia? *Schizophrenia Research*, Vol 2(1-2):49, 1989.
2. Singh, H., Levinson, D.F., Simpson, G.M., and Cooper T.M.: Acute dystonic reactions during fixed-dose neuroleptic treatment. *Schizophrenia Research*, Vol. 2(1-2):247, 1989.
3. Friedman, E., Wang, H.Y., Singh, H., Levinson, D., and Connell T.: Altered protein kinase C (PKC) activity during lithium treatment. *Biological Psychiatry*, Vol. 25, No. 274, 1989.
4. Singh, H., Levinson, D., and Simpson, G.: Acute dystonia during fixed-dose neuroleptic treatment. *Biological Psychiatry*, Vol. 25, No. 328, 1989.
5. Levinson, D., Singh, H., Simpson, G., Cooper, T. and Friedman, E.: Acute HVA and prolactin response to fluphenazine challenge in patients with psychosis and/or stimulant abuse. *Biological Psychiatry*, Vol. 25, No. 357, 1989.
6. Levinson, D., Singh, H., and Simpson, G.: Timing of clinical improvement during acute fluphenazine treatment. *Biological Psychiatry*, Vol. 25, No. 361, 1989.
7. Levinson, D.F., Mowry, B.J., and Gladis, M.M.: Sooner rather than later: A rationale for large collaborative linkage studies of schizophrenia and other major disorders. *Psychiatric Genetics*, 3:157, 1993.
8. Gladis, M.M., Webb, C.T., McGrady, N., Bosch, U., Mensch, E., and Levinson, D.F.: Genetic risk perceptions among family members of schizophrenia patients. *Psychiatric Genetics*, 3:191, 1993.
9. Levinson, Douglas F., Sandkuil, Lodewijk A., and Mowry, Bryan J.: "Robust weighting" of broader diagnostic categories in one model can improve power over use of multiple models. *Psychiatric Genetics*, 5:S42, 1995.
10. Mowry, Bryan J., Mahtani, Melanie, Hudson, James R., Crowe, Raymond R., Silverman, Jeremy M., Hayward, Nicholas, Nancarrow, Derek, Sandkuil, Lodewijk, Sharpe, Lawrence, Endicott, Jean, and Levinson, Douglas F.: Genome screen of schizophrenia in 45 multiplex families. *Psychiatric Genetics*, 5:S59-60, 1995.

Book Chapters

1. Crabtree, Loren H., Jr., Levinson, Douglas F.: Recurrent large-group phenomena: Studies of an adolescent therapeutic community. In S. Feinstein, et al., eds., *Adolescent Psychiatry*, Volume VIII, pp. 512-527, University of Chicago Press, Chicago: 1980.
2. Levinson, Douglas F., and Simpson, George M.: The emergency treatment of affective disorders. In E.S. O'Neill, ed: *The Psychiatric Emergency: Its Recognition and Management*. The Haworth Press, New York, 1986, pp.45-54.
3. Goldstein, Perry C., and Levinson, Douglas F.: Psychiatric aspects of neurological disorders. In R.L. Morrison and A.S. Bellack, eds: *Medical Factors in Psychological Disorders: A Handbook for Psychologists*. Plenum Press, New York, 1987, pp. 232-259.
4. Levinson, Douglas F., and Simpson, George M.: Anti-psychotic drug side effects. In R.E. Hales and A.J. Frances, eds.: *American Psychiatric Association Annual Review, Volume 6: Psychopharmacology*. American Psychiatric Press, Washington, D.C., 1986, pp. 12-31.

5. Levinson, Douglas F., and Simpson, George M.: Serious non-extrapyramidal adverse effects of neuroleptics: Sudden death, agranulocytosis and hepatotoxicity. In H. Meltzer, et al., eds.: *Psychopharmacology: A Generation of Progress (III)*. Raven Press, New York, 1987, pp. 1431-6.
6. Simpson, George M., and Levinson, Douglas F.: Can we increase the response to somatic therapies for schizophrenia? In S.J. Dencker and F. Kuhanek, eds.: *Treatment Resistance in Schizophrenia*. Freidr, Vieweg & Son, Braunschweig/Weslbaden, 1988, pp. 44-55.
7. Gratz, Silvia S., Levinson, Douglas F., Simpson, George M.: Neuroleptic malignant syndrome. In J.M. Kane and J. A. Lieberman, eds.: *Adverse Effects of Psychotropic Drugs*, Raven Press, New York, 1992, pp. 266-284.
8. Levinson, Douglas F., Simpson, George M., Lo, E.-S., Cooper, Thomas B.: Fluphenazine plasma levels, dose, and acute treatment response. In S.R. Marder, et al., eds.: *Clinical Use of Neuroleptic Plasma Levels*, American Psychiatric Press, Washington, D.C., 1993, pp. 45-61.

Other Scientific Presentations

1. Levinson, Douglas F.: Habituation of the skin conductance orienting response (SCOR) in schizophrenia: proposed resolution of a controversy. 38th Annual Convention, Society for Biological Psychiatry, April 29, 1983, New York.
2. Simpson, George M., Levinson, Douglas F., Midha, Kamal K., Yadalam, Kashinath, Jain, Anil, Singh, Hardeep, Stephanos, Mary Jeanne, Levitt, Maria E.: Fluphenazine blood levels and therapeutic efficacy. World Congress of Biological Psychiatry, Sept 10, 1985, Philadelphia.
3. Simpson, George M., Yadalam, Kashinath, Levinson, Douglas F., Stephanos, Mary Jeanne, Cooper, Thomas B., Lo, E.-S.: Single-dose kinetics of fluphenazine decanoate. American Psychiatric Association, 139th Annual Meeting, May 13, 1986, Washington, D.C.
4. Levinson, Douglas F., Simpson, George M.: Serious non-extrapyramidal adverse effects of neuroleptics: sudden death, agranulocytosis and hepatotoxicity. American College of Neuropsychopharmacology, 25th Annual Meeting, Dec 12, 1986, Washington, D.C.
5. Levinson, Douglas F., Simpson, George M.: Anti-psychotic drug side effects. American Psychiatric Association, 140th Annual Meeting, May 14, 1987, Chicago.
6. Levinson, Douglas F. Levitt, M.E.M.: Autonomic and clinical abnormalities in RDC schizoaffective (mainly schizophrenia) vs. schizophrenic and affective disorders. The 42nd Annual Convention, Society of Biological Psychiatry (poster session), May 7, 1987.
7. Levinson, Douglas F., Singh, H., Simpson, G.M., Friedman, E.: Acute increase in plasma homovanillic acid after oral fluphenazine in psychiatric patients. American College of Neuropsychopharmacology, 26th Annual Meeting, Dec 8, 1987, San Juan.
8. Levinson, Douglas F., Simpson, G.M.: Problems in defining the relationship between neuroleptic drug levels and drug effects. American College of Neuropsychopharmacology, 26th Annual Meeting, Dec 11, 1987, San Juan.
9. Levinson, Douglas F., Singh, H., Yadalam, K.: Fluphenazine dose and clinical response. American Psychiatric Association, 141st Annual Meeting, May 12, 1988, Montreal.
10. Simpson, George M., Levinson, D.F., Singh, H., Stephanos, M.J., Yadalam, K.G.: Akathisia as a predictor of outcome in neuroleptic treatment. Sixteenth CINP Congress, Munich, August, 1988.

11. Levinson, Douglas F.: Who is an affected relative in genetic linkage studies of schizophrenia? Second International Congress on Schizophrenia Research, San Diego, April, 1989.
12. Singh, H., Levinson, D.F., Simpson, G.M., and Cooper T.M.: Acute dystonic reactions during fixed-dose neuroleptic treatment. Second International Congress on Schizophrenia Research, San Diego, April 1-5, 1989.
13. Friedman, E., Wang, H.Y., Singh, H., Levinson, D., and Connell T.: Altered protein kinase C (PKC) activity during lithium treatment. Forty-fourth annual convention, Society of Biological Psychiatry, San Francisco, May 4-8, 1989.
14. Singh, H., Levinson, D., and Simpson, G.: Acute dystonia during fixed-dose neuroleptic treatment. Forty-fourth annual convention, Society of Biological Psychiatry, San Francisco, May 4-8, 1989.
15. Levinson, D., Singh, H., Simpson, G., Cooper, T. and Friedman, E.: Acute HVA and prolactin response to fluphenazine challenge in patients with psychosis and/or stimulant abuse. Forty-fourth annual convention, Society of Biological Psychiatry, San Francisco, May 4-8, 1989.
16. Levinson, D., Singh, H., and Simpson, G.: Timing of clinical improvement during acute fluphenazine treatment. Forty-fourth annual convention, Society of Biological Psychiatry, San Francisco, May 4-8, 1989.
17. Levinson, D., and Green, P.: Linkage information in studies of small families. First World Congress on Psychiatric Genetics, Cambridge, England, August 3-5, 1989.
18. Levinson, D.F., Singh, H., Simpson, G.M., Cooper, T.B., Lo, E.S.: Fluphenazine dose-response and plasma levels studies. American Psychiatric Association 143rd Annual Meeting, New York, May, 1990.
19. Levinson, D.: Genetics of schizophrenia. Seventh Annual Pennsylvania Conference on Schizophrenia, Philadelphia, PA, March 13, 1992.
20. Levinson, D.F., Simpson, G.M., Cooper, T.B., Lo, E.S., Singh, H.: Fluphenazine dose, plasma level and clinical response. American Psychiatric Association 145th Annual Meeting, Washington, D.C., May, 1992.
21. Levinson, D.F., Simpson, G.M., Lo, E.S., Cooper, T.B.: Fluphenazine plasma levels, dosage, efficacy and side effects. American College of Neuropsychopharmacology, 33rd Annual Meeting, San Juan, December 14, 1994.

Continuing Medical Education

1. Levinson, D.F., Berrettini, W.: Overview of Psychiatric Genetics. CME course (Invited), American Psychiatric Association 145th Annual Meeting, Washington, D.C., May, 1992.

Research funding

Past:

1. Autonomic OR in Schizophrenia (PI). NIMH MH-40803. 4/1/86-3/30/89.
2. Fluphenazine blood levels, efficacy and pharmacokinetics (Project Director). George M. Simpson, M.D., PI. NIMH MH-41585. 7/1/86-6/30/91.
3. Ascertainment of multiply affected families for RFLP study of schizophrenia (PI). Scottish Rite Schizophrenia Research Program. 8/1/88-7/31/90.

Present:

1. Genetic linkage of schizophrenia using an RFLP map of the genome (PI).
4/1/90-3/31/95, with one-year extension in time. Approximately \$1,700,000 total direct costs.

DISPLAY THIS CERTIFICATE PROMINENTLY • NOT TO BE REPRODUCED OR COPIED WITHOUT THE WRITTEN PERMISSION OF THE BOARD OF PROFESSIONAL AND OCCUPATIONAL AFFAIRS

Commonwealth of Pennsylvania
Department of State
Bureau of Professional and Occupational Affairs
P.O. BOX 2845, Harrisburg, PA 17103-2845

MEDICAL PHYSICIAN AND SURGEON

Certificate Number: [REDACTED]
Certification Date: SEP 15 1996
Expires: DEC 31 1998

Issued To:
DOUGLAS FREDERICK LEVINSON
[REDACTED]

Signature: *Dorothy Childress*
Commissioner of Professional and Occupational Affairs

ALTERATION OF THIS DOCUMENT IS A CRIMINAL OFFENSE UNDER 18 P.S. § 4911

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE		
UNITED STATES DEPARTMENT OF JUSTICE		
DRUG ENFORCEMENT ADMINISTRATION		
WASHINGTON, D.C. 20537		
Sections 304 and 1008 (21 U.S.C. 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.		
DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
[REDACTED]	03-31-2000	\$210.00
SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3,3N,4,5	PRACTITIONER	03-10-1997
LEVINSUN, DOUGLAS FREDRICK MD DEPT OF PSYCHIATRY EASTERN PENN PSYCHIATRIC INSTI 3200 HENRY AVE PHILADELPHIA, PA 19129		
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.		

Form DEA-223 (10/96)

DISPLAY THIS CERTIFICATE PROMINENTLY • NOTIFY AGENCY WITHIN 10 DAYS OF ANY CHANGE

Commonwealth of Pennsylvania
Department of State
Bureau of Professional and Occupational Affairs
P.O. BOX 2649, Harrisburg, PA 17105-2649

MEDICAL PHYSICIAN AND SURGEON

Certificate Number: [REDACTED]

Certification Date: SEP 15 1998

Expires: DEC 31 2000

Issued To: DOUGLAS FREDERICK LEVINSON

Signature: [REDACTED]

Commissioner of Professional and Occupational Affairs

ALTERATION OF THIS DOCUMENT IS A FEDERAL OFFENSE UNDER 18 PA.C.S. § 901

BIOGRAPHICAL SKETCH

Give the following information for the key personnel, consultants, and collaborators. Begin with the principal investigator/program director. Photocopy this page for each person.

NAME	POSITION TITLE		
Jean-Pierre Lindenmayer, M.D.	Director, Research		
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
University of Basel Medical School Basel, Switzerland	Diploma of Med. & Surg.	1967	
Downstate Medical Center, State University of New York, Brooklyn, New York	Psychiatric Residency	1970-73	Psychiatric
Downstate Medical Center	Fellowship	1973-74	Research

RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list in chronological order previous employment, experience, and honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on any Federal Government Public Advisory Committee. List, in chronological order, the titles and complete references to all publications during the past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES.

1973-76 Attending Physician, Psychiatric Inpatient Service, University Hospital Downstate Medical Center, State University of New York, Brooklyn, New York
 1973-74 Staff Psychiatrist, Brooklyn Community Counseling Center, Brooklyn, New York
 1974- Private Practice, New York, New York
 Present
 1976-77 Acting Director, Psychiatric Inpatient Service, University Hospital, Downstate Medical Center, State University of New York, Brooklyn, New York
 1977-79 Chief Attending, Bronx Municipal Hospital Center/Albert Einstein College of Medicine, Bronx, New York
 1979-80 Director, Adult Psychiatric Inpatient Service, Department of Psychiatry, Bronx Municipal Hospital Center/Albert Einstein College of Medicine, Bronx, New York
 1980-83 Supervising Psychiatrist, Northwest Bronx Unit, Bronx Psychiatric Center, Bronx, New York
 1983-86 Unit Chief, Residency Training Unit, Bronx Psychiatric Center, Bronx, New York
 1986-91 Director, Movement Disorder Clinic, Bronx Psychiatric Center, Bronx, New York
 1986-88 Director, Department of Psychiatry, Bronx Psychiatric Center, Bronx, New York
 1988-94 Director, Schizophrenia Research Unit, Albert Einstein College of Medicine-Bronx Psychiatric Center, Bronx, New York
 1994- Director, Psychopharmacology Research Unit, Manhattan Psychiatric Center,
 Present New York, New York

Academic Appointments:

1974-75 Assistant Instructor, Downstate Medical Center, State University of New York, Brooklyn, New York
 1973-77 Assistant Professor, Department of Psychiatry, Downstate Medical Center, State University of New York, Brooklyn, New York
 1977-87 Assistant Clinical Professor, Department of Psychiatry, Albert Einstein College of Medicine, Bronx, New York
 1987-91 Associate Clinical Professor, Department of Psychiatry, Albert Einstein College of Medicine, Bronx, New York
 1994- Clinical Professor, Department of Psychiatry, New York
 present University School of Medicine, New York, NY

PUBLICATIONS:

1. Lindenmayer J.P.: Heredity in Familial Oxalosis. J Gen Hum., Vol 18, #1:31-44, 1970
2. Lindenmayer J.P. and Papenheim.: Else, A Case of Accidental Electrocution: A Clinical-Pathological Report. Psych Quarterly, Vol. 47, #2:218-227, 1973
3. Lindenmayer J.P. and Grad G.F.: The Psychiatric Emergency Room: A Study of Patient Treatment Requests. Int J Soc Psy. Vol 23, #2:132-139, 1977
4. Lindenmayer J.P., Steinberg M.D., Bjork D. and Padres H.: Voluntary Sterilization in Young, Childless Women. J of Reprod Medicine, Vol. 19 #2:87-91, 1977.
5. Bjork D., Steinberg M., Lindenmayer J.P. and Pardes H.: Mania and Mileu. Hosp Comm Psych, Vol. 28, #6:431-436, 1977.
6. Lindenmayer J.P. and Kline N.S.: Psychiatric Emergencies (12 chapters), in: "Principles and Management of Emergency Medicine" edited by GR Schwartz, Saunders, Philadelphia, 1978. 2nd Edition 1985.
7. Lindenmayer J.P.: Handling Sterilization Requests of Nulliparous Women: Hum Sexuality, #13:87-88, June 1979.
8. Lindenmayer J.P. and Vargas, Pilar: Psychosis Following Use of Quinacrine. J of Clin Psychiatry, #42:162-164, 1981.
9. Lindenmayer J.P.: Teaching Psychopharmacology to Psychiatric Residents. J of Psych Educ., Vol. 5, #1:40-43, 1981.
10. Karasu T.B., Waltzman S., Lindenmayer J.P. and Buckley P.: Psychiatric Patients and Medical Illness. Hosp Comm Psych., #31:463-472, 1980.
11. Kline N.S. and Lindenmayer J.P.: Psychotropic Drugs: Manual for Emergency Management of Overdosage. Medical Economics Company, Oradell, New Jersey, 1981.
12. Lindenmayer J.P.: Outcomes of Psychosocial Treatments in Schizophrenia. Méd et Hygiène, Vol. 39:3103-3108.
13. Opler L., Kay S., Rosado V., and Lindenmayer J.P.: Positive and Negative Syndromes in Chronic Schizophrenic Inpatients. J of Mental and Nerv Dis, 172:317-325, 1984.
14. Lindenmayer J.P., Katz I., Smith D.: Radioreceptor Essay of Neuroleptics in Treatment Refractory Chronic Schizophrenic Patients. J of Clin Psych, 45:117-119, 1984.

15. Lindenmayer J.P., Kay S and Opler L. Positive and Negative Subtypes in Acute Schizophrenia. Compr Psych, 25:455-464, 1984.
16. Lindenmayer J.P., Kay S. and Friedman C.: Follow-up of positive and negative symptoms in young acute schizophrenics. Abstracts of the IVth World Congress of Biological Psychiatry, Philadelphia Society of Biological Psychiatry, 1985, p. 50.
17. Lindenmayer J.P., Kay S. and Friedman C.: Negative and Positive Schizophrenic Syndromes after the Acute Phase: A Follow-Up. Compr Psych, 27:276-296, 1986.
18. Kay S., Fiszbein A., Lindenmayer J.P. and Opler L.: Positive and Negative Syndromes in Schizophrenia as a Function of Chronicity. Acta Psych Scand, 74:507-518, 1986.
19. Kay S and Lindenmayer J.P.: Outcome Predictors in Acute Schizophrenia. J. of Mental and Nerv. Dis., 175:152-160, 1987.
20. Lindenmayer J.P.: Book Review: Clinical Handbook of Depression: J.W. Wetzel. J Am Orthopsych. Assoc., 56:639, 1986.
21. Lindenmayer J.P., Kay S.R., Friedman C.: Follow-up of Positive and Negative Symptoms in Young Acute Schizophrenics. Int J. Neuroscience, 31:86-87, 1986.
22. Kanofsky J.D., Kay S.R., Lindenmayer J.P. and Opler L.A.: Catatonic Schizophrenia and Negative Syndrome. Can. J. Psychiatry, 32:162, 1987.
23. Kay S.R., Kanofsky J.D., Lindenmayer J.P. and Opler L.A.: The Changing Presentation of Catatonia. Am. J. Psychiatry, 144:834-835, 1987.
24. Lindenmayer J.P., Kay S.R. and Opler L.A.: Catamnestic Course of Positive and Negative Syndromes. Continuing Medical Education Syllabus and Scientific Proceeding of the American Psychiatric Association. Washington, D.C.: APA, 1987, p. 149.
25. Kay S.R. and Lindenmayer J.P.: Outcome Predictors in Acute Schizophrenia. Psychiatry Digest, #8:11-13, 1987.
26. Lindenmayer J.P., Weiner M., Kay S.R., Opler L.A., Gardner E. and van Praag H.M.: High Dose Naloxone in Tardive Dyskinesia Patients. Continuing Medical Education Syllabus and Scientific Proceedings of the American Psychiatric Association. Washington, D.C.: APA, 1987, p. 245.
27. Kay S.R., Opler L.A. and Lindenmayer J.P.: Reliability and Validity of the Positive and Negative Syndrome Scale for Schizophrenics. Psych Res, #123:99-110, 1988.
28. Lindenmayer J.P., Gardner E., Kay S.R., Opler L.A., Goldberg E.,

- van Praag H.M., Zukin S. and Weiner M.: High Dose Naloxone in Tardive Dyskinesia. Psych Res, #26:19-28, 1988.
29. Kay S.R., Opler L.A. and Lindenmayer J.P.: The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardization. Brit J Psychiatry #155:59-65, 1989.
30. Lindenmayer J.P. and Kay S.R.: Depression, Affect and Negative Symptoms in Schizophrenia. Brit J Psychiatry #155:108-114, 1989.
31. Kay S.R., Fiszbein A., Lindenmayer J.P. and Opler L.A.: Positive and Negative Syndromes in Schizophrenia as a Function of Chronicity. In H. Weiner (Ed.), Year Book of Psychiatry and Applied Mental Health. Chicago: Year Book Medical Publishers, 1988.
32. Lindenmayer J.P., Kay S.R. and van Praag H.M.: Schizoaffective Disorder: A Distinct Entity? New Research Program and Abstracts of the 141st Annual Meeting of the American Psychiatric Association. Washington, D.C.: APA, 1988 p. 37.
33. Kanofsky J.D., Kay S.R., Lindenmayer J.P. and Seifter L.: Ascorbic Acid and Dopamine Activity. Am J Psychiatry #145:904-905, 1988.
34. Lindenmayer J.P.: Book Review of the Stanley Dean Award Lectures: Research in Schizophrenia. Am J Psychiatry (In Press).
35. Lindenmayer J.P.: Book Review: Handbook of Clinical Neuropsychology (ed.) S. Filskov and Boll, T.J. Readings (In Press).
36. Lindenmayer J.P.: Book Review: Clinical Research in Schizophrenia. R.R. Grinker and M. Harrow (eds). Am J Psych #146:933-934, 1989.
37. Lindenmayer J.P., Kay S.R. and van Praag H.: Distinction of Schizoaffective and Schizophrenic Profile: Independent Validation. Schizophrenia Research #2:423-424, 1989.
38. Lindenmayer J.P., Vakharia M. and Kanofsky D.: Fluoxetine in Chronic Schizophrenia. J Clin Psychopharmacol (letter) #19:76, 1990.
39. Kay S.R. and Lindenmayer J.P.: Stability of Psychopathology Dimensions in Chronic Schizophrenia: Response to Clozapine Treatment. Comp Psychiatry 32:28-35, 1991.
40. Lindenmayer J.P., Kay S.R. and Plutchik R.: Multivantaged Assessment of Emotions Schizophrenia. Psych Res #42:199-207, 1992.
41. Lindenmayer J.P., Mabusat L., Kay S.R., Murril L. and Sevy S.: Clozapine Effects on Positive Versus Negative Symptoms. J Clin Psychopharmacol #14:201-204, 1994.
42. Lindenmayer J.P. and Grochowski S.: Schizophrenic Patients with Depression: Psychopathological Profiles and Relationship with

- Negative Symptoms. Comp. Psychiatry #32:528-533, 1991.
43. Lindenmayer J.P. and Kay S.R. (eds): New Biological Vistas in Schizophrenia. Brunner/Mazel, New York, 1992.
44. Bark N. and Lindenmayer J.P.: Ineffectiveness of Clomipramine for Obsessive-compulsive Symptoms in a Patient with Schizophrenia. Am J Psychiatry (letter) #149:136-137, 1991.
45. Fields J.H., Grochowski S., B.A., Lindenmayer J.P., Kay S.R., Grosz D., Hyman R.B. and Alexander G.: Assessing Positive and Negative Symptoms in Children and Adolescents. Am J Psychiatry. #151:249-253, 1994.
46. Lindenmayer J.P.: Les symptômes négatifs de la schizophrénie: aspects psychiatriques et biologiques. Cahiers Psychiatriques Genèveois. #13:135-148, 1992.
47. Lindenmayer J.P., Grochowski S. and Hyman R.B.: Five Factor Model of Schizophrenia: Replication Across Samples. Schizophrenia Res #14:229-234, 1995.
48. Lindenmayer J.P., Bernstein-Hyman RB and Grochowski S.: Five Factor Model of Schizophrenia: Initial Validation. J. Nerv. Ment. Disease #182:631-638, 1994.
49. Lindenmayer J.P., Adiyantje Moynihan N., Bark N., Grochowski S., V. Praag H. and Handler H. Behavioral Response to MCPP in Chronic Schizophrenics. Clinical Neuropharmacology 15, suppl. 1, part B, 23, 1992.
50. Fields J.H., Kay S., Grochowski S., Lindenmayer J.P., Grosz D., Alexander G., Paul G., Fiszbein A. and Opler L. A positive and Negative Symptom Scale for Children and Adolescents. Clinical Neuropharmacology 15, suppl. 1, part B, 52B, 1992.
51. Opler L.A., Ramirez P.M., Lindenmayer J.P. and Wilken C.: Social Unrelatedness as a Schizophrenic Dimension. Int. J. of Neuroscience (in press).
52. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U. and Lindenmayer J.P.: Glycine Augmentation of NMDA-Receptor Mediated Neurotransmission in Schizophrenia: Improvement in Negative Symptoms. Am. J. Psychiatry #151:1234-1236, 1994.
53. Lindenmayer J.P., Bernstein-Hyman R. and Grochowski S.: A new Five Factor Model of Schizophrenia. Psych Quarterly #65:299-322, 1994.
54. Lindenmayer J.P.: The Positive and Negative Syndrome Scale: Its use in psychopharmacological Research. Int J. Methods in Psych Res (in press).
55. Lindenmayer J.P.: Recent Advances in Pharmacotherapy of

- Schizophrenia. Psych Annals #23:201-208, 1993.
56. Lindenmayer J.P.: Risperidone: Efficacy and Side Effects. J Clin Psych (Monogr.) #12:53-58, 1994.
57. Lindenmayer J.P.: New Pharmacotherapeutic Modalities for Negative Symptoms. Acta Psych Scand #91:Suppl.388; 15-19, 1995.
58. Bell M.D., Lysaker P.H., Beam-Goulet J.L., Milstein R. and Lindenmayer J.P.: Five-component Model of Schizophrenia: Assessing the Factorial Invariance of the Positive and Negative Syndrome Scale. Psychiatric Res #52:295-303, 1994.
59. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. and Bark N. Psychopathology of Schizophrenia: Initial Validation of a 5-Factor Model. Psychopathology 28:22-31, 1995.
60. Lindenmayer J.P., DaSilva D., Brendia A., Zylberman I. and Vital-Herne M.: Tic-like Syndrome after Treatment with Clozapine. Am. J. Psychiatry #152:649, 1995.
61. Lindenmayer J.P., Negron A., Shah S., Lowinger R., Kennedy G., Bark N. and Hyman R.: Cognitive Deficits and Psychopathology in Elderly Schizophrenic Patients. Am. J. Geriatric Psychiatry 5:31-42, 1997.
62. Lindenmayer J.P., Adityanjee, Vital-Herne M., Bark N., Grochowski S. and Moynihan N.: Heterogeneity of Serotonergic Response in Treatment Refractory Schizophrenia Patients. Biol. Psychiatry (in press).
63. Lindenmayer J.P., Apergi S.: Clozapine Plasma Levels as Predictors of Outcome. Psychiatric Annals #26:405-411, 1996.
64. Lindenmayer J.P., Vital-Herne M., Simon I. and Zyalan M.: Use of Risperidone in State Hospital Inpatients. (Submitted for publication).
65. Simpson G. and Lindenmayer J.P.: Extra-pyramidal Symptoms in the Use of Risperidone. Clinical Psychopharmacology (in press).
66. Elman I., Sigler M., Kronenberg J., Lindenmayer J.P., Doron A., Mendlovic S. and Gaoni B.: Characteristics of patients with schizophrenia successive to Childhood Attention Deficit Disorder (ADHD). Israel J. Psychiatry (in press).
67. Bartlett E., Brodie J. Simkowitz P., Schloesser R., Dewey S., Lindenmayer J.P., Rusinek H., Wolkin A. and Cancro R.: The effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and non-responsive schizophrenics. Am. J. Psychiatry (submitted).

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED [REDACTED]

LINDENMAYER JEAN PIERRE HANS PETER

[REDACTED] REDACTED

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

06/30/93
REGISTRATION EXPIRATION DATE

[Signature]
SIGNATURE OF REGISTRANT

[REDACTED]
LICENSE / CERTIFICATE NO.

COMMISSIONER OF
EDUCATION

IN CERTIFICATE ... NOT A LICENSE

READ
INSTRUCTIONS
ON REVERSE
SIDE

CUT OFF THIS STRIP

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED

LINDENMAYER JEAN PIERRE HANS PETER

REDACTED

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

06/30/03
REGISTRATION PERIOD ENDS

LICENSE/CERTIFICATE NO.

SIGNATURE OF REGISTRANT

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

CUT OFF
THIS STRIP

440433

READ
INSTRUCTIONS

ON REVERSE
SIDE

7-018842

CUT OFF
THIS STRIP

BIRMINGHAM PSYCHIATRY PHARMACEUTICAL STUDIES, INC.

Curriculum Vitae
April, 1997

Name: H. Edward Logue, M.D.

Position Title: Medical Director, Birmingham Psychiatry Pharmaceutical Studies, Inc.

Address: 3490 Independence Drive
Birmingham, Alabama 35209-5604

Telephone Number: 205-868-4286

Fax Number: 205-868-4293

Education:

Institution and Location	Degree	Year Conferred	Field of Study
Medical College of Georgia, Augusta Ga.	Residency	1969-1972	Psychiatry
University Hospital, Augusta Ga.	Rotating Internship	1963-1964	Medicine
Medical College of Georgia, Augusta, Ga.	M.D.	1958-1963	Medicine
Emory University, Atlanta, Ga.	B.S.	1958	Pre-Med
Emory, Oxford Georgia	A.D.	1955	Science

Professional Experience:

Position	Institution/Employer and Location	Dates of Employment
Private Practice, Psychiatry	Birmingham Psychiatry P.A., Birmingham, AL Brookwood Medical Center 2010 Medical Center Drive Birmingham, Alabama 35209	1972-Present
Medical Director, Partial Hospital	Brookwood Medical Center, B'ham AL	January 1992 - Present
President (founder 1972) of Birmingham Psychiatry, P.A.	3490 Independence Drive Birmingham, Alabama 35209-5604	1972-Present
Medical Director-Development	Brookwood Center for Mental Health	October 1987-Present
Medical Director	Birmingham Psychiatry Pharmaceutical Studies, Inc.	1991 - Present
Founder, Medical Director Chairman of Board	Medical Business Management, Inc. (MBM)	1989 - Present

3490 INDEPENDENCE DRIVE • BIRMINGHAM, ALABAMA 35209-5604
TELEPHONE (205) 868-4286 • FAX (205) 868-4293

Professional Memberships:

- (1) American Psychiatric Association
- (2) American Medical Association
- (3) Alabama Psychiatric Society-District Branch of American Psychiatry Association
- (4) Jefferson County Medical Society
- (5) Medical Association of State of Alabama
- (6) Central Alabama Psychiatric Society

No Publication

Alabama Medical License REDACTED

Research Experience:

1. Principal Investigator
"Insomnia treatment study"
The Upjohn Company 1992
1992
2. Principal Investigator
"Fluvoxamine vs Placebo in the treatment
of Panic Disorder."
Enrolled: 20 patients (6 months)
The Upjohn Company\Pharmaco
1992-1993
3. Principal Investigator
"Fluvoxamine vs Placebo in the treatment of
Panic Disorder: A long term maintenance,
Double Blind study company efficacy and safety."
Enrolled: 20 patients (6 months)
The Upjohn Company\Pharmaco
1993-1994
4. Principal Investigator
"A Randomized, comparative open-labeled study of Paroxetine
in the Treatment of Depression as used in a Clinical Practice Setting."
Smith-Kline Beecham\ClinTrials
Enrolled: 20 patients (3 months)
1993-1994
5. Principal Investigator
"Olanzapine versus Haloperidol in the Treatment of
Schizophrenia and Other Psychotic Disorders." (HGAJ)
Enrolled: 44 patients (12 months)
Eli Lilly\Pharmaco
1994-1995
6. Principal Investigator
"Imitrex Injections in the Treatment of Migraine Headaches."
Enrolled: 40 patients (2 months)
Glaxo\Pact
1994
7. Principal Investigator
"Epidemiologic Survey of Prostep."
Enrolled: 20 patients
1993-1994
8. Principal Investigator
"A Double-Blind, Placebo-controlled, dose response comparison of the
safety and efficacy of three doses of Sertindole and three doses of Haldol
in Schizophrenic Patients." (M93-113)
Abbott Laboratories - Inpatient Study
Enrolled: 34 Patients (6 months)
1994-1995

9. Principal Investigator
"An Open-label Assessment of the long-term safety of Sertindole in the treatment of Schizophrenic Patients". (M92-795)
Enrolled: 17 (Continuation Study from M93-113)
Abbott Laboratories
1995
10. Principal Investigator
"An Open-label Assessment of the Safety of Sertindole". (M94-222)
Enrolled: 15 patients (Continuation Study from M93-113)
Abbott Laboratories
1995
11. Principal Investigator
"A Phase II comparative study using a single dose of Acetaminophen, Acetaminophen/Cyproheptadine, Cyproheptadine Alone and Placebo in the Treatment of Migraine Headache"
Enrolled: 39 Patients (6 months)
McNeil Laboratories
1994 - 1995
12. Principal Investigator
"A prospective, Multi-center, Open-label study of Serzone (nefazodone) in the Management of Patients with Symptoms of Depression in Depression in General Psychiatric Practices" (CN 104-127)
Enrolled: 14 patients (3 months)
Bristol-Myers Squibb/MCRC
1995
13. Principal Investigator
"Olanzapine versus Risperidone in the Treatment of Schizophrenia and other Psychotic Disorders" (FID-MC-HGBG)
Enrolled: 49 patients (4 months)
Eli Lilly
1995
14. Sub Investigator
"A Multi Center, Placebo-Controlled Study of Relapse Prevention By Long-Term Treatment with High or Low Doses of ORG-4428 in Outpatients with Recurrent Major Depressive Episode"
Organon/Pharmaco Enrolled: 35 patients
1995
15. Principal Investigator
"Open-Label Experience with Olanzapine in Patients Who Have Completed a Previous Olanzapine Clinical Trial" protocol. (Compassionate Use Study) (HGDJ)
Eli Lilly
February 1996
Enrolled: 13 patients from previous Olanzapine studies
16. Sub Investigator
"A Randomized Double-Blind, Placebo-Controlled parallel group multicenter, single dose, dose range-finding study to assess the efficacy and tolerability of VML 251 in the acute treatment of migraine."
April 1996 to June 1996
Vanguard Medica Limited Pharmaco

17. Principal Investigator
"Mazapertine dose finding trial, comparing three fixed dosages of Mazapertine to Risperidone and placebo: multicenter, double-blind parallel group study".
Janssen Pharmaceutical Research Foundation
March 1996 to July 2, 1996
Inpatient Study
Phase II Clinical Trial
Screened: 23 patients
Randomized: 20 patients
18. Principal Investigator
"A Comparison of Risperidone and Haloperidol for Prevention of Relapse in subjects with schizophrenia and schizoaffective disorders."
Enrolled: 24 patients
Janssen Pharmaceutical Research
Outpatient Study
19. Sub Investigator
"An Open Label, Multicenter Trial Evaluating the Safety and Efficacy of Donepezil Hydrochloride in Patients with Alzheimer's Disease."
Outpatient
Pfizer Pharmaceutica
20. Investigator
"A Multicenter Double-Blind, Randomized Comparison of Zolmitriptan and Sumatriptan in The Acute Treatment and of Multiple Migraine Headaches."
Outpatient
Zeneca Pharmaceuticals
21. Investigator
"A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Escalating the Dose of Oral Eletriptan in Subjects with Acute Migraine."
Pfizer
22. Investigator
"A 12-Month Study of VML 251 In the Acute Treatment of Migraine"
Vanguard Medica Ltd.
23. Investigator
"A Multi-Center, Randomized, Double-Blind, placebo and active controlled study of MDL 100,907 in Schizophrenic and Schizoaffective Patients."
Hoechst Marion Roussel, Inc.
24. Investigator
"A Multi-Center, Open-Label, Long-Term Follow-Up, Safety Study of MDL 100,907 In Schizophrenic and Schizoaffective Patients Who Participated in Protocol 100907 PR0015."
Hoechst Marion Roussel, Inc.
25. Investigator
"A Phase III, Randomized, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days of Treatment with Intramuscular Ziprasidone (20 to 80 mg. Daily) or Haloperidol (up to 40 mg Daily) Followed by 4 Days of Treatment with Oral Ziprasidone (40 to 200 mg Daily) or Haloperidol in Subjects with a Diagnosis of Psychotic Disorder."
Pfizer

WPS/KAY/VTA/ENEL March 24, 1997

RECEIPT # 9811930



STATE OF ALABAMA
MEDICAL LICENSURE COMMISSION
P.O. BOX 887 - WASHINGTON AVENUE
MONTGOMERY, ALABAMA 36101-0887
334/242-4153

CERTIFICATE OF REGISTRATION

1999

THIS IS TO CERTIFY THAT ANNUAL REGISTRATION HAS BEEN MADE
AND LICENSE TO PRACTICE MEDICINE IN THE STATE OF ALABAMA HAS
BEEN GRANTED FOR THE YEAR ENDING DECEMBER 31, 1999

HARRY EDWARD LOGUE, M.D.
3490 INDEPENDENCE DR
BIRMINGHAM, AL 35209 5604

PAID: \$100

Jimmy N. Gaskins, M.D.
EXECUTIVE OFFICER

LICENSE# [REDACTED]

DATE ISSUED 01/21/1972


DEPT: # [REDACTED]

CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE
ALABAMA STATE BOARD OF MEDICAL EXAMINERS
P.O. BOX 946
MONTGOMERY, ALABAMA 36101

DATE ISSUED: 01/01/1999

FEE PAID: \$50

HARRY EDWARD LOGUE, M.D.
3490 INDEPENDENCE DR
BIRMINGHAM, AL 35209 5604



ALABAMA CONTROLLED
SUBSTANCES CERTIFICATE NUMBER: 5561

REGISTRATION EXPIRES: 12/31/1999

SCHEDULES: 2; 2N; 3; 3N; 4; 5

RESTRICTIONS:

*PLEASE NOTIFY THIS OFFICE AT ONCE
IF THERE IS ANY CHANGE IN YOUR ADDRESS.
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL,
LOCATION OR BUSINESS ACTIVITY.

RECEIPT # 9609407



**STATE OF ALABAMA
MEDICAL LICENSURE COMMISSION**

P.O. BOX 887 • 848 WASHINGTON AVENUE
MONTGOMERY, ALABAMA 36101-0887
334/242-4153

**CERTIFICATE OF REGISTRATION
1997**

THIS IS TO CERTIFY THAT ANNUAL REGISTRATION HAS BEEN MADE AND LICENSE TO PRACTICE MEDICINE IN THE STATE OF ALABAMA HAS
BEEN GRANTED FOR THE YEAR ENDING DECEMBER 31, 1997

HARRY EDWARD LOGUE, M.D.
3490 INDEPENDENCE DR
BIRMINGHAM, AL 35209 5604

PAID: \$100

Jerry N. Gushy, M.D.
DEPUTY OFFICER

LICENSE # [REDACTED]

DATE ISSUED 01/21/1972



STATE OF ALABAMA
MEDICAL LICENSURE COMMISSION
P.O. BOX 887 - WASHINGTON AVENUE
MONTGOMERY, ALABAMA 36101-0887
334/242-4133

CERTIFICATE OF REGISTRATION

1998

THIS IS TO CERTIFY THAT ANNUAL REGISTRATION HAS BEEN MADE
AND LICENSE TO PRACTICE MEDICINE IN THE STATE OF ALABAMA HAS
BEEN GRANTED FOR THE YEAR ENDING DECEMBER 31, 1998

HARRY EDWARD LOGUE, M.D.
3470 INDEPENDENCE DR
BIRMINGHAM, AL 35209 5604

PAID: \$1.00

Jimmy N. Gaskins, M.D.
EXECUTIVE OFFICER

CENSEN REDACTED

DATE ISSUED 01/21/1972

Raymond C. Love, Pharm.D.

Curriculum Vitae

I. Personal Data

A. Residence

REDACTED

B. Office

Department of Pharmacy Practice and Science
100 Penn Street
Baltimore, Maryland 21201-1082
(410) 706-1768
facsimile (410) 706-0319

C. Licensure

Registered Pharmacist, State of Maryland
Registration REDACTED

D. Social Security Number

REDACTED

E. Family

married to Judy Curtis Love
two children - Steven Harrison and Allison Marie

II. Education

A.	1975-1977	Doctor of Pharmacy program, University of Maryland, School of Pharmacy, Doctor of Pharmacy (Pharm.D.) degree awarded June 1977
B.	1973-1975	Bachelor of Science in Pharmacy (five year) program, University of Maryland, School of Pharmacy
C.	1971-1973	School of Arts and Sciences, University of Maryland, College Park, Maryland

III. Employment

- A. 1996 to present Associate Professor, University of Maryland, School of Pharmacy (*funding 60% from School of Pharmacy beginning 1996*)
- B. 1993 to present Vice-chair, Department of Pharmacy Practice and Science, University of Maryland, School of Pharmacy
- C. 1989 to present Director, Clozapine Authorization and Monitoring Program, Mental Hygiene Administration, Department of Health and Mental Hygiene, State of Maryland
- D. 1986 to present Director, Mental Health Programs, University of Maryland, School of Pharmacy
- E. 1986 to 1996 Assistant Professor, University of Maryland, School of Pharmacy (*funding 100% as principal investigator on grants & contracts from 1986 through 1994; funding 50% from School of Pharmacy 1995*)
- F. 1989 to 1990 Acting Director of Pharmacy, Spring Grove Hospital Center, Baltimore, Maryland
- G. 1986 to 1989 Clinical Pharmacist, Springfield Hospital Center, Sykesville, Maryland
- H. 1982 to 1986 Consultant, State of Maryland, Mental Hygiene Administration
- I. 1980 to 1986 Director, Pharmacy Services, Thomas B. Finan Center, Cumberland, Maryland
- J. 1979 to 1980 Clinical Pharmacy Consultant, Thomas B. Finan Center, Cumberland, Maryland
- K. 1977 to 1980 Assistant Professor of Clinical Pharmacy, University of Maryland, School of Pharmacy
- L. 1977 to 1978 Center Director, University of Maryland - Cumberland Area Health Education Center, Cumberland, Maryland
- M. 1977 Clinical Pharmacist, University of Maryland Hospital Primary Care Programs and Loch Raven Veterans Administration Hospital, Baltimore, Maryland

IV. Scholarly Activity

A. Publications in Refereed Journals

1. Love RC, Fulop M. Olanzapine Associated Granulocytopenia. (Letter to the editor) Am J Psychiatry. 1997; submitted
2. Conley RR, Love RC, Carpenter WT. Evaluating Ability to Consent in Psychiatric Inpatients. Arch Gen Psychiatry. 1997; submitted.
3. Love RC. Novel versus Conventional Antipsychotic Drugs. Pharmacotherapy. 1996; 16(1 Pt 2):6S-10S.
4. Mady S, Wax P, Wang D, Goetz C, Hadley C, Love R. Pediatric Clozapine Intoxication. Am J Emerg Med. 1996; 14:462-463.
5. Love RC. Recent Developments in Antipsychotic Therapy. Amer J Health-System Pharm. 1995; 52(S1):3-4.

B. Papers and Posters Read

1. Conley RR, Love RC. Evaluating Ability to Consent in Psychiatric Inpatients. Presentation, New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, Florida, May 1996.
2. Love RC. Phenylpropanolamine-induced Agitation. Platform Presentation, ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1995 and International Pharmaceutical Abstracts 1995;32(21):2325. (Original work, invited)
3. Curtis JL, Moore DB, Love RC. Multi-source Funding for a Psychiatric Pharmacy Practice Residency. Poster Presentation, ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1995 and International Pharmaceutical Abstracts 1995;32(21):2404. (Original work, submitted, reviewed)
4. Goetz C, Love RC. Clozapine Overdose in a Pediatric Patient. Poster Presentation, American Association of Poison Control Centers, New York, New York, September 11, 1993. (Original work, submitted, reviewed)
5. McKay JS, Love RC. Pharmacist Compliance with Clozapine Monitoring Standards. Poster Presentation, ASHP Midyear Clinical Meeting, Orlando, Florida, December 1992. (Original work, submitted, reviewed)

6. Love RC. Clozapine: A Statewide Approach. Platform Presentation, ASHP Midyear Clinical Meeting, Orlando, Florida, December 1992. (Original work, invited)
7. Love RC. Clozapine: A Statewide Approach to Its Use in the Public Sector. Clozaril - A National Dialogue, Virginia Department of Mental Health, Mental Retardation and substance Abuse Services, Arlington, Virginia, July 15, 1992. (Original work, invited)
8. Curtis JL, Love RC, Sherr JD. A Pharmacy Based System for Routine Laboratory Monitoring of Drug Therapy in an ICF-MR. Poster Presentation, ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1989. (Original work, submitted, reviewed)
9. Sherr JD, Love RC. Use of dBase-III Plus for Translation of Patient Profiles into Historical Plots of Psychotropic Drug Exposure. Poster Presentation, ASHP Midyear Year Clinical Meeting, Dallas, Texas, December 1988. (Original work, submitted, reviewed)

C. Grants and Contracts

1. Risperidone Vs. Olanzapine in the Treatment of Schizophrenia (under final preparation)
 - a. Janssen Research Foundation
 - b. \$78,000
 - c. 8/97-4/98
 - d. Principal Investigator
 - e. 5% effort
 - f. Clinical Trial
2. Clinical Pharmacy Services for the Eastern Region, Mental Hygiene Administration (under final preparation)
 - a. State of Maryland
 - b. \$202,349
 - c. 7/97-6/98P
 - d. Principal Investigator
 - e. 2% effort
 - f. Service Contract
3. New Atypical Neuroleptic Strategies in Schizophrenia: Olanzapine
 - a. Eli Lilly and Company
 - b. Provision of investigational agent - olanzapine; other activities supported through existing Maryland Psychiatric Research Center NIMH Clinical Research Center Grant
 - c. 7/94-7/96
 - d. Co-investigator; (Robert Conley, M.D., Principal Investigator)

- e. 5% effort
 - f. Investigational Agent; Creative Grant
4. L-745,870 in Hospitalized Schizophrenic Patients
- a. Merck
 - b. \$42,000
 - c. 8/95-12/95
 - d. Co-investigator; (Robert Conley, M.D., Principal Investigator)
 - e. 5% effort
 - f. Investigational Agent; Clinical Trials
5. Demonstrating Psychiatric Pharmacist Services in an Outpatient Environment
- a. Montgomery County Department of Department of Addiction, Victim and Mental Health Services
 - b. 7/94-6/95 \$9,999 Principal Investigator
 - c. 7/93-6/94 \$14,000 Principal Investigator
 - d. 7/92-6/93 \$7,000 Principal Investigator
 - e. Total of awards.....\$30,999
 - f. 5% effort
 - g. Service Contract; Creative
6. Improving Pharmacy Services - Upper Shore Community Mental Health Center
- a. State of Maryland
 - b. 1/95-6/96 \$128,803 Principal Investigator
 - c. 2% effort
 - d. Service Contract
7. Improving Pharmacy Services - Clifton T. Perkins Hospital Center
- a. State of Maryland
 - b. 7/95-6/98 \$420,287 Principal Investigator
 - c. 7/92-6/95 \$197,443 Principal Investigator
 - d. Total of awards.....\$617,730
 - e. 2% effort
 - f. Service Contract
8. Improving Pharmacy Services - Great Oaks Center
- a. State of Maryland
 - b. 7/92-6/95 \$204,397 Co-investigator
 - c. 2% effort
 - d. Service Contract
9. Clozapine Authorization And Monitoring
- a. State of Maryland
 - b. 7/94-6/96 \$400,448 Principal Investigator

c.	7/92-6/94	\$290,833	Principal Investigator
d.	7/91-6/92	\$141,661	Principal Investigator
e.	7/90-6/91	\$60,507	Principal Investigator
f.	3/90-6/90	\$34,844	Principal Investigator
g.	Total of awards.....		\$928,293
h.	40% of effort		
i.	Service Contract; Creative Service		
10. Central Administration of Pharmacy Services
- | | | | |
|----|------------------------------------|-----------|------------------------|
| a. | State of Maryland | | |
| b. | 7/95-6/98 | \$258,600 | Principal Investigator |
| c. | 7/92-6/95 | \$234,724 | Principal Investigator |
| d. | 7/91-6/92 | \$73,729 | Principal Investigator |
| e. | 7/90-6/91 | \$73,729 | Principal Investigator |
| f. | 7/89-6/90 | \$70,957 | Principal Investigator |
| g. | 7/88-6/89 | \$67,645 | Principal Investigator |
| h. | 7/87-6/88 | \$64,167 | Principal Investigator |
| i. | 7/86-6/87 | \$60,789 | Principal Investigator |
| j. | Total of awards..... | | \$904,340 |
| k. | 50% effort | | |
| l. | Service Contract; Creative Service | | |
11. Improving Pharmacy Services - Crownsville Hospital Center
- | | | | |
|----|----------------------|-----------|------------------------|
| a. | State of Maryland | | |
| b. | 7/95-6/98 | \$305,316 | Principal Investigator |
| c. | 7/92-6/95 | \$225,657 | Principal Investigator |
| d. | 7/91-6/92 | \$64,831 | Principal Investigator |
| e. | 7/90-6/91 | \$64,831 | Principal Investigator |
| f. | 7/89-6/90 | \$58,923 | Principal Investigator |
| g. | 7/88-6/89 | \$55,379 | Principal Investigator |
| h. | 7/87-6/88 | \$52,742 | Principal Investigator |
| i. | 7/86-6/87 | \$42,682 | Principal Investigator |
| j. | Total of awards..... | | \$870,361 |
| k. | 2% effort | | |
| l. | Service Contract | | |
12. Improving Pharmacy Services - Walter P. Carter Center
- | | | | |
|----|-------------------|-----------|------------------------|
| a. | State of Maryland | | |
| b. | 7/95-6/98 | \$504,673 | Principal Investigator |
| c. | 7/92-6/95 | \$421,247 | Co-investigator |
| d. | 7/91-6/92 | \$113,749 | Co-investigator |
| e. | 7/90-6/91 | \$103,385 | Co-investigator |
| f. | 7/89-6/90 | \$49,940 | Principal Investigator |
| g. | 7/88-6/89 | \$52,589 | Principal Investigator |
| h. | 7/87-6/88 | \$50,186 | Principal Investigator |
| i. | 7/86-6/87 | \$42,980 | Principal Investigator |

- j. Total of awards.....\$1,338,749
- k. 5% effort
- l. Service Contract

13. Improving Pharmacy Services - Spring Grove Hospital Center

- a. State of Maryland
- b. 7/95-6/98 \$1,224,131 Co-investigator
- c. 7/92-6/95 \$769,362 Co-investigator
- d. 7/91-6/92 \$113,749 Co-investigator
- e. 7/90-6/91 \$103,385 Principal Investigator
- f. 7/89-6/90 \$49,940 Principal Investigator
- g. 7/88-6/89 \$52,589 Principal Investigator
- h. 7/87-6/88 \$50,186 Principal Investigator
- i. 7/86-6/87 \$42,980 Principal Investigator
- j. Total of awards.....\$3,117,781
- k. 5% effort
- l. Service Contract

14. Improving Pharmacy Services - Springfield Hospital Center

- a. 7/93-12/93 \$56,904 Co-investigator
- b. 7/92-6/93 \$113,906 Principal Investigator
- c. 7/91-6/92 \$105,929 Principal Investigator
- d. 7/90-6/91 \$49,224 Principal Investigator
- e. 7/89-6/90 \$43,258 Principal Investigator
- f. 7/88-6/89 \$41,020 Principal Investigator
- g. 7/87-6/88 \$38,789 Principal Investigator
- h. 7/86-6/87 \$29,531 Principal Investigator
- i. Total of awards.....\$478,560
- j. 10% effort
- k. Service Contract

15. Improving Pharmacy Services - Rosewood Center and FY96 Supplemental Contract

- a. State of Maryland
- b. 7/95-6/98 \$441,227 Co-investigator
- c. 7/95-12/95 \$105,049 Co-investigator
- d. 7/92-6/95 \$904,142 Co-investigator
- e. 7/91-6/92 \$181,468 Co-investigator
- f. 7/90-6/91 \$138,469 Co-investigator
- g. 7/89-6/90 \$92,749 Co-investigator
- h. 7/88-6/89 \$71,709 Co-investigator
- i. 7/87-6/88 \$57,173 Co-investigator
- j. 7/86-6/87 \$54,725 Co-investigator
- k. Total of awards.....\$2,046,711
- l. 1% effort

m. Service Contract

16. A pilot controlled dose study of CI-943 in schizophrenia.
 - a. Warner-Lambert
 - b. \$17,487
 - c. 11/87-6/89
 - d. Principal investigator
 - e. 20% effort
 - f. Investigational agent; Clinical trials
17. An open label study of CI-943 in schizophrenic outpatients.
 - a. Warner-Lambert
 - b. \$67,464
 - c. 11/87-6/89
 - d. Principal Investigator
 - e. 10% effort
 - f. Investigational agent; Clinical trials
18. A placebo controlled study of CI-943 in schizophrenia.
 - a. Warner-Lambert
 - b. \$84,240
 - c. 11/89-6/90
 - d. Principal Investigator
 - e. 20% effort
 - f. Investigational agent; Clinical trials

D. Special Lectures (invited)

1. Love RC. Psychopharmacology Update, 17th Annual Nurse Practitioner Symposium, Baltimore, Maryland, May 7, 1997.
2. Love RC. Placing the Atypical Antipsychotics in Perspective, Delaware Department of Health and Social Services, Delaware State Hospital, Wilmington, Delaware, April 29, 1997.
3. Love RC. The Decision to Employ Atypical Antipsychotics: A Systems Perspective, Boston, Massachusetts, Massachusetts Medicaid and State Hospital Pharmacists Meeting, April 17, 1996.
4. Love RC. Psychopharmacology for Mental Health Professionals. Rockford Center Lecture Series, Rockford Center, Newark, Delaware, November 9, 1995.
5. Love RC. Health System Perspectives on the Costs and Benefits of Atypical Antipsychotics. Risperidal[®] Worldwide Meeting, Janssen Pharmaceutica, Miami, Florida, May 16, 1995.

6. Love RC. Cost Justification of Novel Antipsychotic Agents: A Healthcare System Perspective. Sixth Psychopharmacy Update, College of Pharmacy, University of Texas at Austin, Austin, Texas, October 1, 1994.
7. Love RC. Drug Interactions in Psychiatry. Visiting chief of service, Memorial Hospital of Easton, Easton, Maryland, April 22, 1994.
8. Love RC. Recent Developments in Psychopharmacology. Visiting chief of service, Memorial Hospital of Easton, Easton, Maryland, April 21, 1994.
9. Love RC. Antipsychotic Therapy: The Atypical Agents. Annual Spring Convention, Maine Pharmacy Association, Portland, Maine, March 12, 1994.
10. Love RC. The Role of Valproate in Psychiatric Disorders. Platform Presentation, ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 7, 1993.
11. Love RC. The Management of Psychosis - An Update. Annual Meeting, Maryland Psychological Association, Columbia, Maryland, November 19, 1993.
12. Love RC. Recent Developments in Psychiatric Drug Therapy. Maryland Society of Hospital Pharmacists, Sheppard Pratt Hospital Center, Towson, Maryland, March 11, 1993.
13. The Ethics of Resource Allocation: Clozapine. Clozaril - A National Dialogue, Virginia Department of Mental Health, Mental Retardation and substance Abuse Services, Arlington, Virginia, July 16, 1992, panel member.
14. Love RC. Pharmacy Practice in Specialized Settings: Psychiatric Facilities. Platform Presentation, ASHP Annual Meeting, Washington, D.C., June 4, 1992.
15. Love RC. Prescribing Patterns in Maryland: Opportunities for Improvement, 193rd Annual Meeting, Medical and Chirurgical Faculty of Maryland, College Park, Maryland, May 8, 1991.

16. Love RC. Clozapine: A Statewide Approach. Symposium: New Directions in the Treatment of Schizophrenia, Spring Grove Hospital Center, Maryland Psychiatric Research Center, Baltimore, Maryland, December 6, 1990.
17. Love RC. Governmental Responses to C.P.M.S.: The Maryland Plan. National Meeting of Governmental Affairs Directors, Sandoz Pharmaceuticals, East Hanover, New Jersey, February 14, 1990.
18. Love RC, Grebing, R, Smith, D. Drug Use Evaluation in Psychiatric Facilities. Platform Presentation, ASHP Midyear Clinical Meeting, Dallas, Texas, December 1988.

E. Consulting

1. Janssen Research Foundation
 - a. Consultation regarding clinical aspects of new dosage forms and antipsychotic outcome studies
 - b. 1997
 - c. Paid
2. Perry Point Veterans Affairs Medical Center
 - a. Clinical consultation; consultation regarding V.A. Collaborative Clozapine Trial and Open Label Ziprasidone in the Outpatient Treatment of Schizophrenia
 - b. 1991- 1997
 - c. Paid
3. National Psychiatric Pharmacy Advisory Board, SmithKline Beecham Pharmaceuticals
 - a. Advisory Board
 - b. 1994-present
 - c. Paid
4. Department of Victims, Addictions and Mental Health Services, Montgomery County, Maryland
 - a. Clinical consultation
 - b. 1993-1994
 - c. Unpaid
5. Regional Advisory Board, Janssen Pharmaceutica
 - a. Advisory Board
 - b. 1993-1996
 - c. Paid

6. Regional Advisory Board, SmithKline Beecham Pharmaceuticals
 - a. Advisory Board
 - b. 1992-1993
 - c. Paid
7. Antitrust Division, Office of the Attorney General, State of Maryland and National Association of States Attorneys General
 - a. Consulted regarding multistate litigation against Sandoz Pharmaceuticals for Clozaril[®] Patient Monitoring System
 - b. 1991-1993
 - c. Unpaid
8. Indiana Protection and Advocacy Services, State of Indiana
 - a. Consulted regarding inappropriate drug use and monitoring standards at Indiana state facilities; reviewed several deaths potentially related to inappropriate prescribing/monitoring in facilities; testified before grand jury as expert witness regarding criminal negligence on the part of a prescriber in the state system
 - b. 1991-1993 and 1996
 - c. Paid
9. National Clozaril[®] Advisory Board
 - a. Sandoz Pharmaceuticals Advisory Board
 - b. 1990-1993
 - c. Unpaid
10. Federal Trade Commission
 - a. Consulted regarding action against Sandoz Pharmaceuticals for Patient Monitoring System
 - b. 1991-1992
 - c. Unpaid
11. Human Volunteers Committee, Department of Health and Mental Hygiene, State of Maryland
 - a. Consulted regarding approval of investigational agents in patients treated at DHMH facilities
 - b. 1989-1994
 - c. Unpaid
12. Purchasing Bureau, Department of General Services, State of Maryland
 - a. Consulted regarding pharmaceutical contracts
 - b. 1989-1994
 - c. Unpaid

13. Sinai-GreenSpring Neuropsychiatric Movement Disorders Clinic, Sinai Hospital
 - a. Associate Director of the clinic
 - b. 1986-1992
 - c. Paid
14. State of Connecticut
 - a. Consulted regarding improving pharmaceutical services in state hospitals to meet Health Care Financing Administration standards for reimbursement
 - b. 1986-1987
 - c. Paid

F. Publications Other than Reviewed Articles

1. Book Chapters

- a. Love RC, Grothe DR. Mood Disorders II: Bipolar Affective Disorders. In: Applied Therapeutics: The Clinical Use of Drugs. 6th edition. Koda-Kimble MA, Young LL, eds. Vancouver, WA: Applied Therapeutics, Inc.; 1995.

2. Commentaries

- a. Love RC. Pharmaceutical Care and the Death Chamber. The Maryland Pharmacist. 1994; 70(10):12-13.

3. Monographs

- a. Feinberg M, Love RC. Depression in the Elderly Long-term Care Facility Resident: The Role of the Consultant Pharmacist. Medical Education Systems, Inc.; 1995.
- b. Cohen G, Cohen LJ, Dahlen AL, Grossberg GT, Kirman C, Lawhorne LW, Love RC, Reifler BV, Smyer MA. Tailoring the AHCPR Clinical Practice Guidelines on Depression in Primary Care for Use in Long-Term Care Facilities. Philadelphia College of Pharmacy and Science; 1995.

4. Non-refereed Journals

- a. Curtis JC, Curtis JL, Love RC, Borovicka M, Gammill S, Kelly D, Invernizzi N. Psychotropic medication use in individuals with developmental disabilities. Maryland Medical Journal. Submitted.

- b. Curtis JC, Love RC. Drug-induced aggression and violent behavior. *Pharmaguide to Hospital Medicine*. 1996; 9(3):1-4,9-10.
- c. Love RC. Pharmacy Service Contracts: Do They Harbor Potential Conflicts? *Mid-Atlantic Ethics Committee Newsletter*. Spring 1995, 8-9.
- d. Love RC, Moore DB. The Pharmacist's Role in Investigational Drugs Services. *Pharmacy Times* 59(2):10-12HPT, 1993.
- e. Love RC. The Pharmacist: A Partner in Health Care. *New Beginnings*. 1993;1(2):3-4.
- f. Lamy PP and Love RC. Antipsychotics in Geriatric Practice. *Geriatric Medicine Today* 8(4):36-49, 1989.
- g. Lamy PP and Love RC. Antidepressants in Geriatric Practice. *Geriatric Medicine Today* 8(12):19-24, 1989.
- h. Love, RC, Lamy, PP. Psychotropic Agents. *Elder Care News* 4(2):9-15, 1988.
- i. Love RC. The NARD Clinical Series: The Benzodiazepines. *NARD Journal* 107(11):9-11, 1985.

5. Supplement Edited

- a. Love RC (guest editor). Recent Developments in Antipsychotic Therapy. *Amer J Health-System Pharm*. 1995; 52(S1):1-24.

6. Editorial Board

- a. New Beginnings, Health Science Communications, 1993.

7. Reviewer

- a. The Consultant Pharmacist, reviewer, 1997.
- b. A.S.H.P. Residency Accreditation Standards, Specialized Residency in Psychiatric Pharmacy practice, reviewer, 1997.
- c. A.S.H.P. Therapeutic Position Paper on the Treatment of Sleep in the Elderly, reviewer, 1997.

- d. Journal of the American Pharmaceutical Association, reviewer, 1996.
- e. Psychiatric Services, reviewer, 1996-1997.
- f. Hospital and Community Psychiatry, reviewer, 1994-1995.
- g. A.S.H.P. Midyear Clinical Meeting, reviewer, 1992-1997.
- h. Hospital Pharmacy, reviewer, 1994.
- i. A.S.H.P. Annual Meeting, reviewer, 1994.
- j. Journal of Psychosocial Nursing, reviewer, 1994.
- k. A.S.H.P. Criteria for Drug Use Review, reviewer, 1992-1993.
- l. Contemporary Pharmacy Practice, reviewer, 1979.

G. Honors and Awards

- 1. Hospital Pharmacist of the Year, Maryland Society of Hospital Pharmacists, 1993.
- 2. Lifetime Member, Medical and Professional Staff, Thomas B. Finan Center, 1985.

V. Teaching

A. Residents

- 1. Jay D. Sherr, Pharm.D., completed June 1988
- 2. Janice Hoffman, Pharm.D., completed June 1989
- 3. Glenn Younkens, Pharm.D., completed June 1992
- 4. J. Barton Brown, Pharm.D., completed in June 1993
- 5. Michelle Towle, Pharm.D., completed in June 1994
- 6. Jami S. Lingle, Pharm.D., completed in December 1994
- 7. Bethany Fishman-DiPaula, Pharm.D., completed in January 1996

8. Andrew Falsetti, Pharm.D., completed in June 1996
9. Deanna Kelly, Pharm.D., completed in June 1997
10. Samantha Gammill, Pharm.D., completed in June 1997
11. Nina Invernizzi, Pharm.D.
12. Matthew Nelson, Pharm.D.
13. Don Smith, Pharm.D.

B. Continuing Education Presentations

1. Love RC, Curtis JL. Psychopharmacology, Summer Seminar Series, Delaware Department of Mental Health, Newark, Delaware, July 28-30, 1997.
2. Love RC. The New Antipsychotics: Clinical Update. Pennsylvania Society of Health System Pharmacists (Mideastern), Allentown, Pennsylvania, June 11, 1997.
3. Love RC. Placing the Atypical Antipsychotics in Perspective. Maryland Society of Health Systems Pharmacists, Johns Hopkins Hospital, Baltimore, Maryland, April 10, 1997.
4. Love RC, Curtis JL. Psychopharmacology, Summer Seminar Series, Delaware Department of Mental Health, Newark, Delaware, July 29-31, 1996.
5. Love RC. Evaluating Pharmacoeconomic Data on the Atypical Antipsychotics. Pharmacists, Meeting, Department of Health, Boston, MA, April 17, 1996.
6. Love RC. Update on the Use of Atypical Antipsychotics. Perry Point VAMC, Perryville, Maryland, October 18, 1995.
7. Love RC. Recent Developments in Psychiatric Drugs. Department Seminar, School of Pharmacy, June 28, 1995.
8. Love RC. Recent Developments in the Treatment of Depression. Bureau of Generic Drugs, Food and Drug Administration, Gaithersburg, Maryland, June 22, 1995.

9. Love RC, Curtis JL. Psychopharmacology, Summer Seminar Series, Delaware Department of Mental Health, Newark, Delaware, August 9-11, 1995.
10. Love RC. New Developments in Antidepressant Therapy, AZO Pharmacy Fraternity, Pikesville, Maryland, April 9, 1995.
11. Love RC. Psychopharmacology Update. Geropsychiatry Conference. Baltimore VAMC, March 20, 1995.
12. Love RC. Drug Interactions and the Newer Psychopharmacologic Agents, Grand Rounds, Crownsville Hospital Center, Crownsville, Maryland, March 10, 1995.
13. Love RC. Antipsychotic Therapy: Novel versus Traditional. Mid Winter Meeting, American College of Clinical Pharmacy, February 13, 1995.
14. Love RC. Application of Rating Scales to Drug Monitoring. Rosewood Center, Owings Mills, Maryland, January 5, 1995.
15. Love RC. Contemporary Issues in the Use of Novel Antipsychotic Drugs. ASHP Midyear Clinical Meeting, Miami Beach, Florida, December 7, 1994.
16. Love RC. Recent Developments in Antipsychotic Therapy. Massachusetts mental health pharmacists. Boston, Massachusetts, November 9, 1994.
17. Love RC. Psychopharmacology Update. Regional Institute for Children and Adolescents, Rockville, Maryland, November 7, 1994.
18. Love RC. The New Antidepressants. Montgomery County Department of Victims, Addictions and Mental Health Services, Rockville, Maryland, October 14, 1994.
19. Love RC. Recent Developments in Psychiatric Drugs. Bureau of Generic Drugs, Food and Drug Administration, Rockville, Maryland, August 4, 1994.
20. Love RC. The Clinical Use of Atypical Agents. Department of Psychiatry, Perry Point VAMC, Perryville, Maryland, July 6, 1994.
21. Love RC. Serotonin: Its Implications for Clinical Psychiatric Practice. Department of Psychiatry, Bethesda Naval Medical Center, Bethesda, Maryland, May 19, 1994.

22. Love RC. Clozapine Update, Department of Psychiatry, Baltimore VAMC, Baltimore, Maryland, January 10, 1994.
23. Love RC. Case Studies in Psychiatric Drug Interactions, Grand Rounds, Spring Grove Hospital Center, Baltimore, Maryland, November 18, 1993.
24. Love RC. Current Approaches to the Treatment of Depression, Washington Area Chapter, Chinese Pharmacists Association, Rockville, Maryland, October 16, 1993.
25. Love RC. Drug Interactions in Psychiatry, Grand Rounds, Spring Grove Hospital Center, Baltimore, Maryland, June 17, 1993.
26. Love RC. The Role of the Clinical Pharmacist in Outpatient Mental Health Care, Montgomery County Department of Addictions, Victims and Mental Health Services, Germantown, Maryland, June 10, 1992.
27. Love RC. The Medication Management of Aggression, Psychiatry Grand Rounds, Perry Point VAMC, Perryville, Maryland, April 16, 1992.
28. Love RC. Use of the Brief Psychiatric Rating Scale in Assessing Response to Antipsychotics. Perry Point VAMC, Perryville, Maryland, March 25, 1992.
29. Love RC. Assessing Patients for Atypical Antipsychotic Therapy, Perry Point VAMC, Perryville, Maryland, January 7, 1992.
30. Love RC. Prescribing Parameters for Psychoactive Drugs. Treatment Resistant Unit, Maryland Psychiatric Research Center, Baltimore, Maryland, June 26, 1991.
31. Love RC. Funding Systems for Clozapine. Outpatient Psychiatric Staff, National Institute of Mental Health, Bethesda, Maryland, April 30, 1991.
32. Love RC. Quality Assurance in Pharmaceutical Services. Heron Point Retirement Community, Chestertown, Md., April 26, 1991.
33. Love RC. Clozapine and other Medication Issues in the Ambulatory Chronically Mentally Ill, Prince Georges County Health Department Advisory Board, March 28, 1991.

34. Love RC. Psychoactive Medication Use in the Dually Diagnosed. Department of Health and Mental Hygiene Symposium, Salisbury State College, Salisbury, Maryland, June 13, 1990.
35. Love RC. Managing the Clozapine Patient: Beyond the C.P.M.S., presented at:
 - a. Department of Psychiatry, Sheppard-Pratt Hospital Center, Towson, Maryland, May 17, 1993;
 - b. Department of Psychiatry, UMMS, Baltimore, Maryland, March 18, 1993;
 - c. Mental Health Clinic, Washington County, Hagerstown, Maryland, March 17, 1993;
 - d. Eastern Shore Hospital Center, Cambridge, Maryland, November 14, 1992;
 - e. Sheppard Pratt Hospital, Baltimore, Maryland, October 30, 1992;
 - f. Department of Psychiatry, Johns Hopkins Hospital, Baltimore, Maryland, September 24, 1992;
 - g. Spring Grove Hospital Center, Baltimore, Maryland, August 7, 1992;
 - h. Sinai Hospital of Baltimore, Baltimore, Maryland, April 21, 1992;
 - i. Chestnut Lodge Hospital, Bethesda, Maryland, February 4, 1992;
 - j. Department of Psychiatry, Johns Hopkins Hospital, Baltimore, Maryland, January 30, 1992;
 - k. Grand Rounds, Sheppard Pratt Hospital Center, Towson, Maryland, December 6, 1991;
 - l. Grand Rounds, Department of Psychiatry, Southern, Maryland Hospital Center, November 20, 1991;
 - m. Psychiatric Institute of Montgomery County, Rockville, Maryland, October 30, 1991;
 - n. Outpatient Psychiatrists, Prince Georges County Mental Health Clinics, Cheverly, Maryland, September 17, 1991;
 - o. Regional Institute for Children and Adolescents, Rockville, Maryland, August 29, 1991;
 - p. Grand Rounds, Department of Psychiatry, Suburban Hospital, Bethesda, Maryland, July 26, 1991;
 - q. Department of Addiction, Victim and Mental Health Services, Montgomery County, Wheaton, Maryland, October 17, 1990;
 - r. Department of Mental Health, Prince George's County, Landover, Maryland, September 18, 1990;
 - s. Caremark, Division of Baxter Laboratories, Towson, Maryland, August 15, 1990;
 - t. Department of Psychiatry, Sinai Hospital of Baltimore, Baltimore, Maryland, July 31, 1990;

- u. Joint Departments of Psychiatry, Johns Hopkins Health Care Institutions, Baltimore, Maryland, July 12, 1990;
 - v. Crownsville Hospital Center, Crownsville, Maryland, July 10, 1990;
 - w. Eastern Shore Hospital Center, Cambridge, Maryland, June 26, 1990;
 - x. Department of Mental Health, Washington County, Hagerstown, Maryland, June 20, 1990;
 - y. Clifton T. Perkins Hospital Center, Jessup, Maryland, April 16, 1990;
 - z. Thomas B. Finan Center, Cumberland, Maryland, March 23, 1990.
-
- 36. Love RC. Side Effects, Compliance and Psychotropic Medications. Maryland Pharmacist's Association Convention, Ocean City, Maryland, June 20, 1988.
 - 37. Rudo A, Love RC. Case Conferences in Tardive Dyskinesia. Grand Rounds, Department of Psychiatry, Sinai Hospital, Baltimore, Maryland, March 1988.
 - 38. Love RC. Clinical Applications of the Use of Antipsychotic Agents. Springfield Hospital Center, Sykesville, Maryland, February 18, 1987.
 - 39. Rudo A, Love RC, Force E. The Tardive Dyskinesia Clinic - Ongoing Treatment and Monitoring of Patients With Neuropsychiatric Movement Disorders. Grand Rounds, Department of Psychiatry, Sinai Hospital, Baltimore, Maryland, February 10, 1987.

VI. Service

A. State, School and University Service

- 1. Advisory Board, Maryland Commission on Correctional Standards
 - a. 1997
 - b. Member
- 2. Technical Assistance Committee, Maryland Commission on Correctional Standards
 - a. 1997
 - b. Member

3. Task Force on Pharmacist Administration of Medication
 - a. Maryland Board of Pharmacy
 - b. 1997
 - c. Chair
4. Task Force on Collaborative Practice
 - a. Maryland Board of Pharmacy
 - b. 1997
 - c. Member
5. Ad-hoc Committee on Entrepreneurial Activities
 - a. School of Pharmacy
 - b. 1996-1997
 - c. Member
6. Planning for Mental Health Pharmacy Services under the Maryland Medicaid Waiver Committee
 - a. Mental Hygiene Administration, Department of Health and Mental Hygiene
 - b. 1996-1997
 - c. Chair
7. Collaborative Practice Task Force
 - a. Maryland Board of Pharmacy
 - b. 1996
8. Scope of Practice Work Group, Pharmacy Practice Act Task Force
 - a. Maryland Board of Pharmacy
 - b. 1996
 - c. Alternate for the Dean
9. Entrepreneurial Activities Committee
 - a. School of Pharmacy
 - b. 1996-1997
10. Search Committee, Associate Dean
 - a. School of Pharmacy
 - b. 1995-1996
11. Search Committee, Business Manager, Department of Pharmacy Practice and Science
 - a. School of Pharmacy
 - b. 1995

12. Maryland Board of Pharmacy, School of Pharmacy Liaison
 - a. School of Pharmacy
 - b. 1995-1997
13. Third Year Coursemasters
 - a. School of Pharmacy
 - b. 1995-1997
 - c. Co-chair
14. Mental Health Operations Committee
 - a. School of Pharmacy
 - b. 1986-1997
 - c. Chair from 1986-1994
15. Statewide Pharmacy and Therapeutics Committee
 - a. Department of Health and Mental Hygiene, State of Maryland
 - b. 1986-1997
 - c. Co-chair 1986-1997; chair 1990-1992
16. Research Committee
 - a. Spring Grove Hospital Center
 - b. 1991-1997
 - c. Co-chair from 1993-1997
17. Center for Biomedical Ethics
 - a. UMAB
 - b. 1993-1996
 - c. School of Pharmacy Representative
18. Prior Learning Assessment Panel
 - a. School of Pharmacy
 - b. 1993-1995
19. Computer Services Advisory Group
 - a. School of Pharmacy
 - b. 1994-1995
20. Search Committee, Mental Health Faculty
 - a. School of Pharmacy
 - b. 1994-1995
 - c. Chair

21. Pharmacy Act Modification Task Force
 - a. School of Pharmacy
 - b. 1994-1995
 - c. Chair
22. Integrated Science and Therapeutics Task Force
 - a. School of Pharmacy
 - b. 1995
 - c. Chair
23. Admissions Committee
 - a. School of Pharmacy
 - b. 1991-1994
24. Search Committee, Assistant Director, Maryland Poison Center
 - a. School of Pharmacy
 - b. 1993
25. Search Committee, Drug Information Faculty
 - a. School of Pharmacy
 - b. 1993
26. Strategic Planning Committee
 - a. Department of Clinical Pharmacy, School of Pharmacy
 - b. 1992
27. Search Committee, Clinical Scientist
 - a. School of Pharmacy
 - b. 1992
28. Practice Plan Committee
 - a. Department of Clinical Pharmacy, School of Pharmacy
 - b. 1991-1992
 - c. Chair
29. DRIF Task Force
 - a. Department of Clinical Pharmacy, School of Pharmacy
 - b. 1991
30. Search Committee - Psychiatry/Developmental Disabilities
 - a. UMAB School of Medicine
 - b. 1991
31. Subcommittee on Clozapine Standards
 - a. Department of Health and Mental Hygiene, State of Maryland

- b. 1989-1990
 - c. Chair
- 32. Task Force on Clozapine
 - a. Department of Health and Mental Hygiene, State of Maryland
 - b. 1989
 - c. Co-chair
- 33. CASPR Pharmacy Panel to Study Personnel Positions
 - a. Dept of Personnel, State of Maryland
 - b. 1989-1990
- 34. Manpower Task Force
 - a. Department of Health and Mental Hygiene, State of Maryland
 - b. 1989
- 35. Task Force on Alzheimer's and Related Diseases
 - a. UMAB Campus
 - b. 1988
- 36. Governor's Commission on Black and Minority Mental Health
 - a. State of Maryland
 - b. 1987-1988
- 37. Management Information Committee
 - a. Department of Psychiatry, UMAB School of Medicine
 - b. 1986-1987
- 38. Behavioral Medicine Task Force
 - a. Chancellor's Task Force, UMAB Campus
 - b. 1986-1987
- 39. Management Information Committee
 - a. Department of Health and Mental Hygiene, State of Maryland
 - b. 1986-1987

B. National and Professional Service

- 1. Treasurer
 - a. Maryland Society of Hospital Pharmacists
 - b. 1995

2. Finance Committee
 - a. Maryland Society of Hospital Pharmacists
 - b. 1995-1997
 - c. Chair 1996-1997
3. Specialty Council on Psychopharmacy Practice
 - a. Board of Pharmaceutical Specialties, American Pharmaceutical Association
 - b. 1994-1997
 - c. Council member
4. Conference of Neurologic and Psychiatric Pharmacists
 - a. 1994-1995
 - b. Executive Committee
5. Legislative Committee
 - a. Maryland Society of Hospital Pharmacists
 - b. 1994
 - c. Chair
6. Vice-chair, Specialized Practice Group on Psychopharmacy
 - a. American Society of Hospital Pharmacists
 - b. 1993
7. Contemporary Psychiatric Pharmacy Practice Working Group
 - a. American Society of Hospital Pharmacists
 - b. 1993
8. Advisory Working Group - Board of Pharmaceutical Specialties
Petition for Recognition of Psychiatric Pharmacy Practice as a Specialty
 - a. American Society of Hospital Pharmacists
 - b. 1990-1993
 - c. Chair, subsection on Specialized Knowledge
9. Committee on Public Sector Practice
 - a. ASHP Psychopharmacy Special Practice Group
 - b. 1990
 - c. Chair

C. Organization Memberships

1. American Society of Health-Systems Pharmacists
2. American Association of Colleges of Pharmacy

3. Maryland Society of Health-Systems Pharmacists
4. Conference of Neurologic and Psychiatric Pharmacists

D. Administrative Services

1. Vice-chair, Department of Pharmacy Practice and Science, 1993-1997.

Major areas of emphasis in this position have included auditing the finances of the Maryland Poison Center (MPC), planning for the future viability of the MPC, establishing new financial procedures for the department, budgetary planning, supervision of administrative functions, oversight of various service programs and developing systems for providing administrative functions delegated to the departments from the dean's office.

2. Director, Mental Health Program, Department of Pharmacy Practice and Science, 1986-1997.

Major areas of emphasis have included planning, developing, implementing, maintaining and assuring the quality of innovative pharmacy services for Department of Health and Mental Hygiene facilities throughout the State of Maryland. Specific accomplishments made in this role have been highlighted elsewhere in this document.

E. Additional Service to Profession, Other Professions, Public

1. Organization of Programs or Meetings

- a. Contemporary Issues in the Use of Novel Antipsychotic Drugs. ASHP Midyear Clinical Meeting, Miami Beach, Florida, December 7, 1994, chair and participant.
- b. Paraphilias and Sexual Offenders. ASHP Midyear Clinical Meeting, Miami Beach, Florida, December 5, 1994, chaired and organized.
- c. Recent Developments in Antipsychotic Therapy, Pre-meeting symposium, ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 5, 1993, chair and panel participant.
- d. Managing the Clozapine Patient: Beyond the C.P.M.S. (Clozaril Patient Management System). Mental Hygiene

Administration, Department of Health and Mental Hygiene, Maryland Psychiatric Research Center, March 7, 1990, chair and participant.

2. Professional Service - Other Disciplines

- a. Love RC. Using and Monitoring the New Antidepressants and Antipsychotics. Visiting Nurses Association of Maryland, Baltimore, Maryland, April 16, 1997.
- b. Love RC. Administering Psychiatric Medications in Acute Situations, Mental Hygiene Administration Nurse's Seminar, Marriottsville, Maryland, November 16, 1993.
- c. Love RC. Medication Related Problems in the Elderly, Department of Health and Mental Hygiene, Conference for Staff of Residential Treatment Centers, Crownsville, Maryland, March 29, 1993.
- d. Love RC. Clozapine, Patient Education and Informed Consent, Rights Advisors, Mental Hygiene Administration, Department of Health and Mental Hygiene, State of Maryland, November 21, 1991.
- e. Love RC. Psychiatric Medications: A Primer. Howard County, Maryland Department of Social Services, September 26, 1991.
- f. Love RC. Drug Combinations and Interactions for Psychiatric Inpatients, Statewide Nursing Seminar, Clifton T. Perkins Hospital Center, Jessup, Maryland, October 17, 1989.
- g. Love RC. Psychopharmacologic Aspects of Drug Abuse. Cross Training for Mental Health and Substance Abuse Professionals, Maryland Department of Health and Mental Hygiene, Eastern Shore Hospital Center, Prince Georges Community College, Springfield Hospital Center, Thomas B. Finan Center, September 25-28, 1989.
- h. Love, RC. Pharmacology of Drugs Used in Adult and Pediatric Behavioral Disorders. Ninth Annual National Nurse Practitioner Symposium, Baltimore, Maryland, October 22, 1988.

- i. Love RC. Side Effects, Compliance and Psychotropic Medications. Judicial Conference of Maryland, Clifton T. Perkins Hospital Center, Jessup, Maryland, September 18, 1986.

3. Presentations to Lay Groups

- a. Love RC. Medication Related Problems in the Elderly, Maryland Association of Adult Day Care Providers, Hunt Valley, Maryland, October 15, 1993.
- b. Love RC. Drugs on the Horizon for Psychiatric Disorders National Alliance for the Mentally Ill, Southern Maryland Chapter, St. Mary's County, Maryland, April 8, 1993.
- c. Love RC. Using Psychiatric Drugs in the Aged: A Primer. Medical Care Policy Administration, Department of Health and Mental Hygiene, Annapolis, Maryland, March 29, 1993.

4. Other volunteer outreach clinical activities

- a. Unpaid consultation to Department of Corrections, Montgomery County, Maryland, 1994.

VII. Signature

I certify that this curriculum vitae is complete and accurate.

CURRICULUM VITAE AND BIBLIOGRAPHY

I. PERSONAL DATA

Name: Subramoniam Madhusoodanan, M.D.
S.S.#: REDACTED
Mailing Address: 249 Broadway, Lawrence, New York 11559
Telephone: REDACTED (Home) (718) 869-7248 (Office)
Date and Place of Birth: 9/7/47, India
Country of Citizenship: U.S.A.

II. EDUCATION

A. Degrees:

M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery)
Trivandrum Medical College, India, 1970.

D.L.O. (Diploma in Otorhinolaryngology)
Kurnool Medical College, India, 1975.

M.D. (Doctor of Medicine)
State University of New York, 1992.

B. Training:

Internship - Rotating internship in medicine, surgery,
Obs/Gyn and Preventive Medicine including Pediatrics.
Trivandrum Medical College, India, Nov., 1970 - Oct.,
1971.

Residencies & Fellowships

Postgraduate training in Otorhinolaryngology
Kurnool Medical College, India, July, 1973 - July, 1975.

Residency Training in Psychiatry
Mount Sinai Hospital Services, City Hospital Center at
Elmhurst, New York 11373, July 1976 - July, 1979,
Chief Resident, July, 1978 - July, 1979.

C. Licensures

New York 1979 - REDACTED
New Jersey 1978 - REDACTED (Inactive)
Georgia 1978 - REDACTED (Inactive)

-2-

D. Board Certifications

American Board of Psychiatry & Neurology
(Psychiatry) 1980, REDACTED

Added qualifications in Geriatric Psychiatry of the
American Board of Psychiatry & Neurology, 1991, REDACTED

American Board of Quality Assurance and Utilization
Review Physicians, 1993, REDACTED

III. APPOINTMENTS

A. Academic

Instructor in Psychiatry, Mount Sinai School of Medicine,
City University of New York, July, 1978 - July, 1981

Clinical Instructor, Department of Psychiatry, State
University of New York, Health Science Center at
Brooklyn, New York, March, 1984 to 1995.

Clinical Assistant Professor, Department of Psychiatry,
State University of New York, Health Science Center at
Brooklyn, New York, February 1995 to date.

Program Director, Geriatric Psychiatry Fellowship
Training, St. John's Episcopal Hospital, Far Rockaway,
New York, July, 1993 to date.

Affiliates: 1. Downstate Medical Center, Brooklyn, N.Y.
2. Long Island Jewish Medical Center, N.Y.

B. Hospital & Other

Assistant Attending Psychiatrist, City Hospital Center at
Elmhurst, New York, July, 1979 - December, 1980.

Medical Director, Outpatient Alcoholism Program,
St. John's Episcopal Hospital, 327 Beach 19 Street,
Far Rockaway, New York,
January, 1981 to April, 1982.

Unit Chief of Inpatient Psychiatry, St. John's Episcopal
Hospital, 327 Beach 19th Street,
Far Rockaway, New York, January, 1981 to date.

Acting Director, Department of Psychiatry, St. John's
Episcopal Hospital, 327 Beach 19th Street, Far Rockaway,
New York, March, 1984 to May, 1985.

Director of Psychiatry, Peninsula Hospital Center,
Far Rockaway, New York, January, 1986 to date.

-3-

Associate Chairman, Department of Psychiatry,
St. John's Episcopal Hospital, 327 Beach 19 Street
Far Rockaway, New York
January, 1986 to date.

Consultant Psychiatrist - Peninsula Nursing Home,
St. John's Episcopal Nursing Home, Lawrence Nursing Home,
Rockaway Care Center, Brookhaven Nursing Home, Oceanview
Nursing Home, Far Rockaway Nursing Home and Haven Manor
Health Care Center all in the Rockaway Peninsula,
January, 1987 to date.

Department of Social Services, Social Securities
Administration, 1982 to 1985.

Island Peer Review Organization - from June, 1985 to
1990.

IV. AWARDS AND HONORS

Included in the Silver Anniversary 25th Edition of Marquis
WHO'S WHO IN THE EAST, WHO'S WHO IN SCIENCE AND ENGINEERING
AND WHO'S WHO IN THE WORLD.

V. PROFESSIONAL MEMBERSHIPS

A. Society Memberships

American Psychiatric Association since February, 1980.

American Geriatric Society since January, 1987.

World Federation of Mental Health since October, 1986.

American Association for Geriatric Psychiatry since
November, 1980.

B. Committee Memberships

Chairperson, Quality Improvement Committee, Department of
Psychiatry, St. John's Episcopal Hospital, 1982 to date.

Chairperson, Special Review Committee, Department of
Psychiatry, St. John's Episcopal Hospital, 1984 to date.

Member, Quality Improvement Committee, St. John's
Episcopal Hospital and Peninsula Hospital since 1984.

Member, Patient Care Committee, St. John's Episcopal
Hospital since 1984.

-4-

Member, Pharmacy & Therapeutics Committee, St. John's Episcopal Hospital, 1982 to 1986.

Member, OBRA Sub-committee, American Geriatric Psychiatry Association since 1991.

VI. PAST AND PRESENT RESEARCH ACTIVITIES

GRANT FUNDED PROJECTS:

1. RIS-USA-64 - An open multicenter study to evaluate the tolerability and safety of Risperdal tablets in elderly subjects with Psychotic disorders. Principal investigator. - six months - August, 1995 through January, 1996. Completed.
2. MAZ-INT-01 - Mazapertine dose finding trial, comparing three fixed dosages of Mazapertine to Risperidone and placebo. Multicenter, double blind, parallel group study. Phase II. Principal investigator. - six months - March 1996 through July 1996. Completed.
3. RIS-USA-63B - A randomized, double blind, placebo controlled study of Risperidone for treatment of behavioral disturbances in subjects with dementia. Principal investigator. August, 1996 through March 1997. Completed.
4. RIS-USA-79 - A comparison of Risperidone and Haloperidol for prevention of relapse in subjects with schizophrenia and schizo-affective disorder. Principal Investigator. To start August 1996. 2 years. In progress.
5. RIS-USA-78 - A study of the efficacy of Risperidone, Haloperidol and Clozapine in treatment resistant schizophrenic subjects. Principal Investigator. To start August, 1996. Six months. In progress.
6. CONTACT (Cognex - Neuropsychiatric testing and assessment of care giver time) - Principal Investigator January, 1996. In progress.
7. DONEPEZIL - An open-label, multicenter clinical trial evaluating the safety and efficacy of Donepezil Hydrochloride in patients with Alzheimer's Disease. To start August, 1996. In Progress.

-5-

8. GAL-USA-1 - Efficacy, Tolerability and Safety of Galantamine in the treatment of Alzheimer's Disease. Principal Investigator. In progress.
9. A Phase III Randomized Study Comparing two Doses of Intra-muscular Ziprasidone (2mg and 10 mg) in subjects with Psychosis and Acute Agitation. Starting in March, 1997.
10. An Open Extension Study Evaluating the Safety and Outcome of 40 mg - 200 mg daily of Oral Ziprasidone in the Treatment of Subjects Who have Participated in Previous Ziprasidone Clinical Trials. Starting in March, 1997.
11. An Open Trial of Olanzapine in Elderly Subjects with Psychosis and Behavioral Disturbances Associated with Schizophrenia, Schizoaffective Disorder, Dementias and Bipolar Disorders. In progress.
12. RIS-USA-70 - An Open Label Long Term-Study of Treatment of Behavioral Disturbances in Subjects with Dementia. Principal Investigator. In progress.

NON-FUNDED PROJECTS

Role of Precipitating events in Depressive Disorder - 1976 - 1977. Non funded project. Was principal investigator. Findings presented in Grand Rounds at Mount Sinai Hospital Services, City Hospital Center at Elmhurst, 1977.

Folic Acid and dementias - 1978 to 1979. Project done at the Geriatric Psychiatry Clinic of Elmhurst Hospital. Was principal investigator. Non-funded project.

Epidemiology of alcoholism in the Far Rockaway Population - Project done at St. John's Episcopal Hospital Outpatient Alcoholism Program, 1981 to 1984. Principal investigator, non-funded project.

Impact of OBRA Regulations regarding Psychotropic Drugs in the Nursing Homes. Principal investigator. Project is currently in progress at Peninsula nursing Home. Non-funded project.

Analysis of Falls in Inpatient Geriatric Psychiatry Setting. Principal investigator. Project currently in progress at St. John's Episcopal Hospital. Non-funded.

1075

-6-

COLLABORATIVE PROJECTS

1. Depression and Anxiety Disorder among older African Americans - with Carl Cohen, M.D., SUNY, Health Science Center at Brooklyn.
2. Disappearance rate of hyperprolactinemia following discontinuation of neuroleptic medication and the time it takes for hyperprolactinemia to develop following the initiation of such therapy. With Mark Spitzer, M.D., Mount Sinai School of Medicine.
3. Brain Morphometry in Geriatric Depression. With Blaine Greenwald, M.D. - Long Island Jewish Medical Center.
4. Antidepressant Drug Treatment in Depressed Patients with Parkinson's Disease. With Menek Goldstein, Ph.D. of N.Y.U. Medical Center.
5. Comparison of Nortryptiline versus Paroxetine in the treatment of Major Affective Disorder. With Steven P. Roose, M.D of Columbia University.

VII. PUBLICATIONS

1. "The Effect of Anxiety and Depression on Completion/Withdrawal Status in Patients Admitted to Substance Abuse Detoxification Program." Journal of Substance Abuse Treatment. Vol. 13 No.1, pp61-66, 1996.
2. Efficacy of Risperidone Treatment for Psychoses Associated with Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, or Senile Dementia in 11 Geriatric Patients: A Case Series. Journal of Clinical Psychiatry, 56:11, Nov. 1995, 514-518.
3. Reversible Choreiform Dyskinesia and extrapyramidal symptoms associated with Sertraline Therapy - Journal of Clinical Psychopharmacology. Vol.17/No.2, April, 1997.
4. Risperidone induced ejaculatory and urinary dysfunction - Journal of Clinical Psychiatry. 57-11, November, 1996.
5. "Amitriptyline Induced Hyponatremia" - A Case Report - Mt. Sinai Journal of Medicine 1981, Sept.-Oct.

VIII. PRESENTATIONS

1. "Efficacy and Tolerability of Risperidone in Elderly Patients with Psychotic Disorders - Poster Presented at the American Association for Geriatric Psychiatry, Tenth Annual Meeting, March 2 - 5, 1997, Lake Buena Vista, Florida.
2. "New Antipsychotic Drugs in Geriatric Population" - Geriatric Psychiatry Grand Rounds at SUNY, Health Science Center at Brooklyn - 4/10/96.
3. Geriatric Psychopharmacology lecture series for residents and fellows at St. John's Episcopal Hospital and SUNY, Health Science Center at Brooklyn since 1992.
4. "Euphorogenic Effects of Trihexiphenidyl" - A Case report presented at Grand rounds, Elmhurst Hospital Center, 1977.
5. "Role of Precipitating Events in Depressive Disorder" - Presented at Grand Rounds, Elmhurst Hospital Center, 1977.

INSTRUCTIONS

REVERSE

CUT OFF
THIS STRIP

CUT OFF THIS STRIP

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

[THE STATE EDUCATION DEPARTMENT]

HAS REGISTERED [REDACTED]

MADHUSOODANAN SUBRAMONIAM
249 BROADWAY
LAWRENCE NY 11559-1511

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

08/31/97
REGISTRATION PERIOD ENDS

[REDACTED]
LICENSE/CERTIFICATE NO.

[Signature]
SIGNATURE OF REGISTRANT

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

CUT OFF THIS STRIP

5582

READ
INSTRUCTIONS

ON REVER
SIDE

CUT OFF
THIS STRIP

CUT OFF THIS STRIP

The University of the State of New York	
THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED	
THE STATE EDUCATION DEPARTMENT	
HAS REGISTERED	
MADHUSOODANAN SUBRAMONIAM	REDACTED
249 BROADWAY	
LAWRENCE	NY 11559-1511
FOR PRACTICE IN NEW YORK STATE AS A (N)	
09/31/99	PHYSICIAN
REGISTRATION PERIOD ENDS	REDACTED
<i>Madhusoodanan</i>	COMMISSIONER OF
SIGNATURE OF REGISTRANT	EDUCATION
REGISTRATION CERTIFICATE -- NOT A LICENSE	

218692

READ
INSTRUCTIONS

ON REVERSE
SIDE

CUT OFF
THIS STRIP

CURRICULUM VITAE

NAME: Theo C. Manschreck

Date prepared: 5/12/97

ADDRESS:

REDACTED

(617) 727-7244, x 360, 362

E-Mail Address: Theo.Manschreck@state.ma.usa

PLACE OF BIRTH: New Haven, Connecticut

EDUCATION/DEGREES

1967 B.A.	Carleton College
1971 M.D.	Cornell University Medical College
1971 M.P.H.	Harvard University School of Public Health
1993 A.M. (Hon. a.e.)	Dartmouth Medical School
1996 M.A. (Hon. a.e.)	Brown University

POST DOCTORAL TRAINING

Internship and Residencies

1971 - 1972	Intern Medicine/Surgery, San Francisco General Hospital, San Francisco
1972 - 1975	Resident in Psychiatry, Massachusetts General Hospital
1974 - 1975	Chief Resident, Acute Psychiatry Service, Massachusetts General Hospital

Research Fellowships

1970 - 1971	U.S. Public Health Service Fellowship, Harvard School of Public Health, Behavioral Sciences and Epidemiology
1976 - 1977	Fellow in Psychiatry (Fellowship on Psychosomatic and Consultation Psychiatry), Massachusetts General Hospital

LICENSURE AND CERTIFICATION

1972	National Board of Medical Examiners, Diplomate
1973	Massachusetts License Registration No. REDACTED
1978	American Board of Psychiatry and Neurology
1990	New Hampshire License No. REDACTED
1994	Rhode Island License No. REDACTED

ACADEMIC APPOINTMENTS

1972 - 1978	Clinical Fellow in Psychiatry at the Massachusetts General Hospital, Harvard Medical School

1975 - 1980	Instructor in Psychiatry at the Massachusetts General Hospital, Harvard Medical School
1980 - 1984	Assistant Professor of Psychiatry at the Massachusetts General Hospital, Harvard Medical School
1984 - 1990	Associate Professor of Psychiatry at the Massachusetts General Hospital, Harvard Medical School
1989 - 1994	Professor of Psychiatry, Dartmouth Medical School
1990 -	Lecturer in Psychiatry, Massachusetts General Hospital and Harvard Medical School
1994 -	Professor of Psychiatry and Human Behavior (Research Scholar Track), Brown University School of Medicine
1997 -	Professor of Psychiatry (Clinical), Harvard Medical School

HOSPITAL APPOINTMENTS

1975 - 1977	Clinical Assistant in Psychiatry, Massachusetts General Hospital
1977 - 1978	Assistant Psychiatrist, McLean Hospital
1978 - 1981	Assistant in Psychiatry, Massachusetts General Hospital
1982 - 1986	Assistant Psychiatrist, Massachusetts General Hospital
1986 - 1989	Associate Psychiatrist, Massachusetts General Hospital
1990 - 1993	Psychiatrist, Massachusetts General Hospital
1990 - 1994	Psychiatrist, New Hampshire Hospital
1993 -	Senior Psychiatrist, Massachusetts General Hospital
1994 - 1996	Physician, Department of Psychiatry, Rhode Island Hospital
1994 - 1996	Staff Psychiatrist, Eleanor Slater Hospital
1994 -	Staff Psychiatrist, John C. Corrigan Community Mental Health Center
1994 - 1996	Staff Psychiatrist, Women and Infants Hospital
1997 -	Staff Psychiatrist, Veterans Administration Hospital, Brockton

OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS

1977 - 1982	Director, Investigative Psychiatry Education and Training Program, Massachusetts General Hospital
1982 - 1983	Visiting Professor, Psychiatric Residency Program, Wilford Hall, University of Texas Health Science Center, San Antonio, Texas
1983 - 1985	Faculty Tutor (Psychiatry/Psychology), Leverett House, Harvard College
1983 - 1989	Health Professions Advisory Committee, Leverett House, Harvard College
1985 - 1989	Faculty Associate, Leverett House, Harvard College

AWARDS AND HONORS

1963	William Walter Davies Award, Ohio Wesleyan University
1966	George C. Marshall Fellowship Nominee, Carleton College
1967	B.A. with honors, philosophy, Carleton College
1977	Roche Service Award, Study of Personality Correlates in Stuttering
1977	Milton Fund Award, Study of Biological Feedback in Chronic Severe Stuttering
1977	McLean Hospital General Research Award, Study of

1980	Attention and Language Correlates of Psychiatric Disorders
	Rand Fund Award (with Professor Brendan Maher), Study of
	Schizophrenic Language Disturbance
1985-6	Fulbright Award, Commonwealth of the Bahamas, Study of
	Cocaine Psychosis Psychopathology, U.S. Department of State
1986	International Who's Who in Medicine
1986	Men of Achievement
1988	Association for Research in Nervous and Mental Disease
1989	Who's Who in the East
1989	Fellow, American Psychiatric Association
1992	Guest Editor, Delusions & Delusional Disorder, <u>Psychiatric Annals</u>
1993	Who's Who in Science and Technology
1993	A.M. (Honorary), Dartmouth
1993	International Men of Achievement (2nd award)
	(Cambridge, England)
1993-present	Reviewer, VA Research Administration
1993-present	Reviewer, NIMH Research Review Committee on
	Psychopathology
1996	M.A. (Honorary) Brown University
1997	Who's Who in Medicine and Health Care

MAJOR COMMITTEE ASSIGNMENTS

Massachusetts General Hospital/Erich Lindemann Mental Health Center

1975 - 1976	Residency Training Committee, Department of Psychiatry, MGH
1977 - 1990	Chair, Psychiatry Service Library Committee, MGH
1978 - 1980	Committee on Research, MGH (Psychiatry Service representative)
1980 - 1986	Residency Training Committee, Department of Psychiatry (MGH)
1980 - 1990	Steering Committee, Harbor Area Mental Health Services
1983 - 1990	Chair, Research Committee, Medical Practices Committee, Pharmacy Committee, Training Committee, Seclusion and Restraint Committee, Medical Records Committee, Erich Lindemann Mental Health Center, Harbor Area
1984 - 1985	Executive Committee on Neighborhood Health Centers, Massachusetts General Hospital
1986 - 1990	Appointments and Promotions Committee, Department of Psychiatry, Massachusetts General Hospital

New Hampshire Hospital/Dartmouth Medical School

1990 - 1994	Research Committee, Seminars Committee
1990 - 1994	Continuing Education Committee, Department of Psychiatry, Dartmouth Medical School
1992 - 1994	President, Medical Staff, New Hampshire Hospital, Executive Committee (Chair), Credentialing Committee (Chair), Joint Practice (Co-chair)

Brown University and Hospitals

1994-1996	Policy and Management Advisory Committee, Department of Psychiatry and Human Behavior
1995-	Research Committee, Promotion and Appointments Committee, Department of Psychiatry and Human Behavior
1995-1996	Peer Review, Pharmacy and Therapeutics, and Research Committees, Dr. John C. Corrigan Mental Health Center
1995-1996	Leadership, Consolidation Committees, Eleanor Slater Hospital

Harvard Medical School

1996-	Member, Governing Body, Southeast Area, DMH, Commonwealth of Massachusetts, Dr. John C. Corrigan Mental Health Center
1996-	Member, Medical Directors Committee, Research Committee, Southeast Area, DMH, Commonwealth of Massachusetts
1996-	Chairperson, Medical Staff, Medical Executive, Peer Review, Pharmacy & Therapeutics, Utilization Review Committees, Dr. John C. Corrigan Mental Health Center

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

1975 -	American Association for the Advancement of Science
1979 -	American Psychiatric Association
1980 -	American Academy of Clinical Psychiatrists
1981 - 1982	American Psychiatric Association Task Force on Psychiatric Knowledge and Skills Self-Assessment Program
1982 - 1985	Board of Directors, Massachusetts Biofeedback Society
1982 - 1989	Public Sector Psychiatry Committee, Massachusetts Psychiatric Society
1983 -	Associate, The Behavioral and Brain Sciences, Cambridge University Press
1983 -	Society of Biological Psychiatry
1985	Consultant, Drug Evaluation Program, American Medical Association
1987	Consultant, Massachusetts Psychiatric Society, Superior Court, Commonwealth of Massachusetts
1988 -	New York Academy of Sciences
1988 -	Association for Research in Nervous and Mental Diseases
1991 -	Society for Research in Psychopathology
1992 - 1994	President, Medical Staff, New Hampshire Hospital
1996	Expert Consensus Panel Member, Schizophrenia Treatment Guidelines Project, Expert Consensus Consortium
1996 -	Department of Mental Health, Commonwealth of Massachusetts, Practice Guidelines Review Panel

EDITORIAL BOARDS

1977 - 1984	Editor-in-Chief, <u>Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians (Vols I-III)</u>

- 1981 - Reviewer: Psychosomatics, Language and Speech, New England Journal of Medicine, American Journal of Psychiatry, Culture Medicine and Psychiatry, Journal of Clinical Psychiatry, Culture Medicine and Psychiatry, Perceptual and Motor Skills, Biological Psychiatry, Journal of Clinical Psychiatry, Journal of Neuropsychiatry and Clinical Neuroscience, Schizophrenia Research, Hospital and Community Psychiatry (Psychiatry Services), Schizophrenia Bulletin, Journal of Abnormal Psychology, International Journal of Clinical Psychopharmacology, Acta Psychiatrica Scandinavica, Clinical Drug Investigation, Medscape Mental Health
- 1996 Editorial Board: The Journal of Psychotic Disorders: Reviews and Commentaries,

MAJOR RESEARCH INTERESTS

1. Clinical and experimental psychopathology of language, cognition, and motor behavior; cognitive performance and vocational outcome; handedness/laterality of cognitive functioning; memory mechanisms; cognitive rehabilitation
2. Schizophrenic disorders and psychosis, including genetic markers, heterogeneity; neurology, imaging, memory mechanisms and cognition, speech disturbance
3. Psychopharmacology, clozapine, novel antipsychotic agents; prediction of response, nature of response (symptomatic, cognitive, functional)
4. Psychopathology of cocaine toxicity; substance abuse and severe mental disorder

PRINCIPAL CLINICAL AND HOSPITAL SERVICE AND MAJOR ADMINISTRATIVE RESPONSIBILITIES

Massachusetts General Hospital

1975 - 1976	Chief, Acute Psychiatry Service, Massachusetts General Hospital
1977 - 1990	Director, Laboratory for Clinical and Experimental Psychopathology, Massachusetts General Hospital
1977 - 1982	Director, Investigative Psychiatry Education and Training Program, Massachusetts General Hospital
1980 - 1984	Chief, Adult Inpatient Services, Erich Lindemann Mental Health Center, Commonwealth of Massachusetts, Massachusetts General Hospital and Harvard Medical School
1983 - 1990	Clinical Director, Erich Lindemann Mental Health Center, and Harbor Area Mental Health and Mental Retardation Programs, Commonwealth of Massachusetts, Department of Psychiatry, Massachusetts General Hospital
1989 - 1990	Statewide Clozapine Review Panel, Department of Mental Health, Commonwealth of Massachusetts

New Hampshire Hospital

1990 - 1994	Director of Research, New Hampshire Hospital, Dartmouth Medical School
1990 - 1994	Director, Laboratory for Clinical and Experimental Psychopathology, New Hampshire Hospital, Dartmouth Medical School
1990 - 1994	Director, Clozapine Monitoring Program, New Hampshire Hospital, Concord, NH

1992 - 1994	President, Medical Staff, New Hampshire Hospital
1993 - 1994	Chief, Inpatient Clinical Research Unit, New Hampshire Hospital

Brown University & Hospitals

1994 -	Director, Division of Public Psychiatry
1994 -	Director, Schizophrenia and Related Psychotic Disorders Research Program
1994 - 1996	Director, Laboratory for Clinical and Experimental Psychopathology, Dr. John C. Corrigan Mental Health Center - Brown University School of Medicine Research Program
1994 - 1996	Director, Outpatient Psychiatry, Dr. John C. Corrigan Mental Health Center

Harvard Medical School

1996-	Medical Director, Dr. John C. Corrigan Mental Health Center
1996-	Director, Laboratory for Clinical and Experimental Psychopathology, Dr. John C. Corrigan Mental Health Center

SELF REPORT OF TEACHING

LOCAL CONTRIBUTIONS

Massachusetts General Hospital/Harvard Medical School/Harvard University/Harvard School of Public Health

1974 - 1977	Tutor, Introduction to Clinical Medicine, Harvard Medical School (2-4 students/rotation) 1-2 hours/week 1-2 rotations per year
1976 - 1977	Medical Student Tutor on Psychopathology, Harvard Medical School
1976 - 1980	Attending Psychiatrist, Acute Psychiatry Service, Massachusetts General Hospital (resident supervision, 4-6 hours/week)
1979 - 1990	Attending Psychiatrist, Lindemann Center Inpatient Service (3-4 residents/year; individual and group supervision)
1986 - 1989	Lecturer, Schizophrenic Disorders, Harvard Medical School, New Pathways Program 2 lectures/1 hr each
1988 - 1990	Seminar Leader, Schizophrenic Disorders, Psychiatry Residency Core Curriculum Seminar, Massachusetts General Hospital (6 session seminar, 1hr/session)
1991 - 1992	Lecturer, Schizophrenia Disorder, Psychiatry Residency Core Curriculum Seminar, Massachusetts General Hospital (1 hour lecture)

6

1976 - 1991	Lecturer, Postgraduate Review Courses on General Psychiatry and Contemporary Practice, Department of Psychiatry, Massachusetts General Hospital
1978 - 1982	Lecturer, Postgraduate Course on Differential Diagnosis in Psychiatric Medicine, Massachusetts General Hospital
1983	Seminar Leader, Postgraduate Course on Geriatric Psychiatry, Department of Psychiatry, Massachusetts General Hospital
1985 - 1990	Lecturer, Postgraduate Course on Treatment Resistance in Psychiatric Disorder, Department of Psychiatry, Massachusetts General Hospital
1977 - 1978	Lecturer on Personality Assessment, Behavioral Science Course 207A.B Harvard School of Public Health
1983 - 1988	Graduate Course Instructor, Psychology 2488, Clinical Therapeutics, Department of Psychology, Harvard University
1985 - 1987	Graduate Course Instructor, Psychology 2475, Diagnosis of Psychopathology, Department of Psychology, Harvard University

LEADERSHIP ROLE

1975 - 1976	Co-Leader of Seminar on Advanced Psychopathology, Department of Psychology and Social Relations, Harvard University
1975 - 1982	Co-Leader and Developer of the Massachusetts General Hospital Psychiatry Residency Core Seminar on Descriptive Psychopathology (10-12 sessions, 12 PG2 residents)
1977 - 1984	Preceptor and Coordinator of Preceptors, Investigative Psychiatry Training and Education Program
1977 - 1984	Seminar Developer and Leader, Investigative Psychiatry Methodology and Biostatistics Seminar, Massachusetts General Hospital Psychiatry Residency Training Program (6-10 residents/fellows each year Year long seminar One hour per week
1987 - 1990	Coordinator, Psychopathology Exercises, New Pathways Program, Information Processing and Behavior, Harvard Medical School 3 or 4, 1.5 hours each
1981 - 1982	Course Director, Lecturer, Postgraduate Course on Differential Diagnosis in Psychiatric Medicine, Department of Psychiatry, Massachusetts General Hospital
1990	Course Director, Lecturer, Postgraduate Course on Emergency Psychiatry, Department of Psychiatry, Massachusetts General Hospital

ADVISING ROLE

1980	Doctoral Thesis Committee, K. Stone, Department of Psychology and Social Relations, Harvard University
1981 - 1982	Doctoral Thesis Committee, M. White, Department of Psychology and Social Relations, Harvard University
1981	Honors Thesis Supervisor, M.A. Molino, Department of Psychology and Social Relations, Harvard College
1983	M.A. Thesis Supervisor, T.M. Hoover, Department of Psychology, Harvard University
1983 - 1988	Doctoral Thesis Committees, T.M. Hoover, C. Hellman, D. Briggs, Department of Psychology, Harvard University
1983 - 1986	Pre-medical Tutor, Leverett House, Harvard University
1985 - 1990	Training Supervisor, Psychiatry Residency, Massachusetts General Hospital 2-3 residents per year at different levels of training
1986	Honors Thesis Advisor, J. Berner, L. Fagioli, Department of Psychology, Harvard College
1989	Doctoral Thesis Committee, P. Myers, Department of Psychology, Harvard University
1992 - 1994	Doctoral Thesis Committee, C. Blyler, Department of Psychology, Harvard University

New Hampshire Hospital/Dartmouth Medical School

1990 - 1994	Lecturer, Medical Student Clerkship in Clinical Psychiatry
1990 - 1994	Attending Psychiatrist, Psychiatry Residency Training Program
1991 - 1994	Lecturer, Graduate Program in Cognitive Neurosciences, Dartmouth College
1993 - 1994	Director, Psychopharmacology Module, Psychiatry Residency Training Program
1993	Director, Dartmouth Postgraduate Course, New Directions in Schizophrenia: Diagnosis and Treatment
1994	Director, Dartmouth Postgraduate Course, A Revolution in Care: Clozapine 1990-1994

Brown University and Hospitals

1995-	Lecturer, Psychiatry Residency Training Program
1995-	Lecturer, Schizophrenia series, Core Seminar, Psychology Intern Program; Advanced Psychopharmacology, Neuropsychiatry
1995 - 1996	Supervisor, Fellow in Psychopathology

REGIONAL, NATIONAL, INTERNATIONAL CONTRIBUTIONS

Grand Rounds Presentations (Representative)

Massachusetts General Hospital; University of North Carolina; University of California, Davis, St. Vincent's Hospital Medical Center; University of Washington; Wilford Hall, San Antonio; University of Texas Medical Center, San Antonio; Medical College of Pennsylvania, Johns Hopkins Hospitals; Albert Einstein Medical Center, Hahnemann Medical School; University of Massachusetts Medical Center; University of Minnesota Hospitals; University of South Dakota; Dartmouth Medical School; Brown University, Harvard (VA Brockton) Medical School, University of West Virginia School of Medicine, University of Vermont, Albany Medical College, Cornell University Medical College; University of Connecticut Medical Center; Nathan Kline Research Institute/Rockland Psychiatric Center (New York University)

Invited Scientific Presentations (Representative)

Mar	1979	National Research Council, Washington, D.C.
Nov	1982	World Psychiatric Association, New York, New York
Nov	1985	First International Symposium on Drug Abuse, Nassau, Bahamas
Jan	1986	Biannual Workshop on Schizophrenia, Schladming, Austria
Mar	1987	Guggenheim Foundation Conference on Violence and Drugs, Medical University of South Carolina
Apr	1987	International NIMH Schizophrenia Conference, Clearwater, Florida
May	1987	American Psychiatric Association, Annual Meeting, Symposium on Neurology of Schizophrenia, Chicago
Jul	1987	University of Maryland Psychiatric Research Center
Nov	1987	University of Pittsburgh Fourth Annual Symposium on Schizophrenia
Apr	1988	Boston Psychoanalytic Institute
Aug	1988	Chinese Medical Association-American Psychiatric Association Joint Meeting, Beijing, China
Nov	1988	International Drug Symposium, (organized by Commonwealth of Bahamas, U.S. State Department, Organization of American States), Nassau, Bahamas
Sep	1991	International Symposium on Schizophrenia, Language, and Phenomenology, University of Heidelberg, Heidelberg, Germany
Mar	1992	Update on Schizophrenia, Massachusetts General Hospital
May	1992	Guest Editorship, <i>Psychiatric Annals</i> , Delusional Disorders
Nov	1992	Cognition and Schizophrenia, Dartmouth
Mar	1993	Beth Israel Hospital, Boston, Harvard Medical School
Apr	1993	International Congress on Schizophrenia, Colorado Springs, Colorado
Jun	1993	Symposium on Experimental Psychopathology, University of Heidelberg, Heidelberg, Germany
Jul	1993	McLean Hospital, Harvard Medical School
Oct	1993	Dartmouth Medical School
Nov	1993	Primary Care and Internal Medicine Programs, University of North Carolina
May	1994	Society of Biological Psychiatry, Philadelphia
May	1994	American Psychiatric Association Annual Meeting, Philadelphia
April	1995	International Congress on Schizophrenia, Warm Springs, Virginia
May	1995	American Psychiatric Association, Annual Meeting, Symposium: Psychotic Disorders: Many Forms, Common Themes, Miami
Oct	1995	Society for Research in Psychopathology: Motor Disorder in Schizophrenia
Dec	1995	University of Miami School of Medicine: Psychotic Disorders

May	1996	American Psychiatric Association, Annual Meeting, Symposium: New Findings on Delusional Disorder and Delusions, New York
May	1996	Scientific Symposium: Cocaine Psychosis, Cornell University Medical College
Dec.	1996	Symposium: The Poles of Health: Biological and Social Approaches to Disordered Minds, Boston University

BIBLIOGRAPHY

Original Reports

1. Jacobson G, Baldessarini R, Manschreck TC. Tardive and withdrawal dyskinesia associated with haloperidol. Am. J. Psychiatry, 1974; 191:910-913.
2. Manschreck TC, Petri, M. The paranoid syndrome. Lancet, 1978, 251-253.
3. Jacobson A, Silverberg E, Hackert TP, Manschreck TC. Operant psychological and relaxation factors in treating Raynaud's phenomenon. Psychiatra Clinica, 1978; 11:125-131.
4. Manschreck TC. The atypical psychoses. Culture, Medicine and Psychiatry, 1978; 2:233-268.
5. Jacobson A, Manschreck TC, Silverberg E. Behavioral treatment for Raynaud's disease: a comparative study with long-term follow-up. Am. J. Psychiatry, 1979; 2:844-846.
6. Manschreck TC, Maher BA, Rucklos M, White M. The predictability of thought disordered speech in schizophrenic patients. Br. J. Psychiatry, 1979; 134:595-601.
7. Manschreck TC. The assessment of paranoid features. Compr. Psychiatry, 1979, 20:370-377.
8. Manschreck TC, Kleinman AM. Psychiatry's identity crisis: a critical rational remedy. Gen. Hosp. Psychiatry, 1979, 1:166-173.
9. Manschreck TC. Paranoid disturbances in general medical care. Med. Digest, 1979, 5:6-12.
10. Kalotkin M, Manschreck TC, O'Brien D. Electromyographic tension levels in stutterers and normal speakers. Perceptual and Motor Skills, 1979, 49:109-110.
11. Neu C, Manschreck TC, Flocks J. Renal damage associated with long term use of lithium carbonate. J. Clin. Psychiatry, 1979, 40:460-463.
12. Maher B, Manschreck TC, Rucklos M. Contextual constraint and the recall of verbal material in schizophrenia: the effect of thought disorder. Br. J. Psychiatry, 1980, 137:69-73.
13. Manschreck TC, Kalotkin M, Jacobson A. Utility of electromyographic biological feedback in chronic stuttering: a clinical study with follow-up. Perceptual and Motor Skills, 1980, 51:535-540.
14. Manschreck TC, Maher BA, Rucklos M. Cloze procedure and written language in schizophrenia. Language and Speech, 1980, 22:323-328.
15. Manschreck TC, Maher BA, Ader D. Formal thought disorder, the type-token ratio and disturbed voluntary motor behavior in schizophrenia. Br. J. of Psychiatry, 1981, 139:7-15.
16. Manschreck TC, Maher BA, Rucklos M, Vereen D, Adler D. Deficient motor synchrony in schizophrenia. J. Abnormal Psychology, 1981; 49(4):321-328.
17. Latham C, Holzman P, Manschreck TC, Tole J. Optokinetic nystagmus and smooth pursuit eye movements in schizophrenia. Arch. Gen. Psychiatry, 1981, 38:997-1003.

18. Keller M, Manschreck TC. The bedside mental status examination -- reliability and validity, Compr. Psychiatry, 1981, 22(5):500-511.
19. Manschreck TC. Schizophrenic disorders, N. Engl. J. Med., 1981,305:1628-1632.
20. Manschreck TC, Maher BA, Rucklos M, Vereen D. Disturbed voluntary motor activity in schizophrenic disorder, Psychological Med., 1982, 12:73-84.
21. Sheehan DV, Davidson J, Manschreck TC, Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of a panic disorder with phobias, J. Clin. Psychopharmacology, 1983, 3:28-31.
22. Manschreck TC. A paranoid model of the mind: a limited interpretation, Behavioral and Brain Sciences, 1983, 6:340-342.
23. Manschreck TC. The psychopathology of motor behavior in schizophrenic disorders, Progress in Experimental Personality Research, 1983, 12:53-96.
24. Manschreck TC. Drug treatment of schizophrenia: principles and limitations, Drug Therapy, 1983, 13:185-206.
25. Maher BA, Manschreck TC, Molino MA. Redundancy, pause distributions and thought disorder in schizophrenia, Language and Speech, 1983, 26:191-199.
26. Manschreck TC, Maher BA, Hoover T, Ames D. The type-token ratio in schizophrenia disorders: clinical and research value, Psychological Medicine, 1984, 14:151-158.
27. Manschreck TC, Ames D. Neurological features and psychopathology in schizophrenia disorders, Biological Psychiatry, 1984, 19:703-719.
28. Sederer L, Katz B, Manschreck TC. Inpatient psychiatry: perspectives from the general, the private, and the state hospital. Gen. Hosp. Psychiatry, 1984, 6:180-190.
29. Manschreck TC, Hoover TM, Maher BA, Ames D. Repetition in schizophrenic speech. Language and Speech, 1985, 28(3):255-268.
30. Manschreck TC, Maher BA, Waller N, Ames D, Latham C. Deficient motor synchrony in schizophrenic disorders: clinical correlates, Biological Psychiatry, 1985, 20:990-1002.
31. Ugozara E, Sheehan DV, Manschreck TC, Jones KJ. A combination drug treatment for acute common migraine, Headache, 1986, 26:231-236.
32. Manschreck TC. Schizophrenic disorders and reading disturbance, IEEE Transactions on Professional Communication, 1986, 29(2):27-30.
33. Zusky P, Manschreck TC, Blanchard C, Rosenbaum J, Elliot CE, Lou P. Dothiepin Hcl: Treatment efficacy and safety suggesting a wide range of clinical applications, J. Clin. Psychiatry, 1986,47:504-507.
34. Pollack M, Manschreck TC. Schizophrenia and oculocutaneous albinism, Biological Psychiatry, 1986, 21:830-833.
35. Manschreck TC, Ames D, Maher BA, Schneyer, ML. Impoverished written responses and negative features of schizophrenia, Perceptual and Motor Skills, 1987, 64:1163-1169.
36. Manschreck TC, Allen DR, Neville M. Freebase psychosis: cases from a Bahamian epidemic of cocaine abuse, Comprehensive Psychiatry, 1987, 28(6):555-563.

37. Beckett A, Summergrad P, Manschreck TC, Vitagliano H, Henderson M, Buttolph M, Jenike M. Symptomatic HTLV-III infection of the central nervous system in a patient without clinical evidence of immune deficiency, Am. J. Psychiatry, 1987, 144(10):1342-1344.
38. Manschreck TC, Maher BA, Milavetz J, Ames D, Weisstein C, Schneyer ML. Semantic priming in thought-disordered schizophrenic patients, Schizophrenia Research, 1988, 1:61-66.
39. Garber HJ, Weilburg JB, Buonanno FS, Manschreck TC, New, PFJ. Use of magnetic resonance imaging (MRI) in psychiatry, Am. J. of Psychiatry, 1988, 145(2):164-171.
40. Manoach DS, Maher BA, Manschreck TC. Left handedness and thought disorder in the schizophrenias. J. of Abnormal Psychology, 1988, 97(1):97-99.
41. Zusky PM, Biederman J, Rosenbaum JR, Manschreck TC, Gross C, Weilburg J, Gastfriend D. Adjunct low dose lithium carbonate in treatment resistant depression: a placebo-controlled study and review, J. Clin. Psychopharm., 1988, 8(2):120-124.
42. Manschreck TC. Cocaine abuse, Drug Therapy, 1988, 18(8):26-44.
43. Manschreck TC, Laughery J, Weisstein CC, Allen D, Humblestone B, Neville M, Podlewski H, Mitra N. Characteristics of freebase or crack cocaine psychosis, Yale J. of Biology and Medicine, 1988, 61:115-122.
44. Beckett A, Manschreck TC. Neuropsychiatric complications of immunodeficiency virus infection: public policy implications, New England Journal of Public Policy, 1988, 4:111-119.
45. Maher BA, Manschreck TC, Weisstein C, Okunieff R, Schneyer M. Cloze analysis in schizophrenic disorders: the influence of scoring method and rater selection, Perceptual and Motor Skills, 1988, 67:911-918.
46. Garber HJ, Weilburg JB, Duffy FH, Manschreck TC. Clinical use of topographic brain electrical activity mapping in psychiatry, J. Clinical Psychiatry, 1989, 50:205-211.
47. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders, Biological Psychiatry, 1990, 27:150-158.
48. Manschreck TC, Schneyer ML, Weisstein CC, Laughery J, Rosenthal J, Celada MT, Berner J. Freebase cocaine and memory, Comprehensive Psychiatry, 1990, 31(4): 369-375.
49. Wilson SN, Surman OS, Colvin R, Ozonoff D, Gelenberg A, Jenike MA, Manschreck TC, Pato C. Unusual lymphocyte subset distribution in some depressed patients. J. Clin. Psychiatry, 1990, 51: 51-52.
50. Manschreck TC, Maher BA, Rosenthal J, Berner J. Reduced primacy and related features in schizophrenia, Schizophrenia Research, 1991, 5: 35-41.
51. Manschreck TC, Maher BA. Approximations to a neuropsychological model of schizophrenia, Behavioral and Brain Sciences, 1991, 14(2): 36-37.
52. Manschreck TC, Maher BA, Celada MT, Schneyer ML, Fernandez R. Object chaining and thought disordered schizophrenic speech, Psychological Medicine, 1991, 21: 443-446.
53. Manschreck TC, Leighton AH. Reducing disability in mood disorders and schizophrenia, Hospital and Community Psychiatry, 1992, 43:179-180.
54. Manschreck TC. Delusional disorders: clinical concepts and diagnostic strategies, Psychiatric Annals, 1992, 22:241-251.

55. Manschreck TC. Delusions and delusional disorders: contemporary psychopathology, Psychiatric Annals, 1992, 22:229-231.
56. Manschreck TC. The treatment of cocaine abuse, Psychiatric Quarterly, 1993, 64: 183-197.
57. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Antonarakis S, Housman D, Kazazian H, Meyers D, Nestadt G, Ott J, Lamacz M, Liang KY, Hanfelt J, Ullrich G, DeMarchi N, Ramu E, McHugh PR, Adler L, Thomas M, Carpenter WT, Manschreck T, Gordon CT, Kimberland M, Baab R, Puck J, Childs B: A sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1. part 1, American J. Medical Genetics (Neuropsychiatric Genetics), 1994, 54: 36-43.
58. Welch J, Manschreck TC, Redmond D: Clozapine seizures and EEG changes: clinical characterization and management, J. Clinical Neuropsychiatry and Clinical Neurosciences, 1994, 6: 250-256.
59. Manschreck TC, Redmond D, Beaudette, S.: Clozapine in the back wards. Annals of Clinical Psychiatry, 6:215-225, 1994.
60. Maher BA, Manschreck TC, Woods B, Yergulen-Todd D, Tsuang M: Frontal cortex, context effects, and short term recall in schizophrenia, Biological Psychiatry, 37:144-150, 1995.
61. Manschreck TC, Maher BA, Redmond D, Miller C, Beaudette SM: Laterality, memory, and thought disorder in Schizophrenia, Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 9:1-7, 1996.
62. Manschreck TC. Delusional disorder: The recognition and management of paranoia. Journal of Clinical Psychiatry, 57[suppl]:32-38, 1996.
63. Maher BA, Manschreck TC, Redmond D, Beaudette S. Length of illness and the gradient from positive to negative priming in schizophrenic patients. Schizophrenia Research, 22:127-132, 1996.
64. Manschreck TC, Maher BA, Beaudette S, Redmond D. Context memory in schizophrenic and schizoaffective disorder. Schizophrenia Research, in press.
65. Blyler CR, Maher BA, Manschreck TC, Fenton WF. Line drawing as a possible measure of lateralized motor performance in schizophrenia. Schizophrenia Research, in press.

Proceedings of Meetings

1. Pato C, Schreiber J, Skea S, Manschreck TC, Kelsoe J, Rapaport M, Pickar D, Paul S. Identification and clinical characterization of a large pedigree with a high incidence of chronic psychosis. American College of Neuropsychopharmacology, Puerto Rico, December 1988.
2. Blyler CR, Maher BA, Brooks A, Manschreck TC: A new method to assess motor disorder and handedness in schizophrenia. International Congress on Schizophrenia, Colorado Springs, Co. Schizophrenia Research, 1993, 9: 94.
3. Manschreck TC, Maher BA, Redmond D, Miller-Ventor C: Laterality, thought disorder, and memory in schizophrenia. Society of Biological Psychiatry. Biological Psychiatry, 1994, 35: 633.
4. Manschreck TC, Blyler CR, Maher BA, Redmond D, Beaudette S. The effects of clozapine on cognition in schizophrenia. APA Annual Meeting, 1994. Abstract published in proceedings of the meeting.
5. Manschreck TC, Maher BA, Pulver A, Beaudette S, Redmond D, Blyler C. Risk prediction in schizophrenia using cognitive measures. Society of Biological Psychiatry, Biological Psychiatry, 1994, 35:697.

6. Ames D, Manschreck TC, Buchanan RW. Neurologic abnormalities in schizophrenia. Society of Biological Psychiatry Biological Psychiatry, 1994, 35: 714.
7. Blyler CR, Vogel DG, Manschreck TC. A survey of delusional beliefs in psychiatric inpatients. Presented at the Vth International Congress on Schizophrenia Research, Hot Springs, Va, April 1995. Schizophrenia Research 15:16, 1995.
8. Flashman LA, Saykin AJ, Riordan HJ, Carroll KE, McAllister TW, Weaver JB, Mamourian A, Manschreck TC. Relation of hippocampal and neocortical volumetry to fMRI activation in patients with schizophrenia. Society for Research in Psychopathology, Iowa City, October 1995. Abstract published in proceedings of the meeting.
9. Manschreck TC. Psychopathology and motor behavior in schizophrenia. Symposium. Society for Research in Psychopathology, Annual Meeting, Iowa City, October, 1995. Abstract published in proceedings of the meeting.
10. Manschreck TC. Delusional Disorder. Conference on Psychotic Disorders, University of Miami School of Medicine, December, 1995. Abstract published in proceedings of the meeting.
11. Maher BA, Manschreck TC, Seung F, Tsuang MT. The behavioral correlates of delusions of control in schizophrenia. Presented at the Vth International Congress on Schizophrenia Research, Hot Springs, Va, April 1995. Schizophrenia Research, 15:16, 1995.
12. Manschreck TC, Maher BA, Beaudette S, Redmond D. Context memory in schizoaffective disorder and schizophrenia. Vth International Congress on Schizophrenia Research, Hot Springs, Va, April 1995. Schizophrenia Research, 15:16, 1995.
13. Saykin AJ, Riordan HJ, Weaver JB, Manschreck TC, Flashman LA, Kahn EM, Flannery KA, Mamourian A, McAllister, TW. Memory Activation in Schizophrenia: Preliminary Observations Using Functional Magnetic Resonance Imaging (fMRI). Vth International Congress on Schizophrenia Research, Hot Springs, Va, April 1995. Schizophrenia Research, 15:16, 1995.
14. Manschreck TC. Delusional Disorders. Symposium: New Findings on Delusional Disorder and Delusions. Annual Meeting, American Psychiatric Association, May, 1996. Abstract published in proceedings of the meeting.

Reviews and Educationally Relevant Publications

1. Manschreck TC. Review of abnormalities in parents of schizophrenics, J. Nerv. Ment. Dis., 1976, 163:364-365.
2. Manschreck TC. Acute psychosis: attempts at clarification. In: Manschreck TC, Kleinman AM, (Eds.) Renewal in Psychiatry: A Critical Rational Perspective, Washington DC: Hemisphere Publishing Corp., 1977, 45-96.
3. Manschreck TC. Introduction In: Manschreck TC, Kleinman AM, (Eds.) Renewal in Psychiatry: A Critical Rational Perspective, Washington, DC: Hemisphere Publishing Corp., 1977, 1-41.
4. Manschreck TC: The clinical management of stuttering In: Manschreck TC, Kuehnle J, Murray G, (Eds.) Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians, New York: Elsevier-North Holland, 1979, 163-178.
5. Keller M, Manschreck TC. The biologic approach in psychiatry. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 13-18.
6. Keller M, Manschreck TC. The biologic mental status examination II. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 203-214.

7. Keller M, Manschreck TC. Disorders of higher intellectual functioning. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 276-286.
8. Manschreck TC, Keller M. The biologic mental status examination I. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 178-202.
9. Manschreck TC, Keller M. The biologic mental status examination I. General appearance, emotional state, and treatment. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 172-177.
10. Manschreck TC, Keller M. Disturbances of thinking. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 265-270.
11. Manschreck TC, Keller M. Motor disturbances. In: Lazare A, Ed. Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 287-295.
12. Manschreck TC, Keller M. Perceptual disturbances. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1979, 271-274.
13. Manschreck TC. The diagnosis of paranoid schizophrenia. In: Usdin GL, (Ed.) Classics in Paranoid Schizophrenia, 1980, 1(2):3-13.
14. Manschreck TC. Schizophrenia: medical diagnosis or moral verdict? Soc. Sci. Med., 1982, 16:616.
15. Manschreck TC. Schizophrenic disorders. N. Engl. J. Med., 1981, 305:1628-1672. Reprinted in: Psychiatric Knowledge and Skills Self-Assessment Program V (Module A), Washington, DC: American Psychiatric Association, 1982, 108-113.
16. Manschreck TC. Schizophrenic disorders: a current perspective. In: Manschreck TC, Murray GB, (Eds.) Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians, Third Edition. New York: Elsevier-North Holland, 1984.
17. Manschreck TC. New knowledge of brain disturbance in schizophrenia, Practical Reviews in Psychiatry, 1984, 8:3.
18. Manschreck TC. Motor abnormalities in schizophrenic disorders. In: Nasrallah H, Weinberger D, (Eds.) The Neurology of Schizophrenia. Volume I. Handbook of Schizophrenia, Amsterdam: Elsevier-North Holland, 1986, 65-96.
19. Manschreck TC. Cocaine psychosis: causes and consequences, Practical Reviews in Psychiatry, 1986, 10:2.
20. Groves J, Manschreck TC. Psychotic patients. In: Hackett T, Cassem E, (Eds.) The Massachusetts General Hospital Handbook of General Hospital Psychiatry, Boston: PSG, Inc., 1987.
21. Manschreck TC. Cocaine psychosis. In: Allen D, (Ed.) The Cocaine Crisis, New York: Plenum, 1987, 139-144.
22. Maher BA, Manschreck TC, Hoover TM, Weinstein CC. Thought disorder and measured features of language production in schizophrenia. In: Harvey P, Walker E, (Eds.) Positive and Negative Symptoms in Psychosis: Description, Research, and Future Directions. Hillsboro, NJ: Erlbaum, 1987, 195-215.
23. Day M, Manschreck TC. Delusional (paranoid) disorders. A. Nicoli, (Ed.) New Harvard Guide to Psychiatry, Cambridge: Harvard University Press, 1988, 296-308.
24. Manschreck TC, Keller MB. The mental status examination I. General appearance and behavior. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 160-187.

25. Keller MB, Manschreck TC. The mental status examination II: Higher intellectual functioning. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 160-187.
26. Manschreck TC, Keller MB. Disturbances of thinking. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 267-273.
27. Manschreck TC, Keller MB. Perceptual disturbance. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 274-279.
28. Manschreck TC. Disturbed motor behavior. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 292-300.
29. Manschreck TC. Schizophrenic disorders. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 510-525.
30. Manschreck TC. The paranoid syndrome and delusional disorders. In: Lazare A, (Ed.) Outpatient Psychiatry: Diagnosis and Treatment, Baltimore: Williams and Wilkins, 1989, 526-537.
31. Manschreck TC. Delusional disorders. In: Kaplan HI, Sadock BJ, (Eds.) Comprehensive Textbook of Psychiatry, Fifth Edition. Baltimore: Williams and Wilkins, 1989, 816-829.
32. Manschreck TC. Motor abnormalities and the psychopathology of schizophrenia. In: Kirkcaldy B., (Ed.) Medicine and Sport Science: Normalities and Abnormalities in Human Movement, Vol. 29, Basel: Karger, 1989, 100-127.
33. Manschreck TC. Motor abnormalities and cognitive disturbance in schizophrenic disorders. In: Schulz SC, Tamminga C, (Eds.) Schizophrenia: Scientific Progress, New York: Oxford University Press, 1989, 372-380.
34. Manschreck TC. My fatal disease. In: Messner E, Groves J. (Eds.) Autognosis: Psychiatrists Analyze Themselves. Boston: PSG, Inc. 1989, 83-85.
35. Manschreck TC. Treating schizophrenia. Schizophrenia Research, 1991, 5: 366-367.
36. Goff D, Manschreck TC, Groves JE. Psychotic patients. In: Cassem E, Groves JE, (Eds.) The Massachusetts General Hospital Handbook of General Hospital Psychiatry. Boston: PSG, Inc., 1991, 217-236.
37. Manschreck TC. Clinical and experimental analysis of motor phenomena in schizophrenia. In: Spitzer M, Uehlein F, Schwartz MA, Jundt C. (Eds.) Phenomenology, Language and Schizophrenia. New York: Springer, 258-274, 1993.
38. Manschreck TC. Psychomotor symptoms in schizophrenia. In: Costello CG. (Ed.) Symptoms of Schizophrenia, New York, John Wiley and Sons, 261-290, 1993.
39. Manschreck TC. Delusional disorder and shared psychotic disorder. In: Kaplan HI, Sadock BJ. (Eds.): Comprehensive Textbook of Psychiatry, Sixth Edition, Baltimore, MD: Williams and Wilkins, 1995, 1:1031-1049.
40. Manschreck TC. Paranoid disorders. In: Jacobson JL, Jacobson AM (Eds.) Psychiatric Secrets. St. Louis: Mosby, 1995, 58-66.
41. Manschreck TC: Pathogenesis of delusions. Psychiatric Clinics of North America, 1995, 18:213-229.
42. Maher BA, Manschreck TC, Spitzer M. Cognitive pathology in schizophrenia: explorations in language, memory, associations, and movements. In: Matthysse S, Levy DL (Eds.): Psychopathology: The Evolving Science of Mental Disorder, New York, Cambridge University Press, 1996.

43. Maher BA, Manschreck TC. Measurement in psychopathology. In: Spitzer M, Maher BA (Eds): Experimental Psychopathology. Cambridge: Cambridge University Press, in press.
44. Maher BA, Manschreck TC. Experimental psychopathology of formal thought disorder. In: Spitzer M, Maher BA (Eds): Experimental Psychopathology. Cambridge: Cambridge University Press, in press.
45. Manschreck TC, Maher BA. Observations on motor behavior and the experimental psychopathology of schizophrenia. In: Spitzer M, Maher BA (Eds): Experimental Psychopathology. Cambridge: Cambridge University Press, in press.
46. Goff D, Henderson D, Manschreck TC. Psychotic patients. In Cassem, EH (Ed). The Massachusetts General Hospital Handbook of General Hospital Psychiatry, Third Edition. St. Louis: Mosby, in press.
47. The Expert Consensus Panel for Schizophrenia: Treatment of Schizophrenia. J of Clin Psych, 1996;57(suppl 12B):1-58
48. Maher BA, Manschreck TC, Chu M. Lateralization, memory, and language in schizophrenia: some facts and an artifact. In: Lenzenweger MF & Dworkin RH (Eds) Experimental Psychopathology and Pathogenesis of Schizophrenia. Washington, D.C.: American Psychological Association Press, in press.
49. Manschreck TC. Delusional disorder: a not so rare psychotic disorder. J Psychotic Disorders, in press.

Books and Monographs

1. Manschreck TC, Kleinman AM, (Eds.) Renewal in Psychiatry: A Critical Rational Perspective, Washington DC: Hemisphere Publishing Corp., 1977.
2. Manschreck TC, Murray G, Kuehnle J, (Eds.) Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians, New York: Elsevier-North Holland, 1979.
3. Manschreck TC, Murray G, Kuehnle J, (Eds.) Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians, New York: Elsevier-North Holland, 1981.
4. Manschreck TC, Murray G, (Eds.) Psychiatric Medicine Update: Massachusetts General Hospital Reviews for Physicians, New York: Elsevier-North Holland, 1984.
5. Manschreck, TC, (Ed.) Delusions and Delusional Disorders, special issue, Psychiatric Annals, 1992, 22: 229-285.

Abstracts

1. Manschreck TC, Maher BA, Ader DN. Formal thought disorder, type-token ratio, and disturbed voluntary motor movement in schizophrenia, Psychiatry Digest, 1982, 3.
2. Manschreck TC. Schizophrenic disorders, N. Engl. J Med., 1982, 306:1366-1367.
3. Manschreck TC. Characteristics of freebase or crack cocaine psychosis. In: Yearbook of Neurology and Neurosurgery, 1989.
4. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders, Psychiatry/Neurology Digest, 1990.
5. Manschreck TC, Keuthen NJ, Schneyer ML, Celada MT, Laughery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders, Abstract-A-Card: Psychiatry Edition, 1990, 1(2).

6. Marder SR, Keuthen NJ, Schneier ML, Celada MT, Langhery J, Collins P. Abnormal involuntary movements and chronic schizophrenic disorders, Psychiatry Digest, 1990, 5:24-25.
7. Marder SR, Maher BA, Celada MT, Schneier M, Fernandez R. Object chaining and thought disorder in schizophrenic speech, Clinical Digest (Psychiatry 1992).
8. Marder SR, Leighton AH: Reducing disability in mood disorders and schizophrenia, Clinical Digest, 1993.
9. Marder SR. Delusional disorders: clinical concepts and diagnostic strategies. Innovations and Research, 1993.
10. Marder SR, Leighton AH: Reducing disability in mood disorders and schizophrenia, Innovations & Research, 1993.
11. Dilip VJ, Marder SR, Klausner M, Brecher M, Clyde C, Jones R & the Arcs Study Group: A clinical evaluation of Risperidone in the treatment of schizophrenia; a 10-week, open-label, multicenter trial involving 945 patients. Scientific Assembly: American Academy of Family Physicians, October 2, 1996.

**COMMONWEALTH OF MASSACHUSETTS
BOARD OF REGISTRATION IN MEDICINE**
William F. Weld, Governor

ISSUES THIS LICENSE TO

THEO C MANSCHRECK M.D.

AS A REGISTERED PHYSICIAN

06/21/99

REGISTRATION NO

EXPIRATION DATE

DUKE UNIVERSITY MEDICAL CENTER
CURRICULUM VITAE

Date prepared: 12/22/96

Name: Joseph P. McEvoy, M.D.

Primary Academic Appointment: Psychiatry

Social Security Number: REDACTED

Present Academic Rank: Associate Professor

Date and Rank of First Duke Faculty Appointment:
--- 1-1-89, Associate Professor

Medical Licensure

National Board of Medical Examiners, 1974
North Carolina Board of Medical Examiners, 1989

Specialty Certification

American Board of Psychiatry and Neurology, 1981

Date of Birth: January 26, 1948 Place: Brooklyn, New York

Citizen of: USA

Education:

High School	Regis H.S., New York, NY	1961-65	H.S. Diploma
College	Manhattan College Bronx, NY	1965-69	B.A.
Graduate or Professional School	Vanderbilt Medical School, Nashville, Tennessee	1969-73	M.D.

Professional Training and Academic Career

7/73 - 6/75	University of Utah Hospitals Salt Lake City, Utah	Internship and First Year Residency in Internal Medicine
7/75 - 6/78	Vanderbilt University Nashville, Tennessee	Residency in Psychiatry
7/78 - 6/81	Vanderbilt University Department of Psychiatry Nashville, Tennessee	Assistant Professor
7/81 - 8/87	University of Pittsburgh Department of Psychiatry Pittsburgh, Pennsylvania	Assistant Professor
9/87 - 12/88	University of Pittsburgh Department of Psychiatry Pittsburgh, Pennsylvania	Associate Professor
1/89 - Present	Duke University Medical Center Department of Psychiatry Durham, North Carolina	Associate Professor

Refereed Articles

McEvoy JP, Wells CE: Case studies in neuropsychiatry II: conversion pseudodementia. Journal of Clinical Psychiatry 40:447-449, 1979.

McEvoy JP, Sheridan WF, Stewart WRC, Ban TA, Wilson WH, Guy W, Shaffer JD: Viloxazine in the treatment of depressive neurosis: a placebo and standard (doxepin) controlled clinical study. British Journal of Psychiatry, 137:440-443, 1980.

Petrie WM, McEvoy JP, Wilson WH, Ban TA, Guy W: Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study. International Pharmacopsychiatry, 15:193-196, 1980.

McEvoy JP, Berney S, Wilson WH, Ban TA, Guy W: A double-blind comparison of three dosages of flutroline (CP-36, 584) in the treatment of schizophrenia. International Pharmacopsychiatry, 15:318-324, 1980.

Ban TA, McEvoy JP, Wilson WH: Viloxazine: a review of the literature. International Pharmacopsychiatry, 15:118-123, 1980.

Ban TA, Wilson WH, McEvoy JP: Amoxapine: a review of the literature. International Pharmacopsychiatry 15:166-170, 1980.

Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Ban TA, Berney SA, Schaffer JD: A double blind-comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. *Pharmacopsychiatria* 14:139-140, 1981.

McEvoy JP, Aland J, Wilson WH, Guy W, Hawkins L: Measuring chronic schizophrenic patient's attitudes toward their illness and treatment. *Hospital and Community Psychiatry*, 32:856-858, 1981.

McEvoy JP: Organic brain syndromes. *Annals of Internal Medicine*, 95, 212-220, 1981.

McEvoy JP, Libiger J, Wilson WH, Ban TA, Berney S, Guy WL: Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study. *Journal of Clinical Psychiatry*, 43:111-112, 1982.

Guy W, Ban TA, McEvoy JP, Petrie WM, Wilson WH: A collaborative study of a new antidepressant, Viloxazine, in neurotic and endogenous depression. *International Pharmacopsychiatry*, 17:36-42, 1982.

McEvoy JP, Wilson WH, Ban TA, Brannen JO, Berney S: Bromperidol maintenance in schizophrenia. *Pharmacopsychiatria*, 15:95-96, 1982.

McEvoy JP, Abernethy V: Sociocultural identity and psychogenic psychosis, *Papua New Guinea Medical Journal*, 25:55-59, 1982.

Guy W, McEvoy JP, Ban TA, Wilson WH, Pate K: A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology. *Pharmacotherapy*, 3:45-51, 1983.

McEvoy JP, Hatcher A, Applebaum P, Abernethy V: Chronic schizophrenic women's attitudes toward sex, pregnancy, birth control, and childbearing. *Hospital and Community Psychiatry* 34:536-539, 1983.

McEvoy JP: The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. *Journal of Clinical Psychopharmacology* 3:288-302, 1983.

McEvoy JP, Lohr JB: Diazepam for catatonia. *American Journal of Psychiatry*, 141:284-285, 1984.

McEvoy JP, Howe AC, Hogarty GE: Differences in the nature of relapse and subsequent inpatient course between medication compliant and noncompliant schizophrenic patients. *Journal of Nervous and Mental Disease* 172:412-416, 1984.

McEvoy JP, Stiller RL, Farr R: Plasma haloperidol levels drawn at neuroleptic threshold doses. *Journal of Clinical Psychopharmacology*, 6:133-138, 1986.

McEvoy JP: The neuroleptic threshold as a marker of minimum effective neuroleptic dose. *Comprehensive Psychiatry* 27:327-335, 1986.

McEvoy JP, McCue M, Spring B, Mohs RC, Lavori PW, Farr R. Amantadine versus trihexyphenidyl: effects on memory in elderly normal volunteers. *American Journal of Psychiatry*, 144:573-577, 1987.

McEvoy JP, Freter S, McCue M. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. *Clinical Therapeutics* 9:429-433, 1987.

Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ. Dose of fluphenazine decanoate, familial expressed emotion and outcome in schizophrenia: results of a two year controlled study. *Archives of General Psychiatry*, 45:797-805, 1988.

McEvoy JP, Apperson LJ, Applebaum PS, Ortlip P, Breckosky J, Hammill K, Geller JL, Roth L. Insight in schizophrenia: its relationship to acute psychopathology. *Journal of Nervous and Mental Disease*, 177:43-47, 1989.

McEvoy JP, Freter S, Everett G, Geller JL, Appelbaum PS, Apperson LJ, Roth L. Insight and the clinical outcome of schizophrenic patients. *Journal of Nervous and Mental Disease*, 177:48-51, 1989.

McEvoy JP, Appelbaum PS, Apperson LJ, Geller JL, Freter S. Why must some schizophrenic patients be involuntarily committed? The role of insight. *Comprehensive Psychiatry*, 30:13-17, 1989.

McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. *Comprehensive Psychiatry*, 30:135-138, 1989.

Hammill K, McEvoy JP, Koral H, Schneider N. Views hospitalized schizophrenic patients express about the seclusion process. *Journal of Clinical Psychiatry*, 50:174-177, 1989.

McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. *Archives of General Psychiatry*, 1991; 48:739-745.

McEvoy JP, Freter S, Merritt M, Apperson LJ. Insight into psychosis among outpatients with schizophrenia. *Hospital and Community Psychiatry*, 44:883-884, 1993.

McEvoy JP, Movin-Osswald G, Uppfeldt G, Williams T, Dutcher S, Apperson J. An open study of the pharmacokinetics and tolerability of raclopride extended-release capsules in psychotic patients. *Psychopharmacology* 112:371-374. 1993.

McEvoy JP, Schooler NR, Friedman E, Steingard S, Allen M. Psychopathology vignettes as a shared reference base for judging insight in patients with schizophrenia or schizoaffective disorders. *American Journal of Psychiatry* 150:1649-1653, 1993.

Burke MA, McEvoy JP, Ritchie J. A pilot study of a structured interview addressing sexual function in men with schizophrenia. *Biological Psychiatry* 35:32-35, 1994.

Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Peret J. Pharmacotherapy of impaired affect in recovering schizophrenia. *Archives of General Psychiatry* 52:29-41, 1995.

McEvoy JP, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. *Biological Psychiatry* 37:550-552, 1995.

McEvoy JP, Freudenreich O, Levin Ed, Rose JE. Haloperidol increases smoking in patients with schizophrenia. *Psychopharmacology* 119:124-126, 1995.

Swanson CL, Freudenreich O, McEvoy JP, Nelson L, Kamaraju L, Wilson WH. Insight in schizophrenia and mania. *Journal of Nervous and Mental Disease* 183:752-755, 1995.

Donnelly CL, McEvoy JP, Wilson WH, Narasimhachari N. A study of the potential confounding effects of diet, caffeine, nicotine, and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia. *Biological Psychiatry* 40:1218-1221, 1996.

McEvoy JP, Hartman M, Gottlieb D, Godwin S, Apperson LJ, Wilson WH. Common sense, insight, and neuropsychological test performance in patients with schizophrenia. *Schizophrenia Bulletin* 22:635-642, 1996.

Levin ED, Wilson WH, Rose JE, McEvoy JP. Nicotine-haloperidol interactions and cognitive performance in schizophrenia. *Neuropsychopharmacology* 15:429-436, 1996.

VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. A double-blind, randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with treatment-refractory chronic schizophrenia. *American Journal of Psychiatry* 153:1579-1584, 1996.

Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced EEG changes as a function of clozapine serum levels. *Biological Psychiatry* (In press)

Van Kammen DP, McEvoy JP, Targum SD, Seabree TB, Chung L, Kardatzke D. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. *Psychopharmacology* 124:168-175, 1996.

Chambers RA, Moore J, McEvoy JP, Levin ED. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. *Neuropsychopharmacology* 15:587-594, 1996.

Anton RF, Kranzler HR, McEvoy JP, Moak DH, Bianca R. A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. *Psychopharmacology* (In press).

Non Refereed Publications

Lake CR, Casey DE, McEvoy JP, Siris SG, Boyer WF, Simpson G: The "pros" and "cons" of anticholinergic prophylaxis. Psychopharmacology Bulletin 22:981-984, 1986.

McEvoy JP. A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. Journal of Clinical Psychiatry 48 (9, Suppl.):20-23, 1987.

Soloff P, McEvoy JP, Ganguli M. Is seclusion therapeutic? Psychiatric Annals 19:45-54, 1989.

McEvoy, JP, Schooler, NR, Wilson WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 27:97-101, 1991.

McEvoy J. Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry 55(5, Suppl):18-21, 1994.

McEvoy JP. Update on risperidone. Currents in Affective Illness 13(10):5-13, 1994.

McEvoy JP. Dosing issues: Target symptoms and dose response. Psychiatric Annals 25:297-300, 1995.

McEvoy JP, Lindgren J. Smoking and Schizophrenia. Drug Development Research 38:263-266, 1996.

Book Chapters

Wells CE, McEvoy JP: Organic brain syndromes. In, Treatment of Mental Disorders, (eds.) Greist JH, Jefferson J, Spitzer RL. Oxford University Press, New York, 1982.

McEvoy JP: The chronic neuropsychiatric disorders associated with alcoholism. In, Encyclopedic Handbook of Alcoholism. (Eds.) Pattison EM, Kaurman E, Gardner Press, New York, 1982.

McEvoy JP. Anticholinergic drug-induced dysfunction. In, Drug-Induced Dysfunction in Psychiatry. (Eds.) Keshavan MS, Kennedy JS. Hemisphere Publishing, Washington, D.C., 1992.

McEvoy JP: Psychopharmacological Treatments. In, Psychiatric Rehabilitation: A Handbook for Practitioners. (Ed.) Katz-Garris L. Warren H. Green Publishing, St. Louis, MO, 1992.

McEvoy J. The relationships between insight into psychosis and compliance with medications. In, Insight and Psychosis. (Eds.) Amador XF, David A. Oxford University Press. (In press).

Other Publications

McEvoy JP, Campbell T: Ganser-like symptoms in carbon monoxide encephalopathy. American Journal of Psychiatry, 134:1448-1449, 1977 (Letter).

McEvoy JP: Psychiatric consultations. Southern Medical Journal, 71:1131-1322, 1978 (Editorial).

McEvoy JP: Organic brain syndromes in DSM-III. American Journal of Psychiatry, 138:124-125, 1981 (Letter).

McEvoy JP: Invited review of Tardive Dyskinesia: Research and Treatment. (Eds.) Fann WE, Smith PC, Davis JM, Domino EP. In, Contemporary Psychology, 26:690-691, 1981.

McEvoy, JP, Lohr JB: Reply to Linn L. Intravenous sedatives and catatonia. American Journal of Psychiatry 141:1136, 1984 (Letter).

McEvoy JP: Relief from catatonic immobility can be maintained. Journal of Clinical Psychopharmacology 6:126-127, 1986 (Letter).

McEvoy JP: Invited comments on "Neuroleptics and Sexual Functioning" by Collins AC, Kellner R. Integrative Psychiatry 4:107-108, 1986.

McEvoy JP: Neuroleptic dose and the need for prophylactic anticholinergic drugs. Journal of Clinical Psychiatry 47:611, 1986 (Letter).

McEvoy JP: Rapid shifts in the therapeutic and extrapyramidal effects of neuroleptic drugs. American Journal of Psychiatry 143:1504, 1986 (Letter).

McEvoy JP, Simpson G: Dystonia, neuroleptic dose and anticholinergic drugs. American Journal of Psychiatry 144:393, 1987. (Letter)

McEvoy, JP, Stiller RL, Everett G: Differential therapeutic response by history during treatment with neuroleptic haloperidol doses. Journal of Clinical Psychopharmacology 7:368-369, 1987. (Letter)

McEvoy JP, Lavori PW, McCue M. Reply to Robinson ML. Drug side effects and the double-blind design. American Journal of Psychiatry 145:539, 1988 (Letter).

Krystal AD, McEvoy JP. Shared features of neuroleptic malignant syndrome and alcohol abuse complications. Journal of Clinical Psychiatry 51:523, 1990 (Letter).

McEvoy JP, Kamaraju L, Nelson L. Haase hermeneutics, or the exegesis of the neuroleptic threshold. Journal of Clinical Psychopharmacology 12:64-65, 1992. (Letter)

McEvoy JP. Patient's rights. Hospital and Community Psychiatry 43:407, 1992. (Letter)

Freudenreich O, McEvoy JP. Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. Journal of Clinical Psychiatry 56:173 (Letter)

Freudenreich O, McEvoy JP. How much Haldol Doses Larry really need? Journal of Clinical Psychiatry 56:332-333, 1995. (Letter)

Freudenreich O, McEvoy JP. Palinacousis after closed head injury in a patient with schizophrenia. Journal of Clinical Psychopharmacology 16:94, 1996 (Letter).

Freudenreich O, McEvoy JP, Cooper TB. Monitoring of clozapine blood levels in the real world. Journal of Clinical Psychopharmacology 16:90-91, 1996 (Letter).

Swanson S, Price W, McEvoy, JP. Fever, confusion and creatinine phosphokinase elevation with risperidone and lithium. American Journal of Psychiatry (Letter, in press).

Organizations and Participation:

Member American Psychiatric Association
Member American Psychopathological Association
Member Society for Biological Psychiatry
Board Member VA Merit Review Board for Mental Health and Behavioral Science 1993-1996

Teaching Responsibilities

Principal Faculty Supervisor for Research Fellows at John Umstead Hospital,

July 94-June 95:

Charles Swanson, M.D. A comparison of manic and schizophrenic patients on measures of insight.

Oliver Freudenreich, M.D.. Smoking and Schizophrenia.

July 95 - June 96

John Lindgren, M.D. Free radicals in schizophrenia; Serotonin, smoking and schizophrenia.

Preceptor, NIMH Scientist Development Award to Richard Keefe, Ph.D. 7/1/95-6/30/00 (Neural Circuitry and Cognitive Function in Schizophrenia)

Weekly case conference for Duke Residents at John Umstead Hospital

Lectures for Duke Residents, and for Medical Students from Duke and University of North Carolina, on Schizophrenia, the use of Neuroleptic and Anticholinergic Drugs, and other topics.

External Support

Principal Investigator: Comparison of Amantadine HCl and Trihexyphenidyl HCl in Elderly Normal Volunteers with an Emphasis on Possible Differential Effects on Memory Function. (DuPont Pharmaceuticals, 6/1/84 - 6/30/85; TDC \$38,803).

Co-Investigator: Pharmacotherapy of Impaired Affect in Recovery Schizophrenia. (NIMH MH 39166, P.I. Gerard Hogarty, M.S.W., 4/1/84 - 3/31/88; TDC \$1,152,760).

Principal Investigator: Replacement of Chronically Administered Anticholinergic Drugs by amantadine HCl in Chronic Schizophrenic Outpatients. (DuPont Pharmaceuticals, 6/1/86 - 8/31/86; TDC \$4,241).

Principal Investigator: The Neuroleptic Threshold Dose in Acute Schizophrenia. (NIMH MH41254, 7/1/86 - 6/31/91; TDC \$378,009).

Principal Investigator: Double-Blind Dose Ranging Trial Comparing the Extrapyramidal Liability of CGP 19,486A to Haloperidol in Hospitalized Patients with Chronic Schizophrenia. (CIBA-GEIGY Pharmaceuticals, 4/1/89 - 11/14/90; TDC \$128,191).

Principal Investigator: Raclopride in Schizophrenia: A Haloperidol-Controlled, Double-Blind, Dose-Finding Clinical Trial. (Astra Pharmaceuticals, 9/29/89 - 4/9/90; TDC \$33,760).

Principal Investigator: Double-Blind Dose Ranging Trial Comparing CGP 19,486A (Savoxepine) to Placebo and Haloperidol in Hospitalized Schizophrenic Patients (CIBA-GEIGY Pharmaceuticals, 10/27/89 - 5/15/91; TDC \$81,620).

Principal Investigator: A Triple-Blind, Parallel Study Comparing Remoxipride, Haloperidol and Placebo in Hospitalized Patients with Schizophrenia. (Merck Sharp and Dohme Clinical Research, 7/10/90 - 5/16/90; TDC \$79,515).

Principal Investigator: Risperidone in the Treatment of Schizophrenia, A Double-Blind Parallel Group Study. (Janssen Pharmaceuticals, 8/16/90 - 5/20/91; TDC \$83,190).

Principal Investigator: Comparison of the Efficacy and Safety of HDC 912 and Haloperidol in Schizophrenic Patients. (Sandoz Pharmaceuticals, 10/12/90 - 12/19/90; TDC \$29,616).

10

Principal Investigator: A Prospective, Randomized, Placebo-Controlled, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of Amperozide Low (1-5mg) Dose, High (7.5 - 12.5mg) Dose and Haloperidol (10-30mg) in Institutionalized Schizophrenics. (Sandoz Pharmaceuticals, 1/7/91 - 12/31/91; TDC \$74,280).

Principal Investigator: An Open Study of the Tolerability and Pharmacokinetics of Racolpride Extended Release Capsules in Psychiatric Patients. (Astra Pharmaceuticals, 1/8/91 - 9/30/91; TDC \$42,700).

Principal Investigator: Multicenter, Placebo-Controlled Double-Blind Safety and Efficacy Evaluation of ICI 204,636 in Hospitalized Patients with Acute Exacerbation of Chronic or Subchronic Schizophrenia. (ICI Pharmaceuticals, 6/5/91 - 3/30/92, TDC \$70,000).

Principal Investigator: Double-Blind, Dose Ranging Trial Comparing CGS-15873A to Placebo in Hospitalized Schizophrenic Patients. (CIBA-GEIGY Pharmaceuticals 7/2/91 - 12/31/91, TDC \$40,000).

Principal Investigator: The Efficacy and Tolerability of Sertindole in Schizophrenic Patients: A Pilot Double Blind, Placebo-Controlled, Dose Ranging Study (Abbott Laboratories, 1/15/92 - 5/31/92, TDC \$45,900).

Principal Investigator: Phase II, Four Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Three Doses of Oral CP-88, 959-1 in the Acute Exacerbation of Schizophrenia (Pfizer, Inc., 4/14/92 - 12/31/92; estimated TDC \$107,300).

Principal Investigator: A Multicenter Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Zotepine 75, 150, and 300 mg Daily Doses in the Treatment of Acute Schizophrenia. (Boots Pharmaceuticals 5/28/93 to 4/28/94; estimated TDC \$133,500).

Principal Investigator: A Double-Blind Study Comparing the Efficacy and Safety of Two Doses of Oral CP-88,059-1 in Acute Exacerbations of Schizophrenia and Schizoaffective Disorder (Pfizer, Inc., 9/24/93-7/1/94, TDC \$34,800).

Principal Investigator: Efficacy and Tolerability of Ascending Doses of OPC-14597 Compared to Placebo and to Haloperidol in Acutely Relapsing Hospitalized Schizophrenic Patients (Otsuka America Pharmaceutical, Inc., 10/15/93-9/30/94, TDC, \$66,500).

Principal Investigator: A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Sertindole in Schizophrenic Patients (Abbott Laboratories,, 9/92-9/93, TDC \$65,000).

Principal Investigator: A Prospective, Randomized, Double-Blind, Unbalanced, Parallel-Group, Haloperidol (5-20 mg)-and Placebo-Controlled Study to Determine the Maximum Tolerated Dose of SDZ MAR 327 in Institutionalized Schizophrenics (Sandoz Pharmaceuticals, Inc., 11/93-5/94, TDC \$120,600).

1109

Principal Investigator: Drive To Smoke and Dopamine Blockade (NIDA, 7/1/94-6/30/96), \$226,080).

Mentor: Cigarette Smoking, Nicotine, and Schizophrenia. (NARSAD Young Investigator Award to Edward Levin, Ph.D., 7/1/94 - 6/30/96), TDC \$60,000.

Principal Investigator: A Double-Blind, Placebo-Controlled, Haldol-Referenced Study of the Safety and Efficacy of Two Doses of Sertindole In Schizophrenic Patients (Abbott Laboratories, 4/1/94-3/31/95, TDC \$98,950).

Principal Investigator: A 40 Week, Double-Blind Study Evaluating the Safety and Efficacy of Two Dose Regimens of Oral CP-88,059-1 (80-120 mg, OD, and 40-80 mg, BID) and Haloperidol (5-20 mg daily) in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder (Pfizer, Inc., 4/10/94-4/9/95, \$174,500).

Principal Investigator: A Multi-Center, Double-Blind, Randomized, Comparison of Seroquel (ICI 204,636) and Chlorpromazine in the Treatment of Hospitalized Subjects with Treatment Resistant Schizophrenia (Zeneca Pharmaceuticals Group, 9/1/94-8/31/95, \$168,500).

Principal Investigator: A Dose-Ranging Study of the Efficacy and Tolerability of OPC-14597 in Acutely Relapsing Hospitalized Schizophrenic Patients (Otsuka America Pharmaceuticals, 4/1/95-3/31/96, TDC: \$196,880).

Principal Investigator: A 52 Week Extension Study Evaluating the Safety and Outcome of 40-80 mg, BID of Oral Ziprasidone (CP-88,059-1) Daily in the Treatment of Subjects Who Have Participated in Previous Ziprasidone (88,059-1) Clinical Trials (Pfizer Inc., 5/1/95-4/30/97, TDC: \$45,750).

Principal Investigator: A Double-Blind, Placebo-Controlled, Safety, Tolerability and Preliminary Antipsychotic Activity Study of L-745,870 in Hospitalized Schizophrenic Patients (Merck Research Labs, 5/1/95-4/31/96, TDC: \$61,723).

Principal Investigator: U-101387G/Double-Blind, Haloperidol Controlled, Safety and dose-finding Study in the Treatment of Schizophrenia (Upjohn, 1/1/96 - 10/31/97, \$199,875).

Principal Investigator: Phase 3, Randomized Open Label Study of Intramuscular Ziprasidone (Pfizer, 9/1/96 - 8/31/97, \$70,000).

Principal Investigator: Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of MDL 100,907 in Schizophrenic and Schizoaffective Patients (Hoechst Marion Roussel, \$184,880).

Principal Investigator: Safety and Efficacy of Rapid-Loading Depakote in the Treatment of Acutely Manic Patients with Bipolar Disorder (Abbott 11/1/96 - 10/30/98, \$57,600).

PRESENTATIONS
(1993)

March 19. Bowman-Gray School Medicine, Winston-Salem, NC.
Grand Rounds: "An Update on antipsychotic Drugs"

May 26. American Psychiatric Association, San Francisco, CA.
Symposium #87: "Neuroleptic Threshold Doses for
Schizophrenia"

June 6. World Congress of Psychiatry, Rio de Janeiro, Brazil.
Risperdal Satellite Symposium: "Risperidone: Efficacy on
Positive Symptoms"

July 8. Bezirkskrankenhaus Haar, Haar, Germany
Symposium on Neuroleptic Treatment: "The Neuroleptic
Threshold"

Sept 14. NC Department of Human Resources, Southern Pines, NC
Clinical Update, 1993: "Schizophrenia Update: Clozapine,
Risperidone, and Beyond"

(1994)

Jan 25. Seventh Biennial Winter Workshop on Schizophrenia, Les
Diableret, Switzerland: "Clozapine Decreases Drive to Smoke"

March 29 University of Virginia, Charlottesville, VA. Grand Rounds:
"New Developments in Antipsychotic Drugs"

May 7 International Symposium on Schizophrenia, Buenos Aires,
Argentina: "Risperidone vs Haloperidol and Placebo (The North
American Experience)"

May 20 American Psychiatric Association Satellite Symposium,
Philadelphia, PA: "The Importance of Early Intervention with
Neuroleptics: Prevention of Relapse"

June 29 Collegium Internationale Neuro-Psychopharmacologicum,
Washington, D.C. Symposium on Antipsychotic Dosage Regimens:
"What is the Therapeutic Window for Neuroleptic?"

October 1 Institute on Hospital and Community Psychiatry, San Diego, CA.
Symposium on Clinicians' Measurement of Outcomes in
Schizophrenia: Discussant

October 27 Alden Memorial Lecture, Duke University Medical Center:
"Drive to Smoke and Dopamine Blockade"

November 4 Schizophrenia Treatment Update Symposium, Richmond, VA.
"Insight into Psychosis and Compliance with Medications".

13

(1995)
February 10 University of Miami, Miami, FL. Grand Rounds: "An Update on Antipsychotic Medications".
February 23 East Carolina University, Greenville, NC. Grand Rounds: "An Update on Antipsychotic Medications".
May 22 American Psychiatric Association. Miami, FL. Co-Chair, Symposium: Algorithms for the Pharmacotherapy of Schizophrenia. Presentation: Algorithm for treatment of acute exacerbation".
May 23 APA. Miami, FL. Symposium: Improving the Outcome of Schizophrenia. Presentation: "Improving Outcomes of Schizophrenic Exacerbations".

Clinical Activity

Medical Supervision the 150 bed Adult Admission Unit of John Umstead Hospital, directly supervising 9 Staff Physicians, a Chief Resident, and 5 Junior Residents.

Treatment team leader for the direct clinical care of approximately 15 inpatients on the Schizophrenia Service at John Umstead Hospital.

Participation in Academic and Administrative Activities of the University and Medical Center:

President of the Medical Staff, John Umstead Hospital, 1991-92
Member, Executive Committee of the Medical Staff, John Umstead Hospital
Member, Management Team, John Umstead Hospital
Member, Quality Assurance Committee, John Umstead Hospital
Member, Surgical Case Review Committee, John Umstead Hospital

1112

NORTH CAROLINA MEDICAL BOARD		
PHYSICIAN CERTIFICATE OF REGISTRATION		Issue Date: January 13, 1997 REGISTRATION CERTIFICATE NO. REDACTED
1997		
THIS IS TO CERTIFY THAT THE PHYSICIAN NAMED BELOW HAS REGISTERED WITH THE BOARD AND HAS PAID THE REGISTRATION FEE OF \$ 100.00 FOR THE YEAR ABOVE AS REQUIRED BY THE GENERAL STATUTES OF NORTH CAROLINA, SECTION 90-15.1 AND RULES PROMULGATED PURSUANT THERETO.		
REGISTRATION REQUIRED IN JANUARY 1998		
Joseph Patrick McEvoy MD John Umstead Hospital Adult Admission Unit Butner, NC 27509		
EXECUTIVE DIRECTOR		<i>Bryant D. Paris, Jr.</i>

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE			
UNITED STATES DEPARTMENT OF JUSTICE			
DRUG ENFORCEMENT ADMINISTRATION			
WASHINGTON, D.C. 20537			
Sections 804 and 1008 (11 U.S.C. 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.		DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES
		REDACTED	01-31-2002
			\$210.00
		SCHEDULES	DATE ISSUED
		2, 2H, 3, 3H, 4, 5 PRACTITIONER	01-29-1999
		HCEVOY, JOSEPH P MD JOHN UNSTEAD HOSPITAL 1003 12TH ST BUTNER, NC	
			27509
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY OR VALIDITY AFTER THE EXPIRATION DATE.			


CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

Sections 804 and 806 (21 U.S.C. 824 and 826) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration as manufacturer, distributor, dispenser, importer or exporter of controlled substances.

REGISTRATION NUMBER	EXPIRATION DATE	FEE
REDACTED	01-31-2002	\$210.00
SCHEDULES BUSINESS ACTIVITY DATE ISSUED		
2,2A,3,3A,4,5 PRACTITIONER		01-29-1999

NCEVOY, JOSEPH P MD
 JOHN UNSTEAD HOSPITAL
 1003 12TH ST
 BUTNER, NC 27509

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.



STATE OF NORTH CAROLINA

TO THE PEOPLE OF THE STATE OF NORTH CAROLINA

Whereas **Joseph Patrick McEvoy**
 Has applied to us
The Board of Medical Examiners
 OF THE STATE OF NORTH CAROLINA

For admission to practice as a **PHYSICIAN** within the State aforesaid


We do Certify that he has produced to us sufficient testimonials of his upright character and upon examination before us is found to possess a competent knowledge of the

SCIENCE OF MEDICINE

to entitle him to our License to practice the same within the limits of the said State.

Given under our hands and seals at Raleigh, N.C. this 18th
 day of March A.D. 1989

No **REDACTED**



<u>John D. L. Edwin</u>	Member	M.D. [Seal]
<u>Frederic E. Martin</u>	Member	M.D. [Seal]
<u>Sam Chapman</u>	Member	M.D. [Seal]
<u>John D. L. Edwin</u>	Member	M.D. [Seal]
<u>John H. H. H.</u>	Member	M.D. [Seal]
<u>John W. Moore</u>	Member	M.D. [Seal]
<u>F. H. Minner Patterson</u>	Member	M.D. [Seal]
<u>William H. Wilkins</u>	Member	[Seal]

CURRICULUM VITAE
Susan Regina McGurk
October, 1996

BUSINESS ADDRESS

Psychiatric Hospital at Vanderbilt
1601 23rd Street South, Suite #306
Nashville, TN 37212
615-327-7049

PERSONAL DATA

Place of Birth: Philadelphia, Pennsylvania
Marital Status: Single

EDUCATION

7/93-7/96: Postdoctoral Scholar, Neuropsychiatric Institute,
Department of Psychiatry and Biobehavioral Sciences,
University of California, Los Angeles
9/89-9/92: Clinical Psychology Postdoctoral Training, Department
of Psychology, University of California, Los Angeles
9/83-6/89: Ph.D., Department of Psychology, University of
California, Los Angeles
9/79-9/83: B.A., Department of Psychology, University of California,
Los Angeles

CURRENT POSITION

11/96: Assistant Professor of Psychiatry, Division of
Psychopharmacology, Vanderbilt University

CLINICAL TRAINING

1/94-10/96: Psychological Assistant: Pacific Psychological
Associates, El Segundo, CA
9/92-12/93: Postdoctoral Therapist: Department of Psychology
Clinic University of California, Los Angeles, CA
9/91-9/92: Psychology Intern: Brentwood Veterans
Administration Medical Center, Brentwood, CA

9/89-9/92: Psychology Intern: Department of Psychology Clinic
University of California, Los Angeles, Practicum Training
9/90-9/91: Psychology Intern: Neighborhood Youth
Association, Mar Vista, Practicum Training
9/90-9/91: Psychology Intern: San Fernando High School Mental
Health Clinic, San Fernando, Practicum Training

License:

Clinical Psychology, California: June, 1996

TEACHING POSITIONS

6/90-9/96: Instructor: University of California, Los Angeles, Department
of Psychology
Introductory Psychology
Abnormal Psychology
Fundamentals of Learning

1/91-9/96: Instructor: University of California, Los Angeles, Extension:
Introductory Psychology
Fundamentals of Learning
Abnormal Psychology
Personality Theory

1/92-9/96: Instructor: Pepperdine University Graduate School of
Education and Psychology, Malibu, California
Comprehensive Review
Psychopathology
Psychopharmacology
Physiological Psychology
Theories of Personality

9/93-12/96: Instructor: Mount St. Mary's Weekend College Program,
Brentwood, CA
Abnormal Psychology
Substance Abuse
Forensic Psychology
Brain and Behavior

ACADEMIC HONORS

- 1990 Outstanding Graduate Student, College of Letters and Science,
University of California, Los Angeles
- 1989 Graduate Woman of the Year, University of California,
Los Angeles, Association of Academic Women
- 1988 Elected to Sigma Xi
- 1988 American Psychological Association Dissertation Research
Award
- 1988 Sigma Xi, Grant-in-Aid of Research
- 1988 Dr. Ursula Mandel Scholarship, University of California, Los
Angeles
- 1987 Shephard Ivory Franz Distinguished Teaching Award, University
of California Department of Psychology
- 1986 Hortense Fishbaugh Memorial Scholarship, Mabel Wilson Board
of Trustees, Los Angeles, CA

PROFESSIONAL AFFILIATIONS

American Psychological Association
Association of Academic Women, UCLA
Sigma Xi, The Scientific Research Society
Society for Neuroscience

RESEARCH PUBLICATIONS

- McGurk, S.R., Hartgraves, S.L., Kelly, P.H., Gordon, M., and Butcher, L.L.
(1987). Is ethylcholine mustard aziridinium a specific cholinergic
neurotoxin? Neuroscience, 22:215-224.
- McGurk, S.R., Levin, E.D. and Butcher, L.L. (1988). Cholinergic-dopaminergic
interactions and radial-arm performance. Behavioral and Neural
Biology, 49:234-239.
- Levin, E.D., McGurk, S.R., South, D., and Butcher, L.L. (1989). Effects of
combined muscarinic and nicotinic blockade on choice accuracy in
the radial-arm maze. Behavioral and Neural Biology, 51:78-86.
- McGurk, S.R., Levin, E.D., and Butcher, L.L. (1989). Nicotinic-dopaminergic
relationships and radial-arm maze performance in rats. Behavioral
and Neural Biology, 52:107-114.

Publications (cont)

- McGurk, S.R., Levin, E.D., and Butcher, L.L. (1989). Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs. Psychopharmacology, 99:371-373.
- Levin, E.D., McGurk, S.R., Rose, J.E., and Butcher, L.L. (1989). Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY171555. Pharmacology, Biochemistry, and Behavior, 33:919-922.
- Levin, E.D., McGurk, S.R., Rose, J.E., and Butcher, L.L. (1990). Cholinergic-dopaminergic interactions in cognitive performance. Behavioral and Neural Biology, 54:271-299.
- McGurk, S.R., Levin, E.D., and Butcher, L.L. (1991). Impairment of radial-arm maze performance in rats following lesions involving the cholinergic medial pathway: Reversal by arecoline and differential effects of muscarinic and nicotinic antagonists. Neuroscience, 44:137-147.
- McGurk, S.R., Levin, E.D., and Butcher, L.L. (1992). Dopamine modulation of cholinergic mediated memory deficits following lesions of the cholinergic medial pathway. Neuroscience, 50:129-135.
- McGurk, S.R., Cardenas, J., and Adelman, H. (1993). Utilization of a school-based clinic for the identification and treatment of adolescent sexual abuse. Journal of Adolescent Health, 14:196-201.
- Green, M.G., Marshall, B.D., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S.R., Kern, R.S., Mintz, J., and Van Putten, T. (1996) Does Risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, submitted.
- Green, M.G., Kern, R.S., Williams, O., McGurk, S.R., and Kee, K. (1996) Procedural learning in schizophrenia: Evidence from serial reaction time. American Journal of Psychiatry, submitted.
- McGurk, S.R., Green, M.F., Wirshing, W.C., and Marder, S.R. (Manuscript in preparation). Spatial memory in treatment-resistant schizophrenia.

CONFERENCE PRESENTATIONS

- Woolf, N.J., McGurk, S.R., and Butcher, L.L. (1982). Comparison between neurons demonstrating somatostatin-like immunoreactivity and those containing acetylcholinesterase in the rat forebrain. Society for Neuroscience Abstracts, 8: 112.
- McGurk, S.R., Woolf, N.J., Eckenstein, F., and Butcher, L.L. (1984). Cholinergic pathways III: Projections from the cholinergic pontine tegmentum to the thalamus, tectum, and basal forebrain. Society for Neuroscience Abstracts, 10:1182.
- McGurk, S.R. and Butcher, L.L. (1985). Neuropathologic effects of intracerebral infusion of ethylcholine mustard aziridinium (AF64A). 14th World Congress of Biological Psychiatry, 290.
- McGurk, S.R. and Butcher, L.L. (1985). Cholinergic neuropathology following intracerebral infusion of ethylcholine mustard aziridinium (AF64A). Society for Neuroscience Abstracts, 11:124C.
- McGurk, Levin, E.D., Shields, B., and Butcher, L.L. (1986). Dopamine-acetylcholine interactions in a spatial memory task. Society of Neuroscience Abstracts, 12:717.
- McGurk, S.R. and Butcher, L.L. (1987). The medial cholinergic pathway and memory. Federal Proceedings, 2:A342.
- McGurk, S.R., Levin, E.D., and Butcher, L.L. (1988). Cholinergic-dopaminergic interactions in radial-arm maze performance: Role of nicotinic-cholinergic systems. Society for Neuroscience Abstracts, 14:136.
- Levin, E.D., McGurk, S.R., South, D., and Butcher, L.L. (1988). Effects of combined nicotinic and muscarinic blockade on radial-arm maze performance. Society for Neuroscience Abstracts, 14:57.
- Levin, E.D., Rose, J.E., McGurk, S.R., and Butcher, L.L. (1989). Nicotinic and muscarinic interactions with D1 and D2 dopaminergic systems affecting cognitive behavior of rats. The Toxicologist, 9:106.

Conference Presentations (cont)

McGurk, S.R., Levin, E.D., and Butcher, L.L. (1989). Cholinergic-dopaminergic interactions in radial-arm performance: A lesion study. Society for Neuroscience Abstracts, 15:733.

Levin, E.D., Rose, J.E., McGurk, S.R., and Butcher, L.L. (1989). The impairment of radial-arm maze choice accuracy by combined muscarinic and nicotinic blockade and its reversal by a D2 agonist. Society for Neuroscience Abstracts, 15:733.

McGurk, S.R., Minor, T.R., and Butcher, L.L. (1990). Involvement of nicotinic cholinergic systems in shuttle-escape deficits produced by inescapable shock in rats. Society for Neuroscience Abstracts, 16:138.

McGurk, S.R., Green, M.F., and Marder, S.R. (1994). Spatial memory in treatment-resistant populations. Society for Research in Psychopathology, Miami, Florida.

McGurk, S.R., Green, M.F., Santana, S., Waters, B., McGee, M., and Marder, S.R. (1995). Risperidone vs. haloperidol in spatial working memory. International Congress for Schizophrenia, Warm Springs, Virginia.

McGurk, S.R., Green, M.F., Wirshing, W.C., Ames, D., Marshall, B.D., Santana, S., Marder, S.R. (1995). Effects of risperidone on spatial working memory. American Psychiatric Association, Miami, Florida.
Conference Presentations (con't.)

Green, M.F., McGurk, S.R., Wirshing, W.C., Ames, D., Marshall, B.D., and Marder, S.R. (1995). Rate-limiting factors in skill acquisition: Neurocognitive deficits vs. clinical symptoms. Mount Sinai Schizophrenia Conference, New York, New York.

McGurk, S.R., Green, M.G., Wirshing, W.C., Ames, D., Marshall, B.D., and Marder, S.M. (1995). Effects of risperidone vs. haloperidol on measures of prefrontal functioning. Society for Research in Psychopathology, Iowa City, Iowa.

Conference Presentations (cont)

Wirshing WC, Ames D, Marder SR, Marshall BD, Green MF, McGurk SR: Risperidone in treatment resistant schizophrenia. American College of Neuropsychopharmacology, 34th Annual Meeting, San Juan, Puerto Rico, December 1995. Abstracts of Panels and Posters, Poster Session III: 270.

Wirshing, W.C., Ames, D., Marder, S.R., Marshall, B.D., Green, M.F., and McGurk, S.R. (1995). Risperidone vs. haloperidol in treatment-resistant schizophrenia: Preliminary Results. Eight Biennial Winter Workshop on Schizophrenia, Krans Montana, Switzerland.

McGurk, S.R., Green, M.G., Wirshing, W.C., Ames, D., Marshall, B.D., and Marder, S.M. (1996). The effects of risperidone vs. haloperidol on spatial working memory in treatment-resistant schizophrenia. Fifty-first Annual Meeting of the Society of Biological Psychiatry, New York, New York.

McGurk, S.R., Green, M.G., Wirshing, W.C., Ames, D., Marshall, B.D., and Marder, S.M. (1996). The effects of risperidone vs. haloperidol on measures of prefrontal functioning in treatment-resistant schizophrenia. American Psychiatric Association, New York, NY.

McGurk, S.R., Green, M.G., Wirshing, W.C., Ames, D., Marshall, B.D., Marder, S.M., and Koehn, Henry. (1996). The effects of an anticholinergic on spatial memory in treatment-resistant schizophrenia. Society for Research of Psychopathology, Atlanta, Georgia.

McGurk, S.R. And Meltzer, H.Y. The relationship between plasma cortisol and cognitive functioning in schizophrenia. International Congress on Schizophrenia Research, submitted.

Green, M.F., Marshall, B.D., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S.R., Kern, R.S., and Mintz, J. Risperidone's effects on verbal working memory. International Congress on Schizophrenia Research, submitted.

Conference Presentations (cont)

Kern, R.S., Marshall, B.D., Green, M.F., Wirshing, W.C., Ames, D., Marder, S.M., McGurk, S.R., and Mintz, J. Risperidone vs. Haloperidol on reaction time and fine motor speed. International Congress on Schizophrenia Research. submitted.

PROFESSIONAL REFERENCES

Stephen R. Marder, M.D.

Chief of Psychiatry

West Los Angeles Veterans Administration Medical Center, B151F

11301 Wilshire Blvd.

Building 210, Basement Room 15

Los Angeles, CA 90073

(310)-268-4565

Robert P. Lieberman

Director, Clinical Research Center

West Los Angeles Veterans Administration Medical Center

11301 Wilshire Blvd.

Building 208

Los Angeles, CA 90073

(310)-268-4565

Michael Foster Green, Ph.D.

Associate Professor in Residence

Department of Psychiatry and Biobehavioral Sciences

UCLA-Neuropsychiatric Institute

705 Westwood Blvd.

Los Angeles, CA 90024

(805)-389-2545

Larry L. Butcher, Ph.D.

Professor

Department of Psychology

University of California, Los Angeles

Los Angeles, CA 90024

(310)-825-1962

Megan Suilaway, Ph.D.

Clinical Psychologist

Department of Psychology Clinic

University of California

405 Hilgard Ave

Los Angeles, CA 90024 (310)-825-2305



STATE OF TENNESSEE
DEPARTMENT OF HEALTH
HEALTH RELATED BOARDS
FIRST FLOOR, CORDELL HULL BUILDING
425 FIFTH AVENUE NORTH
NASHVILLE, TENNESSEE 37247-1010

BOARD OF EXAMINERS IN PSYCHOLOGY

Name: SUSAN REGINA MCGURK

Address: REDACTED

Temporary License/Health Service Provider Number: REDACTED
Temporary License /Health Service Provider Issue Date: June 25,
1997

This is to certify that SUSAN REGINA MCGURK has made application to practice as a Psychologist/Health Service Provider in Tennessee and it has been determined that he/she meets the educational requirements for licensure and qualifies to be scheduled for an initial written examination.

This temporary license is valid only until:


1. You have been issued a permanent license.
2. You fail to show for the scheduled written exam.
3. Your grade indicates failure of the written exam.
4. Your grade indicates failure of the second oral exam.

or for no longer than 1 year.


Supervisor:

Name: HOWARD B ROBACK
License REDACTED


Vice Chair
Board of Examiners
in Psychology


Administrator
Board of Examiners
in Psychology

PSYCH1/T1



CURRICULUM VITAE

Name: Herbert Y. Meltzer, M.D.
Date of Birth: July 29, 1937
Place of Birth: Brooklyn, New York
Marital Status: Married (Sharon Bittenson, M.A., 1961, Ph.D. Yale, 1970)
2 children (David, 4/17/64; Danielle, 11/29/70)
Address: Vanderbilt University Medical Center, Department of Psychiatry
University Medical Center, Psychiatric Hospital at Vanderbilt
1601 23rd Avenue South, Suite 306
Nashville, Tennessee 37212
Telephone: (615) 327-7049
Telefax: (615) 327-7093
E-mail: herbert.meltzer@mcnmail.vanderbilt.edu

EDUCATION:

1958 B.A.. Cornell University
Ithaca, New York
1959 M.A.. Harvard University
Cambridge, Massachusetts
1963 M.D.. Yale University
New Haven, Connecticut
1966-1968 Certificate in Community Psychiatry
Associate Faculties Program in Community Psychiatry
Washington School of Psychiatry

TRAINING

1963-1964 Intern in Medicine
St. Luke's Hospital
New York, New York
1964-1966 Resident in Psychiatry
Massachusetts Mental Health Center
Boston, Massachusetts
1965-1966 Ward Administrator
Clinical Research Center
Massachusetts Mental Health Center
1965-1966 Assistant in Medicine
Peter Brent Brigham Hospital
Boston, Massachusetts
1966-1968 Clinical Associate
Laboratory of Clinical Sciences
National Institute of Mental Health
Bethesda, Maryland

~~December 20, 1996~~

H.Y. Meltzer

2

ACADEMIC APPOINTMENTS

1959-1963 Research Associate, Departments of Pharmacology and Anatomy Yale University School of Medicine

1964-1966 Teaching Fellow in Psychiatry, Harvard Medical School

1966-1968 Clinical Associate, Laboratory of Clinical Science, National Institute of Mental Health

1967-1968 Instructor, Graduate Training Program, National Institute of Health

1968-1971 Assistant Professor, Department of Psychiatry, University of Chicago, Chicago, Illinois

1971-1974 Associate Professor, Department of Psychiatry, University of Chicago, Chicago, Illinois

1974-1985 Professor, Department of Psychiatry, University of Chicago Pritzker School of Medicine

1985-1996 Douglas Bond Professor of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio

1985- 1996 Professor of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio

1985-1992 Director of Research, Psychiatry Service, Veterans' Administration Medical Center, Cleveland, Ohio

1989-1996 Vice-Chairman of Research, Department of Psychiatry, University Hospitals of Cleveland, Cleveland, Ohio

1957 Research Assistant, Department of Biochemistry, Eli Lilly and Company, Indianapolis, Indiana (6/15 - 9/15)

1958 Research Assistant, Department of Neurochemistry, Lederle Division of American Cyanamid, Pearl River, New York

1968-1975 Program Director, Acute Psychosis Research Program, Illinois State Psychiatric Institute, Chicago, Illinois

1973-1975 American Psychiatric Association, Task Force on Research Training During Residency

1974-1978 Member, NIMH Clinical Research Projects Committee

1974-1975 Vice President, Association for Research in Nervous and Mental Disease

1975-1979 Director of Adult Services, Illinois State Psychiatric Institute, Chicago, Illinois

1975-1984 Director, Laboratory of Biological Psychiatry, Illinois State Psychiatric Institute, Chicago, Illinois

1978-1980 Chairperson, American College of Neuropsychopharmacology Task Force on Drug Safety

1979-1980 Assistant Secretary-Treasurer, American College of Neuropsychopharmacology

1980-1981 Nominating Committee, American College of Neuropsychopharmacology

1980-1982 Chairperson, American College of Neuropsychopharmacology Program Committee

1981-1984 Member, National Board of Medical Examiners, Part I Psychiatry Examination

1982-1984 Council Member, American College of Neuropsychopharmacology

1984-1985 President, American College of Neuropsychopharmacology

1986-1988 Medical Research Service Merit Review Board for Mental Health and Behavioral Sciences, Veterans Administration

1986- Member, Scientific Council, National Alliance for Research in Schizophrenia and Depression (NARSAD)

1986- Member, Advisory Board of the National Depressive and Manic Depressive Association

1987- Chair, Established Investigator Review Committee, NARSAD

1987- Chairman, Young Investigator Review Committee, NARSAD

1987 Member, Schizophrenia Initiative, NIMH, Research Resource Panel

H.Y. Meltzer

3

ACADEMIC APPOINTMENTS, Continued...

1987 Member, Science Work Group for the Conference on the Future of Psychiatry, American Psychiatric Association

1988-1993 Member of NIMH Intramural Program Science Advisory Board

1988- Member, U.S. Clozapine Scientific Advisory Board

1988- Member, International Clozapine Scientific Advisory Board

1989- Member, Scientific Advisory Board, National Depression and Manic-Depressive Association (NARSAD)

1989 Member, NIMH Clinical Service Research Panel

1989 Member, Veterans Administration Clozapine Task Force

1990-1996 Member, Case Western Reserve University *Ad Hoc* CME Committee of the Core Academic Program Committee

1990- Member, Scientific Advisory Board, National Alliance for the Mentally Ill

1990-1996 Member, Case Western Reserve University Pharmacology Chair Search Committee

1992 Member, Scientific Advisory Board, American Suicide Foundation

1993-1996 Member, Dean's Advisory Committee, CWRU

1994- Chairman, Nominating Committee, Collegium Internationale Neuropsychopharmacologicum (CINP)

1996- Professor of Psychiatry, Vanderbilt University School of Medicine, University Medical Center, Nashville, Tennessee

1996- Professor of Pharmacology, Vanderbilt University School of Medicine, University Medical Center, Nashville, Tennessee

1996- Director of Psychopharmacology Division, Psychiatric Hospital at Vanderbilt, Nashville, Tennessee

HONORS AND AWARDS

Graduation with distinction and honors in chemistry - Cornell University Phi Beta Kappa

New York State Regent's and Cornell University Scholarship

Dean's Scholarship, Cornell University

Telluride Associate Scholarship (Cornell)

George Chapman Caldwell Prize in Chemistry (Cornell)

Harold Adlard Levenberg Prize in Chemistry (Cornell)

General Electric Fellowship in Chemistry (Harvard)

Dean's Scholarship, Yale University School of Medicine

Research Scientist Development Award - Type II, NIMH, 1970-1975

Research Scientist Award, NIMH, 1976

Efron Award, American College of Neuropsychopharmacology, 1980

Who's Who in America

Pfizer Visiting Professor - Tufts University School of Medicine, 1987

Arthur P. Noyes Award in Schizophrenia, Commonwealth of Pennsylvania, 1990

Edward J. Sachar Award, Columbia University, 1991

Lieber Prize for Schizophrenia Research, Washington, DC, 1992

Gold Medal for Schizophrenia Research Award, Society of Biological Psychiatry, San Francisco, California, 1993

Stanley R. Dean Award, American College of Psychiatry, 1996

MEMBERSHIPS

Psychiatric Research Society

American College of Neuropsychopharmacology

American Psychiatric Association

American Society of Pharmacology & Experimental Therapeutics

New York Academy of Sciences

Society of Biological Psychiatry

American Psychosomatic Society

American Association of the Advancement of Science

Illinois State Psychiatric Society

H.Y. Maltzer

4

MEMBERSHIPS, Continued...

International Society for Psychoneuroendocrinology
Collegium Internationale Neuropsychopharmacology
International Academy for Biomedical and Drug Research

GRANT SUPPORT

1968-1979 Principal Investigator, USPHS MH 16,127: "Muscle Enzyme Release in the Acute Psychoses"

1968-1975 Principal Investigator, State of Illinois Department of Mental Health Grant: "Chemical Abnormalities in the Acute Psychoses"

1970-1975 Awardee, USPHS MH 47,808, Research Scientist Development Award: "Muscle Abnormalities in Acutely Psychotic Patients"

1970-1977 Principal Investigator, USPHS MH 18,396: "Myopathy of Psychosis and Psychotomimetic Drugs"

1970-1971 Principal Investigator, Muscular Dystrophy Association Grant: "Normal Levels of Serum Creatine Phosphokinase"

1973- Principal Investigator, USPHS 25,116: "MAO, DBH and ATPase Activity in Psychoses"

1975-1985 Principal Investigator, Laboratory of Biological Psychiatry, Department of Mental Health, State of Illinois

1976-1980 Research Scientist Award, USPHS MH 47,808

1977-1982 Principal Investigator, USPHS MH 29,206: "Chlorpromazine and Prolactin Studies in Schizophrenia"

1977- Principal Investigator, USPHS MH 30,938, Clinical Research Center: "Longitudinal Study of the Major Psychoses"

1978-1980 Principal Investigator, USPHS DA 02081: "Phencyclidine: A Behavioral and Neurochemical Study"

1978-1986 Principal Investigator - USPHS MH 30,059: "Role of Serotonin in Depression: Platelet Serotonin Uptake"

1980-1984 Research Scientist Award, USPHS MH 47,808

1985-1987 Co-Principal Investigator - Clozapine Multicenter Study for Treatment Refractory Schizophrenia, Sandoz, Inc.

1985-1987 Principal Investigator - USPHS MH 40,206: "Lymphocyte Glucocorticoid Receptors and DST Nonsuppressors"

1985- Principal Investigator, Cleveland Foundation Grant: "Biological Studies of Major Affective Disorders"

1986- Stuart Pharmaceuticals, Co.: Neuropharmacological Studies of ICI 169,369

1987- Co-Principal Investigator - Alzheimer's Disease Clinical Research Center, NIMH

1987- Ferrosan, Inc.: Neuropharmacological Studies of Amperozide and Melperone

1987 John Pascal Sawyer Foundation: Research in Schizophrenia

1988- Co-Principal Investigator - USPHS MH 454,488: "Serotonin Receptors in Suicide with Psychiatric Autopsy"

1987-1988 Bristol Meyers: Effect of Tiospirone in Chronic Schizophrenia

1987-1988 Ciba-Geigy: Effect of Savoxepine in Chronic Schizophrenia

1989 Prentiss Foundation: Research in Schizophrenia

1989-1990 NARSAD: Established Investigator Award

1990 Effect of Savoxepine in Normal Controls

1990-1993 Sandoz: Early Schizophrenia: Effect of Clozapine

1992-1993 Eli Lilly: Effect of Olanzapine in Schizophrenia

1992 Sihler Foundation: Premorbid Function in Schizophrenia

GRANT SUPPORT, Continued...

- 1993-1994 Robinson Gift: Amperozide and Substance Abuse
- 1993-1997 Maltz Gift: Obsessive-Compulsive Aspects of Schizophrenia
- 1993 Janssen Labs: Effect of Risperidone in Treatment Resistant Schizophrenia
- 1993- Pfizer Inc.: Effect of CP88,059-01 in Schizophrenia
- 1993- Upjohn Inc.: Effect of Pramipexole in Schizophrenics with Tardive Dyskinesia

EDITORIAL ACTIVITIES

- 1977- Editorial Board, *Progress in Neuropsychopharmacology*
- 1979- Editorial Board, *Psychiatry Research*
- 1980- Editorial Board, *Biological Psychiatry*
- 1980- Editorial Board, *Journal of Clinical Psychopharmacology*
- 1981-1989 Editorial Board, *American Journal of Psychiatry*
- 1981- Coeditor, *The Yearbook of Psychiatry and Applied Mental Health*
- 1981-1985 Associate Editor, *Schizophrenia Bulletin*
- 1984- Editorial Board, *Biochemical Pharmacology*
- 1984- Editorial Board, *Life Sciences*
- 1986- Editor, *Psychopharmacology, The Third Generation of Progress*, Raven Press and the American College of Neuropsychopharmacology
- 1986-1993 Editorial Board, *Journal of Neuropsychopharmacology*
- 1989- Editorial Board, *Current Opinion in Psychiatry*
- 1989- Editorial Associate, Institute for Health Policy Analysis, Georgetown University Medical Center
- 1990- Editorial Board, *International Journal of Methods in Psychiatric Research*
- 1990- Editorial Board, *European Journal of Neuropsychopharmacology*
- 1992 Editorial Board, *The Italian Journal of Psychiatry and Behavioural Sciences*
- 1992 Associate Editor, *Journal of Psychiatry & Neuroscience*
- 1993 Editorial Board, *Journal of Serotonin Research*
- 1993- Co-Editor, *Journal of Neuropsychopharmacology*
- 1996- Editorial Board, *CNS Spectrums*

CONSULTANTSHIPS

- 1972 Merck Pharmaceutical Company
- 1974 Pfizer, Inc.
Parke-Davis, Inc.
- 1976 Smith Kline French, Inc.
Eli Lilly, Inc.
- 1977 Roche, Inc.

H.Y. Meltzer

6

CONSULTANTSHIPS, Continued...

1977 Sandoz, Inc.
 1978 Stuart Pharmaceutical, Inc.
 1979-1983 Pfizer, Inc.
 1981- Schizophrenia Research Center, Bronx VA
 1985 Warner Chilcott
 1986- Delagrang, Inc.
 1986- Ferrosan, Inc.
 1986- Differential Diagnostics, Inc.
 1987- CIBA-Geigy, Inc.
 1987 Abbott Laboratories
 1987 Knoll Laboratories
 1988- Kabi Pharmacia
 1989 Warner-Chilcott
 1991-1993 Glaxo Inc.
 1992- Janssen, Inc.
 1993 Jouvienal, Inc.
 1994- Hoechst-Roussel Pharmaceuticals, Inc.

MEDICAL LICENSING & CERTIFICATION

1963 Licensed, State of California
 1968 Licensed, State of Illinois
 1966 Licensed, State of Maryland
 1964 Licensed, State of Massachusetts
 1985 Licensed, State of Ohio
 1980 Diplomate, American Board of Psychiatry and Neurology
 1996 Licensed, State of Tennessee

HONORIFIC LECTURES

Goodman Lectureship - New York Medical College, 1982
 DiMascio Lecturer - Tufts University School of Medicine, 1985
 Psychiatrische Munich - Munich, Germany, March, 1989
 King Khalid Hospital - Riyadh, Saudi Arabia, March, 1989
 Grass Lecturer - University of Ottawa, Ottawa, Canada, February, 1992
 Phineas J. Sporer Distinguished Visiting Professor - University of Tennessee, Memphis, Tennessee, May, 1992
 Frank and Milbrey Luten Lecturer - Vanderbilt University, Nashville, Tennessee, 1993
 2nd Benedum Lecture - West Virginia University, Morgantown, West Virginia, October, 1996

PUBLISHED PAPERS

1. Meltzer, H.Y.: The effect of thiamine on monoamine oxidase. *Biochemical Pharmacology* 7:277-278, 1961.
2. Meltzer, H.Y.: The effect of pyridine aldoxime dodecylidide on monoamine oxidase and bound amines. *Biochemical Pharmacology* 11:617-625, 1962.
3. Shader, R. and Meltzer, H.Y.: The breast metaphor and the group. *International Journal of Group Psychotherapies* 18:110-113, 1968.
4. Meltzer, H.Y.: Creatine kinase and aldolase in serum: abnormality common to acute psychoses. *Science* 159: 1368-1370, 1968.
5. Meltzer, H.Y.: Muscle enzyme release in the acute psychoses. *Archives of General Psychiatry* 21:102-112, 1969.
6. Meltzer, H.Y., Shader, R. and Grinspoon, L.: The effect of nicotinamide adenine dinucleotide on chronic schizophrenics. *Psychopharmacology* 13:144-152, 1969.
7. Meltzer, H.Y., Elkun, L. and Moline, R.: Serum enzyme changes in psychiatric patients. I. *Archives of General Psychiatry* 21:731-738, 1969.
8. Meltzer, H.Y., Mrozak, S. and Boyer, M.: Effects of intramuscular injections on serum creatine phosphokinase activity. *American Journal of the Medical Sciences* 259:42-48, 1970.
9. Meltzer, H.Y. and Boyer, M.: Effects of blood serum or plasma from schizophrenic patients and others on an action of 3,4-dimethoxyphenylethylamine: a failure to replicate. *Archives of International Pharmacodynamics* 182:481-488, 1969.
10. Meltzer, H.Y., Pahnke, W., Kurland, A. and Henkin, R.: Serum CPK and aldolase activity in man following controlled administration of psychotomimetic drugs. *Psychopharmacology* 16:419-423, 1970.
11. Meltzer, H.Y., Kupfer, D., Wyatt, R. and Snyder, F.: Sleep disturbance and serum CPK activity in acute psychosis. *Archives of General Psychiatry* 22:398-405, 1970.
12. Meltzer, H.Y. and Moline, R.: Plasma enzymatic activity after exercise. Study of psychiatric patients and their relatives. *Archives of General Psychiatry* 22:390-397, 1970.
113. Engle, W.K. and Meltzer, H.Y.: Histochemical abnormalities of skeletal muscle in patients with acute psychoses. *Science* 168:273-276, 1970.
14. Meltzer, H.Y.: Increased activity of creatine phosphokinase and aldolase in the acute psychoses: Case reports. *Journal of Psychiatric Research* 7:249-262, 1970.
15. Meltzer, H.Y. and Moline R.: Muscle abnormalities in acute psychoses. *Archives of General Psychiatry* 23:481-491, 1970.
16. Meltzer, H.Y. and Engel, W.K.: Histochemical abnormalities of skeletal muscle in acutely psychotic patients. Part II. *Archives of General Psychiatry* 23: 492-502, 1970.
17. Fischman, D., Meltzer, H.Y. and Poppei, R.: Disruption of myofibrils in the skeletal muscle of psychotic patients. *Archives of General Psychiatry* 23:503-515, 1970.
18. Kupfer, D., Meltzer, H.Y., Wyatt, R. and Snyder, F.: Serum enzyme changes in sleep deprivation. *Nature* 228:768-770, 1970.
19. Meltzer, H.Y., Grinspoon, L. and Shader, R.: Serum creatine kinase activity in acute schizophrenic patients and their relatives. *Comprehensive Psychiatry* 11:552-558, 1970.
20. Narasimhachari, N., Heller, B., Spaide, J., Haskovec, L., Meltzer, H.Y., Strabelevitz, M. and Himwich, H.E.: N,N-Dimethylated indoleamines in blood. *Biological Psychiatry* 3:21-25, 1971.
21. Meltzer, H.Y.: Factors affecting serum CPK levels in the general population: The role of race, activity and age. *Clinica Chimica Acta* 33:165-172, 1971.
22. Meltzer, H.Y., Nankin, R. and Raftery, J.: Serum creatine phosphokinase (CPK) activity in newly admitted psychiatric patients. II. *Archives of General Psychiatry* 24:568-572, 1971.
23. Meltzer, H.Y.: Adenosine 3',5'-monophosphate and mania. *Journal of the American Medical Association* 216: 1856-1857, 1971.

¹Selected for inclusion in *The Schizophrenias: An Annual Review*, Vol. 1, (Ed.) R. Cancro.

24. Meltzer, H.Y.: Creatine phosphokinase activity in cerebrospinal fluid. *American Journal of Diseases of Children* **122**:85-86, 1971.
25. Meltzer, H.Y.: Plasma creatine phosphokinase activity, hypothermia and stress. *American Journal of Physiology* **221**:896-901, 1971.
26. Meltzer, H.Y. and Guschwan, A.: Effect of isoproterenol on rat plasma creatine phosphokinase activity. *Archives internationales de Pharmacodynamie et de Thérapie* **194**:141-146, 1971.
27. Meltzer, H.Y.: Chlorpromazine-induced hypothermia and increased plasma creatine phosphokinase activity. *Biochemical Pharmacology* **20**:1739-1748, 1971.
28. Meltzer, H.Y. and Margulies, P.: Release of creatine phosphokinase from muscle. I. Effect of polymyxin B, compound 48/80 and serotonin. *Biochemical Pharmacology* **20**:3501-3508, 1971.
29. Meltzer, H.Y. and Guschwan, A.: Type I (brain type) creatine phosphokinase (CPK) activity in rat platelets. *Life Sciences* **11**:121-130, 1972.
30. Meltzer, H.Y.: Muscle toxicity produced by phenylcyclidine and restraint stress. *Research Communications in Chemical Pathology and Pharmacology* **2**:369-382, 1972.
31. Meltzer, H.Y.: Central core fibers in an acutely psychotic patients. Evidence for a neurogenic basis for the muscle abnormalities in the acute psychoses. *Archives of General Psychiatry* **27**:125-132, 1972.
32. Meltzer, H.Y., Holzman, P.S., Hassan, S.Z. and Guschwan, A.: Effects of phenylcyclidine and stress on plasma creatine phosphokinase (CPK) and aldolase activities in man. *Psychopharmacologia* **25**:44-53, 1972.
33. Meltzer, H.Y.: Effects of phenylcyclidine and restraint at 2°C on rat plasma creatine phosphokinase activity. *Research Communications in Chemical Pathology and Pharmacology* **5**:117-127, 1973.
34. Meltzer, H.Y., Margulies, P. and Cho, H.W.: Release of creatine phosphokinase from muscle. II. Effect of multiple doses of polymyxin B or compound 48/80 on increases in plasma enzyme levels. *Biochemical Pharmacology* **22**:857-863, 1973.
35. Meltzer, H.Y.: Effect of theophylline on alkaline phosphatase activity of denervated skeletal muscle fibers. *Research Communications in Chemical Pathology and Pharmacology* **5**:539-542, 1973.
36. Meltzer, H.Y.: Skeletal muscle abnormalities in patients with affective disorders. *Journal of Psychiatric Research* **10**:43-57, 1973.
37. Meltzer, H.Y., McBride, E. and Poppei, R.W.: Rod (nemaline) bodies in the skeletal muscle of an acute schizophrenic patient. *Neurology* **23**:769-780, 1973.
38. Meltzer, H.Y.: Rigidity, hyperpyrexia and coma following fluphenazine enanthate. *Psychopharmacologia* **29**:337-346, 1973.
39. Meltzer, H.Y.: Morphological effects of compound 48/80, polymyxin B sulfate, and dextran on rat skeletal muscle. *Archives of Pathology* **26**:118-123, 1973.
40. Meltzer, H.Y.: Plasma creatine phosphokinase activity in the rat after tenotomy or denervation. *Experimental Neurology* **40**: 547-551, 1973.
41. Goode, D.J., Dekirmenjian, H., Meltzer, H.Y. and Maas, J.: Relation of exercise to MHPG excretion in normal subjects. *Archives of General Psychiatry* **29**:391-396, 1973.
42. Meltzer, H.Y.: Creatine phosphokinase activity and clinical symptomatology: A study in acute schizophrenic patients. *Archives of General Psychiatry* **29**:589-593, 1973.
43. Meltzer, H.Y. and Crayton, J.W.: Subterminal motor nerve abnormalities in psychotic patients. *Nature* **249**:373-375, 1974.
44. Meltzer, H.Y. and Stahl, S.M.: Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. *Research Communications in Chemical Pathology and Pharmacology* **2**:419-431, 1974.
45. Meltzer, H.Y. and Crayton, J.W.: Muscle abnormalities in psychotic patients. II. Serum CPK activity, fiber abnormalities and branching and sprouting of subterminal nerve. *Biological Psychiatry* **8**:191-208, 1974.
46. Meltzer, H.Y. and Holy, P.A.: Black-white differences in serum creatine phosphokinase (CPK) activity. *Clinica Chimica Acta* **54**:215-224, 1974.

47. Holzman, P.S., Proctor, L.R., Levy, D.L., Yasillo, N.Y., Meltzer, H.Y. and Hurt, S.W.: Eye-tracking dysfunctions in schizophrenic patients and their relatives. *Archives of General Psychiatry* 31:143-154, 1974.
48. Cho, H.W. and Meltzer, H.Y.: Mg^{++} - Dependent ATPase activity in erythrocyte ghosts of schizophrenic patients. *Biological Psychiatry* 21:143-154, 1974.
49. Goode, D.J. and Meltzer, H.Y.: Cytotoxic effects of imipramine on platelets. *Biochemical Pharmacology* 23:2629-2635, 1974.
50. Kuncel, R.W. and Meltzer, H.Y.: Pathologic effect of phencyclidine and restraint on rat skeletal muscle structure: Prevention of prior denervation. *Experimental Neurology* 45:387-402, 1974.
51. Meltzer, H.Y., Sachar, E.J. and Frantz, A.G.: Serum prolactin levels in unmedicated schizophrenic patients. *Archives of General Psychiatry* 31:564-569, 1974.
52. Strahilevitz, M., Narasimhachari, N., Fischer, G.W., Meltzer, H.Y. and Himwich, H.E.: Indolcthyllamine-n-methyltransferase activity in psychiatric patients and controls. *Biological Psychiatry* 10:287-302, 1975.
53. Goode, D.J. and Meltzer, H.Y.: The role of isometric muscle tension in the production of muscle toxicity by phencyclidine and restraint stress. *Psychopharmacologia* 42:105-108, 1975.
54. Meltzer, H.Y., Sachar, E.J. and Frantz, A.G.: Serum prolactin levels in unmedicated schizophrenic patients. *Arch Gen Psychiatry* 31:564-569, 1975.
55. Meltzer, H.Y.: Lack of effect of ouabain on creatine phosphokinase (CPK) efflux from skeletal muscle. *Biochemical Pharmacology* 24:419-421, 1975.
56. Meltzer, H.Y., Hassan, S.Z., Moretti, R., Hengeveld, C. and Brueckner, D.: Effect of ketamine on creatine phosphokinase levels. *Lancet* i:1195-1196, 1975.
57. Meltzer, H.Y., Daniels, S. and Fang, V.S.: Clozapine increases rat serum prolactin levels. *Life Sciences* 17:339-342, 1975.
58. Fang, V.S., Cho, H.W. and Meltzer, H.Y.: Labeling of creatine phosphokinase without loss of enzyme activity. *Biochemical and Biophysical Research Communications* 63:413-419, 1975.
59. Meltzer, H.Y.: Plasma creatine phosphokinase levels in rats following lysergic acid diethylamide. *Psychopharmacologia* 44: 91-93, 1975.
60. Kanner, M., Finnegan, K. and Meltzer, H.Y.: Dopaminergic effects of phencyclidine in rats with nigrostriatal lesions. *Psychopharmacology Communications* 1:393-401, 1975.
61. Meltzer, H.Y.: Serum creatine phosphokinase in schizophrenia. *American Journal of Psychiatry* 133:192-197, 1976.
62. Meltzer, H.Y. and Fang, V.S.: The effect of neuroleptics on serum prolactin in schizophrenic patients. *Archives of General Psychiatry* 23:279-286, 1976.
63. Crayton, J.W. and Meltzer, H.Y.: Serum creatine phosphokinase activity in psychiatrically hospitalized children. *Archives of General Psychiatry* 23:679-682, 1976.
64. Meltzer, H.Y., Cho, H., Carroll, B.J. and Russo, P.: Serum dopamine- β -hydroxylase activity in the affective psychoses and schizophrenia. *Archives of General Psychiatry* 23:585-591, 1976.
65. Meltzer, H.Y., Belmaker, R., Wyatt, R.J., Pollin, W. and Cohen, S.: Serum creatine phosphokinase (CPK) activity in mono-zygotic twins discordant for schizophrenia: Heritability of serum (CPK) activity. *Comprehensive Psychiatry* 17:469-475, 1976.
66. Meltzer, H.Y.: Biochemical studies in schizophrenia. *Schizophrenia Bulletin* 2:11-18, 1976.
67. Meltzer, H.Y. and Stahl, S.M.: The dopamine hypothesis of schizophrenia: A review. *Schizophrenia Bulletin* 2:19-76, 1976.
68. Meltzer, H.Y.: Neuromuscular dysfunction in schizophrenia. *Schizophrenia Bulletin* 2:106-135, 1976.
69. Meltzer, H.Y.: Skeletal muscle necrosis following membrane-activity drugs plus serotonin. *Journal of Neurological Sciences* 28:41-56, 1976.
70. Meltzer, H.Y., Kuncel, R.W., Click, J. and Yang, V.: Incidence of Z-band streaming and myofibrillar disruptions in skeletal muscle from healthy young people. *Neurology* 26:853-857, 1976.

71. Meltzer, H.Y., Rastogi, S. and Ellison, J.: Quantitative histochemical evaluation of normal human skeletal muscle. *Neurology* **26**:849-852, 1976.
72. Meltzer, H.Y. and Fang, V.S.: Effect of apomorphine plus 5-hydroxytryptophan on plasma prolactin levels in male rats. *Psychopharmacology Communications* **2**:189-198, 1976.
73. Goode, D.J. and Meltzer, H.Y.: Effects of isometric exercise on serum creatine phosphokinase activity. *Archives of General Psychiatry* **33**:1207-1211, 1976.
74. Arora, R.C. and Meltzer, H.Y.: *In vitro* and *in vivo* inhibition of rat liver, brain and muscle monoamine oxidase by chlorpromazine and imipramine. *Research Communications in Chemical Pathology and Pharmacology* **14**:755-758, 1976.
75. Meltzer, H.Y., Fang, V.S., Paul, S.N. and Kaluskar, R.: Effect of quipazine on rat plasma prolactin levels. *Life Sciences* **19**:1073-1078, 1976.
76. Meltzer, H.Y., Hassan, S.Z., Russo, P. and Cho, H.W.: Isoenzymes of creatine phosphokinase in serum of families with malignant hyperpyrexia. *Anesthesia and Analgesia* **55**:797-799, 1976.
77. Cho, H.W., Meltzer, H.Y., Joung, J.I. and Goode, D.J.: Effect of incubation in human plasma on electrophoretic mobility of brain-type creatine phosphokinase. *Clinica Chimica Acta* **73**:257-265, 1976.
78. Crayton, J.W. and Meltzer, H.Y.: Motor endplate alterations in schizophrenic patients. *Nature* **262**:658-659, 1976.
79. Finnegan, K.T., Kanner, M.I. and Meltzer, H.Y.: Phencyclidine-induced rotational behavior in rats with nigrostriatal lesions and its modulation by dopaminergic and cholinergic agents. *Pharmacology, Biochemistry and Behavior* **5**:651-660, 1976.
80. Meltzer, H.Y., Piyakulmala, S., Schyve, P. and Fang, V.S.: Lack of effect of tricyclic antidepressants on serum prolactin levels. *Psychopharmacology* **51**:185-187, 1977.
81. Stahl, S.M. and Meltzer, H.Y.: Serotonin accumulation by skeletal muscle. *Experimental Neurology* **54**:42-53, 1977.
82. Meltzer, H.Y., Paul, S.M. and Fang, V.S.: Effect of flupenthixol and buraclamol isomers on prolactin secretion in rats. *Psychopharmacology* **51**:181-183, 1977.
83. Meltzer, H.Y., Fang, V.S., Simonovic, M. and Paul, S.M.: Effect of metabolites of chlorpromazine on plasma prolactin levels in male rats. *European Journal of Pharmacology* **41**:431-436, 1977.
84. Meltzer, H.Y., Goode, D.J. and Fang, V.S.: Effects of chlorpromazine on plasma prolactin and chlorpromazine levels. *Psychopharmacology Bulletin* **13**:39-60, 1977.
85. Cho, H.W., Prilipko, L., Meltzer, H.Y. and Keller, C.: Isoenzymes of creatine phosphokinase in white blood cells. *Experientia* **33**:166-167, 1977.
86. Meltzer, H.Y. and Fang, V.S.: Effect of γ -butyrolactone and baclofen on plasma prolactin in male rats. *Biochemical Pharmacology* **26**:645-646, 1977.
87. Arora, R.C. and Meltzer, H.Y.: Characterization of rat skeletal muscle monoamine oxidase. *Biochemical Pharmacology* **26**:45-49, 1977.
88. Arora, R.C. and Meltzer, H.Y.: Isoenzymes of monoamine oxidase in human skeletal muscle. *Experimental Neurology* **55**:318-326, 1977.
89. Goode, D.J., Meltzer, H.Y., Crayton, J.W. and Mazura, T.A.: Physiologic abnormalities of the neuromuscular system in schizophrenia. *Schizophrenia Bulletin* **3**:121-138, 1977.
90. Smith, R.C., Meltzer, H.Y., Arora, R.C. and Davis, J.D.: Effects of phencyclidine [^{3} H]catecholamine and [^{3} H] serotonin uptake in synaptosomal preparations from rat brain. *Biochemical Pharmacology* **26**:1435-1439, 1977.
91. Crayton, J.W., Meltzer, H.Y. and Goode, D.J.: Motoneuron excitability in psychiatric patients. *Biological Psychiatry* **12**:545-561, 1977.
92. Meltzer, H.Y., Fessler, R.G., Simonovic, M., Doherty, J. and Fang, V.S.: Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. *Psychopharmacology* **54**:39-44, 1977.
93. Fang, V.S., Cho, H.W. and Meltzer, H.Y.: Radioimmunoassay for MM and BB isoenzymes of creatine kinase substantiated by clinical application. *Clinica Chimica Acta* **73**:1898-1902, 1977.

94. Piyakulmala, S., Corbett, L., Ahluwalia, Y., Berry, R.A. and Meltzer, H.Y.: High dose pimozide in the treatment of acutely agitated schizophrenia. *Current Therapies in Research* 22:453-461, 1977.
95. Kuncel, R.S. and Meltzer, H.Y.: Role of the adrenal in an experimental myopathy. *Experimental Neurology* 57:322-330, 1977.
96. Goode, D.J., Weinberg, D.H., Mazura, T.A., Curtiss, G., Moretti, R.J. and Meltzer, H.Y.: Effect of limb restraints on serum creatine phosphokinase activity in normal volunteers. *Biological Psychiatry* 12:743-755, 1977.
97. Meltzer, H.Y., Fessler, R.G. and Fang, V.S.: Periapine: relationship between stimulation of prolactin secretion and anti-psychotic activity. *Psychopharmacology* 54:183-186, 1977.
98. Stahl, S.M. and Meltzer, H.Y.: The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. *Experimental Neurology* 59:1-15, 1978.
99. Meltzer, H.Y., Fessler, R.G., Simonovic, M. and Fang, V.S.: Stimulation of rat prolactin secretion by indolalkylamine hallucinogens. *Psychopharmacology* 56:255-259, 1978.
100. Stahl, S.M. and Meltzer, H.Y.: A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. *Journal of Pharmacology and Experimental Therapeutics* 205:118-132, 1978.
101. Fang, V.S., Ho, B.T., Meltzer, H.Y.: Effect of 6-methoxy-tetrahydro- β -carboline on serum prolactin levels of male rats. *Communications in Psychopharmacology* 2:59-63, 1978.
102. Fang, V.S., Cho, H.W. and Meltzer, H.Y.: Enzymic, electrophoretic and immunoreactive properties of labeled MM and BB isoenzymes of human creatine kinase. *Enzyme* 23:210-214, 1978.
103. Meltzer, H.Y., Miller, R.J., Fessler, R.G., Simonovic, M. and Fang, V.S.: Effects of enkephalin analogues on prolactin release in the rat. *Life Sciences* 22:1931-1938, 1978.
104. Meltzer, H.Y., Dorus, E., Grunhaus, L., Davis, J.M. and Belmaker, R.: Genetic control of human plasma creatine phosphokinase activity. *Clinical Genetics* 13:321-326, 1978.
- *105. Schyve, P.M., Smithline, F. and Meltzer, H.Y.: Neuroleptic-induced prolactin level elevation and breast cancer. *Psycho-pharmacology Bulletin* 14:17-19, 1978.
106. Meltzer, H.Y., Simonovic, M., Fang, C., Piyakulmala, S. and Young, M.: A comparison of the effects of antipsychotic drugs on pituitary, striatal and limbic systems post-synaptic dopamine receptors. *Life Sciences* 23:605-610, 1978.
107. Meltzer, H.Y., Fessler, R.G., Simonovic, M. and Fang, V.S.: The effect of mescaline, 3,4-dimethoxyphenethylamine and 2,5-dimethoxy- α -methylamphetamine on rat plasma prolactin: evidence for serotonergic mediation. *Life Sciences* 23:1185-1192, 1978.
108. Meltzer, H.Y., Simonovic, M. and Fang, V.S.: The effect of muscimol on prolactin secretion in male rats. *Communications in Psychopharmacology* 2:231-236, 1978.
109. Meltzer, H.Y., Fessler, R.G. and Fang, V.S.: Effect of piperhexane on rat plasma prolactin. *Communications in Psycho-pharmacology* 2:237-242, 1978.
110. Meltzer, H.Y., Stanisic, D., Simonovic, M. and Fang, V.S.: Ketamine as an anesthetic for obtaining plasma for rat prolactin assays. *Proceedings of the Society of Experimental Biology and Medicine* 159:12-15, 1978.
111. Schyve, P.M., Smithline, F. and Meltzer, H.Y.: Neuroleptic-induced prolactin level elevation and breast cancer. *Archives of General Psychiatry* 35:1291-1301, 1978.
- *112. Meltzer, H.Y., Simonovic, M., Fessler, R.G., Miller, R.J., Creese, I.C., Snyder, S.H. and Fang, V.S.: Neuropharmacological studies of prolactin secretion. *Psychopharmacology Bulletin* 14:26-29, 1978.
- *113. Ziemba, T., Meltzer, H.Y. and Davis, J.M.: Do anticholinergics antagonize antipsychotic drug action? *Schizophrenia Bulletin* 4:7-12, 1978.
114. Kuncel, R.W. and Meltzer, H.Y.: Lesions of the myofibril in myopathic and normal tissue from seven striated muscles. *Acta Neuropathology* 45:83-95, 1979.

*Non-Peer Reviewed

115. Cho, H.W. and Meltzer, H.Y.: Factors affecting stability of isoenzymes of creatine phosphokinase. *American Journal of Clinical Pathology* 71:75-82, 1979.
116. Meltzer, H.Y., Fessler, R.G., Simonovic, M., Doherty, J. and Fang, V.S.: Effect of *d*- and *l*-amphetamine on rat plasma prolactin levels. *Psychopharmacology* 61:63-69, 1979.
117. Fessler, R.G., Sturgeon, R.D. and Meltzer, H.Y.: Phencyclidine-induced ipsilateral rotation in rats with unilateral 6-hydroxydopamine-induced lesions of the substantia nigra. *Life Sciences* 24:1281-1288, 1979.
118. Meltzer, H.Y., Young, M., Metz, J., Fang, V.S., Schyve, P.M. and Arora, R.C.: Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. *Journal of Neural Transmission* 45:165-175, 1979.
- *119. Meltzer, H.Y., Goode, D.J., Arora, R.C., Stanton, J.R., Metz, J. and Ziemba, T.: Neuromuscular dysfunction and vulnerability to psychosis. *Psychopharmacology Bulletin* 15:43-44, 1979.
120. West, A.P. and Meltzer, H.Y.: Paradoxical lithium neurotoxicity: A report of five cases and a hypothesis about risk for neurotoxicity. *American Journal of Psychiatry* 136:963-966, 1979.
121. Meltzer, H.Y., So, R., Miller, R.J. and Fang, V.S.: Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of ³H-spiroperidol in the rat pituitary and striatum with *in vivo* effects on rat prolactin secretion. *Life Sciences* 25:573-584, 1979.
122. Jackman, H., Arora, R. and Meltzer, H.Y.: Comparison of platelet count and platelet protein methods for determination of platelet MAO activity. *Clinica Chimica Acta* 26:15-23, 1979.
123. Goode, D.J., Meltzer, H.Y., Moreni, R., Kupfer, D.J. and McPartland, R.J.: The relationship between wrist-monitored motor activity and serum CPK activity in psychiatry inpatients. *British Journal of Psychiatry* 135:62-66, 1979.
124. Meltzer, H.Y.: Biology of schizophrenia subtypes: A review and proposal for method of study. *Schizophrenia Bulletin* 5:460-479, 1979.
125. Meltzer, H.Y. and So, R.: Effect of morphine, β -endorphin and *leu*-enkephalin on ³H-spiroperidol binding to bovine pituitary membranes. *Life Sciences* 25:531-536, 1979.
126. Crayton, J.W. and Meltzer, H.Y.: Degeneration and regeneration of motor neurons in psychotic patients. *Biological Psychiatry* 14:803-819, 1979.
127. Simonovic, M. and Meltzer, H.Y.: Repeated administration of 5-methoxy-N,N-dimethyltryptamine to male rats potentiates stimulation of prolactin secretion by serotonin agonists. *European Journal of Pharmacology* 58:399-405, 1979.
128. Busch, D.A., Fang, V.S. and Meltzer, H.Y.: Serum prolactin levels following intramuscular chlorpromazine: Two- and three-hour response as predictors of six-hour response. *Psychiatry Research* 1:153-159, 1979.
129. Prange, A.M., Loosen, P.T., Wilson, I.C., Meltzer, H.Y. and Fang, V.S.: Behavioral and endocrine responses of schizophrenic patients to TRH (proirelin). *Archives of General Psychiatry* 36:1086-1093, 1979.
130. Meltzer, H.Y., Goode, D.J., Schyve, P.M., Young, M. and Fang, V.S.: Effect of clozapine on human serum prolactin levels. *American Journal of Psychiatry* 136:1550-1555, 1979.
131. Meltzer, H.Y. and Simonovic, M.: Reserpine and PCP psychosis. *American Journal of Psychiatry* 136:1618-1620, 1979.
132. Ross-Stanton, J. and Meltzer, H.Y.: Skeletal muscle morphology of depressed patients after medication. *Muscle and Nerve* 2:239-240, 1979.
133. Holtzman, P.S., Meltzer, H.Y., Kringlen, E., Levy, D.L., Haberman, S.J. and Davis, J.M.: Plasma CPK levels in monozygotic and dizygotic twins discordant for schizophrenia. *Journal of Psychiatric Research* 15:127-131, 1979.
134. Sturgeon, R.D., Fessler, R.G. and Meltzer, H.Y.: Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. *European Journal of Pharmacology* 59:169-179, 1979.
135. Meltzer, H.Y. and Arora, R.C.: Distribution of type A and type B monoamine oxidase activities in rat and chicken skeletal muscle and nerves. *Biochemical Pharmacology* 28:3261-3264, 1979.

*Non-Peer Reviewed

136. Stern, W.C., Rogers, J., Fang, V. and Meltzer, H.Y.: Influence of bupropion HCL (Wellbutrin®), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. *Life Sciences* 23:1717-1724, 1979.
137. Meltzer, H.Y.: Clinical evidence for multiple dopamine receptors in man. *Communications in Psychopharmacology* 3:457-470, 1979.
- *138. Meltzer, H.Y., Fang, V.S., Young M.A.: Clozapine-like drugs. *Psychopharmacology Bulletin* 16:32-34, 1980.
139. Young, M.A. and Meltzer, H.Y.: RMI-81-582, a novel antipsychotic drug. *Psychopharmacology* 62:101-106, 1980.
140. Arora, R.C. and Meltzer, H.Y.: Muscle cholinesterase: Effect of phencyclidine and ketamine on rat and human muscle cholinesterase activity. *Experimental Neurology* 67:1-10, 1980.
141. Meltzer, H.Y. and Arora, R.C.: Skeletal muscle MAO in the major psychoses. *Archives of General Psychiatry* 37:325-332, 1980.
142. Meltzer, H.Y., Arora, R.C., Babar, R., Jackman, H., Nasr, S., Pscheidt, G., Smith, M. and Strahilevitz, M.: Platelet monoamine oxidase activity and schizophrenia. *Archives of General Psychiatry* 37:357-358, 1980.
143. Mosher, L.R. and Meltzer, H.Y.: Neuroleptics and psychosocial treatment. *Schizophrenia Bulletin* 6:8-9, 1980.
144. Young, M.A. and Meltzer, H.Y.: The relationship of demographic, clinical and outcome variable to neuroleptic treatment requirements. *Schizophrenia Bulletin* 6:88-101, 1980.
145. Meltzer, H.Y., Arora, R.C., Jackman, H., Pscheidt, G. and Smith, M.D.: Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients. *Schizophrenia Bulletin* 6:213-219, 1980.
146. Jackman, H.L. and Meltzer, H.Y.: Factors affecting determination of platelet monoamine oxidase activity. *Schizophrenia Bulletin* 6:259-266, 1980.
147. Meltzer, H.Y., Jackman, H., Arora, R.C.: Brain and skeletal monoamine oxidase activity in schizophrenia. *Schizophrenia Bulletin* 6:208-212, 1980.
148. Meltzer, H.Y., Ross-Stanton, J. and Schlessinger, S.: Mean serum creatine kinase activity in patients with functional psychoses. *Archives of General Psychiatry* 37:650-655, 1980.
149. Kaskey, G., Nasr, S. and Meltzer, H.Y.: Drug treatment in delusional depression. *Psychiatry Research* 2:267-278, 1980.
150. Arora, R.C. and Meltzer, H.Y.: *In vitro* effect of phencyclidine and other psychomotor stimulants on serotonin uptake in human platelets. *Life Sciences* 27:1607-1613, 1980.
151. Ross-Stanton, J., Schlessinger, S. and Meltzer, H.Y.: Multiple neuromuscular abnormalities in a paranoid schizophrenic. *Psychiatry Research* 3:55-68, 1980.
152. Meltzer, H.Y.: Relevance of dopamine autoreceptors for psychiatry: clinical and preclinical studies. *Schizophrenia Bulletin* 6:456-475, 1980.
153. Doherty, J.D., Simonovic, M., So, R. and Meltzer, H.Y.: The effect of phencyclidine on dopamine synthesis and metabolism in rat striatum. *European Journal of Pharmacology* 65:136-149, 1980.
154. Huang, C.C., Friedman, A.M., So, R., Simonovic, M. and Meltzer, H.Y.: Synthesis and biological evaluation of *p*-bromo-spiperone as potential neuroleptic drug. *Journal of Pharmaceutical Sciences* 69:984-986, 1980.
155. Meltzer, H.Y., Nasr, S.D. and Tong, C.: Serum dopamine- β -hydroxylase activity in schizophrenia. *Biological Psychiatry* 15:781-788, 1980.
- *156. Meltzer, H.Y., Surgeon, R.D., Simonovic, M. and Fessler, R.G.: Phencyclidine as an indirect dopamine agonist. *Psychopharmacology Bulletin* 16:62-65, 1980.
157. Fessler, R.G., Surgeon, R.D. and Meltzer, H.Y.: Effects of phencyclidine and methylphenidate on *d*-amphetamine-induced behaviors in reserpine pretreated rats. *Pharmacology, Biochemistry and Behavior* 13:835-842, 1980.
158. Nasr, S., Daigujl, M., Tong, C. and Meltzer, H.Y.: Comparison of midday serum dopamine- β -hydroxylase activity in depressed patients and normal controls. *Communications in Psychopharmacology* 4:263-268, 1980.

*Non-Peer Reviewed

159. Bowers, M.B. Jr., Heninger, G.R., Sternberg, D. and Meltzer, H.Y.: Clinical processes and central dopaminergic activity in psychotic disorders. *Communications in Psychopharmacology* 4:177-188, 1980.
160. Jackman, H.L. and Meltzer, H.Y.: Human platelet monoamine oxidase activity and *in vivo* manipulation of plasma glucose concentration. *Communications in Psychopharmacology* 4:335-338, 1980.
161. Metz, J., Goode, D.J. and Meltzer, H.Y.: Descriptive studies of H-reflex recovery curves in psychiatric patients. *Psychological Medicine* 10:541-548, 1980.
162. Goode, D.J., Meltzer, H.Y. and Fang, V.S.: Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six post partum women. *Psychoneuroendocrinology* 5:345-351, 1980.
163. Meltzer, H.Y., Simonovic, M., Surgeon, R.D. and Fang, V.S.: Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. *Acta Psychiatrica Scandinavica* 63:100-121, 1981.
164. Metz, J., Busch, D.A. and Meltzer, H.Y.: Des-tyrosine- γ -endorphin H-reflex response similar to neuroleptics. *Life Sciences* 28:2003-2008, 1981.
165. Meltzer, H.Y., Simonovic, M. and Carlsson, A.: Effect of N-N-propyl-3-(3-hydroxyphenyl)-(3-PPP), a putative dopamine autoreceptor agonist on rat serum prolactin levels. *Life Sciences* 29:99-105, 1981.
166. Arora, R.C. and Meltzer, H.Y.: A modified assay method for determining serotonin uptake in human platelets. *Clinica Chimica Acta* 112:225-233, 1981.
167. Daiguji, M., Meltzer, H.Y. and U'Prichard, D.C.: Human platelet α_2 -adrenergic receptors: labeling with ^3H -yohimbine, a selective antagonist ligand. *Life Sciences* 28:2705-2717, 1981.
168. Daiguji, M., Meltzer, H.Y., Tong, C., U'Prichard, D.C., Young, M. and Kravitz, H.: α_2 -adrenergic receptors in platelet membranes of depressed patients: no change in number of ^3H -yohimbine affinity. *Life Sciences* 29:2059-2064, 1981.
169. Fang, V.S., Tricou, B.J., Robertson, A. and Meltzer, H.Y.: Plasma ACTH and cortisol levels in depressed patients: relation to dexamethasone suppression test. *Life Sciences* 29:931-938, 1981.
170. Meltzer, H.Y., Busch, D.A., Creese, I.R., Snyder, S.H. and Fang, V.S.: Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. *Psychiatry Research* 5:95-105, 1981.
171. Sahai, S., Arora, R.C. and Meltzer, H.Y.: Effect of chlorpromazine treatment on monoamine oxidase activity in platelets isolated by the Corash method. *Psychiatry Research* 5:111-114, 1981.
172. Goode, D.J., Meltzer, H.Y. and Fang, V.S.: Daytime variation in serum prolactin levels in patients receiving oral and depot antipsychotic medication. *Biological Psychiatry* 16:653-662, 1981.
173. Meltzer, H.Y., Busch, D. and Fang, V.S.: Hormone, dopamine receptors and schizophrenia. *Psychoneuroendocrinology* 6:17-36, 1981.
- *174. Meltzer, H.Y., Jackman, H., Arora, R.C., Sahai, S. and Duncavage, M.: Platelet monoamine oxidase activity in schizophrenia. *Psychopharmacology Bulletin* 17:26-28, 1981.
- *175. Metz, J. and Meltzer, H.Y.: Pharmacologic studies of the Hoffman reflex recovery curve in humans. *Psychopharmacology Bulletin* 17:34-35, 1981.
176. Sahai, S., Arora, R.C., Meltzer, H.Y.: Platelet MAO: effect of temperature anticoagulant and centrifugation technique. *Biological Psychiatry* 16:1077-1083, 1981.
177. Nasr, S., Altman, E.G. and Meltzer, H.Y.: Concordance of atopic and affective disorders. *Journal of Affective Disorders* 3:291-296, 1981.
178. Meltzer, H.Y., Arora, R.C., Baber, R. and Tricou, B.J.: Serotonin uptake in blood platelets of psychiatric patients. *Archives of General Psychiatry* 38:1322-1326, 1981.
179. Ross-Stanton, J. and Meltzer, H.Y.: Motor neuron branching patterns in psychotic patients. *Archives of General Psychiatry* 38:1097-1103, 1981.
- *180. Meltzer, H.Y., Busch, D.A., Lee, J., and Papacostas, Y.: Effect of des-tyr- γ -endorphin in schizophrenia. *Psychopharmacology Bulletin* 17:44-47, 1982.

*Non-Peer Reviewed

181. Meltzer, H.Y., Tuetting, P. and Jackman, H.: The effect of lithium on platelet monoamine oxidase activity in bipolar and schizoaffective disorders. *British Journal of Psychiatry* 140:192-198, 1982.
182. Meltzer, H.Y., Busch, D.A., Tricou, B.J. and Robertson, A.: Effect of (des-tyr)- γ -endorphin in schizophrenia. *Psychiatry Research* 6:313-326, 1982.
183. Arora, R.C. and Meltzer, H.Y.: Serotonin uptake by blood platelets of schizophrenic patients. *Psychiatry Research* 6:327-334, 1982.
184. Surgeon, R.D., Fessler, R.G., London, S.F. and Meltzer, H.Y.: Behavioral effects of chronic phencyclidine administration in rats. *Psychopharmacology* 76:52-56, 1982.
185. Meltzer, H.Y., Fang, V.S., Tricou, B.J., Robertson, A. and Song, P.: Effect of dexamethasone on plasma prolactin and corti-sol levels in psychiatric patients. *American Journal of Psychiatry* 139:763-768, 1982.
186. Meltzer, H.Y. and Liberman, R.P.: What is schizophrenia? *Schizophrenia Bulletin* 8:433-435, 1982.
187. Brockington, I.F. and Meltzer, H.Y.: Documenting an episode of psychiatric illness: need for multiple information sources, multiple raters and narrative. *Schizophrenia Bulletin* 8:485-492, 1982.
188. Harrow, M., Grossman, L.S., Silverstein, M. and Meltzer, H.Y.: Thought pathology in manic and schizophrenic patients. *Archives of General Psychiatry* 39:665-671, 1982.
189. Nasr, S.J., Altman, E., Pscheidt, G. and Meltzer, H.Y.: Glucose-6-phosphate dehydrogenase deficiency in a psychiatry population: A preliminary study. *Biological Psychiatry* 17:925-928, 1982.
190. Duncavage, M., Luchins, D.J. and Meltzer, H.Y.: Platelet MAO activity and family history of schizophrenia. *Psychiatry Research* 2:47-51, 1982.
191. Young, M.A., Tanner, M.A. and Meltzer, H.Y.: Operational definitions of schizophrenia. What do they identify? *Journal of Nervous and Mental Disease* 170:443-447, 1982.
192. Meltzer, H.Y., Duncavage, M.B., Jackman, H., Arora, R.C., Tricou, B.J. and Young, M.: Effect of neuroleptic drugs on platelet monoamine oxidase activity in psychiatric patients. *American Journal of Psychiatry* 139: 1242-1247, 1982.
193. Bowers, M.B., Jr., Meltzer, H.Y. and Heninger, G.R.: Correlation of plasma and CSF prolactin with CSF GABA during neuroleptic treatment. *Life Sciences* 31:59-95, 1982.
194. Fang, V.S., Warenica, B. and Meltzer, H.Y.: Dexamethasone suppression test: technique and accuracy. *Archives of General Psychiatry* 39:1217-1218, 1982.
195. Meltzer, H.Y.: Dopamine autoreceptor stimulation: clinical significance. *Pharmacology, Biochemistry and Behavior* 17:1-10, 1982.
196. Arora, R.C. and Meltzer, H.Y.: Serotonin uptake in subpopulations of normal human blood platelets. *Biological Psychiatry* 17:1157-1161, 1982.
197. Maruzas, W., Meltzer, H.Y., Uhlenhuth, E.H. and Glass, R.M.: Plasma dopamine- β -hydroxylase in depressed patients. *Biological Psychiatry* 17:1415-1424, 1982.
198. Robertson, A.G., Berry, R. and Meltzer, H.Y.: Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. *Psychopharmacology* 78:287-292, 1982.
199. Meltzer, H.Y., Pertine, R. and Lewine, R.: Biological studies of DSM-III psychotic disorders. 1. Platelet measures and apomorphine-induced growth hormone response. *Journal of Nervous and Mental Disease* 170:758-763, 1982.
200. Meltzer, H.Y., Simonovic, M., Fang, V.S. and Gudelsky, G.A.: Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover. *Psychopharmacology* 78:49-53, 1982.
201. Brockington, I.F., Ferris, C. and Meltzer, H.Y.: Cycloid psychoses: diagnoses and heuristic value. *Journal of Nervous and Mental Disease* 170:651-656, 1982.
- *202. Robertson, A.G., Tricou, B.J., Fang, V.S. and Meltzer, H.Y.: Biological markers for depressive illness. *Psychopharmacology Bulletin* 18:120-121, 1982.

*Non-Peer Reviewed

203. Brockington, I.F., Altman, E., Hillier, V., Meltzer, H.Y. and Nand, S.: The clinical picture of bipolar affective disorder in its depressed phase. A report from London and Chicago. *British Journal of Psychiatry* 141:558-562, 1982.
204. Metz, J., Holcomb, H.H. and Meltzer, H.Y.: Effect of chlorpromazine on H-reflex recovery curves in normal subjects and schizophrenic patients. *Psychopharmacology* 78:342-345, 1982.
205. Fessler, R.G., Sturgeon, R.D., London, S.F. and Meltzer, H.Y.: Effects of lithium on behavior induced by phencyclidine and amphetamine in rats. *Psychopharmacology* 78:373-376, 1982.
206. Daiguji, M. and Meltzer, H.Y.: Effect of chronic phencyclidine or d-amphetamine treatment on ³H-spiroperidol binding in rat caudate putamen and nucleus accumbens. *European Journal of Pharmacology* 83:339-342, 1982.
207. Meltzer, H.Y. and Luchins, D.J.: Platelet MAO and family history of schizophrenia: method and madness. *Psychiatry Research* 8:83-85, 1983.
208. Meltzer, H.Y., Mikuni, M., Simonovic, M. and Gudelsky, G.A.: Effect of a novel benzamide, YM-09151-2, on rat serum prolactin levels. *Life Sciences* 32:1015-1021, 1983.
209. Meltzer, H.Y., Arora, R.C., Tricou, B.J. and Fang, V.S.: Serotonin uptake in blood platelets and the dexamethasone suppression test in depressed patients. *Psychiatry Research* 8:41-48, 1983.
210. Arora, R.C., Sabai, S. and Meltzer, H.Y.: Correlation between MAO activity in blood platelets obtained by single and multiple centrifugations. *Psychiatry Research* 8:147-151, 1983.
211. Meltzer, H.Y., Simonovic, M. and Gudelsky, G.A.: Effect of yohimbine on rat prolactin secretion. *Journal of Pharmacology and Experimental Therapeutics* 224:21-27, 1983.
212. Ross-Canada, J., Chizzonite, R.A. and Meltzer, H.Y.: Retention of sarcoplasmic calcium inhibits the development of the phencyclidine-restraint experimental myopathy. *Experimental Neurology* 79:1-10, 1983.
213. Meltzer, H.Y. and Fang, V.S.: Cortisol determination and the dexamethasone suppression test: a review. *Archives of General Psychiatry* 40: 501-505, 1983.
214. Arora, R.C., Fessler, R.G. and Meltzer, H.Y.: Effect of lithium carbonate on serotonin uptake in rat blood platelets. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 7:39-45, 1983.
215. Meltzer, H.Y., Simonovic, M. and So, R.: Effects of a series of substituted benzamides on rat prolactin secretion and ³H-spiroperone binding to bovine anterior pituitary membranes. *Life Sciences* 32:2877-2886, 1983.
216. Luchins, D.J., Jackman, H. and Meltzer, H.Y.: Lateral ventricular size and drug-induced parkinsonism. *Psychiatry Research* 9:9-16, 1983.
217. Arora, R.C. and Meltzer, H.Y.: Effects of chlorpromazine on serotonin uptake in blood platelets. *Psychiatry Research* 9:23-28, 1983.
218. Jackman, H., Luchins, D. and Meltzer, H.Y.: Platelet serotonin levels in schizophrenia: relationship to race and psycho-pathology. *Biological Psychiatry* 18:887-902, 1983.
219. Arora, R.C. and Meltzer, H.Y.: Effects of amoxapine on serotonin uptake in human blood platelets of depressed patients and normal controls. *Psychiatry Research* 9:29-36, 1983.
220. Jackman, H.L. and Meltzer, H.Y.: Kinetic constants of platelet monoamine oxidase in schizophrenia. *American Journal of Psychiatry* 140:1044-1048, 1983.
221. Goodnick, P.J. and Meltzer, H.Y.: Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion. *Journal of Clinical Psychopharmacology* 3:239-242, 1983.
222. Brockington, I.F. and Meltzer, H.Y.: The nosology of schizoaffective psychosis. *Psychiatric Developments* 4:317-338, 1983.
223. Meltzer, H.Y., Fleming, R. and Robertson, A.: The effect of buspirone on prolactin and growth hormone secretion in man. *Archives of General Psychiatry* 40:1099-1104, 1983.
224. Lewine, R.J., Fogg, L. and Meltzer, H.Y.: Assessment of negative and positive symptoms in schizophrenia. *Schizophrenia Bulletin* 9:368-376, 1983.

*Non-Peer Reviewed

225. Meltzer, H.Y., Busch, D.A. and Fang, V.S.: Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. *Psychiatry Research* 9:271-284, 1983.
226. Meltzer, H.Y. and Busch, D.: Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. *Psychiatry Research* 9:285-299, 1983.
227. Luchins, D.J. and Meltzer, H.Y.: A blind, controlled study of occipital cerebral asymmetry in schizophrenia. *Psychiatry Research* 10:87-95, 1983.
228. Meltzer, H.Y., Uberkorn-Wiita, B., Robertson, A., Tricou, B.J. and Lowy, M.: Enhanced serum cortisol response to 5-hydroxytryptophan in depression and mania. *Life Sciences* 33:2541-2549, 1983.
229. Meltzer, H.Y., Kolakowska, T., Robertson, A. and Tricou, B.J.: Effect of low dose bromocriptine in the treatment of psychosis: the dopamine autoreceptor stimulation strategy. *Psychopharmacology* 81:37-41, 1983.
230. Mikuni, M., Stoff, D.M. and Meltzer, H.Y.: Effects of combined administration of imipramine and chlorpromazine on β - α_2 -adrenergic receptors in rat cerebral cortex. *European Journal of Pharmacology* 82:313-316, 1983.
231. Meltzer, H.Y., Simonovic, M. and Gudelsky, G.A.: Effects of pirenperone and ketanserin on rat prolactin secretion *in vivo* and *in vitro*. *European Journal of Pharmacology* 92:83-89, 1983.
232. Meltzer, H.Y., Arora, R.C. and Goodnick, P.: Effect of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. *Journal of Affective Disorders* 5:215-221, 1983.
233. Young, M.A., Abrams, R., Taylor, M.A. and Meltzer, H.Y.: Establishing diagnostic criteria for mania. *Journal of Nervous and Mental Disease* 171:676-682, 1983.
234. Simonovic, M. and Meltzer, H.Y.: Biphasic effect of 5-methoxy-N,N-dimethyltryptamine on rat prolactin secretion. *Brain Research* 272:269-275, 1983.
235. Gudelsky, G.A., Passaro, E. and Meltzer, H.Y.: Effect of two dopamine agonists, TL-99 and 3-PPP on prolactin secretion in the rat. *European Journal of Pharmacology* 90:423-425, 1983.
236. Arora, R.C., Tong, C., Jackman, H.J., Stoff, D. and Meltzer, H.Y.: Serotonin uptake and imipramine binding in blood platelets and brain of fawn-hooded and Sprague-Dawley rats. *Life Sciences* 33:437-442, 1983.
237. Mikuni, M. and Meltzer, H.Y.: Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. *Life Sciences* 34:87-92, 1984.
238. Mikuni, M., Gudelsky, G.A., Simonovic, M. and Meltzer, H.Y.: Interaction of (+) and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland. *Life Sciences* 34:239-246, 1984.
239. Meltzer, H.Y.: Schizoaffective disorder: is the news of its nonexistence premature? *Schizophrenia Bulletin* 10:11-12, 1984.
240. Goodnick, P.J. and Meltzer, H.Y.: Treatment of schizoaffective disorders. *Schizophrenia Bulletin* 10:30-48, 1984.
241. Meltzer, H.Y., Arora, R.C. and Metz, J.: Biological studies of schizoaffective disorders. *Schizophrenia Bulletin* 10:49-70, 1984.
242. Meltzer, H.Y., Umberkorn-Wiita, B., Robertson, A., Tricou, B.J., Lowy, M. and Perlman, R.: Effect of 5-hydroxytryptophan on serum cortisol levels in the major affective disorders and normal controls. I. Enhanced response in depression and mania. *Archives of General Psychiatry* 41:366-374, 1984.
243. Meltzer, H.Y., Perlman, R., Tricou, B.J., Lowy, M. and Robertson, A.: Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis and depressive symptoms. *Archives of General Psychiatry* 41:379-387, 1984.
244. Meltzer, H.Y., Lowy, M., Robertson, A., Goodnick, P. and Perlman, R.: Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders: III. Effect of antidepressants and lithium. *Archives of General Psychiatry* 41:391-402, 1984.
245. Grossman, L.S., Harrow, M., Fuydala, J.L. and Meltzer, H.Y.: The longitudinal course of schizoaffective disorders. *Journal of Nervous Mental Disorder* 172:140-149, 1984.
246. Gudelsky, G.A. and Meltzer, H.Y.: Function of tuberoinfundibular dopamine neurons in pargyline and reserpine-treated rats. *Neuroendocrinology* 38:51-55, 1984.

*Non-Peer Reviewed

247. Arora, R.C. and Meltzer, H.Y.: Imipramine binding in the subpopulations of normal human blood platelets. *Biological Psychiatry* 19:257-262, 1984.
248. Simonovic, M., Gudelsky, G.A. and Meltzer, H.Y.: Effect of 8-hydroxy-2-(di-n-propylamino)tetralin on rat prolactin secretion. *Journal of Neural Transmission* 22:143-149, 1984.
249. Meltzer, H.Y. and Luchins, D.J.: Effect of clozapine in severe tardive dyskinesia: A case report. *Journal of Clinical Psychopharmacology* 4:286-287, 1984.
250. Louie, A.K. and Meltzer, H.Y.: Lithium potentiation of antidepressant treatment. *Journal of Clinical Psychopharmacology* 4:316-322, 1984.
251. Burbach, D.J., Lewine, R. and Meltzer, H.Y.: Diagnostic concordance for schizophrenia as a function of sex. *Consulting Psychologist* 52:478-479, 1984. Brief Report.
252. Arora, R.C., Kregel, L. and Meltzer, H.Y.: Circadian rhythm of serotonin uptake in the blood platelets of normal controls. *Biological Psychiatry* 19:1579-1584, 1984.
253. Meltzer, H.Y., Tong, C. and Luchins, D.: Serum dopamine- β -hydroxylase activity and lateral ventricular size in affective disorders and schizophrenia. *Biological Psychiatry* 19:1395-1402, 1984.
254. Moretti, R.J., Hassan, S.Z., Goodman, L.I. and Meltzer, H.Y.: Comparison of ketamine and thiopental in healthy volunteers: effects on mental status, mood and personality. *Anesthesia Analgesics* (Cleve.) 62:1087-1096, 1984.
- *255. Andree, T.H., Mikuni, M. and Meltzer, H.Y.: Effect of subchronic treatment with neuroleptic, imipramine and the combination on serotonin receptor binding in rat cerebral cortex. *Psychopharmacology Bulletin* 20:349-353, 1984.
256. Lowy, M.T., Reder, A.T., Antel, J.P. and Meltzer, H.Y.: Glucocorticoid resistance in depression. DST and lymphocyte sensitivity to dexamethasone. *American Journal of Psychiatry* 141:1365-1370, 1984.
257. Luchins, D.J., Robertson, A.G. and Meltzer, H.Y.: Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia. *Psychiatry Research* 12:149-153, 1984.
258. Meltzer, H.Y., Kolakowska, T., Fang, V.S., Fogg, L., Robertson, A., Lewine, R., Strahilevitz, M. and Busch, D.: Growth hormone and prolactin response to apomorphine in schizophrenia and the affective disorders: relation to duration of illness and depressive symptoms. *Archives of General Psychiatry* 41:572-579, 1984.
259. Meltzer, H.Y., Arora, R.C., Robertson, A., and Lowy, M.: Platelet ^3H -imipramine binding and platelet 5-HT uptake in affective disorders and schizophrenia. *Clinical Neuropharmacology* 7:320-324, 1984.
260. Luchins, D.J., Lewine, R.J. and Meltzer, H.Y.: Lateral ventricular size, psychopathology, and medication response in the psychoses. *Biological Psychiatry* 19:29-44, 1984.
261. Meltzer, H.Y., Simonovic, M. and Gudelsky, G.A.: Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine. *European Journal of Pharmacology* 110:143-146, 1985.
262. Gudelsky, G.A., Koenig, J.I. and Meltzer, H.Y.: Altered responses to serotonergic agents in Fawn-hooded rats. *Pharmacology, Biochemistry and Behavior* 22:489-492, 1985.
263. Roos, R.P., Davis, K. and Meltzer, H.Y.: Immunoglobulin studies in patients with psychiatric diseases. *Archives General Psychiatry* 42:124-128, 1985.
264. Arora, R.C., Wunnicke, V. and Meltzer, H.Y.: Effect of protein concentration on kinetic constants (K_d and B_{max}) of ^3H -imipramine binding in blood platelets. *Biological Psychiatry* 20:116-119, 1985.
265. Gormley, G.J., Lowy, M.T., Reder, A.T., Hospelhom, V.D., Antel, J.P. and Meltzer, H.Y.: Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test. *American Journal of Psychiatry* 142:1278-1284, 1985.
- *266. Cohn, J.B., Wilcox, C.S. and Meltzer, H.Y.: Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. *American Journal of Medicine* 80:(Suppl. 3B), pp 36-40, 1986.
267. Koenig, J.I., Meltzer, H.Y., DeVane, G.D. and Gudelsky, G.A.: The concentration of arginine vasopressin in the pituitary stalk plasma of the rat after adrenalectomy or morphine. *Endocrinology* 118:2534-2539, 1986.

*Non-Peer Reviewed

268. Gudelsky, G.A., Passaro, E. and Meltzer, H.Y.: Delayed activation of tuberoinfundibular dopamine neurons and suppression of prolactin secretion in the rat after morphine administration. *Journal of Pharmacology and Experimental Therapeutics* 236:641-646, 1986.
269. Andree, T.H., Mikuni, M., Tong, C.Y., Koenig, J.I. and Meltzer, H.Y.: Differential effect of subchronic treatment with various neuroleptic agents on serotonin receptors in rat cerebral cortex. *Journal of Neurochemistry* 46:191-197, 1986.
270. Luchins, D.J. and Meltzer, H.Y.: A comparison on CT findings in acute and chronic ward schizophrenics. *Psychiatry Research* 17:7-14, 1986.
271. Arora, R.C. and Meltzer, H.Y.: Effect of adrenalectomy and corticosterone on ³H-imipramine binding in rat blood platelets and brain. *European Journal of Pharmacology* 123:415-419, 1986.
272. Harrow, M., Grossman, L.S., Silverstein, M.L., Meltzer, H.Y. and Kennering, M.L.: A longitudinal study of thought disorder in manic patients. *Archives of General Psychiatry* 43:781-785, 1986.
273. Arora, R.C. and Meltzer, H.Y.: Effect of subchronic treatment with imipramine, chlorpromazine and the combination on ³H-imipramine binding in rat blood platelets and frontal cortex. *Life Sciences* 32:2289-2296, 1986.
274. Arora, R.C., Locascio, J.J. and Meltzer, H.Y.: ³H-imipramine binding in blood platelets of schizophrenic patients. *Psychiatry Research* 19:215-224, 1986.
275. Meltzer, H.Y.: Novel approaches to the pharmacotherapy of schizophrenia. *Drug Development Research* 2:23-40, 1986.
276. Koenig, J.I., Meltzer, H.Y. and Gudelsky, G.A.: Morphine or capsaicin administration alters the secretion of β -endorphin into the hypophyseal portal vasculature of the rat. *Neuroendocrinology* 43:611-617, 1986.
277. Meltzer, H.Y., Sommers, A.A. and Luchins, D.J.: The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. *Journal Clinical Psychopharmacology* 6:329-338, 1986.
278. Gudelsky, G.A., Koenig, J.I., Jackman, H. and Meltzer, H.Y.: Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat: evidence for opposing roles of 5-HT₂ and 5-HT_{1A} receptors. *Neuropharmacology* 25:1307-1313, 1986.
279. Meltzer, H.Y., Nash, J.F., Koenig, J.I. and Gudelsky, G.A.: Clozapine: Neuroendocrine studies of an atypical neuroleptic. *Clinical Neuropharmacology* 2(Suppl. 4):316-318, 1986.
280. Gudelsky, G.A., Koenig, J.I., Jackman, H. and Meltzer, H.Y.: Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. *Psychopharmacology* 90:403-407, 1986.
281. Locascio, J.J., Lee, J.-C. and Meltzer, H.Y.: The importance of adjusting for correlated concomitant variables. *Psychiatry Research* 23:311-327, 1986.
282. Kovama, T., Lowy, M.T. and Meltzer, H.Y.: 5-hydroxytryptophan-induced cortisol response and CSF 5-HIAA. *American Journal of Psychiatry* 144:334-337, 1987.
283. Arora, R.C., Kuncel, R.W., Morgan, J., Cohen, L. and Meltzer, H.Y.: Serotonin uptake in blood platelets of Duchenne muscular dystrophy (DMD) patients. *Muscle and Nerve* 10:359-362, 1987.
284. Gudelsky, G.A., Koenig, J.I., Simonovic, M., Kovama, T., Ohnori, T. and Meltzer, H.Y.: Differential effects of haloperidol, clozapine and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. *Journal of Neural Transmission* 68:227-240, 1987.
285. Koenig, J.I., Gudelsky, G.A. and Meltzer, H.Y.: Stimulation of corticosterone and β -endorphin secretion by selective 5-HT receptor subtype activation. *European Journal of Pharmacology* 137:1-8, 1987.
286. Meltzer, H.Y.: Biological studies in schizophrenia. *Schizophrenia Bulletin* 13:77-111, 1987.
287. Meltzer, H.Y. and Zureick, J.L.: Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: sex and race interactions. *Psychiatry Research* 22:99-109, 1987.
288. Gudelsky, G.A., Koenig, J.I. and Meltzer, H.Y.: Selective desensitization of serotonin (5-HT) receptor-mediated hyperthermia by mianserin and other 5-HT antagonists. *Neuropharmacology* 26:707-712, 1987.

*Non-Peer Reviewed

289. Reder, A.T., Lowy, M.T., Meltzer, H.Y. and Antel, J.P.: Dexamethasone suppression test abnormalities in patients with multiple sclerosis: Relation to ACTH therapy. *Neurology* 27:849-853, 1987.
290. Passaro, E., Meltzer, H.Y. and Gudelsky, G.A.: Effects of acute and chronic dexamethasone treatment on stimulated prolactin secretion in the rat. *Endocrine Research* 12:173-182, 1987.
- *291. Gudelsky, G.A., Nash, J.F., Koenig, J.I. and Meltzer, H.Y.: Neuroendocrine effects of typical and atypical antipsychotics in the rat. *Psychopharmacology Bulletin* 23:483-486, 1987.
292. Lowy, M.T. and Meltzer, H.Y.: Dexamethasone bioavailability: Implications for DST research. *Biological Psychiatry* 22:373-385, 1987.
293. Kettering, R.L., Harrow, M., Grossman, L. and Meltzer, H.Y.: The prognostic relevance of delusions in depression: A follow-up study. *American Journal of Psychiatry* 144(9):1154-1160, 1987.
294. Gudelsky, G.A., Koenig, J.I., Kovama, T. and Meltzer, H.Y.: Activity of tuberoinfundibular dopaminergic neurons and concentrations of serum prolactin in the rat following lithium administration. *Psychopharmacology* 94:92-96, 1988.
295. Arora, R.C. and Meltzer, H.Y.: Effect of desipramine treatment on ³H-imipramine binding in the blood platelets of depressed patients. *Biological Psychiatry* 23:397-404, 1988.
296. Breslau, N. and Meltzer, H.Y.: The validity of subtyping psychotic depression: an examination of phenomenology and demographic characteristics. *American Journal of Psychiatry* 145:35-40, 1988.
297. Metz, J.T., Holcomb, H.H. and Meltzer, H.Y.: Effect of 5-hydroxytryptophan on H-reflex recovery curves in normal subjects and patients with affective disorders. *Biological Psychiatry* 23:602-611, 1988.
298. Zureick, J.L. and Meltzer, H.Y.: Platelet MAO activity in hallucinating and paranoid schizophrenics. A review and meta-analysis. *Biological Psychiatry* 24:63-78, 1988.
299. Arora, R.C. and Meltzer, H.Y.: Seasonal variation of imipramine binding in the blood platelets of normal controls and depressed patients. *Biological Psychiatry* 23:217-226, 1988.
300. Lowy, M.T. and Meltzer, H.Y.: Stimulation of serum cortisol and prolactin in humans by MK-212, a centrally active serotonin agonist. *Biological Psychiatry* 23:818-828, 1988.
301. Meltzer, H.Y., Lowy, M.T. and Locascio, J.J.: Platelet MAO activity and the cortisol response to dexamethasone in major depression. *Biological Psychiatry* 24:129-142, 1988.
302. Koenig, J.I., Meltzer, H.Y. and Gudelsky, G.A.: 5-Hydroxytryptamine_{1A} receptor-mediated effects of buspirone, gepirone and ipsapirone. *Pharmacology, Biochemistry and Behavior* 29:711-715, 1988.
303. Nash, J.F., Jr., Meltzer, H.Y., Gudelsky, G.A.: Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. *Journal of Pharmacology and Experimental Therapeutics* 245:873-879, 1988.
304. Meltzer, H.Y. and Arora, R.C.: Genetic control of serotonin uptake in blood platelets: A twin study. *Psychiatry Research* 24:263-269, 1988.
305. Nash, J.F., Jr., Meltzer, H.Y., Gudelsky, G.A.: Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. *European Journal of Pharmacology* 151:463-469, 1988.
306. Barchas, J.D., Hadley, S.W., Detre, T., Endicott, J., Glover, R., King, R., Meltzer, H.Y., Sackheim, H., Strauss, J.S., Wahl, P. and Williams, D.: A national plan for schizophrenia research: Panel recommendations: Research resources. *Schizophrenia Bulletin* 14:439-461, 1988.
307. Meltzer, H.Y.: New insights into schizophrenia through atypical antipsychotic drugs. Comments on "The current status of the dopamine hypothesis of schizophrenia". *Neuropsychopharmacology* 3:193-196, 1988.
308. Lowy, M.T., Reder, A.T., Antel, J.D. and Meltzer, H.Y.: Comparison of *in vivo* and *in vitro* glucocorticoid sensitivity in depression: Relationship to the DST. *Biological Psychiatry* 24:619-630, 1988.
309. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y. and the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. *Archives of General Psychiatry* 45:789-796, 1988.

*Non-Peer Reviewed

310. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y. and the Clozaril Collaborative Study Group: Clozapine for the treatment- resistant schizophrenic: A double-blind comparison with chlorpromazine. *Psychopharmacology* 99:S60-S63, 1989.
311. Arora, R.C. and Meltzer, H.Y.: Increased serotonin (5-HT₂) receptor binding as measured by ³H-lysergic acid diethylamide (³H-LSD) in the blood platelets of depressed patients. *Life Sciences* 44:725-734, 1989.
312. Gudelsky, G.A. and Meltzer, H.Y.: Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. *Neuropsychopharmacology* 2:No.1:45-51, 1989.
313. Lowy, M.T., Nash, Jr., J.F. and Meltzer, H.Y.: Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA). *European Journal of Pharmacology* 163:157-161, 1989.
314. Nash, Jr., J.F. and Meltzer, H.Y.: Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat. *Journal of Pharmacology and Experimental Therapeutics* 249:236-241, 1989.
315. Vrtunski, P.B., Simpson, D.M. and Meltzer, H.Y.: Voluntary movement dysfunction in schizophrenics. *Biological Psychiatry* 24:529-539, 1989.
316. Arora, R.C. and Meltzer, H.Y.: Serotonergic measures in suicide brain - III: Increased 5-HT₂ binding sites in frontal cortex suicide victims. *American Journal of Psychiatry* 146:730-736, 1989.
317. Gudelsky, G.A., Berry, S.A. and Meltzer, H.Y.: Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat. *Neuroendocrinology* 42:604-609, 1989.
318. Matsubara, S. and Meltzer, H.Y.: Effect of typical and atypical antipsychotic drugs on 5-HT₂ receptor density in rat cerebral cortex. *Life Sciences* 45:1397-1406, 1989.
319. Meltzer, H.Y., Bastani, B., Ramirez, L.F. and Matsubara, S.: Clozapine: New research on efficacy and mechanism of action. *European Archives of Psychiatry and Neurological Science* 238:332-339, 1989.
320. Gudelsky, G.A., Nash, J.F., Berry, S.A. and Meltzer, H.Y.: Basic biology of clozapine: Electrophysiological and neuroendocrinological studies. *Psychopharmacology* 99:S13-S17, 1989.
321. Meltzer, H.Y., Matsubara, S. and Lee, J.-C.: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin, pKi values. *Journal of Pharmacology and Experimental Therapeutics* 251:238-246, 1989.
322. Meltzer, H.Y.: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. *Psychopharmacology* 99:S18-S27, 1989.
323. Meltzer, H.Y., Bastani, B., Kwon, K.Y., Ramirez, L.F., Burnett, S. and Sharpe, J.: A prospective study of clozapine in treatment-resistant patients: I: Preliminary report. *Psychopharmacology* 99(Suppl.):S68-S72, 1989.
- *324. Bastani, B., Alphs, L.D. and Meltzer, H.Y.: Development of the clozaril patient management system. *Psychopharmacology* 99(Suppl.):S122-S125, 1989.
325. Nash, J.F., Meltzer, H.Y. and Gudelsky, G.A.: Selective cross-tolerance to 5-HT_{1A} and 5-HT₂ receptor-mediated temperature and corticosterone responses. *Pharmacology, Biochemistry and Behavior* 33:781-785, 1989.
326. Helmuth, D., Ljaljevic, Z., Ramirez, L.F. and Meltzer, H.Y.: Choreoathetosis induced by verapamil and lithium treatment. *Journal of Clinical Psychopharmacology* 9:454-455, 1989.
- *327. Meltzer, H.Y., Matsubara, S. and Lee, J.-C.: The ratios of serotonin and dopamine, affinities differentiate atypical and typical antipsychotic drugs. *Psychopharmacology Bulletin* 25:No.3:390-392, 1989.
- *328. Gudelsky, G.A., Berry, S.A. and Meltzer, H.Y.: The mechanisms of action of atypical and novel antipsychotic drugs: actions of typical and atypical antipsychotics on tuberoinfundibular dopamine neurons. *Psychopharmacology Bulletin* 25:377-382, 1989.
329. Meltzer, H.Y.: Serotonergic dysfunction in depression. *British Journal of Psychiatry* 155(Suppl. 8):24-31, 1989.
330. Arora, R.C. and Meltzer, H.Y.: [³H]-Imipramine binding in the frontal cortex of suicides. *Psychiatry Research* 30:125-135, 1989.
- *331. Meltzer, H.Y., Koenig, J.L., Nash, J.F. and Gudelsky, G.A.: Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. G. Sedvall (ed), *Acta Psychiatrica Scandinavica*, 5 352, 80:24-26, 1989.

*Non-Peer Reviewed

332. Ichikawa, J. and Meltzer, H.Y.: The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by *in vivo* microdialysis. *European Journal of Pharmacology* **176**:371-374, 1990.
333. Lowy, M.T., Nash, J.F., and Meltzer, H.Y.: Reserpine-induced DST nonsuppression in rats. *Biological Psychiatry* **27**:546-548, 1990.
334. Ichikawa, J.I. and Meltzer, H.Y.: Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment. *Brain Research* **507**:138-142, 1990.
335. Nash, J.F., Meltzer, H.Y. and Gudelesky, G.A.: Effect of 3,4-methylenedioxymethamphetamine on 3,4-di-hydroxyphenyl-L-tyrosine in the striatum and nucleus accumbens. *Journal of Neurochemistry* **54**:1062-1067, 1990.
336. Harrow, M., Goldberg, J.F., Grossman, L.S. and Meltzer, H.Y.: Outcome in manic disorders: A naturalistic followup study. *Archives of General Psychiatry* **47**:665-671, 1990.
337. Meltzer, H.Y., Burnett, S., Bastani, B. and Ramirez, L.F.: Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. *Hospital and Community Psychiatry* **41**:892-897, 1990.
338. Arora, R.C. and Meltzer, H.Y.: [³H]-Imipramine binding in the blood platelets of normal twins. *Psychiatry Research* **32**:265-273, 1990.
339. Lee, M.A., Bowers, M.B., Nash, J.F., Meltzer, H.Y.: Neuroendocrine measures of dopaminergic function in chronic cocaine users. *Psychiatry Research* **33**:151-159, 1990.
340. Bastani, B., Nash, J.F. and Meltzer, H.Y.: Prolactin and cortisol responses to MK-212, a 5-HT agonist in OCD. *Archives of General Psychiatry* **47**:833-839, 1990.
341. Nerozzi, D., Magnani, A., Sforza, V., Scaramucci, E., Cerilli, M., Moretti, C., Frajese, G., Antonozzi, I. and Meltzer, H.Y.: Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. *Psychiatry Research* **34**:139-147, 1990.
- *342. Meltzer, H.Y.: The role of serotonin in the action of atypical antipsychotic drugs. *Psychiatric Annals* **20**:571-579, 1990.
343. Meltzer, H.Y.: Commentary: Defining treatment refractoriness in schizophrenia. *Schizophrenia Bulletin* **16**:563-565, 1990.
344. Parsa, M.A., Rohr, T., Ramirez, L.F. and Meltzer, H.Y.: Neuroleptic malignant-like syndrome, without neuroleptics. *Journal of Clinical Psychopharmacology* **10**:437-438, 1990.
345. Stockmeier, C.A. and Meltzer, H.Y.: β -adrenergic receptor binding in frontal cortex of suicide victims. *Biological Psychiatry* **29**:183-191, 1991.
346. Ichikawa, J. and Meltzer, H.Y.: Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. *Journal of Pharmacology and Experimental Therapeutics* **256**:348-357, 1991.
347. Lee, M.A., Nash, J.F., Barnes, M. and Meltzer, H.Y.: Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. *Psychopharmacology* **103**:258-264, 1991.
348. Meltzer, H.Y.: Atypical antipsychotic drugs and the negative symptoms of schizophrenia. *Korean Journal of Psychopharmacology* **2**:11-19, 1991.
- *349. Meltzer, H.Y.: Beyond serotonin. *Journal of Clinical Psychiatry* **52**:65-69, 1991.
350. Vrnuski, P.B., Alphas, L.D. and Meltzer, H.Y.: Isometric force control in schizophrenics with tardive dyskinesia. *Psychiatry Research* **37**:57-72, 1991.
351. Bastani, B., Arora, R.C. and Meltzer, H.Y.: Serotonin uptake and imipramine binding in the blood platelets of OCD patients. *Biological Psychiatry* **30**:131-139, 1991.
352. Arora, R.C., Emery, O.B. and Meltzer, H.Y.: Serotonin uptake and ³H-imipramine binding in the blood platelets of Alzheimer's disease patients. *Neurology* **41**:1307-1309, 1991.
353. Arora, R.C. and Meltzer, H.Y.: Laterality and ³H-imipramine binding: Studies in the frontal cortex of normal controls and suicide victims. *Biological Psychiatry* **29**:1016-1022, 1991.
354. Meltzer, H.Y.: The mechanism of action of novel antipsychotic drugs. *Schizophrenia Bulletin* **17**:263-287, 1991.

*Non-Peer Reviewed

355. Friedman, L., Knutson, L., Shurell, M. and Meltzer, H.Y.: Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenic patients. *Biological Psychiatry* 29:865-877, 1991.
356. Abel, L.A., Friedman, L., Jesberger, J., Malki, A. and Meltzer, H.Y.: Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders. *Biological Psychiatry* 29:1063-1072, 1991.
357. Markovitz, P.J., Calabrese, J.R., Schulz, S.C. and Meltzer, H.Y.: Fluoxetine in borderline and schizotypal personality disorder. *American Journal of Psychiatry* 148:1064-1067, 1991.
358. Nash, J.F., Arora, R.C., Schreiber, M. and Meltzer, H.Y.: Effect of 3,4-methylenedioxymethamphetamine on [³H]paroxetine binding in the frontal cortex and blood platelets of rats. *Biochemical Pharmacology* 41:79-84, 1991.
359. Arora, R.C. and Meltzer, H.Y.: Serotonin, (5-HT₂) receptor binding in the frontal cortex of schizophrenic patients. *Journal of Neural Transmission* 85:19-29, 1991.
- *360. Meltzer, H.Y.: The neurobiology of schizophrenia. *Current Opinion in Psychiatry* 4:90-95, 1991.
361. Kenny, J.T. and Meltzer, H.Y.: Attention and higher cortical functions in schizophrenia. *The Journal of Neuropsychiatry and Clinical Neurosciences* 3:269-275, 1991.
362. Matsubara, S., Arora, R.C. and Meltzer, H.Y.: Serotonergic measures in suicide brain: 5-HT_{1A} binding sites in frontal cortex of suicide victims. *Journal of Neural Transmission* 85:181-194, 1991.
363. Lee, H.S. and Meltzer, H.Y.: Buspirone does not produce a 5-HT_{1A}-mediated decrease in temperature in man. *Journal of Neural Transmission* 86:71-76, 1991.
- *364. Meltzer, H.Y.: Recovery from schizophrenia: New advances in pharmacological treatments. *The Human Mind, Dolentium Hominum* 16:139-143, 1991.
365. Lee, M.A. and Meltzer, H.Y.: Neuroendocrine responses to serotonin agonists in alcoholics. *Biological Psychiatry* 30:1017-1030, 1991.
366. Meltzer, H.Y.: Summary: The significance of serotonin for neuropsychiatric disorders. *Journal of Clinical Psychiatry* 52:70-72, 1991.
367. Meltzer, H.Y. and Nash, J.F.: VII. Effects of antipsychotic drugs on serotonin receptors. *Pharmacological Reviews* 43:587-604, 1991.
368. Brockington, I., Roper, A., Buckley, M., Copas, J., Andrade, C., Wigg, P., Farmer, A., Kaufman, C., Hawley, R. and Meltzer, H.Y.: Bipolar disorder, cycloid psychosis and schizophrenia: A study using "lifetime" psychopathology ratings. factor analysis and canonical variate analysis. *European Psychiatry* 6:223-236, 1991.
369. Friedman, L., Jesberger, J.A. and Meltzer, H.Y.: A model of smooth pursuit performance illustrates the relationship between gain, catch-up saccade rate, and catch-up saccade amplitude in normal controls and patients with schizophrenia. *Biological Psychiatry* 30:537-556, 1991.
370. Ambrosini, P.J., Metz, C., Arora, R.C., Lee, J.-C., Kregel, L., Meltzer, H.Y.: Platelet imipramine binding in depressed children and adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry*, 1992.
371. Lee, H.S., Bastani, B., Friedman, L., Ramirez, L. and Meltzer, H.Y.: Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. *Biological Psychiatry* 31:460-470, 1992.
372. Mikuni, M., Kagaya, A., Takahashi, K. and Meltzer, H.Y.: Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. *Psychopharmacology* 106:331-314, 1992.
373. Friedman, L., Jesberger, J.A. and Meltzer, H.Y.: Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. *Psychiatry Research* 41:25-36, 1992.
374. Roth, B.L., Ciaranello, R.D. and Meltzer, H.Y.: Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT_{1C} receptors. *Journal of Pharmacology and Experimental Therapeutics* 260:1361-1378, 1992.
375. Ichikawa, J. and Meltzer, H.Y.: The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release *in vivo*. *Brain Research* 574:98-104, 1992.
376. Ichikawa, J. and Meltzer, H.Y.: Amperozide, a novel antipsychotic drug, inhibits the ability of *d*-amphetamine to increase dopamine release *in vivo* in rat striatum and nucleus accumbens. *Journal of Neurochemistry* 58:2285-2291, 1992.

*Non-Peer Reviewed

377. Friedman, L., Jesberger, J.A., Abel, L.A. and Meltzer, H.Y.: Catch-up saccade amplitude is related to square wave jerk rate. *Investigative Ophthalmology & Visual Science* 33:228-233, 1992.
378. Meltzer, H.Y., Zhang, Y. and Stockmeier, C.A.: Effect of amperozide on rat cortical 5-HT₂ and striatal and limbic dopa-mine D₂ receptor occupancy: implications for antipsychotic action. *European Journal of Pharmacology* 216:67-71, 1992.
379. Gerson, S.L. and Meltzer, H.Y.: Mechanisms of clozapine-induced agranulocytosis. *Drug Safety* 7:17-25, 1992.
- *380. Meltzer, H.Y.: The importance of serotonin-dopamine interactions in the action of clozapine. *British Journal of Psychiatry* 160(Suppl. 17):22-29, 1992.
381. Meltzer, H.Y.: Dimensions of outcome with clozapine. *British Journal of Psychiatry* 160(Suppl. 17):46-53, 1992.
382. Meltzer, H.Y.: Discussion. *British Journal of Psychiatry* 160(Suppl. 17):60-64, 1992.
383. Friedman, L., Abel, L.A., Jesberger, J.A., Malki, A. and Meltzer, H.Y.: Saccadic intrusions into smooth pursuit in patients with schizophrenia or affective disorder, and normal controls. *Biological Psychiatry* 31:1110-1118, 1992.
384. Friedman, L., Abel, L.A., Jesberger, J.A., Malki, A., Brar, R., Meltzer, H.Y.: A methodology for the assessment of smooth pursuit dysfunction. *International Journal of Methods in Psychiatric Research* 2:209-216, 1992.
385. Chai, B.L. and Meltzer, H.Y.: The effect of chronic clozapine on basal dopamine release and apomorphine-induced DA release in the striatum and nucleus accumbens as measured by *in vivo* brain microdialysis. *Neuroscience Letters* 136:47-50, 1992.
386. Meltzer, H.Y.: Treatment of the neuroleptic non-responsive schizophrenic patient. *Schizophrenia Bulletin* 18:515-542, 1992.
387. Ohmori, T., Arora, R.C. and Meltzer, H.Y.: Serotonergic measures in suicide brain: The concentration of 5-HIAA, HVA and tryptophan in frontal cortex of suicide victims. *Biological Psychiatry* 32:57-71, 1992.
388. Yamamoto, B.K. and Meltzer, H.Y.: The effect of the atypical antipsychotic drug, amperozide on carrier-mediated striatal dopamine release measured *in vivo*. *Journal of Pharmacology and Experimental Therapeutics* 263:180-185, 1992.
389. Nerozzi, D., Magnani, A., Dastoli, C., Ferri, E., Capescioiti, G., Antonozzi, I., Frajese, G. and Meltzer, H.Y.: Prolactin responses to domperidone in chronic schizophrenia. *Psychiatry Research* 42:159-169, 1992.
390. Brockington, I.F., Roper, A., Meltzer, H.Y., Altman, E. and Berry, R.: Multiple raters. *International Journal of Methods in Psychiatric Research* 2:187-190, 1992.
391. Arora, R.C. and Meltzer, H.Y.: Serotonin (5-HT₂) receptor binding in blood platelets of schizophrenic patients. *Psychiatry Research* 47:111-119, 1993.
392. Hasegawa, M., Gutierrez-Esteirou, R., Way, L. and Meltzer, H.Y.: Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. *Journal of Clinical Psychopharmacology* 13:383-390, 1993.
393. Thompson, P.A. and Meltzer, H.Y.: Positive, negative and disorganisation factors from the Schedule of Affective Disorders and Schizophrenia and the Present State Examination. A three-factor solution. *British Journal of Psychiatry* 163:111-119, 1993.
394. Meltzer, H.Y., Maes, M. and Lee, M.A.: The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. *Psychopharmacology* 112:S95-S104, 1993.
- *395. Meltzer, H.Y.: Pharmacological treatment of schizophrenia. *Triangle* 32:33-37, 1993.
- *396. Meltzer, H.Y.: Serotonin-dopamine interactions and atypical antipsychotic drugs. *Psychiatric Annals* 23:193-200, 1993.
- *397. Meltzer, H.Y.: Paroxetine: A safe and effective once-daily oral antidepressant agent. *Hospital Formulary* 28(Suppl. 3):4-13, 1993.
398. Parsa, M.A., Simon, M., Dubrow, C., Ramirez, L.F. and Meltzer, H.Y.: Psychiatric manifestations of olivoponto-cerebellar atrophy and treatment with clozapine. *International Journal of Psychiatry in Medicine* 23:149-156, 1993.
399. Meltzer, H.Y., Cola, P., Way, L., Thompson, P.A., Bastani, B., Davies, M.A. and Snitz, B.: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. *American Journal of Psychiatry* 150:1630-1638, 1993.
400. Pehek, E.A., Meltzer, H.Y., and Yamamoto, B.K.: The atypical drug amperozide enhances rat cortical and striatal dopamine efflux. *European Journal of Pharmacology* 240:107-109, 1993.

*Non-Peer Reviewed

401. Stockmeier, C.A., DiCarlo, J.J., Zhang, Y., Thompson, P. and Meltzer, H.Y.: Characterization of typical and atypical antipsychotic drugs based on *in vivo* occupancy of serotonin₂ and dopamine₂ receptors. *Journal of Pharmacology and Experimental Therapeutics* 266:1374-1384, 1995.
402. Hagger, C., Buckley, P., Kenny, J.T., Friedman, L., Ubogy, D. and Meltzer, H.Y.: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. *Biological Psychiatry* 34:702-712, 1993.
403. Maes, M., Cosyns, P., Meltzer, H.Y., DeMeyer, F. and Peeters, D.: Seasonality in violent suicide but not in nonviolent suicide or homicide. *American Journal of Psychiatry* 150:1380-1385, 1993.
404. Vrnuski P.B., Lewis, K. and Meltzer, H.Y.: Visual feedback in force control of schizophrenics. *Biological Psychiatry* 34:667-670, 1993.
405. Maes, M., Meltzer, H.Y., Scharpé, S., Cooreman, W., Uytendaele, W., Suy, E., Vandervorst, C., Raus, J. and Cosyns, P.: Psychomotor retardation, anorexia, weight loss, sleep disturbances and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. *Psychiatry Research* 47:229-241, 1993.
406. Sajatovic, M. and Meltzer, H.Y.: The effect of short-term electroconvulsive treatment plus neuroleptic in treatment-resistant schizophrenia and schizoaffective disorder. *Convulsive Therapy* 2:167-175, 1993.
407. Maes, M., Scharpé, S., Meltzer, H.Y., Uytendaele, W., Calabrese, J., Stevens, W. and Cosyns, P.: Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. *Biological Psychiatry* 34:690-701, 1993.
408. Maes, M., Meltzer, H.Y., Scharpé, S., Bosmans, E., Suy, E., De Meester, I., Calabrese, J. and Cosyns, P.: Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. *Psychiatric Research* 49:151-165, 1993.
409. Lai, S., Hopkins, A., Haacke, E.M., Li, D., Wasserman, B.A., Buckley, P., Friedman, L., Meltzer, H.Y., Hedera, P. and Friedland, B.: Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: Preliminary results. *Magnetic Resonance in Medicine* 30:387-392, 1993.
410. Maes, M., Meltzer, H.Y., Jacobs, J., Suy, E., Calabrese, J., Minner, B. and Raus, J.: Autoimmunity in depression: increase antiphospholipid autoantibodies. *Acta Psychiatrica Scandinavica* (Munksgaard) 87:160-166, 1993.
411. Buckley, P., Thompson, P., Way, L. and Meltzer, H.Y.: Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. *American Journal of Psychiatry* 151:385-389, 1994.
412. Maes, M., Calabrese, J. and Meltzer, H.Y.: The relevance of the in- versus outpatient status for studies on HPA axis in depression: Spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression *per se*. *Progress in Psychopharmacology and Biological Psychiatry* 18:503-517, 1994.
413. Meltzer, H.Y., Chai, B.L., Thompson, P.A. and Yamamoto, B.K.: Effect of scopolamine on the efflux of dopamine and its metabolites following clozapine, haloperidol or thioridazine. *Journal of Pharmacology and Experimental Therapeutics* 268:1452-1461, 1994.
414. Maes, M., Delanghe, J., Scharpé, S., Meltzer, H.Y., Cosyns, P., Suy, E. and Bosmans, E.: Haptoglobin phenotypes and gene frequencies in unipolar major depression. *American Journal of Psychiatry* 151:112-116, 1994.
415. Maes, M., Meltzer, H.Y., Martin, M., Suy, E., Blockx, P. and Cosyns, P.: An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: ratio of a large scaled and controlled study. *Psychoneuroendocrinology* 18:607-620, 1994.
416. Gerson, S.L., Acre, C. and Meltzer, H.Y.: *n*-Desmethyleclozapine: a clozapine metabolite that suppresses haemopoiesis. *British Journal of Haematology* 86:555-561, 1994.
417. Maes, M., Goossens, F., Scharpé, S., Meltzer, H.Y., D'Hondt, P. and Cosyns, P.: Lower serum prolidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. *Biological Psychiatry* 35:545-552, 1994.
418. Maes, M., Lee, Y., Calabrese, J. and Meltzer, H.Y.: Effects of ageing on spontaneous cortisolaemia of normal men and depressed patients. *Psychoneuroendocrinology* 19:79-84, 1994.
419. Roth, B.L., Craig, S.C., Choudhary, M.S., Uler, A., Monsma, F.J., Shen, Y., Meltzer, H.Y. and Sibley, D.R.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine₂ (5-HT₂) and 5-hydroxytryptamine₁ (5-HT₁) receptors. *Journal of Pharmacology and Experimental Therapeutics* 268:1406-1410, 1994.

*Non-Peer Reviewed

420. Meltzer, H.Y. and Maes, M.: Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. *Biological Psychiatry* 35:316-323, 1994.
421. Maes, M., Meltzer, H.Y., Stevens, W., Cosyns, P. and Blockx, P.: Multiple reciprocal relationships between *in vivo* cellular immunity and hypothalamic-pituitary-adrenal axis in depression. *Psychological Medicine* 24:167-177, 1994.
422. Arora, R.C. and Meltzer, H.Y.: Effect of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients. *Neuropsychopharmacology* 10:109-114, 1994.
423. Meltzer, H.Y. and Maes, M.: Effects of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. *Psychopharmacology* 114:635-643, 1994.
424. Thompson, P.A., Maes, M. and Meltzer, H.Y.: Effect of placebo control condition in neuroendocrine challenge studies. *Psychiatry Research* 52:317-326, 1994.
425. Hasegawa, M., Cola, P.A. and Meltzer, H.Y.: Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulo-cytosis. *Neuropsychopharmacology* 11:45-47, 1994.
426. Sajovic, M., Ramirez, L.F., Kenny, J.T. and Meltzer, H.Y.: The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. *Comprehensive Psychiatry* 35:29-33, 1994.
427. Friedman, L., Jesberger, J.A. and Meltzer, H.Y.: The effects of apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and placebo on smooth pursuit gain and corrective saccades in normal subjects. *Neuropsychopharmacology* 11:49-62, 1994.
428. Lee, M.A. and Meltzer, H.Y.: Blunted oral body temperature response to MK-212 in cocaine addicts. *Drug and Alcohol Dependence* 35:217-222, 1994.
429. Thompson, P.A., Buckley, P.F. and Meltzer, H.Y.: The Brief Psychiatric Rating Scale: effect of scaling system on clinical response assessment. *Journal of Clinical Psychopharmacology* 14:344-346, 1994.
- *430. Kimmel, S.E., Calabrese, J.R., Woyshtville, M.J. and Meltzer, H.Y.: Clozapine in treatment-refractory mood disorders. *Journal of Clinical Psychiatry* 55(Supplement B):91-93, 1994.
- *431. Yamamoto, B.K., Pehek, E.A. and Meltzer, H.Y.: Brain region effects of clozapine on amino acid and monoamine transmission. *Journal of Clinical Psychiatry* 55(Supplement B):8-14, 1994.
- *432. Lee, M.A., Thompson, P. and Meltzer, H.Y.: Effects of clozapine on cognitive function in schizophrenia. *Journal of Clinical Psychiatry* 55(Supplement B):82-87, 1994.
- *433. Meltzer, H.Y.: An overview of the mechanism of action of clozapine. *Journal of Clinical Psychiatry* 55(Supplement B):47-52, 1994.
- *434. Buckley, P., Thompson, P.A., Way, L. and Meltzer, H.Y.: Substance abuse and clozapine treatment. *Journal of Clinical Psychiatry* 55(Supplement B):114-116, 1994.
- *435. Meltzer, H.Y. and Cola, P.A.: The pharmacoeconomics of clozapine: a review. *Journal of Clinical Psychiatry* 55(Supplement B):161-165, 1994.
436. Maes, M., Meltzer, H.Y., D'Hondt, P., Cosyns, P. and Blockx, P.: Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal-axis function in depression. *Psychoneuroendocrinology* 20:149-167, 1994.
437. Vrtunski P.B., Alphs, L.D. and Meltzer, H.Y.: Motor mechanisms in schizophrenic patients with tardive dyskinesia. *Psychiatry Research* 54:71-86, 1994.
438. Maes, M., Meltzer, H.Y. and Bosmans, E.: Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. *Acta Psychiatrica Scandinavica* 89:346-351, 1994.
439. Maes, M., Scharpé, S., Meltzer, H.Y., Okayli, G., Bosmans, E., D'Hondt, P., Vanden Bossche, D. and Cosyns, P.: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophen in major depression: further evidence for an immune response. *Psychiatry Research* 54:145-160, 1994.
440. Haacke, E.M., Hopkins, A., Lai, S., Buckley, P., Friedman, L., Meltzer, H.Y., Hedera, P., Friedland, R., Klein, S., Thompson, L., Dennerman, D., Tkach, J. and Lewin, J.S.: 2D and 3D high resolution gradient echo functional imaging of the brain: venous contributions to signal in motor cortex studies. *NMR in Biomedicine* 7:1-9, 1994.

*Non-Peer Reviewed

- *441. Meltzer, H.Y., Lee, M.A. and Ranjan, R.: Recent advances in the pharmacotherapy of schizophrenia. *Acta Psychiatrica Scandinavica* 90(Supplement 384):95-101, 1994.
- 442. Maes, M., Meltzer, H.Y., Cosyns, P., Calabrese, J., D'Hondt, P. and Blockx, P.: Adrenocorticotrophic hormone, β -endorphin and cortisol responses to oCRH in unipolar depressed patients pretreated with dexamethasone. *Progress in Neuro-Psychopharmacology* 18:1273-1292, 1995.
- 443. Lozoff, B., Felt, B.T., Nelson, E.C., Wolf, A.W., Meltzer, H.Y. and Jimenez, E.: Serum prolactin levels and behavior in infants. *Biological Psychiatry* 37:4-12, 1995.
- 444. Kennedy, J.L., Billett, E.A., Macciardi, F.M., Verga, M., Parsons, T.J., Meltzer, H.Y., Lieberman, J. and Buchanan, J.A.: Association study of dopamine D₂ receptor gene and schizophrenia. *American Journal of Medicine Genetics (Neuropsychiatric Genetics)* 60:558-562, 1995.
- 445. Meltzer, H.Y., Kennedy, J., Dai, J., Parsa, M. and Riley, D.: Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: a high potency effect of clozapine. *Neuropsychopharmacology* 12:39-45, 1995.
- 446. Friedman, L., Kenny, J.T., Jesberger, J.A., Choy, M.M. and Meltzer, H.Y.: Relationship between smooth pursuit eye-tracking and cognitive performance in schizophrenia. *Biological Psychiatry* 37:265-272, 1995.
- *447. Meltzer, H.Y. and Hippus, H.: The consensus: the assessment and management of treatment-resistant schizophrenia in perspective. *European Psychiatry* 10(Supplement 1):3s-5s, 1995.
- *448. Meltzer, H.Y.: Multiple outcome criteria in schizophrenia: an overview of outcome with clozapine. *European Psychiatry* 10(Supplement 1):19s-25s, 1995.
- *449. Meltzer, H.Y.: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. *Journal of Clinical Psychopharmacology* 15:S2-S3, 1995.
- 450. Meltzer H.Y.: Role of serotonin in the action of atypical antipsychotic drugs. *Clinical Neuroscience* 3:64-75, 1995.
- 451. Hudgel, D.W., Gordon, E.A. and Meltzer, H.Y.: Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea. *American Journal of Respiratory and Critical Care Medicine* 152:186-192, 1995.
- 452. Sumiyoshi, T., Stockmeier, C.A., Overholser, J.C., Thompson, P.A. and Meltzer, H.Y.: Dopamine D₂ receptors and effects of guanine nucleotides on [³H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. *Brain Research* 681:109-116, 1995.
- 453. Maes, M., Bosmans, E., Calabrese, J., Smith, R. and Meltzer, H.Y.: Interleukin-2 and -6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. *Journal of Psychiatry Research* 29:141-152, 1995.
- 454. Maes, M., Bosmans, E. and Meltzer, H.Y.: Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. *European Archives of Psychiatry and Clinical Neuroscience* 245:172-178, 1995.
- 455. Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R. and Meltzer, H.Y.: D₂ dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. *Psychopharmacology* 120:365-368, 1995.
- 456. Meltzer, H.Y. and Maes, M.: Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. *Biological Psychiatry* 38:310-318, 1995.
- 457. Petronis, A., Macciardi, F., Athanassiades, A., Verga, M., Meltzer, H.Y., Cola, P., Van Tol, H.H.M. and Kennedy, J.L.: An association study between dopamine D₂ receptor gene and schizophrenia. *American Journal of Medicine Genetics (Neuropsychiatric Genetics)* 60:452-455, 1995.
- 458. Meltzer, H.Y. and Maes, M.: Effects of ipsapirone on plasma cortisol and body temperature in major depression. *Biological Psychiatry* 38:450-457, 1995.
- 459. Meltzer, H.Y. and Maes, M.: Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. *Psychiatry Research* 58:89-98, 1995.
- *460. Meltzer, H.Y.: A szkizofrénia tickainak felfedése - a clozapin-terápia története. *Psychiatria Hungarica (X. évf. I. Supplementum)*:5-11, 1995.

*Non-Peer Reviewed

461. Elkis, H., Friedman, L., Wise, A. and Meltzer, H.Y.: Meta-Analyses of studies of ventricular enlargement or cortical sulcal prominence in mood disorders - comparison to controls or patients with schizophrenia. *Archives of General Psychiatry* 52:735-746, 1995.
462. Ichikawa, J. and Meltzer, H.Y.: Effect of antidepressants on striatal and accumbens extracellular dopamine levels. *European Journal of Pharmacology* 281:255-261, 1995.
463. Ichikawa, J. and Meltzer, H.Y.: DOI, a 5-HT_{2A} receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. *Brain Research* 698:204-208, 1995.
464. Ordway, G.A., Stockmeier, C.A., Meltzer, H.Y., Overholser, J.C., Jaconetta, S. and Widdowson, P.S.: Neuropeptide Y in frontal cortex is not altered in major depression. *Journal of Neurochemistry* 65:1646-1650, 1995.
465. Maes, M., Goossens, F., Scharpé, S., Calabrese, J., Desnyder, R. and Meltzer, H.Y.: Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. *Psychiatry Research* 58:217-225, 1995.
466. Maes, M., Meltzer, H.Y., Buckley, P. and Bosmans, E.: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. *European Archives of Psychiatry and Clinical Neuroscience* 244:325-329, 1995.
467. Maes, M., Van Gastel, A., Blockx, P., Martin, M., Bosyns, P., Scharpé, S. and Desnyder, R.: An augmented escape of adrenomedullary from suppression by dexamethasone in melancholia: relationships to intact ACTH and cortisol nonsuppression. *Journal of Affective Disorders* 34:291-300, 1995.
468. Ranjan, R., Lee, M.A. and Meltzer, H.Y.: Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia. *Biological Psychiatry* 32:678-679, 1995.
469. Maes, M., Meltzer, H.Y., D'Hondt, P., Cosyns, P. and Blockx, P.: Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. *Psychoneuroendocrinology* 20:149-167, 1995.
470. Ordway, G.A., Stockmeier, C.A., Meltzer, H.Y., Overholser, J.C., Jaconetta, S. and Widdowson, P.W.: Neuropeptide Y in frontal cortex is not altered in major depression. *Journal of Neurochemistry* 65:1646-1650, 1995.
- *471. Meltzer, H.Y. and Okayli, G.: The reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. *American Journal of Psychiatry* 152:183-190, 1995.
472. Ichikawa, J., Kuroki, T., Kitchen, M.T. and Meltzer, H.Y.: R(+)-8-OH-DPAT, a 5-HT_{1A} receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. *European Journal of Pharmacology* 287:179-184, 1995.
473. Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Bandoelaege, E., Ranjan, R. and Desnyder, R.: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. *Journal of Affective Disorders* 34:301-309, 1995.
474. Meltzer, H.Y., Lee, M.A., Ranjan, R., Mason, E.D. and Cola, P.A.: Relapse following clozapine withdrawal: effect of cyproheptadine plus neuroleptic. *Psychopharmacology* 124:176-187, 1996.
475. Meltzer, H.Y. and Maes, M.: Effect of pindolol on hormone secretion and body temperature: partial agonist effects. *Journal of Neural Transmission* 103(1-2):77-88, 1996.
476. Maes, M., Gastel, A.V., Meltzer, H.Y., Cosyns, P., Blockx, P. and Desnyder, R.: Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. *Psychoneuroendocrinology* 21(1):67-81, 1996.
477. Meltzer, H.Y.: Preclinical pharmacology of atypical antipsychotic drugs: A brief review. *British Journal of Psychiatry (Supplement)* 168(Supplement 29):23-31, 1996.
478. Sumiyoshi, T., Stockmeier, C.A., Overholser, J.C., Diley, G.E. and Meltzer, H.Y.: Serotonin_{1A} receptors are increased in postmortem prefrontal cortex in schizophrenia. *Brain Research* 708:209-214, 1996.
479. Sajatovic, M. and Meltzer, H.Y.: Clozapine-induced myoclonus and generalized seizures. *Biological Psychiatry* 39:367-370, 1996.
480. Calabrese, J., Kimmel, S.E., Woyshville, M., Rapport, W.J., Trivedi, C.J. and Meltzer, H.Y.: Clozapine in treatment-refractory mania. *American Journal of Psychiatry* 153:759-764, 1996.

*Non-Peer Reviewed

481. Stockmeier, C.A. and Meltzer, H.Y.: Biological studies of suicide in schizophrenia. *Clinical Neuropharmacology* 18:S9-S17, 1996.
482. Elkis, H., Friedman, L., Buckley, P.F., Lee, H.S., Lye, C., Kaufman, B. and Meltzer, H.Y.: Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. *Psychiatry Research - Neuroimaging* 67(2):123-134, 1996.
483. Meltzer, H.Y., Cola, P.A. and Parsa, M.: Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. *Neuropsychopharmacology* 15(4):395-405, 1996.
484. Maes, M., Gasrel, A.V., Ranjan, R., Blockx, P., Cosyns, P., Meltzer, H.Y. and Desnyder R.: Stimulatory effects of L-5-hydroxytryptophan on postdexamethasone β -endorphin levels in major depression. *Neuropsychopharmacology* 15(4):340-348, 1996.
485. Ranjan, R. and Meltzer, H.Y.: Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. *Biological Psychiatry* 40(4):253-258, 1996.
486. Kohen, R., Metcalf, M.A., Khan, N., Druck, T., Huebner, K., Lachowicz, J.E., Meltzer, H.Y., Sibley, D.R., Roth, B.L., and Hamblin, M.W.: Cloning, characterization, and chromosomal localization of a human 5-H₂ serotonin receptor. *Journal of Neurochemistry* 66:47-56, 1996.
487. Sasaki, T., Billett, E., Petronis, A., Ying, D., Parsons, T., Macciardi, F.M., Meltzer, H.Y., Lieberman, J., Joffe, R.T., Ross, C.A., McInnis, M.G., Li S.-H. and Kennedy, J.L.: Psychosis and genes with trinucleotide repeat polymorphism. *Human Genetics* 97:244-246, 1996.
488. Findling, R.L., Jayatilake, K. and Meltzer, H.Y.: Pre-morbid asociality in neuroleptic-resistant and -responsive schizophrenia. *Psychological Medicine* 26:1033-1041, 1996.
489. Pacheco, M.A., Stockmeier, C.A., Meltzer, H.Y., Overholser, J.C., Dilley, G.E. and Jope, R.S.: Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. *Brain Research* 723(1-2):37-45, 1996.
490. Maes, M., Smith, R., Christophe, A., Cosyns, P., Desnyder, R. and Meltzer, H.: Fatty acid composition in major depression: decreased ω 3 fractions in cholesteryl esters and increased C20:4 ω 6/C20:5 ω 3 ratio in cholesteryl esters and phospholipids. *Journal of Affective Disorders* 38:35-46, 1996.
491. Sasaki, T., Macciardi, F.M., Badri, F., Verga, M., Meltzer, H.Y., Lieberman, J., Howard, A., Bean, G., Joffe, R.T., Hudson, C.J. and Kennedy, J.L.: No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 67:415-417, 1996.
492. Sumiyoshi, T., Ichikawa, J. and Meltzer, H.Y.: Increased S(-)-apomorphine-induced vacuolar chewing and attenuated effect of chronic haloperidol treatment in streptozotocin-induced diabetic rat. *Pharmacology Biochemistry and Behavior* (In Press) 1996.
493. Meltzer, H.Y., Findling, R.L., Ranjan, R., Cola, P.A., Lee, M.A. and Thompson, P.A.: Early onset schizophrenia: adult outcome and neuroleptic response. *American Journal of Psychiatry* (In Press) 1996.
494. Ranjan, R. and Meltzer, H.Y.: Clozapine and mood disorders. *Italian Journal of Psychiatry and Behavioural Sciences* (In Press) 1996.
495. Sumiyoshi, T., Hasegawa, M. and Meltzer, H.Y.: Sex differences in plasma homovanillic acid levels in schizophrenic patients and normal controls: relation to neuroleptic-resistance. *Biological Psychiatry* (In Press) 1996.
496. Sumiyoshi, T., Hasegawa, M. and Meltzer, H.Y.: Prediction of long-term outcome of clozapine treatment by plasma homovanillic acid levels in patients with schizophrenia. *Biological Psychiatry* (In Press) 1996.
497. Maes, M., Meltzer, H.Y., Cosyns, P., Blockx, P. and Calabrese, J.: The determination of the intact ACTH molecule by means of an ultrasensitive assay: an asset in depression research. *Neuropsychobiology* (In Press) 1996.
498. Maes, M., Meltzer, H.Y., Cosyns, P. and Schotte, C.: Evidence for the existence of major depression with and without anxiety features. *Psychopathology* (In Press) 1996.
499. Meltzer, H.Y., Thompson, P.A., Lee, M.A. and Ranjan, R.: Neuropsychologic deficits in schizophrenia. Relation to social function and effect of antipsychotic drug treatment. *Neuropsychopharmacology* (In Press) 1996.
500. Goyer, P.F., Berridge, M.S., Morris, E.D., Semple, W.E., Compton-Toth, B.A., Schulz, S.C., Wong, D.F., Miraldi, F. and Meltzer, H.Y.: PET measurements of neuroreceptor antagonism. *Journal of Nuclear Medicine* (In Press) 1995.

*Non-Peer Reviewed

501. Stockmeier, C.A., Dilley, G.E., Shapiro, L.A., Overholser, J.C., Thompson, P.A. and Meltzer, H.Y.: Serotonin receptors in suicide victims with major depression. *Neuropsychopharmacology* (In Press) 1996.
502. Stuve, T.A., Friedman, L., Jesberger, J.A., Gilmore, G.C., Strauss, M.E. and Meltzer, H.Y.: The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. *Psychological Medicine* (In Press) 1996.
503. Kuroki, H., Ichikawa, J., Dai, J. and Meltzer, H.Y.: Inhibition of amphetamine-induced dopamine and serotonin release by R(+)-8-OH-DPAT, a 5-HT_{1A} receptor agonist, in rat medial prefrontal cortex. *Brain Research* (In Press) 1996.
504. Sumiyoshi, T., Ichikawa, J. and Meltzer, H.Y.: The effect of streptozotocin-induced diabetes on dopamine $_D$, serotonin $_{1A}$, and serotonin $_{2A}$ receptors in rat brain. *Neuropsychopharmacology* (In Press) 1996.
505. Sernaan, Y.M., Clay, H.A. and Meltzer, H.Y.: Clozapine in treatment of bromocriptine-induced psychosis. *J Clin Psychopharm* (In Press) 1996.

*Non-Peer Reviewed

MANUSCRIPTS IN PREPARATION OR SUBMITTED

1. Meltzer, H.Y. and Maes, M.: Effects of fluoxetine on central serotonergic activity in major depression and obsessive-compulsive disorder. *Psychopharmacology*. (In Preparation) 1996.
2. Hudson, C.J., Kennedy, J.L., Gotowicz, A., Lin, A., King, N., Gojtan, K., Macciardi, F., Skorecki, K., Meltzer, H.Y., Warsh, J.J. and Horrobin, D.F.: Genetic variant near cytosolic phospholipase A₂ associated with schizophrenia. *American Journal of Human Genetics*. (Submitted) 1996.
3. Meltzer, H.Y., Altamura, C.A., Cola, P.A. and Lee, M.A.: Clozapine plasma concentrations in refractory- and non-refractory schizophrenic patients. *Biological Psychiatry*. (In Preparation) 1996.
4. Lee, J.H., Thompson, P. and Meltzer, H.Y.: The effect of clozapine administration on sleep measures and hormones in chronic schizophrenia. (In Preparation) 1996.
5. Buckley, P.F., Cola, P.A., Hasegawa, M., Lys, C. and Meltzer, H.Y.: Clozapine plasma levels and dosing strategies in treatment-refractory schizophrenic patients. *Journal of Clinical Psychopharmacology*. (Submitted) 1996.
6. Abraham, J., Brown, R., and Meltzer, H.Y.: Development of paroxysmal tardive dystonia and dyskinesia in a patient associated with concomitant paroxetine and sumatriptan treatment. (In Preparation) 1996.
7. Meltzer, H.Y. and Fatemi, S.H.: Sulcide in schizophrenia: the effect of clozapine. *European Journal of Neuropsychopharmacology*. (In Preparation) 1996.
8. Meltzer, H.Y.: A risk-benefit assessment of clozapine in the treatment of schizophrenia. *Drug Safety*. (In Preparation). 1996.
9. Kazawa, T., Meltzer, H.Y. and Mückli, M.: D-4 signal in rat frontal cortex labelled by ³H-YM-09151-2. (In Preparation) 1996.
10. Ichikawa, J., Kuroki, H. and Meltzer, H.Y.: Modulation of amphetamine-induced dopamine release by dopamine autoreceptors in rat striatum and nucleus accumbens. *Journal of Pharmacology and Experimental Therapeutics*. (Submitted) 1996.
11. Meltzer, H.Y.: Predictors of response to clozapine. *Psychiatric Annals*. (Submitted) 1996.
12. Findling, R.L., Weishampel, P., Cola, P.A., Jayatilake, K. and Meltzer, H.Y.: Childhood and adolescent psychosocial functioning in neuroleptic-resistant and -responsive adults with schizophrenia. *Journal of the American Academy of Child and Adolescent Psychiatry*. (Submitted) 1996.
13. Goyer, P.F., Semple, W.E., Berridge, M.S., Morris, E.D., Compton-Toth, B.A., Garnett, M.L., Sharkoff, J.A., Miraldi, F., Schulz, S.C. and Meltzer, H.Y.: Regional cerebral blood flow response to MK-212. (In Preparation) 1996.
14. Kuroki, H., Ichikawa, H. and Meltzer, H.Y.: Comparison between haloperidol and atypical antipsychotic drugs, clozapine, olanzapine and risperidone, in the effect on dopamine and serotonin release in rat medial prefrontal cortex and nucleus accumbens. *Journal of Pharmacology and Experimental Therapeutics*. (In Preparation) 1996.
15. Ichikawa, J., Kuroki, H. and Meltzer, H.Y.: Modulation of subcortical dopamine release by atypical and typical antipsychotics by 5-HT_{1A} receptors. *Journal of Pharmacology and Experimental Therapeutics*. (In Preparation) 1996.
16. Ichikawa, J., Kuroki, H., Dai, J. and Meltzer, H.Y.: Modulation *in vivo* dopamine and serotonin synthesis by serotonin_{1A} receptors and amphetamine in rat striatum, nucleus accumbens and medial prefrontal cortex. *Brain Research*. (In Preparation) 1996.
17. Ichikawa, J., Kuroki, H. and Meltzer, H.Y.: Differential effects of 5-HT_{1A} and 5-HT_{2A} receptors on subcortical dopamine release. *Journal of Pharmacology and Experimental Therapeutics*. (In Preparation) 1996.
18. Ichikawa, J., Kuroki, H. and Meltzer, H.Y.: Differential effects of fluoxetine, clomipramine and imipramine on basal and amphetamine-induced dopamine release after chronic treatment. *Journal of Pharmacology and Experimental Therapeutics*. (In Preparation) 1996.
19. Elkis, H., Friedmann, L., Ownby, R., Maes, M. and Meltzer, H.Y.: The concept of schizophrenia and the phenomenological (dimensional) models of Kraepelin, Bleuler and Schneider: a confirmatory factor analysis study. (Submitted) 1996.
20. Young, C.D., Meltzer, H.Y. and Deutch, A.Y.: The effects of desmethylclozapine on fos protein expression in the forebrain: *In vivo* biological activity of the clozapine metabolite. (In Preparation) 1996.

BOOK CHAPTERS

1. Meltzer, H.Y.: Studies on the biology of the neuroactive amines: a morphologic and pharmacologic approach. Thesis submitted for the M.D. to the Yale University School of Medicine. pp 155. 1963.
2. Fischman, D.A., Meltzer, H.Y. and Poppei, R.W.: The ultrastructure of human skeletal muscle: variations from archetypal morphology. In: *"The Striated Muscle"*. C. Pearson (ed). The Williams & Wilkins Co., Baltimore, Maryland, pp 58-76, 1973.
3. Meltzer, H.Y.: Serum creatine phosphokinase and serum aldolase levels in acutely psychotic patients. In: *Enzymology in the Practice of Laboratory Medicine*, P. Blume and E.F. Freier (eds). Academic Press, Inc., New York, pp 351-379, 1974.
4. Meltzer, H.Y., Sachar, E.J. and Frantz, A.A.: Serum prolactin levels in newly admitted psychiatric patients. In: *"Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes"*, E. Usdin (ed). Raven Press, 1974.
5. Arora, R.C. and Meltzer, H.Y.: Characterization of monoamine oxidase (MAO) in rat skeletal muscle. *The Pharmacologist* 17:160. 1975.
6. Meltzer, H.Y.: Neuromuscular abnormalities in the major mental illnesses. I. Serum enzyme studies. In: *Biology of the Major Psychoses*, D.X. Freedman (ed). Research Publications Association of the Research in Nervous Mental Disorders, Vol. 54, Raven Press, New York, pp 165-188. 1975.
7. Meltzer, H.Y. and Crayton, J.W.: Neuromuscular abnormalities in the major mental illnesses. II. Muscle fiber and subterminal motor nerve abnormalities. In: *Biology of the Major Psychoses*, D.X. Freedman (ed). Research Publications Association of the Research in Nervous Mental Disorders, Vol. 54, Raven Press, New York, pp 189-207, 1975.
8. Meltzer, H.Y.: Regression is unnecessary. In: *The Psychotherapy of Schizophrenia*, J.G. Gunderson and L.B. Mosher (eds). Jason Aronson, New York, pp 123-138, 1975.
9. Meltzer, H.Y. and Fang, V.S.: Serum prolactin levels in schizophrenia: effect of antipsychotic drugs. A preliminary report. In: *Hormones, Behavior and Psychopathology*, E.J. Sachar (ed). Raven Press, New York, pp 177-192, 1976.
10. Meltzer, H.Y., Fang, V.S., Fessler, R., Simonovic, M. and Stanisic, D.: Neuroleptic-stimulated prolactin secretion in the rat as an animal model for biological psychiatry: I. Comparison with antipsychotic activity. In: *Animal Models in Psychiatry and Neurology*, I. Hanin and E. Usdin (eds). Pergamon Press, New York, pp 443-455, 1977.
11. Meltzer, H.Y., Goode, D.J. and Fang, V.S.: The effect of psychotropic drugs on endocrine function. I. Neuroleptics, precursors and agonists. In: *Psychopharmacology: A Generation of Progress*, M.A. Lipton, A. Di Mascio and K.F. Killam (eds). Raven Press, New York, pp 509-529, 1978.
12. Hassan, S.Z., Meltzer, H.Y. and Cho, H.Y.: Isoenzymes of creatine phosphokinase in serum of families with malignant hyperthermia. In: *Malignant Hyperthermia*, J.A. Aldrete and B.A. Britt (eds). Grune & Stratton, New York, pp 233-238, 1978.
13. Arora, R.C. and Meltzer, H.Y.: Skeletal muscle monoamine oxidase activity in psychiatric patients and normal controls. In: *Catecholamines: Basic and Clinical Frontiers*, Vol. 2, E. Usdin, I.J. Kopin and J. Barchas (eds). Pergamon Press, New York, pp 1848-1850, 1979.
14. Meltzer, H.Y., Simonovic, M., Nichols, D.W., Miller, R.J., McDermid, J. and Fang, V.S.: Relative potencies of dopamine agonists on prolactin secretion in rats. In: *Catecholamines: Basic and Clinical Frontiers*, Vol. 2, E. Usdin, I.J. Kopin and J. Barchas (eds). Pergamon Press, New York, pp 1251-1253, 1979.
15. Simonovic, M., Doherty, J., So, R. and Meltzer, H.Y.: Phencyclidine inhibits the activity of striatal tyrosine hydroxylase *in vivo*. In: *Catecholamines: Basic and Clinical Frontiers*, Vol. 2, E. Usdin, I.J. Kopin and J. Barchas (eds). Pergamon Press, New York, pp 710-712, 1979.
16. Bowers, M.B., Jr., Heninger, G.R. and Meltzer, H.Y.: Cerebrospinal fluid (CSF) homovanillic acid (HVA), cyclic adenosine monophosphate (cAMP), prolactin and serum prolactin in acute psychotic patients at two points during early chlorpromazine (CPA) treatment. In: *Catecholamines: Basic and Clinical Frontiers*, Vol. 2, E. Usdin, I.J. Kopin and J. Barchas (eds). Pergamon Press, New York, pp 1893-1895, 1979.
17. Miller, R.J., Meltzer, H.Y. and Fang, V.S.: Distribution and pharmacology of the enkephalins. In: *Endorphins in Mental Health Research*, E. Usdin et al. (eds). Oxford Press, 1979.
18. Meltzer, H.Y.: Biochemical studies in schizophrenia. In: *Disorders of the Schizophrenic Syndrome*, L. Bellak (ed). Basic Books, Inc., New York, pp 45-149, 1979.

19. Meltzer, H.Y.: Effect of psychotropic drugs on neuroendocrine function. In: *Advances in Psychoneuroendocrinology. Psychiatry Clinics of North America* 3:277-298, 1980.
20. Meltzer, H.Y., Busch, D., Young, M., Tricou, B.J., Nasr, S., Metz, J. and Fang, V.S.: Prolactin and growth hormone studies in schizophrenic patients and normal controls. In: *Progress in Psychoneuroendocrinology*, F. Brambilla, G. Racagni and D. de Weid. (eds). Elsevier/North Holland, Amsterdam, pp 283-294, 1980.
21. Meltzer, H.Y., Busch, D., So, R., Holcomb, H. and Fang, V.S.: Neuroleptic-induced elevations in serum prolactin levels: etiology and significance. In: *Perspectives in Schizophrenia Research*, C. Baxter, T. Melnechuk (eds). Raven Press, New York, pp 149-176, 1980.
22. Meltzer, H.Y.: Prolactin and psychiatry. Editorial. *American Journal of Psychiatry* 138:1203-1206, 1981.
23. Meltzer, H.Y., Busch, D.A. and Fang, V.S.: Effect of neuroleptics on serum prolactin levels in relation to clinical response and neuroleptic blood levels. In: *Clinical Pharmacology in Psychiatry*, E. Usdin (ed), Elsevier, New York, pp 251-268, 1981.
24. Meltzer, H.Y., Sturgeon, R.D., Simonovic, M. and Fessler, R.G.: Phencyclidine as an indirect dopamine agonist. In: *PCP (Phencyclidine): Historical and Current Perspectives*, E.F. Domino (ed). NPP Books, Ann Arbor, Michigan, pp 207-242, 1981.
25. Meltzer, H.Y., Simonovic, M., Fang, V.S. and Goode, D.J.: Neuroendocrine effects of psychotomimetic drugs. In: *Psychotropic Drugs: Biological Assessment and Prediction of Response*, McLean Hospital Journal 5:115-137, 1981.
26. Meltzer, H.Y., Fang, V.S., Tricou, B.J. and Robertson, A.: Effect of antidepressants on neuroendocrine axis in humans. In: *Typical and Atypical Antidepressants* 32:289-296, Raven Press, New York, 1982.
27. Meltzer, H.Y., Simonovic, M., Ravitz, A.J., Fang, V.S. and Goode, D.J.: Effect of psychotomimetic drugs on rat and human prolactin and growth hormone levels. In: *Handbook of Psychiatry and Neurology*, P.J.V. Beaumont and G.D. Burrows (eds). Elsevier Biomedical Press, Amsterdam, pp 215-238, 1982.
28. Meltzer, H.Y., Arora, R.C. and Song, P.: Serotonin uptake in blood platelets as a biological marker for major depressive disorders. In: *Biological Markers in Psychiatry and Neurology*, E. Usdin and E. Costa (eds). Pergamon Press, New York, pp 39-48, 1982.
29. Meltzer, H.Y., Wita, B., Tricou, B.J., Simonovic, M. and Fang, V.S.: Effect of serotonin precursors and serotonin agonists on plasma hormone levels. In: *Serotonin in Biological Psychiatry*, B. Ho et al., *Advances in Biological Psychiatry* 34:117-140, 1982.
30. Meltzer, H.Y., So, R. and Fang, V.S.: Effect of benzamide drugs on prolactin secretion: Relation to the dopamine receptor. In: *The Benzamides: Pharmacology, Neurobiology and Clinical Aspects*, J. Rotrosen and M. Stanley (eds). Raven Press, New York, pp 61-82, 1982.
31. U'Prichard, D.C., Daigujl, M., Mitrus, J.C. and Meltzer, H.Y.: α -adrenergic receptors: comparative biochemistry of neural and non-neural receptors, and *in vitro* analysis in psychiatric patients. In: *Biological Markers in Psychiatry and Neurology*, I. Hanin and E. Usdin (eds). Pergamon Press, New York, pp 205-218, 1982.
32. Metz, J., Busch, D.A. and Meltzer, H.Y.: Clinical electrophysiological and biochemical effects of des-tyrosine- γ -endorphin in psychiatric patients. In: *Opioids in Mental Illness: Theories, Clinical Observations, and Treatment Possibilities*, K. Vereby (ed). *Annals of the New York Academy of Sciences* 398:496-508, 1983.
33. Meltzer, H.Y., Kane, J. and Kolakowska, T.: Plasma levels of neuroleptics, prolactin levels and clinical response. In: *Neuroleptics. Neurochemical, Behavioral and Clinical Perspectives*, J.T. Coyle and S.J. Enna (eds). Raven Press, pp 255-279, 1983.
34. Meltzer, H.Y., Boutros, N.N., Simonovic, M., Gudelsky, G.A. and Fang, V.S.: Hallucinogenic drugs and neuroendocrine secretion. In: *Integrative Neurohumoral Mechanisms*, E. Endroczi, D. de Wied, L. Angelucci and U. Scapagnini (eds). Elsevier Science Publishers, Amsterdam, 1983.
35. Meltzer, H.Y., Gudelsky, G.A., Simonovic, M. and Fang, V.S.: Effect of dopamine agonists and antagonists on prolactin and growth hormone secretion. In: *Dopamine Receptor Agonists*, A. Carlsson and J.L.G. Nilsson (eds). *Acta Pharmaceutica Suecica*, Suppl. 1, Swedish Pharmaceutical Press, Stockholm, pp 200-218, 1983.
36. Silverstein, M.L. and Meltzer, H.Y.: Neuropsychological dysfunction in the major psychoses: Relation to premorbid adjustment and social class. In: *Laterality and Psychopathology*, P. Flor-Heury and J.H. Gruzelier (eds). Elsevier/North Holland Biomedical Press, Amsterdam, pp 143-152, 1983.
37. Gudelsky, G.A., Simonovic, M. and Meltzer, H.Y.: Dopaminergic and serotonergic control of neuroendocrine function. In: *Monographs in Neural Sciences*, M.M. Cohen (ed), *Neuroreceptors in Health and Disease*, Vol. 10, J. Marwaha and W.J. Anderson (eds). S. Karger, New York, pp 85-102, 1984.

38. Fang, V.S., Meltzer, H.Y., Tricou, B.J. and Robertson, A.: Studies of the hypothalamic-pituitary-adrenocortical axis in mental patients. In: *Neuropeptides and Psychosomatic Processes*, E. Androcz et al. (eds). Publishing House of the Hungarian Academy of Sciences, Budapest, pp 637-644, 1984.
39. Meltzer, H.Y., Busch, D.A. and Fang, V.S.: Neuroendocrine abnormalities in schizophrenia: Prolactin, growth hormone and gonadotropins. In: *Neuroendocrinology and Psychiatric Disorders*, G.M. Brown, S.H. Koslow and S. Reichlin (eds). Raven Press, pp 1-28, 1984.
40. Meltzer, H.Y.: Serotonergic function in the affective disorders: The effect of antidepressants and lithium on the 5-hydroxytryptophan-induced increase in serum cortisol. In: *Presynaptic Modulation of Postsynaptic Receptors in Mental Diseases*, A.I. Salama (ed). *Annals of the New York Academy of Sciences* 430:115-137, 1984.
41. Meltzer, H.Y. and Fang, V.S.: Laboratory error in plasma cortisol measurement and the dexamethasone suppression test. In: *Clinical Utility of the Dexamethasone Suppression Test*, preceding of a National Institute of Mental Health Workshop, R.M.A. Hirschfeld, S.H. Koslow and D.J. Kupfer (eds), pp 54-58, 1985.
42. Meltzer, H.Y.: Long-term effects of neuroleptic drugs on the neuroendocrine system. In: *Chronic Treatments in Neuro-psychiatry*, D. Kemali and G. Racagni (eds). Raven Press, New York, 1985.
43. Meltzer, H.Y.: Dopamine and negative symptoms in schizophrenia: critique of the Type I-Type II hypothesis. In: *Controversies in Schizophrenia: Changes and Continuities*, M. Alpert (ed). Guilford Press, pp. 110-136, 1985.
44. Meltzer, H.Y., Kolakowska, T., Fang, V.S., Fogg, L., Robertson, A., Lewine, R., Strahilevitz, M. and Busch, D.: Section 1: Biological Psychiatry. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders: relation to duration of illness and depressive symptoms. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 16-17, 1985.
45. Meltzer, H.Y.: Section 1: Biological Psychiatry. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, p 22, 1985.
46. Meltzer, H.Y., Kolakowska, T., Robertson A. and Tricou, B.J.: Section 1: Biological Psychiatry. Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 26-27, 1985.
47. Jackman, H., Luchins, D. and Meltzer, H.Y.: Section 1: Biological Psychiatry. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 30-31, 1985.
48. Meltzer, H.Y., Uberkman-Wiita, B., Robertson A., Tricou, B.J. and Lowy, M.: Section 1: Biological Psychiatry. Enhanced serum cortisol response to 5-hydroxytryptophan in depression and mania. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 39-40, 1985.
49. Meltzer, H.Y., Lowy, M., Robertson, A., Goodnick, P. and Pertine, R.: Section 1: Biological Psychiatry. Effect of 5-hydroxytryptophan on serum levels in major affective disorders: III. Effect of antidepressants and lithium carbonate. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 40-41, 1985.
50. Mikuni, M. and Meltzer, H.Y.: Section 1: Biological Psychiatry. Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. In: *The Year Book of Psychiatry and Applied Mental Health*, D.X. Freedman, R.S. Lurie, H.Y. Meltzer, J.C. Nemiah, J.A. Talbot and H. Weiner (eds). Mosby Yearbook Publishers, Chicago, Illinois, pp 72-73, 1985.
51. Meltzer, H.Y.: Biological studies of the nosology of the major psychoses: A status report on the schizoaffective disorders. *The Schizoaffective Disorders*, A. Maneros (ed). Springer-Verlag, pp. 232-259, 1986.
52. Koyama, T. and Meltzer, H.Y.: A biochemical and neuroendocrine study of the serotonergic system in depression. In: *New Results in Depression*, H. Hippus et al. (eds). Springer-Verlag, Berlin, pp 169-188, 1986.
53. Meltzer, H.Y. and Schyve, P.M.: Psychiatric Disorders: Introduction. In: *Pharmacology in Medicine: Principles and Practice*, S.N. Pradhan, R.P. Maickel, S.N. Dutta (eds). SP Press International, Inc., pp 316-324, 1986.
54. Meltzer, H.Y., Schyve, P.M. and Moore, K.E.: Drugs for therapy of psychosis. In: *Pharmacology in Medicine: Principles and Practice*, S.N. Pradhan, R.P. Maickel, S.N. Dutta (eds). SP Press International, Inc., pp 325-337, 1986.

55. Sanders-Bush, E., Meltzer, H.Y. and Sulser, F.: Drugs for therapy of affective disorders. In: *Pharmacology in Medicine: Principles and Practice*, S.N. Pradhan, R.P. Maickel, S.N. Dutta (eds). SP Press International, Inc., pp 338-348, 1986.
56. Meltzer, H.Y. and Lowy, M.T.: Neuroendocrine function in psychiatric disorders and behavior. In: *American Handbook of Psychiatry*, Vol. VIII, pp 111-150, 1986.
57. Meltzer, H.Y. and Arora, R.C.: Platelet markers of suicidality. In: *The Psychobiology of Suicidal Behavior*, J.J. Mann and M. Stanley (eds). *New York Academy of Science* 487:271-280, 1986.
58. Meltzer, H.Y.: Effect of neuroleptics on the schizophrenia syndrome. In: *Psychopharmacology Series 3—Clinical Pharmacology in Psychiatry—Selectivity in Psychotropic Drug Action—Promises and Problems? (Psychopharmacology Supplement)*, S.G. Dahl, L.F. Gram, S.M. Paul and W.Z. Potter (eds). Springer-Verlag Press, Berlin-Heidelberg, pp 255-265, 1987.
59. Meltzer, H.Y., Lowy, M.T. and Koenig, J.I.: The hypothalamic-pituitary-adrenal axis in depression. In: *Hypothalamic Dysfunction in Neuropsychiatric Disorders*, F.K. Goodwin (ed). New York, Raven Press, pp 165-182, 1987.
60. Lowy, M.T., Gormley, G.J., Reder, A.T., Hospelhorn, V.D., Antel, J.P. and Meltzer, H.Y.: Glucocorticoid receptor function in depression. In: *Hormones and Depression*, U. Halbreich and R. Rose (eds). Raven Press, New York, pp 91-112, 1987.
61. Meltzer, H.Y. and Lowy, M.T.: The serotonin hypothesis of depression. In: *Psychopharmacology. The Third Generation of Progress*, H.Y. Meltzer, (ed). Raven Press, pp 513-526, 1987.
62. Meltzer, H.Y.: An overview of hormones and monoamine receptors. In: *Hormones and Depression*, U. Halbreich and R. Rose (eds). Raven Press, New York, pp 49-58, 1987.
63. Meltzer, H.Y., Lowy, M.T. and Robertson, A.G.: The hypothalamic-pituitary-adrenal axis and suicide. In: *The Psychobiology of Suicidal Behavior*, J.J. Mann and M. Stanley (eds). New York Academy of Science, New York, pp 165-182, 1987.
64. Meltzer, H.Y., Lowy, M.T., Robertson, A., Gormley, G.J., Reder, A.T., Hospelhorn, V.D. and Antel, J.P.: The hypothalamic-pituitary-adrenal axis abnormality in depression: relation to the glucocorticoid receptor. In: *Perspectives in Psychopharmacology*, J. Barchas & W.E. Bunney (eds). Alan R. Liss, Inc., New York, pp 553-570, 1988.
65. Meltzer, H.Y. and Nash, J.F., Jr.: Serotonin and Mood: Neuroendocrine aspects. In: *Current Topics in Neuroendocrinology*, Vol. 8. D. Granten and D. Pfaff (eds). Springer-Verlag, Heidelberg, Germany, pp 183-210, 1988.
66. Meltzer, H.Y.: Clozapine: The next stage in drug treatment of schizophrenia. In: *Psychiatry Letter VI*, M.S. Gold, A.C. Pottash and I. Extein (eds). pp 10-14, 1988.
67. Koenig, J.I., Meltzer, H.Y. and Gudelsky, G.A.: Hormone responses to selective serotonin receptor stimulation in the rat. In: *5-HT Agonists As Psychoactive Drugs*, R.H. Reich and G.A. Gudelsky (eds). NPP Books, Ann Arbor, Michigan, pp 283-298, 1988.
68. Gudelsky, G.A., Koenig, J.I. and Meltzer, H.Y.: Involvement of serotonin receptor subtypes in thermoregulatory responses. In: *5-HT Agonists As Psychoactive Drugs*, R.H. Reich and G.A. Gudelsky (eds). NPP Books, Ann Arbor, Michigan, pp 127-142, 1988.
69. Meltzer, H.Y.: Clozapine: Clinical advantages and biological mechanisms. In: *Schizophrenia: A Scientific Focus*, International Conference on Schizophrenia, S.C. Schulz and Tamminga C. (eds). Oxford Press, New York, pp 302-309, 1988.
70. Pincus, H., Goodwin, F.K., Barchas, J.D., Cohen, D.J., Judd, L.L., Meltzer, H.Y. and Vaillant, G.E.: Chapter 4: The future of the science of psychiatry. In: *Future of Psychiatry*, J.A. Talbot (ed). APA Press, pp 75-106, 1989.
71. Meltzer, H.Y.: Clozapine. In: *Neuroscience Year*, Supplement 1 to the *Encyclopedia of Neuroscience*, G. Adelman (ed). Birkhäuser, Boston-Basel-Berlin, pp 32-34, 1989.
72. Meltzer, H.Y. and Lowy, M.T.: The neuroendocrine system and suicide. In: *Report of the Secretary's Task Force on Youth Suicide, Volume 2: Risk Factors for Youth Suicide*, L. Davidson and M. Linnoila (eds). U.S. Government Printing Office, pp 2-235-2-246, 1989.
73. Meltzer, H.Y. and Zureick, J.L.: Negative symptoms in schizophrenia. A target for new drug development. In: *Clinical Pharmacology in Psychiatry*, Volume 1, S.G. Dahl and L.F. Gram (eds). (Psychopharmacology Series 7), Springer-Verlag, Berlin, Heidelberg, pp 68-77, 1989.
74. Nash, J.F. and Meltzer, H.Y.: Chapter 13: Neuroendocrinological effects of MDMA (Ecstasy) in the rat. In: *Ecstasy: The Clinical Pharmacological and Neurotoxicological Effects of the Drug MDMA*, S.J. Peroutka (ed). Kluwer Academic Publishers, Norwell, MA, pp 225-239, 1990.

75. Gudelsky, G.A., Nash, J.F., Koenig, J.I. and Meltzer, H.Y.: Serotonin agonist-induced corticosterone and prolactin secretion. In: *Serotonin: From Cell Biology to Pharmacology and Therapeutics*, P. Paoletti, P.M. Vanhoutte, N. Brunello and F. Majgi (eds). Kluwer Academic Publishers, Netherlands, pp 589-593, 1990.
76. Lowy, M.T., Gormley, G.J., Reder, A.T. and Meltzer, H.Y.: Immune function, glucocorticoid receptor regulation and depression. In: *Depressive Disorders and Immunity*, A.H. Miller (ed). American Psychiatric Association Press pp 105-134, 1990.
77. Meltzer, H.Y.: Clozapine: mechanism of action in relation to its clinical advantages. In: *Recent Advances in Schizophrenia*, A. Kales, G.N. Stefanos and J.A. Talbot (eds). Springer-Verlag, Heidelberg, New York and Tokyo, pp 237-246, 1990.
78. Meltzer, H.Y.: Presynaptic receptors: Relevance to psychotropic drug action in man. In: *Presynaptic Receptors and the Question of Autoregulation of Neurotransmitter Release*, S. Kalsner and T.C. Westfall (eds). *Annals of the New York Academy of Sciences* 604:353-371, 1990.
79. Meltzer, H.Y., Gudelsky, G.A. and Koenig, J.I.: Antipsychotics, tricyclic antidepressants and lithium on neuroendocrine function. In: *Handbook of Clinical Psychopharmacology*, P. Loosen and C.B. Nemeroff (eds). Guilford Press, New York, 1990.
80. Meltzer, H.Y.: Role of serotonin in depression. In: *The Neuropharmacology of Serotonin*, P.M. Whitaker-Azmitia and S.J. Peroutka (eds). *Annals of the New York Academy of Sciences* 600:486-500, 1990.
81. Meltzer, H.Y.: Chapter 24: Atypical antipsychotic drugs: the 5-HT₂/DA₁ ratio. In: *5-Hydroxytryptamine in Psychiatry. A Spectrum of Ideas*, M. Sandler, A. Coppen and S. Harnett (eds). Oxford University Press, London, England, pp 331-335, 1991.
82. Meltzer, H.Y.: Dopaminergic and serotonergic mechanisms in the action of clozapine. Chapter 33. In: *Advances in Neuropsychiatry and Psychopharmacology. Volume 1: Schizophrenia Research*, S.C. Schulz and C.A. Tamminga (eds). Raven Press Ltd., New York, pp 335-340, 1991.
83. Nash, J.F. and Meltzer, H.Y.: Chapter 4: Neuroendocrine studies in psychiatric disorders: The role of serotonin. In: *The Role of Serotonin in the Psychiatric Disorders*, S.L. Brown and H.M. van Praag (eds). Brunner-Mazel, New York, pp 57-90, 1991.
84. Meltzer, H.Y., Gudelsky, G., Lowy, M.T., Nash, J.F. and Koenig, J.I.: Chapter 11: Neuroendocrine effects of buspirone mediated by dopaminergic and serotonergic mechanisms. In: *Buspirone: Mechanisms and Clinical Aspects*, G. Tunnicliff, A. Eison and D. Taylor (eds). New York: Academic Press, Inc. pp 177-192, 1991.
85. Meltzer, H.Y. and Arora, R.C.: Chapter 6: Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality? In: *5-Hydroxytryptamine in Psychiatry. A Spectrum of Ideas*, M. Sandler, A. Coppen and S. Harnett (eds). Oxford University Press, London, England, pp 50-89, 1991.
86. Meltzer, H.Y.: The effect clozapine and other of atypical antipsychotic drugs on negative symptoms. *Negative Versus Positive Schizophrenia*, A. Marneros, N.C. Andreasen and M.T. Tsuang (eds). Springer-Verlag, Heidelberg-Berlin, pp 365-375, 1991.
87. Gudelsky, G.A. and Meltzer, H.Y.: Neuropharmacology of atypical antipsychotics: Potential mechanisms of action. In: *Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders*, D. Nerozzi and H.Y. Meltzer (eds). Elsevier Scientific Publishers, B.V., Excerpta Medica, pp 31-37, 1991.
88. Meltzer, H.Y.: Atypical antipsychotic drugs: a clinical update. In: *Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders*, D. Nerozzi and H.Y. Meltzer (eds). Elsevier Scientific Publishers, B.V., Excerpta Medica, pp 59-65, 1991.
89. Costall, B., Domeney, A.M., Kelly, M.E., Naylor, R.J. and Meltzer, H.Y.: 5-HT₂ receptor antagonists: Preclinical and clinical considerations. In: *Biological Psychiatry - Volume 1*, G. Racagni, N. Brunello and T. Fukuda (eds). Excerpta Medica, Elsevier Science Publishers, pp 538-540, 1991.
90. Meltzer, H.Y. and Stockmeier, C.A.: 5-HT₂, 5-HT_{1C}, and DA₁ receptors in the action of clozapine and other atypical anti-psychotic drugs. In: *Biological Psychiatry - Volume 1*, G. Racagni, N. Brunello and T. Fukuda (eds). Excerpta Medica, Elsevier Science Publishers, pp 570-573, 1991.
91. Meltzer, H.Y.: Studies of ondansetron in schizophrenia. In: *Biological Psychiatry - Volume 2*, G. Racagni, N. Brunello and T. Fukuda (eds). Excerpta Medica, Elsevier Science Publishers, pp 891-893, 1991.
92. Ichikawa, J. and Meltzer, H.Y.: Effect of chronic atypical antipsychotic drugs on basal and amphetamine-induced dopamine (DA) release. In: *Biological Psychiatry - Volume 2*, G. Racagni, Brunello, N. and T. Fukuda (eds). Excerpta Medica, Elsevier Science Publishers, pp 831-833, 1991.
93. Meltzer, H.Y.: Pharmacologic treatment of negative symptoms. Progress in Psychiatry Series #28. In: *Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications*, J.F. Greden and R. Tandon (eds). American Psychiatric Press, Inc., Washington, DC, pp 214-231, 1991.

94. Gudelsky, G.A. and Meltzer, H.Y.: Clozapine: A major advance in the treatment of schizophrenia. Clinical and basic studies. In: *Reflections on Modern Psychiatry*, D. Kupfer (ed). American Psychiatric Research, pp 105-116, 1992.
95. Meltzer, H.Y.: The role of dopamine in schizophrenia. In: *Clinical and Experimental Psychiatry Monograph No. 6: New Biological Vistas on Schizophrenia*, J.-P. Lindenmayer and S.R. Kay (eds). New York, Brunner/Mazel, Inc., pp 131-157, 1992.
96. Meltzer, H.Y. and Gudelsky, G.A.: Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. In: *Arzneimittel-Forschung Drug Research* 42:268-272, 1992.
97. Meltzer, H.Y.: Preface. *Novel Antipsychotic Drugs*. H.Y. Meltzer (ed). New York, Raven Press xv, 1992.
98. Meltzer, H.Y.: Chapter 1: The mechanism of action of clozapine in relation to its clinical advantage. *Novel Antipsychotic Drugs*. H.Y. Meltzer (ed). New York, Raven Press, pp 1-13, 1992.
99. Meltzer, H.Y.: Chapter 4: Pattern of efficacy in treatment-resistant schizophrenia. *Novel Antipsychotic Drugs*. H.Y. Meltzer (ed). New York, Raven Press, pp 33-46, 1992.
100. Meltzer, H.Y.: The neuroendocrine profile of clozapine, an atypical antipsychotic agent. In: *Clozapine: A Compendium of Selected Readings*, J. Yesavage (ed). Current Medical Directions, Inc., New York pp 41-48, 1992.
101. Meltzer, H.Y.: Serotonin receptors and antipsychotic drug action. In: *Clinical Pharmacology in Psychiatry. Strategies in Psychotropic Drug Development*, L.F. Gram, L.P. Balant, H.Y. Meltzer and S.G. Dahl, (eds). Psychopharmacology Series, Springer-Verlag, Heidelberg, pp 70-81, 1993.
102. Meltzer, H.Y.: Preface. In: *Clinical Pharmacology in Psychiatry. Strategies in Psychotropic Drug Development*. L.F. Gram, L.P. Balant, H.Y. Meltzer and S.G. Dahl, (eds). Psychopharmacology Series, Springer-Verlag, Heidelberg, 1993.
103. Meltzer, H.Y.: Utilization, multidimensional outcome measures, and risk-benefit considerations for the use of clozapine in schizophrenia. In: *Proceedings of the International Academy for Biomedical and Drug Research: "New Generation of Antipsychotic Drugs: Novel Mechanisms of Action"*, Karger Press, Milan, pp 105-117, 1993.
104. Meltzer, H.Y.: The treatment of schizophrenia - cost-benefit and risk-benefit issues - Panel Discussion. In: *Proceedings of the International Academy for Biomedical and Drug Research: "New Generation of Antipsychotic Drugs: Novel Mechanisms of Action"*, Karger Press, Milan, pp 143-145, 1993.
105. Meltzer, H.Y.: New drugs for the treatment of schizophrenia. In: *Psychiatric Clinics of North America*, P. Powchick and S.C. Schulz (Eds.) 16:365-383, 1993.
106. Meltzer, H.Y. Role of the serotonergic system in pituitary hormone secretion: the pharmacologic challenge paradigm in man. In: *Second Serotonin from Cell Biology to Pharmacology and Therapeutics*, V. Vanhoutte, P.R. Saxena, R. Paoletti, N. Brunello, and A.S. Jackson (eds). Kluwer Academic Publishers, The Netherlands, 239-247, 1993.
107. Lai, S., Hopkins, A.L., Haacke, E.M., Li, D., Wasserman, B.A., Buckley, P., Friedman, L., Meltzer, H.Y., Hedera, P. and Friedland, R.: Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T: preliminary results. *Magnetic Resonance in Medicine*, Williams & Wilkins, Baltimore, M.D., pp 387-392, 1993.
108. Meltzer, H.Y., Maes, M. and Elkis, H.: The biological basis of refractory depression. In: *Refractory Depression: Current Strategies and Future Directions*, W. Nolen, J. Zohar, S. Roose and J. Amsterdam (Eds.), Wiley & Sons, Ltd., England, pp 177-198, 1994.
109. Meltzer, H.Y.: Clozapine and other atypical neuroleptics: Efficacy, side effects, optimal utilization. In: "Update on Serotonin/Dopamine Antagonists in Psychiatry", H.Y. Meltzer (ed.) *Journal of Clinical Psychiatry Monograph Series* 12:38-42, 1994.
110. Buckley, P.F. and Meltzer, H.Y.: Treatment of schizophrenia. In: *Textbook of Psychopharmacology*, A. Schatzberg (Ed.), APA, Inc., Washington, DC, pp 615-639, 1994.
111. Elkis, H., Friedman, L., Lys, C. and Meltzer, H.Y.: Relationship between positive and negative symptoms: response to antipsychotic drugs and structural brain abnormalities. *Past, Present and Future of Psychiatry. IX World Congress of Psychiatry. Volume 1*, Rio De Janeiro, Brazil. A. Beigel, J.J. Lopez Ibor Jr. and J.A. Costa e Silva (Eds.), World Scientific Press, Singapore, pp 430-434, 1994.
112. Maes, M. and Meltzer, H.Y.: Chapter 81. The serotonin hypothesis of depression. In: *Psychopharmacology: The Fourth Generation of Progress*. C.B. Nemeroff and D. Kupfer (Eds.), Raven Press, New York, New York, pp 933-944, 1995.
113. Meltzer, H.Y.: Dopamine, serotonin and hormones: relation to psychopathology. In: *Schizophrenia. Alfred Benzon Symposium No. 38*, R. Fog, J. Gerlach and R. Hemmingen (Eds.). Munksgaard International Publishers, Ltd., Copenhagen, Denmark, pp 74-91, 1995.

114. Meltzer, H.Y.: Chapter 108. Atypical antipsychotic drugs. In: *Psychopharmacology: The Fourth Generation of Progress*. C.B. Nemeroff and D. Kupfer (Eds.), Raven Press, New York, New York, pp 1277-1286, 1995.
115. Roth, B.L. and Meltzer, H.Y.: Chapter 102. The role of serotonin in schizophrenia. In: *Psychopharmacology: The Fourth Generation of Progress*. C.B. Nemeroff and D. Kupfer (Eds.), Raven Press, New York, New York, pp 1215-1227, 1995.
116. Meltzer, H.Y.: Schizophrenia-psychotic continuum or distinct entities: perspective from psychopharmacology. In: *Proceedings from the Heidelberg Continuum Conference*, A. Marneros, N.C. Andreasen, M.T. Tsuang (Eds.), pp 31-55, 1995.
117. Yamamoto, B.K. and Meltzer, H.Y.: Basic neuropharmacology of antipsychotic drugs. In: *Treatments of Psychiatric Disorders: The DSM-IV Edition*, G.O. Gabbard (Ed.), American Psychiatric Press, Inc., Washington, DC, pp 947-967, 1995.
118. Meltzer, H.Y.: The concept of atypical antipsychotics. In: *Advances in the Neurobiology of Schizophrenia, Volume 1*, I.A. den Boer, H.G.M. Westenberg and H.M. van Praag (Eds.), Wiley & Sons, Ltd., England, pp 265-273, 1995.
119. Meltzer, H.Y.: Chapter 1. Schizophrenia treatment strategies. In: *Neurotherapeutics Emerging Strategies*, L. Pullen and J. Patel (Eds.), Humana Press, Totowa, New Jersey, pp 1-34, 1995.
120. Meltzer, H.Y.: The role of serotonin receptor antagonism: the action of atypical antipsychotic drugs. In: *Serotonin in the Central Nervous System and Periphery*, A. Takada and G. Curzon (Eds.), Elsevier Science B.V. Excerpta Medica, pp 169-174, 1995.
121. Meltzer, H.Y. and Fatemi, S.H.: Predictors of response to neuroleptics and clozapine in mood disorders and schizophrenia. In: *Predictors of Treatment-Response in Mood Disorders*, P.J. Goodnick (Ed.), American Psychiatric Press, Washington, DC pp 147-176, 1995.
122. Meltzer, H.Y., Yamamoto, B.K., Lowy, M.T. and Stockmeier, C.A.: The mechanism of action of atypical antipsychotic drugs: an update. In: *Biology of Schizophrenia and Affective Disease - ARNMD Series*, S.J. Watson (Ed.), American Psychiatric Press, Inc., Washington, D.C., pp 451-492, 1996.
123. Meltzer, H.Y. and Fatemi, S.H.: Chapter 5. The role of serotonin in schizophrenia and the mechanism of action of anti-psychotic drugs. In: *Serotonergic Mechanisms in Antipsychotic Treatment*, J.M. Kane, H.-J. Möller and F. Aouwers (Eds.), Marcel Dekker, New York, pp 77-107, 1996.
124. Meltzer, H.Y.: Cognitive and other nonconventional benefits of clozapine treatment. *Journal of Clinical Psychiatry Monograph* 14:22-23, 1996.
125. Meltzer, H.Y.: Introduction. *Journal of Clinical Psychiatry Monograph* 14:2, 1996.
126. Meltzer, H.Y.: Suicidality and clozapine. *Journal of Clinical Psychiatry Monograph* 14:16-14, 1996.
127. Meltzer, H.Y.: The clozapine story. In: *Clinical Trials in CNS Psychopharmacology*, M. Hertzman and D. Feltner (Eds.), New York University Press, New York (Submitted) 1994.
128. Meltzer, H.Y., Alphas, L.D., Bastani, B., Kwon, K.Y. and Ramirez, L.F.: One year outcome of study of clozapine in treatment-resistant schizophrenia. *World Congress of Biological Psychiatry*, Springer-Verlag, Heidelberg-Berlin (In Press) 1996.
129. Meltzer, H.Y. and Ranjan R.: Chapter 12: Efficacy of novel antipsychotic drugs in treatment-refractory schizophrenia. In: *Handbook of Experimental Pharmacology, Antipsychotics*, J.G. Csernansky (Ed.), Springer-Verlag Publishers, Heidelberg, 120 (In Press) 1996.
130. Meltzer, H.Y.: Clozapine. In: *Neuroscience Year*, Supplement 2 to the *Encyclopedia of Neuroscience*, G. Adelman and B. Smith (Eds.), Elsevier Science Publishers, New York, (In Press) 1996.
131. Meltzer, H.Y.: Pharmacological treatment of negative symptoms. In: *Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications*, American Psychiatric Press Progress in Psychiatry Series (In press) 1996.
132. Buckley, P.F. and Meltzer, H.Y.: Schizophrenia and the organic psychoses. *Current Practices of Medicine - Psychiatry Volume* (In Press) 1996.
133. Fatemi, S.H., Meltzer, H.Y. and Roth, B.L.: Atypical antipsychotic drugs: clinical and preclinical studies. In: *Handbook of Experimental Pharmacology, Antipsychotics*, J.G. Csernansky (Ed.), Springer-Verlag Publishers, Heidelberg (Submitted) 1996.
134. Meltzer, H.Y.: Atypical antipsychotic drug therapy for treatment-resistant schizophrenia. In: *Schizophrenia*, S.R. Hirsch and D. Weinberger (Eds.), Blackwell Scientific Publications, Oxford, England (In Press) 1996.

135. Meltzer, H.Y. and Fatemi, S.H.: Schizophrenia. In: *Corn's Current Therapy*, R.E. Rakel (Ed.), W.B. Saunders Company, Harcourt Brace & Company, Houston (Submitted) 1996.
136. Meltzer, H.Y.: Chapter 21. A career in biological psychiatry. In: *The Psychopharmacologists*, Interviews by Dr. David Healy. Chapman & Hall, London, United Kingdom, 1996.

BOOK REVIEWS, SPECIAL ARTICLES AND LETTERS


1. Meltzer, H.Y. and Haven, L.: Schizophrenia and vitamin therapy. *Journal of the American Medical Association* 197:827, 1966.
2. Meltzer, H.Y.: Intramuscular chlorpromazine and creatine kinase: acute psychosis or local muscle trauma. Technical comment in response to technical comment of Warnock, D. and Ellman, G., *Science* 164:726, 1969.
3. Meltzer, H.Y.: Possible mechanism of increase intravascular clotting in malignant hyperpyrexia. *Lancet* 1:918, 1971.
4. Meltzer, H.Y.: Interpretation of CPK activity (Letter). *Journal American Medical Association* 229:1169, 1974.
5. Pscheidt, G.R. and Meltzer, H.Y.: Lithium and pyruvate kinase. *Lancet* 1:932, 1975.
6. Meltzer, H.Y. and Pscheidt, G.R.: Siliconising agent inhibits platelet MAO. Letter to the Editor, *Lancet*, p 474, August 28, 1976.
7. Meltzer, H.Y.: Black-white difference in serum CPK activity. Letter to the Editor. *Archives of Internal Medicine* 136:1336, 1976.
8. Meltzer, H.Y., Goode, D.J., Fang, V.S., Schyve, P. and Young, M.: Dopamine and schizophrenia. *Lancet* 2:1142, 1976.
9. Meltzer, H.Y.: Dopamine receptors and average clinical doses. *Science* 194:545-546, 1976.
10. Meltzer, H.Y.: Dopamine receptor and average clinical doses. (Letter to the Editor) *Science* 194:545-546, 1979.
11. Meltzer, H.Y.: *Review of Aromatic Amino Acid Hydroxylases and Mental Disease*. M.B.H. Youdim (ed). John Wiley & Sons, Somerset, New Jersey, ix + 390 pp, 1983.
12. Meltzer, H.Y. and Teuring, P.: Antipsychotic and MAO activities: Reply. Letter to the Editor. *American Journal of Psychiatry* 140:956-957, 1983.
13. Meltzer, H.Y., Tricou, B.J., Robertson, A. and Lowy, M.T.: Hormone response to 5-HTP. Letter to the Editor. *Psychiatry Research* 10:151-152, 1983.
14. Lowy, M.T., Reder, A.T. and Meltzer, H.Y.: Hypercortisolism and depression. Letter to the Editor. *New England Journal of Medicine* 312:791, 1985.
15. Lowy, M.T., Reder, A.T., Antel, J.P. and Meltzer, H.Y.: Lymphocyte sensitivity to glucocorticoids. Letter to the Editor. *American Journal of Psychiatry* 142:989-990, 1985.
16. Meltzer, H.Y. and Locascio, J.J.: Positive and negative subtypes in schizophrenia. Letter to Editor. *American Journal of Psychiatry* 144:1366-1367, 1987.
17. Meltzer, H.Y.: *Review of Neuropharmacology of Serotonin*. A.R. Green (ed). Oxford University Press, New York, New York, 1985. 420 pp. *American Journal of Psychiatry* 144:1233, 1987.
18. Meltzer, H.Y.: Letter to the Editor. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. *Archives of General Psychiatry* 46:672, 1989.
19. Meltzer, H.Y.: Letter to the Editor. Clozapine and electroconvulsive therapy. *Archives of General Psychiatry* 47:290-291, 1989.
20. Meltzer, H.Y.: *Review of Receptors and Ligands in Psychiatry*. A.K. Sen and T. Lee (eds). Cambridge University Press, Cambridge, United Kingdom, 578 pp, ill., *Neurology* 40:1156, 1990.
21. Parsa, M., Rhor, T., Ramirez, L.F. and Meltzer, H.Y.: Neuroleptic malignant syndrome without neuroleptics. *Journal of Clinical Psychopharmacology* 10:437-438, 1990.
22. Meltzer, H.Y.: Section 1: Biologic Psychiatry. Literature reviews. In: *The Year Book of Psychiatry and Applied Mental Health*. Talbot, J.A. (Editor-in-Chief). Year Book Medical Publishers, Inc., Chicago, London, Boca Raton, Littleton, Massachusetts, pp 1-59, 1990.
23. Meltzer, H.Y.: Letter to the Editor. Advances in the Clinical Use of Clozapine. In: *Psychiatry Letter*, R. Schaumburg (ed), 1990.
24. Meltzer, H.Y.: Research Highlights. Clozapine: Who benefits and at what cost? In: *Focus on Mental Health Services Research*. Bergman, G.T. (ed). Washington, DC, Foundation for Health Services Research, pp 3-8, 1991.
25. Lee, H.S., Kwon, K.Y., Alpha, L.D. and Meltzer, H.Y.: Letter to the Editor: Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. *Journal of Clinical Psychopharmacology* 11:222-223, 1991.

26. Gerson, S.L., Lieberman, J.A., Friedenberg, W.R., Lee, D., Marx, Jr., J.J. and Meltzer, H.Y.: Polypharmacy in fatal clozapine-associated agranulocytosis. *The Lancet* 338:262, 1991.
27. Sajatovic, M., Verbanac, P., Ramirez, L.F. and Meltzer, H.Y.: Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. *Neurology* 41:156, 1991.
28. Calabrese, J.R., Meltzer, H.Y. and Markovitz, P.J.: Clozapine prophylaxis in rapid cycling bipolar disorder. Letter to Editor. *Journal of Clinical Psychopharmacology* 11:396-397, 1991.
29. Meltzer, H.Y.: Letter to the Editor. Response - Clozapine versus chlorpromazine treatment. *Archives of General Psychiatry*, 1991.
30. Meltzer, H.Y. and Kane, J.: Letter to the Editor. Response. *Archives of General Psychiatry*, 1991.
31. Meltzer, H.Y.: Clozapine-like antipsychotic drugs. In: *The Psychiatric Times*, 1991.
32. Meltzer, H.Y.: Race and platelet activity in schizophrenic patients. Letter to the Editor. *Psychiatry Research*, 1991.
33. Meltzer, H.Y.: A new class of drug for the treatment of depression. *Symposium Digest*, 1991.
34. Meltzer, H.Y.: Review of *International Perspectives in Schizophrenia: Biological, Social and Epidemiological Findings*, M. Weller (ed). John Libbey and Company, Ltd., *Journal of Neuropsychopharmacology*, 1991.
35. Meltzer, H.Y.: Atypical antipsychotic drugs: A clinical update. In: *The Psychiatric Times*, 1991.
36. Meltzer, H.Y., Alphs, L.D., Bastani, B., Ramirez, L.F. and Kwon, K.: Clinical efficacy of clozapine in the treatment of schizophrenia. *Pharmacopsychiatry* 24:44-45, 1991.
37. Alphs, L.D., Meltzer, H.Y., Bastani, B. and Ramirez, L.F.: Side effects of clozapine and their management. *Pharmacopsychiatry* 24:46, 1991.
38. Parsa, M., Ramirez, L.F., Loula, E.C. and Meltzer, H.Y.: Effect of clozapine on psychotic depression and Parkinsonism. Letter to the Editors. *Journal of Clinical Psychopharmacology* 11:330-331, 1991.
39. Sajatovic, M., Verbanac, P., Ramirez, L.F. and Meltzer, H.Y.: Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. *Neurology* 41:156, 1991.
40. Meltzer, H.Y. and Stockmeier, C.A.: Occupancy of D₂ receptors. *Archives of General Psychiatry* 49:588-589, 1992.
41. Meltzer, H.Y., Lee, H.S. and Nash, J.F.: Letter to the Editor. Effects of buspirone on prolactin secretion is not mediated by 5-HT_{1A} receptor stimulation. *Archives of General Psychiatry* 49:163, 1992.
42. Lee, H.S., Kwon, K.Y., Meltzer, H.Y. and Alphs, L.: Clozapine treatment of polydispsia: a prolactin connection? Reply to Dr. Verghese and associates. Letter to the Editors. *Journal of Clinical Psychopharmacology* 12:218, 1992.
43. Meltzer, H.Y.: Discussion. *The Cost of Schizophrenia*, Edited by Robert Michels. Round Table Series 27. Hypothetical Situations. Royal Society of Medicine, pp 30-32, 1992.
44. Parsa, M.A., Al-Lahham, Y.H., Ramirez, L.F. and Meltzer, H.Y.: Prolonged psychotic relapse after abrupt clozapine withdrawal. Letter to the Editor. *Journal of Clinical Psychopharmacology* 13:154-155, 1993.
45. Buckley, P.F. and Meltzer, H.Y.: Clozapine and NMS. *British Journal of Psychiatry* 163:566, 1993.
46. Meltzer, H.Y.: Quality of life in schizophrenia: importance for psychopharmacology research and practice. *Quality of Life Newsletter* 2:8-9, 1994.
47. Meltzer, H.Y. and Ranjan, R.: Valproic acid treatment of clozapine-induced myoclonus. *American Journal of Psychiatry* 151:1246-1247, 1994.
48. Meltzer, H.Y.: Letter to Editor. Serotonin_{1A} receptors in schizophrenia: relation to suicide. *Archives of General Psychiatry* 51:1003, 1994.
49. Meltzer, H.Y.: Penetrating the secrets of schizophrenia: the history of clozapine therapy. *Sandoz Bulletin* 30:16-22, 1994.
50. Buckley, P.F., Sajatovic, M. and Meltzer, H.Y.: Treatment of delusional disorders with clozapine. *American Journal of Psychiatry* 151:1394-1395, 1994.

51. Meltzer, H.Y. and Cola, P.: Response. Clozapine's cost effectiveness. *American Journal of Psychiatry* 152:151-154, 1995.
52. Meltzer, H.Y.: Neuroleptic withdrawal in schizophrenic patients: an idea whose time has come. *Archives of General Psychiatry* 52:200-202, 1995.
53. Meltzer, H.Y.: Clozapine: Is Another View Valid? (Editorial) *American Journal of Psychiatry* 152(6):821-825, 1995.
54. Meltzer, H.Y., Ranjan, R., Lee, M.A. and Kennedy, J.: Emerging clinical uses of clozapine. *Reviews in Contemporary Pharmacotherapy: Emerging Clinical Claims for Clozapine*. S. Johnson and F.N. Johnson (Eds.), Marius Press, RICP, Lancashire, United Kingdom, 6:187-195, 1995.
55. Masellis, M., Peterson, A.D., Badri, F., Lieberman, J.A., Meltzer, H.Y., Cavazzoni, P. and Kennedy, J.L.: Genetic variation of 5-HT_{2A} receptor and response to clozapine. *Lancet* 346:1108, 1995.
56. Bunney, W.E. Jr. and Meltzer, H.Y.: Schizophrenia overview. In: *Clinical Neuroscience*, W.E. Bunney, Jr. and H.Y. Meltzer (Eds.), Wiley-Liss, New York, 3:55-56, 1995.
57. Buckley, P.F. and Meltzer, H.Y.: Clozapine and NMS. *British Journal of Psychiatry* (In Press) 1995.
58. Meltzer, H.Y. and Fibiger, H.C.: Olanzapine: a new atypical antipsychotic drug. (Editorial) *Neuropsychopharmacology* 14:83-85, 1996.
59. Meltzer, H.Y.: Clozapine withdrawal: serotonergic or dopaminergic mechanisms? *Archives of General Psychiatry* (Submitted) 1996.

PUBLICATIONS (Needs Update on Count)

505	Published Papers
20	Manuscripts in Preparation or Submitted
136	Book Chapters
59	Book Reviews, Special Articles and Letters
118	Abstracts



CURRICULUM VITAE

ALAN MENDELOWITZ, M.D.


5/8/97

ADDRESS:

Home:

REDACTED

Office:

Hillside Hospital,
Division of Long Island Jewish
Medical Center
75-59 263 Street
Glen Oaks, New York 11004
(718) 470-8397

SOCIAL SECURITY NO.

REDACTED

BIRTH DATE/PLACE:

July 14, 1960; Hollywood, Florida

MARITAL STATUS:

Married

EDUCATION:

1978-1982

Rutgers College - B.A.
New Brunswick, New Jersey
Phi Beta Kappa; Graduated Cum Laude

1983 - 1987

Rutgers Medical School - M.D.
Piscataway, New Jersey

POST GRADUATE TRAINING:

7/87 - 6/91

Internship/Residency
Hillside Hospital
Glen Oaks, New York

7/90 - 6/91

Chief Resident Psychiatry
Hillside Hospital
Glen Oaks, New York

BOARD CERTIFICATION:

1988 - National Board of Medical
Examiners
1992 - American Board of Psychiatry
and Neurology
1994 - Added Qualification in Geriatric
Psychiatry

Page 2

MEDICAL LICENSE:

New York - 1988 - REDACTED

PROFESSIONAL ASSOCIATIONS:

American Medical Association
American Psychiatric Association
Nassau Psychiatric Society

STAFF APPOINTMENTS:

7/91 - Present

Unit Chief - Residency Training/
Research Unit
Responsible for 30 bed acute inpatient
locked psychiatric unit and its
interdisciplinary staff. Coordinate
and supervise teaching program for
second and fourth year psychiatry
residents.
Hillside Hospital
Glen Oaks, New York

10/92 - 10/93

Consulting Psychiatrist to Epilepsy
Center
Provide diagnostic and consultation
services for regional epilepsy center
Long Island Jewish Medical Center
New Hyde Park, New York

ACADEMIC APPOINTMENTS/
TEACHING ACTIVITIES:

7/92 - Present

Assistant Professor of Psychiatry
Albert Einstein College of Medicine
Bronx, New York

2/90 - 7/91

Adjunct Professor, Masters Program
in Rehabilitation Counseling
"Psychiatric Aspects of Counseling"
Hunter College
City University of New York
New York, New York

Page 3

LECTURES/PRESENTATION:

10/94	Treatment Resistant Depression Grand Rounds Woodhull Hospital Brooklyn, N.Y.
10/94	Treatment Refractory Schizophrenia Grand Rounds St. Vincent's Medical Center Staten Island, N.Y.
10/94	New Treatment Strategies for Depression Grand Rounds Kings Park Psychiatric Center
10/94	Risperidone in Treatment - Resistant Schizophrenic & Schizoaffective Patients Poster Session at Hospital and Community Psychiatry Conference
5/94	Risperidone for Treatment Refractory Schizophrenia Poster Session at American Psychiatric Association Meeting
3/94	Novel antipsychotic agents Grand Rounds Coney Island Hospital Coney Island, N.Y.
12/93	Panic Disorder. Etiology and Treatment Teaching Rounds, New York State Office of Disability
10/92	"Ask the Physicians - Advances in Treatment and Research" Sixth Annual Community Conference for Families of the Mentally Ill Hillside Hospital, Glen Oaks, N.Y.
5/92	"Adverse Drug Interactions" Grand Rounds, Pilgrim State Hospital Brentwood, New York
10/91	"Psychotropic Drug Interactions" Grand Rounds, Hillside Hospital, Glen Oaks, New York.

Page 4

8/91

"Psychiatric Aspects of Alcohol, Drugs and AIDS" to graduate students at Hunter College, City University of New York.

1/91

"The Planning and Implementation of a Resident Retreat" at the 1991 National Meeting of the American Association of Directors of Psychiatric Residency Training.

RESEARCH:

7/90 - Present

Participation in inpatient clinical research trials with Clozapine, Risperidone. Coordinate inpatient care of 1st episode study of schizophrenia

PUBLICATIONS:

1993

Lavin MR, Mendelowitz AJ, Kronig MR.
"Spontaneous Hypertensive Reactions with Monoamine Oxidase Inhibitors".
Biological psychiatry 1993 34 146-151

Lavin MR, Mendelowitz AJ, Black S.
"Adverse Reaction to High Dose Fluoxetine (letter). Journal Clinical Psychopharmacology 1993 13 452-453

1992

Leipzig RM, Mendelowitz AJ:
"Psychotropic Drug-Drug Interactions" in Adverse Effect of Psychotropic Drugs. Kane JM, Lieberman JA (Eds), Guilford Publications, New York.

CUT OFF THIS STRIP

978

INSTRUCTIONS
ON REVERSE
DE

READ
INSTR.
ON RE
SIDE

CUT OFF
THIS STRIP

CUT THIS

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED **REDACTED**

MENDELOJITZ ALAN JOEL
REDACTED

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

06/30/98
REGISTRATION PERIOD ENDS

REDACTED
LICENSE/CERTIFICATE NO.

REDACTED
COMMISSIONER OF
EDUCATION

SIGNATURE OF REGISTRANT

REGISTRATION CERTIFICATE --- NOT A LICENSE

[Handwritten Signature] 9/8/97

[Signature] 4/14/98

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE		
UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON, D.C. 20537		
Sections 304 and 1008 (21 U.S.C. 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.		
DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
REDACTED	01-31-2000	\$210.00
SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2, 3, 4, 5	PRACTITIONER	01-19-1997
MEVOLOWITZ, ALAN J MD HILLSIDE HOSPITAL 75-59 263ST GLEN OAKS, NY		11004
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.		

[Signature] 4/14/98

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE		
UNITED STATES DEPARTMENT OF JUSTICE		
DRUG ENFORCEMENT ADMINISTRATION		
WASHINGTON, D.C. 20537		
Sections 304 and 1008 (21 U.S.C. 824 and 858) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.		
DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
REDACTED	01-31-2000	\$210.00
SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2, 3, 3N, 4, 5	PRACTITIONER	01-12-1997
MENDELWITZ, ALAN J MD HILLSIDE HOSPITAL 75-59 253ST GLEN JACS, NY		11004
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.		

CUT OFF THIS STRIP

THE UNIVERSITY OF THE STATE OF NEW YORK

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED **REDACTED**

MENDELWITZ ALAN JOEL
REDACTED

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

76/30/50
REGISTRATION PERIOD ENDS

REDACTED
LICENSE/CERTIFICATE NO.

SIGNATURE OF REGISTRANT

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE --- NOT A LICENSE

4210

READ
INSTRUCTIONS
ON REVERSE
SIDE

CUT OFF
THIS STRIP

8/14/97

CURRICULUM VITAE

Alexander Lewis Miller

Date of Birth: March 15, 1943, Glen Cove, New York

Education:

1965 B.A. Yale University, New Haven, Connecticut
1970 M.D. Washington University Medical School, St. Louis, Missouri

Professional Experience:

1964 (Summer) Research Assistant with Seymour Levine, Ph.D., Department of Psychiatry, Stanford University Medical School
1966-69 (Summers) Research Assistant with Ferris N. Pitts, M.D., Department of Psychiatry, Washington University Medical School
1970-71 Medical Intern, Jewish Hospital of St. Louis (Washington University Affiliated Hospital)
1971-73 Staff Associate, Section on Neurochemistry, National Institute of Mental Health, St. Elizabeth's Hospital, Washington, D.C.
1973-76 Resident in Psychiatry, Massachusetts General Hospital and Clinical Fellow in Psychiatry, Harvard Medical School
1975-76 Clinical and Research Fellow, Massachusetts General Hospital
1976-77 Clinical Assistant in Psychiatry, Massachusetts General Hospital
1976-77 Instructor in Psychiatry, Harvard Medical School
1977-80 Clinical Associate in Psychiatry, Massachusetts General Hospital
1977-80 Assistant Psychiatrist, McLean Hospital
1977-80 Assistant Professor of Psychiatry, Harvard Medical School
1980-87 Associate Professor of Psychiatry, The University of Texas Health Science Center at San Antonio
1986-1989 Chief, Psychiatry Service, Audie Murphy Memorial Veterans Hospital
1987-Present Professor of Psychiatry, The University of Texas Health Science Center at San Antonio
1989-Present Director of Clinical Research, San Antonio State Hospital
1996-Present Director, Schizophrenia Module, Texas Medication Algorithm Project

Licensure: Texas Medical License # [REDACTED] University Health Center-Downtown
West Annex
1115 West Martin
San Antonio, TX 78207

4cvreg

Memberships:

1976	Society for Neuroscience
1976	American Society for Neurochemistry
1974	American Psychiatric Association; Fellow, 1989
1976	American Association for the Advancement of Science
1980	International Society of Cerebral Blood Flow and Metabolism
1980	Bexar County Psychiatric Society
1986-89	National Association of VA Chiefs of Psychiatry
1988	The American College of Psychiatrists
1995	American Society of Clinical Psychopharmacology

Honors:

1966-67	Lange Book Award, Washington University Medical School
1967	Biochemistry Prize, Washington University Medical School
1970	Missouri Medical Association Award
1970	Alpha Omega Alpha, Washington University Medical School
1975-76	Ethel DuPont Warren Fellow, Harvard Medical School
1977	Diplomate, American Board of Psychiatry and Neurology (Psychiatry)
1984	Visiting Scholar, College of Medicine, University of Vermont
1984-86	Visiting Faculty Program in Psychiatry (Sponsored by Mead Johnson Pharmaceutical Division)
1987	Acknowledgment of teaching excellence by senior medical class
1989	Fellowship in the American Psychiatric Association
1995	National Alliance for the Mentally Ill Exemplary Psychiatrist
1996	Listed in <i>The Best Doctors in America®: Central Region 1996-1997</i>
1997	Speakers Bureaus: Zeneca Pharmaceuticals, Eli Lilly and Company, Janssen Pharmaceutica Research Foundation, Novartis Company

Consultantships to Government Agencies:

Department of Veterans Affairs Research Advisory Group

Ad Hoc Grant Reviews:

National Science Foundation
National Institute on Aging
American Heart Association
MacArthur Foundation
Ohio Department of Mental Health and Mental Retardation

March of Dimes Birth Defects Foundation
National Research Review Committee: 1990-94

Journal Reviews and Consultantships:

Journal of Neurochemistry
Science

Archives of General Psychiatry

American Journal of Psychiatry

American Journal of Physiology

Journal of Affective Disorders

New England Journal of Medicine

Consultant to the Neurochemistry and Neuropharmacology Panel of the
National Plan for Schizophrenia Research (NIMH), 1987

Neuroscience Advisory Panel for the Southwest Area, Eli Lilly and Company,
1996

Regional Advisory Meeting to discuss Serlect™, Abbott Psychopharmacology
Venture, Abbott Laboratories, 1996

Dallas Advisory Board for Janssen Pharmaceutica and Research Foundation,
1997

Editorial Board:

Metabolic Brain Disease

Today in Medicine (Contributing Editor)

Courses Taught:

a)	Psychiatry Residents:	Neurophysiology and Neuropharmacology Somatotherapies
b)	Medical Students:	Seniors - Research Elective Juniors - Teaching Seminar Sophomores - Psychopathology Seminar Freshmen - Psychosocial Seminar
c)	Pharmacology Graduate Students:	Neuropsychopharmacology - Intro to Biological Psychiatry
d)	Psychiatrists:	Kerrville State Hospital Staff Development Conference

Clinical Responsibilities:

- a) Mood Disorders Clinic
- b) Department patients referred for psychopharmacological evaluation and treatment.

Committees:

1980-present	Biological Research Committee - Department
1981-1984	Research and Development - Veterans Hospital, Chairman, 1984
1981-1983	Laboratory Animal Resources Committee - University
1982-1984	General Clinical Research Center Advisory Committee - University
1984	Residency Training Coordinator Search Committee, Chairman -Department
1984-1985	Committee on Committees - Medical Faculty
1985-1987	Pharmacy and Therapeutics Committee - University
1985-1986	Medical Faculty Forum Assembly Committee - University
1986	Ad hoc Committee to Evaluate a Joint UTSA-UTHSC Neurobiology Graduate Program - University
1986-1989	Residency Training Committee - Department
1986-1989	Academic Advisory Committee - Department
1986	Committee on Committees - University
1986-1989	Clinical Executive Board - Veterans Hospital
1986-1989	Mental Health and Behavioral Science Council, Chairman - Veterans Hospital
1986-1989	Housestaff Review Committee - Veterans Hospital
1987-1989	Ethics Committee, Chairman - Veterans Hospital
1987-1988	Administrative Executive Board - Veterans Hospital
1987-1988	Medical Faculty Assembly, Secretary/Treasurer - University
1988-1989	Medical Faculty Assembly, Chair - University
1988	Basic Science Departments Self-Study Committee - University
1991-present	Clinical Academic Coordinating Committee - Department
1991-present	Program Coordinating Committee - Department
1995-present	Psychiatry Chairman Search Committee - University

4CVREG

-4-

Grant Support:

1975-1977

and

1979-1986	National Institute of Child Health and Human Development
1976-1980	National Institute of Mental Health
1978-1982	National Science Foundation
1981-1984	Department of the Army
1979-1980	Marion Ireland Benton Trust
1980-present	Mary Yates Fund
1980-1981	Institutional Research Grant
1982-1984	Morrison Trust
1985-1987	Institutional Research Grant
1986-1989	Upjohn Company
1986-1992	Texas Consortium for Biological and Psychiatric Research, The Hogg Foundation
1987-1988	VA RAGs
1988-1991	VA Merit Review
1990-1996	National Institute of Mental Health
1990-1991	Merck Sharp & Dohme Inc. (Remoxipride)
1990-1992	Janssen Foundation (Risperidone)
1990-1991	Sandoz Co.
1991-1992	ICI (Zeneca Pharmaceuticals)
1991-1992	Eli Lilly & Company
1993-present	Zeneca Pharmaceuticals
1993-present	Eli Lilly & Company
1994-present	Pfizer Inc.
1994-present	Friends for Psychiatric Research
1995-present	Abbott Laboratories

4CVREG

-5-

1183

PUBLICATIONS

1. Miller, A.L. and Pitts, F.N., Jr.: Brain succinate semialdehyde dehydrogenase-III. *Journal of Neurochemistry* 14:579-584, 1967.
2. Miller, A.L., Hawkins, R.A., Harris, R.L. and Veech, R.L.: The effects of acute and chronic morphine treatment and of morphine withdrawal on rat brain *in vivo*. *Biochemical Journal* 129:463-469, 1972.
3. Miller, A.L., Hawkins, R.A. and Veech, R.L.: Phenylketonuria: phenylalanine inhibits brain pyruvate kinase *in vivo*. *Science* 179: 904-906, 1973.
4. Miller, A.L., Hawkins, R.A. and Veech, R.L.: The mitochondrial redox state of rat brain. *Journal Neurochemistry* 20:1393-1400, 1973.
5. Hawkins, R.A., Miller, A.L., Nielsen, R.C. and Veech, R.L.: The acute action of ammonia on rat brain metabolism *in vivo*. *Biochemical Journal* 134:1001-1008, 1973.
6. Hawkins, R.A., Miller, A.L., Cremer, J.E. and Veech, R.L.: Measurement of the rate of glucose utilization by rat brain *in vivo*. *Journal of Neurochemistry* 23:917-923, 1974.
7. Miller, A.L., Hawkins, R.A. and Veech, R.L.: Decreased rate of glucose utilization by rat brain *in vivo* after exposure to atmospheres containing high concentrations of CO₂. *Journal of Neurochemistry* 25:553-558, 1975.
8. Miller, A.L. and Shamban, A.: A comparison of methods for stopping intermediary metabolism of developing rat brain. *Journal of Neurochemistry* 28:1327-1334, 1977.
9. Hawkins, R.A. and Miller, A.L.: Loss of radioactive 2-deoxy-D-glucose 6-phosphate from brains of conscious rats: implications for quantitative autoradiographic determination of regional glucose utilization. *Neuroscience* 3:251-258, 1978.
10. Cohen, B.M., Miller, A.L., Lipinski, J.F. and Pope, H.G.: Lecithin in mania: a preliminary report. *American Journal of Psychiatry* 137:242-243, 1980.
11. Miller, A.L.: Use of [2-¹⁴C]glucose for measuring whole brain glucose utilization and its application to the study of the effects of carbon dioxide. In: Cerebral Metabolism and Neural Function (Passonneau, J.V., Hawkins, R.A., Lust, D. and Welsh, F., eds.). Williams and Wilkins, Baltimore, 1980.
12. Stewart, R.M., Hemli, S., Kolodny, E.H., Miller, A.L. and Pallotta, J.A.: Carbohydrate metabolism in phenylketonuria. *Pediatric Research* 14:849-853, 1980.
13. Mandel, M.R., Madsen, J., Miller, A.L. and Baldessarini, R.J.: Intoxication associated with lithium and ECT. *American Journal of Psychiatry* 137:1107-1109, 1980.
14. Miller, A.L.: Brain intermediary metabolism *in vivo*: changes with carbon dioxide, development and seizures. *International Review of Neurobiology* 22:47-82, 1981.
15. Miller, A.L. and Corrdry, D.H.: Brain carbohydrate metabolism in developing rats during hypercapnia. *Journal of Neurochemistry* 36:1202-1210, 1981.
16. Miller, A.L. and Kiney, C.A.: Metabolism of [U-¹⁴C]fluorodeoxyglucose by rat brain *in vivo*. *Life Science* 28:2071-2076, 1981.

4CVREG

-6-

1184

17. Miller, A.L., Shamban, A.T., Corddry, D.H. and Kiney, C.A.: Cerebral metabolic responses to electroconvulsive shock and their modification by hypercapnia. *Journal of Neurochemistry* **38**:916-924, 1982.
18. Miller, A.L., Kiney, C.A., Corddry, D.H., and Staton, D.M.: Interactions between glucose and ketone body use by developing brain. *Developmental Brain Research* **4**:443-450, 1982.
19. Miller, A.L., Kiney, C.A., and Staton, D.M.: Effects of lactate on glucose metabolism of developing rat brain. *Developmental Brain Research* **14**:33-40, 1984.
20. Miller, A.L., The tricarboxylic acid cycle. In: *Developmental Neurochemistry* (Wiggins, R.C., McCandless, D.W., and Enna, S.J., eds.). University of Texas Press, Austin, Texas, pp. 127-159, 1985.
21. Miller, A.L. Carbon dioxide narcosis. In: *Cerebral Energy Metabolism and Metabolic Encephalopathy* (McCandless, D.W., ed.). Plenum Publishing, New York, pp. 143-162, 1985.
22. Eidelberg, E. and Miller, A.L. Effects of sensory deafferentation on glucose metabolism of muscles during locomotion. *Brain Research* **327**:316-318, 1985.
23. Miller, A.L., Bowden, C.L., and Plewes, J. Lithium and impairment of renal concentrating ability. *Journal of Affective Disorders* **2**:115-119, 1985.
24. Miller, A.L., Faber, R.A., Hatch, J.P., and Alexander, H.E. Factors affecting amnesia, seizure duration, and efficacy in ECT. *American Journal of Psychiatry* **146**:692-696, 1985.
25. Miller, A.L. Controversies surrounding the deoxyglucose method. Letter to the Editor, *Trends in NeuroSciences* **9**:62, 1986.
26. Miller, A.L. Regional glucose and beta-hydroxybutyrate use by developing rat brain. *Metabolic Brain Disease* **1**:53-61, 1986.
27. Miller, A.L. and Medina, M.A. Cerebral metabolic effects of organophosphorus anticholinesterase compounds. *Metabolic Brain Disease* **1**:147-156, 1986.
28. Miller, A.L. Alternative energy sources to glucose in brain. In: *Biological Psychiatry 1985* (Shagars, C., Josiassen, R.L., Bridger, W.H., Weiss, K.J., Staff, D., and Simpson, G.M., eds.). Elsevier, New York, pp 1334-1336, 1986.
29. King, T.S., Rohrbach, D.H., Miller, A.L., and Morgan, W.W. Reduced hypothalamic serotonin synthesis and serum luteinizing hormone levels in streptozotocin-diabetic male rats. *Biomedical Research* **8**:137-143, 1987.
30. Miller, A.L., Keenan, R.W., Maas, J.W., and Asch, R.H. Disposition of homovanillic acid in the primate. *Metabolic Brain Disease*, **2**:207-212, 1987.
31. Eidelberg, E., Miller, A.L., Schwartzman, R.J., and Alexander, G.M. Measurements of regional glucose metabolism in studies of motor control. *Journal of Neuroscience Methods* **21**:139-144, 1987.

32. Hawkins, R.A., and Miller, A.L. Deoxyglucose-6-phosphate stability *in vivo* and the deoxyglucose method. *Journal of Neurochemistry* 49:1941-1949, 1987.
33. Bowden, C.L., Miller, A.L., and Seleshi, E. New developments in the treatment of anxiety disorders. *Texas Medicine* 84:38-42, 1988.
34. Miller, A.L. Comparison of labeled glucose and deoxyglucose in rat brain. *Journal of Cerebral Blood Flow and Metabolism* 9:426-427, 1989.
35. Miller, A.L., and Hawkins, R.A. Fluorodeoxyglucose rate constants in rat brain. *Neuroscience*, 30:557-558, 1989.
36. Miller, A.L., The Missing Items. In: Messner, E., Groves, J., and Schwartz, J., Eds. Autognosis: How Psychiatrists Analyze Themselves, Chicago:Yearbook Medical Publishers;1989,91-94.
37. Miller, A.L. Effects of dichloroacetate on regional brain glucose metabolism. *Journal of Cerebral Blood Flow and Metabolism* 2(S1):S211, 1989.
38. Miller, A.L. and Hawkins, R.A. Kinetic models of deoxyglucose metabolism. *Journal of Cerebral Blood Flow and Metabolism* 10:147-148, 1990.
39. Miller, A.L., Hatch, J.P., and Prihoda, T.J. Dichloroacetate increases glucose use and decreases lactate in developing rat brain. *Metabolic Brain Disease* 5:195-204, 1990.
40. Maas, J.W., Contreras, S.A., Miller, A.L., Berman, N., Bowden, C.L., Javors, M.A., Seleshi, E., and Weintraub, S. Studies of catecholamine metabolism in schizophrenia/psychosis-I. *Neuropsychopharmacology* 8:97-109, 1993.
41. Maas, J.W., Contreras, S.A., Miller, A.L., Berman, N., Bowden, C.L., Javors, M.A., Seleshi, E., and Weintraub, S. Studies of catecholamine metabolism in schizophrenia/psychosis-II. *Neuropsychopharmacology* 8:111-116, 1993.
42. Miller, A.L., Maas, J.W., Contreras, S.A., Seleshi, E., True, J.E., Bowden, C.L., and Castiglioni, J. Acute effects of neuroleptics on unmedicated schizophrenics and controls. *Biological Psychiatry* 34:178-187, 1993.
43. Royall, D.R., Mahurin, R.K., True, J., Anderson, B., Brock, I.P., Freeburger, L., Miller, A.L. Executive impairment among the functionally dependent: Comparisons between schizophrenia and the elderly. *American Journal of Psychiatry* 150:1813-1819, 1993.
44. Lyster, C., Miller, A.L., Seidel, D., Kavanagh, J. Polydipsia and Clozapine. *Hospital and Community Psychiatry* 45:610-611, 1994.
45. Funderburg, L.G., Vertrees, J.E., True, J.E., Miller, A.L. Seizures with Clozapine. Letter to the Editor, *American Journal of Psychiatry*, 151, 1840-1841 (1994).
46. Dassori, A.M., Miller, A.L., Saldana, D. Schizophrenia Among Hispanics: Epidemiology, Phenomenology, Course, and Outcome. *Schizophrenia Bulletin*, 21: 303-312, 1995.
47. Brannan, S.K., Miller, A.L., Jones, D.J., Kraemer, G.L. and Petty, F. β -Adrenergic Receptor Changes in Learned Helplessness May Depend on Stress and Test Parameters. *Pharmacology, Biochemistry and Behavior*, 51: 553-556 (1995).

48. Velligan, D.I., Funderburg, L.G., Giesecke, S.L., Miller, A.L.: Longitudinal Analysis of Communication Deviance in the Families of Schizophrenic Patients. *Psychiatry*, 58:6-19, (1995).
49. Miller, A.L., Mahurin, R.K., Velligan, D.I., Maas, J.W.: Negative symptoms of schizophrenia: Where do we go from here? *Biological Psychiatry*, 37: 691-693 (1995).
50. Maas, J.W., Miller, A.L., Tekell, J., Funderburg, L., Silva, J.A., True, J., Velligan, D., Berman, N., Bowden, C.L.: Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. *Journal of Clinical Psychopharmacology*, 15: 361-364 (1995).
51. Silva, J.A., Leong, G.B., Miller, A.L.: Delusional Misidentification Syndromes: Drug Treatment Options. *CNS Drugs* 2:89-102, 1996.
52. Eckert, S.L., Diamond, P.M., Miller, A.L., Velligan, D.V., Funderburg, L.G., and True, J.E. A comparison of instrument sensitivity to negative symptom change. *Psychiatry Research*, 63(1)67-75; 1996.
53. Velligan, D.I., Miller, A.L., Giesecke, S.L., Funderburg, L.G., True, J.E., Mahurin, R.K., Diamond, P., and Hazelton, B.C. The relationship between parental CD and relapse in schizophrenic patients in the one year period following hospital discharge: A pilot study. *Journal of Nervous and Mental Disease*, 184(8):490-496, 1996.
54. Maas, J.W., Bowden, C.L., Miller, A.L., Javors, M.A., Funderburg, L.G., Berman, N., Weintraub, S.T.: Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations. *Schizophrenia Bulletin*, 23(1): 147-154, 1997.
55. Miller, A.L., True, J.E., Funderburg, L., and Maas, J.W., Methodological issues in interpreting plasma HVA levels in studies of schizophrenia, in Plasma Homovanillic Acid in Schizophrenia: Implications for Presynaptic Dopamine Dysfunction. Edited by Friedhoff, A.J. and Amin F. Washington, DC, American Psychiatric Press, Inc. 1997. pp 151-171.
56. Miller, A.L., and Ereshefsky, L. Schizophrenia: how should we look at it? *Journal of Psychopharmacology* 11(1): 21-23, 1997.
57. Brannan, S.K., Jones, D.J. and Miller, A.L. Effects of repeated electroconvulsive shock on brain adrenergic receptors. Submitted to *Biological Psychiatry*.

REVIEWS

Miller, A.L., Review of Neuropsychiatry of Traumatic Brain Injury, (Silver, Yudofsky, Hales, eds.) in *New England Journal of Medicine* 333(9):604-605, 1995.

ABSTRACTS

1. Miller, A.L., Harris, R.L., Veloso, D., and Veech, R.L.: The apparent equilibrium constant of the glutamate-oxaloacetate transaminase reaction, the mitochondrial redox state, and metabolite levels in freeze-clamped rat brain under different dietary conditions. *Trans. Amer. Soc. Neurochem.* 3:106, 1972.
2. Sims, K.L., Miller, A.L. and Pitts, F.N., Jr.: Regional changes in glutamic acid decarboxylase in developing rat brain. *Trans. Amer. Soc. Neurochem.* 3:122, 1972.

3. Miller, A.L., Hawkins, R.A., Harris, R.L. and Veech, R.L.: Effects of acute and chronic morphine administration and withdrawal on rat brain. *Fed. Proc.* 31:1:527 Abs., 1972.
4. Miller, A.L., Hawkins, R.A. and Veech, R.L.: Metabolic effects of phenylalanine on brain. *Fed. Proc.* 32:1:727 Abs., 1973.
5. Miller, A.L., Corddry, D.H. and Kiney, C.A.: Effects of hypercapnia on intermediary metabolism of developing rat brain. *Abst. Soc. Neurosci.* 5:90, 1979.
6. Miller, A.L., Shamban, A.T., Corddry, D.H. and Kiney, C.A.: Brain glucose metabolism during single seizures. *Trans. Amer. Soc. Neurochem.* 11:223, 1980.
7. Miller, A.L., Kiney, C.A., Corddry, D.H. and Staton, D.M.: Interactions between glucose and ketone body use by developing brain. *Abst. Soc. Neurosci.* 6:131, 1980.
8. Miller, A. L. and Kiney, C.A.: Metabolism of [¹⁴C]fluorodeoxyglucose by rat brain *in vivo*. *Trans. Amer. Soc. Neurochem.* 12:264, 1981.
9. Miller, A.L., Jones, D.J., Stavinoha, W.B. and Modak, A.T.: Electrode placement and metabolic effects of electroshock. *Abst. Soc. Neurosci.* 7:377, 1981.
10. Miller, A.L. and Medina, M.A.: Effects of organophosphorus anticholinesterase compounds on brain glucose and energy metabolism. *Third Annual Chemical Defense Bioscience Review*. June, 1983.
11. Miller, A.L., Kiney, C.A. and Staton, D.M.: Depression of cerebral glucose utilization by high blood lactate levels in normoglycemic developing rats. *J. Cerebral Blood Flow Metab.* 3 (Suppl. 1):S672, 1983.
12. Miller, A.L., Faber, R., Alexander, H., Redmond, F.: Seizure duration and memory disturbance with ECT. *Abstracts VII World Congress of Psychiatry*: p. 569, 1983.
13. Eidelberg, E., Miller, A.L. and Lewis, C.S.: Energy metabolism of muscle after sensory deafferentation. Presented at the Satellite Meeting of the International Congress of Physiological Science. August, 1983.
14. Miller, A.L., Kiney, C.A., and Staton, D.M.: Hyperlactatemia decreases CMR_G in developing Brain. *Trans. Amer. Soc. Neurochem.* 15:187, 1984.
15. Miller, A.L., Stone, L.J., and Kwan, J.: Regional brain glucose and energy metabolism in normocapnic and hypercapnic rats during brief seizure activity. *Abst. Soc. Neurosci.* 10:1001, 1984.
16. Jones, D., Ademe, R.M., Stone, L.J. and Miller, A.L.: Effects of alternate day electroconvulsive shock on adrenergic receptors in rat brain. *Abst. Soc. Neurosci.* 10:1132, 1984.
17. Miller, A.L., Faber, R., Hatch, J., and Alexander, H: Seizure duration and the clinical effects of ECT. 1985 American Psychiatric Association Meeting New Research Program and Abstracts, p. 69.
18. Miller, A.L., Stone, L.J., Kwan, J.: Regional Glucose and beta-hydroxybutyrate use by developing rat brain. *Abst. Soc. Neurosci.* 11:1089, 1985.

19. Miller, A.L. Dichloroacetate increases brain glucose use and decreases brain lactate. *Trans. Am. Soc. Neurochem.*, 17:312, 1986.
20. Eidelberg, E., Miller, A.L., Schwartzman, R.J. and Alexander, G.M.: Regional energy metabolic measurements with 2-deoxyglucose. Presented at the Satellite Meeting of the International Congress of Physiological Science. July, 1986.
21. King, T.S., Rohrbach, D.H., Miller, A.L. and Morgan, W.W.: Reduced hypothalamic serotonin synthesis and serum LH levels in streptozotocin-diabetic male rats. *Abst. Soc. Neurosci.*, 12:1415, 1986.
22. Miller, A.L., Kennan, R.W., Maas, J.W., and Asch, R.H.: Disposition of homovanillic acid in the primate. *J. Neurochem.* 48:S29, 1987.
23. Maas, J.W., Contreras, S.A., Bowden, C.L., Seleshi E., Miller, A.L.: Neurotransmitter systems function in schizophrenia/psychosis. *Schizophrenia Research* 2:165, 1989.
24. Maas, J.W., Contreras, S.A., Seleshi, E., True, J.E., Bowden, C.L., Miller, A.L.: Studies of catecholamine metabolism in schizophrenia/psychosis. American College of Neuropsychopharmacology, 28th Annual Meeting, December 1989. page 52.
25. Maas, M.A., Contreras, S.A., Seleshi, E., Bowden, C.L. and Miller, A.L. Catecholamine metabolism in psychotic/schizophrenic patients. *Schizophrenia Research* 4(3):352, 1991.
26. Brannan, S.K., Jones, D.J., and Miller, A.L.: Noradrenergic system changes induced by electroconvulsive shock. 1992 New Research Program and Abstracts (NR43) American Psychiatric Association 145th Annual Meeting, Washington, D.C. May, 1992, page 3.
27. Royall, D.R., Mahurin, R., True, J., Anderson, B., Miller, A.: Executive Impairment in Schizophrenia and Old Age (NR11). 1992 New Research Program and Abstracts, APA 145th Annual Meeting, Washington, D.C. May, 1992, page 51.
28. Maas, J.W., Katz, M.M., Friedhoff, A.J., Guze, S.B., Miller, A.L. Van Praag, H.M., Winokur, G. Neurobiology and Psychopathological States - Are We Looking In the Right Place? 1992 Abstracts of Panels and Posters ACNP 31st Annual Meeting, San Juan, Puerto Rico, December 1992, page 44.
29. Dassori, A.M., Miller, A.L., Velligan, D.I., Saldana, D., Mahurin, R.: Negative Symptoms in Anglo-American and Mexican-American Schizophrenics. *Schizophrenia Research* 9:97, 1993.
30. Mahurin, R.K., Velligan, D.I., Miller, A.L.: Negative Symptom Expression and Cognitive Impairment in Schizophrenic Patients and Their Biological Mothers. *Schizophrenia Research* 9:182, 1993.
31. Miller, A.L., Maas, J.W., Contreras, S., Seleshi, E., True, J.E., Bowden, C., Castiglioni, J.: Acute Effects of Neuroleptics on Unmedicated Schizophrenics and Controls. *Schizophrenia Research* 9:224, 1993.
32. Velligan, D.I., Mahurin R.K., Miller, A.L., Funderburg, L.G.: Communication Deviance and Attentional Deficits. *Schizophrenia Research* 9:273, 1993.

33. Ereshefsky, L., Anderson, C.B., True, J., Saklad, S.R., Riesenman, C., Toney G., Miller, A.L.: Plasma concentration of oral risperidone and active metabolite in schizophrenics. Abstract of the Clinical Pharmacy Meeting, Reno, NV, August, 1993.
34. Anderson C., Clark, W.R., True, J., Ereshefsky, L., Miller, A.L.: Risperidone, a novel antipsychotic, and weight change. Abstract of the American College of Clinical Pharmacy Meeting, Reno, NV, August, 1993.
35. Anderson, C.B., True, J.E., Ereshefsky, L., Miller, A.L.: Risperidone clinical efficacy: Role of metabolite 9-Hydroxy-Risperidone. Abstract of the NCDEU Annual Meeting, Boca Raton, FL, June, 1993.
36. Anderson, C.B., True, J.E., Ereshefsky, L., Miller, A.L., Peters B., Velligan, D.: Risperidone dose, plasma levels and response. Abstract of the American Psychiatric Association 146th Annual Meeting, San Francisco, CA, May, 1993.
37. Maas, J.W., Miller, A.L., Bowden, C.L., Funderburg, L.G. and Silva, J.A. Effects of Clonidine plus Haloperidol in Schizophrenia. Abstract of the NCDEU 34th Annual Meeting, Marco Island, FL, June, 1994.
38. Funderburg LG, True JE, Velligan DI, Miller AL, Moore T (abstract) Neurological changes with clozapine treatment. *Neuropsychopharmacology*, 11:(4): 269, 1994.
39. Giesecke SL, Miller AL, Diamond P, Velligan DI, Funderburg LG, True JE (abstract) Sensitivity to negative symptom change: SANS, NSA, and BPRS-R. *Neuropsychopharmacology*, 11:(4): 270, 1994.
40. Velligan DI, True J, Lefton R, Miller AL (abstract) The functional significance of symptomatology and cognitive dysfunction in schizophrenia. *Neuropsychopharmacology*, 11:(4): 288, 1994.
41. Giesecke SL, Velligan DI, Saldana DH, Diamond P, Funderburg LG, Miller AL (abstract) Validity of the brief psychiatric rating scale and the negative symptom assessment: A tri-ethnic comparison. *Schizophrenia Research*, 15:(1,2):11-12, 1995.
42. Miller AL, Velligan DI, Mahurin R, Maas JW (abstract) On assessing and treating negative symptoms. *Schizophrenia Research*, 15:(1,2):18, 1995.
43. Maas JW, Miller AL, Mahurin R (abstract) A unified hypothesis as to the etiology of the multiple components of the schizophrenic/psychotic syndrome. *Schizophrenia Research*, 15:(1,2): 65-66, 1995.
44. Mahurin R, Miller A, Velligan D, Ryder K, Lancaster J, Fox P (abstract) Brainmap modeling of prefrontal cognitive dysfunction in negative symptom schizophrenia. *Schizophrenia Research*, 15:(1,2):90-91, 1995.
45. Velligan DI, True JE, Lefton RS, Flores C, Miller AL (abstract) Cognitive adaptation training: compensatory strategies in psychosocial intervention with schizophrenic patients. *Schizophrenia Research*, 15:(1,2):222, 1995.
46. Mahurin R, Velligan D, Gieseckes S, Funderburg L, True J, Miller, A, A multifactorial model of executive cognitive dysfunction in schizophrenia. (abstract) Conference on the

Role of Cognitive Dysfunction in Schizophrenia, Mt. Sinai Hospital, New York, April, 1995.

INVITED LECTURES AND PRESENTATIONS

Peruvian Congress of Neurosurgery, Lima, Peru - October 23-27, 1983

Grand Rounds Presentation, The University of Vermont, "Electroconvulsive Therapy: Recent Biological and Clinical Discoveries," Burlington, Vermont - January 8, 1984

Heart of Texas Psychiatric Society, "New and Old Antidepressants," Waco, Texas - March 28, 1985

Hendrick Medical Center, "Differential Diagnosis and Treatment for Depression," Abilene, Texas - May 2, 1985

Granville C. Morton Hospital, "Differential Diagnosis and Treatment for Depression," Dallas, Texas - May 6, 1985

Dallas Diagnostic Association, "Recent Findings in the Diagnosis and Treatment for Anxiety," Dallas, Texas - May 23, 1985

Charter Rio Grande Hospital, "Differential Diagnosis and Treatment for Depression and Anxiety," Laredo, Texas - June 4, 1985

St. Louis Society of Family Physicians, "Differential Diagnosis and Treatment for Depression and Anxiety," St. Louis, Missouri - July 18, 1985

World Congress of Biological Psychiatry, "Brain Energy Sources Alternative to Glucose and Their Possible Role in Normal and Pathological Aging, Correlation with Brain Organic Syndromes," Philadelphia, Pennsylvania - September, 1985

County Psychiatric Society, "Depression: Differential Diagnosis and Treatment," Petersburg, Virginia - September 12, 1985

State Psychiatric Hospital, "New and Old Antidepressants," Big Spring, Texas - September 18-19, 1985

Continuing Medical Education, The University of Texas Health Science Center at San Antonio, "Depression: A Primary Care Approach," San Antonio, Texas - October 4, 1985

Dallas Memorial Hospital, "Differential Diagnosis of Depression and Anxiety: Implications for Drug Treatment," Dallas, Texas - October 7, 1985

Tri-County Medical Society Meeting, "Treatment of Depression," Laredo, Texas - October 12-13, 1985

County Medical Society and Counseling Center, "Differential Diagnosis and Treatment for Depression," Alamogordo, New Mexico - October 24-25, 1985

Grand Rounds Presentation, Texas Tech Health Science Center, "Treatment-resistant Depressions," Lubbock, Texas - February 27-28, 1986

Park Place Hospital, "Differential Diagnosis of Depression and Anxiety: Implications for Drug Treatment," Port Arthur, Texas - April 24, 1986

El Paso Psychiatric Association, "Electroconvulsive Therapy: Update and Recent Findings," El Paso, Texas -- May 23, 1986

Houston Northwest Medical Center, "Differential Diagnosis and Treatment of Anxiety," Houston, Texas -- July 15, 1986

Texas Tech University Health Science Center at El Paso, 5th Annual Psychiatric Symposium, "Anti-depressant Treatments: The New and the Old," El Paso, Texas -- October 2 - 3, 1986

Grand Rounds Presentation Family Practice, The University of Texas Health Science Center at San Antonio, "Rational Use of Sedatives and Tranquilizers in the Elderly," San Antonio, Texas -- October 29, 1986

Hale, Floyd, Briscoe County Medical Society, "Anxiety: Diagnosis and Current Treatment Perspectives," Plainview, Texas -- December 8 - 10, 1987

Texas Tech University Health Science Center at El Paso, "Anxiety: Diagnosis and Current Treatment Perspectives," El Paso, Texas -- August 13, 1987

The University of Texas Health Science Center at San Antonio, Conference on Anxiety Disorders, "Pathophysiological Correlates of Anxiety Disorders," San Antonio, Texas -- November 21, 1987.

Teleconference Network of Texas program "Clinical Topics in Medicine" (course for primary care physicians) in cooperation with the Department of Family Practice at The University of Texas Health Science Center: "Rational Use of Sedatives and Tranquilizers" -- July 28, 1988.

Texas Department of Mental Health and Mental Retardation Physicians' Conference. "Clinical Research Unit Studies of Negative Symptoms of Schizophrenia," Austin, Texas -- October 1, 1990.

Mental Illness Awareness Week Alliance for the Mentally Ill banquet on "Positron Emission Tomography and Negative Symptoms of Schizophrenia," San Antonio, Texas -- October 6, 1990.

Texas Department of Mental Health and Mental Retardation Public-Academic Liaison Committee, "Clinical Research in the TDMHMR System," Austin, Texas -- May 7, 1991.

Corpus Christi Alliance for the Mentally Ill, "San Antonio State Hospital's Clinical Research Unit," Corpus Christi, Texas -- May 21, 1991.

Manic Depressive Association of San Antonio "Clinical Research Unit at San Antonio State Hospital," San Antonio, Texas -- July 29, 1991.

TXMHMR Physician' Conference, "Brain Imaging," Austin, Texas -- September 17, 1991.

Travis County Mental Health and Mental Retardation Agency Annual Retreat, "Clozapine," Austin, Texas -- October 3, 1991.

Seventh National Fairweather Lodge Conference, "Schizophrenia - New Findings - Old Myths," Austin, Texas -- October 30, 1991.

Trevino, F .M., Roberts, R.E., Miller, A.L., Casat, C., Briones, D., Martinez, C.: The NIMH Minority Research Centers: New Initiatives. Center for Cross-Cultural Research. Symposium 31. Presented at the American Psychiatric Association 145th Annual Meeting, May, 1992.

American Society of Mental Health Association Professional's (ASMHAP) Summer Institute, "Medication Issues," San Antonio, Texas -- July 21, 1992.

TXMHMR Physician' Conference, "Brain Imaging," Austin, Texas -- September 17, 1991.

Travis County Mental Health and Mental Retardation Agency Annual Retreat, "Clozapine," Austin, Texas -- October 3, 1991.

Seventh National Fairweather Lodge Conference, "Schizophrenia - New Findings - Old Myths," Austin, Texas -- October 30, 1991.

Texas Alliance for the Mentally Ill (TEXAMI) Conference and Distinguished Speaker Series, "Negative Symptoms of Schizophrenia," San Antonio, Texas -- October 10, 1992

Miller, A.L., Ricketts, R.W.: TXMHMR Physicians' Conference, "Current Research in TXMHMR - Part 1," Houston, Texas -- November 9, 1992

Texas Alliance for the Mentally Ill (TEXAMI) Annual Convention. Workshop presentation "New Hope in Research on Medication", Austin, Texas -- September 24, 1993

Miller, A.L., Funderburg, L., Chiles, J., Ereshefsky, L., Vertrees, J.: 1994 National Alliance for the Mentally Ill (NAMI) Annual Convention "New Drugs for Schizophrenia" San Antonio, Texas -- July 9, 1994

"New antipsychotics," Rio Grande State Center, Harlingen, Texas -- June 16, 1994

"New medications for schizophrenia", Laredo, Texas.-- June 23, 1994.

"New Approaches to Treatment of Schizophrenia", Harris County MHMR, Houston, Texas -- October 12, 1994.

"New Antipsychotics and Approaches to Schizophrenia", Grand Rounds, Department of Psychiatry, Texas Tech Health Sciences Center, Lubbock, Texas -- October 21, 1994.

"New views of psychosis and antipsychotics", Grand Rounds, Department of Psychiatry, Texas A & M Medical School, Temple, Texas -- April 21, 1995.

"Atypical Antipsychotics", Center for Health Care Services, San Antonio, Texas -- May 19, 1995.

"Phenomenology of Psychotic Illnessess", Armed Forces Update in Psychiatry, San Antonio, Texas -- August 24, 1995.

"New Views of Schizophrenic Symptomatology", Grand Rounds, Department of Psychiatry, Texas Tech University Health Sciences Center at El Paso, Texas -- August 25, 1995.

"Psychopharmacology of Violence in Psychosis", Janssen CNS Roundtable, San Antonio -- Texas, September 1, 1995.

"Client, Family and Psychosocial Perspectives" presented at A Community Forum entitled "New Medications: The Impact and Future Value in Treating Severe Mental Illness from Clinical and Budgetary Perspectives." The forum was moderated by A. John Rush, M.D. and Alexander L. Miller, M.D. and sponsored by the Texas Alliance for the Mentally Ill and the Texas Council of Community MHMR Centers, Inc. Austin, Texas -- June 7, 1996.

"Diagnosis and Treatment of Serious Mental Illness" presented at TEXAMI Community Forum entitled "Insight, Hope, and Care for Mental Illness." The forum was sponsored by The Texas

Alliance for the Mentally Ill (TEXAMI) and the Llano Estacado and Panhandle Alliances for the Mentally Ill. Lubbock, Texas – August 10, 1996.

“Dopamine in Psychotic Disorders.” Sponsored by the Texas Alliance for the Mentally Ill. Dallas, Texas – September 27, 1996.

“New Antipsychotic Medications” Research seminar presented in the Department of Pediatrics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, October, 1996.


“Diagnosis and Treatment of Serious Mental Illness.” Sponsored by the Texas Alliance for the Mentally Ill and the Community Mental Health Forum. El Paso, Texas – November 2, 1996.

“Schizophrenia: Phenomenology and New Treatments”. Grand Rounds, Division of Psychiatry, Harvard Medical School, Boston, Massachusetts -- December, 1996.

“New Antipsychotics and the Symptoms of Schizophrenia.” Tropical Texas Mental Health and Mental Retardation Center, Edinburg, Texas – March 12, 1997.

“New Antipsychotics and the Symptoms of Schizophrenia.” Tropical Texas Mental Health and Mental Retardation Center, Brownsville, Texas – March 12, 1997.

“Texas Medication Algorithm and Negative Symptoms of Schizophrenia.” Life Management Centers, El Paso, Texas – June 24, 1997.



TEXAS STATE BOARD OF MEDICAL EXAMINERS	
P.O. BOX 2018 • AUSTIN, TEXAS 78768-2018	
PHYSICIAN PERMIT	
LICENSE NUMBER REDACTED	EXPIRATION DATE 11-30-1998
ALEXANDER LEWIS MILLER, MD DEPT. PSYCHIATRY, UTHSC 7703 FLOYD CURL SAN ANTONIO, TX 78284	
THIS CERTIFIES THAT THE LICENSEE NAMED AND NUMBERED HEREON HAS PROVIDED THIS BOARD THE INFORMATION REQUIRED AND HAS PAID THE FEE FOR ANNUAL REGISTRATION FOR THE YEAR INDICATED ABOVE. PLEASE KEEP THIS BOARD NOTIFIED OF CHANGE OF ADDRESS	

TEXAS STATE BOARD OF MEDICAL EXAMINERS	
IDENTIFICATION CARD	
LICENSE NUMBER REDACTED	EXPIRATION DATE 11-30-1998
ALEXANDER LEWIS MILLER, MD DEPT. PSYCHIATRY, UTHSC 7703 FLOYD CURL SAN ANTONIO, TX 78284 PHYSICIAN PERMIT	

PLEASE NOTE OUR NEW ADDRESS AND PHONE NUMBER -
P.O. BOX 2018, AUSTIN, TX 78768-2018, 512/305-71

[Handwritten signature]
[Handwritten checkmark]

TEXAS STATE BOARD OF MEDICAL EXAMINERS	
P.O. BOX 2018 • AUSTIN, TEXAS 78768-2018	
PHYSICIAN PERMIT	
LICENSE/PERMIT NUMBER REDACTED	EXPIRATION DATE 11-30-1999
ALEXANDER LEWIS MILLER, MD DEPT PSYCHIATRY, UTHSC 7703 FLOYD CURL SAN ANTONIO, TX 78284	
THIS CERTIFIES THAT THE LICENSEE/PERMIT HOLDER NAMED AND NUMBERED HEREON HAS PROVIDED THIS BOARD THE INFORMATION REQUIRED AND HAS PAID THE FEE FOR ANNUAL REGISTRATION FOR THE YEAR INDICATED ABOVE. PLEASE KEEP THIS BOARD NOTIFIED OF CHANGE OF ADDRESS.	

TEXAS STATE BOARD OF MEDICAL EXAMINERS	
IDENTIFICATION CARD	
LICENSE/PERMIT NUMBER REDACTED	EXPIRATION DATE 11-30-1999
ALEXANDER LEWIS MILLER, MD DEPT PSYCHIATRY, UTHSC 7703 FLOYD CURL SAN ANTONIO, TX 78284 PHYSICIAN PERMIT	

PLEASE NOTE OUR NEW ADDRESS AND PHONE NUMBER -
P.O. BOX 2018, AUSTIN, TX 78768-2018
512/305-7010

CURRICULUM VITAE

RAJ NAKRA, M.D.

REDACTED

DATE CV REVISED: March, 1997

FULL NAME: Bharat Raj Swaroop Nakra

BIRTHPLACE: India

BIRTHDATE: May 23, 1943

CITIZENSHIP: United States

ADDRESS & PHONE: Office: Department of Psychiatry
Washington University School of Medicine
16216 Baxter Rd., Ste 320
Chesterfield, MO 63017
Phone: (314)454-5450
Fax: (314) 454-5460

Home: **REDACTED**

PRESENT POSITION: Professor of Psychiatry
Washington University School of Medicine

EDUCATION: Punjab University, India
Pre-medical, 1961 (with distinction)

Punjab University, India
M.B.,B.S., 1966 (equivalent to M.D. in USA)

Postgraduate Institute of Medical Education
and Research, Chandigarh, India
M.D. (Psychiatry) 1971 (equivalent to Ph.D. in USA)

Guy's Medical School, and Institute of Psychiatry,
London University, England, U.K.
Residency training in Psychiatry and Fellowship
in Psychopharmacology 1972-75

2

ACADEMIC POSITIONS:

University & Hospital Appointments:

Guy's Hospital, London, U.K.
Registrar & Senior Registrar 1972-76

Bedford General Hospital, U.K.
Consultant Psychiatrist 1976-77

Malcolm Bliss Mental Health Center
Clinical Director 1977-82

St. Louis University Hospital
Faculty 1982-92

Barnes Hospital

Jewish Hospital

UNIVERSITY COMMITTEES:

Director Psychiatric Residency Training
St. Louis University, 1989-90

Member, Psychiatry Residency Selection Committee
St. Louis University, 1989-90

Member, Department of Executive Council

MEDICAL LICENSURE: Missouri **REDACTED** 1978 - current

BOARD CERTIFICATION: Royal College of Psychiatrists
England, U.K., 1972

Postgraduate Institute of Medical Education and Research
Chandigarh, India, 1971

HONORS & AWARDS: Merit certificate & scholarship
Punjab University, 1957, 1959, and 1961

EDITORIAL RESPONSIBILITIES

Ad Hoc Reviewer: American Family Physician, International Psychogeriatric Association

PROFESSIONAL SOCIETIES: American Psychiatric Association (Fellow)
Eastern Missouri Psychiatric Society (Executive Committee member)
International Psychogeriatric Association
St. Louis Metropolitan Medical Society

3

BOARD MEMBERSHIPS:

President, Missouri Psychiatric Society, 1989-90

President, Eastern Missouri Psychiatric Society (Local Branch of APA), 1988-89

Member, Executive Council, Eastern Missouri Psychiatric Society, 1986-current

Chairman, Board of Directors, St. Elizabeth Day Care Center, St. Louis, MO, 1982 -87

Member, Board of Directors, Alzheimer's Association (St. Louis Chapter), 1986-88

Founder member, SLU/ADRDA Brain Bank for the study of Alzheimer's Disease, 1986

Member, Criteria Committee, Missouri Patient Care Review Foundation, Jefferson City, MO, 1989-91

Member, Commission on Interdisciplinary Commission, Missouri State Medical Association, 1988-90

President, Indian Medical Council of Greater St. Louis, 1991-92

Delegate, Missouri State Medical Association, 1991-93

Member, CME committee, Missouri State Medical Association, 1992

CME Program Director, Eastern Missouri Psychiatric Society, 1993-current

HOSPITAL POSITIONS:

Senior Registrar in Psychiatry, Guy's Medical School and Hospital, London (U.K.), May 1974-August 1976.

Consultant Psychiatrist, Bedford Area Health Authority, Bedford, England (U.K.), September 1976-April 1977.

Clinical Director, Inpatient and Emergency Room Service, Malcolm Bliss Mental Health Center, St. Louis, Missouri, May 1978-July 1982.

Director of Clinical Research, Division of Geriatric Psychiatry, Department of Psychiatry and Human Behavior, St. Louis University School of Medicine, St. Louis, Missouri, August 1982-1990.

Assistant Director, Division of Geriatric Psychiatry, St. Louis University School of Medicine, St. Louis, Missouri, August 1982-1990.

Director, Psychiatric Outpatient Clinic, St. Louis University Medical Center, St. Louis, Missouri, July 1990-1992.

ACADEMIC POSITIONS:

Clinical Instructor in Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 1971-1972.

Senior Registrar in Psychiatry, Guy's Medical School and Hospital, London, England (U.K.), 1974-1976.

Clinical Tutor, Department of Psychiatry, Bedford General Hospital, Bedford, England (U.K.), 1976-1977.

Assistant Professor in Psychiatry, Washington University School of Medicine, St. Louis, Missouri, 1979-1982.

Assistant Professor, Department of Psychiatry and Human Behavior, St. Louis University School of Medicine, St. Louis, Missouri, 1982-1988.

Associate Professor, Department of Psychiatry and Human Behavior, St. Louis University School of Medicine, St. Louis, Missouri, 1988-1992

Director of Residency Training in Psychiatry, St. Louis University School of Medicine, St. Louis, Missouri, 1989-1990.

Professor Of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, 1993-present.

CONSULTANT PSYCHIATRIST TO NURSING HOMES:

1. Barnes Extended Care
2. Gatesworth
3. McKnight Place
4. Gardenvue
5. Mark Twain Manor
6. Masonic Home
7. Friendship Village

CONSULTANT PSYCHIATRIST TO OTHER ORGANIZATIONS:

1. Midwest Psychiatry- St. Louis Mental Health Ctr Affiliate
2. Partial Hospitalization Program, ADAPT of Missouri

5

RESEARCH SUPPORT:

Governmental - None

Non-Governmental -

- Steady State Plasma Levels of Amitriptyline In Single and Multiple Dosage Schedules. Merek. (U.K.) 1972
- Plasma Level of New Pelletized Form Of Amitriptyline for Maintenance Therapy. Merel. (U.K.) 1973
- Comparative Psychotropic Effects of Metoclopramide and Prochlorperazine in Normal Subjects. A.M. Robins. (U.K.) 1974
- Preliminary Evaluation of a New Psychotropic Drug, Lenperone, in the Treatment of Acute Schizophrenia. A.H. Robins. (U.K.) 1974
- Steady State Serum Concentrations of Dothiepin and Northiaden after Two Dosage Regimens of Dothiepin Hcl (prothiaden). Boots Pharmaceuticals. (U.K.) 1975
- Pimozide as an Adjuvant to Maintenance Therapy in Chronic Schizophrenia. Janssen. (U.K.) 1975
- Safety and Efficacy of Vinpocetine in Multi-Infarct Dementia—a Double-Blind Study. Protocol 83-064. Wyeth-Ayerst Pharmaceutical. 1984
- Long-term Safety of Vinpocetine Treatment of Multi-Infarct Dementia. Protocol 83-065. Wyeth-Ayerst Pharmaceutical. 1985
- Long-term Safety of Vinpocetine in Progressive Dementia. Protocol 83-110. Wyeth-Ayerst Pharmaceutical. 1985
- Extended Long-Term Safety of Vinpocetine Treatment. Protocol 86-003. Wyeth -Ayerst Pharmaceutical. 1985
- Vasopressin—A Diagnostic Marker in Alzheimer's disease. ADRDA St. Louis Chapter. 1986
- Safety and Efficacy of Vinpocetine in the Treatment of Alzheimer's Disease—a Double-Blind Study. Protocol 86-061. Wyeth-Ayerst Pharmaceutical. 1986
- Double-Blind, Parallel Comparison of Sertraline, Desipramine, and Placebo in Depressed Geriatric Outpatients. International Clinical Research Corporation. 1987
- Safety and Efficacy of High Dose Hydergine FAS in Alzheimer's disease. Sandoz Pharmaceutical. 1987
- Fluoxetine/Placebo Trial in Geriatric Patients with Major Depressive Disorder. Eli Lilly Research Laboratories. 1988
- A Multi-Center, Double-Blind, Placebo Controlled Investigation of Efficacy and Safety of Oral Trental in Patients with Multi-Infarct Dementia. Hoechst-Roussel Pharmaceutical, Inc. 1988
- A Long Term Tolerance and Safety Study of HP029 in Patients with Alzheimer's Disease. Hoechst-Roussel Pharmaceutical, Inc. 1988
- Nootropic Effects of Ramipril in Health of Elderly Subjects. Hoechst-Roussel Pharmaceutical, Inc. 1989

6

RESEARCH SUPPORT (Cont.):

Double-Blind Comparison of Sertraline, Imipramine, and placebo in inpatients with major depression or bipolar disorder, depressed. Pfizer Pharmaceutical.	1989
Double-Blind Comparison of Restoril, Halcion and Placebo in Elderly Patients with Insomnia. Sandoz Pharmaceutical.	1990
Effect of Temazepam, Triazolam and Placebo on Cognitive and Psychomotor Performance in the elderly. Sandoz Pharmaceutical.	1990
Open Label Study of Sertraline in Depressed Outpatients Discontinued from Fluoxetine. Pfizer Pharmaceutical.	1990
Open Follow-up Study of Sertraline in Outpatient with Major Depression. Pfizer Pharmaceutical.	1990
Double-Blind Parallel Comparison of Sertraline, Amitriptyline, and Placebo in Outpatients with Depression. Pfizer Pharmaceutical.	1991
Double-blind Parallel Comparison of 3 doses of Sertraline and Placebo in Outpatients with Panic Disorder. Pfizer Pharmaceutical.	1991
Double-Blind comparison of Sertraline, Clomipramine, and Placebo in Outpatients with Obsessive-Compulsive Disorder. Pfizer Pharmaceutical.	1991
Multi-center Trial to Evaluate the Efficacy of Sertraline in the Treatment of Major Depression. Pfizer, Inc.	1991
Double-Blind Study of the Efficacy of Sertraline in Geriatric Depression. Pfizer Pharmaceutical	1992
A Double-Blind Comparison of Sertraline (Zoloft) and Paroxetine (Paxil) in Major Depression. Pfizer Pharmaceutical.	1992
Double-Blind Parallel Comparison of Sertraline and Fluoxetine in Depressed Geriatric Outpatients. Pfizer Pharmaceutical.	1992
Clinical Evaluation of Sabeluzole in the Treatment of Patients with Dementia of the Alzheimer's Type (DAT). Janssen Research Foundation.	1992
A Double-Blind Comparison of Triazolam and Placebo on the Daytime Cognitive Performance of Elderly Insomniacs. UpJohn Pharmaceutical.	1992
Evaluation of Wellbutrin in Depressed Elderly Outpatients who Failed to Tolerate or Respond to Fluoxetine. Burroughs Wellcome Co.	1992
Olanzapine versus Placebo in the Treatment of Patients with Psychosis associated with Dementia, Olanzapine LY170053. Eli Lilly Pharmaceutical.	1992
Safety and Efficacy of Wellbutrin in Major Depression in an Open Multi-center Trial. Burroughs Wellcome Co.	1993
Open Label Multi-center Trial of Paroxetine (Paxil) in Major Depression. SmithKline-Beecham.	1993
LY246708 Tartrate vs. Placebo in Mild to Moderate Alzheimer's Disease. Eli Lilly Research Laboratories.	1993

7

RESEARCH SUPPORT (Cont.):

- Multi-center, 30-week, Double-Blind, Parallel Group Safety, Tolerance and Efficacy Comparison of Placebo and HP029 (150mg/d, 225mg/d, 300mg/d) in Outpatients with Alzheimer's Disease (NINCDS/ADRDA) Criteria. Hoechst-Roussel Pharmaceuticals, Inc. 1993
- Double-Blind Comparison of Tandosprone GITS and Placebo in the Treatment of Outpatients with Major Depression. Pfizer Pharmaceutical. 1993
- A Phase II, Four Week, Double-Blind Placebo-controlled Study Evaluating the Efficacy and Safety of Two Doses of One CP-88, 059-1 in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder. Pfizer Pharmaceutical. 1993
- Double-Blind Flexible Dose Parallel Comparison of Sertraline and Placebo in Outpatients with Panic Disorder. Pfizer Pharmaceutical. 1994
- Sertraline and Placebo in the Treatment and Prevention of Relapse in Outpatients with Obsessive Compulsive Disorder. Pfizer Pharmaceutical. 1994
- Clinical Evaluation of Efficacy and Safety of Sabeluzole in the Treatment of Alzheimer's Disease. Janssen Pharmaceutical Research Foundation. 1994
- Safety and Efficacy of Depakote in the Prevention of Mania in Patients with Bipolar Disorder. Abbott Laboratories. 1994
- Open-Label Extension of LZZA: LY246708 Tartrate in Alzheimer's Disease. Eli Lilly Pharmaceutical. 1994
- Tacrine Safety Study: A 16-week Open-Label Safety study of Tacrine with monitoring of serum alanine aminotransferase (ALT at weeks 4,6,8,12, and 16). Parke-Davis. 1995
- SAB-USA-24: Safety of Sabeluzole in the Treatment of Alzheimer's Disease. An open label extension study Sabeluzole RO58735. Janssen Research Foundation. 1995
- SAB-USA-25: Clinical Evaluation of Efficacy and Safety of Sabeluzole in the Treatment of Alzheimer's Disease. A one-year double-blind placebo-controlled study. Janssen Research Foundation. 1995
- SAB-USA-26: Safety of Sabeluzole in the Long-Term Treatment of Alzheimer's Disease. An open label extension study. Janssen Research Foundation. 1995
- Propentofylline (HWA 285/1/USA/301/DZ): Forty-Eight Week Efficacy and Safety Study of Propentofylline (HWA 285) in Patients with Alzheimer's Disease. Hoechst-Roussel Pharmaceuticals Inc. 1995
- Propentofylline (HWA 285/1/USA/302/DZ): Twenty-Four Week Efficacy and Safety Study of Propentofylline (HWA 285) in Patients with Vascular Dementia. Hoechst-Roussel Pharmaceuticals Inc. 1995
- RIS-USA-79: A Comparison of Risperidone and Haloperidol for prevention of Relapse in patients with Schizophrenia and Schizoaffective Disorder. Janssen Research Foundation. 1995
- Post Traumatic Stress Disorder: Fourteen Week Placebo-Controlled, Double-Blind, Flexible Dose Study of Sertraline in the Treatment of PTSD. Pfizer, Inc. 1996
- Post Traumatic Stress Disorder: Twenty-Four Week Open-Label Extension Study of Sertraline in Out-Patients with PTSD. Pfizer, Inc. 1996

8

RESEARCH SUPPORT (Cont.):

SB 202026/023: A 48 week double-blind, placebo controlled, parallel group, fixed dose study of the efficacy, safety study of 25ug SB 202026 in patients suffering from dementia of the probable Alzheimer's type. SmithKline Beecham Pharmaceuticals. 1996

Major Depression: A Double-blind, Placebo Controlled Trial to Compare the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression. SmithLine Beecham Pharmaceuticals. 1996

Major Depression: A Double-blind, Placebo Controlled Trial to evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression in elderly patients. SmithKline Beecham Pharmaceuticals. 1996

Alzheimer's Disease: Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease. Janssen Research Foundation. 1996

BIBLIOGRAPHY:

Peer Reviewed

Teja, J.S., Nakra, B.R.S., Salman Akhtar: Depersonalization: a phenomenological study in Indian Patients. Indian Journal of Psychiatry 15:166-178, 1973.

Nakra, B.R.S., Lee, F.E., Gaiind, R.: Risk of Paracetamol abuse. Lancet 2(826):451-452, 1973

Nakra, B.R.S., Gaiind R.: Psychiatric aspects of sterilization. British Medical Journal 4(885):168-169, 1973

Briathwalte, R., Nakra, B.R.S., Gaiind, R.: Steady state plasma levels of Amitriptyline In single and multiple dosage schedules. Psychological Medicine 4:338-341, 1974.

Hucker, H.B., Stauffer, S.C., Clayton, F.G., Nakra, B.R.S., Gaiind, R.: Plasma levels of a new pelletized form of amitriptyline for maintenance therapy. The Journal of Clinical Pharmacology 15:2,3:168-172, 1975.

Nakra, B.R.S., Bond, A.J., Lader, M.D.: Comparative psychotropic effects of Metoclopramide and Prochlorperazine in normal subjects. The Journal of Clinical Pharmacology 15:5,6:449-454, 1975.

Nakra, B.R.S., Jones, C.J., Majumdar, A.K., Gaiind, R.: Preliminary evaluation of a new psychotropic drug, Lenperone, in the treatment of acute schizophrenia. Current medical Research and Opinion 4:8:529-534, 1977.

Nakra, B.R.S., Rutland, P., Verma, S., Gaiind, R.: Amitriptyline and weight gain: a biochemical and endocrinological study. Current Medical Research and Opinion 4:8:602-606, 1977.

Nakra, B.R.S., Glass, R.D., Rees, J.A.: Steady state serum concentrations of Dothiepin and Northiaden after two dosage regimens of Dothiepin Hc1 (prothiaden). The Journal of International Medical Research 5:6:391-397, 1977.

Nakra, B.R.S., Wig, N.N., Varma, V.K.: Sexual behavior in the adult Indian male. Indian Journal of Psychiatry 20L178-182, 1978.

Nakra, B.R.S., Wickramasinghe, N.A.V.: Pimozide as an adjuvant to maintenance therapy in chronic schizophrenia. Pharmacotherapy 2:5:337-340, 1980.

BIBLIOGRAPHY (Cont.):

- Nakra, B.R.S., Hwu, H.G.: Catatonic-like syndrome during neuroleptic therapy. Psychosomatics 23:7:769-770, 1982.
- Shen, W.W., Nakra, B.R.S., Park, S.: Use of MAOIs. Hospital and Community Psychiatry 34:9:854, 1983.
- Nakra, B.R.S., Grossberg, G.T.: Carbohydrate craving and weight gain with Maprotiline. Psychosomatics 27(5)a:380-381, 1986.
- Grossberg, G.T., Nakra, B.R.S.: diagnosis and treatment of depression in the elderly. Comprehensive Therapy 12(10):16-20, 1986.
- Nakra, B.R.S., Grossberg, G.T.: Diagnosis and treatment of anxiety in the elderly. Comprehensive Therapy 12(10):53-60, 1986.
- Nakra, B.R.S., Grossberg, G.T.: Use of Lithium in the elderly. Journal of Geriatric Drug Therapy 2:1, 1987.
- Burke, W.J., Marshall, G.L., Chung, H.D., Nakra, R., Grossberg, G.T., Joh, T.H.: Phenylethanolamine N-Methyltransferase is Decreased in Alzheimer's Disease Brains. Annals of Neurology 22:278-180, 1987.
- Grossberg, G.T., Nakra, R., Woodward, V., Russell, T.: Smoking as a risk factor in Alzheimer's Disease. JAGS 1989.
- Nakra, B.R.S., Szwabo, P., Grossberg, G.T.: Mania Induced by Fluoxetine. Am J Psychiatry 146:11:1516-1516, November, 1989.
- Albert, S.G., Nakra, B.R.S., Grossberg, G.T., and Caminal, E.R.: Vasopressin Response to Dehydration in Alzheimer's Disease. JAGS 37:843-847, 1989.
- Ross, Michael J., Tait, R.C., Grossberg, G.T., Brandeberry, L., Nakra, R.: Age Difference in Body Consciousness. Journal of Gerontology Vol. 44, No.1, pp. 23-25, January, 1989.
- Grossberg, G.T., Nakra, R., Woodward V., Russel, T. Woodward, J.: Head trauma as a risk factor for Alzheimer's Disease. Journal of the American Geriatric Society Vol. 37, No. 926, p. 915, 1989.
- Grossberg, G.T., Hassan, R., Szwabo, P.A., Morley, J.E., Nakra, B.R.S., Bretscher, C.W., Zimny, G.H., Solomon K.: St. Louis University Grand Rounds: Psychiatric Disturbances In the Nursing Home. Int. American Geriatric Society Vol. 38, No. 7, pp. 907-917, 1990.
- Grossberg, G.T., Zimny, G.H., Nakra, B.R.S.: Geriatric psychiatry consultations in a university hospital. International Psychogeriatrics Vol. 2, No. 2, pp. 161-168, 1990.
- Nakra, B.R.S., Grossberg, G.T.: Insomnia in the elderly. Amer. Family Physician Vol. 43, No. 2, 477-483, 1991.
- Nakra, B.R.S., Gfeller, J.D., Hassan, R.: A double-blind comparison of Temazepam and Triazolam on residual daytime performance in the elderly insomniacs. International Psychogeriatrics Vol. 4, No.1, 1992.
- Nakra, B.R.S., Margolis, R.B., Gfeller, J.D., Grossberg, G.T., Sata, L.: The effect of a single dose of Trihexyphenidyl on memory functions in the healthy elderly. International Psychogeriatrics Vol. 4, No. 2, 1992.

10

BIBLIOGRAPHY (Cont.):

Albert, S.G., Nakra, B.R.S., Grossberg, G.T., Caminal, E.R.: Drinking Behavior and Vasopressin Responses to Hyperosmolality in Alzheimer's disease. International Psychogeriatrics Vol. 6, No. 1, 1994.

Nakra, B.R.S.: The Physician Under Stress. St. Louis Metropolitan Medicine Vol. 16, No. 10, 1994.

Kumar, Vijay B., Nakra, Raj: C3b/C4b complement Receptor (CR1) Polymorphism In Alzheimer's Disease. Clinical Research Vol. 42, No. 2, 1994.

Articles Submitted

Wolkow, R., Nakra, B., Sheikh, J.: Sertraline in Panic Disorder With or Without Agoraphobia: A Double-Blind, Placebo-Controlled, Multicenter Study, 1996.

BOOK CHAPTERS

Grossberg, G.T., Nakra, R.: Prevention of Mental and Emotional Disability in the Elderly: Past, Present, and Future. In The Prevention of Mental and Emotional Disabilities. National. Mental Health Assoc., Alexandria, VA, 1986.

Burke, W.J., Chung, H.D., Strong, R., Mattammal, M.B., Marshall, G.L., Nakra, B.R.S., Grossberg, G.T., Richardson, A., Haring, J.A., Gomez, C.R., Joh, T.H.: Mechanism of Degeneration of Epinephrine Neurons in Alzheimer's Disease. In R. Strong, Ed.: Central Nervous System Disorder of Aging: Strategies for Intervention. Raven Press, pp. 41-70, 1987.

Burke, W.J., Chung, H.D., Huang, J.S., Mattammal, M.B., Luque, F.A., Nakra B.R.S., Grossberg, G.T., Marshall, G.L., Haring, J.H., Joh, T.H., and Strong, R.: Degeneration of Epinephrine Neurons in Alzheimer's Dementia: Possible Role for a Locus Coeruleus Mitogen. Progress in Catecholamine Research Part C: Clinical Aspects, Alan R. Liss, Inc., 71, pp. 421-425, 1988.

Burke, W.J., Chung, H.D., Huang, J.S. Mattammal, M.B., Luque, F.A., Nakra, B.R.s., Grossberg, G.T., Marshall G.L. Haring, J.H., Joh, T.H., Strong, R.: Degeneration of Epinephrine Neurons in Alzheimer's Dementia: Possible Role for a Locus Ceruleus Mitogen. Proceedings of the Sixth International Catecholamine Symposium. M. Sandler and R.H. Belmaker (Eds.) Alan R. Liss, Inc., New York, 1989. .

Nakra, B.R.S., Grossberg, G.T.: Mood Disorders. In: Verwoerd's Clinical Geropsychiatry. Edited by Bienenfeld, D., Williams & Wilkins, Baltimore, MD., pp. 107-124, 1990.

Grossberg, G.T., Nakra, B.R.S.: Psychiatry in the Nursing Home. In: Verwoerd's Clinical Geropsychiatry. Edited by Bienenfeld, D., Williams & Wilkins, Baltimore, MD, pp. 285-297, 1990.

ABSTRACTS

Nakra, B.R.S., Grossberg, G.T. Margolis, R.B., Sata, L.S.: Anticholinergics and Memory Functioning in the Elderly. American Psychiatric Association, Dallas, 1985.

Ross, M.J., Tait, R.C., Grossberg, G.T., Brandeberry, L., Nakra, R.: Age Differences in Emotional and Physical Health. American Psychological Association, Chicago, 1986.

1207

Grossberg, G.T., Zimny, G., Nakra, R.: Effects of Geropsychiatric Experience on Medical Students' Attitudes Toward Geropsychiatric Patients. Gerontological Society of America, Chicago, 1986.

Burke, W.J., Chung, H.D., Marshall, G.L., Gomez, C., Grossberg, G.T., Nakra, R., Strong, R., Richardson, A., John, T.H.: Mechanism of Degeneration in C-1, C-2 Epinephrine Neurons in Alzheimer's Disease. Xth International Congress of Neuropathology, Stockholm, Sweden, 1986.

Nakra, B.R.S.: Therapeutic Efficacy of Vinpocetine in Alzheimer's disease: A Preliminary Communication. Satellite symposium: New Drug Strategies in the Therapy of Senile Dementias of Different Origin. Second World Congress of Neurosciences, Budapest, Hungary, 1987.

Rappaport, S., Nakra, B.R.S., Hancock, R., Gajderowicz, S., Woods, J.: Efficacy and Quality of Life for Hypnotic Medication Geriatric Patients. American Geriatric Association, 1990.

Linden, R.D., Newhouse, P., Krishnan, K.R., Farmer, M., Goldstein, B., Lazarus L.W., Nakra, R., Hartford, J., Reisenberg, R., Margolin, R.A., Ferguson, J., Rothman, M., Richter, E.M.: SSRIs in the depressed elderly: A Double-Blind comparison of Sertraline and Fluoxetine In Depressed Geriatric Outpatients. Presented at Annual meeting APA, May, 1995.

Kumar, V.B., Nakra, Raj: Changes in C3b/c4b Complement receptors as markers in Alzheimer's Disease. GRECC Symposium: Alzheimer's Disease: Advance in Basic Sciences, 1995.

Program chairman for CME (category 1) for Psychiatrists and Primary Care Physicians

Treatment of Psychosis in the Elderly, April 9, and 10, 1990, St. Louis Univ.

Treatment of Panic Disorders, June 8, 1991, St. Louis University

Missouri Psychiatry Symposium, Dec. 12, 1992, Missouri Institute of Mental Health

Depression and related disorders in Gynecological Practice, May 1, 1993, Washington University School of Medicine

Alzheimer's Disease - Recent Advances in diagnosis and treatment, June 11 and 12, 1993, Washington University School of Medicine

Suicide - Diagnosis, treatment and prevention, September 18, 1993, Washington University School of Medicine

Serotonin and Major Depression - the theory behind the practice, November 18, 1993, Eastern Missouri Psychiatric Society

Drug therapy of Alzheimer's Disease, June 8, 1994, Washington University School of Medicine

Abusable Medications and Clinical Challenges, June 23, 24 and 25, 1994, Washington University School of Medicine

New Developments in the Pharmacological Treatment of Schizophrenia, October 8, 1994, Eastern Missouri Psychiatric Society

Clinical Challenges in the Treatment of Depression, April 8, 1994, Eastern Missouri Psychiatric Society

Antidepressant Drug Interactions: Medical and Legal Challenges for a Practicing Psychiatrist, March 14, 1995, Eastern Missouri Psychiatric Society

12

Abusable Medications and Clinical Challenges, 2nd Annual Symposium, March 30, 31, and April 1, 1995, Washington University School of Medicine

Role of Serotonin in Psychiatric Illnesses, September 26, 1995, Washington University School of Medicine

Bipolar Disorder - Recent Developments, December 9, 1995, Eastern Missouri Psychiatric Society

Managed Care and Practice of Psychiatry, February 27, 1996, Eastern Missouri Psychiatric Society

Abusable Medications and Clinical Challenges, 3rd Annual Symposium, March 21, 22, and 23, 1996, Washington University School of Medicine

OCD and Panic Disorder - An Update, April 27, 1996, Eastern Missouri Psychiatric Society

Psychobiology of Personality and Its Significance in Drug Response with Psychotropic Drugs, July 17, 1996, Eastern Missouri Psychiatric Society

Program chairman for CME (category 1) programs for Psychiatrists and Primary Care Physicians (Cont.)



New Developments in Treatment of Psychosis, October 12, 1996, Eastern Missouri Psychiatric Society

Alzheimer's Disease, Recent Developments in Diagnosis, Pathogenesis and Treatment, February 22, 1997, Washington University School of Medicine

Abusable Medications and Clinical Challenges, 4th Annual Symposium, March 20, 21, and 23, 1997, Washington University School of Medicine



Recent Developments in the Mechanism of Action of Electro Convulsive Therapy, March 26, 1997, Eastern Missouri Psychiatric Society

1209





The 5" x 7" license above is to be prominently displayed if required by applicable statute and/or rule.

THE LICENSE DOCUMENTS PROVIDED HERE ARE PRINTED ON SECURITY PAPER. IF PHOTOCOPIED, THE WORD "COPY" WILL APPEAR ON THE FACE OF EACH LICENSE DOCUMENT.



The 5" x 7" license above is to be prominently displayed if required by applicable statute and/or rule.

THE LICENSE DOCUMENTS PROVIDED HERE ARE PRINTED ON SECURITY PAPER. IF PHOTOCOPIED, THE WORD "COPY" WILL APPEAR ON THE FACE OF EACH LICENSE DOCUMENT.




The 5" x 7" license above is to be prominently displayed if required by applicable statute and/or rule.

THE LICENSE DOCUMENTS PROVIDED HERE ARE PRINTED ON SECURITY PAPER. IF PHOTOCOPIED, THE WORD "COPY" WILL APPEAR ON THE FACE OF EACH LICENSE DOCUMENT.

MISSOURI REGISTRATION NUMBER [REDACTED]		BUREAU OF NARCOTICS AND DANGEROUS DRUGS		Direct Inquiries to: P.O. Box 570 Jefferson City, MO 65102	
		MISSOURI DEPARTMENT OF HEALTH			
EXPIRATION DATE DECEMBER 31, 1997		MISSOURI CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE THIS REGISTRATION IS NOT TRANSFERABLE AND IS VALID ONLY AT PRINCIPAL PLACE OF BUSINESS INDICATED BELOW.			
PROFESSIONAL ACTIVITY PRACTITIONER		CONTROLLED SUBSTANCE SCHEDULE(S) 2,2N,3,3N			
NAKRA, BHARAT RAJ S MD WASHINGTON UNIV MEDICAL CENTER DEPT OF PSYCHIATRY WEST COUNTY 16216 BAXTER ROAD SUITE 190 CHESTERFIELD		MO 63017		Section 195.040 RSMo states the grounds for revocation, suspension or refusal of renewal of this registration. NDD 3 Rev. 2/95	

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE		
UNITED STATES DEPARTMENT OF JUSTICE		
DRUG ENFORCEMENT ADMINISTRATION		
WASHINGTON, D.C. 20537		
Sections 304 and 1008 of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.	DEA REGISTRATION NUMBER [REDACTED]	THIS REGISTRATION EXPIRES 10-31-1997
		FEE PAID \$210.00
Form DEA-223 (8/95)	SCHEDULES 2,2N,3,3N,4,5	BUSINESS ACTIVITY PRACTITIONER
		DATE ISSUED 10-16-1996
NAKRA, BHARAT RAJ SHARADH MD WASHINGTON UNIV MED CTR DEPT OF PSYCHIATRY WEST COUNTY 16216 BAXTER ROAD STE 190 CHESTERFIELD, MO		
		63017
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.		



The 5" x 7" license above is to be prominently displayed if required by applicable statute and/or rule.

THE LICENSE DOCUMENTS PROVIDED HERE ARE PRINTED ON SECURITY PAPER. IF PHOTOCOPIED, THE WORD "COPY" WILL APPEAR ON THE FACE OF EACH LICENSE DOCUMENT.

CURRICULUM VITAE



Jörg J. Pahl, M.D., FCP(SA)

**Director of Research and Education
NeuroScience Institute at Mercy
Oklahoma City, OK**

**PAHL BRAIN ASSOCIATES, P.C.
13301 N. Meridian, Suite 101 & 200
Oklahoma City, OK 73120
Tel: 405-752-5011
Fax: 405-752-0484**

January 1997

PERSONAL:

Date of Birth: May 29, 1947
Citizenship: Permanent U.S. Resident
Social Security No.: REDACTED
Marital Status: Married (Wife: Ursula)
Children: Patrick, Mark, William

EDUCATION:

1964 High School: Paul Roos Gymnasium, South Africa
1965 U.S. Grant High School, Sacramento, California
(American Field Service Scholar)
1971 M.B. Ch.B. University of Stellenbosch, South Africa
1978 FCP (SA) University of Stellenbosch, South Africa
1984 M.D. , University of Munich, Germany

POSTGRADUATE EDUCATION:

1974 - 1977 Resident: Medicine/Neurology
University of Stellenbosch, South Africa
1980 - 1981 Resident: Neurology/Psychiatry
University of Saarland, Munich, Germany
1982 - 1984 Resident: Psychiatry, Max-Planck Institute for Psychiatry,
Munich, Germany

OCCUPATION:

Internist	South Africa
Neurologist / Psychiatrist	Germany
Neurologist / Psychiatrist	USA

FELLOWSHIP:

1985 - 1988 Postdoctoral Fellow in Positron Emission Tomography, Division of Nuclear Medicine and Biophysics, Department of Radiological Sciences, UCLA School of Medicine

QUALIFYING USA EXAMINATIONS:

1985 VQE/FMGEMS REDACTED

1988 FLEX REDACTED

BOARD CERTIFICATION:

1978 Internal Medicine
South African Medical and Dental Board

1984 Neurology and Psychiatry (Nervenarzt)
Bavarian Medical Council, Germany

LICENSURES:

General Practitioner
Specialist Physician (Internist)
General Practitioner
Neurologist/Psychiatrist
REDACTED U.S.A.-Iowa (inactive)
REDACTED U.S.A.-Oklahoma

South Africa
South Africa (inactive)
United Kingdom
Germany (E.E.C.)

HONORS AND AWARDS:

American Field Service Scholar, 1965-1966

NARSAD Award (Simon Young Investigator), 1989

NAMI Exemplary Psychiatrist Award, 1992

OAMI Provider Award, Oklahoma Alliance for Mentally Ill, 1992

OAMI Provider Award, Oklahoma Alliance for Mentally Ill, 1995

ACADEMIC POSITIONS:

Tenure:

1991 Tenured in the Department of Psychiatry and Behavioral Sciences, University of Oklahoma, Oklahoma City, Oklahoma USA

Positions:

1978 - 1979 Consultant: Neurology, University of Stellenbosch, South Africa
1985 - 1988 Consultant: Neurology/Psychiatry, Taufkirchen/Vils Psychiatric Hospital, Germany
1988 - 1990 Associate/Staff Psychiatrist, Department of Psychiatry, University of Iowa, Iowa City, Iowa USA
1990 - 1995 Associate Professor/Staff Psychiatrist, Department of Psychiatry and Behavioral Sciences, University of Oklahoma, Oklahoma City, Oklahoma USA
1990 - 1995 Associate Clinical Professor, Department of Radiological Sciences, University of Oklahoma, Oklahoma City, Oklahoma USA
1992 - 1995 Associate Chair for Research, Department of Psychiatry and Behavioral Sciences, University of Oklahoma, Oklahoma City, Oklahoma USA
1995 - Present Director of Research and Education, The Neuroscience Institute at Mercy, Oklahoma City, Oklahoma USA
1996 -Present Medical Director, Alzheimer's Care Unit Convalescent Nursing Home Center, Oklahoma City, Oklahoma USA

PROFESSIONAL AFFILIATIONS:

Fellow of the College of Physicians of South Africa, FCP(SA), South Africa
Member of the Bavarian Medical Council (Ärztchamber), Germany
Oklahoma County Medical Society, USA
Oklahoma State Medical Society, USA
American Medical Association, USA
International Society for Neuroimaging in Psychiatry
Society of Nuclear Medicine, USA
Diplomate of the American Board of Forensic Medicine, USA

REVIEWER (past and present):

1. Archives of General Psychiatry
2. Neuropsychiatry, Neuropsychology, and Behavioral Neurology
3. Journal of Affective Disorders
4. American Journal of Psychiatry
5. National Institute of Mental Health: Research Scientist Development Review Committee. (NIMH - Ad Hoc Reviewer)
6. Research Advisory Group (RAG) proposals for Veterans Administration (VA)

AREAS OF INTEREST:

Psychopharmacological Research
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Magnetic Resonance Imaging (MRI)
Three-Dimensional Image Analysis
TeleMedicine

TEACHING ACTIVITIES (USA):

- 1989 - 1990 Supervision and teaching of residents and students on the Psychiatric Inpatient Service, University of Iowa.
- 1989 - 1990 Introduction to Clinical Medicine (Psychiatry) Small Group Sessions. Department of Psychiatry, University of Iowa.
- 1988 - 1990 MRI, Xe-133 and Tc-99m HMPAO SPECT film reading sessions, University of Iowa.
- 1989 - 1990 Coordination of PET, SPECT and MRI lecture series for the Department of Psychiatry, University of Iowa.
- 1990 - 1991 Organizer and Director, Intake & Evaluation Conference of the Department of Psychiatry, University of Oklahoma.
- 1990 - 1995 Teacher/Lecturer/Supervisor: MS1/MS2/MS3/MS4 & PGY1/PGY4, University of the Department of Psychiatry, University of Oklahoma.
- 1991 - 1993 Organizer and Director, Grand Rounds of the Department of Psychiatry, University of Oklahoma.
- 1992 - 1995 Introduction to Clinical Medicine/Psychiatric history and mental status examination: Small Group Sessions, Department of Psychiatry and Behavioral Sciences University of Oklahoma.

CLINICAL ACTIVITIES:

- 1989 - 1990 Management and medication of inpatients on a 30 bed ward (mainly psychotic disorders), Department of Psychiatry, University of Iowa.
- 1990 - 1992 Director of Psychiatric Inpatient Unit, Oklahoma Memorial Hospital, University of Oklahoma Health Sciences Center.
- 1990 - 1995 Director of the Schizophrenia and Neuropsychiatric Disorders Clinic, Department of Psychiatry and Behavioral Sciences (includes the Treatment Resistant Schizophrenia Program) University of Oklahoma Health Sciences Center.
- 1990 - 1991 Director Outpatient Clinics, University of Oklahoma Health Sciences Center.
- 1990 - 1991 Director of Adult Services, University of Oklahoma Health Sciences Center.
- 1991 - 1992 Medical Director (Acting) Alcohol Center, University of Oklahoma Health Sciences Center.
- 1992 - 1995 Director of the Memory Disorders Clinic, Department of Psychiatry and Behavioral Sciences (Alzheimer's Disease Program) University of Oklahoma Health Sciences Center.
- 1992 - 1995 Director of the Mood Disorders Clinic, Department of Psychiatry and Behavioral Sciences (includes the Mood Disorders Program) University of Oklahoma Health Sciences Center.
- 1995 - Present Staff Psychiatrist, Bethany Pavilion
- 1995 - Present Private Practice, Pahl Brain Associates.

RESEARCH ACTIVITIES

- 1992 - 1995 Associate Chair for Research, Department of Psychiatry and Behavioral Sciences, University of Oklahoma Health Sciences Center.
- 1990 - 1993 Research Director, Psychiatric Brain Imaging Program (includes Psychiatric Image Analysis Laboratory and Three-Dimensional Image Analysis Workstation and Three Headed SPECT Camera).
- 1991 - 1993 Research Director, Schizophrenia Research Project (Includes Treatment Resistant Schizophrenia Program).
- 1990 - 1992 Director of the Psychiatric Brain Bank, University of Oklahoma Health Sciences Center.

COMMITTEES AND COUNCILS:

Department of Psychiatry and Behavioral Sciences,
University of Oklahoma:

- 1990 - 1993 Executive Committee
- 1990 - 1991 Promotions and Tenure Committee
- 1990 - 1992 Finance Committee
- 1990 - 1992 Research Committee
- 1990 - 1992 Computer Committee
- 1990 - 1992 Post-Doctoral Transcultural Fellowship Committee
- 1990 - 1991 Chair, Faculty Search Committee
- 1990 - 1992 Honors Research Program Advisory Committee, Dean's Office
- 1990 - 1991 Psychiatry Residency Training Committee
- 1990 - 1991 Student Curriculum Committee
- 1991 - 1992 Chairman, Clinical Council
- 1991 - 1995 Pharmacy and Therapeutics Committee, Oklahoma Memorial Hospital
- 1991 - 1993 Vice-Chairman, Triple-headed SPECT Operational Committee

COMMUNITY SERVICE:

- 1991 - Multiple Presentations regarding HIV/AIDS, Schizophrenia, Clozapine, Alzheimer's Disease, SPECT on T.V. Stations 4, 5, 9, 14 in Oklahoma City, Oklahoma AND ON Medstar TV.
- 1992 - Oklahoma Alliance for Mentally Ill (OAMI), Board Member.
- 1996 - Hope Community Mental Health Center, Oklahoma City, Oklahoma.

FINANCIAL RESOURCES: GRANTS, GIFTS AND CONTRACTS

Funded (Grant):

1. 123 I-Iodoamphetamine ([123I]IMP) Single Photon Emission Computer Tomography (SPECT) Brain Imaging in Schizophrenia. (NARSAD) PI: Jörg J. Pahl, M.D.; 07/01/89 - 06/30/91; \$60,000.00
2. MRI in Adolescents Experiencing Emotional Problems and Social Dysfunction. (Warren Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 1991 - 1992; \$20,000.00
3. SPECT Assessment of Clozapine Effects on rCBF in Schizophrenia. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 05/01/92 - 12/31/93; \$94,100.20
4. SPECT Brain Imaging in Possible and Probable Alzheimer's Disease. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 05/01/92 - 12/31/93; \$81,382.60.
5. Xenon Development Project for SPECT Camera. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; CoPI: John Prince, Ph.D.; 1991 - 1993; \$200,000.00

Funded (Gifts to OU Department of Psychiatry):

1. Genetic-Environmental Interactions in Schizophrenia. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 1991 - 1992; \$20,000.00
2. University of Oklahoma Psychiatric Brain Bank. (Warren Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 1991 - 1992; \$45,000.00
3. Image Analysis Workstation: Instrumentation Grant. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; 1991; \$120,000.00
4. Three Headed SPECT Camera: Instrumentation Grant. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; CoPI: John Prince, Ph.D.; 1991 - 1992; \$560,000.00
5. Study of a Novel Cocaine Receptor Ligand with SPECT. (Laureate Foundation, Tulsa) PI: Jörg J. Pahl, M.D.; CoPI: Garo Basmadjian, Ph.D.; 1991 - 1992; \$20,000.00

Pharmaceutical Studies & Contracts (Pahl Brain Associates, P.C.):

1. Janssen Pharmaceutica - Safety of Sabeluzole in the long-term treatment of Alzheimer's disease. An open label extension study - Sabeluzole R052735. Protocol # SAB-USA-26 \$38,250.00
2. Janssen Pharmaceutica - A randomized trial to assess the outcomes and costs of Risperdal versus conventional antipsychotic therapy in patients with chronic Schizophrenia. Protocol #RIS-USA-56A \$380,000
3. Janssen Pharmaceutica - A randomized, double-blind, placebo-controlled study of Risperdal for treatment of behavioral disturbances in subjects with dementia. Protocol #RIS-USA-63B \$249,600
4. Janssen Pharmaceutica - An open-label, long-term study of Risperdal for treatment of behavioral disturbances in subjects with dementia. Protocol #RIS-USA-70 \$149,600
5. Janssen Pharmaceutica - Mazapertine dose-finding trial, comparing three fixed dosages of Mazapertine to Risperdal and placebo: multicenter, double-blind, parallel-group study. Protocol # MAZ-INT-01 \$450,000.
6. Janssen Pharmaceutica - A randomized, double-blind, multi-center, Haloperidol and Clozapine controlled, parallel group trial, studying the efficacy of Risperdal, Haloperidol and Clozapine in treatment resistant Schizophrenic subjects. Protocol # RIS-USA-78
7. Parke-Davis - A double-blind, placebo-controlled, parallel-group, 3-day treatment and 3-month follow-up. Multicenter study to evaluate the safety and efficacy of intravenous Fosphenytoin (Cerebyx®) in patients with acute ischemic stroke. Protocol # 982-025 \$100,000
8. Janssen Pharmaceutica - An open comparative Multicenter study of Intravenous Itraconazole followed by Itraconazole Oral Solution versus Fluconazole followed by oral Fluconazole tablets in Treatment of Candidemia in Non-Neutropenic Patients. Protocol # ITR-INT-61 \$79,300
9. Parke-Davis - A 52-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study of Milameline (C1-979/RU) in patients with probable Alzheimer's Disease with long-term open label extension. Protocol #979-15 \$119,430
10. Pfizer - 40 week, double-blind study evaluating the safety and efficacy of two dose regimens of oral Ziprasidone (cp-88, 059-1) (80-120 mg, QD, and 40-80 mg BID) and Haloperidol (5-20 mg daily) in the maintenance treatment of outpatients with Schizophrenia or Schizoaffective disorder. Protocol #128-108-617 \$126,060

- 1987 Clinical Applications of Positron Emission Tomography. Seminar held at the German Cancer Institute (Deutsches Krebsforschungszentrum). Heidelberg, West Germany.
- 1987 PET Findings in Huntington's Disease. Seminar held in the Department of Neurology, University of Düsseldorf. Düsseldorf, West Germany.
- 1988 Psychiatric Applications of Positron Emission Tomography (PET). Department of Psychiatry, University of Erlangen/Nürnberg. Erlangen, West Germany.
- 1992 Structural and Functional Brain Imaging in Alzheimer's Disease. Division of Nuclear Medicine: Department of Radiological Sciences, University of Stellenbosch. Parow, South Africa.
- 1992 Schizophrenia: Current Status of Brain Imaging Research. Department of Psychiatry, University of Stellenbosch. Parow, South Africa.

National:

- 1986 Psychiatric Aspects of Movement Disorders. Laboratory of Nuclear Medicine Neuroscience Section, UCLA. Los Angeles, California.
- 1986 Studies of Patients with Tardive Dyskinesias. Laboratory of Nuclear Medicine, Neuroscience Section, UCLA. Los Angeles, California.
- 1987 Tardive Dyskinesia and FDG-PET. Laboratory of Nuclear Medicine, Neuroscience Section, UCLA. Los Angeles, California.
- 1988 PET Methodological Issues in the Study of Psychiatric Disorders. Bentwood VA. West Los Angeles, California.
- 1988 PET Data Management/Display/Needs-Neuroscience. 1987-1988. Neuroscience Laboratory Seminar Mini-Course Series, UCLA. Los Angeles, California.
- 1988 PET Studies of Higher Cognitive Functions. Lake Arrowhead, California.
- 1988 Positron Emission Tomography in Schizophrenics with Tardive Dyskinesia. West Coast Biological Psychiatry Meeting. Seattle, Washington.
- 1988 Phenotypic, Biochemical and Genetic Heterogeneity in Huntington's Disease and Schizophrenia. Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1988 PET and Cocaine Addiction. Schick Shadel Hospital. Santa Barbara, California.
- 1989 PET Studies of Neurodegenerative Disease. Schneiders Hospital. Glenn Oaks, Long Island, New York.
- 1989 PET Applications in Psychiatry. Mount Pleasant Mental Health Institute. Mount Pleasant, Iowa.

- 1989 PET and Genetic Linkage Studies in Schizophrenia. Genetics Seminar in the Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1989 I-123 IMP Cerebral Perfusion in Drug-Naive Schizophrenics. College of Medicine Research Day XIV. University of Iowa, College of Medicine. Iowa City, Iowa.
- 1989 Clinical Applications of Brain Imaging in Psychiatry. Grand Rounds, Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1989 Neuropathology of Schizophrenia. Psychiatric Postgraduate Conference and Meeting of the Iowa Psychiatric Society. Iowa City, Iowa.
- 1989 Tardive Dyskinesia. Psychiatric Postgraduate Conference and Meeting of the Iowa Psychiatric Society. Iowa City, Iowa.
- 1989 Limbic System and Basal Ganglia Neuropathology in Schizophrenia. Long Island Jewish Hillside Hospital. Glenn Oaks, Long Island, New York.
- 1989 Brain Imaging in Psychiatry: A Vision of the 1990s. Research Seminar, Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1990 Brain Imaging in Affective Disorders. Grand Rounds, Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1990 Non-Convulsive Status Epilepticus in Catatonia. Grand Rounds, Department of Psychiatry, University of Iowa, College of Medicine. Iowa City, Iowa.
- 1990 Brain Imaging: Mapping Function to Structure. Psychiatric Research Institute, St. Francis Hospital and the Wichita Veterans Administration Medical Center. Wichita, Kansas.
- 1990 Schizophrenia Research. Broadlawns Medical Center. Des Moines, Iowa.
- 1990 Chemical Brain Imaging in Psychiatry: A diagnostic modality for the 1990s. University of Texas, Southwestern Medical Center. Dallas, Texas.
- 1992 Antidepressant Choice in the Treatment of Depression. Texas Tech. El Paso, Texas.
- 1992 Treatment Resistant Schizophrenia. Larned State Mental Hospital. Larned, Kansas.
- 1992 Treatment and Recognition of Depression. Fort Smith, Arkansas.
- 1992 Use of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression. Lubbock, Texas.
- 1992 Brain Imaging in Depression. Huey P. Long Memorial Hospital. Alexandria, Louisiana.
- 1992 Brain Imaging in Depression. Big Springs VA Hospital. Big Springs, Texas.

- 1992 Brain Imaging as a Laboratory Test In Depression. Springfield Federal Psychiatric Prison. Springfield, Missouri.
- 1992 Brain Imaging in the Differential Diagnosis of Dementia. Bentonville, Arkansas.
- 1992 SSRIs: The New Generation Antidepressants. Texas Tech. Amarillo, Texas.
- 1992 SPECT as a Diagnostic Tool in Depression and Dementia. Green Oaks Hospital. Dallas, Texas.
- 1993 SSRI's: A NEW Generation of Anti-Depressants. Charta Vista Psychiatric Hospital. Fayetteville, Arkansas.
- 1993 Depression and AIDS: Diagnostic Brain Imaging in the AIDS Patient. Springdale, Arkansas.
- 1993 Usefulness of New Anti-Depressants. Presentation to Psychiatrists, Internists and Family Practitioners, Oakbrook. Chicago, Illinois.
- 1993 SSRI's: A New Generation of Anti-Depressants. Presentation to Oncologists, Internists, Family Practitioners. Toni Town, Arkansas.
- 1993 Psychiatry and the Law presentation. Lubbock, Texas.
- 1993 Brain Imaging in Depression. Amarillo, Texas.
- 1993 SPECT Brain Imaging: Applications in Psychiatry and Neurology. Kansas City, Missouri.
- 1993 Medical Management of Alzheimer's Disease. Fort Worth, Texas.
- 1993 Psycho-Economics of Depression - Aging American Session, Eighth National Conference of Chronic Disease Prevention and Control. Kansas City, Missouri.

Local:

- 1989 PET and Psychiatric Disorders. Department of Psychiatry and Behavioral Sciences, University of Oklahoma. Oklahoma City, Oklahoma.
- 1990 Brain Imaging in Psychiatric Disorders. Veterans Administration Medical Center. Oklahoma City, Oklahoma.
- 1990 SPECT AND PET Brain Imaging: Department of Neurology Grand Rounds Presentation, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 The Use of Image Analysis Workstations in Psychiatric Brain Imaging. Neuropsychology Case Conference, Department of Psychiatry and Behavioral Sciences, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 1991 Pfizer Symposium, University of Oklahoma - The Genetics of Schizophrenia. Department of Psychiatry and Behavioral Sciences, University of Oklahoma. Oklahoma City, Oklahoma.

- 1991 Brain Imaging in Neuropsychiatric Disorders. Oklahoma Memorial Hospital, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 Brain Imaging in Eating Disorders. Department of Obstetrics and Gynecology, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 Management of Patients with Mental Health Problems. Oklahoma Bar Association (Lawyers Helping Lawyers). Oklahoma City, Oklahoma.
- 1991 Treatment Resistant Schizophrenia. Grand Rounds, Department of Psychiatry, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 Clinical Applications of Brain Imaging in Psychiatry. Grand Rounds, Department of Psychiatry, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 The University of Oklahoma's Psychiatric Brain Imaging Program. Presented at the Research Council Meeting, Department of Psychiatry, University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 Indications for Clozapine Use in Treatment Refractory Schizophrenia. Presented at Griffin Memorial (Central State) Hospital. Norman, Oklahoma.
- 1991 Mapping the Brain's Cognitive and Chemical Functions Program. The Oklahoma Center for Neurosciences University of Oklahoma. Oklahoma City, Oklahoma.
- 1991 Schizophrenia: Indications for Typical and Atypical Antipsychotics. Presented to the Oklahoma City Branch of the Oklahoma Alliance for the Mentally Ill (OAMI). Oklahoma City, Oklahoma.
- 1992 The Diagnosis and Treatment of Depression. Roerig-Pfizer Preceptorship. Oklahoma City, Oklahoma.
- 1992 Schizophrenia and Alzheimer's Disease. Presented to the McAlester Branch of the Oklahoma Alliance for the Mentally Ill (OAMI) at Carl Albert Mental Health Community Center. McAlester, Oklahoma.
- 1992 Clozapine Use in Treatment Resistant Schizophrenia. Presented at the PAC Board Meeting, Grand Lake Mental Health Center. Nowata, Oklahoma.
- 1992 Diagnosis of Alzheimer's Disease. Conference Rounds, Department of Psychiatry and Behavioral Sciences, University of Oklahoma. Oklahoma City, Oklahoma.
- 1992 Clozapine in the Treatment of Schizophrenia. Tulsa Alliance for the Mentally Ill (TAMI). Tulsa, Oklahoma
- 1992 New Antidepressant for the Treatment of Depression. Enid, Oklahoma.
- 1992 Recognizing and Treating Depression. Talk for the Okmulgee Family Practitioners. Okmulgee, Oklahoma.
- 1992 SPECT Brain Imaging: A Neuropsychological Probe. Neuropsychology Case. Conference Rounds, Department of Psychiatry and Behavioral Sciences, University of Oklahoma. Oklahoma City, Oklahoma.

- 1992 Sertraline and Fluoxetine in the Treatment of Depression. Tulsa, Oklahoma.
- 1992 Indications for Clozaril (Clozapine) Use in Treatment Resistant Schizophrenia. University of Science and Arts of Oklahoma. Chickasha, Oklahoma.
- 1992 Cognex (THA) Treatment in Alzheimer's Disease. Forgetfulness: How do we know if it's Alzheimer's? Alzheimer's Symposium, University of Oklahoma Health Science Center. Oklahoma City, Oklahoma.
- 1992 Treatment Resistant Depression. Presentation to Physicians of Norman Regional Hospital. Norman, Oklahoma.
- 1992 SSRIs: Efficacy, Side Effect Profile and Safety in Overdose. Presentation to University of Oklahoma College of Medicine. Tulsa, Oklahoma
- 1992 Update on Parkinson's Disease and Its Treatments. Presentation to Edmond Family Medicine Practitioners. Edmond, Oklahoma.
- 1992 Molecular and Psychiatric Aspects of AIDS. University of Oklahoma Health Science Center. Oklahoma City, Oklahoma.
- 1993 Anti-Depressant Management of Secondary Major Depression. Presentation to Internists, Mercy Hospital. Oklahoma City, Oklahoma.
- 1993 Recognition and Treatment of Depression: Advances in Diagnosis and Management. Carl Albert State Mental Hospital. McAlester, Oklahoma.
- 1993 Alzheimer's Disease. Presentation for General Practitioners. Clinton Tradewinds. Clinton, Oklahoma.
- 1993 Alzheimer's Disease. Presentation for General Practitioners and Psychiatrists. Warren Duck Club, Doubletree Hotel. Tulsa, Oklahoma.
- 1993 Medical Management of Alzheimer's Disease. Presentation for General Practitioners and Psychiatrists. Applewood's. Oklahoma City, Oklahoma.
- 1993 Alzheimer's Disease: New Research Findings. Tulsa Regional Osteopathic Hospital Grand Rounds. Tulsa, Oklahoma.
- 1993 Alzheimer's Disease. Presentation for Family Practitioners. Enid, Oklahoma.
- 1993 Clozaril use in Treatment Resistant Schizophrenia. Presentation to State of Oklahoma Community Mental Health Directors, at Western Hills Lodge. Wagner, Oklahoma
- 1993 Alzheimer's Disease - Medical Management. Presentation for General Practitioners. Ponca City, Oklahoma.
- 1993 Alzheimer's Disease. Presentation for General Practitioners. Shawnee, Oklahoma.
- 1993 Alzheimer's Disease. Presentation for General Practitioners. Ada, Oklahoma.
- 1993 SPECT Brain Imaging in Alzheimer's Disease. Grand Rounds, Department of Psychiatry & Behavioral Sciences; University of Oklahoma. Oklahoma City, Oklahoma.

- 1993 **Brain Imaging in HIV/AIDS. Oklahoma Center For Neurosciences Meeting at University Of Oklahoma Health Sciences Center. Oklahoma City, Oklahoma.**
- 1993 **Early Recognition and Treatment of Alzheimer's Disease. Presentation for General Practitioners. Muskogee, Oklahoma.**
- 1993 **National Depression Conference, Department of Psychiatry & Behavioral Sciences; Faculty Club, University of Oklahoma. Oklahoma City, Oklahoma.**
- 1993 **Alzheimer's Disease Advances In Diagnosis and Treatment. Presentation for General Practitioners, Student Union, University of Oklahoma. Norman, Oklahoma.**
- 1993 **Brain Imaging in AIDS. Grand Rounds, Department of Psychiatry & Behavioral Sciences; University of Oklahoma. Oklahoma City, Oklahoma**
- 1993 **Medical Management of Alzheimer's Disease. Presentation for General Practitioners, Faculty House, Oklahoma City, Oklahoma.**
- 1993 **Alzheimer's Disease Advances In Diagnosis & Treatment. Presentation for General Practitioners. McAlester, Oklahoma.**
- 1993 **"Early Recognition of Alzheimer's Disease" Grand Rounds Presbyterian Hospital. Oklahoma City, Oklahoma.**
- 1993 **"New Approaches to the Treatment of Schizophrenia". All Souls Episcopal Church. Oklahoma City, Oklahoma.**
- 1993 **Advances in the Treatment of Alzheimer's Disease. Presentation for Family Practitioners, Faculty House. Oklahoma City, Oklahoma.**

PUBLICATIONS:

Doctoral Thesis:

Anorexia Nervosa - Eine Verlaufsstudie Psychischer und Somatischer Parameter.
(Anorexia nervosa - A Longitudinal Study of Psychiatric and Somatic
Parameters) Doctoral Thesis: Technical University, Munich, West Germany,
1985.

Book Chapters:

1. Emrich HM, Pahl JJ, Herholz K, Pawlik G, Pirke KM, Gerlinghoff M, Wienhard W, Heiss WD: PET Investigation In Anorexia Nervosa: Normal Glucose Metabolism During Pseudoatrophie Of The Brain. In: The Psychobiology of Anorexia Nervosa, Pirke KM, Ploog D (eds.), Springer-Verlag: Berlin, Heidelberg 1984.
2. Herholz K, Emrich HM, Pahl JJ, Pawlik G, Pirke KM, Wienhard W, Heiss WD: PET Investigation In Anorexia Nervosa: Preliminary results. Plenum Press, 1984.
3. Pahl JJ, Bartzokis G, Mazziotta JC, Cummings J, Altshuler L, Marder S, Phelps ME: Positronenemissionstomographie (PET) In der Schizophrenieforschung: 1980-1987. In: Die Schizophrenien: Biologische und Familiendynamische Konzepte zur Pathogenese. Kaschka WP, Joraschky P, Lungershausen E, (eds.). Springer Verlag: Berlin, Heidelberg 1988.
4. Pahl JJ, Swayze V, Andreasen NC: Diagnostic Advances In Anatomical And Functional Brain Imaging In Schizophrenia. In: Recent Advances in Schizophrenia, Kales A, Stefanis CN, Talbott JA (eds.). Springer Verlag, Berlin, Heidelberg, New York, Tokyo, 1989.
5. Pahl JJ. Positron Emission Tomography (PET) in the Study Of Higher Cognitive Functions. In: Higher Cognitive Functions. Scheibel, A. Wechsler, A (eds) Guilford Press, 1990.
6. Pahl JJ, Rezai K, O'Leary DS, Andreasen NC: The Study of Schizophrenia with SPECT. In: Radiopharmaceuticals and Brain Pathology studied with PET and SPECT, Diksic M, Reba R. (eds.). CRC Press, 1990

ACP Psychiatric Update Program (Tape):

Andreasen NC, Baxter LR, Pahl JJ: Brain Imaging: Applications in Psychiatry.
ACP Psychiatric Update, G. Usdine (ed).

Original Articles:

1. Pirke KM, Pahl JJ: Somatische Befunde bei der Anorexia Nervosa. In: *Aktuel Ernährung*, 1:14-19, 1984.
2. Pahl JJ, Pirke KM, Schweiger U, Warnhoff M, Gerlinghoff M, Brinkmann W, Berger M, Krieg CH: Anorectic Behavior, Mood, Metabolic and Endocrine Adaptation to Starvation in Anorexia Nervosa During In-Patient Treatment. *Biol Psychiatry* 20:874-887, 1985.
3. Pirke KM, Pahl J, Schweiger U, Warnhoff N: Metabolic and Endocrine Indices Of Starvation in Bulimia: A Comparison with Anorexia Nervosa. *Psychiatry Res* 15:33-39, 1985.
4. Pirke KM, Fichter M, Pahl JJ: Noradrenaline, Trijodthyronine Growth Hormone and Prolactin During Weight Gain in Anorexia Nervosa. *Int J of Eating Disorders* 4:449-509, 1985.
5. Pirke KM, Pahl J, Schweiger U, Münzing W, Lang P, Büll U: Total Body Potassium, Intracellular Potassium And Body Composition in Patients with Anorexia Nervosa During Refeeding. *Int J of Eating Disorders* 5:347-354, 1986.
6. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH: Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease. *N Eng J Med* 316:357-362, 1987.
7. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Hoffman JM, Markham CH, Riege WH, Lanto AB, Wapenski JA: Studies In Persons at Risk for Huntington's Disease (Letter). *N Eng J Med* 317:382-384, 1987.
8. Herholz K, Krieg JC, Emrich HM, Pawlik G, Beil C, Pirke KM, Pahl JJ, Wagner R, Wienhard K, Ploog D, Heiss WD: Regional Cerebral Glucose Metabolism in Anorexia Nervosa Measured by Positron Emission Tomography. *Biol Psychiatry* 22:43-51, 1987.
9. Baxter LR, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH., Fairbanks L. Cerebral Glucose Metabolic Rates In Non-Depressed Obsessive-Compulsives. *Am J Psychiatry* 145:1560-1563, 1988.
10. Pahl JJ. Cerebral Metabolic Decline: A Biochemical Marker of Genetic Expression in Huntington's Disease. *Functional Neuroimaging* 2: 3-8, 1989.
11. Pahl JJ. Basal Ganglia Metabolic Dysfunction in Hyperkinetic Movement Disorders. *Functional Neuroimaging* 2: 9-13, 1989.
12. Brenner M, Berberich R, Haas A, Schimrigk K, Pahl J. *Platlet Scintigraphy in Cerebrovascular Diseases*. *Eur Neurol* 29:197-201, 1989.
13. Lanto AB, Riege WH, Mazziotta JC, Pahl JJ, Phelps ME: Increased False Alarms In a Subset of Persons at Risk for Huntington's Disease. *Arch Clin Neuropsychology* 5:393-404, 1990.

14. Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop PS, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME: A Comparison of Neurologic, Metabolic, Structural and Genetic Evaluations in Persons at Risk for Huntington's Disease. *Ann Neurol*, 28:614-621, 1990.
15. Baxter LR, Mazziotta JC, Pahl JJ, Grafton ST, Haines JL, George-Hyslop PS, Haines JL, Gusella J, Szuba M P, Selin C.E., Guze B.H., Phelps ME: Psychiatric, Genetic and PET Evaluation of Persons at Risk for Huntington's Disease. *Arch Gen Psychiatry*, 1992;49:148-154.
16. Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop PS, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME: Serial Changes of Cerebral Glucose Metabolism and Caudate Size in Persons at Risk for Huntington's Disease. *Arch Neurol*. 1992;49:1161-1167.
17. Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop PS, Haines JL, Gusella J, Baxter LR, , Phelps ME: Temporal Changes of Cerebral Glucose Metabolism in Persons at Risk for Huntington's Disease. (Submitted to Neurology)
18. Wang C, Pahl JJ, and Hogue RE: A Method For Registering Three-Dimensional Multi-Modality Brain Images. (Submitted to Computer Methods and Programs in Biomedicine)
19. Pahl JJ, Wang C, Hogue RE, Fites G, Adams R, Wilson DA, and Allen EW: Three-Dimensional Brain Imaging in Alzheimer's Disease: A MRI-SPECT study. (submitted to Journal of Clinical Nuclear Medicine).
20. Pahl JJ, Mazziotta JC, Bartzokis G, Cummings J, Altschuler L, Mintz J, Marder SR, and Phelps ME: Positron Emission Tomography (PET) In Tardive Dyskinesia. (Journal of Neuropsychiatry and Clinical Neuroscience, 1995; 7:457-465)
21. D'Souza MF, Mumma CG, Mohapatra SM, Allen EW, Pahl JJ, Prince JR: Physical and Subjective Evaluation of a Three-Detector (Triad88) SPECT System. (Australasian Physical & Engineering Sciences in Medicine, 1995, Vol. 18 No. 4:185-196)

Abstracts:

1. Mazziotta JC, Phelps ME, Pahl JJ, Wapenski J, Baxter LR, Riege R, Selin C, Noetling R, Sumida R: Local Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease. *Neurology* 36(Suppl 1):310, 1986.
2. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Wapenski J, Baxter LR, Riege W, Kuhl DE, Selin C, Sumida R, Markham CH. Caudate Hypometabolism in Asymptomatic Subjects at Risk for Huntington's Disease. *J Nucl Med* 27:920, 1986.

3. **Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Wapenski J, Baxter LR, Riege WR, Kuhl DE, Selin C, Sumida R, Markham CH. Cerebral Glucose Utilization Reductions in Clinically Asymptomatic Subjects at Risk for Huntington's Disease. Proc Soc Neurosci 12:968, 1986.**
4. **Riege WH, Mazziotta JC, Phelps ME, Lanto A, Pahl J, Kuhl DE, Baxter LR. Brain-Behavioral Clustering of Asymptomatic Persons at Risk for Huntington's Disease. Proc Soc Neurosci 12:968, 1986.**
5. **Pahl JJ, Mazziotta JC, Cummings J, Bartzokis G, Marder S, Schwab R, Sumida R, Kuhl DE, Baxter LR, Phelps ME: Positron Emission Tomography in Tardive Dyskinesia and Huntington's Disease: LCMRG1c in Two Patient Populations With Chorea. J Cereb Blood Flow Metab 7(Suppl 1):S373, 1987.**
6. **Mazziotta JC, Phelps ME, Pahl JJ, Baxter LR, Riege WR, Hoffman JM, Huang SC, Gusella J, Hyslop P, Kuhl DE, Markham C: Glucose Metabolism and DNA Polymorphism Studies in Huntington's Disease (HD). J Nucl Med 28:655, 1987.**
7. **Mazziotta JC, Pahl JJ, Phelps ME, Baxter LR, Riege WR, Hoffman JE, Huang SC, Gusella J, Hyslop P, Schwab R, Selin C, Sumida R, Kuhl DE, Wapenski J, Coneally M, Markham CH: In the PET and DNA Polymorphism Results Presymptomatic Evaluation of Subjects at Risk for Huntington's Disease (HD). Neurology 37(Suppl 1): 211, 1987.**
8. **Mazziotta JC, Pahl JJ, Phelps ME, Baxter LR, Riege WR, Hoffman EJ, Huang SC, Gusella J, Hyslop P, Schwab R, Selin C, Sumida R, Kuhl DE, Wapenski J, Conneally M, Markham CH: Presymptomatic Evaluation of Subjects at Risk for Huntington's Disease (HD): PET and DNA polymorphism studies. J. Cereb Blood Flow Metab 7(Suppl 1):S366, 1987.**
9. **Pahl JJ, Mazziotta JC, Baxter LR, Riege WR, Sumida R, Selin C, Lanto A, Dorsey D, Maltese A, Phelps ME: PET Studies in Symptomatic Huntington's Disease. Neurology 38(Suppl 1):124,1988.**
10. **Pahl JJ, Mazziotta JC, Bartzokis G, Cummings J, Baxter LR, Sumida R, Phelps ME: Metabolic Dysfunction in Tardive Dyskinesia and Huntington's Disease. Neurology 38(Suppl 1):361,1988.**
11. **Pahl JJ, Bartzokis G, Mazziotta JC, Cummings J, Altshuler L, Marder S, Phelps ME: PET Studies in Tardive Dyskinesia (TD). Neurology 38(Suppl 1):400,1988.**
12. **Pahl JJ, Mazziotta JC, Hawkins RA, Bartzokis G, Cummings J, Altshuler L, Marder S, Phelps ME: PET in Hyperkinetic Movement Disorders. J Nucl Med 29:839, 1988.**
13. **Pahl JJ, Mazziotta JC, Bartzokis G, Cummings J, Altshuler L, Marder S, Phelps ME. PET Studies of the Motor System in Tardive Dyskinesia. J Nucl Med 29:821, 1988.**

14. **Mazziotta JC, Pahl JJ, Phelps ME, St. George-Hyslop P, Gusella J, Baxter LR, Riege WH, Lanto AB, Dorsey D, Maltese A. PET and Genetic Linkage Results in Individuals at risk for Huntington's Disease. J Nucl Med 29:821, 1988.**
15. **Hoffman JM, Guze BH, Hawk TC, Pahl JJ, Sumida R, Baxter LR, Mazziotta JC, Phelps ME: Cerebral Glucose Metabolism in Normal Individuals: Effects of Aging, Sex and Handedness. Neurology 38(Suppl 1):371,1988.**
16. **Pahl JJ, Bartzokis G, Mazziotta JC, Cummings J.L., Altshuler L, Marder SM. Pallidal Hypermetabolism in Schizophrenics with TD. APA (NR50) 43,1988 (American Psychiatric Association,141 st Annual Meeting Meeting Montreal, Canada).**
17. **Pahl JJ, Rezai K, Cohen GA, Alliger RJ, Swayze VW, Andreasen. IMP SPECT Cerebral Perfusion Studies in Drug-Naïve Schizophrenics. Second International Schizophrenia Symposium, San Diego, California (1989).**
18. **Pahl JJ, Baxter, Jr, LR, Mazziotta JC, Phelps ME. Psychiatric Features in 50 HD at Risk Subjects. (American Psychiatric Association, 142nd Annual Meeting Meeting, San Francisco, California) (NR192, 1989).**
19. **Pahl JJ, Andreasen NC, Cohen GA, Rezai K, Kirchner PK. Frontal Hypoperfusion In Drug-Naïve Schizophrenics. (American Psychiatric Association, 142nd Annual Meeting Meeting, San Francisco, California) (NR95, 1989).**
20. **Andreasen NC, Crowe RR, Black DW, Pahl JJ. Multiplex Family Studies of Schizophrenia, First World Congress on Psychiatric Genetics (London, England, 1988).**
21. **Baxter LR, Schwartz JM, Guze BH, Phelps ME, Mazziotta JC, Pahl J, Selin CE. Neuroanatomical Studies of Obsessive-Compulsive Disorders, ACNP Meeting Puerto Rico, 1989).**
22. **Baxter LR, Mazziotta JC, Pahl JJ, Selin CE, Grafton ST, Phelps ME, Szuba MP, Guze BH, Gusella J, Baxter LR, George-Hyslop PS: Psychiatric, Genetic and PET Evaluation of Persons at-Risk for Huntington's Disease Submitted to APA (1989).**
23. **Pahl JJ, Allen EW, Adams R, Winn P, Beatty W, Hogue R, Fites G, Prince J, Tompkins R. SPECT A Non-Invasive Probe. In Alzheimer's Disease. Oklahoma Center for the Neuro Sciences, OCNS, University of Oklahoma 1992)**
24. **Basmadjian GP, Kanvinde M.H., Jain SP, Mills SL, Hofstetter J, Bourne D, Pahl J, Allen W, Leonard JC: No-Carrier Added Radionated Cocaine Analogs: Synthesis, Ligand Binding and Animal Biodistribution. Submitted to Soc for Neuroscience, 1992.**

25. Basmadjian GP, Mills SL, Jain S, Kanvinde MH, Leonard JC, Pahl J, Allen W. I-4-Iodococaine: A Potential Probe For The *In-Vivo* Mapping of The Brain Cocaine Receptors. University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, Oklahoma.
26. Wang C, D'Souza MF, Prince JR, and Pahl JJ. Analysis of scatter fraction for Xe-133 used in rCBF measurement on a three-head SPECT camera. 35th Annual Meeting of American Association of Physicists in Medicine, August 8-12, 1993. Washington, D.C.
27. Wang C, Pahl JJ, and Hogue RE. Three-dimensional displays of SPECT brain images, a useful tool for neuropsychiatric diagnosis. The Oklahoma Center for NeuroSciences, 2nd Annual Symposium, October 15-16, 1993. Oklahoma City, Oklahoma.
28. Hogue RE, Pahl JJ, Wang C, Fites G, Adams R, Winn P, and Allen EW. SPECT Assessment of Regional Cerebral Blood Flow in Possible and Probable Alzheimer's Disease. The Oklahoma Center for NeuroSciences 2nd Annual Symposium, October 15-16, 1993. Oklahoma City, Oklahoma.
29. Pahl JJ, Wilson DA, Hogue RE, Fites G, Brando FM, and Wang C. Cortical Localization of Atrophy in Treatment Resistant Schizophrenia. The Oklahoma Center for NeuroSciences 2nd Annual Symposium, October 15-16, 1993. Oklahoma City, Oklahoma.
30. D'souza MF, Prince JR, Pahl JJ, Allen EW, Suwondo P, Walker RW, Barsamian S, Kline BD, Lim CB, Fantanos C, MacIntyre WJ, Saha GB, and Go RT: "Methodology for and Performance Characteristics of a System for Measuring rCBF Using Xe-133 and a Three-Detector SPECT Camera". (European Association of Nuclear Medicine Congress, October 10-14, 1993, Lausanne, Switzerland)
31. Pahl JJ, Wang C, Hogue RE, Fites G, Wilson DA, and Allen EW. 3-D MRI-SPECT Imaging in Schizophrenia. January 23-28, 1994, Les Diablerets, Switzerland.
32. Wang C, and Pahl JJ. A Co-Registration Method for Three-Dimensional Functional Brain Images. The Society of Nuclear Medicine, Computer & Instrumentation Council Meeting on Dedicated Instruments and Computer Processing Techniques for Cardiac and Brain Imaging. February 7-8, 1994, Seattle, Washington.
33. Suwondo P, Walker RW, Barsamian S, Kline BD, Lim CB, Fantanos C, MacIntyre WJ, Saha GB, Go RT, D'Souza MF, Prince JR, Pahl JJ, Allen EW. Development of and Initial Results From a Xe-133 rCBF System Using a Triple-headed SPECT camera SNM, 1993.
34. Hogue RE, Pahl JJ, Wang C, Adams R, and Allen EW: "SPECT Assessment of Parietal and Temporal Lobe Perfusion in Possible and Probable Alzheimer's Disease". (submitted to Southwestern Chapter, Society of Nuclear Medicine, Albuquerque, New Mexico, 1993)

35. Pahl JJ, Hogue RE, Wang C, Wilson DA, and Chacko G: "3-D HMPAO SPECT Surface Renderings in Schizophrenia". (submitted to Southwestern Chapter, Society of Nuclear Medicine, Albuquerque, New Mexico, 1993)
36. Wang C, Pahl JJ, Hogue RE. An interactive method for co-registering SPECT and MR brain images. Submitted to 39th Annual Meeting of the Southwestern Chapter of The Society of Nuclear Medicine, April 7-10, 1994. Albuquerque, New Mexico.

PHYSICAL FACILITIES:

Office:

Office 2500 square feet

Research Support:

Pharmaceutical Study Coordinators (6)

Office Manager (1)

Secretaries (2)

Computers (6)

PERSONAL REFERENCES

W.D. Heiss, M.D.

Professor of Neurology

Director, Max-Planck-Institute für Neurologische Forschung

Ostmerheimerstrasse 200

D-5000 Köln

Germany

J.C. Mazziotta, M.D., Ph.D.

Professor of Neurology and Radiology

Departments of Neurology and Neuroradiological Sciences

UCLA School of Medicine

Los Angeles, California 90024

USA

**Pahl Brain Associates
List of Rating Scales**

- STUDY:** Risperidone for treatment of behavioral disturbances in subjects with dementia (Janssen)
- Rating Instruments:** Functional Assessment Staging Scale (FAST)
Mini-Mental State Exam (MMSE)
Behave-AD
Cohen-Mansfield Agitation Inventory (CMAI)
Clinical Global Impression (CGI/CGI-C)
Physical Self-Maintenance Scale (PSMS)
Extrapyramidal Symptoms Rating Scale (ESRS)
- STUDY:** Ziprasidone vs. Placebo for inpatient treatment of acute exacerbation of schizophrenia and schizoaffective disorder. (Pfizer)
- Rating Instruments:** Structured Clinical interview for DSM-III-R (SCID-P)
Positive and Negative Syndrome Scale (PANSS)
Clinical Global Impression (CGI/CGI-C)
Montgomery-Asberg Depression Rating Scale (MADRS)
Quality of Life Scale (QLS)
- STUDY:** Ziprasidone vs. Halperidol in Maintenance of treatment of outpatients with schizophrenia or schizoaffective disorder. (Pfizer)
- Rating Instruments:** Structured Clinical interview for DSM-III-R (SCID-P)
Global Assessment Functioning Scale (GAF)
Sexual Dysfunctional Questionnaire
Positive and Negative Syndrome Scale (PANSS)
Clinical Global Impression (CGI/CGI-C)
Quality of Life Scale (QLS)
Montgomery-Asberg Depression Rating Scale (MADRS)
Psychological General Well-Being Schedule (PGWB)
Drug Attitude Inventory (DAI)
Resource Utilization Questionnaire (RUQ)
- STUDY:** Risperidol vs. Conventional antipsychotics in patients with chronic schizophrenia - Outcomes Study (Janssen)
- Rating Instruments:** Quality of Life Scale (QLS)
Medical Outcomes Study Short form (SF-36)
Drug Attitude Inventory (DAI)
Positive and Negative Syndrome Scale (PANSS)
Simpson-Angus, Barnes Akathisia Abnormal Involuntary Movement Scale (AIMS)

Alfred...
9.15.94 1

CURRICULUM VITAE

Personal Information:

Name in full: Ananda K. Pandurangi
Date and place of birth: July 8, 1951
Dharwar, India
Citizenship: U.S.A.
Social Security Number: REDACTED
Family Status: Married. Spouse - Rama;
Sons - Abhinav, Ashvin;
Home Address & Phone: REDACTED
Office Address & Phone: Medical College of Virginia
Department of Psychiatry,
Box 980710.
Richmond, Virginia, 23298
(804) 828-4570
Fax: 828-4614

Current Position:

Professor of Psychiatry
Director, Schizophrenia Program
Chairman, Division of Inpatient
Psychiatry

Licensure:

Commonwealth of Virginia
REDACTED (active)
Commonwealth of Massachusetts
REDACTED (registration inactive)
State of New York REDACTED
(registration inactive)
Madras Medical Council, India
REDACTED

Boards/Certification:

M.B.B.S., Madras University,
India, 1975
Educational Council For Foreign
Medical Graduates Certificate,
U.S.A. (ECFMG), 1975
M.D. (Psychological Medicine)
Bangalore University, India, 1978
Diplomate, American Board of Psychiatry and
Neurology, 1985 (General Psychiatry)

Education:

July 1982 - June 1984 Clinical Research Fellow
Department of Psychiatry
College of Physicians and Surgeons
Columbia University, New York
July 1982 - June 1983 Resident in Psychiatry
New York State Psychiatric Institute
July 1980 - June 1982 Resident in Psychiatry
Upstate Medical Center, SUNY
Syracuse, New York
July 1979 - June 1980 Intern, Medicine/ Psychiatry Program
Upstate Medical Center, SUNY

	Syracuse, New York
<u>Education (contd):</u>	
July 1975 - June 1978	Resident in Psychiatry National Institute of Mental Health & Neuro- Sciences, Bangalore University, Bangalore, India
Jan 1974 - March 1975	Intern - Flexible Program JIPMER Hospital, Pondicherry, India University of Madras
April 1975 - July 1975	Senior Houseman (Psychiatry, Chest Diseases) JIPMER Hospital Pondicherry, India
July 1968 - March 1975	Medical College of Pondicherry (Jawaharlal Institute of Post-Graduate Medical Education and Research - JIPMER) Pondicherry, Madras U, India
July 1967 - June 1968	National College Bangalore, India
<u>Military Service:</u>	None
<u>Post Doctoral Training:</u>	See under Education
<u>Academic Appointments:</u>	
July 1995 -	Professor of Psychiatry (with tenure) Adjunct Prof. of Radiology, MCV/VCU
July 1990 - June 1995	Associate Professor of Psychiatry (with tenure) & Adjunct Assoc Prof of Radiology, MCV/VCU
July 1984 - June 1990	Assistant Professor of Psychiatry Adjunct Assistant Professor of Radiology (since July 1988) Medical College of Virginia
July 1979 - June 1982	Assistant Instructor Department of Psychiatry SUNY, Syracuse, NY
July 1978 - June 1979	Research Associate and Lecturer in Psychiatry National Institute of Mental Health & Neuro- Sciences, Bangalore, India
<u>Membership in Scientific & Professional Organizations:</u>	Member, American Psychiatric Association (1980-93), Fellow (1993-present) and its Virginia chapter (1984-present) Member, Indian Psychiatric Society (1976-85) Fellow, Indian Psychiatric Society (1985-Present) Member, Society of Biological Psychiatry, U.S.A (1984-present) Member, Association of Asian-Indian Psychiatrists, U.S.A (1983-present) Virginia Chapter (1985-present) Member, Central Virginia Chapter of the Society for Neuroscience (1986-present) Member, New York Academy of Sciences (1987- present)

**Membership in Community
Organizations:**

Member, American Society of Clinical
Psychopharmacology (1993-present)

National Alliance For the Mentally Ill
Virginia Chapter (1984-present)

Board of Directors
Gateway Homes Foundation (for the chronic
mentally ill), Richmond, Virginia (1985-1991)
and Member, Professional and Resident Care
Committees (1985-1989).

Hindu Center of Virginia (1984-present)
Member (84-88), Life Member (89-present),
Corporate Member (94'- present)

Board of Directors
Bharat Swa-Mukti Foundation
(India Self-Liberation Foundation)
Ohio, U.S.A. (1989-present)

Advisory Council Member
Richmond City Street Team (for the
Homeless Mentally Ill, 1988-1990

Richmond Kannadigas (1984-present)
(South Indian language based ethnic group)

Special Awards/Honors:

Second Rank, Bangalore University, India
(1967) in Pre-University Course (out of
approximately 10,000 students)

National Merit Scholar, India (1968-1974)

Distinction in Physiology, JIPMER, University
of Madras (1970)

Nominated for Laughlin Fellowship of American
Psychiatric Association, 1979

Young Investigator In Schizophrenia Research
Award, National Institute of Mental Health,
USA (1987)

Special Award For Expert and Compassionate
Care: Virginia Alliance For The Mentally Ill,
(1988)

Excellence in Service Award (1991)
Department of Psychiatry, MCV/VCU

Exemplary Psychiatrist Award, the National
Alliance for the Mentally Ill. 1992.

Fellow, American Psychiatric Society (1993)

"Professional of the Year" Award
Central Virginia Alliance for the
Mentally Ill (1993)

Marquis Who's Who in Science & Engineering
2nd Edition, 1994-95

The Best Doctors in America: Southeast Region
1st Edition, Woodward/White, Inc, 1995

Nancy C.A. Roeske Certificate of Excellence
in Teaching, American Psychiatric Association
May 7, 1996

Teaching Experience:

Course Coordinator. Lectures on Psychotic Disorders for PGY-1 & PGY-2 psychiatry residents (1978-79). NIMHANS, Bangalore, India.

Seminar Coordinator. Seminar series on International Pilot Study of Schizophrenia (1978). NIMHANS, Bangalore, India.

Editor. "Capsule" bimonthly letter on recent developments in psychopharmacology for residents and faculty, Department of Psychiatry, SUNY, Syracuse, New York (1980-1982).

Supervision of PGY-4 resident (1 per year) in research elective (1982-84). Department of Psychiatry, Columbia University, New York and New York State Psychiatric Institute, New York.

Clinical Training of M-III students (8-16 per year) and PGY-1, 2 and 3 psychiatry residents (8-12 per year). Medical College of Virginia (MCV), Virginia Commonwealth University (VCU), Richmond, Virginia (1984-present).

Clinical teaching of pharmacy interns (1-4 per year), doctoral psychology interns (4 per year) and graduate students in Occupational therapy (4 per year). MCV/VCU, Richmond, Virginia (1984-present).

Didactics to psychiatry trainees (PGY-1, PGY-2, PGY-3) on the following topics: Phenomenology of Psychosis; Diagnosis and Management of Schizophrenia; Pharmacotherapy of Major Mental Illness; Advanced Psychopharmacology of Psychotic Disorders; Tardive Dyskinesia and Its Management; Treatment Resistant Schizophrenia; Electroconvulsive Therapy; MCV/VCU, Richmond, Virginia (1984-present).

Supervision of PGY-4 residents (4 per year) in providing mental health services to homeless persons in Richmond. MCV/VCU, Richmond, Virginia (1987-1991).

Supervision and training of PGY-2 residents (8 per year) in the theory and administration of ECT. MCV Hospitals/VCU, Richmond, Virginia (1987-present).

Introduction to Clinical Medicine: Teaching signs and symptoms of medical

4

illness to M-I (medical) students in small groups - conjointly with a family practice physician at MCV/VCU, Richmond, Virginia (1991,92',93',94', 97').

Introduction to Clinical Interview: Teaching clinical interview techniques to M-II (medical) students in small group format, MCV/VCU, Richmond, VA (1986-present).

Moderator, monthly morbidity conference in inpatient psychiatry (12/year) clinical case conferences (4/year), journal club (4/year), and administrative psychiatry conference (4 year), for M-III (medical students, PGY-1 and PGY-2 psychiatry residents at MCV Hospitals/VCU, Richmond, Virginia (1989-present).

Psychopharmacology: Small group discussion for M-III (medical) students, MCV Hospitals/VCU, Richmond, Virginia (1992, 93',94', 95', 96').

Psychopharmacology: 1/2 day workshops for non-physician mental health professional groups in Virginia (1987,88',89',92',93',94').

Supervision of graduate social work student (1 student per year) from the School of Social Work/VCU for 8 months of a year, in the psychosocial management of schizophrenia (1985, 86', & 87'). MCV Hospital Clinics/VCU, Richmond, Virginia.

Supervision of elective experiences in Biological Psychiatry, Schizophrenia and ECT for 4th year medical students and PGY-4 psychiatry residents. MCV/VCU, Richmond, Virginia (1985-present).

Didactic to social work students (Masters), School of Social Work/VCU on Pharmacotherapy of Psychiatric Disorders (1989, 90', 91', 93', 94').

Mentoring:

Mentor for senior residents/junior faculty to facilitate career development with emphasis on clinical research.

Matcheri Keshavan, M.D., MRCPsych (1978)
Alex Wisnewski, M.D. (1984)
Anthony L. Pelonero, M.D. (1987,88',89',90')
Edwin J. Nieves, M.D. (1990,91',92')
Rakesh K.Sood, M.D. (1991,92',93')
Rochelle S. Klinger, M.D. (1992,93',94')
Kenji Sax, M.S., Ph.D. (1991,92',93')
Rosemary Farmer, M.S.W., Ph.D. (1992,93')
G. Sampath, M.D., MRCPsych (1995)
Helen Keighron, Governor's School Student (Summer 1995)
Yekeen Aderibigbe, M.D. (1997)

Fellowship:

Director, Fellowship in Biological Psychiatry, MCV-VCU (1986, 95, 96', 97')
Director, Research Fellowship, MCV-CSH Collaborative Program (1997)

Administrative Experience:

Member, Research Committee, Upstate Medical Center, Department of Psychiatry, Syracuse, New York (1980-1982)

Member, Working Committees to establish the collaboration between Department of Psychiatry, Columbia University, New York and Creedmoor Psychiatric Center, New York and, facilitate research and teaching activities to further the collaborative relation between the two institutions (1982-84).

Director, Schizophrenia Program, Medical College of Virginia, Department of Psychiatry. Responsible for the following (i) attending physician & team leader of 9 bed, acute inpatient service for patients with schizophrenia and other psychoses; (ii) specialty clinic focussing on short term and long term outpatient treatment of schizophrenia; (iii) development of appropriate teaching and clinical research programs in schizophrenia; (iv) public education in schizophrenia and chronic mental illness (1984 July - Present).

Member, Chronic Mental Illness Training Program - Ad Hoc Committee, Medical College of Virginia, Department of Psychiatry (1985-1990).

Member of working committees to enhance the collaboration between the Department of Psychiatry, Medical College of Virginia, Richmond, Virginia and Central State Hospital, Petersburg, Virginia including the Clinical Care Committee and Research Development Committee. Also member of advisory committees on continuing education & program development at the latter institution (1986-1988).

Chief Coordinator of the above programs between the Department of Psychiatry and Central State Hospital, Petersburg, Virginia (1987 January - 1989 June).

Member, Pharmacy & Therapeutics Committee, Medical College of Virginia Hospitals, (1986 - present).

Interim Director (June 1986-May 1987), Inpatient Psychiatry Service, Medical College of Virginia, Richmond, Virginia.

Member, Committee on the Conduct of Human Research, Medical College of Virginia/Virginia Commonwealth University (1988 - 1993).

Coordinator of psychiatrist services, Project on Mental Health Services to the Homeless, Richmond City Mental Health Clinic and Department of MH/MR/SA, Commonwealth of Virginia. Supported by a demonstration grant from the National Institute of Mental Health, USA (1989,90',91').

Member, Psychopharmacology Curriculum Committee, Department of Psychiatry, Medical College of Virginia (1988).

Chief Organizer and Moderator: National symposium on schizophrenia titled "Schizophrenia: Has the Code been broken?" Richmond, Virginia, June 1989.

Member, Program Committee, Psychiatric Society Of Virginia: 1986-88. Assisted in the development of continuing education programs and lectures as part of the society's activities and annual meetings.

6

Member, Advisory Council for Training In Long Term Mental Illness -School of Social Work, Virginia Commonwealth University (1986 -1988)

Member of State Committee on Human Development Resources, Department of Mental Health/Mental Retardation/Substance Abuse Services, Commonwealth of Virginia (1990).

Director, ECT Services, MCV Hospitals, Virginia Commonwealth University (1990-95) Co-Director (1996-)

Member of State Task Force on Clozapine, Department of Mental Health/Mental Retardation/Substance Abuse Services, Commonwealth of Virginia (1990).

Member, Research Advisory Council, Department of Mental Health/Mental Retardation/Substance Abuse Services, Commonwealth of Virginia (1990, 1991).

Member, State Committee on Research and Clozapine. Virginia Alliance for the Mentally Ill (1990, 1991).

Interim Chairman, Division of Inpatient Psychiatry. Medical College of Virginia/VCU (December 1990-December 1991)

Chairman, Division of Inpatient Psychiatry. Medical College of Virginia/VCU (January 1992 - Present)

Chairman, Program Committee, Psychiatric Society of Virginia (1991,92,93).

Member, Finance Committee, MCV-Psychiatry Associates, Department of Psychiatry, MCV/VCU (1992-94).

Board of Directors, MCV-Psychiatry Associates, Department of Psychiatry, MCV/VCU (1992,93,94,95).

President, American Association of Psychiatrists From India, Virginia Chapter (1993,94).

Chair, Promotions Committee, Department of Psychiatry, MCV/VCU, (1992, 1993).

Member, Strategic Re-review Committees (Administration, Clinical Care-Managed Care), Department of Psychiatry, MCV/VCU (1993).

Member, Substance Abuse Services Committee, School of Medicine & MCV Hospitals, MCV/VCU, 1993-94.

Member, Managed Care Committee, Department of Psychiatry, MCV/VCU (1994-)

Chair, Tenure Committee, Department of Psychiatry, MCV/VCU (1995)

Chair, Promotions Committee, Department of Psychiatry, MCV/VCU (1994, 1996)

Member, Department of Psychiatry Task Group for establishing collaborative and contractual relationship with Richmond Behavioral Health Authority (1997)

Journal and Agency Review, Consultancy:

Reviewer, Biological Psychiatry (1988, 89', 91', 93', 94').

Reviewer, Journal of Neuropsychiatry & Clinical Neuroscience (1989, 91, 94)

Consultant, Worldwide Auditing - Rehabilitation Consultants, Philadelphia, PA (1989).

Consultant, Central State Hospital, Petersburg, Virginia (1985-1991).

Book Reviewer, American Journal of Psychiatry (1990).

Reviewer, Schizophrenia Research (1990, 93', 94', 96')

Research Review Panel, (Training Grants in Substance Abuse Research), Department of Mental Health/Mental Retardation/Substance Abuse Services, Commonwealth of Virginia (1990, 1991, 1992).

Post-doctoral (Ph.D) examiner, School of Social Work, Virginia Commonwealth University (1990, 91').

Post-doctoral (Ph.D) examiner, Department of Psychology, Virginia Commonwealth University (1992, 94').

Member, Question Writing Committee, American Board of Psychiatry & Neurology, Part I examination in Neurology (1992 - present).

Member, Oral Examinations Committee, American Board of Psychiatry & Neurology, Part II examination in Psychiatry (1992).

Book Reviewer, International Medical Communications, New York, NY (1992).

Expert Witness/Consultant/Reviewer in Disability litigation, Malpractice litigation, Capital Punishment appeal (1990, 91', 93', 95').

Mail Box - The Doctor Answers: Consultation service for the Central Virginia Alliance for the Mentally Ill (1993, 94').

Member CNS Advisory Forum, Jannssen Pharmaceuticals/Excerpta Medica (1993, 95', 97')

Reviewer, Psychosomatics, (1995)

Physician Reviewer, Audit Team, Dept of MH/MR/SAA for Western State Hospital, Staunton, Virginia (1996)

New Medications Work Group, Commonwealth of Virginia, Department of MH/MR/SAS Services (1997)

Experts Panel for Schizophrenia, Virginia Health Outcomes Program, Department of Health Administration, Virginia Commonwealth University (1997)

Grants & Contracts:

Principal Investigator:

1. Stipendee, NIMH, Post-doctoral Fellowship Training Grant to Columbia University, Department of Psychiatry, New York, New York: (1982-84)
2. Principal Investigator, Project title: "Familial and Sporadic subtypes of Schizophrenia; A.D. Williams Research Grant, Medical College of Virginia, Richmond, Virginia. \$8600/-, (1984-85)
3. Principal Investigator, Project title: Labelled Dopamine uptake by platelets in healthy volunteers and schizophrenic subjects. Virginia Commonwealth University - Faculty Grant-in-Aid. \$5,000.00/-, (1985-86).
4. Principal Investigator: Project title: Labelled Dopamine uptake by platelets and Magnetic Resonance Imaging in Schizophrenia. Biomedical Support Grant (NIH), Medical College of Virginia, Richmond, Virginia. \$4600/-, (1986-87).
5. Principal Investigator, Project title: Serum Molindone Levels and Treatment of Psychosis. Educational Support grant from Dupont Nemours, Inc., Delaware. \$1300/-, (1986-87).
6. Principal Investigator, Project title: Bio-Behavioral Heterogeneity in Schizophrenia. FIRST Award, National Institute of Mental Health (PHS). Total cost \$ 232000/-, 1989-92.
7. Principal Investigator, Project title: Schizophrenia Program Development & Medical Management during Clozapine Treatment, Sandoz Pharmaceuticals, E. Hanover, New Jersey. Program Development Grant, \$8,000/-, 1990-91,
8. Principal Investigator, MCV-VCU site: Study of EM 62-100-004 (Roxindole), a potential antidepressant/antipsychotic compound - A phase II, multicenter, randomized, parallel group, double blind, dose finding study of Roxindole vs Placebo". E.Merck Industries, Hawthorne, New York and Darmstadt, Germany. Total Cost \$106,000/-, (1992-93).
9. Awardee, State Council on Higher Education in Virginia, Equipment Grant for Brain Imaging (1992) \$28000/-
10. Principal Investigator, MCV-VCU site: RIS-63-USA "A Randomized, Double Blind, Placebo Controlled Study of Risperidone for the Treatment of Psychosis and Behavioral Disturbances in Subjects with Dementia". Victor Vieweg, M.D., Co-Principal Investigator. Janssen Research Foundation, Titusville, New Jersey, \$156,000/- (1995).
11. Project Director: Crisis Stabilization and Residential Program, MCV Hospitals, Richmond, Virginia. Contract with City of Richmond, Community Services Board, \$285,000/- per annum (1995, 1996, 1997).
12. Principal Investigator, MCV-VCU site: A Multicenter, Open, Randomized Comparison of ICI 204634 (Seroquel) and Usual Care on Health Outcomes in Subjects with Schizophrenia and Schizoaffective Disorder. Zeneca

Pharmaceuticals, Wilmington, Delaware. Total cost \$114,276/- (1996-97).

13. Principal Investigator: RIS-70-USA "An Open Label Long Term Study of Risperidone for Treatment of Behavioral Disturbances in Subjects with Dementia". Victor Vieweg, M.D., Co-Principal Investigator. Janssen Research Foundation, Titusville, New Jersey. Total Cost \$116,880/- (1996-97).

14. Principal Investigator: A Study of Iloperidone Treatment in Schizophrenia, Protocol #300 & 306. Titan Pharmaceuticals, So San Francisco, California. Total Cost \$130,000 (1997-).

15. Principal Invesigator, MCV-VCU site: RIS-USA-112 & 113. A Study Comparing Olanzapine and Risperidone in the treatment of schizophrenia. Janssen Research Foundation, Titusville, New Jersey. Total cost \$120,000. (1997-)

Co-Investigator:

1. Coinvestigator, Project title: Computed Tomographic Findings In Schizophrenia; Mental Illness Research Foundation, New York State. Principal Investigator: Ronald O. Rieder, M.D. \$25,000/-, (1982-84)

2. Coinvestigator, Training Program in Chronic Mental Illness. National Institutes of Mental Health (PHS) Teaching Grant. Principal Investigator J.J. Silverman, M.D. \$360,000.00 (1985-1988).

3. Co-investigator and Site Coordinator: DSM-IV Field Trials for Psychotic Disorders - NIMH grant to the American Psychiatric Association. Allen Frances P.I., (1990-92) Site contract: \$14,000/-

4. Co-investigator, m-CPP challenge in Schizophrenia - grant by the Scottish Rite Foundation to Dr Adityanjee at MCV/VCU, \$70,000/-, 1993-94.

5. Co-investigator, Acute and Convalescent Serum Antibody Titers to Herpes Virus - grant by the Stanley Foundation to Dr Anthony Pelonero at MCV/VCU, \$15000/-, 1994.

BIBLIOGRAPHY:

Articles:

- (1) Pandurangi AK, Ananth J, Channabassavanna SM: Tardive Dyskinesia in an Indian Mental Hospital: Indian J Psychiat, 1978, 20, 339-342.
- (2) Kapur RL, Pandurangi AK: A Comparative Study of Reactive Psychosis and Acute Onset Psychosis without Antecedent Stress: Brit J Psychiat, 1979, 135, 544-550.
- (3) Pandurangi AK, Kapur RL: Reactive Psychosis-A Prospective Study: Acta Psychiat Scand, 1980, 61, 89-95.
- (4) Pandurangi AK, Vasundhara Devi, Channabassavanna SM: Caudate Nucleus Atrophy in Irreversible Tardive Dyskinesia- A Pneumoencephalographic Study: J of Clin Psychiat, 1980, 41, 7-10.

10

- (5) Dewan MK, Pandurangi AK, Major L et al: Abnormal Dexamethasone Suppression Test in Nondepressed Chronic Schizophrenics: Am J Psychiat, 1982, 139, 1501-1503.
- (6) Deveauh-Geiss J, Pandurangi AK: Confusional Paranoid Psychoses after Withdrawal from Sympathomimetic Amines: Am J Psychiat, 1982, 139, 1190-91.
- (7) Dewan MK, Pandurangi AK, Lee SH et al: Central-Diencephalic Morphology in Chronic Schizophrenia - A Computerized Tomographic Study: Biol Psychiat, 1983, v 18, n 10, p 1133-1140.
- (8) Pandurangi AK, Dewan MK, Lee SH et al: The Ventricular System in Chronic Schizophrenia - A Computerized Tomographic Study: Brit J Psychiat, 1984, 144, 2, 172-176.
- (9) Devanand DP, Pandurangi AK, Dewan MK: Abnormal DST following Neuroleptic Withdrawal: J of Clin Psychiat, 1984, 45, 6, 275-276.
- (10) Dewan MK, Pandurangi AK, Lee at al: Cerebellar Abnormalities In Chronic Schizophrenic Patients - A Computerized Tomographic Study: Psychiatry Res, 1983, v 10, n 2, p 97-103.
- (11) Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK: Symptomatic and Neuropsychological Components of Defect States. Schizophr Bulletin, 1985, 11, 3, 409-419.
- (12) Dewan MJ, Pandurangi AK, Lee SH et al: Quantitative Computed Tomography - Cerebral Density, Ventricle and Sulcal Measures; Acta Psychiat Scand, 1986, 73, 152-160.
- (13) Pandurangi AK, Dewan MJ, Lee SH et al: EEG, Biochemical and Neuropsychological Correlates of CT Normal and Abnormal Schizophrenics - Acta Psychiat Scand, 1986, 73, 161-170.
- (14) Dewan MJ, Pandurangi AK, Levy BP et al: Are Schizophrenics with Abnormal DST Results a Distinct Subgroup? Acta Psychiat Scand, 1985, 72, 274-277.
- (15) Pandurangi AK: On Schizophrenia: Light At the End of the Tunnel. Virginia Medical Monthly, 1986, July, 113, 7, 406-407.
- (16) Boucher ML, Dewan MJ, Donnelly P, Pandurangi AK et al: Relative Utility of Three Indices of Neuropsychological Impairment in a Young, Chronic Schizophrenic Population. J Nervous Mental Disorder, 174, 1, 44, 1986.
- (17) Pandurangi AK, Bilder RM, Rieder RO, Mukherjee S: Schizophrenic symptoms and deterioration: Relation with Computer Tomographic Findings. J of Nervous and Mental Diseases. 176, 4 200-206, 1988
- (18) Ross DE, Ochs AL, Hill M, Goldberg SC, Pandurangi AK, Winfrey CJ: Erratic eye tracking in schizophrenic patients: High Resolution Techniques Reveal a Bimodal Distribution. Biol Psychiatry, 1988,

24,675-688.

- (19) Bilder RM, Rieder RO, Pandurangi AK, Mukherjee S, Saribeyoglu S: Neuropsychological Correlates of Computerized Tomographic Features in Chronic Schizophrenia. Schizophrenia Research, 1,1, 37-46, 1988
- (20) Narasimhachari N, Pandurangi AK, Landa B: Serum Molindone Levels. A Simple HPLC Assay Technique. J. Liquid Chromat. 11,4, 983-990, 1988
- (21) Pandurangi AK, Pelonero AL, Goldberg SC, Gulati AN, Hill MH: Differences in Computerized Tomographic Findings in Schizophrenia may be due to Varying Severity of the Illness: Schizophrenia Research. 1, 273,276, 1988
- (22) Pandurangi AK, Goldberg SC, Brink DD, Hill MH, Gulati AN, Hamer RM: Amphetamine Challenge Test, Response to Treatment, and Lateral Ventricle Size in Schizophrenia: Biological Psychiatry. 1989, 25, 207-214.
- (23) Pandurangi AK, Narasimhachari N, Landa B: Levels of Serum Molindone, Serum Prolactin and Antipsychotic Response. J. Clin. Psychiatry. 1989, 50,10, 379-381.
- (24) Pelonero AL, Pandurangi AK, Calabrese VP: Antibrain Lipid Antibodies in Schizophrenia, American Journal of Psychiatry,147:5, May 1990, pages 661-662
- (25) Pelonero AL, Pandurangi AK, Calabrese VP: Serum IgG Antibody to Herpes Viruses in Schizophrenia. Psychiatry Research 33:11-17, 1990.
- (26) Pandurangi, AK, Narasimhachari, N, Hamer, RM: Dopamine Uptake by the Platelet: Poor Intertest Reliability in Normal Volunteers. Research Communications in Psychology, Psychiatry and Behavior. 1991, 16, 129-139.
- (27)* Pelonero AL, Pandurangi AK, Levenson JL: Neuroleptic Malignant Syndrome. In Disorders of Movement in Psychiatry and Neurology. Editors: Joseph A.B., Young R.R.,1st edition 1992, Chapter 16, pages 125-133, 2nd edition 1997, Blackwell Scientific Publications, Cambridge, MA.
- (28) Vieweg WVR, Pandurangi AK, Pelonero AL: Estimating Daily Urine Volume in Chronic Psychosis. Schizophrenia Research, 1992, 8, 89-91 (ltr, with original data, peer reviewed).
- (29) Pandurangi AK, Pelonero AL, Nadel L, Calabrese VP: Brain Structure Changes in Schizophrenics With High Serum Titers of Antibodies to Herpes Virus. Schizophrenia Research. 1994, 11, 245-250.
- (30) Pandurangi, AK, Sax, KW, Pelonero, AL, Goldberg, SC: Sustained Attention And Positive Formal Thought Disorder in Schizophrenia. Schizophrenia Research. 13, 1994, 109-116.
- (31) The DSM-IV Schizophrenia and Other Psychotic Disorders Field Trial Group: The DSM-IV Field Trial For Schizophrenia and Other Psychotic Disorders. In Press, Am J. Psychiatry.

12

- (32) Vieweg V, Pandurangi, A, Levenson, J and Silverman, J: The Consulting Psychiatrist and The Polydipsia-Hyponatremia Syndrome in Schizophrenia. The International Journal of Psychiatry in Medicine, 24, 1994, 275-303.
- (33)*Pandurangi, A.K.,: Schizophrenia in DSM-IV and Implications for Biological Psychiatry Research, Methods in Biological Psychiatry, (eds) S. Khanna, Channabasavanna, S.M., & Keshavan, M.S. In press, Bombay, India, Tata-McGraw Hill Publications.
- (34)*Pandurangi, A.K.,: Structural Brain Imaging in Schizophrenia. In Methods in Biological Psychiatry, (eds) S Khanna, Channabasavanna, S.M., & Keshavan, M.S.,. In press, Bombay, India, Tata-McGraw Hill Publications.
- (35) Vieweg, V., Levenson, J., Pandurangi, A., Silverman, J.: Medical Disorders in the Schizophrenic Patient. The International Journal of Psychiatry in Medicine. 25 (2) 135-170, 1995
- (36) Pandurangi, AK, Aderibigbe, Y: Tardive Dyskinesia - An International Survey of Epidemiological Studies. European Archives of Clinical Neuroscience. 246,:47-52, 1995
- (37) Ross, DE, Ochs, AL, Pandurangi, AK, Thacker, LR, Kendler, KS: Mixture Analysis of Smooth Pursuit Eye Movements in Schizophrenia. Psychophysiology. v33, 390-397, 1996.
- (38) Farmer, R, Pandurangi, A.K.: Neuropsychiatric Impairment and Schizophrenia: Implications for Social work Practice. Health & Social Work, v 122, 109-116, 1997,
- (39) Aderibigbe, Y.A., Pandurangi, A.K.: The Neglect of Culture in Psychiatric Nosology: The Case of Culture Bound Syndromes: Int J. Soc Psychiat, 41, 235-241, 1995.
- (40) Adityanjee, Pandurangi, A.K., Lindenmayer, J.P., Jampala, V.C.: m-CPP Challenge Test As Predictor of Response to Clozapine in schizophrenia. Psychiat Annals, June, 1996.
- (41) Strakowski, SM, Flaum, M, Xavier Amador, H. Stefan Bracha, Pandurangi, AK, Delbert Robinson, Mauricio Tohen: Racial Differences in the Expression of Psychosis. Schizophrenia Research, v21, 117-124, 1996.
- (42) Sampath G, Pandurangi, A.K.: Bilateral ulnar nerve pParalysis - an unexpected complication of drug induced extra-pyramidal rigidity. In print Australian & New Zealand Journal of Psychiatry.

In Review

- (43) Pandurangi, AK, Hamer, RM, Pelonero, AL, Otero, JM, Nadel, L, Thacker, LR: Spin-Spin Relaxation Time (T2) of Grey and White Matter in Schizophrenia. In review, Schizophrenia Research.
- (44) Pandurangi, AK, Syed, E, Levenson, JL: Diagnostic Considerations in a Case of Confusional Psychosis: In review, Gen Hosp Psychiat.

- (45) Pandurangi, AK, Brink, D, Lakhani, S: Medical Issues in the Management of Clozapine Patients. In review, Southern Medical Journal.
- (46) Farmer, R, Pandurangi, AK: Demographic Variables that point to a more Benign Course of Schizophrenia. In review, J.Nervous.Ment.Dis.
- (47) Pelonero AL, Pandurangi AK, Levenson JL: Neuroleptic Malignant Syndrome. In review, Psychiatric Services.

*Book Chapter

Letters & Abstracts:

- (1) Pandurangi AK, Ananth J, Channabasavanna SM: Prevalence and Etiology of Tardive Dyskinesia in an Inpatient Mental Hospital Population. Indian Psychiatric Society Annual Meeting Abstracts, 1977, page 49, New Delhi, India.
- (2) Narayan HS, Mallikarjuniah M, Pandurangi AK: Pathological Grief Reactions. Indian Psychiatric Society Annual Meeting Abstracts, 1978, Calcutta, India.
- (3) Pandurangi AK, Channabasavanna SM: Phenomenology of Tardive Dyskinesia. Indian Psychiatric Society Annual Meeting Abstracts, 1979, Pune, India.
- (4) Dewan M.J., Pandurangi AK, Major L: "DST in Schizophrenia" (ltr) Am J Psychiat, 140, 1101, 1983.
- (5) Deveaugh-Geiss J, Pandurangi AK: Effects of d-amphetamine withdrawal in rats and man. (ltr) Am J. Psychiat, 140, 954, 1983.
- (6) Dewan MJ, Pandurangi AK, Major L: "Abnormal DST results in Schizophrenia." (ltr) Am J Psychiat, 140, 818, 1983.
- (7) Dewan MJ, Pandurangi AK, Major L: Abnormal DST results in patients with Chronic Schizophrenia. (ltr) Am J Psychiat, 140, 1261, 1983.
- (8) Pandurangi AK, Bilder RM, Rieder RO, Mukherjee SM: Computed Tomographic Correlates of Cognitive Deficits In Schizophrenia. American Psychiatric Association, Annual Meeting New Research Abstracts, 1984, NR #127.
- (9) Dewan MJ, Devanand DP, Pandurangi AK: Errors in administration of the Dexamethasone Suppression Test. (ltr) Arch Gen Psychiat, 41:725, 1984.
- (10) Rieder RO, Pandurangi AK, Bilder RM, Mukherjee SM: Neuropsychological Profiles of Positive and Negative Schizophrenia. American Psychiatric Association Annual Meeting New Research Abstracts, 1984, NR #128.
- (11) Feldmar GG, Bilder RM, Rieder RO, Mukherjee SM, Pandurangi AK, :

14

- Reaction Time Correlates of CT Findings In Chronic Schizophrenia. World Congress of Biological Psychiatry. Abstracts, Philadelphia, Pennsylvania 1985, page 99.
- (12) Pandurangi AK, Dewan MJ, Lee SH, et al: Organic Schizophrenia - A Subgroup of Chronic Schizophrenia. American Psychiatric Society Annual Meeting Research Abstracts, 1985, page 255.
- (13) Pandurangi AK, Bilder RM, Rieder RO, Mukherjee SM: Structural Basis of Deterioration in Patients with Chronic Schizophrenia. Indian Psychiatric Society, Annual Meeting Abstracts, page 8, 1982, Jaipur, India.
- (14) Pandurangi AK, Dewan MJ, Lee SH, Ramachandran T, Levy B, Boucher M, Yozawitz A, Major L: Studies with Brain Imaging in Chronic Schizophrenics. Digest Neuro Psychiat, p. 37 and 186, 1986.
- (15) Pandurangi AK, Dewan MJ, Lee SH, Ramachandran T, Levy B, Boucher M, Yozawitz A, Major L: A Comprehensive Study of Chronic Schizophrenic Patients Parts I and II. Digest Neuro Psychiat, Part I p. 228; Part II p.229, 1986.
- (16) Ochs AL, Ross DE, Goldberg SC, Pandurangi AK, Hill MR,: Predictive Slow Tracking By Schizophrenic Patients. Clinical Eye Movements Society, Annual Meeting Abstracts, 1987.
- (17) Pandurangi AK, Goldberg SC, Brink DD, Hill M, Gulati AN: Amphetamine Challenge Test and Lateral Ventricular Size In Schizophrenia. Society of Biological Psychiatry, Annual Meeting Abstracts, 1987, page 136.
- (18) Nedathur Chari, Pandurangi AK, Landa BS: A simple HPLC Method For The Quantitation of Molindone In Human Plasma Or Serum. Society of Biological Psychiatry, Annual Meeting Abstracts, 1987, page 104.
- (19) Pandurangi AK, Goldberg SC, Brink DD, Hill MH, Hart RP, Gulati AN, Hamer RM: Amphetamine Challenge, Treatment Response and Lateral Ventricular Size In Schizophrenia. International Congress on Schizophrenia Research. Poster presentation, 1987.
- (20) Pandurangi AK, Narasimhachari N: Molindone Toxicity - A Case of Rhabdomyolysis (ltr) J. Clin of Psychiat.49, 37-38, 1988.
- (21) Pelonero AL, Pandurangi AK: Re-evaluation of chronically ill psychiatric patients. (ltr) J. Clin. Psychiatry 413, October, 1988.
- (22) Pandurangi AK, Pelonero AL: A Comparative Trial of Pharmacologic Strategies in Schizophrenia. (ltr) Am J Psychiatry, 145, 7, 900-901, 1988.
- (23) Pandurangi AK, Bilder RM: Letter; The Symptoms of Chronic Schizophrenia. (ltr) British J. Psychiatry, 152, 127, 1988.
- (24) Pandurangi AK, Goldberg SC, Ross D, Ochs AL, Brink DD, Hill MH: Biological Markers of Positive And Negative Syndromes. American Psychiatric Association, Annual Meeting New Research Abstracts, 1988,

Page 59.

- (25) Nakatsuka M, O'Shanick GJ, Colenda CC, Pandurangi AK: Changes In Cardiac Output During Electroconvulsive Therapy. Anaesthesia Analgesia, 1989; 68:S1-S321, Abstracts, S208.
- (26) Pandurangi AK, Pelonero AL, Otero J, Nadel L: Frontal Lobe Size in Schizophrenics by MRI: New Research Abstracts, Page 71, American Psychiatric Association Annual Meeting, 1989, San Francisco, CA.
- (27) Ross DE, Ochs AL, Goldberg SC, Pandurangi AK, Kendler KS: Abnormal Oscillations In The Slow Pursuit Eye Movements Of Schizophrenic Patients. Schizophrenia Research, Jan/April, 1989, page 91.
- (28) Pandurangi AK, Pelonero AL, Otero J, Nadel L, Lee JY: Frontal Lobe Size in Schizophrenics by MRI. New Research Abstracts, American Psychiatric Association Meeting, San Francisco, CA, 5/89, page 71.
- (29) Pandurangi AK, Pelonero AL, Otero JM, Nadel L: Magnetic Resonance Imaging in Schizophrenia. Schizophrenia Research special issue 2:127, 1989. Poster Abstract presented at the International Congress on Schizophrenia Research, 4/89.
- (30) Pandurangi AK, Pelonero AL, Nadel L, Calabreses VP: Cortical Atrophy in Seropositive Schizophrenia. CME Syllabus and Proceedings Summary, Symposium on "Viruses, Immunity and Schizophrenia", American Psychiatric Association Meeting, New York, NY 5/90, pp. 201-202.
- (31) Pandurangi, AK, Pelonero AL, Narasimhachari, Nedathur: Role of Serotonin in Schizophrenia. Poster Abstract presented at the American Psychiatric Association Meeting, 5/91 New Orleans, LA.
- (32) Pandurangi AK, Pelonero AL, Hamer, R, Otero J, Nadel L: "Spin-spin Relaxation Time (T2) in Schizophrenia." Poster Abstract presented at the International Congress on Schizophrenia, 4/91. Schizophrenia Research, special issue, 1991, page 408.
- (33) Pelonero AL, Pandurangi AK: "Immunoblotting to HSV in Schizophrenia." Poster Abstract presented at the International Congress on Schizophrenia, San Diego, CA. 4/91.
- (34) Pandurangi AK, Pelonero AL, Narasimhachari N: "Serotonin in Schizophrenia." New Research Poster Abstract, Presented at the American Psychiatric Association, May 15, 1991 in New Orleans, LA
- (35) Lewelt W, Hummel BS, Pandurangi AK, Sood R, Keenan R: "Cerebral Blood Flow During Electroconvulsive Therapy." Abstract, Presented at the World Congress of Anesthesiology, June 12th - 19th, 1992 Hague, Netherlands.
- (36) Pelonero, AL, Pandurangi, AK: An Untoward side effect of clozapine. Ltr. J. Nervous & Mental Disease, 1992, 536.
- (37) Pandurangi AK: Problems in Differential Diagnosis: From DSM-III to DSM-III-R in Clinical Practice, by Andrew E. Skodol, M.D. Washington

16

- D.C., American Psychiatric Press, 1989 - Book review, Am. J. Psychiat., 1992, 149, 10, 1402-1403.
- (38) Lewelt W, Hummel BS, Pandurangi AK, Sood R, Keenan R: "Hemodynamic Response To Electroconvulsive Therapy." Abstract. Proceedings of the 7th International Symposium, Institute of Applied Physiology & Medicine, Seattle, Washington, page 31, 1993. February 6-10, Lake Buena Vista, Florida.
 - (39) Pandurangi AK, Sax KW, Pelonero AL: Attention Deficit and Psychopathology in Schizophrenia. Poster presented at the International Schizophrenia Research Congress, Colorado Springs, Colorado, Schizophrenia Research, 1993, 9, 2.3, page 107.
 - (40) Pelonero, AL, Pandurangi, AK: Systematized Treatment in Schizophrenia. Poster presented at the 146th annual meeting of the American Psychiatric Association in San Francisco, CA, May 26, 1993. New Research Program and Abstracts, APA, p 195.
 - (41) Farmer, R, Pandurangi, A: Brain Impairment and Adaptation in Schizophrenia. New Research Abstracts, 147th Annual Meeting of the American Psychiatric Association, pages 141-142. Poster presented at the same meeting in Philadelphia, PA, 1994.
 - (42) Pandurangi, A: Book Review - "Psychophysiology and Experimental Psychopathology: A Tribute to Samuel Sutton (eds) David Freedman & Gerard Bruder. Annals of the New York Academy of Sciences - Vol 658. In Press. Communications in Psychology, Psychiatry and Behavior. P.J.D. Publications, New York, New York.
 - (43) Sood, RK, Pandurangi, AK, Kirkwood, CK, Sood, B: Treatment Resistant Depression And Narcolepsy. (ltr) In Review. Neurology
 - (44) Habib, A, Pandurangi, A.K.,: Electroconvulsive Therapy: Efficacy and Safety. Presented at the Eighth Annual Meeting of the Southern Association for Research in Psychiatry, New Orleans, March 25, 1995.
 - (45) Pandurangi A.K., Sax K, Ochs A.L., Thacker L: Ventricle Size and the Three Syndromes in Schizophrenia. Fourth International Congress of Schizophrenia Research, Hot Springs, Virginia, April 8-12th, 1995.
 - (46) Kronengold, H, Amador, X.F., Bracha, S.H., Flaum, M.A., McGlashan, T, Pandurangi, A.K., Robinson, D, Tohen, M.: Schizophrenia, Season of Birth, and Phenomenological Features. Schizophrenia Research, April 1995, Special Issue, Page 14. Poster presented at the International Congress of Schizophrenia Research, Hot Springs, VA, 1995.
 - (47) Marchinko, L, Amador X.F., Flaum, M, McGlashan, T, Pandurangi, A.K., Robinson, D, Tohen, M: Gender Differences in Schizophrenia: Findings From the DSM-IV Field Trials. Schizophrenia Research, April 1995, Special Issue, Page 16. Poster presented at the International Congress of Schizophrenia Research, Hot Springs, VA, 1995.
 - (48) Strakowski, S.M. Flaum, M, Amador, X.F., Bracha, H.S., Pandurangi, A.K., Tohen, M: Racial Differences in the Expression of Psychosis.

Schizophrenia Research, April 1995, Special Issue, Page 21. Poster presented at the International Congress of Schizophrenia Research, Hot Springs, VA, 1995.

- (49) Adityanjee, Pandurangi, A.K., Pelonero, A.L.: m-CPP Challenge Response as Predictor of Response to Clozapine in Neuroleptic Resistant Schizophrenic Patients. Schizophrenia Research, April 1995, Special Issue, Page 141.
- (50) Farmer, R., Pandurangi, A.K., Laine, F.: Brain Changes and Psychosocial Adaptation in Schizophrenia. Schizophrenia Research, April 1995, Special Issue, Page 215. Poster presented at the International Congress of Schizophrenia Research, Hot Springs, VA, 1995.
- (51) Pandurangi, A.K., Thacker, L: Response to Amphetamine Challenge and the Three Dimension Hypothesis of Schizophrenia. Presented at the V International Congress of Schizophrenia Research, Colorado Springs, Colorado. Schizophrenia Research, special Issue, 1997
- (52) Ghaemi, S.N., Sachs, G.S., Chiou, A.M., Pandurangi, A, Goodwin, F: Differential Diagnosis of Bipolar Disorder and the Use of Antidepressants. Poster presentation at the ACNP meeting, Hawaii, 1996.
- (53) Ghaemi, S.N., Sachs, G.S., Chiou, A.M., Pandurangi, A, Goodwin, F: Adjunctive treatments in Bipolar and Schizoaffective Disorder: Comparison of Risperidone, Conventional Neuroleptics, or Clonazepam with Mood Stabilizers. Poster presentation at the American Psychiatric Association meeting, San Diego, California 1997.

JOHN W. HASTY
DIRECTOR

COMMONWEALTH OF VIRGINIA
DEPARTMENT OF HEALTH PROFESSIONS

6606 WEST BROAD STREET
4TH FLOOR
RICHMOND, VA 23230-1717

BOARD OF MEDICINE
CHARLES H. CROWDER, M.D., PRESIDENT

LICENSE TO PRACTICE
MEDICINE AND SURGERY

ANANDA PANDURANGI, MD
P.O. BOX 980710
MEDICAL COLLEGE OF VA
RICHMOND, VA 232980710

TO PROVIDE INFORMATION OR FILE A
COMPLAINT ABOUT A LICENSEE, CALL: 1-800-533-1560

(SEE REVERSE SIDE FOR NAME AND ADDRESS CHANGE)

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE			
UNITED STATES DEPARTMENT OF JUSTICE			
DRUG ENFORCEMENT ADMINISTRATION			
WASHINGTON, D.C. 20537			
Sections 304 and 1008 of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.	DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
	[REDACTED]	03-31-99	\$210.00
	SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
	2, 2N, 3, 3N, 4, 5	PRACTITIONER	02-27-96
PANOURANGI, ANANDA K MD PROF OF PSYCHIATRY MEDICAL COLLEGE OF VA BOX 710 RICHMOND, VA 23229			
THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.			

Form DEA-223 (9/95)

CURRICULUM VITAE

Personal Information:

Name: Michael Gregory Plopper, M.D.

Business Address: Mesa Vista Hospital
7850 Vista Hill Avenue
San Diego, California 92123

Date of Birth: August 25, 1948

Place of Birth: Evansville, Indiana

Citizenship: United States of America

Marital Status: Married, one child

Social Security Number: REDACTED

Licensure: California, 1976 REDACTED DEA #REDACTED

Education:

University: Northwestern University
B.S., Biological Sciences, 1970

Medical School: Indiana University School of Medicine
M.S., Physiology, 1972 M.D., 1975

Residency: Los Angeles County/University of Southern
California Medical Center, Department of Psychiatry
1975 - 1978

Psychiatric Fellowship: Consultation - Liaison Psychiatry, 1978-79
Geropsychiatry, 1979-80, LAC/USC Medical Center

Board Certification: Diplomate, American Board of Psychiatry and
Neurology, 1981
Added qualification in Geriatric Psychiatry, American
Board of Psychiatry and Neurology, 1994

Faculty and Administrative Positions:

1995 - Present	Vice President/Medical Director, Direct Care Vista Hill Foundation
1994 - Present	Medical Director, Mesa Vista Hospital
1992 - Present	Clinical Director, Senior Program, Mesa Vista Hospital
1990 - 1994	Medical Director, Older Adult Program, Sharp Cabrillo Hospital
1990 - 1991	Chief of Staff, Mesa Vista Hospital
1983 - 1989	Clinical Assistant Professor of Psychiatry and the Behavioral Sciences, University of Southern California School of Medicine
1979 - 1982	Assistant Professor Clinical Psychiatry University of Southern California School of Medicine
1980 - 1982	Training Director, USC/Rancho Los Amigos Hospital Research & Training Center on Aging
1980 - 1982	Co-Chief, Rancho Los Amigos Hospital Older Adult Health Center
1978 - 1980	Instructor in Geropsychiatry, Ethel Percy Andrus Gerontology Center, University of Southern California
1972	Instructor in Physiology, Indiana University School of Medicine

Research Activities:

1995 - 1996	MAZ-INT-01 - Site 07 Principal Investigator - Mazapertin: dose-finding trial, comparing three fixed dosages of mazapertine to risperidone and placebo: multicenter, double- blind, parallel-group study, Janssen Research Foundation.

1996 - Present	RIS-USA-79 Principal Investigator - A comparison of risperidone and haloperidol for prevention of relapse in subjects with schizophrenia and schizoaffective disorders, Janssen Research Foundation.
1996 - 1997	RIS-USA-78 Principal Investigator A study of the efficacy of risperidone, haloperidol and clozapine in treatment resistant schizophrenic subjects, Janssen Research Foundation.
1996 - 1997	RP66203X-202 Principal Investigator - A Phase II, multicenter, double-blind, parallel, randomized comparison of oral fananserin and placebo over 28 days in inpatients with schizophrenia, Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1997 - Present	RIS-USA-112 & 113 Principal Investigator - Risperidone vs. Olanzapine in the treatment of schizophrenia, Janssen Research Foundation.
1997 - Present	F1D-MC-HGFW Principal Investigator - Strategies for switching from conventional antipsychotics to olanzapine, Lilly Research Laboratories.
1997 - Present	F1D-MC-HGFU Principal Investigator Olanzapine Added to Mood Stabilizers in the Treatment of Bipolar Disorders, Lilly Research Laboratories.
<u>Managed Care Activities:</u>	
1993 - Present	Member, Board of Directors, Integrated Mental Health Professionals
1993 - Present	Utilization Review/Quality Improvement Committee, Integrated Mental Health Professionals

1988 - 1993	Member, Board of Directors, Vista Psychiatric Physicians Association
1988 - 1993	Utilization Review Committee, Vista Psychiatric Physicians Association

Committees:

1997 - Present	Regional Integrated Services System Planning Committee County of San Diego
1996 - Present	Government Affairs Committee California Psychiatric Association
1996 - Present	San Diego Psychiatric Society Council State Legislative Representative SDPS
1986 - Present	Executive Committee, Mesa Vista Hospital
1987 - 1988	Chairman, Medical Quality Assurance, Mesa Vista Hospital, San Diego, California
1986 - 1987	Chairman, Credentials Committee, Mesa Vista Hospital
1984 - 1985	Chairman, Geriatrics Committee, San Diego Society of Psychiatric Physicians
1979 - 1982	California State Area Health Education Committee for Geriatrics
1976 - 1977	Graduate Education Committee, Department of Psychiatry, LAC/USC Medical Center.

Grants:

1980 - Present	Co-Principal Investigator, USC/Rancho Los Amigos Hospital Research & Training Center on Aging, funded by NIH, over \$12 million in funding to date

1980 - Present	Co-Principal Investigator, Independent Living Services for the Disabled Elderly, funded by Los Angeles County, over \$2 million in funding to date

Hospital Staff Positions:

1982 - Present	Mesa Vista Hospital
1990 - Present	Sharp Cabrillo Hospital
1982 - Present	Sharp Memorial Community Hospital

Professional Societies:

American Medical Association
American Psychiatric Association
San Diego Psychiatric Society
San Diego County Medical Society
California Medical Association
California Psychiatric Association
American Association of Geriatric Psychiatry

Publications:

Plopper, M.G., Mental Health in the Elderly, Aging: Prospects and Issues, R. Davis (ed.), University of Southern California Press, 1980.

Plopper, M.G. and Chui, Helena, Evaluation and Treatment of Dementia, USC Press, 1983.

Lopez-Agueros, W., Kemp, B., Plopper, M.G., Staples, F.R., Brummel-Smith, K., Health Needs of the Hispanic Elderly, Journal American Geriatrics Society, Volume 32, pp 191-198, 1984.

Plopper, M.G., Evaluation and Treatment of Depression, in Geriatric Rehabilitation, Little, Brown & Co., 1990.

Plopper, M.G., Commonly Encountered Psychiatric Problems, in Ambulatory Geriatric Care, Mosby-Year Book Inc., 1993.

10/97

CURRICULUM VITAE
Narayana Reddy, M.D.

SPECIALTY: Psychiatry

OFFICE ADDRESS:

Correspondence:
Health Advance Institute
One Illini Drive
Peoria, IL 61605

Practice Location:
Human Service Center
228 NE Jefferson Ave.
Peoria, IL

LICENSURE:

State of Maryland
State of Illinois
State of Florida

BOARD CERTIFICATION:

Board Eligible

EDUCATION:

1990-1991	Internship, University of Massachusetts Pittsfield, MA
Sept. 1979	M.D., Bangalore Medical College, Bangalore, India
Sept. 1973	Bangalore Medical College, Bangalore, India.

WORK EXPERIENCE:

Human Service Center, 1994-Present
Director of Clinical Services
Supervision of Multi-disciplinary Teams
Instructor, Psychopharmacology, Psychotropics
& Special Clinics, Clozaril
Psychiatric Consultant for White Oaks Companies
Methodist Medical Center and St. Francis Hospital
Psychiatric Consultant & Inpatient Services:
University of West Indies, Jamaica
District Medical Officer & Family Practitioner, 1980-1990

AFFILIATIONS:

Health Advance Institute Medical Research Centers, Peoria, IL
Methodist Medical Center, Peoria, Illinois, Active Medical Staff
St. Francis Medical Center, Peoria, Illinois, Active Medical Staff

ACADEMIC APPOINTMENTS:

Adjunct Professor, University of Illinois College of Medicine-Peoria,
Department of Psychiatry and Behavioral Medicine.


RESEARCH EXPERIENCE:

Phase III, Randomized, Multicenter, Open Label Study Evaluating the Toleration and Safety of Intramuscular Study Drug or Haloperidol Followed by 4 Days of Treatment with Oral Study Drug or Haloperidol in Subjects with a Diagnosis of Psychotic Disorder. Principal Investigator.

A Phase III, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Risperidone or Placebo in Patients with Schizophrenic or Schizoaffective Disorder. Sub-Investigator.

PROFESSIONAL SOCIETIES:

American Psychiatric Association
American Medical Association



Peter Roy-Byrne, M.D.

2/19/97

PETER PAUL ROY-BYRNE, M.D.

Curriculum Vitae

Birthplace: May 1, 1951
New York, NY

Office Address: Department of Psychiatry and Behavioral Sciences
Harborview Medical Center, Box 359911
325 Ninth Avenue
Seattle, WA 98104
Telephone: (206) 223-3404

Marital Status: Married, 1978 (Janice M. Roy-Byrne)
Two Children: Jordan and Reed

EDUCATION

Vassar College, Poughkeepsie, NY, B.A., Psychology, 1974
Tufts University School of Medicine, M.D., 1978

POSTGRADUATE TRAINING

Internship, Internal Medicine, Carney Hospital, Boston, MA, 1978-1979
Resident in Psychiatry, UCLA Neuropsychiatric Institute, Los Angeles, CA, 1979-1981
Chief Resident, Adult Inpatient Psychiatry, UCLA Neuropsychiatric Institute, Los Angeles, CA, 1981-1982
Medical Staff Fellow, Unit on Anxiety and Affective Disorders, Biological Psychiatry Branch, National Institute of Mental Health, 1982-1984
Senior Staff Fellow, Unit on Anxiety and Affective Disorders, Biological Psychiatry Branch, National Institute of Mental Health, 1984-1985

FACULTY POSITIONS

1995 - present Director of Managed Care, Department of Psychiatry and Behavioral Sciences, University of Washington Medical School, Seattle, WA.

1993 - present Vice-Chairman, Department of Psychiatry and Behavioral Sciences, University of Washington Medical School, Seattle, WA.

1992 - present Chief of Psychiatry, Harborview Medical Center, Seattle, WA.

1990 - present Professor of Psychiatry and Behavioral Sciences, University of Washington Medical School, Seattle, WA.

1986 - present Director, Anxiety Disorders Program; Co-Director, Center for Anxiety and Depression, University of Washington Medical School, Seattle, WA.

1989 - 1992 Associate Medical Director, Outpatient Psychiatry, University of Washington, Seattle, WA.

1986 - 1992 Attending Psychiatrist, Consultation/Liaison Service, University Hospital, Seattle, WA.

1986 - 1989 Associate Professor of Psychiatry and Behavioral Sciences, University of Washington Medical School, Seattle, WA.

1985 - 1986 Special Assistant to the Director, Intramural Research Program, National Institute of Mental Health.

1985 - 1986 Senior Staff Psychiatrist, Intramural Research Program, National Institute of Mental Health.

Peter Roy-Byrne, M.D.

Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology
Journal of Nervous and Mental Disease
Journal of Neuropsychiatry and Clinical Neurosciences
Journal of Obstetrics and Gynecology
Life Sciences
Psychiatric Services
Psychiatry Research
Psychopharmacology
Psychosomatics
Psychosomatic Medicine

PROFESSIONAL ORGANIZATIONS

American Psychiatric Association
Society for Biological Psychiatry
West Coast College of Biological Psychiatry
American Association for the Advancement of Science
American College of Neuropsychopharmacology

HONORS AND AWARDS

B.A. Magna Cum Laude, Phi Beta Kappa, 1974
Rock 'Sleyster Scholar in Psychiatry, Tufts Medical School, 1977
Distinguished Visiting Professor, Wilford Hall Medical Center, San Antonio, Texas, November 18-22, 1985
Teaching Award, Department of Psychiatry, University of Washington School of Medicine, 1988
Visiting Professor, Cleveland Clinic, Cleveland, Ohio, March 3-4, 1989
Visiting Professor, University of Hawaii, Honolulu, Hawaii, March 11-15, 1991; April 6-10, 1992
Included in The Best Doctors in America, 1992-1993, 1994-1995 editions

GRANTS RECEIVED

Neurobiology and Psychopathology

NIMH #1R01 MH49413-01
Benzodiazepine Sensitivity in Human Anxiety
Principal Investigator - 4/92 to 4/96 - \$382,000

Research and Development Grant - Parke Davis Pharmaceuticals
Blockade of Lactate-induced panic by a novel CCK antagonist
Principal Investigator - 9/92 to 9/93 - \$70,000

NIMH/APA
DSM-IV Field Trial of Mixed Anxiety and Depression in Primary Care
Site Principal Investigator - 7/1/91 to 7/1/92 - \$20,000

NIH, #1 R03DE0980A-01
Benzodiazepines and Cognitive Behavioral Therapy
Co-Investigator - 7/1/91 to 6/30/92 - \$33,300

Biomedical Research Support Grant, University of Washington
Dental Fear Research Clinical Assessment Battery
Co-Investigator - 9/1/90 to 8/31/91 - \$5,345

Research and Development Grant - Upjohn Pharmaceuticals
Cerebral Blood Flow Effects of Acute and Chronic Alprazolam
Principal Investigator - 1/90 to 1/91 - \$70,000

NIAAA, #5 R29 AA 08161-02
Benzodiazepine Sensitivity in Sons of Alcoholic Fathers
Co-Investigator - 9/89 to 9/94 - \$343,000.

Peter Roy-Byrne, M.D.

Phase 3 Clinical Trial - International Clinical Research
Efficacy of SM-3997 in Panic Disorder
Principal Investigator - 12/87 to 1/90 - \$72,500

Phase 3 Clinical Trial - Pfizer Pharmaceuticals
Efficacy of SM-3997 in Generalized Anxiety
Principal Investigator - 9/87 to 1/90 - \$87,000

Phase 3 Clinical Trial - Kale-Duphar Pharmaceuticals
Efficacy of Fluvoxamine in Panic Disorder
Principal Investigator - 1/87 to 1/90 - \$154,000

Peter Roy-Byrne, M.D.

Publications

1984

- (15) Roy-Byrne PP, Uhde TW, and Post RM: Antidepressant effects of one night's sleep deprivation: Clinical and theoretical implications. In Post RM, Ballenger JC (eds.), Neurobiology of Mood Disorders. Baltimore: Williams and Wilkins, 1984.
- (16) Gwirtsman H, Roy-Byrne PP, Lerner L: Bulimia in men: A report of three cases, with neuroendocrine findings. *Journal of Clinical Psychiatry* 42:78-81, 1984.
- (17) Rubinow DR and Roy-Byrne PP: Premenstrual syndromes: Overview from a methodologic perspective. *American Journal of Psychiatry* 141: 163-172, 1984.
- (18) Roy-Byrne PP, Uhde TW, Post RM: Carbamazepine for aggression, schizophrenia and non-affective syndromes. *International Drug Therapies in Psychiatry*, F. Ayd (ed.) 19:9-12, 1984.
- (19) Roy-Byrne PP, Lee-Benner K, and Yager J: Group therapy for bulimia. *International Journal of Eating Disorders* 3:97-116, 1984.
- (20) Roy-Byrne PP, Gwirtsman HG, Sternbach H, and Gerner RH: Effect of acute hospitalization on the dexamethasone suppression and TRH stimulation tests. *Biological Psychiatry* 19:607-612, 1984.
- (21) Rubinow DR, Roy-Byrne PP, Hoban MC, Gold PW, and Post RM: Prospective assessment of menstrually-related mood disorders. *American Journal of Psychiatry* 141:684-686, 1984.
- (22) Roy-Byrne PP, Uhde TW, Post RM, and Joffe RT: Relationship of response to sleep deprivation and carbamazepine in depressed patients. *Acta Psychiatrica Scandinavia* 69:379-382, 1984.
- (23) Rubinow DR, Roy-Byrne PP, and Hoban MC: Menstrually-related mood disorders: Methodologic and conceptual issues. In Phillips A, McGuire JL (eds.), Premenstrual Syndrome and Dysmenorrhea. Baltimore: Williams and Wilkins, 1984.
- (24) Roy-Byrne PP, Rubinow DR, Gold PC, and Post RM: Possible antidepressant effect of oral contraceptives: Case report. *Journal of Clinical Psychiatry* 45:350-352, 1984.
- (25) Uhde TW, Roy-Byrne PP, Gillin JC, Mendlesohn W, Boulenger JP, Vittone BJ, and Post RM: The sleep of patients with panic disorders. *Psychiatry Research* 12:251-259, 1984.
- (26) Uhde TW, Boulenger JP, Post RM, Siever LH, Vittone BJ, Jimerson DC, and Roy-Byrne PP: Fear and anxiety: Relationship to noradrenergic function. *Psychopathology* 17:8-23, 1984.
- (27) Roy-Byrne PP, Joffe, RT, Uhde TW, and Post RM: Approaches to the evaluation and treatment of rapid-cycling affective illness. *British Journal of Psychiatry* 145:543-550, 1984.
- (28) Joffe RT, Roy-Byrne PP, Uhde TW, and Post RM: Thyroid function and affective illness: A reappraisal. *Biological Psychiatry* 19:1685-1691, 1984.
- (29) Roy-Byrne PP, Joffe RT, Uhde TW, and Post RM: Carbamazepine and thyroid function in affectively-ill patients. *Archives of General Psychiatry* 41:1150-1153, 1984.
- (30) Roy-Byrne PP, Uhde TW, and Post RM: Carbamazepine for hyperactive syndromes, anxiety disorders and withdrawal syndromes. *International Drug Therapies in Psychiatry*, Ayd F (ed.) 19:25-28, 1984.

1985

- (31) Uhde TW, Roy-Byrne PP, Vittone BJ, Boulenger JP, and Post RM: Phenomenology and neurobiology of panic disorder. In Maser JD, Tuma AH (eds.), Anxiety and Anxiety Disorders. Hillsdale, New Jersey: Lawrence Erlbaum Assoc., 1985, pp. 557-579.

Peter Roy-Byrne, M.D.

Publications

- (48) Gwirtsman HG, Hohlstein LA, Roy-Byrne PP: New neuroendocrine findings in anorexia nervosa and bulimia. In Blinder B (ed.), *Modern Concepts in Eating Disorders*, 1986.
 - (49) Roy-Byrne PP, Byrnes S, Rubinow DR, Hoban MC, Parry BL, Rosenthal NE, Nurnberger JE: Premenstrual changes: A comparison of five populations. *Psychiatry Research* 17:77-85, 1986.
 - (50) Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Antidepressant effects of carbamazepine. *American Journal of Psychiatry* 143:29-34, 1986.
 - (51) Roy-Byrne P, Weingartner H, Bierer L, Post RM: Effortful and automatic cognitive processes in depression. *Archives of General Psychiatry* 43:265-267, 1986.
 - (52) Roy-Byrne P, Pynoos R, Glick ID: The inpatient psychiatric unit as a consultation service. *Canadian Journal of Psychiatry* 31:54-58, 1986.
 - (53) Roy-Byrne PP, Uhde TW, Rubinow DR, Post RM: Reduced TSH and prolactin responses to TRH in patients with panic disorder. *American Journal of Psychiatry* 143:503-507, 1986.
 - (54) Baxter LR, Roy-Byrne PP, Liston EH, Fairbanks L: Informing patients about ECT: Effects of a videotape presentation. *Convulsive Therapy* 2:25-29, 1986.
 - (55) Roy-Byrne PP, Uhde TW, Post RM, Gold PW: The CRH stimulation test in patients with panic disorders. *American Journal of Psychiatry* 143: 896-899, 1986.
 - (56) Roy-Byrne P, Geraci M, Uhde TW: Life events and the onset of panic disorder. In Shagass C (ed.), *Biological Psychiatry*, 1985. Elsevier Science Publishing Co., Inc., 1986, pp. 457-459.
 - (57) Roy-Byrne P, Uhde TW, Sack DA, Limbolla M, Post RM: Plasma HVA and anxiety in patients with panic disorder. *Biological Psychiatry* 21:849-853, 1986.
 - (58) Uhde TW, Roy-Byrne P, Post RM: Panic disorder and major depression: Biological relationships. In Shagass C (ed.), *Biological Psychiatry*, 1985. Elsevier Science Publishing Co., Inc., 1986, pp. 472-474.
 - (59) Rubinow DR, Roy-Byrne P, Hoban MC, Gerner GN, Stambler N, Post RM: Premenstrual mood changes, I: Characteristic patterns in women with and without premenstrual syndrome. *Journal of Affective Disorders* 10:85-90, 1986.
 - (60) Roy-Byrne P, Geraci M, Uhde TW: Life events and course of illness in patients with panic disorder. *American Journal of Psychiatry* 143:1033-1035, 1986.
 - (61) Roy-Byrne PP, Uhde TW, Post RM: Effects of one night's sleep deprivation on mood and behavior in panic disorder. *Archives of General Psychiatry* 43:895-899, 1986.
 - (62) Baxter L, Roy-Byrne PP, Liston EH, Fairbanks L: The experience of ECT in the 1980's. *Convulsive Therapy* 2:179-189, 1986.
 - (63) Roy-Byrne P, Geraci M, Uhde TW: Life events and the onset of panic disorder. *American Journal of Psychiatry* 143:1424-1427, 1986.
 - (64) Strauss GD, Spiegel J, Daniels M, Spiegel T, Landsvark J, Roy-Byrne PP, Edelstein C, Ehhardt S, Falk R, Hinden L, Zackler L: Group therapies for rheumatoid arthritis: A controlled study of two approaches. *Arthritis and Rheumatism* 29:1203-1209, 1986.
 - (65) Goodwin FK and Roy-Byrne PP: Research careers in biological psychiatry. In Pardes H, Pincus HA (eds.), *Clinical Research Careers in Psychiatry*. American Psychiatric Press, Inc. 1986.
- 1987
- (66) Goodwin FK and Roy-Byrne PP: Future directions in biological psychiatry. In Melzer H (ed.), *Psychopharmacology the Third Generation of Progress*. Raven Press, 1987.

Peter Roy-Byrne, M.D.

Publications

- (85) Roy-Byrne PP and Hommer D: Benzodiazepine withdrawal: Overview and implications for the treatment of anxiety. *American Journal of Medicine* 84:1041-1050, 1988.
 - (86) Roy-Byrne P, Post RM, Uhde TW, Davis D, Leverich G, Rosoff A: Suicide and life course of illness in major affective disorder. *Journal of Affective Disorders* 15:1-8, 1988.
 - (87) Roy-Byrne P, Risch SC, and Uhde TW: Neuroendocrine effects of diazepam in normal subjects following brief painful stress. *Journal of Clinical Psychopharmacology* 8:331-335, 1988.
 - (88) Roy-Byrne PP and Lydiard RB: New developments in the psychopharmacologic treatment of anxiety. In Roy-Byrne PP (ed.), *Anxiety: New Findings for the Clinician*. Washington, D.C.: APA Press, 1988.
 - (89) Cowley D and Roy-Byrne PP: Panic disorder and hyperventilation syndrome: Implications of recent research. In Roy-Byrne PP (ed.), *Anxiety: New Findings for the Clinician*. Washington, D.C.: APA Press, 1988.
 - (90) Walker E and Roy-Byrne PP: Irritable bowel syndrome and anxiety. In Roy-Byrne PP (ed.), *Anxiety: New Findings for the Clinician*. Washington, D.C.: APA Press, 1988.
 - (91) Post RM, Roy-Byrne PP, Uhde TW: Graphic representation of the life course of illness in patients with affective disorders. *American Journal of Psychiatry* 145:844-848, 1988.
 - (92) Cowley DS, Dager SR, McClellan JC, Roy-Byrne PP, Dunner DL: Response to lactate infusion in generalized anxiety disorder. *Biological Psychiatry* 24:409-414, 1988.
 - (93) Roy-Byrne PP, Cowley DS: Panic disorder: Biological Aspects. *Psychiatric Annals* 18:457-463, 1988.
 - (94) Cowley DS, Roy-Byrne PP: Panic disorder: Psychosocial aspects. *Psychiatric Annals* 18:464-467, 1988.
 - (95) Roy-Byrne, P, Lewis N, Villacres E, Greenblatt DJ, Shader RI, Veith R: Suppression of norepinephrine appearance rate in plasma by diazepam in man. *Life Sciences* 43:1615-1623, 1988.
 - (96) Guze B, Baxter LR, Liston EH, Roy-Byrne P: Attorney's perceptions of ECT: Impact of instruction with an ECT videotape demonstration. *Comprehensive Psychiatry* 29:520-522, 1988.
 - (97) Lydiard RB, Roy-Byrne P, Ballenger JC: Recent advances in the psychopharmacologic treatment of anxiety disorders. *Hospital and Community Psychiatry* 39:1157-1165.
 - (98) Dager S, Roy-Byrne P, Dunner D: Stress, anxiety and the cardiovascular system. In Roth M, Noyes R, Burrows GD (eds.), *Handbook of Anxiety*, Vol. 2. Amsterdam: Elsevier, 1988; pp. 399-429.
 - (99) Roy-Byrne P, Ashleigh A, Carr J: Personality and the anxiety disorders: A review of clinical findings. In Roth M, Noyes R, Burrows GD (eds.), *Handbook of Anxiety*, Vol. 2. Amsterdam: Elsevier, 1988; pp. 175-188.
- 1989
- (100) Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S: Carbamazepine treatment for benzodiazepine withdrawal. *American Journal of Psychiatry* 146:536-537, 1989.
 - (101) Roy-Byrne PP, Dager S, Cowley DS, Vitaliano P, Dunner D: Relapse and rebound following benzodiazepine treatment of panic attacks: Alprazolam vs. diazepam. *American Journal of Psychiatry* 146:860-865, 1989.
 - (102) Cowley D, Roy-Byrne P: Panic disorder during pregnancy. *Journal of Psychosomatic Obstetrics and Gynecology* 10:193-210, 1989.

Peter Roy-Byrne, M.D.

Publications

- (120) Roy-Byrne PP and Swanson RP: Interactions of benzodiazepines with psychological and behavioral treatment. In Roy-Byrne PP, Cowley DS (eds), Benzodiazepines in Clinical Practice: Risks and Benefits. Washington, D.C.: APA Press, 1991.
 - (121) Katon W, Roy-Byrne PP: Mixed anxiety and depression. *Journal of Abnormal Psychology* 100:337-345, 1991.
 - (122) Roy-Byrne PP, Cowley DS, Hommer D: Benzodiazepine sensitivity in panic disorder (in reply). *Archives of General Psychiatry* 48:669-671, 1991.
 - (123) Cowley DS, Dager SR, Roy-Byrne PP, Avery DH, Dunner DL: Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. *Biological Psychiatry* 30:49-56, 1991.
 - (124) Roy-Byrne PP, Cowley DS, Hommer D, Ritchie J, Greenblatt D, Nemeroff C: Neuroendocrine effects of diazepam in panic and generalized anxiety disorders. *Biological Psychiatry* 30:73-80, 1991.
 - (125) Cowley DS, Roy-Byrne P: The biology of generalized anxiety. In Barlow D, Rapee R (eds.), Chronic Anxiety and Generalized Anxiety Disorder. New York: Guilford Press, 1991, pp. 52-75.
 - (126) Jensen CF, Peskind ER, Veith RC, Hughes J, Cowley DS, Roy-Byrne P, Raskind MA: Hypertonic saline infusion induces panic in patients with panic disorder. *Biological Psychiatry* 30:628-631, 1991.
 - (127) Szuba MP, Baxter LR, Liston EH, Roy-Byrne P: Patient and family perspectives of ECT: correlations with outcome. *Convulsive Therapy* 7:175-183, 1991.
- 1992
- (128) Roy-Byrne PP, Wingerson D: Pharmacotherapy of the anxiety disorders. APA Review of Psychiatry, Vol. 11. APA Press, Inc., 1992, pp. 260-284.
 - (129) Walker EA, Katon WJ, Jemelka RP, Roy-Byrne PP: Co-morbidity of gastrointestinal complaints, depression and anxiety in the ECA study. *American Journal of Medicine* 92:265-305, 1992.
 - (130) Roy-Byrne PP: Integrated treatment of panic disorder: a practical approach. *American Journal of Medicine* 92:495-545, 1992.
 - (131) Roy-Byrne PP, Vitaliano PP, Cowley DS, Luciano GS, Zheng Y, Dunner DL: Coping in panic and major depressive disorder: relative effects of symptom severity and diagnostic co-morbidity. *Journal of Nervous and Mental Disease* 180:179-183, 1992.
 - (132) Roy-Byrne PP: Benzodiazepine dependence. Editorial, *Journal of American Board of Family Practice* 5:225-226, 1992.
 - (133) Wingerson D and Roy-Byrne PP: Anxiety disorders: review of anxiolytic drugs. In Dunner DL (ed.), Current Psychiatric Therapy. W.B. Sanders, 1992, pp. 295-302.
 - (134) Shores M, Glubin T, Cowley DS, Dager SR, Roy-Byrne PP, Dunner DL: The relationship between anxiety and depression: A clinical comparison of generalized anxiety disorder, dysthymic disorder, panic disorder and major depressive disorder. *Comprehensive Psychiatry* 33:237-244, 1992.
 - (135) Szuba MP, Guze BH, Liston EH, Baxter LR, Roy-Byrne PP: Psychiatry resident and medical student perspective of ECT: the influence of exposure and education. *Convulsive Therapy* 8:110-117, 1992.
 - (136) Fiset L, Milgrom P, Beirne OR, Roy-Byrne P, Weinstein P: Disinhibition of behaviors with midazolam: report of a case. *J Oral Max Surg* 50:645-649, 1992.
 - (137) Wingerson D, Nguyen C, Roy-Byrne PP: Clomipramine treatment for generalized anxiety disorder. *Journal of Clinical Psychopharmacology* 12:214-215, 1992.

Peter Roy-Byrne, M.D.

Publications

1994

- (154) Roy-Byrne PP, Milgrom P, Tay KM, Weinstein P, Katon W: Psychopathology and psychiatric diagnosis in subjects with dental phobia. *Journal of Anxiety Disorders* 8:19-31, 1994.
- (155) Cowley DS, Roy-Byrne PP, Radant A, Hommer DW, Greenblatt DJ, Vitaliano PP, Godon C: Eye movement effects of diazepam in sons of alcoholic fathers and male control subjects. *Alcoholism: Clinical and Experimental Research* 18:324-332, 1994.
- (156) Zinbarg RE, Barlow DH, Liebowitz M, Street L, Broadhead E, Katon W, Roy-Byrne P, Lepine J-P, Teherani M, Richards J, Brantley PJ, Kraemer H: The DSM-IV field trial for mixed anxiety-depression. *Am J Psychiatry* 151:1153-1162, 1994.
- (157) Roy-Byrne P, Katon W, Broadhead WE, Lepine J-P, Richards J, Brantley PJ, Russo J, Zinbarg R, Barlow D, Liebowitz M: Subsyndromal ("mixed") anxiety-depression in primary care. *Journal of General Internal Medicine* 9:507-512, 1994.

1995

- (158) Roy-Byrne P, Dagadakis C, Ries R, Decker K, Jones R, Bolte MA, Scher M, Brinkley J, Gallagher M, Patrick DL, Mark H: I. A psychiatrist-rated battery of measures for assessing the clinical status of psychiatric inpatients. *Psychiatric Services* 46:347-352, 1995.
- (159) Cowley DS, Roy-Byrne PP, Radant A, Greenblatt DJ, Nemeroff C, Hommer DW: Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam. *Neuropsychopharmacology* 12:147-158, 1995.
- (160) Roy-Byrne PP, Cowley DS: Course and outcome in panic disorder: a review of recent follow-up studies. *Anxiety* 1:151-160, 1995.
- (161) Roy-Byrne P, Radant A, Wingerson D, Cowley DS: Human oculomotor function: reliability and diurnal variation. *Biological Psychiatry* 38:92-97, 1995.
- (162) Hopfenbeck JR, Cowley DS, Radant A, Greenblatt DJ, Roy-Byrne PP: Effects of diphenhydramine on human eye movements. *Psychopharmacology* 118:280-286, 1995.
- (163) Decker K, Roy-Byrne P, Merchant K: Effects of muscimol on haloperidol regulation of neurotensin gene expression in rat striatum and accumbens. *Brain Research* 691:9-17, 1995.
- (164) Tsuang D, Cowley DS, Ries R, Dunner DL, Roy-Byrne P: The effects of substance abuse on the clinical presentation of mood and anxiety disorders. *J Clin Psychiatry* 56:549-555, 1995.

1996

- (165) Moras K, Clark LA, Katon W, Roy-Byrne PP, Watson D, Barlow DH: Mixed anxiety depression. In *DSM-IV Sourcebook, Volume 2*. APA Press, Inc., Washington DC, 1996. pp. 623-643.
- (166) Cowley DS, Flick SN, Roy-Byrne PP: Long-term course and outcome in panic disorder: a naturalistic follow-up study in treatment-resistant patients. *Anxiety*, 2:13-21, 1996.
- (167) Cowley DS, Roy-Byrne PP, Greenblatt DJ, Kramer GL, Petty F: Effect of diazepam on plasma GABA in sons of alcoholic fathers. *Alcoholism: Clin & Exp Research*, 20:343-347, 1996.
- (168) Roy-Byrne P, Dagadakis C, Unitzer J, Ries R: Evidence for limited validity of the revised QAF/SOFAS. *Psychiatric Services*, 47:864-866, 1996.
- (169) Roy-Byrne P: Generalized anxiety and mixed anxiety-depression: effects on disability and health care utilization. *J Clin Psychiatry*, 57 (57): 86-91, 1996.

Peter Roy-Byrne, M.D.

Publications

- (186) Roy-Byrne PP, Cowley DS: Pharmacologic treatment of panic, generalized anxiety and phobic disorder. In J. Gorman, P. Nathan (eds), Treatments That Work. Oxford University Press. In press.
- (187) Roy-Byrne P: Current trends in the management of psychiatric disorders: Psychopharmacologic treatment. In Tucker G. (ed.) Continuum: Psychiatric Update. In press.
- (188) Roy-Byrne PP: Restoring the Balance. Commentary on psychosocial approaches to panic disorder and agoraphobia in primary care. Mind/Body Medicine, in press.
- (189) Roy-Byrne P, Cowley DS: Pharmacotherapy of anxiety. In Barchas J, Elliot G, Ciaranello RD (eds.), Psychopharmacology: From Theory to Practice (2nd ed.). In press.

SUBMITTED FOR PUBLICATION

- (190) Comtois K, Cowley DS, Dunner DL, Roy-Byrne P: Severity of anxiety and depression in borderline personality: independence from Axis I mood and anxiety disorders.
- (191) Fawcett J, Hoehn-Saric R, Munjack DJ, Roy-Byrne PP: A multicenter, double blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder in outpatients.
- (192) Radant AD, Bowdle A, Cowley DS, Kharasch E, Roy-Byrne P: Does ketamine-mediated NMDA receptor antagonism cause schizophrenia-like oculomotor abnormalities?
- (193) Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassvar RJ, Roy-Byrne PP: Psychedelic effects of ketamine in normal volunteers: Relationship to steady state plasma concentrations.
- (194) Russo J, Roy-Byrne P, Jaffe C, Ries R, Patrick D, Dagadakis C: Predicting psychiatric outcomes in acute psychiatric inpatients: the role of level of care, psychiatric status and quality of life.
- (195) Elliot AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne P: A randomized, placebo-controlled trial of paroxetine vs. imipramine in depressed HIV positive individuals.
- (196) Elliot AJ, Haven G, Roy-Byrne P: HIV-1 protease inhibitor-induced nefazodone toxicity.
- (197) Cowley DS, Ha E, Roy-Byrne P: Determinants of pharmacologic treatment failure in panic disorder.
- (198) Kronig MH, Apter J, Asnis G, Bystrisky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenbergr R, Robinson D, Roy-Byrne P, Phillips K, DuPont JJ: A placebo controlled multicenter study of sertraline treatment for obsessive compulsive disorder.

EDITED VOLUMES

- (1) Anxiety: New Findings for the Clinician. P.P. Roy-Byrne (ed.). Washington D.C.: APA Press, 1988.
- (2) Panic Disorder, Psychiatric Annals 18:8, 1988. P. Roy-Byrne, M.D., Guest Editor.
- (3) Benzodiazepines in Clinical Practice: Risks and Benefits. P.P. Roy-Byrne and D.S. Cowley (eds.), Washington D.C., APA Press, 1991.

SELECTED ABSTRACTS

- 1. Roy-Byrne PP, Gwirtsman H, Yager J, Germer RH, and Lerner L: Neuroendocrine tests in bulimia. Papers on new research, the 135th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 15-21, 1982.
- 2. Edelstein CK, Roy-Byrne PP, Fawzy FI, and Dornfeld L: Effects of weight loss on the dexamethasone suppression test. Papers on new research, the 136th Annual Meeting of the American Psychiatric Association, New York, NY, 1983.

Peter Roy-Byrne, M.D.

Publications

19. Roy-Byrne PP, Uhde TW, Weingartner HH, and Holcomb HH: Effects of diazepam on mood, memory, and pain. Scientific Proceedings of the American Psychiatric Association, Washington, D.C., May 12-18, 1986.
20. Roy-Byrne PP, Rubinow DR, Hoban MC, Grover GN: TSH response to TRH in women with premenstrual syndrome. Scientific Proceedings of the American Psychiatric Association, Chicago, IL, May 9-14, 1987.
21. Roy-Byrne PP, Lewis N, Villacres E, Shader RI, Greenblatt D, Veith R: Suppression of norepinephrine appearance rate in plasma by diazepam in humans. Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 6-10, 1987.
22. Roy-Byrne PP: Anti-convulsants in anxiety and withdrawal syndromes. Scientific Proceedings of the American Psychiatric Association, Montreal, Quebec, Canada, May 7-12, 1988.
23. Uhde TW, Stein MB, Roy-Byrne PP, Post RM: Neuroendocrine and noradrenergic studies in panic. Scientific Proceedings of the American Psychiatric Association, Montreal, Quebec, Canada, May 7-12, 1988.
24. Fossey MD, Roy-Byrne PP, Cowley DS, Lydiard RB, Laraia MT, Zealborg JL, Ballenger JC: Personality assessment using the TPQ in patients with panic disorder and generalized anxiety disorder. Proceedings of the Society of Biological Psychiatry 25:12A, May 4-8, 1989.
25. Cowley DS, Roy-Byrne PP, Hommer D: Benzodiazepine sensitivity and personality in normal subjects. Proceedings of the Society of Biological Psychiatry 25:12A, May 4-8, 1989.
26. Roy-Byrne PP, Cowley DS, Hommer DW, Greenblatt DJ, Shader RI: Benzodiazepine sensitivity in panic disorder. Proceedings of the Society of Biological Psychiatry 25:12A, May 4-8, 1989.
27. Roy-Byrne PP, Rubinow DR, Cannon RO, Diem H, Schmidt PJ: The relationship between microvascular angina and panic. Scientific Proceedings of the American Psychiatric Association, San Francisco, CA, May 6-11, 1989.
28. Roy-Byrne PP, Lydiard RB, Ballenger JC: Anxiolytic drug therapy: New developments. Scientific Proceedings of the American Psychiatric Association, San Francisco, CA, May 6-11, 1989.
29. Katon W, Buchwald D, Simon G, Meese P, Roy-Byrne P, Russo J: Pain complaints in chronic fatigue syndrome and rheumatoid arthritis. Abstracts of the 8th Annual Scientific Meeting of the American Pain Society, Phoenix, AZ, October 26-29, 1989.
30. Roy-Byrne P, Cowley DS, Greenblatt D, Shader RS, Hommer D: Reduced benzodiazepine sensitivity in panic disorder. Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology, Maui, HI, December 10-15, 1989.
31. Dager SR, Khan A, Cowley D, Avery D, Elder J, Roy-Byrne P, Dunner DL: Clinical characteristics of placebo response among panic patients. Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology, Maui, HI, December 10-15, 1989.
32. Roy-Byrne PP: Adjunctive treatments of benzodiazepine discontinuation syndromes: a review. J Psychiatric Res 24(s):85A, 1990.
33. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D: Effects of diazepam on eye movements. Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 10-15, 1990.
34. Roy-Byrne PP, Cowley DS, Ritchie J, Nemeroff C, Hommer DW: Benzodiazepine sensitivity in panic disorder: effects of alprazolam treatment. Biol Psychiatry 29:27A, 1991.
35. Cowley DS, Roy-Byrne PP, Hommer DW, Greenblatt DJ, Nemeroff C, Ritchie J: Benzodiazepine sensitivity in anxiety disorders. Biol Psychiatry 29:33A, 1991.

Peter Roy-Byrne, M.D.

Publications

51. Radant AD, Wingerson DK, Cowley DS, Roy-Byrne PP: Performance of schizophrenia patients and controls on a battery of oculomotor tasks. Abstract of the West Coast College of Biological Psychiatry Annual Meeting, April 22 and 23, 1995.
52. Cowley DS, Howard M, Hopfenbeck J, Roy-Byrne P: Predictors of euphoric response to diazepam in sons of alcoholics. Abstract of the West Coast College of Biological Psychiatry Annual Meeting, April 22 and 23, 1995.
53. Cowley DS, Flick S, Roy-Byrne PP: Long-term course and outcome in panic disorder. Abstract of the West Coast College of Biological Psychiatry Annual Meeting, April 22 and 23, 1995.
54. Elliot AJ, Pages K, Johnson D, Wilson L, Roy-Byrne PP: Profile of medically serious suicide attempters. Abstract of the American Psychiatric Association Annual Meeting, Miami, FL, May 20-25, 1995.
55. Cowley D, Howard M, Hopfenbeck J, Roy-Byrne P: Predictors of euphoric response to diazepam in sons of alcoholics. Abstract of the Research Society in Alcoholism Annual Scientific Meeting, June 17-22, 1995.
56. Howard MO, Cowley DS, Roy-Byrne PP, Hopfenbeck J: Sensation seeking and tridimensional personality traits in high-risk young adult males and controls. Abstract of the Research Society in Alcoholism Annual Scientific Meeting, June 17-22, 1995.
57. Roy-Byrne PP, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS: Benzodiazepine sensitivity in panic and obsessive compulsive disorder. Abstracts of the American College of Neuropsychopharmacology, San Juan Puerto Rico, December 10-15, 1995.
58. Radant A, Bowdle A, Cowley DS, Kharash E, Roy-Byrne PP: Oculomotor, cognitive and subjective effects of ketamine in normals. Abstracts of the American College of Neuropsychopharmacology, San Juan Puerto Rico, December 10-15, 1995.
59. Roy-Byrne P, Radant A, Bowdle A, Kharash E, Cowley D: Oculomotor, cognitive and subjective effects of ketamine in normals. Abstracts of the Society of Biologic Psychiatry, New York, New York, May 1-5, 1996.
60. Elliott A, Roy-Byrne P, Tucker G: Auditory hallucinations: Relationship to diagnosis and severity of illness characteristics. Abstracts of the Society of Biologic Psychiatry, New York, New York, May 1-5, 1996.
61. Roy-Byrne P, Wingerson D, Radant A, Greenblatt D, Cowley D: Benzodiazepine sensitivity in panic and obsessive compulsive disorder. Abstracts of the Society of Biologic Psychiatry, New York, New York, May 1-5, 1996.

Peter Roy-Byrne, M.D.

Invited Lectures and Presentations

- (20) "Benzodiazepine Sensitivity in Panic Disorder", West Coast College of Biological Psychiatry, Seattle, WA, April 13, 1988.
- (21) "Anticonvulsants in Anxiety and Withdrawal Syndromes", Annual American Psychiatric Association Meeting, Montreal, Canada, May 9, 1988.
- (22) "Benzodiazepine Sensitivity in Panic Disorder", New Research Session, Phobia Society of America, Boston, MA, October 27, 1988.
- (23) "Benzodiazepines in Panic Disorder", Grand Rounds, Medical University of South Carolina, Charleston, SC, November 1, 1988.
- (24) "Benzodiazepine Use, Abuse and Withdrawal", Grand Rounds, University of Utah, Salt Lake City, UT, December 7, 1988.
- (25) "Recognition and Management of Panic Disorder", Conference on the Difficult to Treat Patient, University of Colorado, Denver, CO, January 14, 1989.
- (26) "Benzodiazepines in Clinical Practice: Risks and Benefits", 32nd Annual Meeting of the Western Pharmacologic Society, Breckenridge, CO, January 24, 1989.
- (27) "Benzodiazepine Withdrawal: Normal-Dose Withdrawal Problems and the Use of Carbamazepine," Substance Abuse Grand Rounds, VA Medical Center, San Francisco, CA, February 17, 1989.
- (28) "Benzodiazepine Dependence and Withdrawal," Cleveland Psychiatric Society, Cleveland, OH, March 1, 1989.
- (29) "Panic and Generalized Anxiety: Evaluation and Treatment," Grand Rounds, Cleveland Clinic, Cleveland, OH, March 2, 1989.
- (30) "Benzodiazepines in Panic and Generalized Anxiety: Treatment Implications of Neurobiologic Testing," Joint Grand Rounds, Baylor and University of Texas, Baylor College of Medicine, Houston, TX, March 15, 1989.
- (31) "Irritable Bowel Syndrome and Psychiatric Illness," Conference on Psychiatric Aspects of Medical Illness, Texas Tech Medical Center, El Paso, TX, March 17, 1989.
- (32) "Benzodiazepine Sensitivity in Panic Disorder," Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 8, 1989.
- (33) "Microvascular Angina and Panic Disorder," Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 10, 1989.
- (34) "Anxiolytic Drug Therapy: New Developments," Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 12, 1989.
- (35) "Evaluation and Treatment of Benzodiazepine Dependence," University of Toronto Update on Benzodiazepines, Toronto, Canada, October 21, 1989.
- (36) "Evaluation and Treatment of Benzodiazepine Dependence," the Institute of Pennsylvania Hospital Conference on Benzodiazepines in the Age of Anxiety, Philadelphia, PA, November 4, 1989.
- (37) "Evaluation and Treatment of Benzodiazepine Dependence," Conference on Addiction Medicine: State of the Art, San Diego, CA, November 11, 1989.
- (38) "Benzodiazepine Sensitivity in Human Anxiety," Colloquium for the BioBehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, CA, November 13, 1989.
- (39) "Reduced Benzodiazepine Sensitivity in Panic Disorder," Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, December 12, 1989.

Peter Roy-Byrne, M.D.

Invited Lectures and Presentations

- (61) "Neurobiology of Anxiety," Grand Rounds, University of Hawaii, April 10, 1992.
- (62) "Carbamazepine for Benzodiazepine Withdrawal," Annual Meeting of the American Psychiatric Association, Washington, DC, May 4, 1992.
- (63) "Pharmacotherapy of Anxiety Disorders," Annual Meeting of the American Psychiatric Association, Washington, DC, May 5, 1992.
- (64) "Psychiatric Diagnoses in Dental Phobic Patients," Annual Meeting of the American Psychiatric Association, New Research Program, Washington, DC, May 6, 1992.
- (65) "Benzodiazepine Sensitivity in Human Anxiety," Grand Rounds, Stanford University, Palo Alto, CA, June 11, 1992.
- (66) "The Neurobiology of Anxiety," Grand Rounds, University of Kansas Medical Center, Kansas City, Kansas, September 11, 1992.
- (67) "Anxiety and Depression" Course on "Treating Complicated Depression", Stanford University, Palo Alto, CA, January 16, 1993.
- (68) "Benzodiazepine Protracted Abstinence Controversy: Point/Counterpoint," 26th Anniversary Conference of Haight Ashbury Free Clinics, San Francisco, CA, June 5, 1993.
- (69) "Mixed Anxiety-Depression in Primary Care," Grand Rounds, Medical College of Pennsylvania, June 21, 1993.
- (70) Benzodiazepine Receptor Sensitivity in Human Anxiety: Single Dose and Chronic Benzodiazepine Effects," Grand Rounds, University of Louisville School of Medicine, Louisville, KY, November 4, 1993.
- (71) "Human Oculomotor Function: Reliability and Diurnal Variation," Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 13-17, 1993.
- (72) "Benzodiazepine Sensitivity in Human Anxiety," Grand Rounds, Hillside Hospital, Glen Oaks, NY, March 30, 1994.
- (73) "Anxiety Disorders: Varied Presentations and Strategies," Psychopharmacology 1994 Clinical and Research Update, San Francisco, CA, October 14, 1994.
- (74) "Anxiety Disorders: Chronic Treatment and Discontinuation Strategies," Psychopharmacology 1994 Clinical and Research Update, San Francisco, CA, October 14, 1994.
- (75) "Treatment of Anxiety: An Update," UCLA Colloquium for the Biobehavioral Sciences, Los Angeles, CA, November 11, 1994.
- (76) "Benzodiazepine Sensitivity in Human Anxiety," Grand Rounds, University of Texas, San Antonio, TX, August 23, 1995.
- (77) "Update on Panic Disorder," Smith Kline Beecham Consultants Update, Aventura, FL, September 23, 1995.
- (78) "Benzodiazepine Sensitivity in Panic and Obsessive Compulsive Disorders," Annual Meeting of the American College of Neuropsychopharmacology, San Juan Puerto Rico, December 11, 1995.
- (79) "Benzodiazepine Sensitivity in Panic and Obsessive Compulsive Disorders," Annual meeting at the West Coast College of Biological Psychiatry, Los Angeles CA, April 20, 1996.

Peter Roy-Byrne, M.D.

Invited Lectures and Presentations

- (15) "Panic and Generalized Anxiety--Evaluation and Treatment," Valley Medical Center, Renton, WA, July 30, 1987.
- (16) "Life Events and the Onset of Anxiety Disorder," Oregon Nurses Association Annual Conference, Bend, OR, September 25, 1987.
- (17) "Benzodiazepines and Anxiety," Oregon Nurses Association Annual Conference, Bend, OR, September 26, 1987.
- (18) "Evaluation and Treatment of Anxiety Disorders," Deaconess Hospital, Billings, MT, October 7, 1988.
- (19) "Panic Disorder: Evaluation and Treatment," Clinical Pain Service Conference, University of Washington, Seattle, WA, October 16, 1987.
- (20) "New Developments in the Psychopharmacology of Anxiety," Western Canada District Branch of the APA, Vancouver, British Columbia, October 24, 1987.
- (21) "Anxiety Disorders," St. Patrick's Hospital, Missoula, MT, October 29, 1988.
- (22) "Use and Misuse of Benzodiazepines," Internal Medicine Visiting Professor Conference, Deaconess Hospital, Spokane, WA, November 6, 1987.
- (23) "Approaches to the Evaluation and Treatment of Panic," Clinical Topics for Nurse Practitioners, University of Washington, Seattle, WA, November 14, 1987.
- (24) "Panic Disorder," Medical Grand Rounds, University of Washington, Seattle, WA, November 19, 1987.
- (25) "Anxiety Disorders: The Diagnosis and Treatment of Acute and Chronic Conditions," College of Medical Education, Tacoma, WA, December 3, 1987.
- (26) "Benzodiazepines: Use, Abuse, Efficacy and Withdrawal," Conference on Somatization of Psychiatric Illness in Primary Care, Tacoma, WA, December 17, 1987.
- (27) "Pathologic Anxiety: Current Concepts and Future Directions," Seattle King County Chapter of WSPA, Seattle, WA, January 13, 1988.
- (28) "Evaluation and Treatment of Panic Disorder," Virginia Mason Medical Center Grand Rounds, Seattle, WA, January 22, 1988.
- (29) "Irritable Bowel Syndrome," Conference on Psychophysiologic Disorders in Clinical Practice, Anchorage, AK, January 29, 1988.
- (30) "Panic Disorder: Neurobiologic Aspects," Conference on Psychophysiologic Disorders in Clinical Practice, Anchorage, AK, January 29, 1988.
- (31) "Benzodiazepines: Use, Abuse and Withdrawal," Grand Rounds, Sacred Heart Medical Center, Spokane, WA, February 1, 1988.
- (32) "Biologic Perspectives on Panic Disorders," Washington State Psychiatric Association Annual Meeting, Seattle, WA, February 6, 1988.
- (33) "Evaluation and Treatment of Panic and Generalized Anxiety," Idaho District Branch of the APA Annual Meeting, Boise, ID, February 20, 1988.
- (34) "Benzodiazepines in the Treatment of Anxiety," Whidbey General Hospital, Whidbey Island, WA, March 1, 1988.
- (35) "Panic Disorder," Grand Rounds, Department of Otolaryngology, University of Washington, Seattle, WA, March 14, 1988.
- (36) "Benzodiazepines: Use, Abuse, Efficacy and Withdrawal," Conference on Somatization of Psychiatric Illness in Primary Care, Seattle, WA, April 14, 1988.

Peter Roy-Byrne, M.D.

Invited Lectures and Presentations

- (58) "Anxiolytics: New Developments," Clinical Seminars in Psychiatric/Mental Health Practice, Northwest Hospital, Seattle, WA, January 26, 1991.
- (59) "Panic and Anxiety Disorder: New Treatment Perspectives", Valley Medical Center, Renton, WA, March 19, 1991.
- (60) "Pharmacotherapy and Neurobiology of Post-Traumatic Stress Disorder," Conference of Traumatic Stress, Children's Hospital, Seattle, WA, March 25, 1991.
- (61) "How to Assess and Manage the Anxious Patient," Grand Rounds, Overlake Hospital, Bellevue, WA, May 15, 1991.
- (62) "Treatment of Anxiety Disorders," Conference on Panic Disorders: Somatization, Medical Utilization and Treatment, Seattle, WA, May 31, 1991.
- (63) "New Approaches to the Treatment of Benzodiazepine Dependence and Withdrawal," Conference on Neuropsychiatry in the '90's: New Treatment Developments, Seattle, WA, June 19, 1991.
- (64) "Recognition of Depression," Symposium on the Depressed Patient in Family Practice, Bellevue, WA, September 28, 1991.
- (65) "The Biologic Basis of Mental Illness: Brain Changes with the Changing Times," Washington State Psychiatric Society, Seattle, WA, January 23, 1992.
- (66) "Diagnosis and Treatment of Panic Disorder," Holiday Park Hospital, Portland, OR, April 25, 1992.
- (67) "Recognition of Depression," Conference on Evaluation and Treatment of Depression, Bellevue, WA, December 5, 1992.
- (68) "New Developments in Schizophrenia" Annual Meeting of the Washington State Psychiatric Society, Vancouver, WA, April 3, 1993.
- (69) "Anxiety Treatment Strategies and Their Neurobiologic Basis," The Kikel Memorial Lecture, Annual Meeting of the Oregon Psychiatric Society, Portland, OR, April 16, 1993.
- (70) "Anxiety and Depression: Relationship and Treatment," Vancouver Psychiatric Society, Vancouver, BC, November 16, 1993.
- (71) "Approaches to the Evaluation and Treatment of Depression and Anxiety," Bremerton Naval Hospital, Bremerton, WA, February 18, 1994.
- (72) "New Psychotropic Agents: Focus on Risperidone and Venlafaxine," Washington State Association of Community Psychiatrists, Seattle, WA, May 4, 1994.
- (73) "Panic and Obsessive Compulsive Disorders: Nature and Treatment," Washington Pharmacists Association, Lynnwood, WA, October 16, 1994.
- (74) "Co-Morbid Anxiety and Depression: Nature and Treatment," Providence Hospital, Seattle, WA, January 22, 1995.
- (75) "Obsessive-Compulsive Disorder," Spokane Community Mental Health Center, Spokane, WA, March 21, 1995.
- (76) "New Developments in the Treatment of Panic Disorder," Madigan Medical Center, Tacoma, WA, May 3, 1995.
- (77) "Obsessive-Compulsive Disorders," Sacred Heart Medical Center, Eugene, OR, August 1, 1995.

Peter Roy-Byrne, M.D.

Current Research

CURRENT RESEARCH INTERESTS

1. Benzodiazepine Receptor Sensitivity in Psychiatric Disorders (with D. Cowley, M.D.)

Investigation of the effects of intravenous diazepam on eye movements, cognitive function and mood, in patients with panic and obsessive compulsive disorder as compared with controls and in subjects at risk for alcoholism as compared with controls. Determination of the effects of variations in physiologic and psychologic arousal and of chronic benzodiazepine treatment on benzodiazepine sensitivity.

2. Eye Movements, Brain Dysfunction and Psychiatric Illness (with A. Radant, M.D. and D. Cowley, M.D.)

Use of eye movements to identify subtle neurologic dysfunction and specify possible neuroanatomic sites of pathophysiology in patients with schizophrenia and HIV infection. Search for clinical and treatment response correlates to these findings. Studies of normals, using IV Ketamine to simulate oculomotor abnormalities. Genetic linkage studies of oculomotor dysfunction.

3. Psychophysiology of Human Emotion (with D. Cowley, M.D.)

Use of fear potentiated and pleasure inhibited acoustic startle response, vagal tone, and systolic time interval to explore the intensity and time course of autonomic nervous system characteristics of positive and negative emotions in depressed and anxious patients compared with controls.

4. Outcomes Assessment Tools in Psychiatry (with J. Russo Ph.D. and R. Ries, M.D.)

Development of a standardized information system to measure patient case mix and treatment response characteristics in psychiatric inpatient, outpatient and ER settings; demonstration of psychometric reliability, validity and responsiveness; incorporation into the usual structure of clinical care; utility in changing clinician practice via practical feedback; generation of predictors of poor outcomes.

5. Antidepressant Treatment in HIV Patients with Major Depression (with K. Uldall, M.D. and A. Elliott, M.D.)

Comparison of the relative efficacy and side effect profile of imipramine and paroxetine in depressed HIV patients, and identification of any neuropsychologic or oculomotor findings predictive of efficacy and/or side effects.

6. Antidepressant Treatment of Depression with Alcoholism (with D. Cowley, M.D. and R. Ries, M.D.)

Evaluation of the efficacy of nefazodone vs. placebo added to weekly substance abuse counseling in depressed alcoholics.

7. Medically-Serious Suicide Attempts (with A. Elliott, M.D. and W. Katon, M.D.)

Investigation of the psychiatric characteristics of patients making medically-serious (i.e. requiring medical hospitalization) suicide attempts, using structured diagnostic interviews, rating scales, and personality inventories.

8. Intervention for Panic Disorder in Primary Care (with W. Katon, M.D.)

Investigation of the efficacy of a combined cognitive therapy and expert pharmacotherapy intervention compared to "usual care" for patients in the primary care setting with panic disorder.

C:\MSOFFICE\WINWORD\FACROYSAVE.DOC mar 2/13/97


STATE OF WASHINGTON						
HEALTH PROFESSIONS QUALITY ASSURANCE DIVISION						
THIS CERTIFIES THAT THE PERSON NAMED HEREON IS AUTHORIZED AS PROVIDED BY LAW AS A						
PHYSICIAN AND SURGEON						
ACTIVE						
ROY-BYRNE, PETER PAUL HARBORVIEW MEDICAL CENTER ZA-15 325 9TH AVENUE SEATTLE, WA 98104						
 SECRETARY	NUMBER [REDACTED]	<table border="1"><tr><td>DATE ISSUED</td><td>EXPIRATION DATE</td></tr><tr><td>06-06-86</td><td>05-01-98</td></tr></table>	DATE ISSUED	EXPIRATION DATE	06-06-86	05-01-98
DATE ISSUED	EXPIRATION DATE					
06-06-86	05-01-98					

1284

R. 5259

Confidential/Produced in Litigation Pursuant to Protective O

JJRS 03530190

STATE OF WASHINGTON		
HEALTH PROFESSIONS QUALITY ASSURANCE DIVISION		
THIS CERTIFIES THAT THE PERSON OR ESTABLISHMENT NAMED HEREON IS AUTHORIZED AS PROVIDED BY LAW AS A		
PHYSICIAN AND SURGEON		
ACTIVE		
ROY-BYRNE, PETER PAUL		
HARBORVIEW MED CTR BOX 35-9911		
325 9TH AVE		
SEATTLE, WA 98104		
 SECRETARY	NUMBER [REDACTED]	DATE ISSUED 06-06-86
		EXPIRATION DATE 05-01-99

PERSONAL COPY OF YOUR LICENSE	
STATE OF WASHINGTON	
HEALTH PROFESSIONS QUALITY ASSURANCE DIVISION	
PHYSICIAN AND SURGEON	
ACTIVE	
ROY-BYRNE, PETER PAUL	
HARBORVIEW MED CTR BOX 35-9911	
325 9TH AVE	
SEATTLE, WA 98104	
 SECRETARY	NUMBER [REDACTED]
	Expiration Date 05-01-99

March 13, 1996

CURRICULUM VITAE

PERSONAL INFORMATION:

Name: Sellmann Charles Schulz, II, M.D.
Date and Place of Birth: December 18, 1945, Evanston, IL
Citizenship: United States
Social Security Number: REDACTED
Business Address: Department of Psychiatry
Case Western Reserve University
11100 Euclid Avenue
Cleveland, Ohio 44106
Telephone: (216) 844-3883
Fax: (216) 844-3851

ACADEMIC BACKGROUND:

1971 - 1973 M.D. - UCLA Medical School, Los Angeles, California
1970 - 1971 - National Institute of Health Pathology Fellowship at UCLA
1968 - 1970 - UCLA Medical School
1964 - 1968 B.A. - University of Southern California, Los Angeles, California - Cum laude

POSTDOCTORAL TRAINING:

1995 Course on Programs for Chiefs of Clinical Services - Harvard School of Public Health

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

POSTDOCTORAL TRAINING (continued):

1988	Course in Medical and Experimental Mammalian Genetics - The Jackson Laboratory and the Johns Hopkins University School of Medicine
1976 - 1977	Senior Resident Inpatient Psychiatry UCLA-NPI Los Angeles, California
1974 - 1976	Psychiatry Resident UCLA-NPI Los Angeles, California
1973 - 1974	Rotating Intern (Neurology, Pediatrics, Medicine) UCLA-NPI Los Angeles, California

LICENSURE:

1989 - present	State of Ohio
1988 - present	District of Columbia
1986 - present	State of Maryland
1983 - present	State of Pennsylvania
1977 - 1980	State of Maryland

CERTIFICATION:

Diplomate, National Board of Medical
Examiners - [REDACTED]

American Board of Psychiatry and
Neurology - 1978

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS:

1989 - present	Professor and Chair, Department of Psychiatry Case Western Reserve University Director, Department of Psychiatry University Hospitals of Cleveland Cleveland, Ohio 44106
1989 - present	Faculty Member Center for Adolescent Health Case Western Reserve University University Hospitals of Cleveland Cleveland, Ohio 44106
1988 - 1989	Chief, Schizophrenia Research Branch Division of Clinical Research National Institute of Mental Health Rockville, Maryland 20857
1986 - 1989	Guest Scientist Clinical Neuroscience Branch Division of Intramural Research Programs National Institute of Mental Health Bethesda, Maryland 20892
1986 - 1988	Chief, Pharmacologic and Somatic Treatments Program Schizophrenia Research Branch Division of Clinical Research National Institute of Mental Health Rockville, Maryland 20857
1983 - 1986	Consultant Veterans Administration Medical Center Highland Drive Pittsburgh, Pennsylvania 15213
1983 - 1986	Associate Professor of Psychiatry Medical Director, Schizophrenia Module Western Psychiatric Institute and Clinic University of Pittsburgh Pittsburgh, Pennsylvania 15213

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS (continued):

1983	Associate Professor of Psychiatry Medical College of Virginia Virginia Commonwealth University Richmond, Virginia 23298
1981 - 1983	Director, Inpatient Service Department of Psychiatry Medical College of Virginia Virginia Commonwealth University Richmond, Virginia 23298
1980 - 1983	Consultant, Veterans Administration Medical Center Department of Psychiatry Richmond, Virginia 23298
1980 - 1983	Assistant Professor Director of Schizophrenia Studies Program Department of Psychiatry Medical College of Virginia Virginia Commonwealth University Richmond, Virginia 23298
1980 - 1982	Consultant to Section on Neuropharmacology Biological Research Branch National Institute of Mental Health Bethesda, Maryland 20205
1979 - 1980	Staff Psychiatrist, Research Coordinator Section of Neuropsychopharmacology Biological Psychiatry Branch National Institute of Mental Health Bethesda, Maryland 20205
1977 - 1980	Assistant Clinical Professor Department of Psychiatry Georgetown University Washington, D.C.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS (continued):

1977 - 1979 Staff Psychiatrist, Clinical Associate
 Section on Neuropsychopharmacology
 Biological Psychiatry Branch
 National Institute of Mental Health
 Bethesda, Maryland 20205

CONFERENCE COORDINATOR:

"Pharmacotherapy treatment for Borderline Patients" Course. Washington, D.C., 1992; San Francisco, California, 1993; Philadelphia, Pennsylvania, 1993, Philadelphia Pennsylvania, 1994, Miami, Florida, 1995.

International Congress on Schizophrenia Research, Warm Springs, VA, April 8-12, 1995; Colorado Springs, Colorado, April 17-21, 1993; Tucson, Arizona, April 21-25, 1991; San Diego, California, April 1-5, 1989; Clearwater, Florida, March 28-April 1, 1987 (Co-coordinator with Dr. Carol Tamminga, University of Maryland)

New Clinical Drug Evaluation Unit Annual Meeting - Co-coordinator with Dr. Robert Prien of NIMH 1988-1989

"Second Annual Schizophrenia Conference" Pittsburgh, Pennsylvania, November 18, 1985

"Pharmacological and Psychosocial Approaches to the Schizophrenic Patient" Pittsburgh, Pennsylvania, November 17, 1984

"Biomedical Topics in Psychiatry" Homestead, Virginia, February 22, 1983

REVIEWER:

The American Journal of Psychiatry
Archives General Psychiatry
Canadian Research Council
Journal of Clinical Psychiatry
Oxford University Press
Biological Psychiatry

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

EDITORIAL BOARDS:

1989 - present	Scientific Advisory Board, <u>Schizophrenia Bulletin</u>
1989 - present	Editorial Board, <u>Advances in Neuropsychiatry and Psychopharmacology</u> , Raven Press
1988 - 1989	Editor-in-Chief, <u>Psychopharmacology Bulletin</u>
1988 - present	Editorial Board, <u>Schizophrenia Research</u> , Elsevier Science Publishers
1987 - 1988	Deputy Editor, <u>Psychopharmacology Bulletin</u>

OTHER ACTIVITIES:

1995-1996	Chair, VA Merit Review Board, Merit Review Committee for Mental Health and Behavioral Sciences
1992-1995	Advisory Board to Neuroscience Venture, Abbott Pharmaceuticals
1994	Psychiatric Research Mentor Program for Minority Research Training in Psychiatry (PMPTP), APA annual meeting, Philadelphia, PA
1994 - present	Finance Committee International Congress of Psychiatric Genetics
1993 - 1995	VA Merit Review Committee for Mental Health and Behavioral Sciences
1992 - present	Treasurer University Independent Practice Association University Hospitals of Cleveland
1992	Examiner American Board of Psychiatry and Neurology, New York, New York

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

ACTIVITIES (continued):

1990 - 1993	Secretary-Treasurer Council of Clinical Chairmen University Hospitals of Cleveland
1990 - 1993	Committee on Medical Education Faculty of Medicine Case Western Reserve University
1981 - 1983	Project Sleep Sponsored by Upjohn Pharmaceutical and the National Institutes of Mental Health
1980 - 1983	Hospital Formulary Committee Medical College of Virginia
1979 - 1980	Clinical Care Committee National Institutes of Health
1976 - 1977	First President, UCLA Psychiatry Residents' Union
1970 - 1971	Medical School Council Chairman
1969 - 1970	Medical School Class President

MILITARY EXPERIENCE:

1986 - 1989	Commander, United States Public Health Service
1977 - 1980	Lieutenant Commander, United States Public Health Service

HONORS:

1995-1996	Who's Who Among Outstanding Americans
1994	Fellow, American Psychiatric Association
1993	Alliance for the Mentally Ill of Greater Cleveland award for encouraging family involvement in professional education

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

HONORS (continued):

1992 - 1994	Recognized in <u>The Best Doctors in America</u> , 1992-1993 and 1993-1994. Naifeh, S., and Smith, G.W. Woodward/White, Aiken, S.C. 1992.
1991	Who's Who Among Human Services Professionals
1990	The "Lawrence J. Roose, M.D. Memorial Lecture" at The Mount Sinai School of Medicine, Department of Psychiatry, New York.
1989	Medal of Commendation, USPHS, for development of Public Academic Liaison (PAL) Program
1986	Certificate of Merit for Distinguished Achievement in the Field of Mental Health, Neuropsychiatric Institute and Hospital, University of California at Los Angeles
1986	United Mental Health Achievement Award Pittsburgh, Pennsylvania
1986	Teacher of the Year Award Western Psychiatric Institute and Clinic Psychiatry Residents
1981	Teacher of the Year Award Medical College of Virginia Psychiatry Residents
1975 - 1977	Falk Fellowship, American Psychiatric Association
1973	Medical School Graduation Speaker
1968	Jess Mortensen Award Captain, NCAA Champion Track and Field Team
1965	Alpha Epsilon Delta, Pre-med Honorary Society
1965	Phi Eta Sigma, Academic Honorary Fraternity
1964 - 1968	Dean's List University of Southern California

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC, HONORARY AND PROFESSIONAL SOCIETY MEMBERSHIPS:

1996 - 1997	The Best Doctors in America. Midwest Region
1993 - present	The International Society of Psychiatric Genetics
1989 - present	American College of Psychosocial Research (Fellow)
1989 - present	Cleveland Psychiatric Society Chairman, Public Relations Committee, 1991-1991 Treasurer, 1991-1993 President-Elect, 1993-1994 President, 1994-1995
1989 - present	Ohio Association of Chairmen of Departments of Psychiatry
1989 - present	American Association of Chairmen of Departments of Psychiatry
1989 - present	Ohio Psychiatric Association
1988 - present	American Psychopathologic Association (Fellow)
1984 - 1989	New York Academy of Sciences
1983 - present	Association of Academic Psychiatrists
1983 - 1989	Society for Clinical Trials
1981 - 1983	Richmond Psychiatry Society Committee on Public Relations - 1981-1982
1980 - present	Society of Biological Psychiatry Committee on Public Relations - 1982
1978 - 1980	Washington, D.C. Psychiatric Society
1975 - 1977	Southern California Psychiatry Society Constitution Committee Committee of Residents

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC, HONORARY AND PROFESSIONAL MEMBERSHIPS (continued):

1975 - present American Psychiatric Association
Member, Reference Committee - 1976-1977
Member, Committee National Affairs - 1975-1976

SCIENTIFIC ABSTRACTS:

Pack A, Schulz SC: Follow through by psychiatric walk-in patients, World Congress of Psychiatry, Hawaii, 1977.

Schulz SC, van Kammen DP, Balow JE, Bunney WE Jr: No clinical improvement with hemodialysis in schizophrenia patients, Society of Biological Psychiatry, Boston, September 1980.

Balow JE, Schulz SC, van Kammen DP, Flye W, Bunney WE Jr: Double-blind evaluation of dialysis evaluation in schizophrenia, American Nephrology Association, Washington DC, November 1980.

van Kammen DP, Schulz SC, Balow JE, Flye W, Bunney WE Jr: Double-blind evaluation of the potential therapeutic effects of hemodialysis in schizophrenia, Society of Neuroscience, Cincinnati, November 1980.

Schulz SC, van Kammen DP, Rogol AD, Ebert M, Pickar D, Cohen MR, Naber D: Amphetamine increased prolactin but not growth hormone or endorphins in schizophrenic patients, ACNP, Puerto Rico, December 1980.

Schulz SC, van Kammen DP, Balow JE, Flye W, Bunney WE Jr: Double-blind evaluation of dialysis in schizophrenia, American Psychiatric Association, San Francisco, May 1980.

Flye MW, Munding GH, Schulz SC, Karsh J, van Kammen DP: Successful creation of arteriovenous fistulae in non-uremic patients with heparin and aspirin therapy, Southwest Surgical Congress, Monterey, May 1981.

Schulz PM, Schulz SC, Dibble E, Gershon E, Targum S, van Kammen DP: Genetic counseling for schizophrenia: Family and patient attitudes, APA, New Orleans, May 1981.

Schulz SC, van Kammen DP, Waters R, Klein H, Balow J, Bunney WE Jr: Plasmapheresis trial for schizophrenic patients, APA, New Orleans, May 1981.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

SCIENTIFIC ABSTRACTS (continued):

Dommissive C, Schulz SC, Narasimhachari N, Hamer R: The neuroendocrine and behavior response to extroamphetamine in normal individuals, ACCP, Washington DC; Society of Biological Psychiatry, Toronto, Canada, May 1982.

van Kammen DP, Schulz SC, David G, Bunney WE Jr: Cortisol response to d-amphetamine in man with and without naltrexone. Thirteenth CINP, Jerusalem, Israel, June 1982.

Schulz SC, Sinicrope P, Koller M, Kishore P, Friedel RO: Treatment response and ventricular brain ratio in young schizophrenic patients, Society of Biological Psychiatry, Toronto, Canada, May 1982; and ACNP, San Juan, Puerto Rico, December 1982.

Hart R, Schulz SC, Hamer RM, Silverman J: Neuropsychological function following mild exposure to pentaborane. American Psychological Association Meeting, Los Angeles, August 1983.

Schulz SC, Schulz P, Dommissive C, Narasimhachari N, Friedel R: Altered response to amphetamine in borderline patients: A controlled study, Society of Biological Psychiatry, New York, April 1983; & ACNP, Puerto Rico, December 1983.

Schulz SC, Goldberg SC: Is borderline personality an illness? ACNP, San Juan, Puerto Rico, December 1983.

Schulz PM, Schulz SC, Goldberg S, Hamer R, Ettigi PG, Friedel RO: Affective disorders in relatives of borderlines, ACNP, Puerto Rico, December 1983; and APA New Research Section, Los Angeles, May 1984; CINP, Florence, Italy, 1984.

Schulz SC, Silverman JJ, Hart RP, Garrettson LK, Narasimhachari N, Hamer R, Stockman S: Increased VBRs following pentaborane exposure: Any clues for psychiatric research? Society of Biological Psychiatry, Los Angeles, May 1984.

Jennings WS, Schulz SC, Hamer RM, Narasimhachari N, Friedel RO: HVA and 5HIAA negatively correlated with VBR in psychotic adolescents. Society of Biological Psychiatry, Los Angeles, May 1984.

Schulz PM, Hamer R, Schulz SC, Resnick R, Goldberg S: Family psycho-education for borderline schizotypals. American Psychiatric Association, Los Angeles, May 1984.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued):

Schulz SC, Goldberg SC, Resnick RJ, Schulz PM, Hamer R, Friedel RO: Double-blind trial of thiothixene in borderlines. American Psychiatric Association, Los Angeles, May 1984.

Goldberg SC, Schulz SC, Resnick RJ, Schulz PM, Hamer RM, Friedel RO: Treatment outcome in borderline and schizotypal personality disorders treated by navane or placebo. ACNP, Puerto Rico, 1983 & CINP, Florence, Italy, 1984.

Schulz SC, Cornelius J, Brenner R, Schulz PM, Soloff PH: Abnormal sensitivity to D-amphetamine in borderline patients, Society of Biological Psychiatry, Dallas, May 15-19, 1985.

Ganguli R, Stiller R, Perel J, Raghu U, Ulrich R, Schulz SC: Monitoring compliance with oral medication using riboflavin: details of a new method used in day hospital schizophrenics. Society of Biological Psychiatry, Dallas, May 15-19, 1985.

Cornelius J, Soloff PH, Schulz SC, Rameshwari TV, Brenner RP: EEG abnormalities in borderline personality disorder: specific or nonspecific. Society of Biological Psychiatry, Dallas, May 15-19, 1985.

Schulz SC, Cornelius J, Brenner R, Soloff PH: Can amphetamine solve borderline heterogeneity? American Psychiatric Association, Dallas, May 18-24, 1985; and IVth World Congress of Biological Psychiatry, Philadelphia, September 8-13, 1985.

Schulz PM, Schulz SC, Ulrich RF, Hamer R, Friedel RO, Goldberg SC: Borderline traits in relatives of borderlines. American Psychiatric Association, Dallas, May 18-24, 1985; and IVth World Congress of Biological Psychiatry, Philadelphia, September 8-13, 1985.

Schulz SC, House J, Andrews MB: Helping the parents in a schizophrenia program. American Psychiatric Association, Dallas, May 18-24, 1985.

Conley R, Schulz SC, Pollock B: Non-responders: Who are they? IVth World Congress of Biological Psychiatry, Philadelphia, September 8-13, 1985.

Goldberg SC, Resnick RJ, Hamer RM, Schulz SC, Schulz PM, Friedel RO: Borderline personality disorder: Replication of MMPI profiles. American College of Neuropsychopharmacology, Maui, Hawaii, December 9-13, 1985.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued):

Munetz MR, Schulz SC, Bellin M, Harty I: The comparative efficacy and safety of haloperidol and a novel antipsychotic drug, BW234U in outpatients with schizophrenia. Presented at the Society of Biological Psychiatry, Washington DC, May 7-11, 1986.

Cornelius JR, Soloff PH, Schulz SC, Brenner RP, Ulrich RF, Schulz PM: Changes in EEG frequency associated with anxiety and with amphetamine challenge in BPD. Presented at the Society of Biological Psychiatry, Washington DC, May 7-11, 1986.

Schulz SC, Schulz PM: Response to medication in borderline patients. Presented at the American Psychiatric Association, Washington DC, May 10-16, 1986.

Schulz SC, Conley RM, Pollock B: Does lithium or carbamazepine augment neuroleptics? Presented at the American Psychiatric Association, Washington DC, May 10-16, 1986.

Davies MA, Bromet E, Schulz SC: Does environment influence community adjustment? Presented at the American Psychiatric Association, Washington DC, May 10-16, 1986.

Bromet E, Schulz SC, Schulberg H: Mental illness among the homeless. Presented at the American Psychiatric Association, Washington DC, May 10-16, 1986.

Schulz SC, Cornelius J, Jarret D, Schulz PM, Soloff P: Psychopharmacology of personality disorders: Pharmacodynamic probes in personality disorders. Presented at the American College of Neuropsychopharmacology, Washington DC, December 8-12, 1986.

Schulz SC, Conley R, Baker RW, Collins JF, Bell JA: Schizophrenic non-responders treated with clozapine. Presented at the Society of Biological Psychiatry Annual Meeting, Chicago, May 6-10, 1987.

Kahn EM, Weiner RD, Schulz SC: The EEG in schizophrenia: Findings and phantoms - EEG, brain change and clinical state in schizophrenia. Presented at the American Psychiatric Association, Chicago, May 9-14, 1987.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued):

Schulz SC, Goldberg SC: Current controversies in personality disorders: Psychological vs pharmacological split. Presented at the American Psychiatric Association, Chicago, May 9-14, 1987.

Conley RR, Schulz SC, Baker RW, Collins JF, Bell J: Neurobiology of schizophrenia: Clozapine efficacy in schizophrenic nonresponders. Presented at the American Psychiatric Association, Chicago, May 9-14, 1987.

Schulz SC, Conley RR, Benjamin L: Treatment of schizophrenia: Can science deliver? Progress in the treatment of nonresponders. Presented at the American Psychiatric Association, Chicago, May 9-14, 1987.

Schulz SC, Davies MA: Schizophrenia. Neuro Endocrinology Letters, Vol. 9, Issue 3, June 1987, pp 146. Presented at ISPNE, June 30, 1987.

Schulz SC, Kahn EM, Conley R, Alexander J: Neuroleptic augmentation for refractory patients: Lithium versus carbamazepine added to neuroleptics. Presented at the American Psychiatric Association, Montreal, Quebec, Canada, May 7-12, 1988.

Kahn EM, Schulz SC, Baker RW, Brenner RP: EEG and medication response in schizophrenia. Schizophrenia Research, 2:76, 1989. Presented at the International Congress on Schizophrenia Research, San Diego, California, April 1-5, 1989.

Markovitz PJ, Calabrese JR, Schulz SC: Fluoxetine in borderline personality disorder. Presented at the Society of Biological Psychiatry, New York, May 9-13, 1990.

Thaker GK, Moran MJ, Cassady SL, Schulz SC, Tamminga CA: Eye movement measurements in volunteer subjects with schizoid/schizotypal personality diagnoses. Presented at the Society of Biological Psychiatry, New York, May 9-13, 1990.

Schulz SC: The reintegrating schizophrenic patient: A film. Presented at the American Psychiatry Association, New York, May 12-17, 1990.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued):

Schulz SC, Cornelius J, Jarret DB, Schulz PM, Alexander J, Soloff PH: Neuroendocrine response to amphetamine in patients with personality disorder. Presented at the Second International Congress on the Disorders of the Personality, Oslo, Norway, July 30th-August 2nd, 1991.

Ramirez LF, Meltzer HY, Bastani B, Calabrese JR, Schulz SC: Effect of clozapine in schizoaffective disorder and affective symptoms in schizophrenia. Presented at the American Psychiatric Association-144th Annual Meeting, New Orleans, Louisiana, May 11-16, 1991.

Konicki PE, Shea MT, Fenton WA, Schulz SC, Pickar D: Quantitative neuroanatomy and psychopathology in borderline personality disorder. Presented at the Second International Congress on the Disorders of the Personality, Oslo, Norway, July 30th-August 2nd, 1991.

Goyer PF, Andreason PJ, Semple WE, Clayton AH, King AC, Schulz SC, Cohen RM: PET and personality disorders. Presented at the Society of Biological Psychiatry-46th Annual Convention & Scientific Program, New Orleans, Louisiana, May 8-12, 1991; Second International Congress on the Disorders of the Personality, Oslo, Norway, July 30th-August 2nd, 1991.

Davies MA, Schulz SC, Meltzer HY: Family integration of clozapine-treated patients. Presented at the International Congress on Schizophrenia Research, Tucson, Arizona, April 21-25, 1991.

Schulz SC, Goyer P, Friedman L, Kenry JT: A pilot MRI study of adolescents suffering from psychosis. Presented at the VIth Biennial European Workshop on Schizophrenia, Badgastein, Austria, January 26-31, 1992, and American Psychiatric Association, Washington, D.C., May 2-7, 1992.

Friedman L, Schulz SC, Lys C, Lee HS, Meltzer HY: VBR and adolescent onset of schizophrenia. Presented at the VIth Biennial European Workshop on Schizophrenia, Badgastein, Austria, January 26-31, 1992.

Semple WE, Goyer P, McCormick R, Morris E, Compton B, Donovan B, Berridge M, Miraldi F, Schulz SC: Increased orbital frontal cortex blood flow and hippocampal abnormality in PTSD: A pilot pet study. Presented at the Society of Biological Psychiatry-47th Annual Convention and Scientific Program, Washington, D.C., April 29-May 3, 1992.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued):

Konicki PE, Shea MT, Fenton WS, Schulz SC, Pickar D: Brain structure and severity in borderline disorder. American Psychiatric Association-145th Annual Meeting, Washington, D.C., May 2-7, 1992.

Schulz SC, Goyer P, Kenny J, Friedman L, Semple W, Low Beer, J. Brain imaging, neuropsychological, and eye tracking assessments of adolescents with psychosis, AGNP 31st Meeting, San Juan, Puerto Rico, December 14-18, 1992.

Friedman L, Schulz SC, Jesberger JA: Smooth pursuit eye movement performance in adolescent-onset psychosis. The IVth International Congress On Schizophrenia Research, Colorado Springs, CO., April 17-21, 1993.

Goldberg TE, Weinberger DR, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, Kleinman JE: Neuropsychological specificity and schizophrenia: A comparison with affective groups. The IVth International Congress On Schizophrenia Research, Colorado Springs, CO., April 17-21, 1993.

Kenny JT, Schulz SC: Neuropsychological functioning in adolescent psychosis. The IVth International Congress On Schizophrenia Research, Colorado Springs, CO., April 17-21, 1993.

Goyer PF, Semple WE, Morris ED, Muswick GJ, Compton BA, Garnett ML, Nelson DA, Miraldi F, Schulz SC, Meltzer HY: Effects of MK-212 on regional cerebral blood flow in humans. The IVth International Congress On Schizophrenia Research, Colorado Springs, CO., April 17-21, 1993.

Semple WE, Cohen RM, Nordahl TE, King AC, Kosmidis M, Zametkin A, Schulz SC, Goyer PF: PET study correlates of psychometric psychoticism in normals. The IVth International Congress On Schizophrenia Research, Colorado Springs, CO., April 17-21, 1993.

Semple WE, Goyer PF, McCormick R, Donovan B, Miraldi F, Schulz SC: Brain blood flow in post traumatic stress disorder using PET. American Psychiatric Association, San Francisco, CA., May 22-27, 1993.

Semple WE, Goyer PF, Compton BA, Morris E, Garnett BA, Sharkoff JA, Anderson G, Muswick GJ, Nelson DA, Miraldi F, Schulz SC: PET studies of auditory attention. American Psychiatric Association, San Francisco, CA., May 22-27, 1993.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

SCIENTIFIC ABSTRACTS (continued)

Goyer, PF, Berridge, MS, Semple, WE, Morris, ED, Wong, DF, Schulz, SC, Miraldi, F, and Meltzer, HY. Dopamine-2 and Serotonin-2 Receptor Indices in Clozapine treated Schizophrenic Patients. Schizophrenia Research, 9:199, 1993.

Kenny JT, Friedman L, Cola D, Strauss M, Findling R, Schulz SC: Neuropsychological impairments in adolescent schizophrenics. Biological Psychiatry, Philadelphia, PA, May 21, 1994.

Friedman L, Cola D, Kuo H, Buck J, Findling R, Schulz SC: MRI Measures in adolescent schizophrenics: Comparison to controls. Biological Psychiatry, Philadelphia, PA, May 21, 1994.

Friedman L, Kenny JT, Cola DM, Buck J, Findling R, Schulz SC: Adolescent schizophrenia: Reduced memory & brain volume. American Psychiatric Association, Philadelphia, PA, May 22-26, 1994.

Schulz SC, Staser J, Schmitz P, Mack R, Sebree T: An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenic patients. The Psychopharmacology Venture, Abbott Laboratories, Washington, DC., June 26-27, 1994.

Schulz, SC. Treatment of Special Populations. Roundtable, Chicago, IL, April 28-29, 1995.

Schulz SC, Tamminga C, Davies M, Casey D, McGlashan T. Advances in the treatment of schizophrenia. American Psychiatric Association Annual Meeting, Miami, FL, May 21-25, 1995.

Schulz SC, Bark NM, Zborowski J, Schmitz P, Sebree T, Wallin B. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials for schizophrenic patients. American Psychiatric Association, Institute on Psychiatry Services, Boston, Massachusetts, October 6-10, 1995.

Findling RL, Friedman L, Buck J, Cola D, Kenny JT, Swales TP, Schulz SC: Hippocampal measurements in adolescent schizophrenia. The International Congress on Schizophrenia Research, Warm Springs, VA, April 8-12, 1995.

Curriculum Vitae

SCHULZ, S. CHARLES II

SSN REDACTED

SCIENTIFIC ABSTRACTS (continued)

Friedman L, Jesberger J, Cola D, Findling R, Kenny JT, Swales T, Schulz SC: Characterization of smooth pursuit performance in adolescent schizophrenics. The International Congress on Schizophrenia Research, Warm Springs, VA, April 8-12, 1995.

Kenny JT, Friedman L, Cola D, Paganama'a N, Findling R, Swales T, Strauss ME, Schulz SC: Neuropsychological functioning in adolescent schizophrenia. The International Congress on Schizophrenia Research, Warm Springs, VA, April 8-12, 1995.

Swales TEP Findling RL, Friedman L, Kenny JT, Cola D, Schulz SC: Quality of life in adolescents with schizophrenia. The International Congress on Schizophrenia Research, Warm Springs, VA, April 8-12, 1995.

SELECTED PRESENTATIONS:

Schulz SC, van Kammen DP: Methodological issues of hemodialysis in schizophrenia, American College of Neuropsychopharmacology, Maui, Hawaii, December 1978.

Schulz SC: Familial disorders: Genetic and clinical issues, Panel - American Orthopsychiatry Meeting, Washington DC, March 1979 and American Psychiatric Association, Chicago, May 1979.

Schulz SC: Informed consent and ethical issues in research, Panel - American Psychiatric Association, Chicago, May 1979.

Schulz SC, Koller M, Kishore P, Hamer R, Friedel RO: Abnormal CAT scans in adolescent schizophrenics, World Psychiatric Association, New York, October 1981.

Schulz SC: Biological research in schizophrenia. The Psychological Functioning of the Brain Symposium, Winston Salem, North Carolina, November 1981.

Schulz SC, Koller M, Kishore P, Hamer R, Friedel RO: Abnormal CT scan in young schizophrenics, ACNP, San Diego, December 1981; Winter Conference on Brain Research, Steamboat Springs, Colorado, January 1982.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SELECTED PRESENTATIONS (continued):

Schulz SC: Recognition and management of depression, Lewis-Gale Medical Foundation, Roanoke, Virginia, May 1982.

Schulz SC: CT scan study in schizophrenia in adolescence, Psychiatrische Klinik, Munich, Germany, June 1982; British Association for Psychopharmacology, London, England, July 1982.

Schulz SC: Plasmapheresis in schizophrenia, The Royal College of Psychiatrists, London, England, July 1982.

Schulz SC: Treatment of sleep disorders, Annual Summer Retreat, Virginia Beach, Virginia, August 1982.

Schulz SC: Brain imaging in schizophrenia, Richmond Psychiatric Society, Virginia, September 1982.

Schulz SC: Double-blind evaluation of plasmapheresis in schizophrenic patients, International Workshop on Hemodialysis in the Treatment of Schizophrenic Patients, Karolinska Institute, Stockholm, Sweden, December 1982.

Schulz SC: Diagnostic parameters of sleep apnea, Biomedical Topics in Psychiatry, Homestead, Virginia, February 1983.

Schulz SC: Neuroleptic-resistant patients: A decision tree. Biannual State Meeting of Neuropsychiatric Society of Virginia, April 1983.

Schulz SC: Decreased HVA and 5HIAA in psychotic teenagers with enlarged ventricles, Psychiatric Research Society, Park City, Utah, March 8, 1984.

Schulz SC: Characteristics of patients unresponsive to neuroleptics, Johns Hopkins Hospital, Baltimore, Maryland, April 10, 1985.

Schulz SC: DSM-III Axis II classification in a family aggregation study. International Classification in Psychiatry, World Psychiatric Association, Montreal, Quebec, Canada, June 25-29, 1985.

Griffin S, Schulz SC: Can brain ventricular size identify treatment-resistant depressed patients? Academy of Psychosomatic Medicine Annual Meeting, San Francisco, November 7-10, 1985.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SELECTED PRESENTATIONS (continued):

Schulz SC: Treatment resistant schizophrenics: A distinct subtype. International Congress on Schizophrenia Research, Clearwater, Florida, March 28-April 1, 1987.

Schulz SC: Pharmacological treatment: New advances (Negative symptoms and new drugs). Alliance for the Mentally Ill of New York State, Fifth Annual Educational Conference, Bingham, New York, November 7-8, 1987.

Schulz SC: Characteristics and treatment of non-responders to neuroleptics. Medical University of South Carolina, Grand Rounds, September 6, 1987;

Schulz SC: University of Washington Psychosis Conference, October 7, 1988.

Schulz SC: Henry Ford Hospital Grand Rounds, Michigan, January 23, 1988.

Schulz SC: Clinical overview of clozapine. University of Pittsburgh, Pennsylvania, June 3, 1988.

Schulz SC: Lithium treatment for schizophrenic patients. Emory University Department of Psychiatry Grand Rounds, Atlanta, Georgia, September 6, 1988.

Schulz SC: Amphetamine challenge in borderline/schizotypal personality disorder. New York University Medical School Grand Rounds, New York, October 5, 1987; Winter Workshop on Schizophrenia Research, Badgastein, Austria, January 22, 1988; Medical College of Georgia Grand Rounds, June 29, 1988.

Schulz SC: Augmenting medications for neuroleptic non-responders. Yale University, Department of Psychiatry, New Haven, Connecticut, January 13, 1989.

Schulz SC: Biological and pharmacological aspects of borderline personality. Instituto Italiano Per Gli Studi Filosofici, Naples, Italy, October 3, 1989.

Schulz SC: Clozapine: Side Effect Management. International Symposium on Schizophrenia and Clozapine, Department of Psychiatry-Case Western Reserve University, and The NorthEast Ohio Alliance for the Mentally Ill, Cleveland, Ohio, April 16-17, 1990.

Schulz SC: Genetics of schizophrenia. Presented at the APA-DGPN Joint Meeting, Bad Kissingen, Germany, October 6, 1990.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

SELECTED PRESENTATIONS (continued):

Schulz SC: Poor response to pharmacotherapy: What next? American College of Neuropsychopharmacology-29th Annual Meeting, San Juan, Puerto Rico, December 10-14, 1990.

Schulz SC: Genetics of schizophrenia: A status report. American Psychiatric Association-144th Annual Meeting, New Orleans, Louisiana, May 11-16, 1991.

Schulz SC: Psychobiology of borderline/schizotypal disorders. Ohio Psychiatric Association-Fall Meeting, Cleveland, Ohio, October 4-6, 1991.

Schulz SC: Medical, pharmaceutical, family/consumer cost and research issues. Clozaril: A National Dialogue, The Virginia Department of Mental Health-Mental Retardation and Substance Abuse Services, Arlington, Virginia, July 14-16, 1992.

Schulz, SC: Clozapine Treatment and Research. University of California, Irvine Grand Rounds Presentation, November 10, 1992.

Schulz, SC: Brain imaging, neuropsychological and eye-tracking assessments of adolescents with psychosis. American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 14-18, 1992.

Schulz, SC: First Episode Schizophrenia. Clarke Institute of Psychiatry, Toronto, Ontario, Canada, November 17, 1993.

Schulz, SC: Pharmacologic Treatment for Persistently Psychotic Patients: Additional Comments on Adolescent Patients. Wright State University, School of Medicine, Dayton, Ohio, March 3, 1992.

Schulz, SC: Mood Disorders Medical Staff Fellowship; Goals and Experiences. Association for Academic Psychiatry 1992 Annual Meeting, San Antonio, Texas, March 7, 1992.

Schulz, SC: Diagnosis and Treatment of Psychological Injuries, Including Post-Traumatic Stress Disorder. Cleveland Academy of Trial Attorneys Luncheon Seminar, Cleveland, Ohio, March 10, 1992.

Schulz, SC: Psychopharmacological Treatment of Borderline Personality Disorder. Ninth Annual Psychopharmacologic Conference, White Sulphur Springs, West Virginia, March 22, 1992.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

SELECTED PRESENTATIONS (continued):

Schulz, SC: Reintegration of Schizophrenic Patients into Society. The Western Institute, Salt Lake City, Utah, March 24, 1992.

Schulz, SC: Pharmacologic Strategies for Treatment of Refractory Schizophrenia. St. Luke's/Roosevelt Hospital Center, New York, New York, October 21, 1992.

Schulz, SC: Treatment of Persistently Psychotic Patients. Loma Linda University, School of Medicine, Grand Rounds Presentation, Patton State Hospital, Patton, California, November 10, 1992.

Schulz, SC: Understanding the Role of Genetic Factors in Mental Illness: Bridging the Gap between Research and Society Conference. Office of Technology Assessment and National Institute of Mental Health, Washington, D.C., January 21-22, 1993.

Schulz, SC: Update of Brain Imaging in Psychiatric Illnesses; Axis I and Axis II Disorders. State University of New York, University of Buffalo, Grand Rounds Presentation, Buffalo, New York, February, 12, 1993.

Schulz, SC: Thirty-third Annual NCDEU Meeting. Boca Raton, Florida, June 1-4, 1993.

Schulz, SC: "Schizophrenia". Ochsner Clinic Grand Rounds, New Orleans, LA, April 19-20, 1994

Schulz, SC: Schizophrenia: New Research and Treatment Strategies. MidMichigan Regional Medical Center, Midland, Michigan, May 5-6, 1994.

Schulz, SC, Woyshville, M. Depression and Co-morbid Disorders. Smith Kline Beecham Program. Portage Country Club, Philadelphia, PA, August 17, 1994.

Schulz, SC. Clinical Management and Outcome in Early Onset of Schizophrenia. University of Toronto, October 14, 1994.

Schulz, SC. Contemporary Issues in Depression, Stouffer's Tower City, Cleveland, OH, October 23, 1994.

Schulz, SC. Modern Trends in Psychiatry, Neighboring Mental Health Services of Lake County, Mentor, OH, October 25, 1994.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

SELECTED PRESENTATIONS (continued):

Schulz, SC. Recent Developments in Adolescent Psychiatry. Parmadale Training Community Center, Parma, OH, February 16, 1995

Schulz, SC. Adolescents and Depression. Psychiatric Society of Central Ohio; Harding Hospital, Worthington, OH, March 16, 1995.

Schulz, SC. Marcus Wallenberg Symposium towards a rational drug treatment of schizophrenia. Goteborg, Sweden, September 14-17, 1994.

Schulz, SC. Update Schizophrenia - 1994, Persistent psychosis - characteristics and treatment. University of Chicago, IL, November 12, 1994.

Rapoport J, Schulz SC. Why study teenagers with psychosis?. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December 12-16, 1994.

Schulz, SC. Neuroleptic Treatment in Children and Adolescents. Roundtable Symposium, Windsor Court Hotel, New Orleans, LA, March 3-4, 1995

Schulz SC. Imaging Studies on Adolescents with Schizophrenia and Bipolar Disorder. Stanley Foundation-supported satellite symposium, International Congress on Schizophrenia Research. Warm Springs, VA, April 8-12, 1995.

Schulz SC. Phase II and III Trials Results on Sertindole. Lundberg Foundation Symposium, 2nd Sertindole Consensus Meeting, Venice, Italy, September 27-October 5, 1995.

REFEREED SCIENTIFIC PUBLICATIONS:

1. Ashford W, Schulz SC, Walsh G: A case report: violent automatism in a partial complex seizure. Archives of Neurology, 37:120-122, 1980.
2. Schulz SC, Wagner R, van Kammen DP, Rogol AD, Davis GC, Wyatt RJ, Pickar D, Bunney WE Jr, Li CH: Prolactin response to beta-endorphin in man. Life Sci, 27:1735-1741, 1980.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

REFEREED SCIENTIFIC PUBLICATIONS (continued):

3. van Kammen DP, Docherty JP, Marder SR, Schulz SC, Bunney WE Jr: Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. Arch Gen Psych, 37:287-290, 1980.
4. Gillin JC, Schulz SC, van Kammen DP, Balow JE, Bunney WE: EEG sleep patterns in schizophrenic patients undergoing hemodialysis. Psych Res, 5:287-291, 1981.
5. Flye MW, Mundinger GH, Schulz SC, Karsh J, van Kammen DP: Successful creation of arteriovenous fistulae in non-uremic patients with heparin and aspirin therapy. Am J Surgery, 142:759-763, 1981.
6. Schulz SC, van Kammen DP, Buchsbaum MS, Roth RH, Alexander P, Bunney WE Jr: Gamma-hydroxybutyrate treatment of schizophrenia: A pilot study. Pharmacopsychiatry, 14:129-134, 1981.
7. Pickar D, Davis GC, Schulz SC, Extein I, Wagner R, Naber D, Gold PW, van Kammen DP, Goodwin FK, Wyatt RJ, Li CH, Bunney WE Jr: Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. Am J Psych, 138:2, 1981.
8. Schulz SC, van Kammen DP, Balow JE, Flye MW, Bunney WE Jr: Dialysis in schizophrenia: A double-blind evaluation. Science, 211:1066-1068, 1981.
9. Schulz PM, Schulz SC, Dibble E, Targum SD, van Kammen DP, Gershon ES: Patient and family attitudes about schizophrenia: implications for genetic counseling. Schizophrenia Bulletin, 8:504-513, 1982.
10. Schulz SC, van Kammen DP, Pickar D, Cohen MR, Naber D: Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. Psych Res, 7:171-178, 1982.
11. Targum SD, Schulz SC: Clinical applications of psychiatric genetics. Am J Orthopsych, 52:45-57, 1982.
12. van Kammen DP, Docherty JP, Marder SR, Schulz SC, Dalton L, Bunney WE Jr: Antipsychotic effects of pimozide in schizophrenia: Treatment response prediction with acute dextroamphetamine response. Arch Gen Psych, 39:261-266, 1982.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

REFEREED SCIENTIFIC PUBLICATIONS (continued):

13. Resnick RJ, Schulz PM, Schulz SC, Hamer R, Friedel RO, Goldberg SC: Borderline personality disorder: symptomatology and MMPI characteristics. J Clin Psych, 44:289-292, 1983.
14. Schulz SC, Koller M, Kishore P, Hamer R, Gehl J, Friedel RO: Ventricular enlargement in teenage patients with schizophrenia spectrum disorder. Am J Psychiatry, 140:1592-1595, 1983.
15. Hayes PE, Schulz SC: The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy, 3(2):101-117, 1983.
16. Kwentus J, Schulz SC, Hart R: Tardive dystonia, catatonia, and electroconvulsive therapy. J of Nerv and Mental Diseases, 172(3):171-173, 1984.
17. Domisse CS, Schulz SC, Narasimhachari N, Blackard WG, and Hamer RM: The neuroendocrine and behavioral response to dextroamphetamine in normal individuals. Biological Psych, 19(9):1305-1315, 1984.
18. Schulman A, Wetterberg L, Asaba H, Schulz SC, van Kammen DP, Meurice E, Nedopil N, Splendiani G: Hemodialysis in Chronic Schizophrenics. Arch Gen Psych, (letters to the editor), 41(8):817-719, 1984.
19. Hart R, Silverman J, Garrettson L, Schulz SC, Hamer R: Neuropsychological function following mild exposure to pentaborane. Am J Industrial Med, 6:37-44, 1984.
20. Schulz SC, Butterfield L, Garicano M, Narasimhachari N, Friedel RO: Beyond the therapeutic window: A case presentation. J of Clin Psych, 45(5):223-225, May 1984.
21. Silverman JJ, Hart R, Garrettson L, Stockman S, Hamer RM, Schulz SC, Narasimhachari N: Post-traumatic stress disorder from pentaborane intoxication: neuropsychiatric evaluation and short-term follow-up. JAMA, 254(18):2603-2608, 1985.
22. van Kammen DP, Schulz SC: d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment. J of Neural Trans, 64:35-43, 1985.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

REFEREED SCIENTIFIC PUBLICATIONS (continued):

23. Jennings WS, Schulz SC, Narasimhachari N, Hamer RM, Friedel RO: Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population. Psych Research, 16:87-94, 1985.
24. Schulz PM, Schulz SC, Hamer R, Resnick RJ, Friedel RO, Goldberg SC: The impact of borderline and schizotypal personality disorders on patients and their families. Hospital and Community Psych, 36(8):879-881, 1985.
25. Kwentus J, Schulz SC, Fairman P, Isrow L: Sleep apnea: A review. Psychosomatics, 26:9:713-724, September 1985.
26. Schulz SC, Schulz PM, Dommissie C, Hamer RM, Blackard WG, Narasimhachari N, Friedel RO: Amphetamine Response in Borderline Patients. Psych Research, 15:97-108, 1985.
27. Schulz SC: Use of low-dose neuroleptics in treatment of "schizo-obsessive" patients. Am J Psychiatry, (letter) 143:1318-1319, 1986.
28. Schulz PM, Schulz SC, Goldberg S, Ettigi PG, Resnick RJ, Friedel RO: Diagnoses of the relatives of schizotypal outpatients. J of Nervous and Mental Disease, 174:457-463, 1986.
29. Eaves LJ, Kendler KS, Schulz CS: The familial sporadic classification: Its power for the resolution of genetic and environmental etiologic factors. J Psych Research, 21:2:115-130, 1986.
30. Cornelius JR, Brenner RP, Soloff PH, Schulz SC, Tumuluru RV: EEG abnormalities in borderline personality disorder: Specific or non-specific. Biol Psych, 21:974-977, 1986.
31. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO: Borderline and schizotypal personality disorders treated with low dose thiothixene versus placebo. Arch of Gen Psych, 43:680-686, 1986.
32. Jennings WS Jr, Schulz SC: Psychopharmacologic treatment of schizophrenia: Developing a dosing strategy. Hospital Formulary, 21:332-346, 1986.
33. Munetz MR, Schulz SC: Minimization and over-reaction to tardive dyskinesia: Persistent and prevalent phenomena. Schizophrenia Bulletin, 12:(2)168-172, 1986.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

REFEREED SCIENTIFIC PUBLICATIONS (continued):

34. Munetz MR, Schulz SC: Screening for tardive dyskinesia. J Clin Psychiatry, 47:(2)75-77, 1986.
35. Davies MA, Munetz MR, Schulz SC, Bromet EJ: Assessing mental illness in SRO shelter residents. Hospital and Community Psychiatry, 38(10):1114-1116, 1987.
36. Zipursky RB, Schulz SC: Seasonality of birth and CT findings in schizophrenia. Biological Psychiatry, 22(10):1288-1292, 1987.
37. Hayes PE, Schulz SC: Beta-blockers in anxiety disorders. J of Affective Disorders, 13:119-130, 1987.
38. Schulz SC, Schulz PM, Wilson WH: Medication treatment of schizotypal personality disorder. J of Personality Disorders, 2:1-13, 1988.
39. Cornelius JR, Schulz SC, Brenner RP, Soloff PH, Ulrich RF: Changes in EEG mean frequency associated with anxiety and with amphetamine challenge in BPD. Biological Psychiatry, 24:587-594, 1988.
40. Goldberg SC, Schulz SC: Pharmacotherapy for Patients with Borderline Personality Disorder. Arch Gen Psych, (letters to the editor), 45(2):195-196, 1988.
41. Schulz SC, Cornelius J, Schulz PM, Soloff PH: The amphetamine challenge test in patients with borderline disorder. Am J Psychiatry, 145:809-814, 1988.
42. Cornelius JR, Soloff PH, George AV, Schulz SC, Tarter R, Brenner RP: An evaluation of the significance of selected neuropsychiatric abnormalities in the etiology of borderline personality disorder. Journal of Personality Disorders, 3(1): 19-25, 1989.
43. Davies MA, Bromet EJ, Schulz SC, Dunn LO, Morgenstern, M: Community adjustment of chronic schizophrenic patients in urban and rural settings. Hospital and Community Psychiatry, 40:824-830, 1989.
44. Munetz MR, Schulz SC, Bellin M, Harty I: Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Development Research, 16:79-83, 1989.
45. Schulz PM, Soloff PH, Kelly T, Morgenstern M, DiFranco R, Schulz SC: A family history study of borderline subtypes. J of Personality Disorders, 3:217-229, 1989.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

REFEREED SCIENTIFIC PUBLICATIONS (continued):

46. Shore DS, Lash L, Hadley S, Wagman A, Schulz SC: National Institute of Mental Health: Clinical research career opportunities. Academic Psychiatry, 14:1-8, 1990.
47. Kahn EM, Schulz SC, Perel JM, Alexander JE: Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology, 10:54-57, 1990.
48. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY: Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry, 148:1064-1067, 1991.
49. Davies MA, Conley RR, Schulz SC, Bell-Delaney J: One-year follow-up of 24 patients in a clinical trial of clozapine. Hospital and Community Psychiatry, 42:628-629, 1991.
50. Kahn EM, Munitz MR, Davies MA, Schulz SC: Akathisia: Clinical phenomenology and relationship to tardive dyskinesia. Comprehensive Psychiatry, 33:233-236, 1992.
51. Parsa MA, Mehregany D, Schulz SC: Psychiatric manifestation of sickle cell disease and findings on single photon emission computed tomography (letter). Psychosomatics, 33:239-241, 1992.
52. Friedman L, Lys C, Schulz SC: The relationship of structural brain imaging parameters to antipsychotic treatment response: a review. J Psychiatry Neurosci, 17:42-54, 1992.
53. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR: The impact of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162:43-48, 1993.
54. Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, Kleinman JE, Weinberger DR: Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. American Journal of Psychiatry, 150:1355-1362, 1993.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

REFEREED SCIENTIFIC PUBLICATIONS (continued):

55. Semple WE, Goyer P, McCormick R, Morris E, Compton B, Muswick G, Nelson D, Donovan B, Leisure G, Berridge M, Miraldi F, Schulz SC: Preliminary report: Brain blood flow using PET in patients with post traumatic stress disorder or substance abuse histories. Biological Psychiatry, 34:115-118, 1993.
56. Kruegelbach N, McCormick RA, Schulz SC, Grueneich R: Impulsivity, coping styles and triggers for craving in substance abusers with borderline personality disorder. Journal of Personality Disorders, 7:214-222, 1993.
57. Goyer PF, Andreason PJ, Semple WE, Clayton AH, King AC, Compton-Toth BA, Schulz SC, Cohen RM: Positron-Emission Tomography and Personality Disorders. Neuropsychopharmacology, 10:21-28, 1994.
58. Buckley P, Bartell J, Danenwirth K, Lee S, Torigoe F, and Schulz SC. Violence and Schizophrenia: Clozapine as a Specific Antiaggressive Agent. Bull Am Acad Psychiatry Law, 23(4):607-611, 1995.
59. Findling RL, Friedman L, Kenny JT, Swales TP, Cola DM, Schulz SC. Adolescent Schizophrenia: A Methodologic Review of the Current Neuroimaging and Neuropsychologic Literature. Journal of Autism & Developmental Disorders, 25(6):627-639, 1995.
60. Buckley PF, Schulz SC. What's new with the new drugs for schizophrenia? (Submitted).
61. Semple WE, Cohen RM, Nordahl TE, Zametkin AJ, King AC, Schulz SC, Goyer PF. Brain imaging methodology changes can confound psychiatric study outcomes: Modification of transmission scan attenuation correction method alters PET scan results. (Submitted)
62. Goyer, PF, Semple, WE, Morris, ED, Muswick, GJ, Compton, BA, Garnett, ML, Nelson, DA, Miraldi, F, Schulz, SC and Meltzer, HY. Effects of MK-212 on Regional Cerebral Blood Flow in Humans. (Submitted)

NONREFEREED SCIENTIFIC PUBLICATIONS:

1. Schulz SC, van Kammen DP: Methodological issues of hemodialysis in schizophrenia. Psychopharmacology Bulletin, 15(4):15-17, 1979.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

NONREFEREED SCIENTIFIC PUBLICATIONS (continued)

2. Balow JE, Schulz SC, van Kammen DP, Bunney WE Jr: Controlled trial of hemodialysis in schizophrenia. Proc Dialysis Transplant Forum, 10:203-206, 1980.
3. Schulz SC, van Kammen DP, Rogol AD, Ebert M, Pickar D, Cohen MR, and Naber D: Amphetamine increases prolactin but neither growth hormone nor beta-endorphin immunoreactivity in schizophrenic patients. Psychopharmacology Bulletin, 17:193-195, 1981.
4. Schulz SC, Koller M, Kishore P, Hamer R, Friedel RO: Abnormal CT scans in young schizophrenics. Psychopharmacology Bulletin, 18:163-164, 1982.
5. Schulz SC, Sinicrope P, Kishore P, Friedel RO: Treatment response and ventricular brain enlargement in young schizophrenic patients. Psychopharmacology Bulletin, 19(3):510-512, 1983.
6. van Kammen DP, Schulz SC, Balow JE, Zahn TP, Munding G, Flye MW, Bunney WE Jr: Failure of hemodialysis to diminish psychotic behavior in schizophrenia: Behavioral and psychophysiological evaluation. Artificial Organs, 7:310-316, 1983.
7. Schulz SC, van Kammen DP, Waters R, Klein HG, Balow JE, Bunney WE Jr: Double-blind evaluation of plasmapheresis in schizophrenic patients: A pilot study. Artificial Organs, 4:317-321, 1983.
8. Schulz SC, Goldberg SC: Is borderline personality disorder an illness? Psychopharmacology Bulletin, 20(3):554-560, 1984.
9. Schulz SC: CT scan studies in teenagers with schizophrenia. Highland Highlights, 11:6-12, 1986.
10. Goldberg SC, Schulz SC, Resnick RJ, Hamer RM, Schulz PM: Differential prediction of response to thiothixene and placebo in borderline and schizotypal personality disorders. Psychopharmacology Bulletin, 23:342-346, 1987.
11. Schulz SC, Cornelius J, Jarret DB, Schulz PM, Alexander J, Soloff PH: Pharmacodynamic probes in personality disorders. Psychopharmacology Bulletin, 23:337-341, 1987.
12. Shore D, Lash L, Schulz SC: Schizophrenia research career opportunities. Jefferson Journal of Psychiatry, 5:87-89, 1987.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

NONREFEREED SCIENTIFIC PUBLICATIONS (continued):

13. Shore D, Schulz SC: Hemodialysis: Still not an effective treatment for schizophrenia. Seminars in Dialysis, (editorial), 2:80-81, 1988.
14. Tarell JD, Schulz SC: Nursing assessment using the PBRS: A structured interview. Psychopharmacology Bulletin, 24:105-111, 1988.
15. Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA: Clozapine efficacy in schizophrenic nonresponders. Psychopharmacology Bulletin, 24:269-274, 1988.
16. Schulz SC: Personality disorders: An introduction. Psychopharmacology Bulletin, 25(4):505-507, 1989.
17. Konicki PE, Schulz SC: Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior. Psychopharmacology Bulletin, 25(4):556-63, 1989.
18. Schulz SC, Pato CN: Pharmacologic treatment of schizophrenia. Psychiatric Annals, 19:536-541, 1989.
19. Pato CN, Lander ES, Schulz SC: Prospects for the genetic analysis of schizophrenia. Schizophrenia Bulletin, 15:365-372, 1989.
20. Schulz SC, Pato CN: Advances in the genetics of schizophrenia: Editors' introduction. Schizophrenia Bulletin, 15:361-363, 1989.
21. Pato CN, Wolkowitz OM, Rapoport M, Schulz SC, Pickar D: Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacology Bulletin, 25(2):263-72, 1989.
22. Schulz SC: Clinical schizophrenia: Treatment, prognosis, and syndromes. Current Opinion in Psychiatry, 2:45-48, 1989.
23. Schulz SC, Omelsky P: Computerized tomography in adolescent schizophrenic patients. Carrier Foundation Letter, 151:1-2, 7, 1990.
24. Weiden P, Schooler RN, Severe JB, Lee JH, Schulz SC: Stabilization and depot neuroleptic dosages. Psychopharmacology Bulletin 29(2):269-275, 1993.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

NONREFEREED SCIENTIFIC PUBLICATIONS (continued):

25. Markovitz PJ, Schulz SC: Drug treatment of personality disorders (letter). Br Journal Psychiatry, 162:122, 1993.
26. Findling R, Grcevich SJ, Lopez I, Schulz SC. Antipsychotic Medications in Child & Adolescents. (in Press) Journal of Clinical Psychiatry.
27. Findling RL, Roth BL, Schulz SC. Risperidone: Broadening Clinical Indications. (Submitted).

BOOK CHAPTERS:

1. Kaye W, Schulz SC: Consultation to neurology: Brain, behavior, and patient care. In Contemporary Models of Liaison Psychiatry, Spectrum, chapter 14, pp 185-196, 1978.
2. Schulz SC, van Kammen DP, Fletcher JC: Dialysis for schizophrenia: Consent and costs. Hastings Center Report, pp 10-12, April 1979 and in: (Eds.) Levine C and Veatch RM, Cases in Bioethics from the Hastings Center Report, 1982.
3. van Kammen DP, Schulz SC, Rogol AD: Hormonal response to d-amphetamine in schizophrenia. In: (Eds.) Shah ED and Donald AG. Psychoneuroendocrine Dysfunction in Psychiatry and Neurological Illness: Influence of Pharmacological Agents, Plenum Publishing Corp., Ch. 30, pp 549-567, 1984.
4. Schulz SC, Reynolds CF: Sleep Disorders. In: (Eds.) Cavenar JO Jr. Psychiatry (Vol 2): Consultation-Liaison Psychiatry and Behavioral Medicine. J.B. Lippincott Co., Philadelphia, PA. Chapter 105, pp 1-18, 1985.
5. Schulz SC, House J, Andrews MB: Helping families in a schizophrenia program. In: (Eds.) Zucker Goldstein M. Family Involvement in the Treatment of Schizophrenia, American Psychiatric Press, Washington D.C., pp 19-34, 1986.
6. Bromiet EJ, Davies MA, Schulz SC: Basic principles of epidemiologic research in schizophrenia. In: (Eds.) MT Tsuang and JC Simpson. Handbook of Schizophrenia (Vol 3): Nosology, Epidemiology and Genetics of Schizophrenia. Elsevier Science Publishers, New York, 1988.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN [REDACTED]

BOOK CHAPTERS (continued):

7. Schulz SC, Koller MM: Schizophrenia and schizophreniform disorder. In: (Eds.) Hsu LK and Hersen M. Recent Developments in Adolescent Psychiatry, John Wiley & Sons, pp 289-308, 1989.
8. Keith SJ, Schulz SC, Shore D: Introduction: Biomedical models and schizophrenia research. In: (Eds.) Schulz SC and Tamminga CA. Schizophrenia: Scientific Progress, Oxford University Press, pp 3-12, 1989.
9. Schulz SC, Conley RR, Kann EM, Alexander J: Non-responders to neuroleptics: A distinct subtype. In: (Eds.) Schulz SC and Tamminga CA. Schizophrenia: Scientific Progress, Oxford University Press, pp 341-350, 1989.
10. Schulz SC, Kahn EM, Baker RW, Conley RR: Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In: (Eds.) Angrist B and Schulz SC. The Neuroleptic-Nonresponsive Patient: Characterization and Treatment, American Psychiatric Press, pp 111-136, 1990.
11. Angrist B, Schulz SC: The neuroleptic-nonresponsive patient: An introduction. In: (Eds.) Angrist B and Schulz SC. The Neuroleptic-Nonresponsive Patient: Characterization and Treatment, American Psychiatric Press, pp xvii-xxviii, 1990.
12. Schulz SC: Genetics of schizophrenia: A status report. In: (Eds.) Tasman A. and Goldfinger SM. The American Psychiatric Press Review of Psychiatry, Volume 10 American Psychiatric Press, pp 78-96, 1991.
13. Thaker G, Moran M, Lahti A, Adami H, Tamminga CA, Schulz SC: Pilot studies of schizotypal subjects. In (Eds.) Tamminga CA and Schulz SC. Schizophrenia Research: Advances in Neuropsychiatry and Psychopharmacology, Volume 1. Raven Press, New York, pp. 201-208, 1991.
14. Schulz SC, Sajatovic M: Typical antipsychotic medication: Clinical practice. In: (Ed.) Dunner DL. Current Psychiatric Therapy, W.B. Saunders Co., New York, pp 176-182, 1993.
15. Goyer PF, Konicki PE, Schulz SC: Brain Imaging in Personality Disorders. In: Biological and Neurobehavioral Studies of Borderline Personality Disorder (eds) Silk KR. American Psychiatric Press, Inc., Washington, D.C., pp. 109-125, 1994.

Curriculum Vitae
SCHULZ, S. CHARLES II

SSN REDACTED

BOOK CHAPTERS (continued):

16. Schulz SC: Schizophrenia: Somatic Treatment. In (Eds.) Kaplan HI and Sadock BJ. Comprehensive Textbook of Psychiatry/VI, Williams and Wilkins, Baltimore, Maryland, 14:987-994, 1995.
17. Schulz SC, Buckley P: Treatment Resistant Schizophrenia - Concepts, Characteristics, and Management. In: Schizophrenia (eds) Hirsch SR, Weinberger DR., 24:469-484, 1995.

SPECIAL EDITIONS

Issue Editor, Schizophrenia Bulletin, Advances in the Genetics of Schizophrenia, 15(3), 1989.

Special Guest Editor, Psychopharmacology Bulletin, Special Feature: Personality Disorders, 25(4), 1989.


Guest Editor, The Psychiatric Clinics of North America, Schizophrenia, 16, 1993.

BOOKS

Schulz SC, Tamminga CA: Schizophrenia: Scientific Progress. Oxford University Press, New York, N.Y. 1989.

Angrist B, Schulz SC: The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. American Psychiatric Press, Washington DC, 1990.

Tamminga CA, Schulz SC: Schizophrenia Research: Advances in Neuropsychiatry and Psychopharmacology, Volume 1. Raven Press, New York, N.Y. 1991.

DISPLAY THIS CERTIFICATE PROMINENTLY • NOTIFY AGENCY WITHIN 10 DAYS OF ANY CHANGE			
Commonwealth of Pennsylvania Department of State Bureau of Professional and Occupational Affairs P.O. BOX 2649, Harrisburg, PA 17105-2649			
Classification			
MEDICAL PHYSICIAN AND SURGEON			
Certificate Number	Certification Date	Issued	Expires
REDACTED	DEC 23 1983	DEC 31 1996	DEC 31 1998
Signature  Commissioner of Professional and Occupational Affairs		Issued To: SELLMAN CHARLES SCHULZ II CWRU/UHC 2074 ABINGTON ROAD CLEVELAND OH 44106	
ALTERATION OF THIS DOCUMENT IS A CRIMINAL OFFENSE UNDER 18 P.S. 3901			

Please notify the board in writing, of any change in your address.

Please refer to your license number on all correspondence with the board.

Ohio law requires that every physician's wall certificate be displayed in the physician's office where a major portion of such physician's practice is conducted.

SELLMAN CHARLES SCHULZ II, MD
CWRU DEPT OF PSYCHIATRY
11100 EUCLID AVE
CLEVELAND OH 44106

STATE MEDICAL BOARD OF OHIO

77 S. High St., Columbus, Ohio 43268-0315

EXPIRES: 09/30/98

LICENSE NUMBER

REDACTED

1
9
9
6



Celebrating
100 Years
1896-1996

1
9
9
8

SELLMAN CHARLES SCHULZ II, MD

is duly registered and entitled to practice in The State of Ohio
until the expiration date

AUDIT #: 007077

CURRICULUM VITAE
ROBERT GABRIEL STERN, M.D.

Address		REDACTED
Medical School	1977-1984	Sackler School of Medicine, University of Tel-Aviv, Israel.
M.D. License		New York State REDACTED
Boards	1995	Diplomat REDACTED American Board of Psychiatry and Neurology, Added Qualification in Geriatric Psychiatry
	1993	Diplomat REDACTED American Board of Psychiatry and Neurology
Honors	1992	First prize winner of the 1992 American Psychiatric Association, New York County District Branch - APA Residents Research Awards.
	1992	The 1992 Marcel Heiman Memorial Award for Outstanding Research, the Mount Sinai Medical Center, Department of Psychiatry.
Grant Support	1995-1996	Principal Investigator, grant by Janssen Pharmaceutica Inc for the RIS-USA-72 "Safety and efficacy of Risperidone 8mg qd and 4mg qd compared to placebo in the treatment of schizophrenia".
	1995-1996	Co-Investigator, grant by Abbott Laboratories for the study M94-222 "An open-label assessment of the long-term safety of Sertindole"
	1995-1996	Principal Investigator, grant by Hoechst Roussel Pharmaceuticals Inc. for the study HRPI-3003 "A study of the efficacy of 4mg BID and 8 mg QD Iloperidone (HP 873) administered to schizophrenic and schizoaffective patients for 42 days followed by open label treatment for one year".
	1996	Principal Investigator, grant by Zeneca Pharmaceuticals for the study Seroquel™ "Seroquel Health Outcomes Protocol 5077IL/0056".
	1996	Co-Principal Investigator, grant by Abbott Laboratories for the study M94-192 "An open label assessment of the long term safety of Sertindole in the treatment of patients with schizophrenia"
	1990-1994	Co-Investigator at the "Schizophrenia biological research center", Bronx VAMC and Mount Sinai School of Medicine
	1990-1994	Co-Investigator at the "Alzheimer disease research center", Mount Sinai Medical Center and Bronx VAMC
Membership		American Psychiatric Association
Editorial Peer Reviewer		The Federal Practitioner, Psychiatric Services
<u>Academic Appointment</u>		
Assistant Professor	1995-present	Department of Psychiatry, Mount Sinai School of Medicine, New York, New York
Training Director	1997-	Director, Fellowship Training Program, Department of Psychiatry, Mount Sinai School of Medicine

Stern, R.G., C.V.

Hospital Appointments

Director	1997-	Director, Schizophrenia Treatment and Research Program (STAR), Mental Health PCC, Bronx VA Medical Center, Bronx, NY
STAR Program		
Chief, Clin. Research	1995-1997	Chief of clinical research, Psychiatry Service, F.D.R. Montrose VA Hospital, Montrose, NY
Unit Chief	1995-1996	Unit 13AB, Open In-patient schizophrenia service, F.D.R. Montrose VA Hospital, Montrose, NY
Assistant Unit Chief	1994-1995	Geriatric Psychiatry Admission & Research Unit, F.D.R. Montrose VA Hospital, Montrose, NY
Committee Member	1997-	Education Committee, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY
	1995-1997	Pharmacy and Therapeutics Committee, F.D.R. Montrose V.A. Hospital, Montrose, N.Y.
	1995-1997	Investigational Review Board, F.D.R. Montrose V.A. Hospital, Montrose, N.Y.
	1994-1995	Long Term Care Committee, F.D.R. Montrose V.A. hospital, Montrose, N.Y.
	1994-1995	Long Term Care Committee, F.D.R. Montrose V.A. hospital, Montrose, N.Y.
Task Force Chair	1994-1995	Task force on the chronically institutionalized psychiatric patients, F.D.R. Montrose V.A. hospital, Montrose, N.Y.

Private Practice

1995- present	Faculty Practice Associates, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York

Training Record

Fellow	1993-94	Geriatric Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
Fellow	1992-93	Schizophrenia Research, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
Psychotherapy	1989-1994	Dynamic psychotherapy, training and supervision, Division of Psychotherapy, Department of Psychiatry, Mount Sinai School of Medicine New York, NY.
	1992	Brief cognitive behavioral psychotherapy, training and supervision, Beith Israel Medical Center Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
Chief Resident	1990-1991	Psychiatric Research Unit, Bronx VA Medical Center, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
Psychiatry Resident	1988-1990	Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
	1986-1988	The Abarbanel Mental Health Center, Bat-Yam, University of Tel-Aviv, Israel.
Rotating Internship	1985	The Edith Wolfson Medical Center, Holon, University of Tel-Aviv, Israel.

Stern, RG., C.V.

PUBLICATIONS:

1. Davidson M, Stern RG, Bierer LM, Markofsky R, Mohs RC.: Cholinergic strategies in the treatment of Alzheimer's disease. Acta Psychiatrica Scandinavica. 1991; Suppl 366: 47-51.
2. Herman C, Stern RG, Losonczy MF, Jeff S, Davidson M.: Diagnostical and pharmacological approaches in Alzheimer's disease. Drugs & Aging. 1991; 1:144-162.
3. Davidson M, Stern RG.: The treatment of cognitive impairment in Alzheimer's disease: Beyond the cholinergic approach. Psychiatric Clinics of North America 1991; 14:461-482.
4. Stern RG, Duffelmeyer ME, Zemishlani Z, Davidson M.: The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatric Clinics of North America 1991; 14:375-384.
5. Stern RG, Hermann CH, Davidson M.: Pharmacological approaches in Alzheimer's disease. New Ethics 1991:119-133.
6. Kahn RS, Davidson M, Hirschowitz J, Stern RG, Moore C, Davis KL.: Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatry Research 1992; 41:155-161.
7. Stern RG, Mohs RC, Bierer L, Silverman J, Schmeidler J, Davidson M, Davis KL.: Deterioration on the Blessed Test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Research 1992;42:101-110.
8. Stern RG, Mohs RC.: Deterioration on the Blessed Test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes. The authors reply. Psychiatry Research 1992; 42:253.
9. Davidson M, Kahn RS, Stern RG, Harvey PD, Keefe R, Knott P, Apter S, Webster L, Davis KL.: Measurements of plasma homovanillic acid in schizophrenic patients. Clin-Neuropharmacol. 1992; 15 Suppl: 521A-522A
10. Kahn RS, Siever L, Gabriel S, Amin F, Stern RG, DuMont K, Apter S, Davidson M.: Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Research 1992; 43:1-12.
11. Davis KL, Thal LJ, Gamzu ER, et al. and the Tacrine collaborative study group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New England Journal of Medicine 1992; 327:1253-1259.
12. Stern RG, Kahn RS, Davidson M.: Predictors of response to neuroleptic treatment in schizophrenia. Psychiatric Clinics of North America 1993; 16:313-338.
13. Stern RG, Kahn RS, Harvey PD, Amin F, Apter SH, Hirschowitz J.: Early response to haloperidol treatment in chronic schizophrenia. Schizophrenia Research 1993; 10:165-171.
14. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter SA, Knott P, Davis KL.: Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research 1993; 46:151-163.
15. Kahn RS, Davidson M, Knott P, Stern RG, Apter SA, Davis KL.: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolites concentrations in

Stern, RG., C.V.

- schizophrenia: serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 1993; 50:599-605.
16. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Markofsky RE, Kaminsky R, Schmeidler J, Davis KL.: A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer's disease. Alzheimer's disease and related disorders 1993; 7:98-101.
 17. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL.: A longitudinal study of alzheimer's disease: measurement, rate and predictors of cognitive deterioration. American Journal of Psychiatry 1994; 151:390-396.
 18. Stern RG, Kahn RS, Davidson M, Davis KL.: Early response to clozapine in schizophrenia. American Journal of Psychiatry 1994; 151:1817-1818.
 19. Amin F, Davidson M, Kahn RS, Schmeidler J, Stern RG, Knott P, Apter S, Davis KL.: Assessment of the central dopaminergic index of plasma homovanillic acid in schizophrenia. Schiz Bull 1995; 21:53-66.
 20. Stern RG, Schmeidler J, Davidson M.: Augmentation drug trials in schizophrenia: limitations of the statistical design. Biological Psychiatry 1997; 42:138-143.

BOOK CHAPTERS

1. Stern RG, Davis KL.: Treatment approaches in Alzheimer's disease: the past, the present and the future. In: The Dementias: Diagnosis and Management. Weiner M, ed. American Psychiatric Association Press, Washington DC, 1991.
2. Stern RG, Davis KL.: The treatment of cognitive impairment in Alzheimer's disease, in Principles of Pharmacology: Basic Concepts and Clinical Applications. Munson P, Mueller R, and Breese G. editors, p1727-1751, Chapman & Hall Publishers, 1995.
3. Stern RG, Davis KL.: Pharmacological approaches to the treatment of cognitive impairment in Alzheimer's disease. In: The Dementias: Diagnosis, Management and Research. Weiner M, ed. 2nd Ed. American Psychiatric Association Press, Washington DC, 1996.
4. Weiner M, Schneider LS, Gray KF, Stern RG.: Pharmacological management and treatment of dementia and secondary symptoms. In: The Dementias: Diagnosis, Management and Research. Weiner M, ed. 2nd Ed. American Psychiatric Association Press, Washington DC, 1996.
5. Kahn RS, Stern RG, Davidson M.: [Predicting outcome of antipsychotic medication in schizophrenia patients] Dutch, in: Schizofrenie. Onderzoek en implicaties voor der behandeling. Dingemans PMAJ, van den Bosch RJ, Kahn RS, Schene AH, editors. Bohn Stafleu Van Loghum, Houten/Diegem 1995.
6. Stern RS, Kahn RS, Davidson M.: A selective review of studies on plasma homovanillic acid in schizophrenia. In: Plasma HVA in schizophrenia. Amin F, ed. American Psychiatric Association Press, Washington DC, 1997.
7. Stern RG, Mohs RC.: A longitudinal study on the pattern and the predictors of cognitive deterioration in Alzheimer's disease. The Digests PMSI / Bugamor. The Netherlands, in press.

CUT OFF THIS STRIP

READ
INSTRUCTIONS

ON REVERSE
SIDE

The University of the State of New York

THIS IS TO CERTIFY THAT QUALIFICATIONS FOR PROFESSIONAL
PRACTICE IN NEW YORK STATE HAVING BEEN APPROVED

THE STATE EDUCATION DEPARTMENT

HAS REGISTERED

STERN ROBERT GAURIEL

REDACTED

FOR PRACTICE IN NEW YORK STATE AS A (N)

PHYSICIAN

04/30/00

REGISTRATION PERIOD ENDS

SIGNATURE OF REGISTRANT

LICENSE/CERTIFICATE NO

COMMISSIONER OF
EDUCATION

REGISTRATION CERTIFICATE ... NOT A LICENSE

358452

READ
INSTRUCTIONS

ON REVERSE
SIDE

7-046842

CUT OFF
THIS STRIP

CUT OFF
THIS STRIP

CURRICULUM VITAE

Name: Stephen M. Strakowski, MD

Address: University of Cincinnati College of Medicine
231 Bethesda Ave., P.O. Box 670559,
Cincinnati, Ohio 45267

Date of Birth: October 16, 1961

Place of Birth: Elkhart, Indiana

Education:

1984 B.S.E. University of Notre Dame, Notre Dame, IN

1988 M.D. Vanderbilt University School of Medicine, Nashville, TN

Post-Graduate Training:

Internship & Residency:

1988-1989 Categorical Internship, McLean Hospital, Belmont,
Massachusetts

1989-1992 Resident in Adult Psychiatry, McLean Hospital, Belmont,
Massachusetts

Research Training:

1984-1986 Medical Scientist Training Program Fellow, Vanderbilt
University, Dept. of Physiology & Biophysics, Nashville,
Tennessee

1989-1992 Co-investigator, McLean First Episode Psychosis Project,
McLean Hospital, NIMH grant #MH-48444, Belmont,
Massachusetts

1990-1992 Co-principal investigator of Positron Emission Tomography in
the Collaborative Biological Research in Schizophrenia
Program, NIMH grant #MH-31154, McLean Hospital,
Belmont, Massachusetts

Licensure:

1989-1992 Massachusetts License Registration

1992- Ohio License Registration, No. REDACTED

1993- American Board of Psychiatry and Neurology, No. REDACTED

C.V.: Stephen M. Strakowski, MD

2

Academic Appointments:

1988-1992	Clinical Fellow in Adult Psychiatry, Harvard University Medical School, Boston, Massachusetts
1992-	Research Affiliate in Psychiatry, Psychotic Disorders Program, McLean Hospital, Belmont, Massachusetts
1992-1995	Assistant Professor of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio
1995-	Associate Professor of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio

Hospital Appointments:

1990-1992	Consulting Psychopharmacologist, Human Resource Institute, Lawrence, Massachusetts
1991-1992	Chief Resident, Psychotic Disorders Program, McLean Hospital, Belmont, Massachusetts
1992-	Attending Psychiatrist, University of Cincinnati Hospital, Cincinnati, Ohio
1993-	Attending Psychiatrist, Veterans Administration Medical Center, Cincinnati, Ohio
1994-	Consultant, Children's Hospital Medical Center, Cincinnati, Ohio
1994-	Senior Consulting Psychiatrist, Ohio Department of Mental Health, the Pauline Warfield Lewis Center, Cincinnati, Ohio

Awards and Honors:

1982-	Tau Beta Pi (Engineering) Honor Society, University of Notre Dame
1983-	Delta Delta Delta (Premedical) Honor Society, University of Notre Dame
1984	Summa Cum Laude, Bachelor of Science and Engineering, University of Notre Dame
1987	Letter of Commendation, Department of Psychiatry Vanderbilt University School of Medicine
1987	Alpha Omega Alpha Society, Vanderbilt University S.O.M.
1990	Outstanding Resident Award, National Inst. of Mental Health
1992	Laughlin Fellowship Award, American College of Psychiatrists
1992	Resident Research Award, American Psychiatric Association/Dista Products
1992	The 1992 Stanley Cobb Award, Honorable Mention; the Boston Society of Neurology & Psychiatry
1992	Honorable Mention, New Research competition, Schizophrenia

C.V.: Stephen M. Strakowski, MD

3

1992, Vancouver, British Columbia

Major Committee Assignments:

McLean Hospital:

1989-1990 Committee on Hospital Admissions
(Review problems associated with hospital admissions)

University of Cincinnati College of Medicine:

1993-1994 Library Advisory Committee
(Develop information resource management)
1995- Committee on Research
(Develop University research programs)

Department of Psychiatry:

1992-1994 Psychiatric Emergency Service Executive Committee,
(Review psychiatric emergency service activity)
1992-1993 Committee of Disaster Response
(Develop protocol for psychiatric response to natural
disasters in Tri-State area)
1992- Research Committee; Chair 1992-
(Develop research plan for the Department)
Continuing Education Committee
(Coordinate and design CME activities)
Residency Selection Committee
(Interview and evaluate resident applicants)
1993- Practice Management Planning Committee
(Integrate departmental practice with UC Medical Center)
Committee on Computing Resource; Chair 1993-
(Management of computer resources within department)

Editorial Boards:

1992- Reviewer, Psychiatry Research
1994- Reviewer, International Journal of Psychiatry in Medicine
1994- Reviewer, Schizophrenia Research
1995- Reviewer, Journal of Psychiatric Research
1996- Reviewer, American Journal of Psychiatry

Other Professional Activities:

C.V.: Stephen M. Strakowski, MD

4

1991	Rater, DSM-IV Field Trial for Schizophrenia and Other Psychotic Disorders, McLean Site, Belmont MA
1993-	Reviewer, American Psychiatric Association Practice Guidelines for Bipolar Disorder
1994	Site Coordinator, DSM-IV General Reliability Field Trials: Expert Phase; American Psychiatric Association
1995-	Departmental Liason, Office of Psychiatric Research Resource Center, American Psychiatric Association
1996-	External Reviewer, Merit Review Grant Program, U.S. Department of Veterans Affairs

Professional Societies:

1989-	American Association for the Advancement of Science
1989-1993	American Psychiatric Association
1990-1992	Massachusetts Psychiatric Association
1992-1993	Ohio Psychiatric Association, Cincinnati Chapter
1992-	American Medical Association
1993-	Society of Biological Psychiatry

Major Research Interests:

1. Substance abuse comorbidity and outcome of new-onset psychosis
2. Behavioral sensitization as a model for psychiatric disorders
3. The influence of race on diagnosis in psychosis
4. Neuroanatomic abnormalities in bipolar disorder using MRI

Principal Clinical & Hospital Service Responsibilities:

1992-	Director, Division of Psychotic Disorders Research, Biological Psychiatry Program, University of Cincinnati College of Medicine, Cincinnati, Ohio
1992-1994	Attending Psychiatrist, Psychiatric Emergency Service, University of Cincinnati Hospital, Cincinnati, Ohio
1993-1995	Assistant Director, Biological Psychiatry Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
1993-	Resident Research Curriculum Coordinator, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio
1994-	Co-Director, Inpatient Psychobiology Research Unit, University of Cincinnati Hospital, Cincinnati, Ohio

Teaching Experience:

C.V.: Stephen M. Strakowski, MD

5

- 1991-1992 Supervision of medical students and residents in the psychopharmacologic management of psychotic disorders, McLean Hospital
- 1992-1994 Supervision of medical students and residents in the emergency management of psychiatric patients, University of Cincinnati Hospital
- 1992 Emergency psychiatry: Complex clinical problems. American Psychiatric Association Annual meeting, San Francisco, CA; May 25, 1993; Course #98: .
- 1993- Supervision of medical students and residents in the psychopharmacologic management of psychiatric outpatients, Department of Psychiatry, University of Cincinnati College of Medicine
- 1994- Supervision of medical students and residents in inpatients psychiatry, University of Cincinnati Hospital

Course Developer & Course Director:

- 1990-1992 Course developer: "The Diagnosis and Treatment of Psychotic Disorders," Third-year Medical student course, Harvard Medical School, McLean Hospital. This course received consistently high student ratings.
- 1992- Course developer: "The Diagnosis and Treatment of Psychotic and Affective Disorders," Third-year Medical student course, University of Cincinnati College of Medicine.
- 1992- Course developer: "The Reading, Writing, and Research Workshop for Residents and Fellows," University of Cincinnati College of Medicine
- 1993- Course director: "Research methods in psychiatry", second-year psychiatry resident course, University of Cincinnati College of Medicine

Course Participant:

- 1990-1992 Lecturer in Emergency Psychiatry Resident Lecture Series, McLean Hospital
- 1991-1992 Lecturer in Advanced Psychopharmacology for Residents, McLean Hospital
- 1991-1992 Tutor for Medical Student II Course "The Psychiatric Interview," Harvard Medical School McLean Hospital
- 1993 Lecturer in Pharmacology Course "Psychopharmaceuticals", Department of Family Practice, University of Cincinnati College of Medicine
- 1993- Lecturer in Advanced Psychopharmacology Resident Seminar,

C.V.: Stephen M. Strakowski, MD

6

- 1993- University of Cincinnati College of Medicine
Lecturer in Psychiatry/Neuroscience Core Curriculum, Second Year, University of Cincinnati College of Medicine
- 1993- Alternate group leader Psychiatry Core Curriculum, First Year, University of Cincinnati College of Medicine
- 1993- Lecturer in Introduction to Psychiatry Course for First Year Residents, University of Cincinnati College of Medicine
- 1996- Seminar for Senior Residents and Fellows, "Neuroimaging in Psychiatry", University of Cincinnati College of Medicine.

Invited Lecture/Grand Rounds (CME):

- 1992 "Neuroanatomic Abnormalities in First-Episode Mania," McLean Hospital, Belmont, MA
"Munchausen Syndrome," Department of Anesthesiology, Massachusetts General Hospital, Boston, MA
"Comorbidity in First-Episode Psychosis," Dept. of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH
- 1993 "The Treatment of Insomnia," Hamilton-Fairfield Academy of Medicine, Hamilton, OH
"The Pharmacokinetics of the SSRIs," Miami Valley Pharmaceutical Association, Dayton, OH
- 1994 "Treating Psychosis with Atypical Antipsychotic Agents," Andrew McFarland Mental Health Hospital, Springfield, IL
"Serotonin Re-uptake Inhibitors," Dept. of Physical Medicine & Rehabilitation, Ohio State Univ. College of Medicine, Columbus, OH
"Obsessive-Compulsive Disorder," Clermont County Medical Society, Cincinnati, OH
"The Treatment of Bipolar Disorder," Blanchfield Army Community Hospital, Ft. Campbell, KY
"Treatment of Obsessive-Compulsive Disorder," Huntington Physicians Society, Huntington, WV
"The Management of Bipolar Disorder," Ohio Dept. of Mental Health, Columbus, OH
"Diagnosing Depression and the Agents Used for Treatment," Upper Valley Medical Centers, Troy, OH
"The Atypical Antipsychotics," Logansport State Hospital, Logansport, IN
"The Diagnosis & Treatment of OCD," Kettering Medical Center, Kettering, OH
"New Management Options of Bipolar Disorder," Massillon Psychiatric Hospital, Massillon, OH
"The Diagnosis & Treatment of Bipolar Disorder," North

C.V.: Stephen M. Strakowski, MD

7

- Mississippi Medical Center, Tupelo, MS
- "Racial Differences and Bias in the Diagnosis of Psychosis,"
Department of Psychiatry, University of Kentucky,
Lexington, KY
- 1995 "Racial Bias in the Diagnosis of Psychosis", Dept. of Psychiatry,
University of Cincinnati College of Medicine, Cincinnati, OH
- "The Diagnosis and Treatment of Geriatric Depression," St.
Elizabeth's Hospital, Wright State University, Dayton, OH
- "Race Bias in Psychosis", Dayton Mental Health Center, Wright
State University, Dayton, OH
- "Race Bias and Differences in Psychosis", Southeastern Ohio
Psychiatric Center, Ohio University, Athens, OH
- "Progress in Bipolar Disorder," St. Louis University, St. Louis,
MO
- 1996 "The University of Cincinnati First-Episode Psychosis Project,"
McLean Hospital, Harvard University, Belmont, MA

Other Teaching Experience & Invited Lectures (CME):

- 1993 "Update on the Treatment of Bipolar Disorder," Regional
Symposium, Department of Psychiatry, University of
Cincinnati College of Medicine, Cincinnati, OH
- 1994 "Managing Behavioral Issues in Your Medical Practice:
For Primary Care Physicians," Regional Symposium,
Department of Family Practice, University of Cincinnati,
Cincinnati, OH
- "Psychiatric Disorders in Primary Care, Regional
Symposium," Department of Psychiatry, University of
Kentucky, Lexington, KY
- "Managing Behavioral Issues in Your Medical Practice:
For Primary Care Physicians," Regional Symposium, Dayton,
OH
- "Improving Outcomes in Bipolar Disorder, Regional
Symposium," Missouri Institute of Mental Health, University
of Missouri, St. Louis, MO
- 1995 "Health Care for an Aging Population: Challenges and
Solutions," Dayton VAMC, Wright State University, Dayton,
OH
- 1996 "The Manic-Depressive Spectrum: Evolution and Imagination,"
the University of Cincinnati College of Medicine, Cincinnati,
OH
- "Research Advances in Bipolar Disorder," the Florida Hospital
Center for Psychiatry, Orlando, FL

C.V.: Stephen M. Strakowski, MD

8

Bibliography:

Original Peer-Reviewed Articles:

1987

1. Strakowski SM, Butler MG: Paternal hydrocarbon exposure in Prader-Willi syndrome. *The Lancet*, Dec. 19:1458, 1987.

1988

2. Strakowski SM, Butler MG, Cheek JW, Moore WT, Netterville JL, Phillips JA, III: Familial laryngeal web in three generations with probable autosomal dominant transmission. *Dysmorph Clin Gen* 2:9-12, 1988.

1991

3. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C: Episode sequence in bipolar disorder and response to lithium treatment. *Am J Psychiatry* 148:1237-1239, 1991.
4. Strakowski SM, Hudson JI, Keck PE, Wilson DR, Frankenburg F, Alpert JE, Teschke G, Tohen M: Four cases of obstructive sleep apnea associated with treatment resistant mania. *J Clin Psychiatry* 52:156-158, 1991.

1992

5. Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM: The McLean first-episode psychosis project: Six month recovery and recurrence outcome. *Schizophrenia Bull*, 18(2):271-282, 1992.
6. Strakowski SM, Faedda GL, Tohen M, Goodwin DC, Stoll AL: Possible affective state dependence of the tridimensional personality questionnaire in first-episode psychosis. *Psychiatry Res*, 41:215-226, 1992.
7. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC: Comorbidity in mania at first hospitalization. *Am J Psychiatry*, 149:554-556, 1992.

1993

8. Strakowski SM, Stoll AL, Tohen M, Faedda GL, Goodwin DC: The

C.V.: Stephen M. Strakowski, MD

9

tridimensional personality questionnaire as a predictor of six-month outcome in first-episode mania. *Psychiatry Res*, 48:1-8, 1993.

9. Strakowski SM, Woods BT, Tohen M, Wilson DR, Douglass AW, Stoll AL: MRI signal hyperintensities in mania at first hospitalization. *Biol Psychiatry*, 33:204-206, 1993.
10. Strakowski SM, Shelton RC, Kolbrener ML: The effects of race and comorbidity on clinical diagnosis in patients with psychosis. *J Clin Psychiatry*, 54:96-102, 1993.
11. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL: Structural brain abnormalities in mania at first hospitalization. *Biol Psychiatry*, 33:602-609, 1993.
12. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, Goodwin DC: Comorbidity in psychosis at first hospitalization. *Am J Psychiatry*, 150:752-757, 1993.

1994

13. McElroy SL, Keck PE, Pope HG, Smith JM, Strakowski SM: Compulsive buying: a report of 20 cases. *J Clin Psychiatry*, 55:242-248, 1994.
14. Strakowski SM: Diagnostic validity of schizophreniform disorder. *Am J Psychiatry*, 151:815-824, 1994.
15. Greenfield SF, Strakowski SM, Tohen M, Batson SC, Kolbrener ML: Childhood abuse in first-episode psychosis. *Br J Psychiatry*, 164:831-834, 1994.
16. Keck PE, Jr., McElroy SL, Strakowski SM, West SA: Pharmacologic treatment of schizoaffective disorder. *Psychopharmacology*, 114:529-538, 1994.
17. Strakowski SM, McElroy SL, Keck PE, Jr, West SA: The co-occurrence of mania with medical and other psychiatric disorders. *Internat J Psychiatry Med*, 24:305-328, 1994.
18. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM: Neurological factors predict a favorable valproate response in bipolar and schizoaffective disorders. *J Clin Psychopharmacol*, 14:311-313, 1994.

C.V.: Stephen M. Strakowski, MD

10

19. Strakowski SM, Tohen M, Flaum M, Amador X and the DSM-IV Field Trial for Schizophrenia and Other Psychotic Disorders Work Group: Substance abuse in psychotic disorders: associations with affective syndromes. *Schizophrenia Res*, 14:73-81, 1994.
20. Keck PE Jr., Merikangas KR, McElroy SL, Strakowski SM: Diagnostic and treatment implications of psychiatric comorbidity with migraine. *Ann Clin Psychiatry* 6:165-171, 1994.
21. West SA, Keck PE Jr., McElroy SL, Strakowski SM, Minnery KL, McConville BJ, Sorter MT: Open trial of valproate in the treatment of adolescent mania. *J Adol Child Psychopharm* 4:263-267, 1994.
22. Dwight MM, Keck PE, Jr., Stanton SP, Strakowski SM, McElroy SL: Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. *The Lancet* 344:554-555, 1994.

1995

23. West SA, McElroy SL, Strakowski SM, Keck PE, Jr, McConville BJ: The co-occurrence of attention-deficit hyperactivity disorder in adolescent mania. *Am J Psychiatry*, 152:271-273, 1995.
24. Strakowski SM, Keck PE Jr, McElroy SL, Lonczak HS, Tugrul KL, West SA: Chronology of comorbid and principal syndromes in first-episode psychosis. *Compr Psychiatry*, 36:106-112, 1995.
25. Strakowski SM, Lonczak HS, Sax KW, West SA, Crist A, Mehta R, Thienhaus OJ: The effects of race on diagnosis and disposition from a psychiatric emergency service. *J Clin Psychiatry*, 56:101-107, 1995.
26. Sax KW, Strakowski SM, McElroy SL, Keck PE, Jr, West SA, Stanton S: Differences in sustained attention and formal thought disorder between mixed and pure mania. *Biol Psychiatry*, 37:420-423, 1995.
27. Keck PE, Jr, McElroy SL, Strakowski SM, West SA, Hawkins JM, Huber TJ, Newman RM, DePriest M: Outcome and comorbidity in first-compared with multiple-episode mania. *J Nerv Ment Dis*, 183:320-324, 1995.
28. McElroy SL, Strakowski SM, Keck PE Jr., Tugrul KL, West SA, Lonczak HS: Differences and similarities in mixed and pure mania. *Comprehensive Psychiatry*, 36:187-194, 1995.

C.V.: Stephen M. Strakowski, MD

11

29. West SA, Strakowski SM, Sax KW, Minnery KL, McElroy SL, Keck PE, Jr.: The comorbidity of attention-deficit hyperactivity disorder in adolescent mania: Potential diagnostic and treatment implications. *Psychopharm Bull*, 31:347-351, 1995.
30. Hawkins, JM, Archer KJ, Strakowski SM, Keck PE Jr.: Somatic treatments of catatonia. *Int J Psychiatry Med*, 25:335-359, 1995.
31. Strakowski SM, Dunayevich E, Keck PE, Jr., McElroy SL: Affective state dependence of the Tridimensional Personality Questionnaire. *Psychiatry Res*, 57:209-214, 1995.
32. Keck PE, Jr., Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balestreri TM, Holtman HM, DePriest M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. *J Clin Psychiatry*, 56:466-470, 1995.

1996

33. Sax KJ, Strakowski, SM, Keck PE Jr., Upadhyaya V, West SA, McElroy SL: Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. *Br J Psychiatry*, 168: 68-71 1996.

Accepted for Publication

34. West SA, Sax KW, Keck PE, Jr., Stanton SP, Strakowski SM, McElroy SL: Differences in thyroid function studies in acutely manic adolescents with and without ADHD. *Psychopharm Bull*, in press
35. Keck PE, Jr., McElroy SL, Strakowski SM, Balestreri TM, Kizer DL, West SA: Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. *J Clin Psychiatry*, in press.
36. Strakowski SM, McElroy SL, Keck PE Jr., West SA: The effects of antecedent substance abuse on the development of first-episode psychotic mania. *J Psychiatry Res*, in press
37. Strakowski SM, Sax KW, Setters MJ, Keck PE, Jr.: Enhanced response to repeated d-amphetamine challenge: Evidence for behavioral sensitization in humans. *Biol Psychiatry*, in press.
38. West SA, Strakowski SM, Sax KW, McElroy SL, Keck PE, Jr.: The phenomenology and comorbidity of adolescents hospitalized for the treatment

C.V.: Stephen M. Strakowski, MD

12

of acute mania. *Biol Psychiatry*, in press.

39. Keck PE, Jr., McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balesteri TM, Bennett JA, Tugrul KC, West SA: Factors associated with pharmacologic noncompliance in patients with mania. *J Clin Psychiatry*, in press.
40. McElroy SL, Keck PE, Jr., Stanton SP, Tugrul KC, Bennett JA, Strakowski SM: A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. *J Clin Psychiatry*, in press.
41. McElroy SL, Pope HG Jr., Keck PE Jr., Hudson JI, Phillips KA, Strakowski SM: Are impulse control disorders related to bipolar disorder? *Compr Psychiatry*, in press.
42. Strakowski SM, McElroy SL, Keck PE, Jr., West SA: Suicidality in mixed and manic bipolar disorder. *Am J Psychiatry*, in press.
43. Strakowski SM, McElroy SL, Keck, Jr., PE, West SA: Racial influence on diagnosis in psychotic mania. *J Aff Disorders*, in press.
44. Dunayevich E, Strakowski SM, Sax KW, Sorter MT, Keck PE, Jr., McElroy SL, McConville BJ: Personality disorders in first and multiple episode mania. *Psychiatry Res*, in press.

Submitted for Publication

45. Stoll AL, Mayer P, Hanin I, Tohen M, Kolbrener M, Kindel G, Strakowski S, Faedda G, Goodwin D, Cohen B: Erythrocyte choline concentrations in first-episode mania: a predictor of prolonged neuroleptic and lithium treatment. submitted for review.
46. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M: Racial differences in the expression of psychosis. submitted for review.
47. O'Driscoll, Strakowski SM, Alpert NM, Matthyse SW, Nakayama K, Rauch SL, Levy DL, Holzman PS: A comparative study of smooth pursuit and saccadic eye movements in humans using positron emission tomography. submitted for review.
48. McElroy SL, Strakowski SM, West SA, Keck PE, Jr., McConville BJ: A comparison of the phenomenology of adolescent versus adult mania. submitted for review.

C.V.: Stephen M. Strakowski, MD

13

49. Sax KW, Strakowski SM, Setters MJ, Keck PE Jr., McElroy SL, Stanton SP: Symptom markers of attentional functioning in patients with first-episode psychosis. submitted for review.
50. Strakowski SM, Hawkins JM, Keck PE Jr., McElroy SL, West SA, Bourne ML, Sax KW, Tugrul KC: Disagreement between psychiatric emergency service and research diagnoses in first-episode psychosis: Effects of race and information variance. submitted for review.

Letters:

1988

1. Strakowski SM, Butler MG: Paternal hydrocarbon exposure in Prader-Willi syndrome: in reply. *The Lancet*, Mar 19:641, 1988.

Reviews and Book Chapters:

1990

1. Strakowski SM, Phillips JA, III: Mental retardation, Hemoglobin H-related. *Birth Defects Encyclopedia*, ML Buyse, ed, (Center for Birth Defects Information Services, Inc., Dover, MA) pp.1123-1124, 1990.

Accepted for Publication

2. Strakowski SM, McElroy SL, Keck PE, Jr., Friedman LM: Clinical trials in bipolar disorder. In *Clinical Trials of CNS Drugs*, M Hertzman & D Feltner, eds. New York: New York University Press, in press.
3. Keck PE, Jr., McElroy SL, Strakowski SM: New developments in the pharmacologic treatment of schizoaffective disorder. *J Clin Psychiatry, suppl.*, in press.
4. Strakowski SM, McElroy SL, Keck PE, Jr.: Efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. *Pharmacotherapy of Mood and Cognition*. S Montgomery & U Halbreich, eds. Washington, D.C.: American Psychiatric Press, Inc., in press.
5. McElroy SL, Keck PE Jr., Strakowski SM: Mania, psychosis, and antipsychotics. *J Clin Psychiatry, suppl.*, in press.

C.V.: Stephen M. Strakowski, MD

14

Abstracts and Presentations:

1990

1. Wilson DR, Glantz K, Pearce J, Strakowski SM, Heisel JS, Aranow R: Evolutionary psychology: some clinical implications. Animal Behavior Society Meeting, SUNY, Binghamton, NY; June 14, 1990.
2. Strakowski SM, Wilson DR, Glantz K, Aranow R: A phylo-ontogenetic model of personality. Animal Behavior Society Meeting, SUNY, Binghamton, NY; June 14, 1990.

1991

3. Tohen M, Strakowski SM, Stoll AL, Faedda DC, Goodwin DC, Baldessarini RJ: Recovery and six-month outcome of a first psychotic episode. International Congress of Schizophrenia, Tucson, AZ; April 23, 1991.
4. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM: Sequence of episodes predicts response to lithium in bipolar disorders. *Biol Psychiatry* [Abstract] 29:384S, 1991.
5. Strakowski SM, Tohen M, Greenfield SF, Faedda GL: Comorbidity in first episode bipolar disorder. American Psychiatric Association Annual Meeting, New Orleans, LA; May 13, 1991.
6. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C: Sequence of episodes predicts response to lithium in bipolar disorder. American Psychiatric Association Annual Meeting, New Orleans, LA; May 13, 1991.
7. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC: First-episode mania and comorbidity. Canadian Psychiatric Association, 41st Annual Meeting, Saskatoon, Saskatchewan; October 4, 1991.
8. Tohen M, Strakowski SM, Stoll AL, Goodwin DC, Faedda GL, Baldessarini RJ: Recovery in first-episode affective and non-affective psychosis. Regional Symposium World Psychiatric Association, Acapulco, Gro. Mexico, November 19-24, 1991
9. Stoll AL, Mayer PV, Hanin I, Tohen M, Strakowski SM, Faedda GL, Goodwin D, Cohen BM: Erythrocyte choline concentration in first-episode psychotic disorders: a predictor of prolonged neuroleptic treatment. Amer. College of Neuropsychopharmacology, 30th Annual Meeting, San Juan, Puerto

C.V.: Stephen M. Strakowski, MD

15

Rico; Dec. 9-13, 1991

1992

10. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL: Neuroanatomic abnormalities in first-episode mania. *Biological Psychiatry* [Abstract], 31:203A, 1992.
11. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglass AW, Stoll AL: Neuroanatomic abnormalities in first-episode mania. Stanley Cobb Assembly of the Boston Society for Neurology & Psychiatry, Boston, MA; April 16, 1992.
12. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC: Comorbidity in first-episode psychosis. American Psychiatric Association Annual meeting, Washington, D.C.; May 4, 1992.
13. Strakowski SM, Batson SC, Greenfield SF, Tohen M, Kolbrener ML: Dissociation and abuse in first-episode psychosis. American Psychiatric Association Annual Meeting, Washington, D.C.; May 4, 1992.
14. Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM: The McLean First-Episode Psychosis Project. American Psychiatric Association Annual Meeting, Washington, D.C.; May 4, 1992.
15. Faedda GL, Strakowski SM, Tohen M, Suppes T, Stoll AL, Mayer PV, Goodwin DC, Kolbrener ML, Baldessarini RJ: Mixed and dysphoric states in bipolar patients. American Psychiatric Association Annual meeting, Washington, D.C.; May 4, 1992.
16. Strakowski SM, Shelton RC, Kolbrener, ML: The effects of race and comorbidity on clinical diagnosis in patients with psychosis. Schizophrenia 1992, Vancouver, British Columbia, Canada; July 19-22, 1992. Awarded Honorable Mention for New Research competition.

1993

17. O'Driscoll G, Strakowski S, Alpert N, Holzman P: A PET study of differential patterns of brain activation in SPEN versus saccadic eye movements. International Congress of Schizophrenia meeting, Colorado Springs, CO; April, 1993; *Schizophrenia Research* [Abstract], 9:205, 1993.
18. Strakowski SM: Is schizophreniform disorder a valid diagnosis?

C.V.: Stephen M. Strakowski, MD

16

APA Annual meeting, San Francisco, CA; May 26, 1993.

19. O'Driscoll G, Strakowski S, Alpert N, Elliott D, Levy D, Rauch S, Matthyse S, Holzman P: Neural correlates of eye movements. Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, Canada, June 1993. *J Nuc Med Tech* [Abstract], 34:196,1993.
20. Strakowski SM, Keck PE, McElroy SL, Tugrul KL, Huber TJ, Hawkins J, Newman RM: Temporal relationships of age of onset of comorbid and principal diagnoses in first-episode psychosis. American Academy of Clinical Psychiatrists 19th Annual Postgraduate Course, October 8, 1993.
21. McElroy SL, Strakowski SM, Keck PE, Tugrul KC, Huber TJ, Hawkins JM, Newman RM: Comorbidity in dysphoric compared with pure mania. American Academy of Clinical Psychiatrists 19th Annual Postgraduate Course, October 8, 1993.
22. Keck PE, McElroy SL, Strakowski SM, Tugrul KC, Hawkins JM, Huber TJ, Newman RM: Comorbidity in first compared with multiple episode mania. American Academy of Clinical Psychiatrists 19th Annual Postgraduate Course, October 8, 1993.
23. Keck PE, Bennet JA, McElroy SL, Strakowski SM, Tugrul KC, Lonczak HS: Low prevalence of antithyroid antibodies and hypothyroidism in patients with mania. First International Congress on Hormones, Brain and neuropsychopharmacology. Rhodes, Greece, September 13-17, 1993; *Neuropsychopharmacol* [Abstract] 9:109S-110S.

1994

24. Keck PE, Jr., Bennet JA, McElroy SL, Strakowski SM, Tugrul KC: Low prevalence of antithyroid antibodies and hypothyroidism in patients with mania. American College of Clinical Pharmacy, Annual Meeting, San Diego, February, 1994.
25. Hudson JI, McElroy SL, Raymond N, Crow S, Keck PE Jr., Carter WP, Mitchell J, Strakowski S, Pope HG Jr., Coleman B, Jonas J: Fluvoxamine in the treatment of binge eating disorder: A multicenter, placebo-controlled study. Sixth International Conference on Eating Disorders, New York, April 30, 1994.
26. Strakowski SM, Keck PE, Jr, McElroy SL, Lonczak HS, Tugrul KL, West SA: Chronology of principal and comorbid syndromes in first-episode psychosis. *Biological Psychiatry* [Abstract] 35:623-624, 1994.

C.V.: Stephen M. Strakowski, MD

17

27. Suppes T, Yurgelun-Todd DA, Tohen M, Faedda G, Kolbrener M, Weiss M, Strakowski S, Mayer P, Stoll A: Mixed bipolar states at first hospitalization. *Biological Psychiatry* [Abstract] 35:625, 1994.
28. West SA, McElroy SL, Strakowski SM, Keck PE, Jr., McConville BJ: Comorbidity of attention-deficit hyperactivity disorder in adolescent mania. NCDEU Annual Meeting, Marco Island, FL, June 1994.
29. West SA, McElroy SL, Strakowski SM, Keck PE, Jr., McConville BJ: Comorbid attention-deficit hyperactivity disorder in adolescent mania. 1994 APA Annual meeting, Philadelphia, PA; May 22-25, 1994.
30. Stanton SP, Bennett JA, McElroy SL, Keck PE, Jr., Tugrul KC, Strakowski SM: Compliance with pharmacological treatment in mania. APA Annual meeting, Philadelphia, PA; May 22-25, 1994.
31. Sax KW, Strakowski SM, Keck PE, Jr., McElroy SL, West SA, Stanton SP: Attention deficit in mixed and pure mania. APA Annual meeting, Philadelphia, PA; May 22-25, 1994.
32. Suppes T, Tohen M, Faedda G, Kolbrener M, Weiss M, Strakowski S, Mayer P, Stoll A: Mixed bipolar states at first hospitalization. First International Conference on Bipolar Disorder, June 23, 1994.
33. Sax KW, Strakowski SM, West SA: The influence of race in diagnosing patients in a psychiatric emergency room. 46th Institute on Hospital and Community Psychiatry, San Diego, CA, September 30 - October 4, 1994.
34. West SA, Strakowski SM, Sax KW: Clinical correlates to hospitalization from a psychiatric emergency room. 46th Institute on Hospital and Community Psychiatry, San Diego, CA, September 30 - October 4, 1994.
35. Strakowski SM, Keck PE Jr., McElroy SL, Lonczak HS, Tugrul KL, West SA: Chronology of principal and comorbid syndromes in first-episode psychosis. Schizophrenia 1994, Vancouver, BC, Canada, August 23, 1994.

1995

36. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Tohen M: Racial differences in the expression of psychosis. *Schizophrenia Res* [Abstract] 15:21, 1995.
37. Strakowski SM, McElroy SL, Keck PE, Jr., West SA, Tugrul KL, DePriest M: Racial influence on diagnosis in psychotic mania. *Biological Psychiatry*

C.V.: Stephen M. Strakowski, MD

18

[Abstract]. 37:604. 1995.

38. Dwight M, Newman M, Strakowski SM, McElroy SL, Keck PE: Co-occurrence of migraine with mixed and pure mania. APA Annual Meeting; Miami, FL May 21-25, 1995.
39. Chang KD, Stanton SP, Keck PE, Jr., McElroy SL, Strakowski SM: Differences in thyroid function between bipolar patients with mixed mania and pure mania. APA Annual Meeting; Miami, FL May 21-25, 1995.
40. West SA, Strakowski SM, Sax K, Raute NJ, McElroy SL, Keck PE, Jr.: The phenomenology and comorbidity of adolescents hospitalized for the treatment of acute mania. APA Annual Meeting; Miami, FL May 21-25, 1995.
41. West S, Sax K, Keck PE, Strakowski SM, McElroy SL: Thyroid function studies in acutely manic adolescents with and without ADHD. NCDEU Annual Meeting; May 31-June 3, 1995.
42. Keck PE, Jr., Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri T, Holtman H, DePriest M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. APA Annual Meeting; Miami, FL May 21-25, 1995.

Grant Activity (as principal investigator):

1. Sensitization of behavioral and growth hormone response following repeated challenges of d-amphetamine in new onset schizophrenia. Scottish Rite Schizophrenia Research Foundation, 1993-1995. Status: No-cost extension. Effort: 10%
2. Factors predicting short-term treatment failure following a first episode of psychosis. Ohio Department of Mental Health, 1994-1995. University of Cincinnati College of Medicine. Status: No-cost extension. Effort: 10%
3. Substance abuse comorbidity in first episode mania. FIRST Award, National Institute of Health, 1996. Status: Active. Effort: 50%

Grant Activity (as co-investigator):

1. Collaborative Biological Research in Schizophrenia, 1992-1995. Principal Investigators: Philip Holzman, PhD & Steven Matthysse, PhD. National Institute of Mental Health Program grant, McLean Hospital, Belmont, MA.

C.V.: Stephen M. Strakowski, MD

19

Status: completed.

2. NIDA/VA Substance Abuse Medication Development Center, 1995-2000.
Principal Investigator: Gene Somoza, MD, PHD. National Institute of Drug Abuse. University of Cincinnati College of Medicine. Status: Active. Effort: 10%

Clinical Trial Grants Received (as principal investigator):

1. A doubled blind, parallel comparison of sertraline and desipramine in outpatients with concurrent major depression and obsessive-compulsive disorder, Pfizer Inc. (Co-principal investigator with Susan L. McElroy, MD), University of Cincinnati Medical Center, 1992-1995. Status: Completed.
2. A multicenter, double-blind, randomized, controlled, multiple fixed-dose and dose regimen comparison of Seroquel and haloperidol in the prevention of psychotic relapse in clinically stable outpatients with chronic or subchronic schizophrenia, Zeneca Pharmaceuticals; University of Cincinnati Medical Center, 1993-1995. Status: Completed
3. An open-label extension study of Seroquel in the prevention of psychotic relapse in clinically stable outpatients with chronic or subchronic schizophrenia, Zeneca Pharmaceuticals; University of Cincinnati Medical Center, 1993-1996. Status: Active.
4. An open-label evaluation of the long-term safety and clinical acceptability of venlafaxine-extended release capsules in depressed outpatients; Wyeth-Ayerst Pharmaceuticals; University of Cincinnati Medical Center, 1994-1995. Status: Completed.
5. Fifty-two week, open-label, randomized study evaluating the safety and efficacy of oral ziprasidone (CP-88,059-1)(40-80 mg BID) and risperidone (3-5 mg BID) in the maintenance treatment of outpatients with schizophrenia or schizoaffective disorder; Pfizer-Roerig; University of Cincinnati Medical Center, 1995-1996. Status: Active.
6. The effect of multiple doses of cimetidine on the pharmacokinetics of ICI 204,636 (Seroquel) in men with selected psychotic disorders. Zeneca Pharmaceuticals; University of Cincinnati Medical Center, 1995. Status: Completed.

Selected Clinical Trial Grants Received (as co-investigator):

1. Double-blind, placebo-controlled, dose-ranging study of oxcarbazepine in acute

C.V.: Stephen M. Strakowski, MD

20

- mania. Principal Investigator: Paul E. Keck, Jr., MD. Ciba-Geigy, University of Cincinnati Medical Center, 1992-1994. Status: Completed.
2. Phase II, four week, double-blind, placebo-controlled study evaluating the efficacy and safety of two doses of oral CP-88059-1 in the acute exacerbation of schizophrenia and schizoaffective disorders. Principal Investigator: Paul E. Keck, Jr., MD. Pfizer, Inc., University of Cincinnati Medical Center, 1993-1994. Status: Completed.
3. A multicenter, double-blind, placebo-controlled, randomized, multiple fixed dose comparison of Seroquel and haloperidol in the treatment of hospitalized subjects with acute exacerbation of chronic or subchronic schizophrenia. Principal Investigator: Paul E. Keck, Jr., MD. Zeneca Pharmaceuticals Group, University of Cincinnati Medical Center, 1993-1994. Status: Completed.
4. Open-label extension of Seroquel in the treatment of patients with chronic or subchronic schizophrenia. Principal Investigator: Paul E. Keck, Jr., MD. Zeneca Pharmaceuticals, University of Cincinnati Medical Center, 1993-1994. Status: Active.
5. The safety and efficacy of Depakote in the prevention of mania in patients with bipolar disorder. Principal Investigator: Susan L. McElroy, MD. Abbott Laboratories, University of Cincinnati Medical Center, 1993-1995. Status: Completed.
6. A double-blind, randomized evaluation of the safety and efficacy of risperidone versus haloperidol in the treatment of schizoaffective disorder. P.I.: Paul E. Keck, Jr., MD. Janssen Research Foundation, University of Cincinnati Medical Center. 1995-1997. Status: Active.
7. Phase III, six week, double-blind, multicenter, placebo-controlled study evaluating the efficacy and safety of three fixed doses of oral ziprasidone and haloperidol in the acute exacerbation of schizophrenia and schizoaffective disorder. P.I.: PE Keck, Jr. Pfizer Inc. University of Cincinnati Medical Center. 1995-1997. Status: Active.
8. A comparative cost-effectiveness study of Depakote and usual care versus lithium and usual care in the treatment of bipolar disorder. P.I.: PE Keck, Jr. Abbott Labs. University of Cincinnati Medical Center. 1995-1996. Status: Active.
9. A multicenter, double-blind, randomized comparison of ICI204,636 and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia. P.I.: PE Keck, Jr. University of Cincinnati Medical Center.

C.V.: Stephen M. Strakowski, MD

21

1995-1997. Status: Active.

STATE MEDICAL BOARD OF OHIO

77 S. High St., Columbus, Ohio 43266-0315

EXPIRES : 09/30/98

LICENSE NUMBER

REDACTED

1
9
9
6



**Celebrating
100 Years
1896-1996**

1
9
9
8

STEPHEN M STRAKOWSKI,MD

*is duly registered and entitled to practice in The State of Ohio
until the expiration date.*

AUDIT # : 028894

STATE MEDICAL BOARD OF OHIO

77 S. High St., Columbus, Ohio 43266-0315

EXPIRES: 01/01/2000

LICENSE NUMBER



**BETWEEN 07/01/98 AND 10/01/99
YOU MUST COMPLETE 062 HOURS
OF CME. (25 IN CATEGORY I)**

STEPHEN M STRAKOWSKI,MD

*Is duly registered and entitled to practice in The State of Ohio
until the expiration date.*

AUDIT # :025500

CURRICULUM VITAE

May, 1997

NAME: Alan Craig Swann, M.D.

PRESENT TITLE:

Pat R. Rutherford, Jr. Professor and Vice Chair for Research
Department of Psychiatry and Behavioral Sciences
University of Texas Medical School at Houston
Houston, Texas

ADDRESS:

Home: **REDACTED**

Office: The University of Texas Medical School at Houston
Department of Psychiatry and Behavioral Sciences
P.O. Box 20708
Houston, Texas 77225
Phone: (713) 500-2556
FAX: (713) 500-2557

BIRTHDATE: July 21, 1946

CITIZENSHIP: United States

UNDERGRADUATE EDUCATION:

1964-1968 Tulane University
New Orleans, Louisiana
B.S., Chemistry

1966-1967 University of Manchester
England

MEDICAL SCHOOL:

1968-1972 University of Texas Southwestern Medical School at Dallas
M.D., 1972

Alan C. Swann, M.D

GRADUATE EDUCATION:

Graduate courses taken at the Department of Biochemistry
University of Texas Southwestern Medical School
Advanced organic chemistry, molecular genetics, biochemical enzymology

Graduate courses taken at National Institutes of Health
Ordinary differential equations, partial differential equations, mathematics for
physical sciences

POSTGRADUATE TRAINING:

1972-1973	Straight Medicine Internship Columbia-Presbyterian Hospital New York, New York
1973-1975	Research Associate, Laboratory of Neurochemistry National Institute of Neurological and Communicative Disorders and Stroke, NIH
1975-1978	Resident in Psychiatry Yale University School of Medicine
1978-1979	Research Fellow Department of Psychiatry Yale University School of Medicine

ACADEMIC APPOINTMENTS:

1980	Assistant Professor Department of Psychiatry Yale University School of Medicine New Haven, Connecticut
12/1/80 - 8/31/84	Assistant Professor Department of Psychiatry and Behavioral Sciences University of Texas Medical School at Houston
9/1/84 - 8/31/89	Associate Professor with tenure Department of Psychiatry and behavioral Sciences University of Texas Medical School and Graduate School of Biomedical Sciences Houston, Texas

Alan C. Swann, M.D

9/1/89 -
Present Professor with tenure
 Department of Psychiatry and Behavioral Sciences
 University of Texas Medical School and
 Graduate School of Biomedical Sciences
 Houston, Texas

2/1/90 -
Present Vice Chairman for Research
 Department of Psychiatry and Behavioral Sciences
 University of Texas Medical School and
 Graduate School of Biomedical Sciences
 Houston, Texas

HOSPITAL APPOINTMENTS:

1979-1980 Associate Physician
 Yale-New Haven Hospital
 New Haven, Connecticut

1980-Present Attending Physician
 Hermann Hospital
 Houston, Texas

1987-Present Attending Physician
 Harris County Psychiatric Center
 Houston, Texas

LICENSURE:

Texas

CERTIFICATION:

1980 American Board of Psychiatry and Neurology (Psychiatry)

PROFESSIONAL ORGANIZATIONS (AND COMMITTEES OF THESE):

American College of Neuropsychopharmacology
American College of Psychiatrists
American Society for Neurochemistry
American Psychiatric Association (Fellow, 1993-)
Red Cell Club
Research Society on Alcoholism
Society for Neuroscience
Texas Medical Association
Texas Research Society on Alcoholism (Vice-President 1989-1990)

Alan C. Swann, M.D

HONORS AND AWARDS:

Undergraduate

Phi Beta Kappa; cum laude; honors in chemistry
American Institute of Chemists
Outstanding Graduate in Chemistry Award

Medical School

First Prize, Student Research Forum, 1971 and 1972
Vice President, student government, 1970-1971
President, student government, 1971-1972

Postgraduate

National Research Service Award Individual Postdoctoral Fellowship
F32 MH07740,
"Membrane transport mechanisms and affective disorder,"
James W. Maas, M.D., Sponsor

Research Scientist Development Award 1 K04 MH00415
"Depression, cation transport, and energy metabolism"

UTHSC Medical School Dean's Award for teaching Excellence, 1986-1987, 1990-1991,
1991-1992, 1993-1994, 1994-1995, 1995-1996

Research Award, Mental Health Association of Houston and Harris County, 1994

Pfizer Visiting Professorship, Department of Psychiatry, University of Louisville School of
Medicine, April, 1996

GRANTS AWARDED:

MH 37141 Depression, endogenous ATPase regulator, and norepinephrine
5/1/82-8/31/89; 394,760 total direct costs;
Principal Investigator

AA 05785 Alcoholism, (Na⁺,K⁺)-ATPase, and norepinephrine
9/1/82-11/30/89; 399,966; Principal Investigator

American Heart Association, Texas Affiliate
Regulation of the cardiac glycoside receptor
7/1/82-6/30/84; 39,000; Principal Investigator

MH 37836 Biological predictors of violent suicide attempts
9/1/83-8/31/86; 146,731; Co-investigator
(one of two; about 50% of budget)

Alan C. Swann, M.D

MH 00415 Depression, cation transport, and energy metabolism
Research Scientist Development Award
1/1/83-12/31/87; 215,000; Principal Investigator

MH 38084 NIMH-CRB Collaborative Program on the Psychobiology of Depression:
Biological Studies: 7/1/88-6/30/92; 268,159; Co-investigator

MH 39603 PET scan in psychiatry: Development of cholinergic probes
11/1/84-10/31/86; Co-investigator; 33% of budget.

Centers for Disease Control
A Case-Control Study of Attempted Suicide
2/1/92-8/31/95; \$340,000; Principal Investigator (1 of 3)

MH-53932 Treatment of Generalized Anxiety Disorder in the Elderly
7/1/96-6/30/01; \$1,427,312; Co-investigator

DA-10928 Medications Development for Dual Dependence
4/1/97-3/31/02; \$1,914,958; Co-Investigator

HEALTH SCIENCE CENTER COMMITTEES:

Committee for the Protection of Human Subjects, 9/1/83-Present
Vice Chairman, 9/1/85-8/31/89
Chair, 9/1/89-Present
Scientific Council, University of Texas Health Science Center,
9/1/84-8/31/88
Research Committee, 1993-
Center for Neuroscience Research, Executive Committee
2/1/92-

MEDICAL SCHOOL AND HOSPITAL COMMITTEES:

Faculty Senate, 9/1/82-8/31/84
Pharmacy and Therapeutics Committee, Hermann Hospital,
1/1/83-12/31/88
Select Committee on Risk Awareness and Management,
University of Texas Health Science Center, 9/1/85-8/31/90
Curriculum Committee, Graduate School of Biomedical Sciences,
9/1/85-8/31/88
Psychiatry Department: Executive Committee; Chair, Executive Planning
Committee; Chair, Research Committee; Residency Training Committee and
Subcommittees on Recruitment and on Curriculum; Chair, Resources
Committee; Chair, Faculty Recruitment Committee

Alan C. Swann, M.D

SERVICE TO COMMUNITY:

Research Committee, Houston and Harris County Mental Health Association,
5/1/84-4/30/87
Professional Member, National Depressive and Manic-Depressive Association
Coach, Odyssey of the Mind, Houston Independent School District
Member, Board of Directors, Montessori School of Houston
Member, Houston Violence Prevention Coalition

SERVICE ON NATIONAL PANELS AND COMMITTEES:

Neurological Sciences -1 Ad hoc Study Section, NIH, 1989
Merit Review Board for Mental Health and Behavioral Sciences,
Department of Veterans Affairs, ad hoc member, 1991, 1992
Member 1992 - 1995; Chair 1993 - 1995
Associate Principal Investigator, National Institute of Mental Health Clinical
Research Branch Collaborative Program on the Psychobiology of Depression,
Biological Studies
External Reviewer: Veterans Administration; National Science Foundation,
National Institute of Mental Health
Referee: Alcoholism: Clinical and Experimental Research; Alcohol; American
Journal of Physiology; American Journal of Psychiatry; Biobehavior and
Neuroscience Research Reviews; Biochemical Pharmacology; Biological
Psychiatry, Comparative Biochemistry and Physiology, European Journal of
Pharmacology; Journal of Neurochemistry; Life Sciences; Neurochemistry
International; Neuroscience; Proceedings of the National Academy of
Sciences; Psychiatry Research.

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE:

Jeffery D. Steketee, Ph.D., 1989: "A Pharmacologic Investigation of
Noradrenergic Receptor Mechanisms in Neophobia"

PUBLICATIONS

A. Abstracts

1. Prager, M.D., Derr, I., Swann, A.C.: Characterization and enhancement of the immune response to mouse lymphoma 6C3HED. *Fed. Proc.* 29:429, 1970.
2. Swann, A.C., Siperstein, M.D.: Distribution of cholesterol feedback control in the guinea pig. *J. Clin. Invest.* 51:101a, 1972.
3. Swann, A.C., Albers, R.W.: Na^+ , K^+ -ATPase: Na^+ , K^+ , and ATP binding site interactions. *Fed. Proc.* 33:1301, 1974.
4. Swann, A.C.: Interactions of Li^+ and Rb^+ with K^+ sites of mammalian brain (Na^+ , K^+)-ATPase. *Trans. Am. Society Neurochem.* 6:93, 1974.
5. Swann, A.C., Albers, R.W.: Interactions of Mg^{++} with (Na^+ , K^+)-ATPase of mammalian brain. *Fed. Proc.* 35:518, 1975.
6. Swann, A.C., Albers, R.W.: Effects of nucleotide, Na^+ , and phosphorylation on conformation changes of brain (Na^+ , K^+)-ATPase. *Fed. Proc.* 38:242, 1979.
7. Swann, A.C., Maas, J.W., Hattox, S.E., Landis, D.H.: Catecholamine metabolites in human plasma. American Psychiatric Association, 1980.
8. Swann, A.C., Marini, J.L., Sheard, M.H., Maas, J.W.: Effects of chronic lithium on brain (Na^+ , K^+)-ATPase. *Trans. Am. Soc. Neurochem.* 11:165, 1980.
9. Hattox, S.E., Swann, A.C., Jablons, D.M., Maas, J.W.: Debrisoquin, a peripheral monoamine oxidase inhibitor and antihypertensive agent, reduces cortical MHPG in rats. *Soc. Neurosci. Abstr.* 6:5, 1980.
10. Swann, A.C., Grant, S.J.: Decreased beta-noradrenergic receptor binding after daily piperhexane. *Soc. Neurosci. Abstr.* 6:860, 1980.
11. Swann, A.C., Hattox, S.E., Grant, S., Maas, J.W.: (Na^+ , K^+)-ATPase, ouabain binding, and noradrenergic activity. *Neurosci. Abstr.* 7:572, 1981.
12. Swann, A.C.: Brain (Na^+ , K^+)-ATPase: Modulation of K^+ and ATP binding by temperature. *Fed. Proc.* 41:1370, 1982.
13. Swann, A.C., Secunda, S., Davis, J.M., Hanin, I., Robins, E., Maas, J.W., Koslow, S.H.: Cerebrospinal fluid monoamine metabolites in mania. *Amer. Psychiat. Assoc. New Research Abstract NR 16*, 1982.

Alan C. Swann, M.D

Abstracts (Cont'd)

14. Swann, A.C.: Regulation of brain (Na⁺,K⁺)-ATPase by alpha-1 noradrenergic receptors. Soc. Neurosci. Abstr. 8:923, 1982.
15. Swann, A.C.: Noradrenergic regulation of brain (Na⁺,K⁺)-ATPase. American College of Neuropsychopharmacology, 1982.
16. Swann, A.C., Secunda, S., Davis, J., Katz, M., Hanin, I., Koslow, S.H., Maas, J.W.: Mania: Effects of lithium on monoamine metabolites and behavioral measures. American College of Neuropsychopharmacology, 1982.
17. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Apparent thermodynamic properties of cation-related conformation changes. Fed. Proc. 42:1934, 1983.
18. Casper, R.C., Kocsis, J., Javaid, J., Katz, M.M., Ramsey, T.A., Swann, A.C.: Depression and vital physiologic functions. American Psychiatric Association Proceedings, 127, 1983.
19. Stokes, P.E., Stoll, P., Koslow, S.H., Davis, J.M., Swann, A.C., Kocsis, J.: Pretreatment hypothalamic-pituitary-adrenal cortical function in affective disease. APA Proceedings, 127-128, 1983.
20. Swann, A.C., Secunda, S.K., Casper, R.D., Garver, D.L., Croughan, J., Redmond, D.E.: Mania and cerebrospinal fluid amine levels. APA Proceedings, 129, 1983.
21. Swann, A.C.: (Na⁺,K⁺)-ATPase: Regulation of (Na⁺,K⁺)-ATPase by the sympathetic nervous system. J. Neurochem. 41 suppl. S160, 1983.
22. Swann, A.C.: Noradrenergic activity and (Na⁺,K⁺)-ATPase: Effects of norepinephrine depletion and caloric intake on (Na⁺,K⁺)-ATPase and noradrenergic parameters in brain and peripheral tissues. Neurosci. Abstr. 9:1003, 1983.
23. Swann, A.C.: Diet, norepinephrine and (Na⁺,K⁺)-ATPase: Role of alpha-1 and beta receptors. Trans. Am. soc. Neurochem. 15:161, 1984.
24. Swann, A.C.: Chronic ethanol and (Na⁺,K⁺)-ATPase: Evidence for a membrane adaptation. Soc. Neurosci. Abstr. 10:963, 1984.
25. Swann, A.C., Koslow, S.H., Katz, M.M., Secunda, S.K., Maas, J.W. and Robins, E. Mania: Amines, symptoms, and responses to lithium. APA Proceedings, 92:1985.
26. Lingham, R.B., Swann, A.C., Holcombe, V., Khan, S.A., Robinson, G.A., Gottesfeld, Z.: Partial deafferentation induces increased dopamine receptor density and dopamine-sensitive adenylate cyclase, while decreasing (Na⁺,K⁺)-ATPase and ouabain binding in the olfactory tubercle. Soc. Neurosci. Abstr. 11:1103, 1985.
27. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Evidence for membrane adaptation to chronic ethanol and noradrenergic stimulation. Soc. Neurosci. Abstr. 11:828, 1985.

Alan C. Swann, M.D

Abstracts (Cont'd)

28. Swann, A.C., Hewitt, L.O., Guynn, R.W.: Hemicholinium-3 binding to brain membranes relative to cholinergic function. Soc. Neurosci. Abstr. 12:893, 1986.
29. Swann, A.C., Reilly, E.L., Overall, J.E. Membrane adaptation in alcoholism. American Psychiatric Association New Research Abstract NR 66, 1986.
30. Swann, A.C.: Chronic cocaine: Effects on brain neurotransmitters. APA Proceedings, 170, 1986.
31. Steketee, J.S., Swann, A.C.: Comparison of norepinephrine depletion by DSP-4 and 6-hydroxydopamine. Soc. Neurosci. Abstr. 12:1395, 1986.
32. Swann, A.C., Reilly, E.L., Overall, J.E.: Membrane ATPase adaptation in alcoholism. Alc. Drug res., in press.
33. Swann, A.C.: Norepinephrine and membrane regulation of (Na⁺,K⁺)-ATPase. In Molecular Basis of Neural Function (Ed.: Tucek, S., Stipek, S., Stastny, F., Krivanek, J.), 111, 1986.
34. Swann, A.C.: Norepinephrine-thyroid interactions. American College of Neuropsychopharmacology, 1986.
35. Guynn, R.W., Swann, A.C., Redburn, D.: Developing probes for visualizing cholinergic function in vivo. American College of Neuropsychopharmacology, 1986.
36. Casper, R.C., Swann, A.C., Stokes, P.E., Chang, S., Katz, M.M., Garver, D.: Weight loss in depression: Does it affect the hypothalamic-pituitary-adrenal (HPA) axis? American College of Neuropsychopharmacology, 1986.
37. Edlund, M.J., Swann, A.C., Davis, C.M.: Plasma MHPG in untreated panic disorder. Abstracts, Sixth International Catecholamine Symposium, 1987.
38. Swann, A.C., Hewitt, L.O., Burr, M.S., Guynn, R.W.: Alpha-1 receptor stimulation of ouabain-sensitive hyperpolarization in isolated cells. Abstracts, Sixth International Catecholamine Symposium, 1987.
39. Edlund, M.J., Swann, A.C.: Panic disorder: Treatment, symptoms, and plasma MHPG. Soc. Neurosci. Abstr. 13:220, 1987.
40. Swann, A.C., Steketee, J.S.: Thyroid hormone and norepinephrine: Effects on receptor regulation and Na,K-ATPase. Soc. Neurosci. Abstr. 13:482, 1987.
41. Swann, A.C.: Cocaine: Synaptic effects and neural adaptations. APA Proceedings, 117, 1988.

Alan C. Swann, M.D

Abstracts (Cont'd)

42. Swann, A.C., Steketee, J.D.: Regulation of brain Na,K-ATPase by intraventricular noradrenergic receptor ligands. Soc. Neurosci. Abstr. 14:737, 1988.
43. Steketee, J.D., Swann, A.C.: Role of forebrain norepinephrine in selective attention and neophobia. Soc. Neurosci. Abstr. 14:529, 1988.
44. Guynn, R.W., Swann, A.C., Redburn, D.A.: Developing probes for visualizing cholinergic function in vivo. Psychopharmacology, in press.
45. Swann, A.C.: Regulation of brain Na,K-ATPase by noradrenergic receptors and thier second messengers. American College of Neuropsychopharmacology, 1988.
46. Swann, A.C.: Sodium or calcium influx increases ethanol-sensitivity of Na,K-ATPase. Trans. Am. Soc. Neurochem. 20:167, 1989.
47. Swann, A.C.: Cocaine: Transmitter adaptation and interactions. APA Proceedings, 275, 1989.
48. Secunda, S.K., Swann, A.C., Katz, M.M., Croughan, J.L., Koslow, S.H.: Mixed mania: Clinical and behavioral correlates. APA Proceedings, 307, 1989.
49. Swann, A.C., Bowden, C.L., Maas, J.W., Secunda, S.K., Koslow, S.H., Davis, J.M.: Biological correlates of lithium response in mania. APA Proceedings, 307, 1989.
50. Clothier, J.L., Freeman, T., Pazzaglia, P., Lesem, M.D., Swann, A.: Sodium valproate treatment of bipolar patients. APA New Research, 127, 1989.
51. Swann, A.C., Croughan, J., Secunda, S.K., Koslow, S.H., Maas, J.W., Stokes, P.E.: Stress and the biology of affective episodes. APA New Research, 143, 1989.
52. Swann, A.C.: Na⁺ or Ca⁺⁺ influx increase ethanol inhibition of Na,K-ATPase. Research Society on Alcoholism, June, 1989.
53. Swann, A.C., Secunda, S.K., Stokes, P.E., Croughan, J., Davis, J.M., Koslow, S.H., and Maas, J.W.: Stressful events and monamine function in affective episodes. American College of Neuropsychopharmacology, 1989.
54. Swann, A.C.: Neural activity and Na,K-ATPase. Trans. Am. Soc. Neurochem. 41:207, 1990.
55. Swann, A.C.: Adaptation of brain Na,K-ATPase to changes in neural activity. J. Gen. Physiol. 96:85a, 1990.
56. Swann, A.C.: Beta-adrenergic adaptation to cocaine: Role of serotonin. Soc. Neurosci. Abstr. 16:254, 1990.

Alan C. Swann, M.D

Abstracts (Cont'd)

57. Swann, A.C.: Neuroendocrine effects on adaptation of Na,K-ATPase to noradrenergic depletion. Soc. Neurosci. Abstr. 17:269, 1991.
58. Stanley, M.A., Prather, R.C., Wagner, A.L., Davis, M.L., Swann, A.C.: Assessment of trichotillomania with the Yale-Brown obsessive compulsive scale. Association for the Advancement of Behavior Therapy.
59. Dilsaver, S.C., Peck, J.A., Traumata, D., and Swann, A.C.: Carbamazepine enhances clonidine-induced hypothermia. American College of Neuropsychopharmacology, 1991.
60. Swann, A.C., Secunda, S.K., Katz, M.M., Maas, J.W., and Croughan, J.: Syndromal specificity of mixed manic states. American College of Neuropsychopharmacology, 1991.
61. Swann, A.C.: Calcium effects on active transport by Na, K-ATPase. Trans. Am. Soc. Neurochem 43, 1992.
62. Dilsaver, S.C., Swann, A.C.: Chronic treatment with valproate decreases sensitivity to clonidine. Biological Psychiatry 31:222A, 1992.
63. Bowers, T., Shoaib, A.M., Dilsaver, S.C., Swann, A.C.: Concurrent presence of MDD and mania is associated with nonresponse to drug treatments for mania. Biological Psychiatry 31:247A, 1992.
64. Carrion, P.G., Swann, A.C., and Kellert, H.A.: Compliance in patients with schizophrenia. APA New Research, 160, 1992.
65. Dilsaver, S.C., Shoaib, A.M., Bowers, T., Swann, A.C.: The mixed state predicts nonresponse to antimanic agents. Canadian College of Neuropsychopharmacology, Abstracts W20, 1992.
66. Swann, A.C., Secunda, S.K., Bowden, C.L., Stokes, P.E., Maas, J.W., Koslow, S.H.: Biology of mixed mania: Superimposed syndromes? APA Proceedings, 276, 1992.
67. Kellert, H.A., Gomez, P.G., and Swann, A.C.: Reliability of the global assessment scale in a clinical setting. Am. Psychological Assoc., 1992.
68. Swann, A.C., Silverman, S., Dilsaver, S.C., Shoaib, A.M.: Mixed manic states and the course of manic-depressive illness. APA New Research, 1993.
69. Swann, A.C., Davis, J.M., Rush, A.J., Dilsaver, S.C.: Clinical study designs in bipolar disorder. APA Proceedings, 1993.
70. Cherry, L.M., Swann, A.C.: Cation transport by Na,K-ATPase in cultured cells from patients with bipolar disorder, relatives, and unrelated controls. American College of Neuropsychopharmacology, 1993.

Alan C. Swann, M.D.

Abstracts (Cont'd)

71. Dilsaver, S.C., Shoaib, A.M., Chen, Y.-W., Swann, A.C., Krajewski, K.J.: Suicidality in patients with pure and depressive mania. American College of Neuropsychopharmacology, 1993.
72. Bowden, C., Davis, J., Morris, D., Swann, A., Calabrese, J., Lambert, M., Goodnick, P.: Effect size of efficacy measures comparing divalproex, lithium, and placebo in acute mania. American College of Neuropsychopharmacology, 1993.

B. Refereed Original Articles in Journals

1. Prager, M.D., Derr, I., Swann, A.C., Cotropia, J.: Immunization with chemically modified lymphoma cells. *Cancer Res.* 31:1488-1491, 1971.
2. Albers, R.W., Koval, G.J., Swann, A.C.: Analysis of Na⁺, K⁺, and nucleotide interactions in terms of a heterotropic relaxation model for (Na⁺, K⁺)-ATPase. *Ann. NY Acad. Sci.* 242:268-279, 1974.
3. Swann, A.C., Wiley, M.H., Siperstein, M.D.: Tissue sites of feedback control of cholesterol synthesis in the guinea pig. *J. Lipid Res.* 16:360-366, 1975.
4. Swann, A.C., Albers, R.W.: Sodium and potassium activated ATPase of mammalian brain: Regulation of phosphatase activity. *Biochim. Biophys. Acta.* 382:437-456, 1975.
5. Swann, A.C., Daniel, A., Albers, R.W., Koval, G.J.: Interactions of lectins with (Na⁺, K⁺)-ATPase of eel electric organ. *Biochim. Biophys. Acta.* 401:299-306, 1975.
6. Swann, A.C., Albers, R.W.: (Na⁺, K⁺)-ATPase of mammalian brain: Interactions of Mg⁺⁺ ions with the phosphatase site. *Biochim. Biophys. Acta.* 523:215-227, 1978.
7. Swann, A.C., Albers, R.W.: (Na⁺, K⁺)-ATPase of mammalian brain: Catalytic and regulatory K⁺ sites distinguishable by selectivity for lithium. *J. Biol. Chem.* 254:4540-4544, 1979.
8. Swann, A.C., Heninger, G.R., Marini, J.L., Sheard, M.H., Maas, J.W.: Lithium effects on high affinity tryptophan uptake: Evidence against a stabilization mechanism. *Brain. Res.* 194:287-292, 1980.
9. Swann, A.C., Albers, R.W.: (Na⁺, K⁺)-ATPase of mammalian brain: Differential effects on cation affinities of phosphorylation by ATP or acetylphosphate. *Arch. Biochem. Biophys.* 203:422-427, 1980.
10. Swann, A.C., Maas, J.W., Hattox, S.E., Landis, D.H.: Catecholamine metabolites in human plasma as indices of brain function: Effects of debrisoquin. *Life Sci.* 27:1857-1862, 1980.

Refereed Original Articles in Journals (Cont'd)

11. Swann, A.C., Marini, J.L., Sheard, M.H., Maas, J.W.: Effects of chronic lithium on activity and regulation of (Na⁺,K⁺)-ATPase in rat brain. *Biochem. Pharmacol.* 29:2819-2823, 1980.
12. Swann, A.C., Crawley, J.N., Grant, S., Maas, J.W.: Noradrenergic stimulation *in vivo* increases (Na⁺,K⁺)-ATPase activity in noradrenergic projection areas. *Life Sci.* 28:251-256, 1980.
13. Swann, A.C., Ikeninger, G.R., Roth, R.H., Maas, J.W.: Differential effects of short and long term lithium on tryptophan uptake and serotonergic function in cat brain. *Life Sci.* 28:347-354, 1981.
14. Swann, A.C., Albers, R.W.: Temperature effects on cation affinities of the (Na⁺,K⁺)-ATPase of mammalian brain. *Biochim. Biophys. Acta.* 644:36-40, 1981.
15. Swann, A.C., Grant, S., Jablons, D.M., Maas, J.W.: Increased ouabain binding after repeated noradrenergic stimulation. *Brain Res.* 213:481-485, 1981.
16. Swann, A.C., Grant, S., Hattox, S.E., Maas, J.W.: Adrenoreceptor regulation in rat brain. Chronic effects of α_1 and α_2 receptor blockers. *Eur. J. Pharmacol.* 73:301-305, 1981.
17. Katz, M.M., Robins, E., Croughan, J., Secunda, S., Swann, A.C.: Behavioral measurement and drug response characteristics of unipolar and bipolar depression. *Psychol. Med.* 12:25-36, 1982.
18. Swann, A.C., Grant, S.J., Maas, J.W.: Brain (Na⁺,K⁺)-ATPase and noradrenergic activity: Effects of hyperinnervation and denervation on high affinity ouabain binding. *J. Neurochem.* 38:836-839, 1982.
19. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Biphasic interaction with erythrosin B. *Biochem. Pharmacol.* 31:2185-2190, 1982.
20. Frazer, A., Ramsey, T.A., Swann, A., Bowden, C., Brunswick, D., Garver, D., Secunda, S.: Plasma and erythrocyte electrolytes in affective disorders. *J. Affect. Dis.* 5:103-113, 1983.
21. Swann, A.C., Elsworth, J.E., Charney, D.S., Jablons, D., Redmond, D.E., Roth, R.H., Maas, J.W.: Brain catecholamine metabolites and behavior in morphine withdrawal. *Eur. J. Pharmacol.* 86:167-175, 1983.
22. Swann, A.C., Secunda, S., Davis, J.M., Hanin, I., Robins, E., Koslow, S.H., Maas, J.: Cerebrospinal fluid monoamine metabolites in mania. *Am. J. Psychiatry.* 140:396-400, 1983.

Refereed Original Articles in Journals (Cont'd)

23. Swann, A.C.: Stimulation of brain (Na⁺,K⁺)-ATPase by norepinephrine *in vivo*: Prevention by receptor antagonists and enhancement by prior stimulation. *Brain Res.* 260:338-341, 1983.
24. Swann, A.C.: (Na⁺,K⁺)-ATPase of mammalian brain. Effects of temperature on cation and ATP interactions regulating phosphatase activity. *Arch. Biochem. Biophys.* 221:148-157, 1983.
25. Stokes, P.E., Stoll, P., Koslow, S.H., Maas, J., Davis, J., Swann, A.C., Casper, R.: Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. *Arch. Gen. Psychiatry* 41:257-267, 1984.
26. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Opposite effects of ethanol and dimethylsulfoxide on temperature dependence of enzyme conformation and univalent cation binding. *J. Biol. Chem.* 258:11780-11786, 1983.
27. Swann, A.C.: (Na⁺,K⁺)-ATPase stimulation by sucrose feeding: Prevention by 6-hydroxydopamine. *Life Sci.* 34:353-257, 1984.
28. Swann, A.C.: (Na⁺,K⁺)-ATPase regulation by the sympathetic nervous system: Effects of noradrenergic stimulation and depletion *in vivo*. *J. Pharmacol. Exp. Ther.* 288:304-311, 1984.
29. Swann, A.C.: Free fatty acids and (Na⁺,K⁺)-ATPase: Effects on enzyme conformation, cation regulation, and interactions with ethanol. *Arch. Biochem. Biophys.* 233:354-361, 1984.
30. Swann, A.C.: Caloric intake and (Na⁺,K⁺)-ATPase: Differential regulation by alpha-1 and beta noradrenergic receptors. *Am. J. Physiol.* 247:R449-R455, 1984.
31. Peterson, L.G., Peterson, M., O'Shanick, G., Swann, A.C.: Violent suicide attempts: Lethality of method vs. intent. *Am. J. Psychiatry* 142:228-230, 1985.
32. Secunda, S., Ramsey, T.A., Swann, A.C., Katz, M.M., Robins, E., Croughan, J.: Mania: Diagnosis, state measurement, and prediction of treatment response. *J. Aff. Dis.* 8:113-121, 1985.
33. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase and noradrenergic function: Recovery of enzyme activity after norepinephrine depletion. *Brain Res.* 321:323-327, 1984.
34. Swann, A.C., Duman, R., Hewitt, L.O.: Desipramine binding: Relationship to central and peripheral noradrenergic activity. *J. Neurochem.* 44:611-615, 1985.
35. Swann, A.C.: Chronic ethanol effects on (Na⁺,K⁺)-ATPase: Apparent adaptation in cation binding and enzyme conformation. *J. Pharmacol. Exp. Ther.* 232:475-479, 1985.

Refereed Original Articles in Journals (Cont'd)

36. Beller, S.A., Overall, J.E., Swann, A.C.: Efficacy of oral physostigmine in treatment of primary degenerative dementia. *Psychopharmacology* 87:147-151, 1985.
37. Swann, A.C.: (Na⁺,K⁺)-ATPase regulation and NaCl intake: Effects on circulating inhibitor and sensitivity to norepinephrine. *Clin. Sci.* 69:441-447, 1985.
38. Redmond, D.E., Katz, M.M., Maas, J.W., Swann, A.C., Casper, R., Davis, J.M.: CSF biogenic amine metabolite relationships with behavioral measurements in depressed, manic and healthy control subjects. *Arch. Gen. Psychiatry* 43:938-947, 1986.
39. Swann, A.C., Hewitt, L.O., Guynn, R.W.: High affinity hemicholinium-3 binding to brain membranes: Reduction by treatment with physostigmine *in vivo*. *Brain Res.* 363:401-403, 1986.
40. Swann, A.C.: (Na⁺,K⁺)-ATPase and noradrenergic regulation: Effects of cardiac glycoside treatment and noradrenergic manipulations. *Eur. J. Pharmacol.* 119:67-74, 1985.
41. Gibbons, R.D., Maas, J.W., Davis, J.M., Swann, A.C., Redmond, D.E. Jr., Casper, R.C., Hanin, I.: Path analysis of psychopharmacological data: Catecholamine breakdown in man. *Psychiatry Res.* 18:89-105, 1986.
42. Swann, A.C., Secunda, S.K., Katz, M.M., Koslow, S.H., Maas, J.W., Chang, S., Robins, E.: Lithium treatment of mania: Clinical characteristics, specificity of symptom change and outcome. *Psychiatry Res.* 18:127-141, 1986.
43. Swann, A.C., Reilly, E., Overall, J.E.: Reduced sensitivity of red blood cell (Na⁺,K⁺)-ATPase to ethanol *in vitro* in alcoholic patients: Relationship to clinical characteristics. *Alcoholism: Clin. Exp. Res.* 10:526-530, 1986.
44. Swann, A.C., Berman, N., Frazer, A., Koslow, S.H., Secunda, S.K.: Lithium distribution in mania: Plasma and red blood cell lithium, clinical state, and monoamine metabolites during lithium treatment. *Psychiatry Res.* 20:1-12, 1987.
45. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Alteration of ligand affinities and conformation by chronic ethanol and noradrenergic stimulation *in vivo*. *J. Neurochem.* 47:708-715, 1986.
46. Swann, A.C., Koslow, S.H., Katz, M.M., Maas, J.W., Javaid, J., Secunda, S.K., Robins, E.: Lithium treatment of mania: CSF and urinary monoamine metabolites and treatment outcome. *Arch. Gen. Psychiatry* 44:345-354, 1987.
47. Secunda, S.K., Swann, A.C., Katz, M.M., Koslow, S.H., Croughan, J., Chuang, S.: Diagnosis and treatment of mixed mania. *Am. J. Psychiatry* 144:96-98, 1987.

Refereed Original Articles in Journals (Cont'd)

48. Edlund, M., Swann, A., Clothier, J.: Patients with panic attacks and abnormal EEG results. *Am. J. Psychiatry* 144:508-509, 1987.
49. Swann, A.C.: Ouabain binding to brain (Na⁺,K⁺)-ATPase: Interactions of K⁺, ethanol, and norepinephrine with high- and low-affinity binding. *J. Pharmacol. Exp. Ther.* 240:187-195, 1987.
50. Swann, A.C.: (Na⁺,K⁺)-ATPase and noradrenergic function: Effects of chronic ethanol. *Eur. J. Pharmacol.* 134:145-154, 1987.
51. Swann, A.C., Gottesfeld, Z.: Partial deafferentation elicits a transient decrease in Na,K-ATPase in olfactory tubercle. *Brain Res.* 404:323-326, 1987.
52. Edlund, M., Swann, A.C.: Economic and social costs of panic disorder. *J. Hosp. Commun. Psychiatry* 38:1277-1279, 1987.
53. Casper, R.C., Swann, A.C., Stokes, P.E., Chang, S., Katz, M.M., Garver, D.: Weight loss, cortisol levels, and dexamethasone suppression in major depressive disorder. *Acta Psychiat. Scand.* 75:243-250, 1987.
54. Edlund, M.J., Swann, A.C., Davis, C.M.: Plasma MHPG in untreated panic disorder. *Biol. Psychiatry* 22:1491-1495, 1987.
55. Swann, A.C.: Thyroid hormone and norepinephrine: Effects on alpha-2, beta, and reuptake sites in cerebral cortex and heart. *J. Neural Trans.* 71:195-205, 1988.
56. Swann, A.C.: Norepinephrine and (Na⁺,K⁺)-ATPase: Evidence for stabilization by lithium or imipramine. *Neuropharmacol.* 27:261-267, 1988.
57. Swann, A.C., and Hewitt, L.O.: Hemicholinium-3 binding: Correlation with high-affinity choline uptake during changes in cholinergic activity. *Neuropharmacol.* 27:611-615, 1988.
58. Croughan, J., Secunda, S., Katz, M., Robins, E., Mendels, J., Swann, A.C., Harris-Larkin, B.: Sociodemographic and prior clinical course characteristics associated with treatment response in depressed patients. *J. Psychiat. Res.* 22:227-237, 1988.
59. Beller, S.A., Overall, S.E., Rhoades, H., Swann, A.C.: Long-term treatment of senile dementia with oral physostigmine. *J. Clin. Psychiatry* 49:400-404, 1988.
60. Swann, A.C. and Steketee, J.D.: Forskolin infusion in vivo increases brain ouabain binding. *Brain Res.* 476:351-353, 1988.
61. Edlund, M.J. and Swann, A.C.: Remaining in treatment as a form of selection bias. *Am. J. Psychiatry* 146:254-256, 1989.

Refereed Original Articles in Journals (Cont'd)

62. Swann, A.C.: Dexamethasone and adrenalectomy alter brain (Na⁺,K⁺)-ATPase responses to noradrenergic stimulation or depletion. *Eur. J. Pharmacol.* 158:43-52, 1988.
63. Edlund, M.J., Swann, A.C. and Davis, C.M.: Plasma MHPG as a predictor of remaining in treatment in panic disorder. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 13:701-707, 1989.
64. Steketee, J.D., Swann, A.C. and Silverman, P.B. Development of ethanol tolerance not altered by 6-OHDA lesions of dorsal bundle. *Pharmacol. Biochem. Behav.* 33:729-731, 1989.
65. Swann, A.C. and Steketee, J.D.: Subacute noradrenergic agonist infusions in vivo increase Na⁺,K⁺-ATPase and ouabain binding in rat cerebral cortex. *J. Neurochem.* 52:1598-1604, 1989.
66. Swann, A.C.: Noradrenaline and thyroid function regulate (Na⁺,K⁺)-adenosine triphosphatase independently in vivo. *Eur. J. Pharmacol.* 169:275-283, 1989.
67. Swann, A.C.: Inhibition of (Na⁺,K⁺)-ATPase by fluoride: Evidence for a membrane adaptation to ethanol. *Alcohol* 7:91-95, 1990.
68. Steketee, J.D., Silverman, P.B. and Swann, A.C.: Role of forebrain norepinephrine in selective attention and neophobia. *Physiol. Behav.* 46:577-583, 1989.
69. Swann, A.C., Berman, N., Frazer, A., Koslow, S.H., Maas, J.W., Pandey, G., Secunda, S.: Lithium distribution in mania: Single-dose pharmacokinetics and sympathoadrenal function. *Psychiatry Res.* 32:71-84, 1990.
70. Swann, A.C., Secunda, S.K., Stokes, P.E., Croughan, J., Davis, J.M., Koslow, S.H., Maas, J.W.: Stress, depression, and mania: Relationship between perceived role of stressful events and clinical and biochemical characteristics. *Acta Psychiat Scand.* 81:389-397, 1990.
71. Swann A.C.: Ethanol-Inhibition of active ⁸⁶Rb⁺-transport: Evidence for enhancement by sodium or calcium influx. *J. Pharmacol. Exp. Ther.* 254:864-871, 1990.
72. Swann, A.C.: Ethanol and (Na⁺,K⁺)-ATPase: Alteration of Na⁺-K⁺ selectivity. *Alcoholism: Clin. Exp. Res.* 14:922-927, 1990
73. Swann, A.C.: Brain Na,K-ATPase regulation in vivo: Reduction in activity and response to sodium by intracerebroventricular tetrodotoxin. *Brain Res.* 543:251-255, 1991.

Refereed Original Articles in Journals (Cont'd)

74. Swann, A.C., Secunda, S.K., Koslow, S.H., Katz, M.M., Bowden, C.L., Maas, J.W., Davis, J.M. and Robins, E. Mania: Sympathoadrenal function and clinical state. *Psychiatry Res.* 37:195-205, 1991.
75. Maas, J.W., Katz, M.M., Frazer, A., Bowden, C.L., Koslow, S.H., Stokes, P.E., Swann, A.C., Davis, J.M., Casper, R., Berman, N.: Current evidence regarding biological hypotheses of depression and accompanying pathophysiological processes: A critique and synthesis of results using clinical and basic research results. *Integ. Psychiatry* 7:155-161, 1991.
76. Steketee, J.D., Silverman, P.B. and Swann, A.C.: Noradrenergic receptor mechanisms in neophobia. *Psychopharmacology* 106:136-142, 1992.
77. Freeman, T.W., Clothier, J.L., Lesem, M.D., Pazzaglia, P.C. and Swann, A.C. A double-blind comparison of valproic acid and lithium in the treatment of acute mania. *Am. J. Psychiatry* 149:108-111, 1992.
78. Stanley, M.A., Swann, A.C., Bowers, T.C., Davis, M.L., and Taylor, D.J.: A comparison of clinical features in trichotillomania and obsessive-compulsive disorders. *Behav. Res. Ther.* 30:39-44, 1992.
79. Swann, A.C., Stokes, P.E., Casper, R., Secunda, S.K., Bowden, C.L., Berman, N., Katz, M.M., and Robins E.: Hypothalamic-pituitary-adrenocortical function in mixed and pure mania. *Acta Psychiat. Scand.*, 85:270-274, 1992.
80. Stanley, M.A., Prather, R.C., Wagner, A.L., Davis, M.L., Swann, A.C.: Can the Yale-Brown obsessive-compulsive scale be used to assess trichotillomania? *Behav. Res. Ther.*, 31:171-177, 1993.
81. McElroy, S.L., Keck, P.E. Jr., Pope, H.G., Jr., Hudson, J.I., Faedda, G.L., and Swann, A.C.: Dysphoric or mixed mania: Clinical and research implications. *Am. J. Psychiatry* 149:1633-1644, 1992.
82. Dilsaver, S.C., Minkus, D., Swann, A.C.: Chronic treatment with valproate decreases the hypothermic response to clonidine. *Pharmacol. Biochem. Behav.*, 45:247-249, 1993.
83. Swann, A.C., Secunda, S.K., Katz, M.M., Croughan, J., Bowden, C.L., Koslow, S.H., Berman, N., Stokes, P.E.: Specificity of mixed affective states: Clinical comparison of dysphoric mania and agitated depression. *J. Affective Disord.* 28:81-89, 1993.
84. Dilsaver, S.C., Swann, A.C., Shoaib, A.M., Bowers, T.C., and Halle, M.T.: Mixed mania associated with non-response to antimanic agents. *Am. J. Psychiatry*, 150:1548-1551, 1993.
85. Katz, M.M., Wetzler, S., Cloitre, M., Swann, A., Secunda, S., Mendels, J., Robins, E.: Expressive characteristics of anxiety in depressed men and women. *J. Affect. Disord.* 28:267-277, 1993.

Refereed Original Articles in Journals (Cont'd)

86. Carrion, P.G., Swann, A., Kellert, H.: Compliance with clinic attendance in outpatients with schizophrenia. *Hosp. Commun. Psychiatry* 44:764-767, 1993.
87. Dilsaver, S.C., Swann, A.C., Shoaib, A.M., Bowers, T.C.: The manic syndrome: Factors potentially predicting response to lithium, carbamazepine, and valproate. *J. Psychiatry Neurosci.* 18:61-66, 1993.
88. Brown, E.S., Dilsaver, S.C., Shoaib, A.M., Swann, A.C.: Depressive mania: response of residual depression to bupropion. *Biol. Psychiatry* 35:493-494, 1994.
89. Dilsaver, S.C., Peck, J.A., Traumata, D., Swann, A.C.: Treatment with carbamazepine may enhance α_2 -noradrenergic autoreceptor sensitivity. *Biol. Psychiatry* 34:551-557, 1993.
90. Swann, A.C., Stokes, P.E., Secunda, S.K., Maas, J.W., Bowden, C.L., Berman, N., Koslow, S.H.: Depressive mania vs agitated depression: Biogenic amine and hypothalamic-pituitary-adrenocortical function. *Biol. Psychiatry*, 35:803-813, 1994.
91. Bowden, C.L., Brugger, M., Swann, A.C., Calabrese, J.R., Janicak, P.G., Petty, F., Dilsaver, S.C., Davis, J.M., Rush, A.J., Small, J.G., Garza-Trevino, E.S., Risch, S.C., Goodnick, P.H., Morris, D.D.: Efficacy of divalproex sodium vs. lithium and placebo in the treatment of mania. *JAMA* 271:918-924, 1994.
92. Cherry, L., Swann, A.C.: Cation transport mediated by Na^+/K^+ -ATPase in lymphoblastoid cells from patients with bipolar disorder, their relatives, and unrelated controls. *Psychiatry Res.* 53:111-118, 1994.
93. Maas, J.W., Katz, M.M., Koslow, S.H., Swann, A.C., Davis, J.M., Berman, N., Bowden, C.L., Stokes, P.E., Landis, H. Adrenomedullary function in depressed patients. *J. Psychiat. Res.*, 28(4):357-367, 1994.
94. Bowden, C.L., Calabrese, J.R., Walin, B.A., Swann, A.C., McElroy, S.L., Risch, S.C., Hirschfeld, M.A. Who enters therapeutic trials? Illness characteristics of patients in clinical drug studies of mania. *Psychopharmacology Bulletin*, 31:103-109, 1995.
95. Cecil, H., Stanley, M.A., Carrion, P.G., Swann, A.C.: Psychometric Properties of the MSPSS and NOS in Psychiatric Outpatients. *Journal of Clinical Psychology*, 51(5):593-602, 1995.
96. Bonate, P.L., Davis, C.M., Silverman, P.B., Swann, A.C. Determination of cocaine in biological matrices using reversed phase HPLC: Application to plasma and brain tissue. *Journal of Liquid Chromatography*, 18(17):3473-3494, 1995.
97. Dilsaver, S.C., Chen, Y-W., Swann, A.C., Shoaib, A.M., Krajewski, K.J.: Suicidality in patients with pure and depressive mania. *Am. J. Psychiatry*, 151:1312-1315, 1994.

Alan C. Swann, M.D.

Refereed Original Articles in Journals (Cont'd)

98. Dilsaver, S.C., Swann, A.C.: Mixed mania: Apparent induction by a tricyclic antidepressant in five consecutively treated patients with bipolar depression. *Biol. Psychiatry*, 37:60-62, 1995.
99. Gaytan, O., Swann, A.C., Dafny, N.: Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat. *European Journal of Pharmacology*, 300:1-8, 1996.
100. Bowden, C.L., Janicak, P.G., Orsulak, P., Swann, A.C., Davis, J.M., Calabrese, J.R., Goodnick, P., Small, J.G., Rush, A.J., Kimmel, S.E., Risch, S.C., Morris, D.D.: Relation of Serum Valproate Concentration to Response in Mania. *Am. J. Psychiatry*, 153(6):765-770, 1996.
101. Dilsaver, S.C., Swann, A.C., Chen, Y.-W., Shoaib, A., Joe, B., Krajewski, K.J., Gruber, N., Tsai, Y. Treatment of bipolar depression with carbamazepine: Results of an open study. *Biol. Psychiatry*, 40:935-937, 1996.
102. Petty, F., Rush, A.J., Davis, J.M., Calabrese, J.R., Kimmel, S.E., Kramer, G.L., Small, J.C., Miller, M.J., Swann, A.C., Orsulak, P.J., Blake, M.E., Bowden, C.L.: Plasma GABA predicts acute response to divalproex in mania. *Biological Psychiatry*, in press.
103. Swann, A.C., Bowden, C.L., Morris, D., Calabrese, J.R., Petty, F., Small, J., Dilsaver, S.C., Davis, J.M.: Depression during mania: Treatment response to lithium or divalproex. *Arch. Gen. Psychiatry*, 54:37-42, 1997.
104. Gaytan, O., Swann, A.C., Dafny, N.: Dose-response characteristics of methylphenidate on indices of rat locomotor activity at the beginning of the dark cycle. *Brain Res.*, in press.
105. Chen, R.Y., Swann, A.C., Burt, D.B.: Stability of diagnosis in schizophrenia. *Am J. Psychiatry*, 153(5):682-686, 1996.
106. Moeller, F.G., Dougherty, D.M., Swann, A.C., Collins, D., Davis, C.M.: Tryptophan depletion and aggressive responding in healthy males. *Psychopharmacology*, in press.
107. Bjork, J.M., Gayton, G., Patt, N., Swann, A.C., Dafney, N.: Behavioral tolerance to and withdrawal from multiple fluoxetine administration. *Intern. J. Neuroscience*, in press.
108. Bonate, P.L., Swann, A.C., Silverman, P.B.: Context-dependent cross-sensitization between cocaine and amphetamine. *Life Sciences*, in press.
109. Johnson, B.A., Chen, Y., Swann, A.C., Schmitz, J., Lesser, J., Johnson, P., Clyde, C.: Risperidone in the treatment of cocaine dependence. *Biological Psychiatry*, in press.
110. Bonate, P.L., Swann, A.C., Silverman, P.B.: Preliminary physiologically based pharmacokinetic model for cocaine in the rat: Model development and scale-up to humans. *Journal of Pharmaceutical Sciences*, in press.

Alan C. Swann, M.D

111. Gayton, O., Swann, A.C., Dafny, N. Effects of amphetamine at the beginning of the light or dark cycles on motor activity in the rat. *Brain Research*, in press.
112. Gayton, O., Al-Rahim, S., Swann, A., Dafny, N. Sensitization to locomotor effects of methylphenidate in the rat. *Psychopharmacology Letters*, in press.
113. Swann, A.C., Bowden, C.L., Rush, A.J., Rhoades, H., Rose, R., Kobes, R. Desipramine versus phenelzine in recurrent unipolar depression: Clinical characteristics and treatment response. *J. Clin. Psychopharmacology*, 17(2):78-83, 1997.

C. Chapters and Invited Contributions:

1. Swann, A.C.: Brain (Na⁺,K⁺)-ATPase: Regulation by norepinephrine and an endogenous inhibitor. Current Topics in Membrane Transport, Vol. 19. (Eds.: Hoffman, J.F. and Forbush, B.), Academic Press, pp. 931-937, 1983.
2. Swann, A.C.: Comparison of univalent cation binding sites in ouabain binding and (Na⁺,K⁺)-ATPase regulation. In The Sodium Pump (Glynn I.M. and Ellory, J.C., Eds.), 271-275, 1985.
3. Swann, A.C.: Mania: Amines, Symptoms, and Response to Lithium. In Swann, A.C. (Ed.): Mania: New Research and Treatment, American Psychiatric Press, Washington, D.C., pp. 177-200, 1986.
4. Secunda, S.K., Katz, M.M., Swann, A.C., Koslow, S.H.: Mixed Mania: Diagnosis and Treatment. In Swann, A.C. (Ed.): Mania: New Research and Treatment. American Psychiatric Press, Washington, D.C., pp. 79-94, 1986.
5. Swann, A.C.: Membrane effects of ethanol in excitable cells. *Rev. Clin. Basic Pharmacol.* 6:213-248, 1987.
6. Swann, A.C.: Cocaine: Synaptic effects and adaptations. In Volkow, N. and Swann, A.C., (Eds.): Cocaine in the Brain, Rutgers University Press, pp. 58-94, 1990.
7. Koslow, S.H., Maas, J.W., Bowden, C.L., Davis, J.M., Swann, A.C., Stokes, P.E., Katz, M.M.: Catecholamine system function in depression. In Progress in Catecholamine Research: Clinical Aspects. (Eds.: Belmaker, R.H., Sandler, M. and Dahlstrom, A.) Alan Liss, New York, pp. 209-215, 1988.
8. Swann, A.C., Secunda, S.K., Koslow, S.H., Maas, J.W., Davis, J.M.: Catecholamine function in mania. In Progress in Catecholamine Research: Clinical Aspects. (Eds.: Belmaker, R.H., Sandler, M. and Dahlstrom, A.) Alan Liss, New York, pp. 217-221, 1988.
9. Swann, A.C.: Practical management of depressive and manic episodes. In Garza-Trevino, E.S. (Ed.): Medical Psychiatry: Theory and Practice. World Scientific Publishing Co., Teaneck, N.J., pp. 351-400, 1989.

Alan C. Swann, M.D.

Chapters and Invited Contributions (Cont'd)

10. Swann, A.C.: Mania: Phenomenology and treatment response. *Int. Rev. Psychiatry*, 1:119-123, 1990.
11. Swann, A.C. Mood disorders. In Bonjean, C.M. and Foss, D.J. (Eds.): Mental Health Research in Texas: Retrospect and Prospect, Hogg Foundation for Mental Health, pp 80-87, 1990.
12. Swann, A.C.: Adaptation of brain Na,K-ATPase to changes in neural activity. In Kaplan, J. and DeWeer, P (Eds.): The Sodium Pump: Recent Developments. The Rockefeller University Press, New York, pp 591-595, 1991.
13. Swann, A.C.: Biology of Bipolar Disorders. In Mann, J.J. and Kupfer, D.J. (Eds.): The Biology of Depressive Disorders, Part B: Subtypes of Depression and Comorbid Disorders. Plenum Press, New York, pp 1-35, 1993.
14. Swann, A.C. Mixed or dysphoric manic states: Psychopathology and treatment. In Joffe, R.T. and Calabrese, J. (Eds.): Anticonvulsants in Psychiatry, Marcel Dekker, New York, in press.
15. Dager, S.R., Swann, A.C.: Advances in brain metabolism research: Toward a moving picture of neural activity (Editorial). *Biol. Psychiatry*, 39:231-233, 1996.

D. Books:

1. Swann, A.C. (Ed.) Mania: New Research and Treatment. American Psychiatric Press, Washington, D.C., 1986.
2. Volkow, N. and Swann, A.C. (Eds.) Cocaine in the Brain, Rutgers University Press, 1990.

E. Other Professional Communications:


1. Redmond, D.E., Swann, A.C., Heninger, G.R.: Phenoxybenzamine in anorexia nervosa. *Lancet* ii, 309, 1977.
2. Bowden, C.M., Redmond, D.E. Jr., Swann, A.C., Maas, J.W.: Pretreatment amine neurotransmitter system interrelationships in depression. *Psychopharm. Bull.* 17:70-72, 1981.
3. Swann, A.C., Davis, J., Maas, J.W., Secunda, S., Kocsis, J., Javadi, J., Chang, S.: Lithium treatment in mania: Behavioral and neurochemical changes. *Clin. Neuropharmacol.* 7 (suppl 1), S444-S445, 1984.
4. Lloyd, C., Swann, A.C.: Depression and adaptation to stress: Toward a systems model. *Behav. Brain Sci.* 8:371-372, 1984.


Alan C. Swann, M.D

Other Professional Communications (Cont'd)

5. Stokes, P.E., Stoll, P.M., Davis, J.M., Koslow, S.H., Swann, A.C., Maas, J.W., Robins, E.: Limited utility of the 1-mg dexamethasone suppression test as a measure of hypercortisolism. *Arch. Gen. Psychiatry* 42:202-204, 1985.
6. Volkow, N., Swann, A.C., Harper, A.: Temporal lobe abnormalities and panic attacks. *Am. J. Psychiatry* 143:1484-1485, 1986.
7. Swann, A.C., Reilly, E.L., Overall, J.E.: Membrane adaptation to chronic ethanol in man. *Ann. New York Acad. Sci.* 492:136-137, 1987.
8. Swann, A.C.: Alteration of (Na⁺,K⁺)-ATPase regulation by ethanol and noradrenergic manipulations in vivo. *Ann. New York Acad. Sci.* 492:401-402, 1987.
9. Clothier, J.L., Pazzaglia, P.J., Freeman, T.W., Lesem, M.D., Swann, A.C.: Plasma level response characteristics of valproate in the treatment of manic syndrome. *Ann. Clin. Psychiatry*, 3:321-324, 1991.
10. Beller, S.A., Overall, J.E. and Swann, A.C. Drug treatment of patients with senile dementia. *Geriatric Medicine Today*, 8:49-55, 1989.
11. Stanley, M.A., Bowers, T.C., Swann, A.C., Taylor, D.J. Treatment of trichotillomania with fluoxetine. *J. Clin. Psychiatry*, 52:282, 1991.
12. Clothier, J.L., Swann, A.C., and Freeman, T.W.: Dysphoric mania. *J. Clin. Psychopharm.*, 12:13S-16S, 1992.
13. Walls, M.J., Bowers, T.C., Dilsaver, S.C., Swann, A.C.: Catatonia associated with depression secondary to complex-partial epilepsy. *J. Clin. Psychopharm.*, 54:73, 1993.
14. Satel, S.L., Swann, A.C.: Extrapyrarnidal symptoms and cocaine abuse. *Am. J. Psychiatry*, 150:347, 1993.
15. Swann, A.C.: Mixed or dysphoric manic states: Psychopathology and treatment. *J. Clin. Psychiatry*, 56:6S-10S, 1995.

TEXAS STATE BOARD OF MEDICAL EXAMINERS	
PO BOX 2018 • AUSTIN, TEXAS 78768-2018	
PHYSICIAN PERMIT	
LICENSE NUMBER [REDACTED]	EXPIRATION DATE 05-31-98
ALAN CRAIG SWANN, MD [REDACTED]	
THIS CERTIFIES THAT THE LICENSEE NAMED AND NUMBERED HEREON HAS PROVIDED THIS BOARD THE INFORMATION REQUIRED AND HAS PAID THE FEE FOR ANNUAL REGISTRATION FOR THE YEAR INDICATED ABOVE. PLEASE KEEP THIS BOARD NOTIFIED OF CHANGE OF ADDRESS	





CURRICULUM VITAE

Steven D. Targum, M.D.
Clinical Studies, Philadelphia
400 Market Street, Suite 425
Philadelphia, Pa. 19106
(215) 923-2583

Education:

1965 - 1969	Colgate University, Hamilton, NY B.A. magna cum laude with honors in biology
1969 - 1973	Mount Sinai School of Medicine, New York, NY Doctor of Medicine
1973 - 1974	Mount Sinai School of Medicine, New York, NY Residency in Obstetrics-Gynecology
1974 - 1976	Rutgers Institute of Mental Health Science, Piscataway, NJ Residency in Psychiatry
1976 - 1978	National Institute of Mental Health, Bethesda, MD Clinical Associate and Residency, Biological Psychiatry and Psychogenetics

Academic Affiliations:

1989 - Present	Professor of Psychiatry Allegheny University of the Health Sciences, Philadelphia, PA
1989 - 1995	Vice Chairman, Department of Mental Health Sciences Hahnemann University School of Medicine, Philadelphia, PA
1983 - 1989	Clinical Associate Professor of Psychiatry University of South Florida School of Medicine, Tampa, FL
1979 - 1983	Clinical Assistant Professor of Psychiatry Georgetown University School of Medicine, Washington, DC

Curriculum Vitae
Steven D. Targum, M.D.
Page 2

Professional Experience:

10/96 - Present	Vice President of Medical Affairs Clinical Studies Ltd.
10/96 - Present	Principal Investigator Clinical Studies, Philadelphia
10/95 - Present	Director of Research, Department of Psychiatry Crozer-Chester Medical Center, Upland, PA
4/94 - 10/96	Chief Executive Officer Delaware Valley Clinical Studies Center, Philadelphia, PA
10/94 - 10/96	Medical Director Philadelphia Medical Institute and Memory Institute, Philadelphia, PA
1989 - 1995	Chairman, Department of Psychiatry Crozer-Chester Medical Center, Upland, PA
1989 - 1993	Special Reviewer National Institutes of Mental Health, Bethesda, MD
1983 - 1989	Medical Director Sarasota Palms Hospital, Sarasota, Florida
1978 - 1983	Director of Research and Evaluation The Psychiatric Institute of Washington, DC
1978 - 1980	Director, Psychiatric Intensive Care Unit The Psychiatric Institute of Washington
1980 - 1983	Director, Neuropsychiatric Evaluation Program The Psychiatric Institute of Washington, DC
1980 - 1983	Director, National Capital Sleep Centers, Inc. Bethesda, MD

Curriculum Vitae

Steven D. Targum, M.D.

Page 3

Professional Experience

(cont'd):

1978 - 1983 **Guest Worker, Section on Psychogenetics
National Institute of Health, Biological Psychiatry
Branch, Bethesda, MD**

Fellowships:

1968 & 1969 **Downstate Medical Center, Brooklyn, NY
Department of Anatomy for Research in Genetics**

1970 **Mt. Sinai Hospital, New York, NY
Department of Psychiatry, USPHS**

1971 **Mt. Sinai Hospital, New York, NY
Department of Community Medicine, USPHS**

1973 **USPHS-AAMC Fellowship in Belgrade, Yugoslavia**

Professional Memberships/Organizations:

**American Psychiatric Association
American Medical Association
Society of Biological Psychiatry
International Society of Psychoneuroendocrinology
Psychiatric Research Society
Pennsylvania Medical Society
American Academy of Clinical Psychiatrists
Philadelphia Psychiatric Society**

Licenses/Certifications:

Active

1974 **New Jersey REDACTED**
1989 **Pennsylvania, REDACTED**
1974 **National Board of Medical Examiners**
1978 **American Board of Psychiatry and Neurology**

Inactive

1976 **Maryland**
1978 **District of Columbia**
1983 **Florida**

Curriculum Vitae

Steven D. Targum, M.D.

Page 4

Honors/Awards:

Phi Beta Kappa, Elected to Membership, 1969
Nathaniel Stanton Fellowship Award, Colgate University, 1969
Lange Medical Award, Mount Sinai School of Medicine, 1973
A.E. Bennett Award, Honorable Mention, Society of Biological
Psychiatry, 1983
Presidential Award for Research in Psychiatry, National Association
of Private Psychiatric Hospitals, 1985
Fellowship, American Psychiatric Association, 1988

Current Hospital Staff Appointments:

Crozer-Chester Medical Center, Upland, PA
Springfield Hospital, Springfield, PA
Charter Fairmount Behavioral Health System, Philadelphia, PA

Research Experience:

xxx for the Study of Obsessive-Compulsive Disorder xxx

xxx for the Study of Hypnotic Agent xxx

xxx for the Study of Antidepressant Drug, xxx

xxx for the Study of T Cell Function in Depression

xxx Corporate grant for the Study of Seasonal Affective
Disorder

A Double-Blind Parallel Comparison of xxx, xxx and Placebo in
Inpatients with Major Depression or Bipolar Disorder

Efficacy and Safety of xxx in Patients with Alzheimer's Disease

An Open Multicenter Trial of xxx and Placebo in the Treatment of
Depressed Inpatients

Short and Long Term Discontinuation of xxx in the Treatment of
Panic Disorder with Agoraphobia

Curriculum Vitae

Steven D. Targum, M.D.
Page 5

Research Experience

(cont'd):

Double-Blind, Placebo-Controlled Study of xxx in the Treatment of Secondary (Acquired) Male Erectile Disorder

A Placebo-Controlled Study of xxx in the Management of Exogenous Obesity

A Pilot Observation to Develop Information on Sexual Functioning and Quality of Life in Patients with Obsessive Compulsive Disorder

A Controlled Study of xxx in the Treatment of Alzheimer-Type Dementia

A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of xxx in Schizophrenic Patients

An Open-Label Assessment of the Long-Term Safety of xxx in the Treatment of Schizophrenic Patients

Double-Blind Evaluation of the Clinical Usefulness of Low Dose xxx for the Symptomatic Treatment of Dementia in Institutionalized Patients

A Double-Blind Study of xxx in the Treatment of Panic Disorder

A Double-Blind Study of xxx in Generalized Anxiety Disorder

A Double-Blind Study of xxx and xxx in Highly Anxious Outpatients with Major Depression

An Open-Label Study of xxx in Generalized Anxiety Disorder

A Double-Blind Comparison of xxx and xxx in the Prevention of Psychotic Relapse in Outpatients with Schizophrenia

A Double-Blind Study of Single Doses of xxx in Alzheimer's Disease

Clinical Evaluation of Extended-Release Oral xxx in the Treatment of Patients with Dementia of the Alzheimer's Type

Curriculum Vitae

Steven D. Targum, M.D.
Page 6

Research Experience
(cont'd) :

An Open Label Extension of Extended-Release Oral xxx
Treatment of Patients with Dementia of the Alzheimer's Type

A Double-Blind Placebo-Controlled Dose Escalation Study of the
Safety and Efficacy of oral xxx in the Treatment of Patients with
Panic Disorder

A Double-Blind, xxx-Referenced Study of the Safety and Efficacy
of Two Doses of xxx in Schizophrenic Patients

An Open-Label Assessment of the Long-Term Safety of xxx

A Double-Blind Study to Assess the Efficacy and Safety of Four
Oral Dose Levels of xxx in Men with Erectile Disorder

A Randomized Pilot Study to Assess the Efficacy and Safety of
Two Oral Dose Levels of xxx in Men with Erectile Disorder

A Phase II, Double-Blind Study of 3 Different Doses of xxx
vs Placebo in Outpatients Suffering from Depression

A Double-Blind Study Evaluating the Safety and Efficacy of Two
Dose Regimens of Oral xxx and xxx in the Maintenance Treatment
of Outpatients with Schizophrenia or Schizoaffective Disorder

A Phase III, Double-blind, Comparative and Placebo-Controlled
Parallel-Group Safety, Tolerance, and Efficacy Study of xxx,
Compared with xxx or Placebo in Adult Outpatients with Insomnia

xxx Dose Titration Study

A Double-Blind, Placebo-Controlled Dose-Escalation Study of
the Safety and Efficacy of Oral xxx in the Treatment of Patients
with Panic Disorder

A Multi-Center, Open-Label, Flexible-Dose Study to Evaluate the
Long-Term Effects of xxx Administered for an Additional 18
Months to Relatively Healthy Obese Patients Who Have
Participated in xxx

Curriculum Vitae

Steven D. Targum, M.D.

Page 7

Research Experience

(cont'd):

Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Three Doses of xxx Administered for 12 Weeks to Subjects with Alzheimer's Disease

Phase II Open-Label, Multicenter Extension Study of the Safety and Efficacy of xxx Administered for Twenty-Six Weeks to Subjects with Alzheimer's Disease

A Phase II, Eight Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral xxx in Outpatients with Major Depressive Disorder

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of Three Fixed-Doses of xxx per Day in Patients with Probable Mild to Moderate Alzheimer's Disease

A Prospective, Randomized, Multi-Center, Double-Blind, Parallel-Group Study of the Efficacy and Safety of xxx as Compared to xxx and Placebo in Institutionalized Patients with Chronic Schizophrenia

Six Month Efficacy and Safety Study of xxx in Patients with Alzheimer's Disease

A 26-Week, Double-Blind, Parallel, Multicenter, Multi-Country Comparison of xxx and xxx on Cough and Blood Pressure with Essential Hypertension

Open Label Extension of Protocol xxx: xxx Tartrate vs Placebo in Mild to Moderate Alzheimer's Disease

Preliminary Double-blind, Placebo-controlled Evaluation of xxx Capsules in Outpatients with Alzheimer's Disease

A 16 Week Open-Label Safety Study of xxx with Monitoring of Serum Alanine Aminotransferase at Weeks, 4,6,8,12 and 16

Curriculum Vitae

Steven D. Targum, M.D.
Page 8

Research Experience

(cont'd):

A Placebo-Controlled, Randomized, Double-Blind, Multicenter Study of the Efficacy and Safety of xxx in Patients with Probable Alzheimer's Disease of Moderate Severity

Six Month, Open-Label Evaluation of the Safety and Efficacy of xxx Followed by a Randomized, Double-Blind, Placebo-Controlled One Year Evaluation of xxx in Prophylactic Treatment of Recurrent Major Depression

A Double-Blind, Placebo-Controlled, Parallel, Dose-Ranging Assessment of the Safety and Tolerability of the xxx Transdermal System in Patients with Major Depression (Unipolar)

Forty-Eight Week Efficacy and Safety Study of xxx in Patients with Alzheimer's Disease

Twenty-Four Week Efficacy and Safety Study of xxx in Patients with Vascular Dementia

A Fifty-Two Week, Double-blind Extension Study Evaluating the Safety and Efficacy of Two Dose Regimens of xxx and xxx in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder Who Have Successfully Completed Protocol xxx

Safety and Efficacy of xxx Compared to Placebo in the Treatment of Schizophrenia

An Open-Label, Six-Month Extension of xxx Studies xxx and xxx to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 through 6 mg BID xxx in Outpatients with Probable Alzheimer's Disease

A Multicenter, Open Label Trial Evaluating the Safety and Tolerability of xxx in the Treatment of Elderly Subjects with Selected Idiopathic and Organic Psychoses

A Long-term (One-Year) Open-label, Multicenter Extension of Twice Daily Oral xxx in Patients with Essential Hypertension Who Have Completed a Clinical Trial with xxx

Curriculum Vitae

Steven D. Targum, M.D.

Page 9

Research Experience

(cont'd):

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Groups Comparison of the Efficacy and Safety of xxx and xxx in Patients with Mild to Moderate Probable Alzheimer's Disease

A Multicenter, Placebo-Controlled Study of Relapse-Prevention by Long-Term Treatment with High or Low Doses of xxx in Out-Patients with Recurrent Major Depressive Episode

Open Label Extension of Study xxx to Evaluate Long-Term Administration of xxx in the Treatment of Patients with Dementia of the Alzheimer's Type

Forty-Eight Week Efficacy and Safety Study of xxx in Patients with Alzheimer's Disease

An Open-label Sequential Cohort Study of xxx Designed to Prospectively Evaluate the Tolerability and Safety of Titration Doses at Weekly Increases of xxx and xxx to a Maximal Daily dose of xxx of xxx in Outpatients with Probable Alzheimer's Disease

A Forty-Eight Week Study to Compare the Efficacy and Safety of xxx with Placebo in Outpatients with Alzheimer's Disease

A Twenty-Four Week Study to Compare the Efficacy and Safety of xxx with Placebo in Outpatients with Vascular Dementia

A Twelve Month, Double-blind, Placebo-Controlled, Investigation of the Safety and Efficacy of xxx Transdermal System

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of xxx in Patients with Probable Alzheimer's Disease with Long-Term Open-Label Extension

A 24-Week, Double-Blind, Placebo Controlled, Parallel Group, Fixed Dose Study of the Efficacy and Tolerability of xxx in Patients Suffering from Dementia of the Probable Alzheimer's Type

Curriculum Vitae

Steven D. Targum, M.D.

Page 10

Research Experience

(cont'd):

A Double-Blind, Randomized, Comparison of the Safety and Efficacy of xxx and xxx in Treatment Resistant Schizophrenic Patients

A Phase III Efficacy and Safety Study of Three Fixed Doses of xxx Tablets Versus Placebo in the Treatment of Male Erectile Dysfunction

xxx Plus xxx Versus xxx Plus xxx in the Treatment of Major Depression

A Phase III, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days Treatment with Intramuscular xxx or xxx Followed by 4 Days of Treatment with Oral xxx or xxx in Subjects with a Diagnosis of Psychotic Disorder

A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of xxx in Schizophrenic and Schizoaffective Patients

Safety and Efficacy of the xxx Transdermal Therapeutic System in Patients with Mild to Moderate Alzheimer's Disease

Double-Blind Evaluation of xxx vs xxx on the Long-Term Morbidity of Early Psychotic Patients

A Phase II Multicenter, Double-Blind, Parallel, Randomized Comparison of Oral xxx and Placebo Over 28 Days in Patients with Schizophrenia

A Double-Blind, Placebo Controlled Trial to Compare the Clinical Effects of Immediate Release xxx and Modified Release xxx in the Treatment of Major Depression in Elderly Patients

Efficacy, Tolerability, and Safety of xxx in the Treatment of Alzheimer's Disease

Curriculum Vitae

Steven D. Targum, M.D.

Page 11

Research Experience
(cont'd):

An Open-Label Study to Evaluate the Safety and Efficacy of xxx through xxx of xxx in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting

Open Evaluation of the Long Term Efficacy, Safety and Tolerability of xxx in the Acute Treatment of Migraine Attacks

A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release xxx in the Treatment of Panic Disorder

Double-Blind, Placebo-Controlled Study of xxx and xxx in Outpatients with Major Depression

Double-Blind, Placebo-Controlled Study of xxx and xxx in Inpatients with Major Depression and Melancholia

xxx Versus xxx and xxx in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms

A Phase III Long-Term, Open-Label, Flexible Dose, Efficacy and Safety Study of xxx Tablets in the Treatment of Male Erectile Dysfunction

A Long-Term, Open Label, Phase III Trial to Evaluate the Efficacy, Safety and Tolerability of xxx in the Acute Treatment of Migraine Attacks in Subjects Who Previously Completed the xxx or xxx Trial and in xxx Naive Subjects

A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of xxx in Schizophrenic and Schizoaffective Patients

A Multicenter, Open-Label, Long-Term Followup, Safety Study of xxx in Schizophrenia and Schizoaffective Patients who Participated in xxx

Curriculum Vitae

Steven D. Targum, M.D.
Page 12

Research Experience
(cont'd):

An Open Extension Study of the Long Term Safety and Efficacy of xxx in Patients Suffering from Dementia of the Probable Alzheimer's Type

The Efficacy, Safety and Tolerability of xxx Versus Placebo for One Year in Patients Diagnosed with Alzheimer's Disease

A Double-Blind, Randomized, Parallel Group, Multicenter Comparison of the Efficacy and Safety of xxx po and Placebo in Patients with Active Rheumatoid Arthritis Who are Candidates for Immunosuppressive Therapy of RA

A Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Sustained Release xxx in Obese Outpatients

An Open-Label, Long Term Safety Extension of the Four Month Study of Sustained Release xxx in Obese Outpatients

Clinical Protocol for a Double-blind, Placebo Controlled, Randomized Comparison Study of the Efficacy and Safety of xxx bid and xxx bid in Treating the Signs and Symptoms of Osteoarthritis of the Hip

Double-Blind Crossover Comparison of xxx with xxx and xxx in Cancer Patients

A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled, Study to Evaluate the Safety, Efficacy and Tolerability of xxx Therapy when Administered to Patients with Non-Insulin Dependent Diabetes Mellitus Using a Once Daily Dosing Regimen, and to Determine the Therapeutic Equivalence of the Once and Twice Daily Dosing Regimens

A Randomized, Double-Blind, Placebo Controlled Six Month Safety and Efficacy Trial of xxx in Type II Diabetes Millitus Patients

Curriculum Vitae
Steven D Targum, M.D.
Page 13

Research Experience
(cont'd):

A Randomized, Comparative, Multicenter, Safety and Contraceptive Efficacy Study of Two xxx Regimens, and one xxx Regimen

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of xxx in Patients with Alzheimer's Disease

A Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of xxx Given Subcutaneously in the Acute Treatment of Migraine

Efficacy, Tolerability and Safety of xxx in the Treatment of Alzheimer's Disease

A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder

Weekly Enteric-Coated XXX vs Daily XXX of Placebo in the Continuation Treatment of Major Depressive Disorder

Pharmacological Treatment of XXX -Associated Sexual Dysfunction

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Evaluation of the Efficacy and Safety of XXX in Patients with Dementia Associated with Cerebrovascular Disease

Asn Open Extension Study of the Long-Term Safety and Efficacy of XXX in Patients suffering from Dementia of the Alzheimer's Type

The Efficacy, Safety, and Tolerability of XXX vs Placebo Administered for One Year in Patients with Probable Alzheimer's Disease

An Eight-Week, Double-Blind, Placebo-Controlled Study of XXX and XXX in Patients with Major Depressive Disorder

Curriculum Vitae
Steven D. Targum, M.D.
Page 14

Research Experience
(cont'd):

A Double-Blind, Parallel, Placebo-Controlled, Single-Dose Study of the Activity of Four Dose Levels of XXX for the Treatment of Migraine Headaches With or Without an Aura in Females

A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal XXX Compared to Placebo in the Treatment of Anxious Outpatients

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXX in Patients with Dementia Associated with Cerebrovascular Disease

A Clinical Protocol to Evaluate the Long-Term Safety of XXX in Treating the Signs and Symptoms of Osteoarthritis and Rheumatoid Arthritis

A Randomized, Comparative, Multicenter, Safety and Contraceptive Efficacy Study of Two Cyclophasic XXX Regimens, and One Triphasic XXX Regimen and XXX

An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of XXX in Elderly Outpatients with DSM-IV Major Depression

Double-Blind Crossover Comparison of XXX with XXX and XXX on Cancer and Other Chronic Pain

Publications:

1. Targum, S.D., Wright, N.H., "Association of the Intrauterine Device and Pelvic Inflammatory Disease: A Retrospective Pilot Study", AM J Epidemiol 100:262-271, 1974
2. Gershon, E.S., Targum, S.D., Kessler, L.R., Mazure, C.M., Bunney, Jr., W.E., "Genetic Studies and Biological Strategies in the Affective Disorders", Prog Med Genet, II:101-164, 1977

Curriculum Vitae

Steven D. Targum, M.D.

Page 15

Publications

(cont'd):

3. Gershon, E.S., Targum, S.D., Leckman, J.F., "Platelet Monamine Oxidase (MAO) Activity and Genetic Vulnerability to Bipolar (BP) Affective Illness", Psychopharm Bull, 15:27-30,1979
4. Reus, V.I., Targum, S.D., Weingartner, H., Post, R.M., "Effect of Lithium Carbonate on Memory Processes of Bipolar Affectively Ill Patients", Psychopharm 63:39-42,1979
5. Targum, S.D., Gershon, E.S., VanEerdewegh, ., Rogentine, N., "The Human Leukocyte Antigen (HLA) System and Bipolar Affective Illness", Biol Psychiat, 14:615-633,1979
6. Gershon, E.S., Targum, S.D., Matthysse, S., Bunney, Jr., W.E., "Color Blindness Not Closely Linked to Bipolar Illness, A Report of a New Pedigree Series" Arch Gen Psychiat, 36:1423-1430,1979
7. Leckman, J.F., Gershon, E.S., McGinniss, M.H. Targum, S.D., Dibble, E.D., "New Data Do Not Suggest Linkage Between the Xg Blood Group and Bipolar Illness", Arch Gen Psychiat, 36:1435-1441,1979
8. Targum, S.D., Davenport, Y.B., Webster, M.J., "Postpartum Mania in Bipolar Manic-Depressive Patients Withdraw from Lithium Carbonate", J. Nerv Ment Dis, 1976:572-574,1987
9. Targum, S.D., Gershon, E.S., Shen, R., Abell, C.W., "Screening for PKU Heterozygosity in Bipolar Affectively Ill Patients", Biol Psychiat, 14:651-655,1979
10. Sparkes, R.S., Targum, S.D., Gershon, E., Sensabaugh, G.F., Sparkes, M.C., Crist, M., "Evidence for a Null Allele at the Esterase D EC 3.1.1.1.) Locus", Hum Genet, 46:319-323,1979
11. Targum, S.D., "Dealing with Psychosis During Pregnancy", Am Pharm, 19:482-485,1979
12. Targum, S.D., Weiss, J.O., "A Genetic Disease in the Family", Psychiat Opin, 17:23-25-1980

Curriculum Vitae
Steven D. Targum, M.D.
Page 16

Publications:
(cont'd)

13. Targum, S.D., "Family Tree Gives clues to Treating Psychosis", Am Pharm, 11:44-47, 1980
14. Targum, S.D., Gershon, E.S., "Genetic Counseling for Affective Illness", in Mania: an evolving concept, ed by Belmaker, R., Van Praage, H.M., Spectrum Publications, New York: 119-126, 1980
15. Targum, S.D., "Psychotherapeutic Consideration in Genetic Counseling", Am J Med Genetics, 8:281-289, 1981
16. Targum, S.D., "Psychiatric Genetic Counseling", J Psychiat Treat and Eval, 3:263-269, 1981
17. Targum, S.D., Dibble, E.D., Davenport, Y.B., Gershon, E.S., "Family Attitudes Questionnaire: Patients' and Spouses' View Bipolar Illness", Arch Gen Psychiat, 38:562-568, 1981
18. Frank, E., Targum, S.D., Gershon, E.S., Anderson, C., Stewart, B.D., Davenport, Y., Ketchum, K.L., Kupfer, D.J., "A Comparison of Non-Patient and Bipolar Patient-Well Spouse Couples", Am J Psychiat, 138:764-768, 1981
19. Targum, S.D., Chastek, C.T., Sullivan, A.C., "Dexamethasone Suppression Test in Prepubertal Conduct Disorders", Psychiat Res, 4:107-108, 1981
20. Targum, S.D., Gershon, E.S., "Pregnancy, Genetic Counseling, and the Major Psychiatric Disorders", in Genetic Diseases and Pregnancy, ed Schulman, J., Simpson, J., Academic Press, New York, 413-438, 1981
21. Sullivan A.C., Targum, S.D., Advani, M., "Variables Related to the Outcome of Treatment for Inpatient Alcoholics", Alcoh Health and Res Wld, 6:58-60, 1981
22. Targum, S.D., "The Adaptation to Genetic Renal Disease: Polycystic Kidneys" Controversies in Nephrology, ed Schreiner, G.E., Winchester, J.F., Georgetown Univ, 3:175-184, 1981
23. Targum S.D., Schulz, S.C., "Clinical Applications of Psychiatric Genetics", Am J Orthopsychiat, 52:45-57, 1982

Curriculum Vitae
Steven D. Targum, M.D.
Page 17

Publications
(cont'd)

24. Targum, S.D., Capodanno, A.E., Hoffman, H.A., Foudrairie, C., "An Intervention to Reduce the Rate of Hospital Discharges Against Medical Advice" Am J. Psychiat, 139:657-659, 1982
25. Targum, S.D., Sullivan, A.C., Byrnes, S.M., "Compensatory Pituitary-Thyroid Mechanisms in Major Depressive Disorder", Psychiat Res, 6:85-99, 1982
26. Targum, S.D., Byrnes, S.M., Sullivan, A.C., "Subtypes of Unipolar Depression Distinguished by the Dexamethasone Suppression Test", J Affect Dis, 4:21-27, 1982
27. Targum, S.D., Byrnes, S.M., Sullivan, A.C., "The TRH Test in Subtypes of Unipolar Depression", J Affect Dis, 4:29-34, 1982
28. Targum S.D., Sullivan A.C., Byrnes, S.M., "Neuroendocrine Interrelationships in Major Depressive Disorder", Am J Psychiat, 139:282-286, 1982
29. Weinberger, D.R., DeLisi, L.E., Perman, G.P., Targum, S., Wyatt, R.J., "Computed Tomography in Schizophreniform Disorder and Other Acute Psychiatric Disorders", Arch Gen Psychiat, 39:778-793, 1982
30. Targum, S.D., Capodanno, A.E., Unger, S., "The Post Hospital Adjustment of Psychiatric Patients, A Six-Month Follow-Up Survey", The Psychiat Hosp, 13:35-39, 1982
31. Schulz, P.M. Schulz, S.C., Dibble, E., Targum, S.D., van Kammen, D.P., Gershon, E.S., "Patient and Family Attitudes About Schizophrenia: Implications for Genetic Counseling", Schizo Bull, 8:504-513, 1982
32. Targum, S.D., Wheadon, D.E., Chastek, C.T., McCabe, W.J., Advani, M.T., "Dysregulation of Hypothalamic-Pituitary-Adrenal Axis Function in Depressed Alcoholic Patients", J Affect Dis, 4:347-353, 1982
33. Gershon, E.S., Hamovit, J., Guroff, J.J., Dibble, E., Leckman, J., Sceery, W., Targum S.D., Nurnberger, J.I., Goldin, L.R., "A Family Study of Schizoaffective, Bipolar I, Bipolar II, Unipolar, and Normal Control Probands", Arch Gen Psychiat, 39:1157-1167, 1982

Curriculum Vitae

Steven D. Targum, M.D.

Page 18

Publications

(cont'd):

34. Targum, S.D., "The Applications of Serial Neuroendocrine Challenge Studies in the Management of Depressive Disorder", Biol Psychiat, 18:3-19,1983
35. Targum S.D., "Neuroendocrine Dysfunction in Schizophreniform Disorder: Correlation with Six Month Outcome", Am J Psychiat, 140:309-313,1983
36. Targum, S.D., Rosen, L.N., DeLisi, L.E., Weinberger, D.R., Citrin, C.M., "Cerebral Ventricular Size in Major Depressive Disorder: Association with Delusional Symptoms", Biol Psychiat, 18:329-336,1983
37. Targum, S.D., Capodanno, A.E., "The Dexamethasone Suppression Test in Adolescent Psychiatric Patients", Am J Psychiat, 140:589-591,1983
38. Targum, S.D., Rose, L.N., Citrin, C.M., "Delusional Symptoms Associated with Enlarged Cerebral Ventricles in Depressed Patients", South Med J, 76:985-987,1983
39. Siever, L.J., Uhde, T.W., Jimerson, D.C., Kafka, M.S., Lake, C.R., Targum, S., Murphy, D.L., "Clinical Studies of Monoamine Receptors in the Affective Disorders and Receptor Changes with Antidepressant Treatment", Prog Neuro-Psychopharm & Biol Psychiat, 9:249-261,1983
40. Targum, S.D., "Neuroendocrine Challenge Studies in Clinical Psychiatry", Psychiat Ann, 13:385-395,1983
41. Targum, S.D., Rosen, L., Capodanno, A.E., "The Dexamethasone Suppression Test in Suicidal Unipolar Depression", Am J Psychiat, 140:877-879,1983
42. Goldin, L.R., Gershon, E.S., Targum, S.D., Sparkes, R.S., McGinnis, J., "Segregation and Linkage Analysis in Families of Patients with Bipolar, Unipolar and Schizoaffective Mood Disorders", Am J Human Genet, 35:274-287,1983
43. Capodanno, A.E., Targum, S.D., "Assessment of Suicide Risk: Some Limitations in the Prediction of Infrequent Events", J Psychosoc Nurs, 21:11-14,1983
44. DeLisi, L.E., Schwartz, C.C., Targum, S.D., Byrnes, S.M., Cannon-Spoor, E., Weinberger, D.R., Wyatt, R.J., "Ventricular Brain Enlargement and Outcome of Acute Schizophreniform Disorder", Psychiat Res, 9:169-171,1983

Curriculum Vitae
Steven D. Targum, M.D.
Page 19

Publications
(cont'd):

45. Targum, S.D., "Reported Weight Loss and the Dexamethasone Suppression Test", Psychiat Res, 9:173-174, 1983
46. Siever, L.J., Kaye, W.H., Jimerson, D.C., Lake, C.R., Kafka, M., Targum, S.D., Murphy, D.L., "Abnormalities in the Primary Affective Disorders Compared to Other Tricyclic-Responsive Disorders", Psychopharm Bull, 19:435-436, 1983
47. DeLisi, L.E., Karoum, F., Targum, S., Brynes, S., Wyatt, R.J., "The Determination of Urinary 3-Methoxy-4-Hydroxyphenylglycol Excretion in Acute Schizophreniform and Depressed Patients", Biol Psychiat, 18:1189-1196, 1983
48. Targum S.D., "Psychobiologic Evaluation of Psychiatric Disorders", in Textbook of Contemporary Psychiatry, ed Dunn, C., Gibson, The Collamore Press, Lexington, Mass:27-41, 1984
49. Kessler, K., Targum, S.D., "Psychopharmacologic Treatment", in Textbook of Contemporary Psychiatry, ed Dunn, C., Gibson, The Collamore Press, Lexington, Mass: 281-320, 1984
50. Capodanno, A.E., Fram, D.H., Holden, R., Targum, S.D., "The Out-Patient Treatment of Heroin Addicts with Methadone: A Two to Five Year Follow-up Study", Psychiat Hosp, 15:25-30, 1984
51. Targum, S.D., Kessler, K., Waletzky, J., Sullivan, A., "Upgrading Psychopharmacology in a Private Psychiatric Hospital", Hosp Comm Psychiat, 35:385-387, 1984
52. Targum, S.D., "Persistent Neuroendocrine Dysregulation and Major Depressive Disorder: A Marker for Early Relapse", Biol Psychiat, 19:305-318, 1984
53. Targum, S.D., Capodanno, A.E., Unger, S., Advani, M., "Abnormal Dexamethasone Tests in Withdrawing Alcoholic Patients", Biol Psychiat, 19:401-405, 1984
54. Targum, S.D., "Psychiatric Genetics: Implications for Counseling Patients and Their Families", in Genetic Disorders and Birth Defects in Families and Society: Toward Interdisciplinary Understanding, ed Weiss, J., Bernhardt, B., Paul, N., March of Dimes Defects Foundation, White Plains, NY, 50-55, 1984

Curriculum Vitae
Steven D. Targum, M.D.
Page 20

Publications
(cont'd):

55. Targum S.D., Greenberg, R.D., Harmon, R.L., Kessler, K., Salerian, A.J., Fram, D.H., "The TRH Test and Thyroid Hormone in Refractory Depression", Am J Psychiat, 141:463,1984
56. DeLisi, L.E., Murphy, D.L., Karoum, F., Mueller, E., Targum, S.D., Waytt, R.J., "Phenylethylamine Excretion in Depression", Psychiat Res, 13:193-201,1984
57. Walsh, J.K., Targum, S.D., Pegram, V., Allen, R.P., Fillingim, J.M., Parwatikar S., Schweitzer, P.K., "A Multi-Centered Clinical Investigation of Estazolam: Short Term Efficacy", Curr Therap Res, 36:866-874,1984
58. Targum S.D., Greenberg, R., Harmon R., Kessler, K., Salerian, A., Fram, D. "Thyroid Hormone and the TRH Stimulation Test in Refractory Depression", J Clin Psychiat, 45:345-346,1984
59. Targum, S.D., "Serial Dexamethasone Tests and the Prediction of Relapse in Depressive Disorder", South Med J, 77:1402-1405,1984
60. Targum S.D., White, P., Collins-Rothe, H., Sullivan P., "Serum Aldosterone Following Dexamethasone in Depressed Patients", Psychoneuroend, 9:305-309, 1984
61. DeLisi, L.E., King, A.C., Targum, S.D., "Serum Immunoglobulin Concentrations in Patients Admitted to an Acute Psychiatric In-Patient Service", Brit J Psychiat, 145:661-666,1984
62. Siever, L.J., Kafka, M.S., Targum, S.D., Lake, C.R., "Platelet-alpha-Adrenergic Binding and Biochemical Responsiveness in Depressed Patients and Controls", Psychiat Res, 11:287-302,1984
63. Targum S.D., "The Relevance of the Dexamethasone Suppression Test to the Prediction of Treatment Response", Proc NIMH Workshop: Clinical Utility of the Dexamethasone Test, DHHS Publ. (ADM) 85-1313:35-39,1985
64. Silberman, E.K., Weingartner, H., Targum S.D., Byrnes, S., "Cognitive Functioning in Biological Sub-types of Depression", Biol Psychiat, 20:654-661,1985

Curriculum Vitae
Steven D. Targum, M.D.
Page 21

Publications
(cont'd):

65. Siever, L.J., Uhde, T.W., Insel, T.R., Kay, W.H., Jimerson, D.C., Lake, C.R., Kafka, M., Targum, S.D., Murphy, D.L., "Biological Alternations in the Primary Affective Disorders and Other Tricyclic-Responsive Disorders", Prog Neuropsychopharm & Biol Psychiat, 9:15-24, 1984
66. Targum, S.D., Docherty, J.P., "The Future of Research in Private Psychiatric Hospitals", The Psychiat Hosp, 16:115-119, 1985
67. Kafka, M.S., Siever, L.J., Nurnberger, J.I., Uhde, T.W., Targum, S.D., Coopers D.M.J., van Kammen, D.P., Tokola, N.S., "Platelet Alpha-Adrenergic Receptor Function in Affective Disorders and Schizophrenia", Psychopharm Bull, 21:599-602, 1985
68. Capodanno, A.E., Targum, S.D., Unger, S., "Dimensions of Social Adjustment Following Psychiatric Hospitalization: A 6 Month Follow-up Study", The Psychiat Hosp, 17:27-32, 1986
69. Targum, S.D., "Research on the Pharmacology and Psychobiology of Depressive Disorders", Current Research in Private Psychiatric Hospitals, National Association of Private Psychiatric Hospitals, Washington, D.C., 1-12, 1987
70. Targum, S.D., "Genetic issues in treatment", in Affective Disorders and the Family, ed Clarkin, J.F., Haas, G.L., Glick, I.D., Guilford Press, New York, 196-212, 1988
71. Davis, K.L., Davidson, M., Yang, R., Davis, B.M., Siever, L.J., Mohs, R.C., Ryan, T., Coccaro, E., Bierer, L., Targum S.D., "CSF Somatostatin in Alzheimer's Disease, Depressed Patients and Control Subjects", Biol Psychiat, 24:710-712, 1988
72. Targum, S.D., Marshall, L.E., "Fenfluramine Provocation of Anxiety in Patients with Panic Disorder", Psychiat Res, 28:295-306, 1989
73. Targum, S.D., Marshall, L.E., Fischman, P., Martin, D., "Lymphocyte Subpopulations in Depressed Elderly Women", Biol Psychiat, 26:581-589, 1989

Curriculum Vitae

Steven D. Targum, M.D.

Page 22

Publications

(cont'd):

74. Targum, S.D., Marshall, L.E., Magac-Harris, K., Martin, D., "TRH Tests in a Healthy Elderly Population: Demonstration of Gender Differences", J Am Geriat Soc, 37:533-536,1989
75. Targum, S.D., Clarkson, L.L., Magac-Harris, K., Marshall, L.E., Skwerer, R.G., "Measurement of Cortisol and Lymphocyte Subpopulations in Depressed and Conduct Disordered Adolescents", J Affect Disord, 18:91-96,1990
76. Rosen, L.N., Targum, S.D., Terman, M., Bryant, M.J., Hoffman, H., Kasper, S.F., Hamovit, J.R., Docherty, J.P., Welch, B., Rosenthal, N.E., "Prevalence of Seasonal Affective Disorder at Four Latitudes", Psychiat Res, 31:131-144,1990
77. Targum, S.D., "Differential Responses to Anxiogenic Challenge Studies in Patients with Major Depressive Disorder and Panic Disorder", Biol Psychiat, 28:21-34,1990
78. Targum, S.D., "Mechanisms of Anxiogenic Vulnerability in Panic Disorder", Psychiat Res, 31:215-216,1990
79. Targum S.D., "Panic Attack Frequency and Vulnerability to Anxiogenic Challenge Studies", Psychiat Res, 36:75-83,1991
80. Targum, S.D., "Cortisol Response During Different Anxiogenic Challenges in Panic Disorder Patients", Psychoneuroendocrinol, 17:1-7,1992
81. Targum S.D., Caputo, K.P., Ball, S.K., "Menstrual Cycle Distribution and Psychiatric Admissions", J Affect Disor, 22:49-53,1991
82. Carson, S.L., Targum S.D., "Panic Attacks After Cessation of Phenoxybenzamine: A Case Report", Ann of Clin Psychiat, 3:325-327,1991
83. Targum S.D., Marshall, L.E., Fischman, P., "Variability of TRH Test Responses in Depressed and Normal Elderly Subjects", Biol Psychiat, 31:787-793,1992
84. Targum, S.D., "TRH Test in Depression and Use of an Ultrasensitive TSH Assay: Responses to the Editor", Biol Psychiat, 34:122-124,1993

Curriculum Vitae

Steven D. Targum, M.D.

Page 23

Publications

(cont'd):

85. Targum, S.D., Caputo, K., Grebb, J., Chung, L., Kaskin, K., Mendels, J., "Sertindole Treatment of Hospitalized Schizophrenic Patients", NCDEU, May, 1994
86. Cloud, B.S., Shumway, W.E., Targum, S.D., Libon, D.J., Resh, R., Gitlin H.L., "Psychotic Symptoms and Neuropsychological Deficits", New Research APA Annual Meeting, May 1994
87. Targum S., Zborowski, J., Henry, M., Schmitz, P., Seabee, T., Wallin, B., "Efficacy and Safety of Sertindole in Two Double-Blind, Placebo-Controlled Trials of Schizophrenic Patients", presented ECNP, 9/30-10/4/95
88. Cohn, C.K., Feighner, J.P., Targum, S., Tein, S.G., "A Double-Blind Comparison of Nefazodone and Sertraline in Highly Anxious Patients with Major Depression", Annual Meeting of the American Psychiatric Association, May, 1996
89. van Kammen, D.P., McEvoy, J.P., Targum S.D., Kardatzke, D., Seabee, T.B., and the Sertindole Group, "A Randomized, Controlled, Dose-Ranging Trial of Sertindole in Patients with Schizophrenia", Psychopharm, 124:168-175, 1996
90. Potkin, S.G., Targum, S.D., Zborowski, J.G., Morris, D.D., Kaskin, K.B., "Comparative Efficacy and Safety of Sertindole and Haloperidol in Patients with Schizophrenia", submitted for publication Arch Gen Psychiat
91. Ballenger, J.C., DeVaugh-Geiss, J., Evoniuk, G., Liebowitz, M., Metz, A., Targum, S.D., and the Ondansetron Study Group, "A Multicenter Trial of a 5HT₃ Antagonist, Ondansetron, in Panic Disorder", submitted for publication Ann Clin Psychiat
92. Daniel, D., Targum, S., Zimbhoff, D., Mack, R., Zborowski, J., Morris D., Seabee, T., Wallin, B., "Efficacy, Safety, and Dose Response of Three Doses of Sertindole and Three Doses of Haldol in Schizophrenic Patients", Psychopharm Bull (in press)
93. Corrigan, M., Jonas J., Reimherr, F., Targum, S., Salzman, C., "Short- and Long-Term Discontinuation of Alprazolam in patients with Panic Disorder with Agoraphobia", submitted for publication Am J Psychiat

Curriculum Vitae
Steven D. Targum, M.D.
Page 24

Publications
(cont'd):

94. Muthu P., Targum, S.D., "Influence of Age on the Clinical Presentation of Panic Disorder", submitted for publication Ann of Clin Psychiat
95. Targum, S.D., Treat, D., "Early Life Experience and the Development of Panic Disorder", in preparation
96. Targum, S.D., Mishra, A., "Efficacy of Ondansetron in Relieving Comorbid Irritable Bowel Syndrome in Patients with Panic Disorder", submitted for publication J Clin Psychopharm
97. Targum, S.D., Criden, M., Arfanidis, L., "Antipsychotic Effects of Seroquel in Parkinson's Disease with Psychosis", in preparation
98. Targum, S.D., Muthu, P., Marcus, R., "Nefazodone and Sertraline in Concomitant Panic and Major Depressive Disorder", in preparation
99. Feighner, J., Targum, S.D., Bennett, M.E., Roberts, D.L., Kensler, T.T., D'Amico, M.F., Hardy, S.A., "A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression", submitted for publication in J Clin Psychiat
100. Stewart, R.T., Flanders, A.E., Dagher, A.P., Targum S., "Correlating Brain MyoInositol concentrations with Mini-mental Scores in Alzheimer's Disease Using Automated MRS: Preliminary Results", submitted for publication
101. Targum, S.D., Mcentee, W.J., "Fluoxetine versus Sertraline and Paroxetine in Major Depression: a Comparison of Discontinuation-Emergent Signs and Symptoms", in preparation
102. Targum, S.D., Arvanitis, L.A., "Quetiapine: Efficacy, Safety and Tolerability in Elderly Subjects with Psychotic Disorders", abstract NCDEU, May 1997
103. Targum, S.D., Muthu, P., Marcus, R., "Serotonergic Treatment of Concomitant Panic and Major Depressive Disorder, abstract NCDEU, May 1997

Curriculum Vitae
Steven D. Targum
Page 25

Book:

Targum, S.D., "Psychiatric Skeletons: Tracing the Legacy of Mental Illness in the Family", New York, Villard Press, 1989

Steven D Targum MD

9-28-97

February 1, 1997
Updated: Sept. 28, 1997

msword/targum.cv/mlf

Daniel P. van Kammen, M.D., Ph.D.

BIOGRAPHICAL

Birth Date: August 26, 1943
Birthplace: Dordrecht, The Netherlands
Citizenship: U.S.A.
Social Security No.: REDACTED
Home Address: REDACTED
Telephone: REDACTED
Business Address: Department of Veterans Affairs Medical Center
7180 Highland Drive
Pittsburgh, PA 15206-1297
Telephone: 412-365-4730
FAX: 412-365-4779
E-mail: DPVK@PITTSBURGH.VA.GOV
Department of Psychiatry
Western Psychiatric Institute and Clinic
of University of Pittsburgh Medical Center
3811 O'Hara Street
Pittsburgh, PA 15213-2593
Telephone: 412-624-9949
E-mail: DPVK@PITT.EDU
Licensure: Pennsylvania, REDACTED expires 12/98

EDUCATION AND TRAINING

Undergraduate

1955-1961 Johan de Witt Gymnasium, Gymnasium beta
Dordrecht, The Netherlands

Graduate

1961-1966	University of Utrecht, Medical School	M.D.	
1978	University of Utrecht The Netherlands	Ph.D. Pharmacology	H.M.van Praag, MD, Chair and Professor of Psychiatry; D.de Wied, MD, PhD Professor of Pharmacology

Post Graduate

1967-1969	Utrecht, University Hospital, The Netherlands	Intern (rotating)	H. Hulst, MD, PhD Dean, Professor of Internal Medicine; L.J. Jordan, MD, PhD, Professor of Internal Medicine
1968	Utrecht University Utrecht, The Netherlands	Resident (Psychiatry)	J. Plokker, MD, PhD Professor and Chair, Department of Psychiatry
1969-1970	Union Memorial Hospital Baltimore, MD	Intern (General Medicine)	J.E. Howard, MD Professor of Internal Medicine, Johns Hopkins Medical School
1970-1973	Johns Hopkins Hospital Baltimore, MD	Resident (Psychiatry)	J. Elkes, MD Professor and Chair, Department of Psychiatry
1971	Tavestock Conference at Manresa, Maryland	Training in Group Leadership	
1992	Physicians in Management Seminar I and II, American College of Physician Executives, Albany, NY		

APPOINTMENTS AND POSITIONS

Academic

1970-1973	Department of Psychiatry and Behavioral Science Johns Hopkins University School of Medicine Baltimore, MD	Fellow in Psychiatry and Behavioral Sciences	J. Elkes, MD, Professor and Chair
1975-1986	Washington School of Psychiatry	Faculty Member	
1982- Present	Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh	Professor of Psychiatry	

Non-Academic Positions

1973	Laboratory of Clinical Science NIMH, Bethesda, MD	Guest Worker Staff Psychiatrist	I. Kopin, MD
1973-1974	Section on Clinical Neuropharmacology Laboratory of Clinical Science IMRP - NIMH	Visiting Scientist Staff Psychiatrist	D.L. Murphy, MD
1974-1979	Section on Neuropsychopharmacology Biological Psychiatry Branch DCBR IMRP, NIMH	Visiting Scientist Staff Psychiatrist	W.E. Bunney Jr., MD
1975-1982	Section on Neuropsychopharmacology Biological Psychiatry Branch Division of Clinic and Behavioral Research, IMRP, NIMH	Chief, 4-East Clinical Research Unit	W.E. Bunney Jr., MD

1982-1983	VA Medical Center 7180 Highland Drive Pittsburgh, PA	Assistant Chief of Psychiatry, Acting Chief of Psychiatry
1983-1986	VA Medical Centers University Drive and Highland Drive Pittsburgh, PA	Chief, Psychiatry Service
1985-1986	VA Medical Center 7180 Highland Drive Pittsburgh, PA	Acting Chief of Staff
1986- 1997	VA Medical Center 7180 Highland Drive Pittsburgh, PA	Chief of Staff

CERTIFICATION AND LICENSURE

Specialty Certification

1980	Diplomat - Royal Netherlands Board of Psychiatry and Neurology
1983	Diplomat - American Board of Psychiatry and Neurology, Inc. REDACTED

Medical or Other Professional Licensure

1969	The Netherlands (inactive)
1974-1993	Maryland (inactive)
1978-1983	District of Columbia (inactive)
1983-Present	Pennsylvania

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1972-1982	American Psychiatric Association (APA)
1993-Present	
1972-1978	Maryland Psychiatric Association
1974-Present	American Association for the Advancement of Sciences (AAAS)
1978-Present	International Society of Psychoneuroendocrinology (ISPNE)
1978-1982	Washington Psychiatric Society
1980-Present	Society of Biological Psychiatry
1980-Present	Collegium Internationale Neuropsychopharmacologium (CINP) Fellow

1980-Present	American College of Neuropsychopharmacology (ACNP) Fellow
1980-Present	Catecholamine Club
1980-Present	World Psychiatric Association (WPA) 1981-Present Society of Neuroscience
1984-Present	American Psychopathological Association (Fellow)
1983-1985	Public Relations Committee of the Society of Biological Psychiatry
1984-1986	Liaison Committee with Governmental Agencies and the Pharmaceutical Industry (ACNP)
1987-1990	Credentials Committee (ACNP)
1987-Present	National Association of VA Chiefs of Staff (NAVACOS)
1988-1989	Committee on Membership (Soc. of Biological Psychiatry)
1988-Present	International Brain Research Organization (IBRO)
1988-Present	World Schizophrenia Fellowship
1989-1992	Program Committee, 7 th International Catecholamine Symposium
1990-Present	American College of Physician Executives
1991-Present	Centro de Estudos de Psiconeuroendocrinologia de Sao Paulo Corresponding Member
1991-Present	International Society for Neuroimaging in Psychiatry (ISNIP)
1993-1995	American Psychiatric Association, Committee on Veterans Affairs
1994-Present	Psychiatric Physicians of Pennsylvania (PPP)
1994-1996	Committee on the Use of Animals in Neuropsychopharmacology (ACNP)
1994-Present	The American Society of Clinical Psychopharmacology, Inc.
1995-1997	Program Committee, 8th International Catecholamine Symposium
1997-1998	Liaison Committee with Governmental Agencies and the Pharmaceutical Industry (ACNP)

HONORS

1975	Mexican Psychiatric Association (Honorary Member)
1978-1982	Visiting Professor, University of Alabama at Birmingham, Department of Psychiatry, Birmingham, AL
1981	"Schizophrenia," in NIH Lecture Series, "Medicine for the Layman"
1982	49 th St. Görans Lecture, Karolinska Institute, Stockholm, Sweden
1987-1990	O. Rafaelsen Travel Fellowship Committee (CINP)
1988-1993	International Scientific Advisor to the World Psychiatric Association (WPA)
1989	Visiting Professor, Dr. Kees Boelhouwer Memorial Lecture, University of Connecticut, Hartford, CT
1989	Selection Committee (WPA) Ayerst Wyeth Award for Distinguished Research Work in Psychiatry

1990	Selection Max Hamilton Memorial Prize 1990 Committee (CINP)
1990	Commendation Award American Defenders of Bataan & Corregidor Inc.
1992	Consultant to Office of Technology Assessment of U.S. Congress (The Biology of Mental Disorders)
1992	Commendation Award of County of Allegheny Board of Commissioners
1994-Present	Board Member, National Center for Sleep Disorders (Representative DVA Under-Secretary for Health)

PROFESSIONAL ACTIVITIES

SERVICE

Administration

1983-1987	Board Member, District 5 Planning Board (MEDIPP - VA)
1983-1987	Member, Medical Center Planning Committee VAMC, Highland Drive
1983-1987	Chairperson, Pharmacy & Therapeutic Agents Committee VAMC, Highland Drive
1983-1989	Chairman, District 5 Psychiatric Care & Substance Abuse Task Force (MEDIPP - VA)
1983-1985	Member, Clinical Executive Board, VAMC, Highland Drive
1983-1989	Member, Clinical Executive Board, VAMC, University Drive
1983-Present	Member, Research & Development Committee, VAMCs Highland Drive and University Drive
1983-1986	Member, Mental Health & Behavioral Sciences Council, VAMC, University Drive
1983-Present	Member, Academic Promotions and Tenure Committee, W.P.I.C. Department of Psychiatry
1984	Member, Search Committee for Chief of Staff, VAMC, University Drive
1985-1996	Member, Dean's Committee, VAMCs, University Drive and Highland Drive
1985-1996	Chairman, Clinical Executive Board, VAMC, Highland Drive
1985-1997	Chairman, Medical Executive Board, VAMC, Highland Drive
1985-1996	Chairman, Physicians' Staff Meeting, VAMC, Highland Drive
1985-1989	Member, District Executive Council, VA District 5, Region 2
1989, 1992-1994	Acting Chief, Pathology and Laboratory Medicine Service, VAMC, Highland Drive
1989-1990	Acting Chief, Rehabilitation Medicine Service, VAMC, Highland Drive

1989	Residency Allocation Advisory Group, VACO, Washington, DC
1991	Acting Chief, Rehabilitation Medical Service, VAMC Highland Drive
1992	Member, Regional Site Visit Team (VA Region I), Highland Drive
1993	Chair, Title 38 Disciplinary Appeals Board Department of Veterans Affairs
1994	Reinventing the VA: Health Care Reform, Department of Veterans Affairs Work Group; Research
1994-Present	Member, TQI Quality Leadership Team, VAMC, Highland Drive
1995-1996	Member, Executive Committee, NAVACOS
1996-1996	Member, Executive Leadership Council, VISN 4, Department of Veterans Affairs
1996-Present	Member, Academic Council, VISN 4, Department of Veterans Affairs
1996-Present	Member, Management Advisory Council, VISN 4, Department of Veterans Affairs

Teaching

1964-1965	Student supervision of ten 1 st year Medical Students, Pilot Project, University of Utrecht, the Netherlands
1964-1966	Physiology Laboratory course for 2 nd and 3 rd year Medical Students, University of Utrecht, the Netherlands
1971-1972	Interview and Psychopathology course, 2 nd and 3 rd year Medical Students, Johns Hopkins University Medical School
1974-1975	"Pharmacology and Behavioral Effects of Amphetamine" - Psychopharmacology Course (Medical Students), Laboratory of Clinical Science, NIMH Intramural Research Program
1974-1982	Supervision and teaching Clinical, Associates and Staff Psychiatrists, Section of Neuropsychopharmacology Intramural Research Program, NIMH
1975	Supervision and teaching, Psychiatric Clinical Clerkship of Medical Students from Yale University (New Haven) in Section on Neuro Psychopharmacology (July - September)
1975-1982	In-house Lecture Series for 10-20 Medical Students, NIH, Psychopharmacology elective 4 th year. The dopamine hypotheses of schizophrenia, Antipsychotic drug treatment (four times per year)
1975-1982	Supervision and teaching Medical and Psychology Students rotating through the section and IRP, NIMH
1976	George Washington University Psychiatric Residents' course in Psychopharmacology
1977-1982	Schizophrenia course, Washington School of Psychiatry for Psychiatrists, Social Workers and Psychologists

1983-Present	Courses on schizophrenia, psychopharmacology, dopamine and norepinephrine for Psychiatric Residents, Western Psychiatric Institute and Clinic, University of Pittsburgh
1983-Present	Resident supervision - Western Psychiatric Institute and Clinic, University of Pittsburgh and VA Medical Center, Highland Drive
1984	Graduate Student Psychology course: The dopamine hypothesis of schizophrenia, New York University and City College.
1984	Member, Master's Thesis Committee, Richard Day, Ph.D., M.S. University of Pittsburgh, Graduate School of Public Health
1992-Present	External Consultant, Ph.D. Committee, Elizabeth Radomski, B.A., University of South Carolina
1994-Present	Teaching 3 rd year Medical Students, University of Pittsburgh School of Medicine
1995	Member, Master's Thesis Committee, Mary Kelley, M.S., University of Pittsburgh, Graduate School of Public Health

Research

1974-1982	Clinical Investigators Coordinating Committee of the Intramural Research Program, NIMH
1975-1976	Clinical Research Review Committee, Intramural Research Program, National Institute of Mental Health
1976-(Dec.)	Kroc Foundation Conference Participant, Propranolol and Schizophrenia, Santa Ynez, CA
1976-1978	Special Behavioral Research Review Committee, Intramural Research Program, NIMH
1979	Consultant to Veterans Administration Committee on planning of collaborative study of hemodialysis in Schizophrenia
1979	Ad Hoc Member, Veterans Administration Clinical Research Review Committee: Collaborative Projects
1979	Ad Hoc Member, Veterans Administration Cooperative Study Dialysis Treatment Evaluation of Schizophrenia
1979-1982	Member, Institutional Review Board, Intramural Research Papers, NHLBI
1979-1982	Clinical Research Review Board, Intramural Research Program, National Heart, Lung and Blood Institute (NIH)
1982-Present	Member, Research & Development Committee, Highland Drive VAMC
1982-1984	Member, Seed Money Review Committee, WPIC
1984-1988	Member, Research & Development Committee, University Drive VAMC
1984-1985	Director, VA Health Services Research & Development Field Program, (District #5)

1987-Present	Member, Research Committee, University of Pittsburgh School of Medicine, Department of Psychiatry
1989	Ad-Hoc Member, NIMH Study Section TDA2
1994-present	Member, Eligibility Review Committee VA Research and Development, VA Central Office
1994-Present	Member, National Research Council, DVA Office of Research and Development
1994-present	Treasurer/Secretary, Highland Drive Research and Development Foundation

MAJOR RESEARCH INTERESTS

I. Schizophrenia

- a) Relapse and drug response prediction
- b) Biochemistry and endocrinology
- c) Pharmacology
- d) Neuropsychology, sleep and psychophysiology
- e) Brain Imaging
- f) Clinical and biochemical subtyping

II. Posttraumatic Stress Disorder

Research Funding

NIMH Intramural Research Program	Senior Investigator	1973-1982
VA Health Service Research and Development Field Program Project Proposal	P.I.	FY 1984-1986
Scottish Rite Schizophrenia Research Program - "Time-Dependent Sensitization After Acute Neuroleptic Treatment" with S. Antelman, Ph.D.	Co-P.I.	AY 1984
VA RAG Research Advisory Group "Noradrenergic Evaluation of Schizophrenia"	P.I.	FY 1985
VA RAG "Efficacy of Propranolol/Propranolol/Clonidine vs Placebo in Neuroleptic-Induced Akathisia" with J. El-Sabaawi, M.D.	Co-P.I.	12/1986-12/1988
VA Merit Review "Noradrenergic Evaluation of Schizophrenia"	P.I.	FY 1986-1989
VA RAG "Sleep Studies of Vietnam Veterans with PTSD" with C. Christensen, M.D.	P.I.	1/1987-12/1987

VA RAG "A Search for Pre-Blink Cerebral Potentials in Normals and Schizophrenics" with George Dougherty, M.D.	Co-P.I.	4/1987-3/1989
NIMH "Vulnerability to Schizophrenia: Neuro-behavioral Aspects" with S. Steinhauer, Ph.D.	Co-P.I.	9/1987-9/1991
VA RAG "Information Processing Relapse Prevention & Medication Response in Schizophrenics" with D. Shaw, Ph.D.	Co-P.I.	10/1987-10/1988
VA RAG "CT Scan Measurements & CSF Monamine Metabolites in Drug-Free Schizophrenics and Healthy Controls" with J. L. Peters, M.D.	Co-P.I.	1/1988-1/1989
VA RAG "Role of Plasma HVA in Relapse and Treatment of Schizophrenia" with K. Goetz, M.D.	Co-P.I.	4/1988-10/1988
VA Merit Review "Psychophysiological Aspects of Schizophrenia" with S. Steinhauer, Ph.D.	Co-P.I.	4/1988-3/1992
"Membrane Phospholipids Role in Schizophrenia" with Jeffrey Yao, Ph.D.	Co-P.I.	7/1988-6/1993
VA Merit Review "Noradrenergic Activity and Relapse Prediction in Schizophrenia"	P.I.	10/1988-9/1991
VA Merit Bridge Funding	P.I.	10/1991-3/1992
NIMH "Norepinephrine and Relapse Prediction in Schizophrenia"	P.I.	4/1990-3/1996
VA Merit Review "Semantic Processing and Production in Schizophrenia" with R. Condray, Ph.D.	Co-P.I.	4/1990-3/1993
VA RAG State-Trait and Medication "Aspects of Cognitive Deficit" with M. Gilbertson, Ph.D.	Co-P.I. 5%	7/1992-6/1994

VA Merit Review "Evaluation of Catecholamine Activity in Schizophrenia (Relapse Prediction)"	P.I. 20%	4/1992-3/1995
NIMH "Language Processes in Schizophrenia" with R. Condray, Ph.D.	Co-P.I.	5/1993-4/1997
VA Merit Review: "Longitudinal Evaluation of Neuropsychological Function in Schizophrenia " with M. Gilbertson, Ph.D.	Co-P.I. 5%	10/1994-9/1996
Stanley Foundation: "The role of opiate receptor antagonists in treatment of patients with schizophrenia and concurrent alcohol dependence" with D. Allen, Ph.D., M. Kilwein, Ph.D., and John Gurklis, M.D. First year \$64,000, Second year \$64,000	Co-P.I. 5%	8/1996- 7/1998

Pharmaceutical trial participation:

US-Canadian Collaborative Project- Amperozide Study No. B201.	1990-1991
Warner-Lambert/Parke Davis - "A Pilot Positive Pilot Control Dose Finding Study of CI-943 in Hospitalized Patients in Acute Exacerbation," Multi-Center Study	1/1988-9/1988
Warner-Lambert/Parke Davis "A Placebo Controlled Dose-Response Study of CI-943 in Hospitalized Chronic Schizophrenic Patients in Acute Exacerbation"	2/1988-3/1990
Eli Lilly: Olanzapine, a novel antipsychotic, double blind and extended open evaluation.	1994-1997
Abbott: Sertindole (M91-671; M92-762; M94-222; M92-795; M91-645; M95-372), a novel antipsychotic, double blind and extended open evaluation.	1991-present

Pfizer: Ziprasidone (115, 116B, 128-121(IM),
128-126(IM)), a novel antipsychotic, double blind
and extended open evaluation.

4/95-present

Janssen: Mazapertine (MAZINT-1), a novel
antipsychotic, double blind evaluation.

2/1996-present

Zeneca: Seroquel®, a novel antipsychotic,
open outpatient outcomes trial

8/1996-present

COMMUNITY SERVICES

1974-1982	Presentation for local (Greater Washington Area) CMHC's, Community Groups and Catholic University School of Nursing
1974-1982	Private Practice, Psychotherapy and Pharmacotherapy (8hrs/wk)
1978-Present	Board of Directors, Mensana Research Foundation, Stevenson, MD
1981-1982	Interviews about Schizophrenia for Washington, DC. TV Stations and NOVA (Public Broadcasting Service)
1983-Present	Interviews with ABC (20/20) and local TV Stations (Channels 4, 11 - Pittsburgh, PA)
1992	Testified before Senate Veteran Affairs Committee (Operation Desert Storm) (Senators Cranston and Specter)
1993	Testified for Senate Veteran Affairs Committee on behalf of American Psychiatry Association. The role of the Department of Veteran Affairs in the National Health Care Reform. (Senator Jay Rockefeller, WV)
1993-Present	Co-Chair, Scientific Advisory Committee The Joseph Zubin Memorial Prize

Journal Refereeing (Last 12 Months)

Science, American Journal of Psychiatry, Psychiatry Research,
Life Sciences, European Journal of Pharmacology,
Biological Psychiatry, New England Medical Journal,
Archives of General Psychiatry
Schizophrenia Bulletin, Psychopharmacology,
Schizophrenia Research, Psychological Medicine

Grant Reviews

1980-1986	Canada Mental Health Institute
1982-Present	Eastern Research and Development Office (VA)
1989-Present	National Science Foundation
1985-1989	Member, Mental Health & Behavioral Science Research Advisory Group, VA Research Service
1989	Ad Hoc Reviewer for National Institute of Mental Health Treatment Development Assessment Committee
1990	Ad Hoc Reviewer for Commission of the European Communities (CEC)
1990	Ad Hoc Reviewer for National Science Foundation
1990	Ad Hoc Reviewer for State of California Department of Mental Health
1991	Alberta Heritage Foundation for Medical Research
1996	Medical Research Council of Canada

Editor/Editorial Board

1983-Present	Editorial Board, Journal of Neural Transmission
1989-Present	Advisory Board, Progress in Neuro-Psychopharmacology and Biological Psychiatry
1989-1995	Editorial Board, Schizophrenia Research
1992-Present	Editor-in-Chief, Bailliere's Clinical Psychiatry International Practice and Research

Commonwealth of Pennsylvania
Department of State
Bureau of Professional and Occupational Affairs
P.O. BOX 2009 Harrisburg, PA 17103-2009

Classification
MEDICAL PHYSICIAN AND SURGEON

Certificate Number	Certification Date	Issued	Expires
[REDACTED]	OCT 14 1983	OCT 19 1996	DEC 31 1998

Issued To:

D. Paul Vankammen
[REDACTED]

Donna Childress
Commissioner of Professional and Occupational Affairs

**DUKE UNIVERSITY MEDICAL CENTER
CURRICULUM VITAE**

Name: William Herman Wilson, Ph.D.

Academic Appointment: Duke University Medical Center
Department of Psychiatry
Division of Medical Psychology

Social Security Number: REDACTED

Present academic rank : Associate Professor

Education:	Place	Date	Degree
College:	University of Arkansas Fayetteville, AR	1968	B.A.
	Vanderbilt University Nashville, TN	1971 1973	M.A. Ph.D.

Professional Career:

1973-1977 Assistant Professor of Psychology
Middle Tennessee State University
Murfreesboro, Tennessee

1977-1986 Assistant Professor of Psychiatry (Psychology)
Vanderbilt University
Nashville, Tennessee

1986-present Associate Professor of Medical Psychology
Department of Psychiatry
Duke University Medical Center
Durham, North Carolina

Consultant Appointment: Statistical Consultant
Mental Health Division
World Health Organization
1981 - 1986

Organizations: American Psychological Association

Other Appointments: Chairman - John Umstead Hospital I.R.B.
Committee: 1987 - Present

Director: Research Support Office,
Department of Psychiatry, Duke 1986 - 92

William H. Wilson, Ph.D.

PUBLICATIONS IN REFEREED JOURNALS:

1. Wilson WH, Nunnally JC. A naturalistic investigation of acquired meaning in children. Psychonomic Science 1971; 23:149-50.
2. Wilson WH, Nunnally JC. A technique for producing highly complex visual stimuli. Behavioral Research Methods and Instrumentation 1973;5:266-8.
3. Lemond LC, Durham RL, Slater GP, Wilson WH, Nunnally JC. Varying degrees of complexity and isolation in visual exploration. Perceptual and Motor Skills 1974;38:787-94.
4. Wilson WH. Visual Selection: The effects of number of encodable elements and physical complexity. Perception and Psychophysics 1976;20(3):205-9.
5. Nunnally JC, Lemond LC, Wilson WH. Studies of voluntary visual attention - theory, research methods and psychometric issues. Applied Psychological Measurement 1976;1(2):203-18.
6. Wilson WH. The influence of prior level of meaningfulness on acquisition of new meaning. Psychological Reports 1978;42:31-4.
7. Rust JO, Miller LS, Wilson WH. Using a control group to evaluate the effectiveness of a resource room program. Psychology in the School 1978;503-506.
8. Wilson WH, Petrie WM, Ban TA. Possible lack of anticholinergic effects with mianserin: A pilot study. Journal of Clinical Psychiatry 1980;(Feb):63-5.
9. Wilson WH, Freeman FR, Ban TA, Petrie WM, Clinton CL. Acute effects of viloxazine HCl and flurazepam when given alone and in combination on sleep EEG: A double-blind interaction study with normals. Pavlovian J of Biological Science 1980;15(2):68-73.
10. Ban TA, McEvoy JP, Wilson WH. Viloxazine: A review of literature. International Pharmacopsychiatry 1980;15:118-23.
11. Petrie WM, Wilson WH, Ban TA, Guy W, Schaffer JD. Mianserin: Determination of therapeutic dose range. International Pharmacopsychiatry 1980;14:111-7.
12. Ban TA, Wilson WH, McEvoy JP. Amoxapine: A review of literature. International Pharmacopsychiatry 1980;15:166-70.
13. Guy W, Ragheb M, Wilson WH, Schaffer D, Hollender M: Utility of videotape in establishing interrater reliability. Psychopharmacology Bulletin 1980;16(3):71-7.

William H. Wilson, Ph.D.

14. Ragheb M, Wilson WH, Ban TA, Brannen JO. Amoxapine: Once versus divided daily doses in neurotic and endogenous depression. Journal of Clinical Psychiatry 1980;42:166-70.
15. McEvoy JP, Berney W, Wilson WH, Ban TA, Guy W. A double-blind comparison of three dosages of flutroline (CP36584) in the treatment of schizophrenia. International Pharmacopsychiatry 1980;15:318-24.
16. McEvoy JP, Sheridan WF, Stewart WRC Jr., Ban TA, Wilson WH, Guy W, Schaffer JD. Viloxazine in the treatment of depressive neurosis: A controlled clinical study with doxepin and placebo. British Journal of Psychiatry 1980;137:440-3.
17. Petrie WM, McEvoy JP, Wilson WH, Ban TA, Guy W. Viloxazine in the treatment of depressive neurosis: A placebo and standard (imipramine) controlled clinical study. International Pharmacopsychiatry 1980;15:193-196.
18. Wilson WH, Petrie WM, Ban TA. Effects of viloxazine with and without alcohol on performance tests related to driving in normal volunteers. Drug Development Research 1981;1(3):223-7.
19. Petrie WM, Ban TA, Berney S, Guy W, Ragheb M, Wilson WH, Schaffer JD. Loxapine in psychogeriatrics: A placebo and standard controlled clinical investigation. Journal of Clinical Psychopharmacology 1981;2(2):122-6.
20. McEvoy JP, Wilson WH, Ban TA, Brannen JO, Berney S. Bromperidol maintenance in schizophrenia. Pharmacopsychiatry 1981;3(15):95-6.
21. Wilson WH, Ban TA. Repeated measures latin-square design in clinical pharmacology. Methods and Findings in Experimental and Clinical Pharmacology 1981;4(1):34-42.
22. Guy W, Wilson WH, Ban TA, King LD, Manov GA, Fjetland OK. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Drug Development Research 1981;4(4):143-54.
23. Wilson WH, Petrie WM, Ban TA, Barry DE. The effects of amoxapine and ethanol on psychomotor skills related to driving: A placebo and standard controlled study. Progress in Neuro-Psychopharmacology 1981;5(3):213-40.
24. King LD, Akiskal HW, Lenmi H, Wilson WH, Belonni J and Yerevanian BI. REM density in the differential diagnosis of psychiatric from medical-neurological disorders: A replication. Psychiatry Research 1981;5:269-76.

William H. Wilson, Ph.D.

25. Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Berney S, Ban TA, Schaffer JD. A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Pharmacopsychiatry 1981;14:132-40.
26. Ban TA, Guy W, Wilson WH. Psychopharmacology and Leonhard's classification of chronic schizophrenias. International Pharmacopsychiatry 1981;17:153-62.
27. McEvoy JP, Aland J, Wilson WH, Guy W, Hawkins L. Measuring chronic schizophrenic patients' attitudes towards their illness and treatment. Hospital and Community Psychiatry 1981;32(12):856-8.
28. Wilson GP, Rust JO, Wilson WH. Influence of prior level of meaningfulness on condition meaning. Psychological Reports 1981;40:907-12.
29. Petrie WM, Wilson WH, Jamieson RC, Ban TA. Viloxazine and amitriptyline in endogenous depression. Drug Development Research 1982;2:215-8.
30. Wilson WH, Guy W, Ban TA, Adelson LM, Perez-Payan H. A double-blind dose determination study with flutrolone: A new neuroleptic. Drug Development Research 1982;2(4):357-62.
31. Ban TA, Fujumori M, Petrie WM, Ragheb M, Wilson WH. Systematic studies with amoxapine: A new antidepressant. International Pharmacopsychiatry 1982;17:18-24.
32. Guy W, Ban TA, McEvoy JP, Petrie WM, Wilson WH, Schaffer JD. A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depression. International Pharmacopsychiatry 1982;17:36-42.
33. Ban TA, Guy W, Wilson WH, Kelwala S. Psychopharmacology and Leonhard's classification of chronic schizophrenias. International Pharmacopsychiatry 1982;17:153-162.
34. Petrie WM, Ban TA, Wilson WH, Jamieson RC, Guy W. Viloxazine in the treatment of endogenous depression: A standard (amitriptyline) controlled clinical study. International Pharmacopsychiatry 1982;17:280-6.
35. McEvoy JP, Libiger J, Wilson WH, Ban TA, Berney S, Guy W. Viloxazine HCl in the treatment of endogenous depression: A standard (imipramine) controlled clinical study. Journal of Clinical Psychiatry 1982;43:111-2.

William H. Wilson, Ph.D.

36. Rust RJ, Wood JN, Wilson WH. Local norms and two-year reliability for the Slingerland tests. Reading Improvement 1982;19(1):6-9.
37. Guy W, McEvoy JP, Ban TA, Wilson WH, Paté K. A double-blind clinical trial of mianserin versus amitriptyline differentiation by adverse symptomatology. Pharmacotherapy 1983;3(1):45-51.
38. Guy W, Manov G, Wilson WH, Ban TA, Fjetland OK, Manberg JP, Dren AT. Psychotropic actions of BW2340 in the treatment of inpatient schizophrenics: A dose-range study. Drug Development Research 1983;3:245-52.
39. Ban TA, Guy W, Wilson WH. Organizing and conducting clinical trials. Neuropsychobiology 1983;10:137-40.
40. Wilson WH, Higano H, Papadatos Y, Kelwala S, Ban TA. A double-blind placebo controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. British Journal of Clinical Pharmacology 1983;15(3):385-92.
41. Wilson WH, Higano H, Papadatos Y, Kelwala S, Ban TA. Autonomic effects of fluvoxamine versus amitriptyline, doxepin and placebo. Psychopharmacology Bulletin 1983;19(1):111-2.
42. Lehmann HE, Wilson WH, Deutsch M. Minimal maintenance medication: Effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Comprehensive Psychiatry 1983;24(4):293-303.
43. Wilson WH, Ban TA. Distribution of Leonhard subtypes of chronic schizophrenia in two cultures. Canadian Journal of Psychiatry 1983;28:197-8.
44. Mathew RJ, Wilson WH. Carbon dioxide levels and cerebral blood flow. Archives of General Psychiatry 1983;40:1343-4 [letter].
45. Ban TA, Guy W, Wilson WH. Description and distribution of the subtypes of chronic schizophrenia based on Leonhard's classification. Psychiatric Development 1984;3:179-99.
46. Kelwala S, Ban TA, Berney SA, Wilson WH. Rapid tranquilization: A comparative study of thiothixene and haloperidol. Prog. Neuro-Psychopharmacology and Biol. Psychiatr. 1984;8:77-83.
47. Ban TA, Guy W, Wilson WH. Approaches to the management of the acutely psychotic patient. Psychiatric Journal of the University of Ottawa 1984;9(1):36-41.

William H. Wilson, Ph.D.

48. Ban TA, Guy W, Wilson WH. Pharmacotherapy of chronic hospitalized schizophrenics: Diagnosis and treatment. Psychiatric Journal of the University of Ottawa 1984;9:191-5.
49. Ban TA, Guy W, Wilson WH. The psychopharmacological treatment of depression in the medically ill patient. Canadian Journal of Psychiatry 1984;29:461-6.
50. Ban TA, Guy W, Wilson WH. Leonhard's classification of the chronic schizophrenias. Canadian Journal of Psychiatry 1984;29:467-72.
51. Guy W, Wilson WH, Ban TA, King DL, Manov G, Fjetland OK. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Psychopharmacology Bulletin 1984;20(1):73-8.
52. Mathew RJ, Wilson WH. Caffeine induced changes in cerebral circulation. Stroke 1985;5:814-7.
53. Ban TA, Guy W, Wilson WH. Leonhard's classification of the chronic schizophrenias. Current Clinical Briefs 1985;6:11.
54. Guy W, Ban TA, Wilson WH. An international survey of tardive dyskinesia. Prog. Neuro-Psychopharmacology and Biol. Psychiatr. 1985;9:401-5.
55. Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: Prescription practices. Neuropsychobiology 1985;14(2):75-82.
56. Mathew RJ, Wilson WH, Daniel DG. The effect of non-sedating doses of diazepam on regional cerebral blood flow. Biological Psychiatry 1985;20:1109-16.
57. Mathew RJ, Wilson WH. Caffeine consumption, withdrawal and cerebral blood flow. Headache 1985;25:305-9.
58. Ban TA, Guy W, Wilson WH. The AMDP-System in chronic hospitalized schizophrenics. Comprehensive Psychiatry 1985; 26:370-9.
59. Mathew RJ, Rabin P, Stone WJ, Wilson WH. Regional cerebral blood flow in dialysis encephalopathy and primary degenerative dementia. Kidney International 1985;28:64-8.
60. Ban TA, Guy W, Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Canadian Journal of Psychiatry 1985;30:406-8.

William H. Wilson, Ph.D.

61. Mathew RJ, Wilson WH. Dextroamphetamine induced changes in regional cerebral blood flow. Psychopharmacology 1985;87:298-302.
62. Mathew RJ, Partain CL, Prakash R, Luklarni MV, Logan TP, Wilson WH. A study of the septum pellucidum and corpus callosum in schizophrenia with MR imaging. Acta Psychiatrica Scandinavica 1985;72:414-421.
63. Mathew RJ, Wilson WH. Anxiety and Hematocrit. Journal of Psychosomatic Research. 1986;30:307-11.
64. Ban TA, Guy W, Wilson WH. Research methodology and the pharmacotherapy of the chronic schizophrenias. Psychopharmacology Bulletin 1986;22(1):36-41.
65. Guy W, Ban TA, Wilson WH. The prevalence of abnormal involuntary movements among chronic schizophrenics. International Clinical Psychopharmacology. 1986;1:134-144.
66. Guy W, Wilson WH, Brooking B, Manov G, Fjetland OK. Reliability and validity of SAFTEE: Preliminary analyses. Psychopharmacology Bulletin. 1986;22(2):397-401.
67. Mathew RJ, Wilson WH, Tant SR. Determinants of resting regional cerebral blood flow in normal subjects. Biological Psychiatry. 1986;21:907-14.
68. Wilson WH, Ban TA, Guy W. Flexible system criteria in chronic schizophrenia. Comprehensive Psychiatry. 1986; 27(3):259-65.
69. Wilson WH, Ban TA. Effects of antidepressants alone and with alcohol on psychomotor skills. Journal of Clinical Psychiatry (mono). 1986;4(2):27-31.
70. Mathew RJ, Wilson WH, Tant S. Caffeine-induced cerebral blood flow changes in schizophrenia. European Archives of Psychiatry and Neurological Sciences. 1986; 235:206-9.
71. Mathew RJ, Wilson WH. Regional cerebral blood flow changes associated with ethanol intoxication. Stroke. 1986; 17:1156-59.
72. Wilson WH, Ban T, Coleman B, Vause B, Papadatos J. The effects of clovoxanine on sleep of normal volunteers: A double-blind placebo-controlled study. Drug Development Research, 1986;9:293-8.
73. Guy W, Manov G, Wilson W. Double-blind dose determination study of a new antidepressant - Sertraline. Drug Development Research, 1986;9:267-272.

William H. Wilson, Ph.D.

74. Mathew RJ, Wilson WH, Nicassio PM. Cerebral ischemic symptoms in anxiety disorders. American Journal of Psychiatry. 1987;142(2):265 (letter).
75. Guy W, Wilson WH, Brookings B, Fjetland OK. Intra-Interrater reliability of SAFTEE using videotape interviews and clinical trial data. Psychopharmacology Bulletin. 1987;23(1):93-96.
76. Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. Biological Psychiatry. 1987;22:637-649.
77. Mathew RJ, Wilson WH. Elevated hematocrit in patients with schizophrenia. Biological Psychiatry. 1987;22:907-910.
78. Mathew RJ, Wilson WH, Tant SR, Robinson L, Prakash R. Abnormal resting regional cerebral blood flow patterns in schizophrenia and their correlates. Arch. of General Psychiat. 1988;45:542-549.
79. Wilson WH, Rasmussen J, Vause B, Manov G. A double-blind placebo controlled study of the autonomic effects of clovoxamine, imipramine and amitriptyline in normal volunteers. Drug Devel. Res. 1988;14(1):75-84.
80. Mathew RJ and Wilson WH. Cerebral blood flow changes induced by CO-2 in anxiety. Psychiatry Research. 1988;23:285-294.
81. Naylor MR, Krishnan KRR, Manepalli AN, Ritchie JC, Wilson WH, Carroll BJ. Circadian rhythm of adrenergic regulation of adrenocorticotropin and cortisol in man. J. of Endocrinology and Metabolism 1988;67:404-406.
82. Oehler JM, Eckerman CO and Wilson WH. Social stimulation and the regulation of premature infant's state prior to term age. Infant Behavior and Development. 1988;11: 333-351.
83. Schroering ES, Coffey CE, Bryden MP, Wilson WH, Mathew RJ. Regional cerebral blood flow correlates of a dichotic listening task. Neurology 1988, 38(suppl 1), 298(abstract).
84. Danials GD, Mathew RJ, Wilson WH. Sex roles and regional cerebral blood flow. Psychiatry Research, 1988;27: 55-64.
85. Coffey CE, Brayden MP, Schroering ES, Wilson WH, Mathew RJ. Regional cerebral blood flow correlates of a dichotic listening task. J. Neuropsychiatry and Clinical Neurosciences. 1989;1(1):46-52.

William H. Wilson, Ph.D.

86. Mathew RJ, Wilson WH, Tant SR. Acute changes in regional cerebral blood flow associated with marijuana smoking. Acta Psychiatrica Scandi. 1989;79:118-128.
87. Mathew RJ, Wilson WH, Tant SR. Regional cerebral blood flow changes associated with Amyl Nitrite inhalation. British J. of Addiction. 1989;84:293-299.
88. Mathew, RJ, Wilson,WH and Tant S. Response to hypercarbia induced by acetazolamide in panic disorder patients. American J. Psychiatry 1989;146(8):996-1000.
89. Mathew RJ, Wilson WH. Cerebral blood flow responses to CO-2 and acetazolamide: the effect of anxiety. Psychiatry Research 1989;28:241-242 (letter).
90. Mathew RJ, Wilson WH. Changes in CBF and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology 1989;21:117-123.
91. Mathew RJ and Wilson WH. Chronicity and reduction of the antro-posterior gradient of cerebral blood flow in schizophrenia. American J. Psychiatry 1990;147(2):211-213.
92. Mathew, RJ and Wilson, WH. Cerebral blood response to inhaled carbon dioxide in schizophrenia. Acta psychiatrica Scandi. 1990;81:497-506.
93. Krishnan KRR, Ritchie RC, Saunders W, Wilson WH, Nemeroff CB, Carroll BJ. Nocturnal and early morning secretion of ACTH and cortisol in humans. Biological Psychiatry 1990;81:497-506.
94. Mathew RJ and Wilson WH. Anxiety and cerebral blood flow. American J. Psychiatry 1990;147:838-849.
95. Mathew RJ and Wilson WH. Behavioral and cerebrovascular effects of caffeine in patients with anxiety disorders. Acta psychiatrica Scandi. 1990;82:17-22.
96. Mathew RJ and Wilson WH. Substance abuse and cerebral blood flow. American J. Psychiatry. 148, 292-305, 1991.
97. McEvoy JP, Schooler NR, Wilson WH. Predictors of therapeutic response to haloperidol in schizophrenia. Psychopharmacology Bulletin. 1991, 27, 2, 97-101.
98. Mathew RJ and Wilson WH. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. Psychiatry Research: Neuroimaging, 40, 125-134, 1991.

William H. Wilson, Ph.D.

99. Erwin CW, Erwin AC, R. EP T, Hartwell JW and Wilson WH P100 latency as a function of head size. Am J EEG Technology, 31,279-288, 1991.
100. Krishnan KRR, Ritchie JC, Manepalli AN, Wilson WH, Saunders WB, Venkataraman SS, Carroll BJ. Role of serotonin in hypothalmo-pituitary adrenal axis escape from dexamethasone suppression. Prog. Neuro-Psychopharmacol and Biol. Psychiat. 15, 637-642, 1991.
101. Davidson JTR, Potts NLS, Richichi EA, Ford SM, Krishnan KRR, Smith RD, Wilson WH. The Brief Social Phobia Scale. J. Clinical Psychiatry 52;11(suppl): 48-51, 1991
102. Mathew RJ, Wilson, WH, Humphreys DF, Lowe JV, Wiethe KE. Changes in cerebral blood velocity after intravenous diazepam. Biological Psychiatry.31,690-697, 1992.
103. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE. Middle cerebral artery velocity during upright posture after marijuana smoking. Acta Psychiatr Scand. 86, 173-178, 1992.
104. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe K. Regional cerebral blood flow after marijuana smoking. J.Cerebral Blood Flow and Metabolism. 12, 750-758, 1992.
105. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE. Changes in middle cerebral artery velocity after marijuana. Biological Psychiatry 32, 164-169, 1992.
106. Mathew RJ, Wilson, WH, Melges FT. Temporal disintegration and its psychological and physiological correlates: Changes in the experience of time after marijuana smoking. Annals of Clinical Psychiatry. 4,4,235-245, 1992.
107. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE. Depersonalization after marijuana smoking. Biological Psychiatry 33,431-441, 1993.
108. Mathew RJ, Wilson WH, Blazer D, George L. Psychiatric Disorders in individuals with alcoholic parents: an epidemiologic inquiry. American Journal of Psychiatry. 150,5,793-800,1993.
109. Mathew RJ, Wilson, Ph.D. Acute changes in cerebral blood flow after smoking marijuana. Life Sciences, 52, 757-767, 1993.
110. Wilson WH and Mathew RJ Asymmetry of RCBF in schizophrenia: relationship to AP-gradient and duration of illness Biological Psychiatry, 33,806-814, 1993.

William H. Wilson, Ph.D.

111. Davidson JTR, Potts NLS, Richichi EA, Ford SM, Krishnan KRR, Smith RD, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clinical Psychopharmacology, 13,6,423-428, 1993.
112. Wilson WH, Ellinwood E, Mathew RJ and Johnson, K. Effects of marijuana on performance of a computerized cognitive neuromotor test battery. Psychiatry Research, 51,115-125, 1994.
113. Mathew RJ, Georgi J, Wilson WH, Georgi NG, Lowe JV. Substance abuse consultation in a teaching hospital. N. C. Medical J. v56,7,329-333, 1995.
114. Mathew RJ, Mathew VG, Wilson WH, Georgi JM. Measurement of materialism and spiritualism in substance abusers: Validation of a questionnaire. J Studies on Alcohol, 56,4,470-475, 1995.
115. Swanson CL, Freudenreich O, McEvoy JP, Nelson L, Kamaraju L, Wilson WH. Insight in schizophrenia and mania. J Nervous and Mental Disease 193,752-755, 1995.
116. Sundar KS, Kamaraju LS, Dingfelder J, McMahon J, Gollapudi S, Wilson WH, Kong L, Kong JS, Weiss JM, Lee JE. Beta-endorphin enhances the replication of neurotropic human immunodeficiency virus in fetal perivascular microglia. J Neuroimmunology 61, 97-104, 1995.
117. Mathew RJ, Mathew V George, Wilson WH, Georgi JM. Measuring Spirituality. SCI-MAT 1,5,35, 1995.
118. Mathew RJ, Georgi J, Wilson WH, Mathew VG. A retrospective study of the concept of spirituality as understood by recovering individuals. J. Substance Abuse Treatment. 13,1,67-73,1996.
- xxx. McEvoy JP, Hartman M, Gottlieb D, Godwin S, Apperson LJ, Wilson WH. Common sense, insight, and neuropsychological test performance in patients with schizophrenia. Schizophrenia Bulletin (In Press)
- xxx. Levin ED, Wilson WH, Rose JE, McEvoy JP. Nicotine-haloperidol interaction and cognitive performance in schizophrenia. Neuropsychopharmacology (In Press).
- xxx. Donnelly CL, McEvoy JP, Wilson WH, Narasimachari N. A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia. Biological Psychiatry In Press.

William H. Wilson, Ph.D.

*** VanderZwagg C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. A double-blind, randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with treatment-refractory chronic schizophrenia. American J Psychiatry. (In Press).

*** Mathew RJ Wilson WH Lowe JV, Humphries D. Acute changes in Cranial blood flow after cocaine hydrochloride. Biological Psychiatry (In Press).

*** Mathew RJ, Wilson WH, Humphries D, Lowe JV, Waithe KE. Cerebral vasodilation and vasoconstriction associated with acute anxiety. Biological Psychiatry. (In Press)

*** Mathew RJ, Wilson WH, Humphries D, Lowe JV. Effects of Nitrous Oxide on cerebral blood velocity while reclining and standing. Biological Psychiatry (In Press).

William H. Wilson, Ph.D.

BOOK CHAPTERS:

Nunnally JC, with Durham RL, Lemond LC, Wilson WH. Introduction to Statistics for Psychology and Education. New York: McGraw-Hill, 1975. Chaps. 2, 5, 8, 11-12.

Nunnally JC, Wilson WH. Method and theory of developing measures in evaluation research. In: Struening EL, Guttentag M, eds. Handbook of Evaluation Research, Vol. 1. Beverly Hills: Sage Publications, 1975:227-288.

Guy W, Ban TA, McEvoy JP, Petrie WM, Wilson WH, Schaffer JD. A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives. Abstracts 12th CINP Congress. Oxford: Pergamon Press, 1980.

Ban TA, Wilson WH. Multi-center clinical trials: Methodological aspects. In: Modern Problems of Pharmacopsychiatry. 1981;16:9-29.

Vartanian FE, Odejide AO, Wilson WH, Ban TA. Survey of use of psychotropic drugs in developing countries. Vol. 3. In: Companion to the Life Sciences. Life Stress. New York: Van Nostrand Reinhold, 1981 (Feb.).

Wilson, WH, Ban TA, Lehmann HE, Petrie WM, Ragheb M, Berney S. Psychometric performance profiles in psychogeriatric patients with reference to the effects of loxapine. In: Jansson B, Perris C, Struwe G, eds. Proceedings of the Third World Congress of Biological Psychiatry. Amsterdam: Elsevier/North Holland, 1981.

Ban TA, Guy W, Wilson WH. Conditioning and Leonhard's classification of chronic schizophrenias. In: Jansson B, Perris C, Struwe G, eds. Proceedings of the Third World Congress of Biological Psychiatry. Amsterdam: Elsevier/North Holland, 1981.

Kelwala S, Ban TA, Berney S, Wilson WH. Rapid tranquilization: A comparative study of thiothixene and haloperidol. In: Proceedings of CINP Regional Symposium. Hong Kong, October 9-10, 1981.

Ban TA, Kelwala S, Wilson WH. Differential therapeutic responsiveness in the chronic schizophrenias and Leonhard's classification. In: Ohaski H, Nakayama K, Saito M, Saletu B, eds. Proceedings of World Psychiatric Association Regional Symposium. Kyoto Japan: The Japanese Society of Psychiatry and Neurology, 1982:153-5.

Guy W, Ban TA, Wilson WH, Fjetland O, Pate K. Depressive subtypes and treatment of outcome. In: Burrows G. Libbey & Co., Ltd., 1983:126-32.

William H. Wilson, Ph.D.

Ban TA, Guy W, Wilson WH. Neuroleptics and sexual behavior of male schizophrenics. In: Seigal M, ed. Psychopharmacology of Sexual Behavior. London: John Libbey, 1985.

Ban TA, Guy W, Wilson WH. Psychopharmacology in the understanding of the schizophrenias. In: Morgan DW, ed. Psychopharmacology: Impact on Clinical Psychiatry. St. Louis/Tokyo: Ishiyaku EuroAmerica, Inc., 1985.

Mathew RJ, Wilson WH. Epinephrine-induced Anxiety and Regional Cerebral Blood Flow in Anxious Patients. In: Lere B, Gershon S (eds.): New Directions in Affective Disorder. Springer-Verlag Publishers. New York (Chapter 86, 1989).

Mathew RJ, Wilson WH. Cerebral Blood Flow in Anxiety and Panic. In: Ballenger JC (ed.) Neurobiology of Panic Disorder. Alan R. Liss, Inc., New York, Vol. 8, 281-309, 1990.

Mathew RJ and Wilson WH. The Effects of Marijuana on Cerebral Blood Flow and Metabolism In Marijuana and Cannabinoids: Neurobiology and Neurophysiology ed Laura Murphy & Andrzej Bartke. CRC Press, Boca Raton, 1992.

Mathew RJ Wilson WH. Brain Imaging and Substance Abuse in Facets of Substance Abuse - An Update ed. KA Kumar. Divya Colour Printers, India, 1992.

Wilson WH, Mathew RJ. Cerebral blood flow and metabolism in anxiety disorders. In: Biology of Anxiety Disorders: Recent Developments. (Ed) R. Hoehn-Saric and DR McLeod. American Psychiatric Association, Progress in Psychiatry Series. Chap 1 pg 1-59, 1993.

Mathew RJ and Wilson WH. Acute Pharmacological Effects of Tobacco Smoking and Nicotine on Cerebral Circulation In Brain Imaging of Nicotine and Tobacco Smoking (Ed. E.F. Domino) In Press.

Wilson, WH, Mathew RJ. Methods of statistical analysis for rCBF. In: Mathew RJ, ed. Cerebral Blood Flow in Neuropsychiatric Disorders. Jamaica, New York: Spectrum Publications (in press).

Mathew RJ, Wilson WH. Determinants of cerebral blood flow under resting conditions in normal subjects. In: Mathew RJ, ed. Cerebral Blood Flow in Neuropsychiatric Disorders. Jamaica, New York: Spectrum Publications (in press).

Mathew RJ, Wilson WH. Psychopharmacology and regional cerebral blood flow. In: Mathew RJ, ed. Cerebral Blood Flow in Neuropsychiatric Disorders. Jamaica, New York: Spectrum Publications (in press).

William H. Wilson, Ph.D.

PAPERS PRESENTED:

Wilson, W.H. The effects of light and temperature on general activity level of albino rats. Undergraduate Honors Research. Presented at Southwestern Psychological Association, New Orleans, 1968.

Jamieson, R.C., Ban, T.A., Wilson, W.H. and Guy, W. Diagnostic psychiatric profiles of the revised AMP psychopathological assessment form. XI CINP Congress, 1978.

Vartaniann, F., Odejide, A.O., Wilson, W.H., and Ban, T.A. Survey of use of psychotropic drugs in developing countries. IInd World Congress of Biological Psychiatry, Barcelona, 1978.

Petrie, W.M., Wilson, W.H., Ban, T.A., Guy, W. and Schaffer, J.D. Mianserin. Determination of therapeutic dose range. Group Without a Name, Vermont, 1978.

Wilson, W.H., Petrie, W.M. and Ban, T.A. Anticholinergic effects of mianserin: A pilot study. Group Without a Name, Vermont, 1978.

Wilson, W.H., Petrie, W.M., Ban, T.A. and Guy, W. Effects of viloxazine and alcohol on psychomotor skills related to driving. Canadian College of Neuropsychopharmacology, 1978.

Guy, W., Ragheb, M., Wilson, W.H., Schaffer, J.D. and Hollender, M. Utility of videotape in establishing inter-rater reliability. NCDEU, Key Biscayne, 1979.

Wilson, W.H., Freeman, F.R., Ban, T.A., Petrie, W.M. and Clinton, C.L. Acute effects of viloxazine HCl and flurazepam when given alone and in combination on sleep EEG: A double-blind interaction study with normals. Pavlovian Society, St. Petersburg, 1979.

Guy, W., McEvoy, J.P., Petrie, W.M., Wilson, W.H., Ban, T.A., and Schaffer, J.D. A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depression. CINP, June, 1980.

Ban, T.A. and Wilson, W.H. Multi-centre clinical trials: Methodological aspects. CINP, June, 1980.

Petrie, W.M., Ban, T.A., Berney, S., Fujimori, M., Guy, W., Ragheb, M., Wilson, W.H. and Schaffer, J.D. Loxapine in psychogeriatrics: A placebo and standard controlled study. NCDEU Annual Meeting, Key Biscayne, May, 1981.